<SEC-DOCUMENT>0000950123-21-008630.txt : 20210716
<SEC-HEADER>0000950123-21-008630.hdr.sgml : 20210716
<ACCEPTANCE-DATETIME>20210709183034
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-008630
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20210712
<PUBLIC-REL-DATE>20210716
DATE AS OF CHANGE:		20210709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eliem Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001768446
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				832273741
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04848
		FILM NUMBER:		211083882

	BUSINESS ADDRESS:	
		STREET 1:		23515 NE NOVELTY HILL RD., SUITE B221 #1
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98077
		BUSINESS PHONE:		16502240857

	MAIL ADDRESS:	
		STREET 1:		23515 NE NOVELTY HILL RD., SUITE B221 #1
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98077
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Submission No. 3 submitted to the U.S. Securities and Exchange Commission
on July&nbsp;9, 2021. </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This amended draft registration statement has not been publicly filed with the U.S. Securities and
Exchange Commission and all information herein remains strictly confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>ELIEM THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-2273741</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>23515 NE Novelty Hill Road, Suite B221 #125 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redmond, WA 98053 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(425) <FONT
STYLE="white-space:nowrap">276-2300</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
Registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Robert Azelby
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>23515 NE Novelty Hill Road, Suite B221 #125 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redmond, WA 98053 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(425) <FONT
STYLE="white-space:nowrap">276-2300</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent
for service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alan Hambelton</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sonya Erickson</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Julia
Stark</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1700 Seventh Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Seattle, WA 98101</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(206) <FONT
STYLE="white-space:nowrap">452-8756</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>James B. Bucher</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Executive Vice President and General Counsel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>23515 NE Novelty Hill Road, Suite B221 #125</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redmond, WA 98053</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(425) <FONT
STYLE="white-space:nowrap">276-2300</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brian J. Cuneo</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phillip S. Stoup</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>140 Scott Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park,
CA</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">328-4600</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after this Registration Statement is declared
effective. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If
this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of<BR>Securities being Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>Maximum<BR>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;Fee</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule&nbsp;457(o) under
the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes the aggregate offering price of additional shares that the underwriters have the option to purchase, if
any. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on
such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>Subject to Completion. Dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g03v00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the initial public
offering of Eliem Therapeutics, Inc. We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. The initial public offering price is expected to be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been
no public market for our common stock. We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;ELYM.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under applicable Securities and Exchange Commission rules and have elected to comply with certain reduced public company reporting requirements for this prospectus and
future filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#toc105292_4">Risk Factors</A>&#148; beginning on
page&nbsp;13 to read about factors you should consider before buying shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission
nor any other state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:13%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#147;Underwriting&#148; for additional information regarding compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock from us at the initial public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares of common stock to purchasers
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 through the book-entry facilities of The Depository Trust Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="bottom"><B>SVB Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Evercore&nbsp;ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;Guggenheim&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_4a">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_5">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_13">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_19">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_22">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc105292_23">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Eliem,&#148; &#147;Eliem Therapeutics,&#148; the Eliem Therapeutics logo and other trademarks, trade names or service marks of Eliem
Therapeutics, Inc. appearing in this prospectus are the property of Eliem Therapeutics, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the
trademarks and trade names in this prospectus may be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be
construed as any indicator that their respective owners will not assert their rights thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have
authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and
can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The
information contained in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and
prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in
this offering, may be required to deliver a prospectus. This delivery is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: We have not, and the underwriters have not, done
anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of
this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information
you should consider before investing in our common stock. You should read this entire prospectus carefully, including &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148;
and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Unless the context otherwise requires, all references in this prospectus to &#147;Eliem Therapeutics,&#148;
&#147;we,&#148; &#147;us,&#148; &#147;our&#148; and &#147;our company&#148; refer to Eliem Therapeutics, Inc. and its consolidated subsidiaries. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These
disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of
action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our two lead
clinical-stage candidates are <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155.</FONT> <FONT STYLE="white-space:nowrap">ETX-810</FONT> is a novel palmitoylethanolamide (PEA) prodrug initially being
developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSR, commonly referred to as sciatica). <FONT STYLE="white-space:nowrap">ETX-810</FONT> is being evaluated in two Phase 2a
clinical trials that are expected to report topline data in the first half of 2022. <FONT STYLE="white-space:nowrap">ETX-155</FONT> is a neurosteroid GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor positive allosteric
modulator (PAM) initially being developed for the treatment of major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS), the most common type of seizure in people with epilepsy. We plan to initiate two Phase 2a
clinical trials for <FONT STYLE="white-space:nowrap">ETX-155</FONT> in patients with MDD and PMD which are expected to report topline data in the first half of 2023, and a Phase 1b clinical trial in patients with photosensitive epilepsy that is
expected to report topline data by the first half of 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on the development of product candidates whose mechanisms of action
have been clinically validated. By clinically validated we mean there are product candidates with these mechanisms of action that have demonstrated statistical significance on efficacy endpoints in published randomized, controlled clinical trials.
We leverage the deep expertise of our team to generate new chemical entities (NCEs) based on these clinically validated mechanisms of action that we believe can be clinically differentiated and enhance patient outcomes. Through this approach, we
have established a robust pipeline with two clinical product candidates and two preclinical programs, each with the potential to address multiple disorders. Our product candidates are focused on addressing neuronal excitability disorders with large,
well-defined markets, where clinical and regulatory endpoints are clearly established and development pathways are precedented, yet current therapies leave patients with efficacy, safety or tolerability challenges. Our strategy is to initially
pursue indications for each of our product candidates where the clinical translatability of the mechanism of action has been well established and, upon demonstrating clinical proof of concept, evaluate additional indications to maximize the value of
each program. We believe these principles favorably position us to bring novel therapeutics to patients living with challenging disorders while maximizing our probability of clinical development, regulatory and commercial success. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;1&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of our wholly owned pipeline. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g01b28.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own the rights to our product candidates through both acquisitions and internal research and
development efforts. With respect to ETX-810, in February 2019 we acquired in-process research and development (IPR&amp;D) related to the ETX-810 program from Carnot, LLC. With respect to ETX-155, in October 2020, we acquired 100% of the share
capital of Athenen Therapeutics Inc., which included IPR&amp;D related to the ETX-155 program. Following these acquisitions, we have continued the in-house clinical-stage development of the ETX-155 and ETX-810 programs. Our preclinical Kv7 and GAD
programs have been developed by us. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ETX-810</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead investigational program, <FONT STYLE="white-space:nowrap">ETX-810,</FONT> is a novel, oral, NCE prodrug of PEA in clinical development
for chronic pain conditions. Despite a large global prescription drug market for chronic pain therapeutics that is expected to reach approximately $27&nbsp;billion in the next decade, it has been shown that less than half of patients achieve a
50&nbsp;percent reduction in their pain intensity with current first line therapies. In addition to suboptimal efficacy, current therapies are often hindered by dose-limiting side effects such as dizziness, sedation, cognitive impairments,
gastrointestinal disturbances and concerns over abuse liability. Despite these issues, drugs to treat chronic pain, such as Lyrica and Cymbalta, have achieved significant commercial success and have been among the
<FONT STYLE="white-space:nowrap">top-selling</FONT> pharmaceutical products globally, with both achieving annual sales greater than $5&nbsp;billion before losing patent exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PEA pathway, which is believed to play an important role in the regulation of neuroinflammation and pain signaling, represents a promising
potential mechanism to treat multiple conditions of chronic pain. PEA is an endogenous bioactive lipid that has been evaluated for various pain conditions in more than 30&nbsp;clinical studies, with over 2,500 patients, including patients with pain
related to LSR and DPNP, treated with dietary supplement PEA in these studies. Fifteen of these studies were randomized, controlled trials (RCTs) in a total of approximately 1,500 patients, with thirteen of these RCTs demonstrating a statistically
significant improvement in pain reduction endpoints. A peer-reviewed meta-analysis of eight RCTs conducted with PEA demonstrated a weighted mean reduction in pain intensity score (based on Visual Analog Scale, (VAS)) of approximately two points
compared to control, which compares favorably to the reductions in pain intensity reported from clinical </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;2&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials with currently approved chronic pain medications. In addition, few adverse events related to PEA treatment have been reported in these published clinical studies. Despite this promising
precedent clinical data supporting the exploration of the potential utility of PEA in chronic pain treatment, there are no PEA-based therapeutics approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or similar
foreign regulatory authorities. Rather, PEA is only currently available as a dietary supplement (nutraceutical), which has shown low bioavailability and overall poor drug-like properties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a prodrug of PEA, <FONT STYLE="white-space:nowrap">ETX-810</FONT> was designed to significantly improve the absorption and systemic
exposure of PEA beyond what is achievable with currently available formulations, potentially maximizing the therapeutic effect. While to date there have been no PEA-based therapeutics, we believe that the precedent favorable clinical activity of PEA
makes a compelling case for the development of a PEA-based prodrug, and we believe that ETX-810 offers several key differentiating features compared to currently available therapies for chronic pain. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Novel approach to chronic pain with demonstrated clinical proof of concept. </I>ETX-810, which we believe is
the only PEA prodrug in clinical development, is being developed based on a precedent body of data for PEA demonstrating clinically meaningful statistically significant reductions in pain intensity across multiple clinical studies and pain
conditions, with over 3,000 patients evaluated in published clinical studies of PEA. In one randomized, placebo-controlled study in over 600 chronic low back pain patients, PEA demonstrated statistically significant reductions in pain versus
placebo. A published post-hoc analysis of this study further showed a greater than 50% reduction in pain intensity in 82% of patients treated with PEA. We believe this and other clinical studies with PEA provide clinical proof of concept of
PEA&#146;s potential in the treatment of chronic pain, however, data from precedent studies of dietary supplement PEA may not be a reliable predictor of the efficacy or other benefits of ETX-810 and we will not use such data to support an
application for marketing approval by any regulatory body. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Designed for desirable</I><I> pharmacokinetics</I><I>.</I> In clinical studies in a small number (80) of
healthy volunteers, ETX-810 has demonstrated rapid absorption and efficient release of biologically active PEA, resulting in approximately three times higher PEA exposure on a matched dose basis compared to a commercially available dietary
supplement formulation of PEA. Precedent clinical data has demonstrated a clear dose response with respect to PEA&#146;s ability to reduce pain intensity in chronic pain settings, supporting our approach to optimize the pharmacokinetic exposure of
PEA with ETX-810. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Well tolerated and no known abuse liability in clinical studies. </I>Phase 1 single- and multiple-ascending
dose (MAD) clinical trials with ETX-810 have resulted in no serious adverse events (SAEs), no discontinuations and no clinically meaningful differences from placebo. The tolerability data of ETX-810 observed in these trials appears to be consistent
with the precedent clinical studies of PEA. In addition, as an endogenous bioactive lipid, the potential for abuse is considered to be low and precedent clinical studies of PEA have no reported adverse events related to abuse. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Potential to be used as a monotherapy or in combination with other analgesics. </I>In multiple precedent
clinical trials, PEA demonstrated reductions in pain intensity both as a monotherapy and in combination with other pain therapies such as antidepressants, anticonvulsants, and opioids. To date, we have not observed any clinically relevant drug-drug
interactions with ETX-810. We believe the favorable tolerability data in clinical trials and endogenous nature of PEA make ETX-810 unlikely to have drug-to-drug interactions and position it for the potential to be used in combination with other
chronic pain medications, if approved, which is critical as clinicians commonly resort to polypharmacy as a treatment strategy for chronic pain. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the optimized pharmacokinetics and favorable tolerability demonstrated to date for ETX-810, combined with our development and
manufacturing expertise, put us in position to progress a robust clinical development program for ETX-810. Based on the results of our clinical development of ETX-810, our goal is to ultimately bring ETX-810 through registrational studies as the
first PEA-based therapeutic approved for the treatment of chronic pain, potentially addressing the critical unmet need in chronic pain treatment for novel, </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;3&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective, non-opioid, and non-addictive therapeutic options. Our research suggests that a multi-billion dollar commercial opportunity is available for a new chronic pain agent with proven
efficacy and a favorable safety and tolerability profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have initiated two separate Phase 2a clinical trials of <FONT
STYLE="white-space:nowrap">ETX-810</FONT> in the United States, one in patients with pain associated with DPN and another in patients with pain associated with lumbosacral radiculopathy (lumbosacral radicular pain (LSRP)), to evaluate the efficacy
and safety of <FONT STYLE="white-space:nowrap">ETX-810</FONT> in these indications. We expect to report topline data from both trials in the first half of 2022. If these trials are successful, we plan to conduct further studies with a view to
broaden <FONT STYLE="white-space:nowrap">ETX-810&#146;s</FONT> clinical applications in peripheral neuropathic and other chronic pain conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">ETX-155</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second clinical <FONT STYLE="white-space:nowrap">program,&nbsp;ETX-155,</FONT> is an
investigational, oral neuroactive steroid NCE that is designed to act as a positive allosteric modulator of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor (GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R)
and that we are planning to evaluate in patients with depression and epilepsy. MDD affects approximately 35&nbsp;million adults globally and approximately 19&nbsp;million adults in the United States, and causes significant impairment to daily life.
While there are effective therapies available for individuals suffering from MDD, there is considerable variability in patient responsiveness resulting in only approximately one-third of patients benefiting from their first line therapy. There is a
pressing need for safe, well-tolerated and rapidly acting antidepressants that reliably provide clinical improvement faster than the up to six weeks associated with standard of care selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs). Epilepsy affects approximately 4.7&nbsp;million people in the major markets of the United States, Europe, and Japan, with approximately 1&nbsp;million of these patients experiencing uncontrolled
FOS that are refractory to multiple <FONT STYLE="white-space:nowrap">anti-seizure</FONT> medications (ASMs). Despite the existence of over 30 approved ASMs, approximately 30% of epilepsy patients fail to achieve adequate seizure control. FOS has a
high prevalence of psychiatric <FONT STYLE="white-space:nowrap">co-morbidities</FONT> like depression, which can be exacerbated by many of the currently prescribed ASMs. There is a pressing need for new ASMs to not only reduce the number of seizures
but to also provide a positive effect on mood. The GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class has been clinically validated in certain depression and epilepsy indications, and we believe there is a clear
opportunity for clinical differentiation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ETX-155</FONT> was designed to have dual potency at both
synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. <FONT STYLE="white-space:nowrap">ETX-155</FONT> has also shown differentiated pharmacokinetic properties, including no clinically meaningful food
effect and an approximate <FONT STYLE="white-space:nowrap">24-hour</FONT> half-life to enable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-day</FONT></FONT> dosing. Results from our Phase 1 MAD clinical trial demonstrated
favorable tolerability data at exposure levels that are consistent with dosing levels that achieved robust activity in preclinical models of depression, anxiety and epilepsy. We believe <FONT STYLE="white-space:nowrap">ETX-155</FONT> has several
potential advantages that, collectively, differentiate it from other product candidates in the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class and represent a compelling clinical profile. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dual synaptic and extrasynaptic activity</I>. Binding of <FONT STYLE="white-space:nowrap">ETX-155</FONT> at
the synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs causes enhanced phasic and tonic inhibition, leading to decreased neuronal excitability. We believe that both types of inhibition are important for
neurosteroid clinical efficacy in depression and epilepsy, as evidenced by the positive clinical results of brexanolone and zuranolone in depression, and ganaxolone in epilepsy, all of which have dual activity at synaptic and extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Consistency of effect</I>. Phase 1 clinical trials demonstrated that taking
<FONT STYLE="white-space:nowrap">ETX-155</FONT> with or without food did not result in a clinically meaningful difference in pharmacokinetics, specifically with the maximum plasma concentration (Cmax), and the total drug exposure (AUC). This is a
differentiated characteristic in contrast to other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs such as ganaxolone, brexanolone and zuranolone which are reported to require administration timed with a meal to achieve desired
clinical outcomes. Given challenges with patient compliance, we believe the lack of a clinically meaningful food effect is an important patient-centric differentiation that would allow patients the flexibility to take therapy with or without a
meal<I> </I>while maintaining a consistent therapeutic exposure. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;4&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Once-a-day</FONT></FONT> dosing. </I><FONT
STYLE="white-space:nowrap">ETX-155</FONT> has demonstrated a half-life of approximately 24 to 26 hours, which indicates the agent may be utilized in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-day</FONT></FONT> evening
dosing regimen. We believe this will be a competitively differentiated and favorable dosing regimen for patients if ETX-155 is approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Potential for favorable therapeutic window across a broad set of CNS indications</I>. <FONT
STYLE="white-space:nowrap">ETX-155</FONT> has demonstrated favorable safety and tolerability data in its single ascending dose (SAD) / MAD Phase&nbsp;1 trial. The exposures attained from the 60 mg dose in our Phase 1 MAD cohorts are consistent with
the exposures that led to robust activity of <FONT STYLE="white-space:nowrap">ETX-155</FONT> in our preclinical models of depression, anxiety and epilepsy. This increases our confidence that 60 mg has the potential to be an efficacious dose in the
indications we are pursuing. Separately, we believe the favorable tolerability data from our SAD and MAD studies and the activity observed in preclinical models will support our evaluation of a range of doses to potentially offer physicians
different dose levels, allowing for patient-centric dosing. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on these advantages as well as our preclinical
and clinical work to date, we plan to pursue clinical trials in FOS, MDD and PMD. In the second half of 2021, we intend to initiate a Phase 1b photosensitive epilepsy trial, which if successful, would support initiating a Phase 2 clinical trial in
FOS. We plan to announce topline data from the photosensitive epilepsy trial in the first half of 2022. In addition, we intend to initiate a Phase 2 clinical trial in patients with MDD in the second half of 2021 and expect to report topline data in
the first half of 2023. Further, we intend to initiate a Phase 2 clinical trial to support clinical efficacy in patients with PMD in the second half of 2021 and expect to report topline data in the first half of 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preclinical Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our
clinical candidates, we are progressing a preclinical pipeline with two programs currently in discovery stages. Our preclinical programs apply our medicinal chemistry and biology expertise combined with our
<FONT STYLE="white-space:nowrap">in-depth</FONT> understanding of drug discovery and development processes to develop novel product candidates based on clinically validated mechanisms of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead preclinical program is a Kv7.2/3 potassium channel opener. Kv7.2/3 has been clinically validated as a therapeutic target for both
epilepsy and pain. The first generation Kv7 channel opener, ezogabine (Potiga), was approved for refractory FOS in 2011 in both the United States and in Europe (where it was known as retigabine, or Trobalt). Flupirtine (Katadolon) was another first
generation Kv7 channel opener that demonstrated clinical validation and has been used in Europe as a treatment for pain since the 1980s. These molecules showed clinical efficacy but subsequently had to be withdrawn from the market due to safety
issues. We are developing an NCE that harnesses the efficacy of the Kv7.2/3 channel mechanism while attempting to improve the safety and tolerability relative to earlier molecules, based on our insights into the mechanisms of toxicity. We expect to
nominate a clinical candidate in the second half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second preclinical program is focused on developing a novel, potent analog
of an earlier approved 2,3- benzodiazepine for the potential treatment of Generalized Anxiety Disorder (GAD). The aim of our program is to develop a rapidly acting, non-sedating, non-addictive anxiolytic that does not impair motor or cognitive
performance, does not have any adverse drug-drug interactions and has the potential to be dosed once a day. We plan to nominate a clinical candidate for our GAD program in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We follow several key
principles to guide our research and development efforts that we believe will enable us to efficiently bring clinically differentiated therapies to market to help millions of people suffering from CNS disorders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Focus on clinically validated mechanisms of action.</I> We concentrate our research and development efforts on
opportunities within the broad range of neuronal excitability disorders, where there has been </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;5&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
prior clinical validation for the mechanism of action or pathway and where significant unmet need exists due to efficacy and safety limitations of existing therapies. By focusing on products with
mechanisms of action that have clinical validation, we believe we can reduce the clinical translational risk of our product candidates while leveraging our extensive neuroscience drug development expertise to develop products that have the potential
to meaningfully improve clinical outcomes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Establish clinical differentiation for our product candidates.</I> We leverage the deep chemistry,
neuroscience and manufacturing expertise of our team to generate NCEs that we believe can be clinically differentiated and enhance patient outcomes. We intend to improve on efficacy, safety and tolerability limitations of existing therapies that
impact patient convenience, compliance and outcomes. We aim to deliver therapeutic candidates with optimal pharmacological properties that make them both clinically differentiated and commercially attractive. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pursue CNS indications with well-defined regulatory pathways in large markets that are inadequately served by
current therapies.</I> The initial indications we are pursuing for <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155</FONT> are chronic pain, depression and epilepsy, all of which have well-characterized,
large patient populations and are insufficiently addressed by existing therapies. In these indications, clinical endpoints and regulatory pathways are well-defined and precedented. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Develop products that have broad therapeutic potential.</I> We believe that the biological pathways that are
involved in many neuronal excitability disorders are related, and therefore, therapies that effectively address these pathways may be applicable in multiple CNS disorders. Our strategy for each product candidate is to initially pursue tractable
indications where the clinical translatability of the mechanism of action has been validated. Upon positive results from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials, we intend to pursue
additional indications where we believe our product candidates&#146; mechanisms may be relevant, to maximize the potential for each product candidate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Maximize and protect value through a strong global intellectual property portfolio.</I> We have a rigorous
strategy to establish and protect the intellectual property rights for our programs, all of which are wholly owned, to allow us to maximize the therapeutic and commercial potential of our pipeline. This strategy includes seeking patent protection in
the United States and other jurisdictions for our product candidates, each of which is an NCE. Our portfolio includes numerous filings with multiple different sets of claims that cover proprietary aspects of our lead programs and their use. For <FONT
STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155,</FONT> we have issued patents in the United States with coverage to at least 2037 and 2039, respectively, as well as a wide variety of pending applications for
these programs in the United States and elsewhere. We continue to leverage new discoveries in the development of these programs to strengthen the breadth and depth of our intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To execute our approach, we
plan to implement the following key strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance <FONT STYLE="white-space:nowrap">ETX-810</FONT> through clinical trials for DPN and LSR chronic pain and
progress toward commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance <FONT STYLE="white-space:nowrap">ETX-155</FONT> through clinical trials in both depression and epilepsy
indications and progress toward commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to innovate and advance our preclinical programs into clinical trials in multiple neuronal excitability
indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Apply our expertise to expand our lead programs into additional indications representing large markets; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pursue regulatory approvals for our product candidates and commercialize them in key markets.
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;6&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since commencing operations in 2019, we have assembled a seasoned management team with expertise in neuroscience research and development,
medicinal chemistry, clinical development, regulatory affairs, manufacturing and commercialization. Our team includes industry veterans with leadership experience at leading biopharmaceutical companies such as Amgen, Biogen, GSK, Lilly, Novartis and
Pfizer, as well as at successful small biotechnology companies such as Alder Biopharmaceuticals, Convergence Pharmaceuticals, Exelixis and Juno Therapeutics. In addition, members of our team have driven development and operational efforts supporting
the approval of multiple drugs in chronic pain, depression and epilepsy, including Aptiom, Cymbalta, Lamictal, Lyrica and Vyepti. Our leadership team&#146;s track record of success enables us to continue to recruit highly experienced personnel. Our
board of directors is comprised of industry leaders with senior leadership experience at large pharmaceutical organizations and public and private biotechnology companies, bringing significant expertise across neuroscience research and development,
corporate governance, finance, organizational strategy and capital raising. Together, we bring years of experience combined with the resilience needed to confront challenging diseases of the nervous system and we are supported by top tier investors
including RA Capital Management, Access Biotechnology and Intermediate Capital Group plc. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks and uncertainties, including those described in &#147;Risk Factors&#148; and elsewhere in this
prospectus. You should carefully consider these risks before making an investment. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since our inception, anticipate that we will incur substantial losses for the
foreseeable future, and may never achieve or maintain profitability. As of March 31, 2021, we had an accumulated deficit of $46.7&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need additional funding to conduct our future clinical trials and to complete development and
commercialization of our product candidates. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our clinical development programs or commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have never generated any revenue from product sales, and we may never generate revenue or be profitable.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business substantially depends upon the successful development, regulatory approval and commercialization of <FONT
STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155</FONT> in our initial and any potential future indications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome. The outcome of
preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials, may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources
to successfully commercialize any of our products that receive regulatory approval on our own or together with collaborators. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition from other pharmaceutical and biotechnology companies and other research
organizations and our operating results will suffer if we fail to compete effectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical
and clinical trials, business, financial condition and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third parties to conduct, supervise and monitor our preclinical
studies and clinical trials, and those third parties may not perform satisfactorily, including </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;7&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
by failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third parties to manufacture our clinical and ultimately commercial
product supply. Those third parties may not perform satisfactorily, including by failing to meet product specifications, required demand or cost-efficient scale levels. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain, maintain and protect sufficient patent and other intellectual property rights for our
product candidates and technology, or if the scope of patent and other intellectual property rights obtained is not sufficiently broad, we may not be able to compete effectively in our market. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified material weaknesses in our internal control over financial reporting. If we are unable to
remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial
condition or results of operations, which may adversely affect our business. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being an Emerging Growth
Company and a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business
Startups Act (JOBS Act), and therefore we intend to take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our
independent registered public accounting firm pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley Act) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. We may take advantage of these exemptions for up to five years or until we are no longer an
&#147;emerging growth company,&#148; whichever is earlier. In addition, the JOBS Act provides that an &#147;emerging growth company&#148; can delay adopting new or revised accounting standards until those standards apply to private companies. We
have elected to avail ourselves of this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i)&nbsp;are no
longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are also a &#147;smaller reporting company&#148; as defined in the Securities Exchange Act of 1934, as amended. We may
continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled
disclosures for so long as the market value of our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last
business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the information in this prospectus and that we provide to our investors in the future may be different than what you might
receive from other public reporting companies. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the state of Delaware in October 2018. Our principal mailing address is 23515 NE Novelty Hill Road,
Suite B221 #125, Redmond, WA 98053. Our workforce is currently working remotely and we do not currently have a physical office in the United States. Our telephone number is (425) <FONT STYLE="white-space:nowrap">276-2300.&nbsp;Our</FONT> website is
www.eliemtx.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;8&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_2"></A>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the
underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters
exercise their option to purchase additional shares in full), based upon an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, together with our existing cash, to fund the development <FONT STYLE="white-space:nowrap">of&nbsp;ETX-810,</FONT> <FONT STYLE="white-space:nowrap">ETX-155</FONT> and
our preclinical pipeline, including new product candidates, and the remainder to fund working capital and other general corporate purposes. See the section titled &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See the section titled &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of risks you should carefully consider before investing in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq trading symbol </P></TD>
<TD>&#147;ELYM&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock that will be outstanding after this offering is based on
37,916,480 shares of common stock (including shares of redeemable convertible preferred stock on an as-converted basis, which includes the conversion of the 7,692,306 shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold
in May 2021) outstanding as of March&nbsp;31, 2021, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,860,961 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31,
2021, with a weighted-average exercise price of $0.48 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,284,148 additional shares of common stock reserved for future issuance under our 2019 Equity Incentive Plan as
of March&nbsp;31, 2021, which shares will cease to be available for issuance at the time our 2021 Equity Incentive Plan becomes effective upon the execution of the underwriting agreement for this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our 2021 Equity Incentive Plan, which will become effective upon the execution of the underwriting agreement for this offering, as well as any automatic increases in the number of shares of common stock reserved for future
issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our 2021 Employee Stock Purchase Plan, which will become effective upon the execution of the underwriting agreement for this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under this plan. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;9&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, unless we specifically state otherwise, all information in this prospectus
assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that our amended and restated certificate of incorporation, which we will file in connection with the closing of
this offering, and our amended and restated bylaws adopted in connection with this offering are effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all 30,690,573 outstanding shares of redeemable convertible preferred stock outstanding as of
March&nbsp;31, 2021, which includes the conversion of the 7,692,306 shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May 2021, into an equal number of shares of common stock upon the closing of this offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding options described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;10&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_3"></A>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our consolidated financial data for the periods and as of the dates indicated. The summary consolidated
statements of operations data for the years ended December&nbsp;31, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The consolidated statement of operations data for the three
months ended March&nbsp;31, 2020 and 2021 and the consolidated balance sheet data as of March&nbsp;31, 2021 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus and have been prepared on the
same basis as the audited consolidated financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in
those statements. Our historical results are not necessarily indicative of the results that may be expected for any other period in the future and our historical results for the three months ended March 31, 2021 are not necessarily indicative of the
results that may be expected for the remainder of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the consolidated financial data set forth below in conjunction
with our consolidated financial statements and the accompanying notes, and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; contained elsewhere in this prospectus. The summary
financial data included in this section are not intended to replace the financial statements and are qualified in their entirety by the financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred
stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,321,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,375,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,711,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,911,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;11&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The unaudited pro forma net loss per share for the three months ended March&nbsp;31, 2021 was computed using the
weighted-average number of shares of common stock outstanding, including the pro forma effect of the conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock, as if such conversion had occurred at
the beginning of the period, or their issuance dates, if later. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As</B><br><B>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The pro forma column in the balance sheet table above gives effect to (i) the issuance and sale of 7,692,306
shares of Series&nbsp;B redeemable convertible preferred stock and the receipt of $60.0 million of gross proceeds in May 2021, (ii)&nbsp;the conversion of all outstanding shares of redeemable convertible preferred stock, including the Series B
redeemable convertible preferred stock issued in May 2021, into 30,690,573 shares of common stock immediately upon the closing of this offering and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation that
will be in effect upon the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted column in the balance sheet table above further reflects our receipt of the net
proceeds from the sale of shares of common stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the
cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, respectively, the amount of cash, total assets, working
capital and total stockholders&#146; (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the
number of shares we are offering would increase or decrease the amount of cash, total assets, working capital and total stockholders&#146; (deficit) equity by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same and
after deducting underwriting discounts and commissions. The pro forma as adjusted information is illustrative only, and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;12&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This offering and an investment in our common stock involve a high degree of risk. You should carefully consider the risks described below,
together with the financial and other information contained in this prospectus, including the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial
statements and related notes, before you decide to purchase shares of our common stock. If any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial actually occurs, our
business, financial condition, results of operations and prospects could be materially and adversely affected. Unless otherwise indicated, references in these risk factors to our business being harmed will include harm to our business, reputation,
brand, financial condition, results of operations and prospects. As a result, the trading price of our common stock could decline, and you could lose all or part of your investment in our common stock. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since our inception, anticipate that we will incur substantial losses for the foreseeable future and may never
achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company with a limited operating history. For the last
several years, we have focused our efforts primarily on developing our product candidates, including our two lead clinical-stage candidates, <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155,</FONT> with
the goal of achieving regulatory approval and commercialization. Since inception, we have incurred significant operating losses. Our net losses were $6.5&nbsp;million, $20.7&nbsp;million, $1.9&nbsp;million and $18.6&nbsp;million for the years ended
December&nbsp;31, 2019 and December&nbsp;31, 2020 and the three months ended March 31, 2020 and March&nbsp;31, 2021, respectively. As of March&nbsp;31, 2021, we had an accumulated deficit of $46.7&nbsp;million. To date, we have not received
regulatory approvals for any of our product candidates or generated any revenue from the sale of products, and we do not expect to generate any revenue in the foreseeable future. We expect to continue to incur substantial expenses and operating
losses over the next several years as we continue to develop our current and future product candidates. In addition, we expect to incur significant sales, marketing and manufacturing expenses related to the commercialization of our current and
future product candidates, if they are approved by the U.S. Food and Drug Administration (FDA). As a result, we expect to continue to incur significant losses for the foreseeable future. We anticipate that our expenses will increase substantially as
we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to develop and conduct clinical trials, including for <FONT STYLE="white-space:nowrap">ETX-810</FONT>
and <FONT STYLE="white-space:nowrap">ETX-155</FONT> for our initial and any potential additional indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and continue research and development, including preclinical, clinical and discovery efforts for any
future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for <FONT STYLE="white-space:nowrap">ETX-810</FONT> and
<FONT STYLE="white-space:nowrap">ETX-155,</FONT> or any other product candidates that successfully complete clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
product candidate development and help us comply with our obligations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire and retain additional personnel, such as clinical, manufacturing, quality control, scientific, commercial
and administrative personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the
future to commercialize various products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add equipment and physical infrastructure to support our research and development and growing staff;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur increased costs as a result of operating as a public company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;13&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need additional funding to conduct our future clinical trials and to complete development and
commercialization of our product candidates. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had cash of $20.5&nbsp;million and $47.9 million at December 31, 2020 and March 31, 2021, respectively. Our independent registered public
accounting firm included an explanatory paragraph in its report on our financial statements as of, and for the year ended, December&nbsp;31, 2020, describing the existence of substantial doubt about our ability to continue as a going concern at May
12, 2021, the date of their report. On May 21, 2021, we received $60.0 million in gross proceeds from the issuance and sale of our Series B redeemable convertible preferred stock, which we believe will be sufficient to meet our projected operating
requirements for at least the next twelve months from the filing date of this amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon our current operating plan and
assumptions, we believe that our existing cash, including the net proceeds from this initial public offering, will be sufficient to fund our operations for at least the
next&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. However, we will need additional capital to complete the clinical development of our product candidates and to commercialize any approved
products. Our estimates of the sufficiency of our cash are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect.&nbsp;Further, changing circumstances, some of which may be beyond our
control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting clinical trials, pursuing regulatory approvals, establishing outsourced manufacturing relationships and successfully manufacturing
and commercializing our product candidates is, and will be, very time-consuming, expensive and an uncertain process that takes years to complete. Our future need for additional funding depends on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of researching and developing
<FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155</FONT> for our initial and potential additional indications, as well as our preclinical product candidates and other future product candidates we may
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and uncertainty of, and the costs involved in, obtaining marketing approvals for <FONT
STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155</FONT> for our initial and potential additional indications and our preclinical product candidates and other future product candidates we may develop and pursue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of future product candidates that we may pursue and their development requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of jurisdictions in which we plan to seek regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if approved, the costs of commercialization activities for <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT
STYLE="white-space:nowrap">ETX-155</FONT> for any approved indications or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing
of establishing product sales, marketing, distribution and manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of <FONT
STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155</FONT> for any approved indications or any other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products,
product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our research and development, establish or increase our
office space and establish a commercial infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual
property rights, including enforcing and defending intellectual property related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing costs of operating as a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may exacerbate the magnitude
of the factors discussed above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;14&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional funding will be available on acceptable terms, or at
all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and any disruptions to, or volatility in,
the credit and financial markets in the United States and worldwide that arise from the pandemic. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us,
we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are in the early stages of clinical drug development and have a very limited operating history and no products approved for commercial sale, which
may make it difficult to evaluate our current business and predict our future success and viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage,
U.S.-headquartered biotechnology company with a very limited operating history with international operations in the United Kingdom. We commenced operations in 2018, have no products approved for commercial sale and have not generated any revenue
from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We are conducting multiple Phase 2a clinical trials for our <FONT STYLE="white-space:nowrap">ETX-810</FONT> clinical program and plan
to initiate Phase 2a and other clinical trials for our <FONT STYLE="white-space:nowrap">ETX-155</FONT> clinical program, and have not initiated clinical trials for any of our other current research programs. To date, we have not initiated or
completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for
successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by
early-stage biotechnology companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business may be
harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never generated any revenue from product sales and we may never generate revenue or be profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large
enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing and marketing therapies with significant commercial success. Our ability to generate revenue and
achieve profitability depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully completing preclinical and clinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, assessing and/or developing new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing
and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully
complete clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and successfully commercializing product candidates for which we obtain regulatory and marketing
approval, either by establishing a sales, marketing and distribution infrastructure or collaborating with a partner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating and maintaining an adequate price for our product candidates, both in the United States and in
foreign countries where our products are commercialized; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfying any post-marketing requirements and obtaining reimbursement for its products from private insurance or
government payors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;15&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance of our product candidates as viable treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">building out new facilities or expanding existing facilities to support our ongoing development activity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including
patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our
expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA, or foreign regulatory
agencies, to perform studies or clinical trials in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#146; clinical trials or the development of any of our product candidates. Even
if one or more of our product candidates is approved for commercial sale, absent our entering into a collaboration or partnership agreement, we anticipate incurring significant costs associated with commercializing any approved product candidate and
ongoing compliance efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Business and the Development of our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business substantially depends upon the successful development of <FONT STYLE="white-space:nowrap">ETX-810</FONT> and
<FONT STYLE="white-space:nowrap">ETX-155.</FONT> If we are unable to obtain regulatory approval for, and successfully commercialize, <FONT STYLE="white-space:nowrap">ETX-810</FONT> or <FONT STYLE="white-space:nowrap">ETX-155,</FONT> our business
will be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and are investing the majority of our efforts and financial
resources in the development of our lead product candidates, <FONT STYLE="white-space:nowrap">ETX-810</FONT> for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy, and <FONT
STYLE="white-space:nowrap">ETX-155</FONT> for the treatment of major depressive disorder, perimenopausal depression and epilepsy. Successful continued development and potential regulatory approval of <FONT STYLE="white-space:nowrap">ETX-810</FONT>
or <FONT STYLE="white-space:nowrap">ETX-155</FONT> for our initial and potential additional indications is critical to the future success of our business. We will need to raise sufficient funds for, and successfully enroll and complete, our clinical
development programs of <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before we
can generate any revenue from sales of <FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT STYLE="white-space:nowrap">ETX-155</FONT> or any of our other programs, we must undergo additional preclinical and clinical development, regulatory review
and approval in one or more jurisdictions. In addition, if one or more of our product candidates are approved, we must ensure access to sufficient commercial manufacturing capacity and conduct significant marketing efforts in connection with any
commercial launch. These efforts will require substantial investment, and we may not have the financial resources to continue development of our product candidates or commercialization of any products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience setbacks that could delay or prevent regulatory approval of our product candidates or our ability to commercialize any
products, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others
for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related side effects experienced by subjects in our clinical trials or by individuals using drugs or
therapeutics similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting investigational new drug applications (INDs) in the United States or comparable foreign
applications or delays or failure in obtaining the necessary approvals from regulators or institutional review boards to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;16&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the FDA or comparable foreign authorities do not accept the earlier preclinical and clinical trial work, then
we may need to conduct additional preclinical studies or clinical trials beyond that which we currently have planned and significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive
right to commercialize our drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug candidates and may harm our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in contracting with clinical sites or enrolling subjects in clinical trials, including due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in the supply of materials necessary for the conduct of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or institutional review boards (IRBs) or ethics committees may not authorize us or our investigators
to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, including with
respect to dosing levels administered in our planned clinical trials, which may delay or prevent us from initiating our clinical trials with our originally intended trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites and
prospective contract research organizations (CROs) which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate or
subjects may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors for preclinical studies or clinical trials may fail to comply with regulatory
requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or take actions that could cause clinical sites or clinical investigators to drop out of the trial, which may
require that we add new clinical trial sites or investigators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">due to the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may experience some delays
and interruptions to our preclinical studies and clinical trials, we may experience delays or interruptions to our manufacturing supply chain, or we could suffer delays in reaching, or we may fail to reach, agreement on acceptable terms with
third-party service providers on whom we rely; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater than anticipated clinical trial costs, including as a result of delays or interruptions that could
increase the overall costs to finish our clinical trials as our fixed costs are not substantially reduced during delays; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may elect to, or regulators, IRBs, Data Safety Monitoring Boards (DSMBs), or ethics committees may require
that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not have the financial resources available to begin and complete the planned trials, or the cost of
clinical trials of any product candidates may be greater than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our
product candidates may be insufficient or inadequate to initiate or complete a given clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable foreign regulatory authorities may require us to submit additional data such as
long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial, including because the FDA has not reviewed our preclinical or clinical data, to date, having been developed outside the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to compete with other therapies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;17&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">poor efficacy of our product candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA or other regulatory agency inspection and review of clinical trial sites or manufacturing
facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable product labeling associated with any product approvals and any requirements for a Risk Evaluation and
Mitigation Strategy (REMS) that may be required by the FDA or comparable requirements in other jurisdictions to ensure the benefits of an individual product outweigh its risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable acceptance of our clinical trial data by the patient or medical communities or third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet
their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays related to the impact or the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other
pandemics, including the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the FDA&#146;s, or similar foreign regulatory agency&#146;s ability to continue its normal operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our technology in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of data by the FDA and similar foreign regulatory agencies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission
process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, of the large number of drugs in development in the biotechnology industry, only a small percentage result in the submission of a
marketing application, such as a new drug application (NDA) to the FDA, and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval for <FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT
STYLE="white-space:nowrap">ETX-155</FONT> or any other potential product candidate we may develop for any indication, any such approval may be subject to limitations on the indications or uses or patient populations for which we may market the
product. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we cannot assure that we will successfully develop or commercialize <FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT
STYLE="white-space:nowrap">ETX-155</FONT> or any other potential product candidate we may develop for any indication. If we or any of our future collaborators are unable to develop, or obtain regulatory approval for, or, if approved, successfully
commercialize <FONT STYLE="white-space:nowrap">ETX-810</FONT> or <FONT STYLE="white-space:nowrap">ETX-155</FONT> for our initial or potential additional indications, or any other potential product candidate we may develop, we may not be able to
generate sufficient revenue to continue our business. In addition, our failure to demonstrate positive results in our clinical trials in any indication for which we are developing <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT
STYLE="white-space:nowrap">ETX-155</FONT> could adversely affect our development efforts for <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155</FONT> in other indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and clinical development involves a lengthy, complex and expensive process with an uncertain outcome. The outcome of preclinical testing and
early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies
and clinical trials that our product candidates are safe and effective in humans to the satisfaction of FDA. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, in the United
States, the general approach for FDA approval of a new drug is dispositive data from two well-controlled, Phase 3 clinical trials of the relevant drug in the relevant patient population. Phase 3 clinical trials typically involve hundreds to
thousands of patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing, even after observing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;18&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promising signs of activity in earlier preclinical studies or clinical trials. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the
results of later-stage clinical trials. For example, preclinical models evaluating product candidates for pain are notoriously unreliable and, as such, the therapies face substantial translational risk. In addition, initial success in clinical
trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of
clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biotechnology industry have suffered significant setbacks in
advanced clinical trials due to lack of efficacy or emergence of unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved and there can be no assurance
that any of our future clinical trials will ultimately be successful or support further clinical development of <FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT STYLE="white-space:nowrap">ETX-155</FONT> or any of our other product candidates.
The commencement and rate of completion of preclinical studies and clinical trials may be delayed by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of
clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical studies or clinical trials may show the product candidates to be less effective than expected
(<I>e.g.</I>, a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically
meaningful; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult
to extrapolate the results of earlier clinical trials to later clinical trials (<I>e.g.</I>, we are basing our therapeutic hypothesis for ETX-810 on studies conducted in the academic setting and the results from the academic studies may not be
replicated in a clinical setting); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of
our product candidates for use in clinical trials or the inability to do any of the foregoing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in
clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments on trials conducted by competitors for related technology that raises FDA or foreign regulatory
authority concerns about risk to patients of the technology broadly, or if the FDA or a foreign regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting, screening and enrolling patients and delays caused by patients withdrawing from clinical
trials or failing to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties or us to adhere to clinical trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s or any other regulatory authority&#146;s good clinical
practice requirements (GCPs) or applicable regulatory guidelines in other countries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;19&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential
benefits, or occurrence of adverse events in trial of the same class of agents conducted by other companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our
deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by a third-party contract development and
manufacturing organization (CDMO) and delays or failure by our CDMOs or us to make any necessary changes to such manufacturing process; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties being unwilling or unable to satisfy their contractual obligations to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing preclinical studies and clinical trials. Any inability to successfully initiate or complete preclinical studies or clinical trials could result in
additional costs to us or impair our ability to generate revenue from product sales. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to
bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could
impair our ability to successfully commercialize our product candidates and may seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our current and
planned clinical trials do or will contain endpoints that require subjective assessments and subject us to a substantial risk of &#147;placebo effect&#148; which is a well-known risk in clinical trials evaluating therapeutics for pain as well as
depression. While a product candidate may show clinical activity or therapeutic benefit, a high placebo effect in a clinical trial will make it difficult to ascertain that benefit or to show statistically significant effect of the product candidate
as compared to the control arm and may ultimately cause a clinical trial to fail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical
trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable
foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the
study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay
in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the completion of any preclinical studies or clinical trials of our product candidates will increase our costs, slow down our
product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate product revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our preclinical studies or clinical trials that occur as a result could shorten any period during which we may have
the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may
harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we seek to conduct clinical trials in foreign countries or pursue
marketing approvals in foreign jurisdictions, we must comply with numerous foreign regulatory requirements governing, among other things, the conduct of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;20&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and jurisdictions and may include
all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-to-jurisdiction</FONT></FONT> from that required to obtain FDA approval. Approval by foreign regulatory authorities does not ensure approval by the FDA and, similarly,
approval by the FDA does not ensure approval by regulatory authorities outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful completion of clinical
trials is a prerequisite to submitting a marketing application to foreign regulatory authorities or the FDA, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We may experience
negative or inconclusive results, or regulators may be unwilling to accept preclinical or clinical data obtained in foreign jurisdictions, which may result in our deciding, or our being required by regulators, to conduct additional clinical studies
or trials or abandon some or all of our product development programs, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cross-trial comparisons are not reliable
predictors of the relative efficacy of our product candidates against comparators. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not conducted head-to-head clinical
trials to compare our product candidates with competing products. There are risks associated with comparing the results of our clinical trials with results from other independent studies and trials (as we have done in this registration statement),
as cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of our product candidates compared to other product candidates that may be approved or that are in development. Moreover, unless we conduct
head-to-head comparative studies, we will not be able to make any claims of superiority even if our products are approved. Additionally, even though our product candidates are designed to address the same indications as existing therapies, we have
not conducted head-to-head clinical trials comparing our product candidates with such existing drugs and therapies. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered
by clinical and preclinical stage biotechnology companies such as ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public health crises such as pandemics or similar outbreaks could
materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
March 2020, the World Health Organization declared <FONT STYLE="white-space:nowrap">COVID-19</FONT> a global pandemic and the United States declared a national emergency with respect to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> In response
to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, &#147;shelter in place&#148; orders and other public health guidance measures have been implemented across much of the United States and Europe, including in the locations of our
offices, clinical trial sites, key vendors and partners. We expect that our clinical development program timelines will be negatively affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which could materially and adversely affect our
business, financial condition and results of operations. Further, due to &#147;shelter in place&#148; orders and other public health guidance measures, we have implemented a work-from-home policy for all staff members excluding those necessary to
maintain minimum basic operations. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our
research activities that require our personnel to be in our laboratories will be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or similar pandemics, and related &#147;shelter in place&#148; orders and other public health guidance measures, we have and may in the future experience disruptions that could materially and
adversely impact our clinical trials, business, financial condition and results of operations. Potential disruptions include but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical
site initiation and recruiting clinical site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting <FONT
STYLE="white-space:nowrap">COVID-19</FONT> or other health conditions or being forced to quarantine; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;21&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety
and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the
collection and integrity of subject data and clinical study endpoints; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or disruptions in preclinical experiments and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies
due to restrictions of <FONT STYLE="white-space:nowrap">on-site</FONT> staff and unforeseen circumstances at CROs and vendors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing
organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home,
school closures or mass transit disruptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government or contractor personnel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other factors arising from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic could worsen
in countries that are already afflicted with <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could continue to spread to additional countries or could return to countries where the pandemic has been partially contained, each of which could further
adversely impact our ability to conduct clinical trials and our business generally, and could materially and adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> virus. For example, in March 2020, the FDA issued a guidance, which FDA subsequently revised, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of
clinical trials impacted by the pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic continues to rapidly
evolve. The extent to which the outbreak may affect our clinical trials, business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the
ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries,
business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with
respect to our clinical trials, business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading prices for shares of other
biopharmaceutical companies have been highly volatile as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and following this offering the trading prices for shares of our common stock could also experience high volatility.
As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;22&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market event resulting from the spread of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially and adversely affect our business and the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business operations is highly uncertain and
subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that
will emerge concerning the severity and impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the actions taken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or address its impact in the short and long term, among others. We
do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our business could be materially adversely affected by other business disruptions to us or our third-party providers that could
materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our CROs, CDMOs and other contractors, consultants and third parties could be subject to other global
pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters
or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could materially adversely affect our operations and financial condition and increase our costs and expenses. We rely on
third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a
<FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA, the U.S. Securities
and Exchange Commission (SEC) and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being
developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of
the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary
government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, and had to furlough
critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on
our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and
continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020
the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. On July&nbsp;10, 2020,
the FDA announced its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment
system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April&nbsp;15, 2021, the FDA issued a
guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote
interactive evaluations in situations where an <FONT STYLE="white-space:nowrap">in-person</FONT> inspection would not be prioritized, deemed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;23&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. Regulatory authorities
outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to
prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our
regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects or
have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following regulatory approval, if obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by <FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT STYLE="white-space:nowrap">ETX-155</FONT> or any
other current or future product candidate could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable
foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In addition, many compounds that have initially showed promise in clinical or
earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. For example, our lead preclinical program is a Kv7.2/3 potassium channel opener. This mechanism has been
validated through regulatory approvals of multiple first generation Kv7.2/3 openers for the treatment of epilepsy and pain. These molecules showed efficacy but subsequently had to be withdrawn from the market due to significant safety issues. There
is no assurance that, if we are able to move our preclinical program forward, we will be able to avoid similar safety problems. Additionally, the composition of our product candidates or learnings in preclinical studies or clinical trials may result
in contraindications for any product candidates for which we may obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If unacceptable side effects arise in the
development of our product candidates, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate
altogether. We, the FDA, other comparable regulatory authorities or IRBs, DSMBs or independent ethics committees at the institutions in which our trials are conducted could suspend or terminate our trials for various reasons, including a belief that
subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found
to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its
tolerability versus other therapies. Any of these developments could materially adversely affect our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treatment-emergent side effects that are deemed to be drug-related could also result in potential product liability claims. Undesirable side
effects in one of our clinical trials (or in a clinical trial of a competitor with a similar mechanism of action) for our product candidates in one indication could adversely affect enrollment in clinical trials, regulatory approval and
commercialization of our product candidates in other indications. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Any of these occurrences may harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to
identify undesirable side effects. Clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a
significantly larger number of patients exposed to the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;24&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar products) after such
approval, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw or limit their approval of such product candidates, or seek an injunction
against its manufacture or distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, &#147;boxed&#148; warnings, or issue
safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way such product candidates are distributed or administered, or change the
labeling of the product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may require a REMS plan to mitigate risks, which could include medication guides, physician communication
plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools, and regulatory authorities in other jurisdictions may require comparable risk mitigation plans;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to regulatory investigations and government enforcement actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or a comparable foreign regulatory authority may require us to conduct additional clinical trials or
costly post-marketing testing and surveillance to monitor the safety and efficacy of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could
substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter difficulties enrolling and/or retaining patients in our future clinical trials, our clinical development activities could be delayed or
otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue our planned clinical trials on a timely basis or at all
for our product candidates if we are unable to recruit and enroll a sufficient number of eligible patients to participate in these trials through completion of such trials as required by the FDA or other comparable foreign regulatory authorities.
Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. There may be limited patient pools from which to draw for
clinical studies. The eligibility criteria of our clinical studies will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either
severe enough or not too advanced to include them in a study. Patient enrollment for our current or any future clinical trials may be affected by other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability and efficacy of approved drugs for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the product candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;25&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and
risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; willingness to screen their patients for biomarkers to indicate which patients may be eligible
for enrollment in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or temporary suspension of the enrollment of patients in our planned clinical trials due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on clinical trial sites, personnel
and patient travel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion, including as a
result of contracting <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other health conditions or being forced to quarantine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our
product candidates, and this competition would reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our
competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are
available for our clinical trials in such clinical trial site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for our clinical
trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Delays in patient enrollment may result in increased costs, affect the timing or outcome of the planned clinical trials, product
candidate development and approval process and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion of these trials, adversely affect our ability to
advance the development of our product candidates, cause the value of our company to decline and limit our ability to obtain additional financing if needed. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical
trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database,
such as www.ClinicalTrials.gov in the United States, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available, and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time
to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to
change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the
opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once
additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we
previously published. As a result, <FONT STYLE="white-space:nowrap">top-line</FONT> and preliminary data should be viewed with caution until the final data are available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;26&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may also disclose interim data from our preclinical studies and
clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients
from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our
competitors could result in volatility in the price of our common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory
agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or
commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive
information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline or preliminary data that we report differ from actual results, or if others,
including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to the significant resources required for the development of our pipeline, and depending on our ability to access capital, we must prioritize
development of certain product candidates. Moreover, we may fail to expend our limited resources on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have two lead clinical-stage candidates, <FONT STYLE="white-space:nowrap">ETX-810</FONT> and
<FONT STYLE="white-space:nowrap">ETX-155.</FONT> We seek to maintain a process of prioritization and resource allocation to maintain an optimal balance between aggressively advancing product candidates and ensuring replenishment of our portfolio.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the significant resources required for the development of our product candidates, we must focus on specific diseases and disease
pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management, and financial resources toward
particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. If we make incorrect determinations regarding the viability or market
potential of any of our product candidates or misread trends in the biotechnology industry, in particular for disorders of the peripheral and central nervous systems, our business may be harmed. As a result, we may fail to capitalize on viable
commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those
we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole
development and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to continue to create a pipeline of product candidates or to
develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our strategies is to identify and pursue clinical development of additional product candidates. We currently have novel preclinical
candidates in the research, discovery, screening and preclinical stages of development, with two programs currently in advanced discovery stage. Identifying, developing, obtaining regulatory approval and commercializing additional product candidates
for the treatment of disorders of the peripheral and central nervous systems will require substantial additional funding and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be able to
successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble
sufficient resources to identify, acquire, develop or, if approved, commercialize additional product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;27&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunity may be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>One of the core elements of our strategy is to develop our existing products in multiple indications, also referred to as label expansion. Even if we
are successful in developing a product in one indication this does not guarantee that it will be successful in other indications or that we will be able to obtain approval in other patient populations or diseases. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Label expansion is one of the core elements of our strategy. If our current and planned trials are successful, we intend to evaluate additional
potential indications for both <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155.</FONT> For <FONT STYLE="white-space:nowrap">ETX-810,</FONT> we will explore additional pain indications, which could enable
a broad label in peripheral neuropathic pain and chronic pain. For <FONT STYLE="white-space:nowrap">ETX-155,</FONT> we intend to explore a wide-range of compelling opportunities in both psychiatry and neurology, including potentially generalized
anxiety disorder, and bipolar disorder. Even if we are successful in developing a product in one indication does not guarantee that it will be successful in other indications or that we will be able to obtain approval in other patient populations or
diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained,
following our products&#146; marketing approval and commercialization. Product liability lawsuits brought against us or any of our future collaborators could divert our resources and attention, require us to cease clinical testing, cause us to incur
substantial liabilities or limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to potential product liability and
professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of biotechnology products. Currently, we have no products that have been approved for commercial sale; however, the use of our product
candidates by us and any collaborators in clinical trials may expose us to liability claims. We will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be
brought against us or our partners if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable for human use during product testing, manufacturing, marketing or sale. Any such product liability claim may
include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts.
Such claims could be made by participants enrolled in our clinical trials, patients, health care providers, biotechnology companies, our collaborators or others using, administering or selling any of our future approved products. If we cannot
successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the merits or eventual outcome, product liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any of our future approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of clinical trial sites or entire trial programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant litigation costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to, or costly settlements with, patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls or a change in the indications for which any approved drug products may be used;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management and scientific resources from our business operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;28&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the clinical trial process is designed to identify and assess potential side
effects, clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates
were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should
not use our product candidates. If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are
subject to negative publicity associated with illness or other adverse effects resulting from physicians&#146; or patients&#146; use or misuse of our products or any similar products distributed by other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance coverage including clinical trial liability, this insurance may not fully cover potential
liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if we commercialize any product that receives
regulatory approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could
prevent or inhibit the development and commercial production and sale of our product candidates, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal
and Regulatory Compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and
commercialize our product candidates and may affect the prices we may charge for such product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and
many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect
our ability to profitably sell any product for which we obtain marketing approval. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act (ACA), was enacted, which includes measures that have significantly changed the way health care is financed by both
governmental and private insurers. There have been executive, judicial and congressional challenges to certain aspects of the ACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by
several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance
coverage through the ACA marketplace, which began on February&nbsp;15, 2021 and will remain open through August&nbsp;15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and
rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance
coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA. We continue to evaluate the effect that the ACA and its
possible repeal and replacement has on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA
was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030 with the
exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, unless Congress takes additional action. Recently, there has been increasing legislative
and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. presidential executive orders, congressional inquiries and legislation designed to,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;29&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and
reform government program reimbursement methodologies for drugs. At the federal level, the former Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and
policy initiatives. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control costs pharmaceutical and biological products. It is also possible that additional governmental action will be taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the healthcare reform measures that have been adopted and may be adopted in the future may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar
reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and
customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could
face substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers and others play a primary role in the recommendation and prescription of any
products for which we obtain marketing approval. Although we do not currently have any products on the market, our operations may be, directly or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal
and state healthcare laws and regulations. These laws may impact, among other things, our current business operations, including our clinical research activities and proposed sales, marketing and education programs and constrain the business of
financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare,
statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which makes it illegal for any person or entity, including a prescription
drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or
reward, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare
program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal civil and criminal false claims laws, including the False Claims Act (FCA), which can be
enforced through &#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be
presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false record or statement material to a
false, fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing such an obligation to pay money to the
federal government. In addition, a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;30&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created additional
federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses,
representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (<I>e.g.</I>, public or private) and knowingly and willfully falsifying, concealing or
covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or
fraudulent statement or entry in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of
violating HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Physician Payments Sunshine Act and its implementing regulations, which require certain
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services (CMS) an
agency within the U.S. Department of Health and Human Services (HHS) under the Open Payments Program, information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to
include payments and other transfers of value made during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal and state consumer protection and unfair competition laws, which broadly regulate marketplace
activities and activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state laws and regulations, including state anti-kickback and false claims laws that may apply to
items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and other relevant compliance
guidance promulgated by the federal government that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing
and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical
sales representatives; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing
interactions with and payments to healthcare providers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our internal operations and future business
arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future
statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and
regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or
similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or
similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly
and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;31&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be
subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Actual or perceived failure to comply with current or future federal, state and foreign laws and regulations and industry standards
relating to privacy and data protection laws could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our third-party providers may be subject to federal, state and foreign data privacy and security laws and regulations. In
the United States, numerous federal and state laws and regulations, including federal health information privacy laws, data breach notification laws, health information privacy laws, including HIPAA (as amended by the Health Information Technology
for Economic and Clinical Health Act of 2009), and federal and state consumer protection laws (<I>e.g.</I>, Section&nbsp;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other
personal information could apply to our operations or the operations of our collaborators and third-party providers. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical
trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant civil and criminal penalties if we receive, use or disclose individually identifiable health
information in a manner that is not authorized or permitted by HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many jurisdictions, enforcement actions and consequences for
noncompliance are rising. In the United States, these include enforcement actions in response to rules and regulations promulgated under the authority of federal agencies and state attorneys general and legislatures and consumer protection agencies.
In addition, privacy advocates and industry groups have regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us. If we fail to follow these security standards, even if no customer
information is compromised, we may incur significant fines or experience a significant increase in costs. Many state legislatures have adopted legislation that regulates how businesses operate online, including measures relating to privacy, data
security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event
of a widespread data breach is costly. States are also constantly amending existing laws, requiring attention to frequently changing regulatory requirements. Furthermore, California recently enacted the California Consumer Privacy Act (CCPA), which
became effective on January&nbsp;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal
information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Additionally, a new privacy law, the California Privacy Rights Act
(CPRA) was approved by California voters on November&nbsp;3, 2020. The CPRA, which will take effect in most material respects on January&nbsp;1, 2023, modifies the CCPA significantly, including by expanding consumers&#146; rights with respect to
certain sensitive personal information and creating a new state agency to oversee implementation and enforcement efforts, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. At
this time, we do not collect personal data on residents of California, but should we begin to do so, the CCPA and CPRA will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and
class actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign data protection laws, including the EU General Data Protection Regulation (GDPR) may also apply to health-related
and other personal data obtained outside of the United States. The GDPR, which came into effect on May&nbsp;25, 2018, imposes strict requirements for processing the personal data of individuals within the European Economic Area (EEA). Companies that
must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and for noncompliance of up to the greater of &#128;20&nbsp;million or 4% of annual global
revenue. The regulation imposes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;32&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
numerous requirements regarding the collection, use and disclosure of personal information, including requirements relating to processing health and other sensitive data, obtaining consent of the
individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches
and taking certain measures when engaging third-party processors Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal
data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data
transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the vote in the United&nbsp;Kingdom in favor of exiting the EU, referred to as Brexit, has created uncertainty with regard to data
protection regulation in the United Kingdom. From January&nbsp;1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR (U.K. GDPR), which, together with the amended U.K. Data Protection Act 2018, retains the GDPR in U.K.
national law. The U.K. GDPR mirrors the fines under the GDPR, <I>i.e.</I>, fines up to the greater of &#128;20&nbsp;million (&pound;17.5&nbsp;million) or 4% of global turnover. The relationship between the United&nbsp;Kingdom and the European Union
(EU), in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom
will be regulated in the long term. These changes will lead to additional costs and increase our overall risk exposure. Currently there is a four to <FONT STYLE="white-space:nowrap">six-month</FONT> grace period agreed in the EU and United Kingdom
Trade and Cooperation Agreement, ending June&nbsp;30, 2021 at the latest, whilst the parties discuss an adequacy decision. The European Commission published a draft adequacy decision on February&nbsp;19, 2021. If adopted, the decision will enable
data transfers from EU member states to the United Kingdom for a four-year period, subject to subsequent extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we work to
comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another,
and may conflict with one another or other legal obligations with which we must comply. Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability
to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure by us or our collaborators and third-party providers to comply with U.S. and foreign data protection laws and regulations could
result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we
or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights,
failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any of
our products that receive regulatory approval on our own or together with collaborators. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never commercialized a product
candidate. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, and undertaking preclinical studies and clinical trials of our product candidates. We currently have no sales force,
marketing, manufacturing or distribution capabilities. To achieve commercial success of our product candidates, if any are approved, we will have to develop our own sales, marketing, reimbursement and manufacturing capabilities or outsource these
activities to a third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;33&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may affect our ability to commercialize our product candidates on our own
include recruiting and retaining adequate numbers of effective sales and marketing personnel, persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and
marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization
in the United States, the European Union or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may have
difficulties generating revenue from them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition from other pharmaceutical and biotechnology companies and other research
organizations, and our operating results will suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry is
characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. We face potential competition from many different sources, including major and specialty pharmaceutical, biopharmaceutical, and
biotechnology companies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective or more convenient or have fewer or less severe side effects than any products that we may develop. Our
competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to face
competition from existing products and products in development for each of our product candidates. In addition, there may be other earlier stage clinical programs that, if approved, would compete with our product candidates. Many of our competitors
have substantially greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. Additional mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because <FONT STYLE="white-space:nowrap">ETX-810</FONT> is a prodrug of PEA, an endogenous bioactive lipid, which is already marketed by other companies
in various formulations as medical foods, nutraceuticals and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> dietary supplements, we may be exposed to unique risk related to <FONT
STYLE="white-space:nowrap">non-prescription</FONT> competition and consumer substitution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ETX-810</FONT> is a prodrug of PEA, an endogenous bioactive lipid. Various formulations of PEA are currently
marketed by others as medical foods, nutraceuticals and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> dietary supplements. We believe that <FONT STYLE="white-space:nowrap">ETX-810,</FONT> if
approved, will have a superior therapeutic profile to dietary supplement PEA available over the counter. However, we cannot be sure physicians and patients will view <FONT STYLE="white-space:nowrap">ETX-810,</FONT> if approved, as superior. To the
extent the price of <FONT STYLE="white-space:nowrap">ETX-810,</FONT> if approved, is significantly higher than the prices of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> PEA, physicians may
recommend these commercial alternatives instead of writing prescriptions for <FONT STYLE="white-space:nowrap">ETX-810,</FONT> or patients may elect on their own to take
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> PEA products. Additionally, negative experiences with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
PEA may have an adverse impact on our ability to obtain regulatory approval, or if we obtain such approval, on demand for our products. Either of these outcomes may adversely impact our results of operations by limiting how we price our product.
Additionally, any adverse effects experienced by the users of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> PEA could adversely impact the regulatory approval process for <FONT
STYLE="white-space:nowrap">ETX-810</FONT> or physician or patient demand for <FONT STYLE="white-space:nowrap">ETX-810,</FONT> even if we are successful in obtaining regulatory approval for and commercialization of such product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because current formulations of PEA are only available as over-the-counter supplements, the precedent body of data regarding PEA
is based exclusively on studies of PEA in its over-the-counter dietary supplement formulations. There can be no assurance that ETX-810 will achieve the same or similar results in clinical testing as observed in these studies of PEA in its dietary
supplement formulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;34&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of certain of our product candidates will depend in part on the
extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could
limit our ability to market those products and decrease our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and adequacy of coverage
and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford products such as our product candidates, if approved. Our
ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates and
attract additional collaboration partners to invest in the development of our product candidates. Coverage under certain government programs, such as Medicare, Medicaid, the 340B drug pricing program and TRICARE, may not be available for certain of
our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may <FONT STYLE="white-space:nowrap">require&nbsp;co-payments&nbsp;that</FONT> patients
find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased
or eliminated in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and
many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product
candidates and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs
may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us
to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to
obtain a satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance
coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new
drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party
payors may <FONT STYLE="white-space:nowrap">require&nbsp;pre-approval&nbsp;of</FONT> coverage for new or innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict at this
time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and
maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ
significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe
that changes in these rules and regulations are likely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors in the United
States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;35&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health
maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of
new products. The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care may adversely affect:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for any products for which we may obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain coverage and reimbursement approval for a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenues and achieve or maintain profitability; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption
of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Further, coverage policies and third-party payor reimbursement rates may
change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the
future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing approval for any of our product candidates, we may not achieve market acceptance, which would limit the
revenue that we can generate from sales of any of our approved product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA or any comparable foreign
regulatory authority approves the marketing of any product candidates that we develop, physicians, patients, third-party payors or the medical community may not accept or use them. Efforts to educate the medical community and third-party payors on
the benefits of our product candidates may require significant resources and may not be successful. Market acceptance <FONT STYLE="white-space:nowrap">of&nbsp;ETX-810,</FONT> <FONT STYLE="white-space:nowrap">ETX-155&nbsp;and</FONT> our other product
candidates, if any are approved, will depend on a number of factors, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of <FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT STYLE="white-space:nowrap">ETX-155</FONT>
and our other product candidates to treat neuronal excitability disorders, as compared with other available drugs, treatments or therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any adverse side effects associated with
<FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT STYLE="white-space:nowrap">ETX-155</FONT> and our other future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the labeling approved for <FONT STYLE="white-space:nowrap">ETX-810,</FONT> <FONT
STYLE="white-space:nowrap">ETX-155</FONT> or our other future product candidates by the FDA or any comparable foreign regulatory authority; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the target patient population, and the willingness of the target patient population to try new
therapies and of physicians to prescribe these therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support and timing of market introduction of competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity for our product candidates and competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing and cost effectiveness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing strategies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to increase awareness of our product candidates through marketing efforts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;36&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood that the FDA or any comparable foreign regulatory authority may impose additional requirements
that limit the promotion, advertising, distribution or sales of our product candidates.</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any one of our product
candidates is approved but does not achieve an adequate level of acceptance by patients, physicians and third-party payors, we may not generate sufficient revenue to become or remain profitable and our business may be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales, marketing and market access
capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing, reimbursement or distribution capabilities. To achieve commercial success for any approved product for
which we retain sales, marketing and market access and reimbursement responsibilities, we must either develop these capabilities, which would be expensive and time consuming, or outsource these functions to other third parties, some or all of which
may be occur in advance of any approval of the product candidate. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with any future collaborators for, some of our product
candidates if and when they are approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own sales and marketing capabilities and
entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which
we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if
we cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our product
candidates on our own include:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the
benefits of prescribing any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product
revenues or the profitability of these product revenues to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to
sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we
cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales and marketing
capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;37&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If these third
parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party CROs to conduct, supervise, and monitor our preclinical studies and certain clinical trials for our product candidates
and do not currently plan to independently conduct preclinical studies or clinical trials of any other potential product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical
institutions and clinical investigators to conduct our preclinical studies and clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance and control only certain aspects of their
activities. The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm our business because we may not obtain marketing approval for or commercialize our product
candidates in a timely manner or at all. Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our product
development activities and harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for development activities will reduce our control over
these activities. Nevertheless, we are responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not
relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that
our preclinical trials are conducted in accordance with good laboratory practice, or GLP, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred to as good clinical
practices, or GCPs, for conducting, monitoring, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are
protected. As a clinical trial sponsor, we also have regulatory requirements that directly apply to us. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we
or any of our CROs fail to comply with applicable GCPs, we or our CROs may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory
authorities may require us to perform additional clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once we have an approved product, we will be required to
report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA and comparable foreign regulatory authorities may question the integrity of the data from
those clinical trials conducted by investigators who previously served or currently serve as scientific advisors or consultants to us from time to time and receive cash compensation in connection with such services or otherwise receive compensation
from us that could be deemed to impact study outcome, proprietary interests in a product candidate, certain company equity interests or significant payments of other sorts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials complies with GCP regulations. In addition, our clinical trials must be conducted with product candidates that were produced under current Good Manufacturing Process (cGMP) regulations. Our failure to comply with these regulations may require
us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database,
ClinicalTrials.gov, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs may
also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, our CROs are not our
employees, and except for remedies available to us under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;38&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, <FONT STYLE="white-space:nowrap">non-clinical,</FONT> and
preclinical programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if
they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended,
delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates,
or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be
delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third-party CROs terminates, we may not be able to enter into arrangements with alternative CROs or to
do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could
occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that
these delays or challenges will not harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the manufacturers upon whom we rely fail to produce our product candidates in the volumes
that we require on a timely basis, or to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our products and may lose
potential revenues. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not manufacture any of our product candidates, and we do not currently plan to develop any capacity to
do so. We currently outsource all manufacturing of our product candidates to third-party CDMOs, typically without any guarantee that there will be sufficient supplies to fulfill our requirements or that we may obtain such supplies on acceptable
terms. Any delays in obtaining adequate supplies with respect to our product candidates may delay the development or commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for any of our existing or future
product candidates and programs. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. There are a limited number of CDMOs that operate under cGMP regulations and that are both capable
of manufacturing for us and willing to do so. If our existing third-party manufacturers, or the third parties that we engage in the future to manufacture a product for commercial sale or for our clinical trials, should cease to continue to do so for
any reason, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason we
are unable to obtain adequate supplies of our product candidates or the raw materials used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively. Further, even if we do establish such
collaborations or arrangements, our third-party manufacturers may breach, terminate or not renew these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited
number of contract manufacturers for our product candidates. At times we may have only one manufacturer for a product. In addition, we do not have any long-term commitments from our suppliers of clinical trial material or guaranteed prices for our
product candidates. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often
encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields; quality control, including stability of the product candidate and quality assurance testing;
shortages of qualified personnel; and compliance with strictly enforced federal, state, and foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;39&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations. Our manufacturers may not perform as agreed. If our manufacturers were to encounter any of these difficulties, our ability to provide product candidates to patients in our clinical
trials and for commercial use, if approved, would be jeopardized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, all manufacturers of our product candidates must comply
with cGMP requirements enforced by the FDA and comparable foreign regulatory authorities that are applicable to both finished drug products and active pharmaceutical ingredients used both for clinical and commercial supply, through its facilities
inspection program. The FDA must verify our contract manufacturers&#146; compliance with cGMP requirements and comparable foreign regulatory authorities will similarly inspect our contract manufacturers&#146; facilities after we submit our marketing
applications to the agency and comparable foreign regulatory authorities. The cGMP requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to
comply with our specifications, these cGMP requirements and with other FDA, state, and foreign regulatory requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict
regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. While we are ultimately responsible for the manufacture of our product
candidates, other than through our contractual arrangements, we have little control over our manufacturers&#146; compliance with these regulations and standards. If the FDA or a comparable foreign regulatory authority does not approve these
facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory
approval for, or market our product candidates, if approved. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, including
imprisonment; suspension or restrictions of production; suspension, delay, or denial of product approval or supplements to approved products; clinical holds or termination of clinical studies; warning or untitled letters; regulatory authority
communications warning the public about safety issues with the drug; refusal to permit the import or export of the products; product seizure, detention, or recall; civil suits under the FCA; corporate integrity agreements; consent decrees; or
withdrawal of product approval. If the safety of any quantities supplied is compromised due to our manufacturers&#146; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure or refusal to supply our product candidates or components for our current or future
product candidates that we may develop could delay, prevent, or impair our clinical development or commercialization efforts. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable
and because the expenses relating to the transfer of necessary technology and processes could be significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to establish
future collaborations, we may have to alter some of our future development and commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development
programs and the potential commercialization of our product candidates will require substantial additional capital to fund expenses. While currently we have no plans to do so, we may decide to collaborate for the future development and potential
commercialization of our product candidates. Furthermore, we may find that our programs require the use of proprietary rights held by third parties, and the growth of our business may depend in part on our ability to
<FONT STYLE="white-space:nowrap">acquire,&nbsp;in-license&nbsp;or</FONT> use these proprietary rights. We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or
commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration that we have entered into or will enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators, and a number of more established companies may also be pursuing
strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development
and commercialization capabilities. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;40&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon
our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of
clinical trials, the likelihood of approval by the FDA, European Medicines Agency (EMA), the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) or similar foreign regulatory authorities, the potential market for the subject product
candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such
ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on
and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators.
Collaborations are complex and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential
future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate further collaborations on a timely basis, on acceptable terms, or at all. Even if
we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. Our existing collaboration partners may not prioritize our
product candidates or otherwise not effectively pursue the development of our product candidates which may delay, reduce or terminate the development of such product candidate, reduce or delay its development program or delay its potential
commercialization. Further if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to delay, reduce or terminate the development
of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and
undertake development or commercialization activities at our own expense. Doing so will likely harm our ability to execute our business plans. If we elect to increase our expenditures to fund development or commercialization activities on our own,
we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product
revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain, maintain and protect sufficient patent and other intellectual property rights for our product candidates and technology, or
if the scope of patent and other intellectual property rights obtained is not sufficiently broad, we may not be able to compete effectively in our market. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in significant part on our ability and the ability of future licensors, licensees or collaborators to obtain, maintain,
enforce and defend patents and other intellectual property rights with respect to our product candidates and technology and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of
others. As of May 31, 2021, we have nine pending U.S. provisional applications relating to <FONT STYLE="white-space:nowrap">ETX-155</FONT> and one U.S. provisional application relating to <FONT STYLE="white-space:nowrap">ETX-810.</FONT> A U.S.
provisional patent application is not eligible to become an issued patent until, among other things, we <FONT STYLE="white-space:nowrap">file&nbsp;non-provisional&nbsp;patent</FONT> application within 12 months of filing of the provisional patent
application. With regard to such U.S. provisional patent applications, if we do not timely file <FONT STYLE="white-space:nowrap">any&nbsp;non-provisional&nbsp;patent</FONT> applications, we may lose our priority dates with respect to our provisional
patent applications and any patent protection on the inventions disclosed in our provisional patent applications. While we intend to timely <FONT STYLE="white-space:nowrap">file&nbsp;non-provisional&nbsp;patent</FONT> applications relating to our
provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with any competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;41&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and time-consuming. We and our future licensors,
licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our future licensors will fail to identify patentable
aspects of our research and development output in time to obtain patent protection or fail to file patent applications covering inventions made in the course of development and commercialization activities before a competitor or another third party
files a patent application covering, or publishes information disclosing, a similar, independently-developed invention. Such competitor&#146;s or other third party&#146;s patent application may pose obstacles to our ability to obtain patent
protection or limit the scope of the patent protection we may obtain. Although we enter <FONT STYLE="white-space:nowrap">into&nbsp;non-disclosure&nbsp;and</FONT> confidentiality agreements with parties who have access to confidential or patentable
aspects of our research and development output, such as our employees, collaborators, CROs, CDMOs, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is
filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions
are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our future licensors were the first to make the inventions claimed in our owned or any future licensed patents or
pending patent applications, or were the first to file for patent protection of such inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and
pharmaceutical companies generally is uncertain, involves complex legal and factual questions and is the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future
licensors&#146; patent rights are uncertain. Our and our future licensors&#146; pending, and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which
effectively exclude others from commercializing competitive technologies and product candidates. The patent examination process may require us or our future licensors to narrow the scope of the claims of our pending and future patent applications,
and therefore, even if such patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any
competitive advantage. Our and our licensors&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the
extent the issued claims cover such technology. Any patents that we hold <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;in</FONT> the future may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not
know whether any of our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or
products in <FONT STYLE="white-space:nowrap">a&nbsp;non-infringing&nbsp;manner.</FONT> Any of the foregoing could impair our competitive position and harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The patent protection we obtain for our product candidates and technologies may be challenged and rendered invalid and/or unenforceable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our owned patent applications issue as patents, the issuance of any such patents is not conclusive as to their inventorship, scope,
validity or enforceability, and such patents may be challenged, invalidated, narrowed or held to be unenforceable, including in the courts or patent offices in the United States and abroad, or circumvented. We may be subject to a third-party
preissuance submission of prior art to the United States Patent and Trademark Office (USPTO), or equivalent foreign bodies, or become involved in opposition, derivation,
<FONT STYLE="white-space:nowrap">revocation,&nbsp;re-examination,&nbsp;post-grant</FONT> and<I>&nbsp;inter partes</I>&nbsp;review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in
any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our
inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference or derivation proceedings declared by the USPTO to determine priority or ownership of invention or
in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such proceedings and any other patent challenges may result in loss
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;42&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of patent rights, loss of exclusivity, loss of priority or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or
commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our
scientists and management, even if the eventual outcome is favorable to us. Moreover, there could be public announcements of the results of hearings, motions or other developments related to any of the foregoing proceedings. If securities analysts
or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. Any of the foregoing could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our
trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to develop and manufacture our product
candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements,
consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use
or disclose our confidential information, such as trade secrets. Despite these contractual agreements with third parties, sharing trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on
<FONT STYLE="white-space:nowrap">our&nbsp;know-how&nbsp;and</FONT> trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish
data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our
agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive position and harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and
unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors and other third parties may infringe, misappropriate or otherwise violate our issued patents or other intellectual property. In
addition, our patents may become involved in inventorship or priority disputes. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from
such applications. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert
counterclaims against us alleging that we infringe their patents or that our patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part,
construe the patent&#146;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our
patents at risk of being invalidated, held unenforceable or interpreted narrowly. We may find it impractical or undesirable to enforce our intellectual property against some third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a
validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, <FONT STYLE="white-space:nowrap">obviousness,&nbsp;non-enablement&nbsp;or</FONT> insufficient written description. Grounds for
an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;43&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties may also raise similar claims before the USPTO or an equivalent foreign body, even outside the context of litigation. Potential proceedings
<FONT STYLE="white-space:nowrap">include&nbsp;re-examination,&nbsp;post-grant</FONT> review,<I>&nbsp;inter partes</I>&nbsp;review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (<I>e.g.</I>,
opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technology or any product candidates that we may develop. The outcome following
legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during
prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on the applicable product candidates or technology covered by the patent
rendered invalid or unenforceable. Such a loss of patent protection would harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference or derivation proceedings
provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the ownership or priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the
related technology or to attempt to license rights to it from the prevailing party. Such licenses may not be available on commercially reasonable terms, or at all, or may <FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive.&nbsp;If</FONT> we are
unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. In addition, if we or any future licensors are unsuccessful in any
inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or&nbsp;any future
<FONT STYLE="white-space:nowrap">in-licensed&nbsp;patents.</FONT> The loss of exclusivity or the narrowing of such patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any
of the foregoing could harm our business. Even if we are successful in any of the foregoing disputes, it could result in substantial costs and be a distraction to management and other employees. Furthermore, because of the substantial amount of
discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities
or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Most of our competitors are larger than we are and have substantially greater
resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property
portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or otherwise violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings
relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the
funds necessary to continue our clinical trials, continue our internal research programs <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;needed</FONT> technology or other product candidates. There could also be public announcements of the
results of the hearing, motions or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. Any of the foregoing events
could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property rights on our product candidates in all
countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries
do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or
from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;44&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies in jurisdictions where we have not obtained patent protection or other intellectual property rights to develop their own products and may export otherwise infringing,
misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement rights are not as strong as those in the United States. These products may compete with our product candidates, and
our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement of patents and other intellectual property rights, which could make
it difficult for us to stop the infringement, misappropriation or other violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and
divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims
against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be
compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if
patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might
adversely affect our ability to develop and market our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our patent searches or
analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending
patent application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, U.S. patent applications filed before November&nbsp;29, 2000 and certain U.S.
patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest
filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates could have been filed by third parties without our knowledge.
Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is
determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively
impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims
of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to
identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
fail to identify and correctly interpret relevant patents or if we are unable to obtain licenses to relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such
infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from commercializing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;45&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual
property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements,
our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It may be necessary for us to use the patented or proprietary technology of third parties to
commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may
pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater
clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to license such technology, or if we are forced to license such
technology, on unfavorable terms, our business could be harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could harm our business, and the third parties owning
such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may <FONT
STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;thereby</FONT> giving our competitors access to the same technologies licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, some of our patents and patent applications in the future may <FONT STYLE="white-space:nowrap">be&nbsp;co-owned&nbsp;with</FONT>
third parties. If we are unable to obtain an exclusive license to any <FONT STYLE="white-space:nowrap">such&nbsp;co-owners&#146;&nbsp;interest</FONT> in such patents or patent applications,
<FONT STYLE="white-space:nowrap">such&nbsp;co-owners&nbsp;may</FONT> be able to license their rights to other third parties, including our competitors, who could market competing products and technology. In addition, we may need the cooperation of
any <FONT STYLE="white-space:nowrap">such&nbsp;co-owners&nbsp;in</FONT> order to enforce such patents against third parties, and such cooperation may not be provided to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest <FONT STYLE="white-space:nowrap">U.S.&nbsp;non-provisional&nbsp;filing</FONT> date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our
product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and
regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and any future licensed patent portfolio may not provide
us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the
timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984,
referred to as the Hatch-Waxman Amendments, and one or more of our foreign patents may be eligible for patent term extension under similar legislation, for example, in the European Union. In the United States, the Hatch-Waxman Amendments permit a
patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, there are no assurances that the FDA or any
comparable foreign regulatory authority or national patent office will grant such extensions, in whole or in part. For example, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review
process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;46&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those
claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can
enforce our patent rights for the applicable product candidate will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this
occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, and our competitive position and business
could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law could diminish the value of our patents, thereby impairing our ability to protect our product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and enforcing patents in the pharmaceutical industry is inherently uncertain, due in part to ongoing changes in the
patent laws. Depending on decisions by Congress, the federal courts, and the USPTO and equivalent institutions in other jurisdictions, the laws and regulations governing patents, and interpretation thereof, could change in unpredictable ways that
could weaken our ability to obtain new patents or to enforce existing or future patents. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain
circumstances or weakening the rights of patent owners in certain situations. Therefore, there is increased uncertainty with regard to our ability to obtain patents in the future, as well as uncertainty with respect to the value of patents once
obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while
outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted in September 2011, the United States transitioned to a first
inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. These include allowing third-party submission of prior art to the
USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review,&nbsp;<I>inter partes</I>&nbsp;review and derivation proceedings. The USPTO
recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first&nbsp;inventor-to-file&nbsp;provisions.</FONT></FONT> Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patents and applications are required to
be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent. In certain circumstances, we may rely on our future licensors to pay these fees. The USPTO and various foreign patent agencies also require compliance
with a number of procedural, documentary, fee payment and other similar requirements during the patent application and prosecution process. Noncompliance events that could result in abandonment or lapse of a patent or patent application include
failure to respond to official communications within prescribed time <FONT STYLE="white-space:nowrap">limits,&nbsp;non-payment&nbsp;of</FONT> fees and failure to properly legalize and submit formal documents. While an inadvertent lapse can in many
cases be cured by payment of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;47&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
late fee or by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in irrevocable abandonment or
lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we or any future licensors or collaborators fail to maintain the patents and patent applications covering our product
candidates, our competitors might be able to enter the market with similar or identical products or technology, which would harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could negatively impact the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success
depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property
and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or be threatened with, future adversarial proceedings or litigation
regarding intellectual property rights with respect to our product candidates and technology, <FONT STYLE="white-space:nowrap">including&nbsp;re-examination,&nbsp;interference,</FONT> post-grant review, <I>inter partes</I> review or derivation
proceedings before the USPTO or an equivalent foreign body. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. In the event that any
of these patents were asserted against us, we believe that we would have defenses against any such action, including that such patents are not valid or that we would be able to replace such technology with
<FONT STYLE="white-space:nowrap">alternative,&nbsp;non-infringing&nbsp;technology.</FONT> However, if any such patents were to be asserted against us and our defenses to such assertion were unsuccessful and such alternative technology was not
available or technologically or commercially practical, unless we obtain a license to such patents, we could be liable for damages, which could be significant and include treble damages and attorneys&#146; fees if we are found to willfully infringe
such patents, and we could be precluded from commercializing any product candidates that were ultimately held to infringe such patents. Any potential future legal proceedings relating to these patents could cause us to incur significant expenses,
and could distract our technical and management personnel from their normal responsibilities. If we are unsuccessful in our challenges to these patents and become subject to litigation or are unable to obtain a license on commercially reasonable
terms with respect to these patents, it could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert infringement claims against us based on
existing patents or patents that may be granted in the future, regardless of their merit. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of
infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that third-party patents asserted against us are valid, enforceable and infringed, which could adversely affect our ability to commercialize any product
candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption
of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such
U.S. patent. If we are found to infringe, misappropriate or otherwise violate a third party&#146;s intellectual property rights, and we are unsuccessful in demonstrating that such rights are invalid or unenforceable, we could be required to obtain a
license from such a third party in order to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a
license, it could <FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;thereby</FONT> giving our competitors access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could
be forced, including by court order, to cease commercializing the infringing technology or product candidates. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business
operations. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, pay royalties and other fees, redesign our infringing drug
or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;48&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing events would harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their
intellectual property rights, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees were
previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information <FONT STYLE="white-space:nowrap">or&nbsp;know-how&nbsp;of</FONT>
others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s former employer. Litigation
may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we or our future licensors may be subject to claims that former employees,
collaborators or other third parties have an interest in our owned or&nbsp;any future <FONT STYLE="white-space:nowrap">in-licensed&nbsp;patents</FONT> or other intellectual property as an inventor
<FONT STYLE="white-space:nowrap">or&nbsp;co-inventor.&nbsp;While</FONT> it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual
property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives, develops or reduces to practice intellectual property that we regard as our own. Our and their assignment agreements may not be
self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs, delay development of our product candidates and be a distraction to management. Any of the foregoing events
would harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their
normal responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property
claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim
proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our
operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation
or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third
parties or enter into development collaborations that would help us commercialize our product candidates, if approved. Any of the foregoing events would harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets and confidentiality agreements to protect our
<FONT STYLE="white-space:nowrap">unpatented&nbsp;know-how,&nbsp;technology</FONT> and other proprietary information and to maintain our competitive position. Trade secrets <FONT STYLE="white-space:nowrap">and&nbsp;know-how&nbsp;can</FONT> be
difficult to protect. We seek to protect these trade secrets and other proprietary technology, in part, by entering <FONT STYLE="white-space:nowrap">into&nbsp;non-disclosure&nbsp;and</FONT> confidentiality agreements with parties who have access to
them, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;49&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of
these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade
secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to
protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to rely on both registered and common law rights for our trademarks. We plan to apply to register these trademarks with the USPTO and
may in the future seek to register additional trademarks in the United States and other countries. Our trademark applications may not be allowed for registration in a timely fashion or at all, and our future registered trademarks may not be
maintained or enforced. In addition, any registered or unregistered trademarks or trade names that we own or will own may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks.
We may not be able to protect our rights in these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. In addition, third parties
have filed, and may in the future file, for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. If they succeed in registering or
developing common law rights in such trademarks, and if we are not successful in challenging such rights, we may not be able to use these trademarks to develop brand recognition of our technologies, products or services. In addition, there could be
potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions
objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign
jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may in the future be filed against our trademark
applications or registrations, and our trademark applications or registrations may not survive such proceedings. In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and
if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. If we do not secure registrations for our trademarks, we may encounter more difficulty in
enforcing them against third parties than we otherwise would. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, which could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to any product candidates we may develop or utilize similar
technology but that are not covered by the claims of the patents that we own now or own or license in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future licensors, might not have been the first to make the inventions covered by the issued patent or
pending patent application that we own now or own or license in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future licensors, might not have been the first to file patent applications covering certain of our or
their inventions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;50&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending owned patent applications or those that we may own or license in the future will
not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States under <FONT
STYLE="white-space:nowrap">FDA-related</FONT> safe harbor patent infringement exemptions and/or in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our
major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Business Operations, Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the management, research and development, clinical, financial and business development expertise of our
executive officers, as well as the other members of our scientific and clinical teams. Although we have employment offer letters with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain
&#147;key person&#148; insurance for any of our executives or employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific and clinical
personnel and, if we are successful in obtaining marketing approval for our product candidates, sales and marketing personnel, is critical to our success. The loss of the services of our executive officers or other key employees could impede the
achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an
extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our product candidates. Competition to
hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar
personnel. Furthermore, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former
employers own their research output. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical
advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited, and could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a
result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our full-time and part-time
employee base grew from three employees as of December&nbsp;31, 2019 to nine employees as of December&nbsp;31, 2020. As our clinical development progresses, we expect to experience growth in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;51&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the number of our employees and the scope of our operations, particularly in the areas of research, clinical operations, regulatory affairs, general and administrative and, if any of our product
candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to
recruit and train additional qualified personnel. Due to the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train
additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt
our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage
in misconduct or other improper activities, <FONT STYLE="white-space:nowrap">including&nbsp;non-compliance&nbsp;with</FONT> regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs
and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that violates (1)&nbsp;the laws and regulations of the FDA, the
EMA, the MHRA and other similar regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (2)&nbsp;manufacturing standards, (3)&nbsp;federal and state data privacy, security,
fraud and abuse and other healthcare laws and regulations in the United States and abroad and (4)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business
arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of
pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including
information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product candidates, which could result in regulatory sanctions and harm our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and other
third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we
are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including damages, fines,
disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm and the delay, reduction, termination or restructuring of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our international operations in the United Kingdom may expose us to business, regulatory, political, operational, financial, pricing and reimbursement
risks associated with doing business outside of the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting
business internationally. Some of our suppliers, industry partners and clinical study centers are located outside of the United States. Furthermore, our business strategy incorporates potential international expansion as we seek to obtain regulatory
approval for, and commercialize, our product candidates in patient populations outside the United States. If approved, we may hire sales representatives and conduct physician and patient association outreach activities outside of the United States.
Doing business internationally involves a number of risks, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import
restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;52&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rejection or qualification of foreign clinical trial data by the competent authorities of other countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in the supply of clinical trial materials resulting from any events affecting raw
material supply or manufacturing capabilities abroad, including those that may result from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional potentially relevant third-party patent and other intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limits in our ability to penetrate international markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local
and regional financial crises on demand and payment for our product candidates and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">currency exchange rate fluctuations and the resulting effect on our revenue and expenses and the cost and risk of
entering into hedging transactions if we chose to do so in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak
of disease, including <FONT STYLE="white-space:nowrap">COVID-19</FONT> and related <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders, travel, social distancing and quarantine policies, boycotts,
curtailment of trade and other business restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain expenses including, among others, expenses for travel and insurance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within
the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could harm our future international expansion and operations and, consequently, our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to utilize a significant portion of our net operating loss carryforwards. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had net operating loss carryforwards of approximately $8.7&nbsp;million for federal income tax purposes,
$3.6&nbsp;million for foreign income tax purposes and $2.1&nbsp;million for state income tax purposes. These may be used to offset up to 100% of future taxable income. The federal net operation loss carryforward can be carried forward indefinitely
while the state net operating loss carryforward will begin to expire in varying amounts in 2038. The net operating loss carryforwards subject to expiration could expire unused and be unavailable to offset future income tax liabilities. Under the Tax
Cuts and Jobs Act (Tax Act), as modified by the Coronavirus Aid, Relief and Economic Security Act (CARES Act), federal net operating losses incurred in taxable years beginning after December&nbsp;31, 2017 and in future taxable years may be carried
forward indefinitely, but the deductibility of such federal net operating losses in taxable years beginning after December&nbsp;31, 2020 is limited. There is variation in how states will respond to the Tax Act and CARES Act. In addition, for state
income tax purposes, there may be periods during which the use of NOLs is suspended or otherwise limited, such as recent California legislation limiting the usability of NOLs for tax years beginning in 2020 and before 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, (Internal Revenue Code), and corresponding provisions of
state law, if a corporation undergoes an &#147;ownership change,&#148; which is generally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;53&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defined as a greater than 50 percentage point change, by value, in its equity ownership by certain stockholders over a rolling three-year period, the corporation&#146;s ability to use <FONT
STYLE="white-space:nowrap">its&nbsp;pre-change&nbsp;net</FONT> operating loss (NOL) carryforwards and <FONT STYLE="white-space:nowrap">other&nbsp;pre-change&nbsp;tax</FONT> attributes to offset its post-change income or taxes may be limited. The
completion of this offering, together with private placements and other transactions that have occurred since our inception, may trigger such an ownership change pursuant to Section&nbsp;382 of the Internal Revenue Code. We have not completed a
Section&nbsp;382 analysis, and therefore, there can be no assurances that the NOLs carryforward are not already limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we
may experience ownership changes as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it could harm
our future operating results by effectively increasing our future tax obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to grow our business through acquisitions or
investments in new or complementary businesses, products or technologies, through the licensing of products or technologies from third parties or other strategic alliances, and the failure to manage acquisitions, investments, licenses or other
strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders&#146; ownership, increase our debt or cause us to incur significant expense.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing clinician and
patients&#146; needs, competitive technologies and market pressures. Accordingly, from time to time we may consider opportunities to acquire, make investments in or license other technologies, products and businesses that may enhance our
capabilities, complement our existing products and technologies or expand the breadth of our markets or customer base. Potential and completed acquisitions, strategic investments, licenses and other alliances involve numerous risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty assimilating or integrating acquired or licensed technologies, products, employees or business
operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issues maintaining uniform standards, procedures, controls and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or
contingent liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s attention from our core business and disruption of ongoing operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse effects on existing business relationships with suppliers, sales agents, health care facilities, surgeons
and other health care providers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with entering new markets in which we have limited or no experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential losses related to investments in other companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential loss of key employees of acquired businesses; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased legal and accounting compliance costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to identify acquisitions or strategic relationships we deem suitable, whether we will be able to successfully
complete any such transactions on favorable terms, if at all, or whether we will be able to successfully integrate any acquired business, product or technology into our business or retain any key personnel, suppliers, sales agent, health care
facilities, surgeons or other health care providers. Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, technologies or products and to
obtain any necessary financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;54&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pursue any foreign acquisitions, they typically involve unique risks in addition to
those mentioned above, including those related to integration of operations across different cultures, languages and legal and regulatory environments, currency risks and the particular economic, political and regulatory risks associated with
specific countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as
consideration, which could dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration.
Additional funds may not be available on terms that are favorable to us, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results
to fall below expectations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for
us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development and, if approved, commercialization
activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and status of enrollment for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary
depending on the quantity of production and the terms of our agreements with manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies and clinical trials for our product candidates or
competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States
and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our product candidates, if approved, which may vary significantly over time.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and
annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results
as an indication of our future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This variability and unpredictability could also result in our failing to meet the
expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide
to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;55&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously
publicly stated revenue or earnings guidance we may provide. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop and you may not be able
to resell your shares of our common stock at or above the initial offering price, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has
been no public market for our common stock. We cannot predict the extent to which an active market for our common stock will develop or be sustained after this offering, or how the development of such a market might affect the market price for our
common stock. The initial public offering price for our common stock will be determined through negotiations with the underwriters and may not be indicative of the price at which our common stock will trade after the closing of this offering.
Although we have applied to list our common stock on the Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does not develop or is not
sustained, it may be difficult for you to sell shares you purchased in this offering at an attractive price or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of the
shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price may
be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility,
investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse
development with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment or results of any future clinical trials we may conduct, or changes in the
development status of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results from, delays in or termination of our clinical trials or those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower than expected market acceptance of our product candidates following approval for commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by us or by any securities analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the
pharmaceutical industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of
research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;56&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of our company and our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to intellectual property rights, including patents, litigation matters
and our ability to obtain, maintain, defend, protect and enforce patent and other intellectual property rights for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proposed changes to healthcare laws in the United States or foreign jurisdictions, or speculation regarding such
changes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced
significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Further, the stock market in
general has been highly volatile due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and political uncertainty in the United States. Broad market and industry factors may seriously affect the market price of our common stock,
regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. In addition, in the past, stockholders have initiated class action lawsuits against
pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s
attention and resources from our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our operating and financial performance in any given period does not meet any guidance that we
provide to the public, the market price of our common stock may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, but are not obligated to, provide public guidance
on our expected operating and financial results for future periods. Any such guidance will be comprised of forward-looking statements subject to the risks and uncertainties described in this prospectus and in our other public filings and public
statements. Our actual results may not always be in line with or exceed any guidance we have provided, especially in times of economic uncertainty. If, in the future, our operating or financial results for a particular period do not meet any
guidance we provide or the expectations of investment analysts, or if we reduce our guidance for future periods, the market price of our common stock may decline. Even if we do issue public guidance, there can be no assurance that we will continue
to do so in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our common stock in this offering, you will suffer immediate dilution of your investment.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumed initial public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible
book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this
offering. Based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between our pro forma as adjusted net tangible book value per share after this offering and the assumed initial public offering price. In addition, to the extent
outstanding stock options are exercised, there will be further dilution to investors in this offering. In addition, if the underwriters exercise their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;57&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
over-allotment option or if we issued additional equity securities, you will experience additional dilution. See the section titled &#147;Dilution&#148; for a more detailed description of the
dilution to investors in the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are restricted from immediate resale but may be sold
into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to the restrictions and
limitations described below. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market following this offering, the market price of our common stock could
decline significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; outstanding shares of common stock, after giving effect to the conversion of 30,690,573 outstanding shares of redeemable convertible preferred stock,
which includes the conversion of the 7,692,306 shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May 2021, into an equal number of shares of common stock, assuming no exercise of the underwriters&#146;
over-allotment option and no exercise of outstanding options. Of these shares, the shares sold in this offering will be freely tradable and the remaining shares of common stock will be available for sale in the public market beginning after the end
of the 180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus following the expiration <FONT STYLE="white-space:nowrap">of&nbsp;lock-up&nbsp;agreements</FONT> between our stockholders and certain of the
underwriters for this offering, subject, in the case of our affiliates, to the conditions of Rule&nbsp;144 under the Securities Act of 1933, as amended, (Securities Act). SVB Leerink LLC and Evercore Group L.L.C., on behalf of the underwriters, may
release these stockholders from their <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and without notice, which would allow for earlier sales of shares in the public market subject to the conditions of Rule&nbsp;144 under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, promptly following the closing of this offering, we intend to file one or more registration statements <FONT
STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-8&nbsp;registering</FONT> the issuance of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million shares of common stock subject to options or other equity awards
issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-8&nbsp;will</FONT> be available for sale in the public market subject
to vesting arrangements and exercise of options, <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> described above and, in the case of our affiliates, the restrictions of Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, after this offering, the holders of an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock, or their transferees, will have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file
for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market without limitation. If these additional shares are sold, or if it is perceived that they will be sold, in the
public market, the trading price of our common stock could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could
make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or
preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for a classified board of directors whose members serve staggered terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated
preferred stock with terms, rights and preferences determined by our board of directors that may be senior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting
and not by written consent; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;58&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson
of our board of directors or our chief executive officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including
proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit cumulative voting in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may be removed for cause only upon the vote of the holders of at least 66 2/3% of our
outstanding shares of common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office,
even though less than a quorum; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of our board of directors or the holders of at least 66 2/3% of our outstanding shares of
common stock to amend our bylaws and certain provisions of our certificate of incorporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may
frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our
management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law (DGCL), which generally, subject to certain exceptions, prohibits a Delaware corporation
from engaging in any of a broad range of business combinations with any &#147;interested&#148; stockholder for a period of three years following the date on which the stockholder became an &#147;interested&#148; stockholder. Any delay or prevention
of a change of control transaction or changes in our management could cause the market price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims for
indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that we will indemnify our directors and
officers, in each case to the fullest extent permitted by Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as permitted by Section&nbsp;145 of the DGCL, our
amended and restated bylaws to be effective immediately before to the completion of this offering and our indemnification agreements that we have entered into with our directors and officers will provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business
enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not
opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#146;s conduct was unlawful. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is
permitted by applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a
proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to
proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into
indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers,
employees and agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;59&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of ownership of our common stock among our existing executive officers, directors and
principal stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon our common stock
outstanding as of March 31, 2021 and including all of the shares of our redeemable convertible preferred stock outstanding, including all of the Series B redeemable convertible preferred stock issued and sold in May 2021, on an as-converted basis,
and the shares to be sold in this offering, upon the closing of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common stock will, in the aggregate, beneficially own approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock, assuming no purchases of any shares of common stock in this offering. These stockholders, acting together, will be able to significantly influence all matters
requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with the interests of other stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their
shares at prices substantially below the price at which shares are being sold in this offering and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want
us to pursue strategies that deviate from the interests of other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified material weaknesses in our internal control over
financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to
accurately or timely report our financial condition or results of operations, which may adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
the completion of this offering, we have been a private company with limited accounting personnel to adequately execute our accounting processes and other supervisory resources with which to address our internal control over financial reporting. In
connection with the preparation of our consolidated financial statements, we identified material weaknesses in our internal control over financial reporting as of December&nbsp;31, 2020. A material weakness is a deficiency, or combination of
deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis. The
material weaknesses are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design or maintain an effective control environment. Specifically, we lacked a sufficient number of
professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters commensurate with accounting and reporting requirements. The lack of personnel contributed to
additional material weaknesses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate
and timely financial accounting, reporting and disclosures, including segregation of duties and controls over the preparation and review of journal entries, account reconciliations and consolidation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These material weaknesses did not result in a misstatement to the financial statements. However, these material weaknesses could result in a
misstatement of our account balances or disclosures that would result in a material misstatement of our annual or interim financial statements that would not be prevented or detected. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls over information technology (IT) general controls for
information systems that are relevant to the preparation of our financial statements. Specifically, we did not design and maintain (a)&nbsp;program change management controls to ensure that information technology program and data changes affecting
financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, (b)&nbsp;user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged
access to financial applications, programs, and data to appropriate Company personnel, (c)&nbsp;computer operations controls to ensure that critical batch jobs are monitored, and data backups are authorized and monitored, and (d)&nbsp;testing and
approval controls for program development to ensure that new software development is aligned with business and IT requirements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;60&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These IT deficiencies did not result in a misstatement to the financial statements. However,
the IT deficiencies, when aggregated, could impact maintaining effective segregation of duties, as well as the effectiveness of IT-dependent controls (such as automated controls that address the risk of material misstatement to one or more
assertions, along with the IT controls and underlying data that support the effectiveness of system-generated data and reports) that could result in misstatements potentially impacting all financial statement accounts and disclosures that would not
be prevented or detected. Accordingly, management has determined the IT deficiencies in the aggregate constitute a material weakness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
address the material weaknesses, we have begun adding personnel, such as a Chief Financial Officer and Vice President of Accounting, and have implemented new financial processes. We intend to continue to take steps to remediate the material
weaknesses through the hiring of additional experienced accounting and financial reporting personnel, formalizing documentation of policies and procedures and further evolving the accounting processes, including implementing appropriate segregation
of duties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a public company, we will be subject to additional requirements and regulations with respect to our accounting procedures and
internal controls, which will make it more difficult and costly for us to produce timely and accurate financial statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After
the closing of this offering, we will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, (Exchange Act), the Sarbanes-Oxley Act and the rules and regulations of the Nasdaq Stock Market. Section 302 of the
Sarbanes-Oxley Act requires, among other things, that we report on the effectiveness of our disclosure controls and procedures in our quarterly and annual reports and, beginning with our annual report for the year ending 2022, Section 404 of the
Sarbanes-Oxley Act requires that we perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Form
10-K filing for that year. This will require that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. Prior to this offering, we have
never been required to test our internal control within a specified period, and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. In addition, our independent registered public accounting firm
will be required to attest to the effectiveness of our internal control over financial reporting in our first annual report required to be filed with the SEC following the date we are no longer an emerging growth company or a smaller reporting
company with less than $100 million in revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley
Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could
be subject to sanctions or investigations by the Nasdaq Stock Market, the SEC or other regulatory authorities. In addition, our common stock may not be able to remain listed on the Nasdaq Stock Market or any other securities exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that
do not improve our results of operations or enhance the value of our common stock. We intend to use the net proceeds from this offering to fund the development <FONT STYLE="white-space:nowrap">of&nbsp;ETX-810,</FONT>
<FONT STYLE="white-space:nowrap">ETX-155</FONT> and our preclinical pipeline, including new product candidates,&nbsp;and the remainder to fund working capital and other general corporate purposes. The failure by our management to apply these funds
effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a
manner that does not produce income or that loses value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;61&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future,
capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should
not rely on an investment in our common stock to provide dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our
business. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Investors
seeking cash dividends should not purchase our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation will designate the Court of
Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between us and our stockholders, which will restrict our
stockholders&#146; ability to choose the judicial forum for disputes with us or our directors, officers, or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation, as will be in effect upon the completion of this offering, will provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of claims or causes of action under
Delaware statutory or common law: any derivative claims or causes of action brought on our behalf; any claims or causes of action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware
General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, our amended and restated
certificate of incorporation will provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These choice of forum
provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Such provisions are intended to benefit and may be enforced by us, our
officers and directors, employees and agents, including the underwriters and any other professional or entity who has prepared or certified any of this prospectus and may result in increased costs for stockholders to bring a claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws
by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation.
These choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits with respect to
such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. While the Delaware courts have
determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions
will be enforced by a court in those other jurisdictions. If a court were to find either choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur
additional costs associated with resolving such action in other jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our planned operations. Unless and until we can generate
a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the
foregoing. In addition, we may seek additional capital due to favorable market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;62&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, your
ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. In addition, debt financing, if
available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens,
redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate
amount of their attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our management&#146;s ability to oversee the development of our product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations or marketing, distribution, licensing and royalty arrangements with third parties, we
may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay,
limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our
stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and
reports that equity research analysts publish about us and our business. We do not currently have and may never obtain research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common
stock after this offering, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and
opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our
company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur costs and demands upon our management as a result of complying with the laws and regulations affecting public companies in the United
States, which may harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company listed in the United States, we will incur significant additional legal,
accounting and other expenses. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and the Nasdaq Stock Market may increase legal and financial
compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#146;s time and
attention from regular business activities to compliance activities. If, notwithstanding our efforts, we fail to comply with new laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and our business may
be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with these rules might also make it more difficult for us to obtain certain types of insurance, including
director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult
for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;63&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our CROs or other vendors, contractors or consultants,
may fail or experience security breaches or other unauthorized or improper access. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We collect and maintain information in digital
form that is necessary to conduct our business, and we are increasingly dependent on IT systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential
information, including intellectual property, proprietary business information and personal information of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of
such confidential information. We have also outsourced elements of our IT infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Despite the implementation of security measures, our
internal computer systems, and those of our CROs, vendors, contractors, consultants and other third parties on which we rely, are vulnerable to privacy and information security incidents, such as data breaches, damage from computer viruses and
unauthorized access, malware, supply chain attacks, natural disasters, fire, terrorism, war and telecommunication, electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization or
persons with access to systems inside our organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk of a security breach or disruption, particularly through cyber-attacks
or cyber-intrusions, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. As a result
of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional
opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be
unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we do not believe we have experienced any such material system
failure or security breach to our knowledge to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of
clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the
manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also harm our business. These threats pose a risk to the security of our systems and networks, the confidentiality and
the availability and integrity of our data, and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to expend significant resources and make significant capital investment to protect against security breaches or to mitigate the
impact of any such breaches. Further, we cannot provide assurance that we or our third-party providers will be successful in preventing cyber-attacks or mitigating their effects. Unauthorized disclosure of sensitive or confidential data, including
personally identifiable information, whether through a breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by
our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Such unauthorized disclosure could also expose us to sanctions for violations of data privacy laws and regulations around the world. To
the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our
product candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company,&#148; and as a result of
the reduced reporting requirements applicable to &#147;emerging growth companies&#148; and &#147;smaller reporting companies,&#148; our common stock may be less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. For as long as we continue to be an &#147;emerging growth
company,&#148; we may take advantage of exemptions from various reporting requirements that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;64&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
the Sarbanes-Oxley Act, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may take advantage of these exemptions
until we are no longer an &#147;emerging growth company.&#148; We could be an &#147;emerging growth company&#148; for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our
common stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;exceeds</FONT> $700&nbsp;million as of any June&nbsp;30 (the end of our second fiscal quarter) before that time, in which case we would no longer be an &#147;emerging
growth company&#148; as of the following December&nbsp;31 (our&nbsp;fiscal <FONT STYLE="white-space:nowrap">year-end).</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also
a &#147;smaller reporting company,&#148; as defined in the Exchange Act. Even after we no longer qualify as an &#147;emerging growth company,&#148; we may still qualify as a &#147;smaller reporting company,&#148; which would allow us to continue to
take advantage of many of the same exemptions from disclosure requirements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as
a result, there may be a less active trading market for our common stock and the price of our common stock may be more volatile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable
to obtain adequate insurance coverage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We presently have general liability, workers&#146; compensation, directors&#146; and
officers&#146; and product liability insurance coverage. Although we believe we will be able to maintain such coverage for a reasonable cost and obtain any additional coverages that our business may require, no assurances can be made that we will be
able to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws or regulations that are applied adversely to us or our customers may seriously harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax
treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules,
regulations or ordinances could be interpreted, changed, modified or applied adversely to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;65&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_4a"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are
forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; or &#147;would,&#148; or the
negative of these words or other similar terms or expressions. Forward-looking statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost and timing of our product development activities and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize any of our products that are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, if approved for commercial use, and our
ability to serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenues, capital requirements and our needs for or ability
to obtain additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected uses of the net proceeds to us from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection for our products and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to scale up manufacturing of our product candidates to commercial scale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully establish and successfully maintain appropriate collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and develop new products and product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in our clinical trials at the pace that we project; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to retain and recruit key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential effects of the COVID-19 pandemic on our clinical development and business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors or our industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the section of this prospectus titled &#147;Risk Factors&#148; for a discussion of important factors that may cause our
actual results to differ materially from those expressed or implied by our forward-looking statements. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact
of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in
this prospectus primarily on our current expectations and projections about future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;66&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
events and trends that we believe may affect our business, financial condition and operating results. We undertake no obligation to update any forward-looking statements made in this prospectus
to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in
our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or
investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant
subject. These statements are based on information available to us as of the date of this prospectus. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration
statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these
cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;67&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_5"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains estimates and information concerning our industry and our business, including estimated market size, and projected
growth rates of the markets in which we participate. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other information from reports, research surveys, studies and similar data prepared by third parties,
industry, medical and general publications, government data and similar sources. Some data and statistical information are based on independent reports from third parties, including DR/Decision Resources Group. Decision Resources Group makes no
representation or warranty as to the accuracy or completeness of the data (DR Materials) set forth herein and shall have, and accept, no liability of any kind, whether in contract, tort (including negligence) or otherwise, to any third party arising
from or related to use of the DR Materials by us. Any use which we or a third party makes of the DR Materials, or any reliance on it, or decisions to be made based on it, are the sole responsibilities of us and such third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This information involves a number of assumptions and limitations. Although we are responsible for all of the disclosure contained in this
prospectus and we believe the third-party market position, market opportunity and market size data included in this prospectus are reliable, we have not independently verified the accuracy or completeness of this third-party data. In addition,
projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described
in &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in these publications and reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;68&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from this offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in
full), based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting discounts and commissions and
estimated offering expenses payable by us. Similarly, an increase (decrease) of 1,000,000 shares of common stock offered by us would increase (decrease) the net proceeds to us from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, the midpoint of the price range set forth on the cover page
of this prospectus, remains the same, and after deducting underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect to use our net
proceeds from this offering, together with our existing cash, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the development of <FONT
STYLE="white-space:nowrap">ETX-810,</FONT> including through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the development of our <FONT
STYLE="white-space:nowrap">ETX-155,</FONT> including through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the research and development of
our preclinical pipeline, including new product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder to fund working capital and other general corporate activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict with certainty all of the particular uses for the proceeds of this offering or the amounts that we will actually spend on
the uses set forth above. Accordingly, our management will have broad discretion in applying the net proceeds of this offering. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and
the anticipated growth of our business. We may also use a portion of the remaining net proceeds and our existing cash to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses, technologies, products or
assets. However, we have no current commitments or obligations to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our existing cash, together with the net proceeds
from this offering, will be sufficient to fund our operations through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . However, the expected net proceeds from this offering will not be sufficient for us to fund any of our product candidates
through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our product candidates. We expect to finance our cash needs through a combination of equity offerings, debt financings and
potential collaborations, and license and development agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their application, we intend to invest the net proceeds in
short-term, interest-bearing, investment-grade investments, certificates of deposit or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;69&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if
any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends will be at the discretion of our
board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In
addition, we may enter into agreements in the future that contain restrictions on payments of cash dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;70&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and our capitalization as of March&nbsp;31, 2021, on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma basis to give effect to (i) the issuance and sale of 7,692,306 shares of Series&nbsp;B redeemable
convertible preferred stock and the receipt of $60.0 million of gross proceeds in May 2021; (ii)&nbsp;the conversion of all outstanding shares of redeemable convertible preferred stock, of which 22,998,267&nbsp;shares were outstanding as of
March&nbsp;31, 2021, and the conversion of all of our Series B redeemable convertible preferred stock issued and sold in May 2021, into an equal number of shares of common stock upon the closing of this offering and (iii)&nbsp;the filing and
effectiveness of our amended and restated certificate of incorporation, which will be in effect immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma as adjusted basis to give further effect to the issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this information in conjunction with our consolidated financial statements and the related notes included elsewhere in this
prospectus, the information set forth in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other financial information contained elsewhere in this prospectus. The pro forma information below
is illustrative only and our capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.0001 par value &#150; 25,818,779&nbsp;shares
authorized, 22,998,267 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value &#150; no shares authorized, issued, or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value &#150;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro
forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;per
share of common stock, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders (deficit) equity
and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. Similarly, an increase </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;71&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(decrease) of 1,000,000 shares of common stock offered by us would increase (decrease) each of cash, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146;
(deficit) equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts
and commissions. The pro forma as adjusted information is illustrative only, and will depend on the actual initial public offering price, number of shares offered and other terms of this offering determined at pricing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding share information in the table above is based on 37,916,480 shares of common stock (including shares of preferred stock on an
as-converted basis, which includes the conversion of the 7,692,306 shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May 2021) outstanding as of March&nbsp;31, 2021, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,860,961 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31,
2021 with a weighted-average exercise price of $0.48 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,284,148 additional shares of common stock reserved for future issuance under our 2019 Equity Incentive Plan as
of March&nbsp;31, 2021, which shares will cease to be available for issuance at the time our 2021 Equity Incentive Plan becomes effective upon the execution of the underwriting agreement for this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our 2021 Equity Incentive Plan, which will become effective upon the execution of the underwriting agreement for this offering, as well as any automatic increases in the number of shares of common stock reserved for future
issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our 2021 Employee Stock Purchase Plan, which will become effective upon the execution of the underwriting agreement for this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under this plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;72&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, our historical net tangible book value (deficit) was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. Historical net tangible book value per share represents our total tangible assets (total assets less deferred offering costs) less total liabilities, divided by the number
of our shares of common stock outstanding as of March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, our pro forma net tangible book value was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. Pro forma net tangible book value per share represents our total tangible assets less our total liabilities,
divided by the number of shares of common stock outstanding as of March&nbsp;31, 2021, after giving effect to (i) the issuance, sale and conversion into an equal number of shares of common stock of 7,692,306 shares of Series B redeemable convertible
preferred stock and the receipt of $60.0 million of gross proceeds in May 2021 and (ii) the conversion of all 22,998,267 outstanding shares of redeemable convertible preferred stock as of March 31, 2021 into an equal number of shares of common stock
upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to the receipt of the net proceeds from our sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the
cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2021, was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. This represents an immediate increase in pro forma net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors purchasing common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis to investors in this offering: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma decrease in historical net tangible book value per share attributable to the pro forma
transactions described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributed to investors purchasing shares
in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in pro forma net tangible book value per share to investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net
tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and dilution to investors in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting underwriting discounts and commissions. An increase of 1,000,000 shares in the number of shares of common stock offered by us would increase the pro forma as adjusted net tangible book value by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution to investors in this offering would decrease by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the assumed initial public offering price remains the same and after deducting underwriting discounts and commissions. A decrease of
1,000,000 shares in the number of shares of common stock offered by us would decrease the pro forma as adjusted net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and
the dilution to investors in this offering would increase by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the assumed initial public offering price remains the same and after
deducting underwriting discounts and commissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;73&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares in full, the pro
forma as adjusted net tangible book value after the offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the increase in pro forma net tangible book value per share to existing
stockholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution per share to investors in this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, in each case assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information above is for illustration purposes only. Our pro forma as adjusted net tangible book value following the closing of
this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes, as of March&nbsp;31, 2021, on a pro forma basis: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the total number of shares of common stock purchased from us by our existing stockholders and by investors
purchasing shares in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the total consideration paid to us by our existing stockholders and by investors purchasing shares in this
offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, before
deducting underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average price per share paid by existing stockholders and by investors purchasing shares in this offering.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total&nbsp;Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price<BR>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the above discussion and tables assume no exercise of the underwriters&#146;
option to purchase additional shares. If the underwriters exercise their option to purchase an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in full, our existing stockholders would
own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% and investors in this offering would own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock outstanding upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, respectively, the total consideration paid by investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
increase or decrease, respectively, the total consideration paid by investors in this offering by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and before deducting underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding share information in the table above is
based on 37,916,480 shares of common stock (including shares of preferred stock on an as-converted basis, which includes the conversion of the 7,692,306 shares of Series B redeemable convertible preferred stock we issued and sold in May 2021),
outstanding as of March&nbsp;31, 2021, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,860,961 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31,
2021, with a weighted-average exercise price of $0.48 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,284,148 additional shares of common stock reserved for future issuance under our 2019 Equity Incentive Plan as
of March&nbsp;31, 2021, which shares will cease to be available for issuance at the time our 2021 Equity Incentive Plan becomes effective upon the execution of the underwriting agreement for this offering; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;74&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our 2021 Equity Incentive Plan, which will become effective upon the execution of the underwriting agreement for this offering, as well as any automatic increases in the number of shares of common stock reserved for future
issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our 2021 Employee Stock Purchase Plan, which will become effective upon the execution of the underwriting agreement for this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under this plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any outstanding options are exercised, there will be further dilution to
investors purchasing in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;75&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations together with our audited consolidated financial statements and the related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis are set forth elsewhere in this prospectus,
including information with respect to our plans and strategy for our business and related financing, and includes forward-looking&nbsp;statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in
the section of this prospectus titled &#147;Risk Factors,&#148; our actual discussion and analysis could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These
disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of
action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our two lead
clinical-stage candidates are <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155.</FONT> <FONT STYLE="white-space:nowrap">ETX-810</FONT> is a novel palmitoylethanolamide (PEA) prodrug initially being
developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (lumbosacral radicular pain (LSRP) commonly referred to as sciatica). <FONT STYLE="white-space:nowrap">ETX-810</FONT> is
being evaluated in two Phase 2a clinical trials that are expected to report topline data in the first half of 2022. <FONT STYLE="white-space:nowrap">ETX-155</FONT> is a neurosteroid GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>
receptor positive allosteric modulator (PAM) initially being developed for the treatment of major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS), the most common type of seizure in people with epilepsy. We
plan to initiate two Phase 2a clinical trials for <FONT STYLE="white-space:nowrap">ETX-155</FONT> in patients with MDD and PMD which are expected to report topline data in the first half of 2023 and a Phase 1b clinical trial in patients with
photosensitive epilepsy that is expected to report topline data by the first half of 2022. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of our wholly owned
pipeline: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g01b28.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;76&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in October 2018. In February 2019, we acquired 100% of the share
capital of NeoKera, LLC (the NeoKera Acquisition), and we separately acquired in-process research and development (IPR&amp;D) related to the <FONT STYLE="white-space:nowrap">ETX-810</FONT> program. In October 2020, we acquired 100% of the share
capital of Athenen Therapeutics Inc. (the Athenen Acquisition), which included IPR&amp;D related to the <FONT STYLE="white-space:nowrap">ETX-155</FONT> program. We have incurred significant operating losses since inception, as we have devoted
substantially all of our resources to organizing and staffing our company, identifying potential product candidates, business planning, raising capital, undertaking research, executing preclinical studies and clinical development trials, and
providing general and administrative support for business activities. We incurred net losses of $6.5&nbsp;million and $20.7&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively, and $1.9 million and $18.6 million for the
three-months ending March 31, 2020 and 2021, respectively. We had an accumulated deficit of $28.1 million and $46.7 million as of December&nbsp;31, 2020 and March 31, 2021, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have funded our operations with an aggregate of $125.2&nbsp;million in net proceeds from the sale and issuance of
shares of our redeemable convertible preferred stock. We had cash of $20.5&nbsp;million and $47.9 million as of December 31, 2020 and March 31, 2021, respectively. Based on our current operating plan, we estimate that our cash, together with the
anticipated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have based this estimate on
assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that
our expenses and operating losses will increase substantially over the foreseeable future. The expected increase in expenses will be largely driven by our ongoing activities as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to develop and conduct clinical trials, including for ETX-810 and ETX-155 for our initial and any
potential additional indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and continue research and development, including preclinical, clinical and discovery efforts for any
future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for ETX-810 and ETX-155, or any other product candidates that successfully complete
clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
product candidate development and help us comply with our obligations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire and retain additional personnel, such as clinical, manufacturing, quality control, scientific, commercial
and administrative personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the
future to commercialize various products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add equipment and physical infrastructure to support our research and development and growing staff;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or in-license other product candidates and technologies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur increased costs as a result of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any products approved for sale and have not generated any revenue from product sales since our inception. Our ability to
generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates, if approved. We cannot assure you that we will ever be profitable or generate positive
cash flow from operating activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;77&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require substantial additional funding to support our continuing operations and
further the development of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which
could include income from collaborations, strategic partnerships or other strategic arrangements. Adequate funding may not be available when needed or on terms acceptable to us, or at all. If we are unable to raise additional capital as needed, we
may have to significantly delay, scale back or discontinue development of our product candidates. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and
volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and otherwise. If we fail to obtain necessary capital when needed on acceptable
terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an
earlier stage of development or on less favorable terms than we would otherwise choose. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, we acquired 100% of the share capital of NeoKera, LLC in exchange for 166,667 shares of common stock, valued at
$0.1&nbsp;million or $0.75 per share. The IPR&amp;D acquired in this transaction was intended to continue development of the compound acquired; however, in June 2020, we decided to discontinue the further development and dissolve NeoKera, LLC. The
NeoKera acquisition was accounted for as an asset acquisition. Since the acquired IPR&amp;D did not have an alternative future use, we recognized a charge of $0.1&nbsp;million related to the NeoKera Acquisition which is included as a component of
in-process research and development in our consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the NeoKera
Acquisition, we separately acquired IPR&amp;D from Carnot, LLC related to <FONT STYLE="white-space:nowrap">ETX-810</FONT> for 3.5&nbsp;million shares of common stock, valued at $2.6&nbsp;million, or $0.75 per share. We intend to continue the
clinical trials of the compound acquired. We accounted for the acquisition as an asset acquisition. Since the acquired IPR&amp;D did not have an alternative future use, we recognized a charge of $2.6&nbsp;million related to the acquisition which is
included as a component of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development on the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, we acquired 100% of the share capital of Athenen Therapeutics Inc., a company developing
<FONT STYLE="white-space:nowrap">ETX-155,</FONT> in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> exchange of their outstanding preferred and common stock. As a result, we issued a total of
5.0&nbsp;million shares of Series A redeemable convertible preferred stock and 3.1&nbsp;million shares of common stock, valued at $2.90 per share and $0.66 per share, respectively, for total purchase consideration of $16.5&nbsp;million. The
IPR&amp;D acquired in this acquisition will enable us to continue to develop <FONT STYLE="white-space:nowrap">ETX-155.</FONT> The Athenen Acquisition is accounted for as an asset acquisition. Since the acquired IPR&amp;D did not have an alternative
future use, we recognized a charge of $9.2&nbsp;million which is included as a component of in-process research and development on the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;Pandemic</FONT> on Our Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization characterized the outbreak <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;as</FONT> a
global pandemic and recommended containment and mitigation measures. Since then, extraordinary actions have been taken by international, federal, state, and local public health and governmental authorities to contain and combat the outbreak and
spread <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;in</FONT> regions throughout the world, including the United Kingdom (U.K.) and Washington, where most of our operations are conducted. These actions substantially restricted daily
activities for individuals and caused many businesses to curtail or cease normal operations. We have been carefully monitoring <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> as it continues to progress and its potential
impact on our business. As a result <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19,&nbsp;we</FONT> have taken precautionary measures in order to minimize the risk of the virus to our employees, including the suspension of <FONT
STYLE="white-space:nowrap">all&nbsp;non-essential&nbsp;business</FONT> travel. In addition, the majority of our workforce now works remotely. To date, we have been able to continue our key business activities and advance our clinical programs.
However, in the future, it is possible that it will become more difficult to enroll </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;78&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participants in our clinical trials, which could delay our clinical development timelines. While the broader implications of
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> on our results of operations and overall financial performance remain uncertain, <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> has, to date, not had a
material adverse impact on our results of operations or our ability to raise funds to sustain operations. The economic effects of the pandemic and resulting societal changes are currently not predictable, and the future financial impacts could vary
from those foreseen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating
expenses consist of (i)&nbsp;research and development expenses, including expenses incurred with related parties, <FONT STYLE="white-space:nowrap">(ii)&nbsp;in-process</FONT> research and development, and (iii)&nbsp;general and administrative
expenses </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses consist primarily of direct and indirect costs incurred in connection with our discovery efforts,
preclinical studies, and clinical trial activities related to our pipeline, including our lead product candidates, <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our direct research and development costs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred in connection with research, laboratory consumables and preclinical and clinical trial
activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to manufacture drug products for use in our preclinical and trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consulting fees, including services provided by a related party. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our indirect research and development costs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel-related expenses, such as salaries, bonuses, benefits, and stock-based compensation expense, for our
scientific personnel performing research and development activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facility rent. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total direct costs and indirect costs are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indirect costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. <FONT STYLE="white-space:nowrap">Non-refundable</FONT>
advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. Costs to acquire technologies used in research and
development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We categorize costs by stage of development clinical or preclinical. Given our stage of development
and the utilization of our resources across our various programs, we have not historically tracked our research and development costs by program. Research and development expenses are presented net of reimbursement received related to a federal
grant and refundable research and development tax credits from the U.K. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;79&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs by stage of development are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months<BR>Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We expect our research and development
expenses to increase substantially for the foreseeable future as we continue to ramp up our clinical development activities and incur expenses associated with hiring additional personnel to support our research and development efforts. Our research
and development expenses may vary significantly based on factors such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of clinical studies needed for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and investigational new drug (IND)-enabling studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phases of development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and results of our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible subjects and initiate clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects that participate in the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of subject participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the hiring and retention of research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree to which we obtain, maintain, defend and enforce our intellectual property rights; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish collaborations, strategic partnerships or other strategic arrangements and the
performance of any related third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the
development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses, related party included expense reimbursements paid to Carnot Pharma, LLC, a related party, of
$1.5&nbsp;million and $0.6&nbsp;million in 2019 and 2020, respectively and $0.2 million and $0.4 million for the three months ended March 31, 2020 and 2021, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">In-process</FONT> Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our IPR&amp;D expense consists of the relative fair value of the assets acquired and consideration given in connection with our asset
acquisitions. As the assets acquired were in the research and development phase and were determined to not have any alternative future use, it was expensed as in-process research and development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;80&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our general and administrative expenses consist primarily of personnel-related expenses, such as salaries, bonuses, benefits, and stock-based
compensation, for our personnel in executive, finance and accounting, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual
property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, and travel expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
expect that our general and administrative expenses will substantially increase for the foreseeable future as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any
product candidates receive marketing approval, commercialization activities, as well as to support our operations generally. We also expect to incur increased expenses associated with operating as a public company, including costs related to
accounting, audit, legal, regulatory,&nbsp;and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange listing and Securities and Exchange Commission (SEC) requirements, director and officer
insurance costs, and investor and public relations costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Redeemable Convertible Preferred Tranche Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our redeemable convertible preferred stock tranche lability is accounted for at fair value at inception, with changes in the fair value
recorded in earnings at each reporting period through settlement. Refer to Note 6 of the consolidated financial statements and Note 4 of the interim condensed consolidated financial statements for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency Gain (Loss) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our foreign
currency gain (loss) primarily consists of foreign exchanges gains and losses resulting from remeasurement and foreign currency transactions between the British Pound and the U.S.&nbsp;Dollar. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth our results of operations (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign current gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;81&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Three Months Ended March&nbsp;31, 2020 and March&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth our operating expenses (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(dollars in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">576.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development and Research and Development, related party </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased 207.6% from $1.4&nbsp;million for the three months ended March&nbsp;31, 2020 to $4.3&nbsp;million
for the three months ended March&nbsp;31, 2021. Research and development expenses, related party increased 65.8% to $0.4&nbsp;million for the three months ended March&nbsp;31, 2021. In total, research and development expenses increased 187.2% from
$1.6&nbsp;million for the three months ended March&nbsp;31, 2020 to $4.7&nbsp;million the three months ended March&nbsp;31, 2021. This increase was primarily driven by a $2.4&nbsp;million increase in expenses associated with the Phase 1 and Phase 2
clinical trials of <FONT STYLE="white-space:nowrap">ETX-155</FONT> and <FONT STYLE="white-space:nowrap">ETX-810,</FONT> a $0.9&nbsp;million increase in expenses associated with our preclinical pipeline and a $0.5&nbsp;million increase in personnel
related expenses from increased headcount and stock-based compensation. The increase was partially offset by a $0.8&nbsp;million increase in the refundable research and development tax credits from the United Kingdom driven by increased research and
development activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased 576.2% from $0.3&nbsp;million for the three months ended March&nbsp;31, 2020 to $2.2&nbsp;million
for the three months ended March&nbsp;31, 2021. The increase in general and administrative expenses is primarily due to an increase of $0.9&nbsp;million in consulting and legal expenses and a $0.9&nbsp;million increase in personnel related expenses
from increased headcount and stock-based compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our other income (expense) (dollars in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(dollars in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(</TD>
<TD NOWRAP VALIGN="bottom">*)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not meaningful </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of redeemable convertible preferred stock tranche liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31, 2021, we recognized an $11.7&nbsp;million charge from the settlement of our Series&nbsp;A-1 preferred
stock tranche liability and in connection with significant valuation changes in our Series&nbsp;A-1 redeemable convertible preferred stock. The valuation changes were driven primarily by the Phase&nbsp;1 results of ETX-155, as well as an increased
likelihood of future financing events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency Gain (Loss) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign currency gain (loss) decreased from a $35,000 gain for the three months ended March&nbsp;31, 2020 to a $4,000 loss for the three months
ended March&nbsp;31, 2021. The loss was due to unfavorable foreign currency exchange rates between the British Pound and the U.S. Dollar. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;82&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Years Ended December&nbsp;31, 2019 and December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth our operating expenses (dollars in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;6,252</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development and Research and Development, related party </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased 248.4% from $2.5&nbsp;million in 2019 to $8.8&nbsp;million in 2020. Research and development
expenses, related party decreased 61.9% to $0.6&nbsp;million. In total, research and development expenses increased 132.4% from $4.0&nbsp;million in 2019 to $9.3&nbsp;million in 2020. This increase was primarily driven by a $5.8&nbsp;million
increase in expenses associated with Phase 1 and Phase 2 clinical trials of <FONT STYLE="white-space:nowrap">ETX-155</FONT> and <FONT STYLE="white-space:nowrap">ETX-810</FONT> and a $1.4&nbsp;million increase in expenses associated with our
preclinical pipeline. The increase was partially offset by a $2.3&nbsp;million increase in the refundable research and development tax credits from the U.K. driven by increased research and development activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">In-process</FONT> Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In-process research and development expenses increased 233.0% from $2.7&nbsp;million in 2019 to $9.2&nbsp;million in 2020. The increase was
driven by the recognition of IPR&amp;D expense of $9.2&nbsp;million from the Athenen Acquisition completed in October 2020, compared to the $2.7&nbsp;million related to the 2019 asset acquisitions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and
administrative expenses increased 258.2% from $0.7&nbsp;million in 2019 to $2.4&nbsp;million in 2020. The increase in general and administrative expenses is primarily due to a $1.3&nbsp;million increase in personnel-related expenses from increased
headcount and stock-based compensation as well as an increase of $0.5&nbsp;million in consulting and legal expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our other income (expense) (dollars in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,813.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Redeemable Convertible Preferred Tranche Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, we recognized a $0.9&nbsp;million gain, due to a change in the fair value of the redeemable convertible preferred tranche liability
associated with our Series A redeemable convertible share issuances. The fair value of the 2019 redeemable convertible preferred stock tranche liability decreased immediately prior to settlement in October 2019 as a result of a shorter than expected
term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;83&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in October 2020, we issued Series <FONT STYLE="white-space:nowrap">A-1</FONT>
redeemable convertible preferred stock, which included an option to purchase additional shares in a future tranche. As of December&nbsp;31, 2020, the fair value was comparable to the issuance price in October 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency Gain (Loss) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign
currency gain (loss) increased from a $15,000 loss in 2019 to a $257,000 gain in 2020. The gain was due to favorable foreign currency exchange rates between the British Pound and the U.S.&nbsp;Dollar. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We primarily generate cash from the sale of our equity securities, including from the redeemable convertible preferred
stock, and to a lesser extent from cash received pursuant to refundable research and development tax credits. From our inception to March&nbsp;31, 2021, we raised aggregate proceeds of $65.2 million from the issuance of shares of our redeemable
convertible preferred stock. On May 21, 2021, we received $60.0 million in gross proceeds from the issuance of our Series B redeemable convertible preferred stock. We have not generated any revenue from product sales or otherwise. We have incurred
net losses from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December&nbsp;31, 2020, and March 31, 2021, we had cash of $20.5&nbsp;million and $47.9 million, respectively, and
an accumulated deficit of $28.1 and $46.7 million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced recurring net losses since inception. Our transition to profitability is dependent upon the successful development,
approval and commercialization of our product candidates and achieving a level of revenue adequate to support our cost structure. We do not expect to achieve such revenue and expect to continue to incur losses for the foreseeable future. Our
independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of, and for the year ended, December 31, 2020, describing the existence of substantial doubt about our ability to continue
as a going concern as of May 12, 2021, the date of their report. On May 21, 2021, we received $60 million in gross proceeds from the issuance of Series B redeemable convertible preferred stock. We believe our cash balance of $47.9 million as of
March 31, 2021, combined with the $60.0 million raised in May 2021 will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months. As a result of these conditions and events, we have concluded the
substantial doubt of our ability to continue as a going concern no longer exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our research and development and general
and administrative expenses will continue to increase for the foreseeable future. As a result, we will need significant additional capital to fund our operations, which we may obtain through one or more equity offerings, debt financings or other
third-party funding, including potential strategic alliances and licensing or collaboration arrangements. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable
to estimate the amount of increased capital we will need to raise to support our operations and the outlays and operating expenditures necessary to complete the development of our product candidates and build additional manufacturing capacity, and
we may use our available capital resources sooner than we currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our current and future product candidates through preclinical and clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential delays in our preclinical studies and clinical trials, whether current or planned, due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or other factors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing our research and discovery activities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;84&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiating and conducting additional preclinical, clinical or other studies for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changing or adding additional contract manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking regulatory approvals and marketing authorizations for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution infrastructure to commercialize any products for which we obtain
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates, intellectual property and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making milestone, royalty or other payments due under any current or future collaboration or license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, expanding, protecting and enforcing our intellectual property portfolio;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring and retaining qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential delays or other issues related to our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting the requirements and demands of being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defending against any product liability claims or other lawsuits related to our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may exacerbate the magnitude
of the factors discussed above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our existing cash, together with the anticipated net proceeds from this
offering, will enable us to fund our operating expenses and capital expenditure requirements into&nbsp;&nbsp;&nbsp;&nbsp; . We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to
be wrong, and we could use our available capital resources sooner than we currently expect, in which case, we would be required to obtain additional financing sooner than currently projected, which may not be available to us on acceptable terms, or
at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need substantial additional funding to support our continuing operations and pursue our development strategy. Until such time as we
can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or
other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or
discontinue the development and commercialization of our product candidates or delay our efforts to expand our product pipeline. We may also be required to sell or license to other parties&#146; rights to develop or commercialize our product
candidates that we would prefer to retain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarized our cash flows (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2021, net cash used in operating activities was $6.7 million. This consisted primarily of net loss of
$18.6 million and an increase in our operating assets and liabilities of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;85&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$0.1&nbsp;million, mostly related to research and development activities, which was partially offset by the non-cash charges for changes in the fair value of the redeemable convertible preferred
stock tranche liability of $11.7&nbsp;million and stock-based compensation of $0.3 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2020,
net cash used in operating activities was $2.3 million. This consisted primarily of a net loss of $1.9 million and an increase in our operating assets and liabilities of $0.5&nbsp;million, which was partially offset by the non-cash charge for
stock-based compensation of $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, net cash used in operating activities was $14.1&nbsp;million. This consisted primarily
of net loss of $20.7&nbsp;million and an increase in our operating assets and liabilities of $2.9&nbsp;million, mostly related to research and development activities, which was partially offset by the <FONT STYLE="white-space:nowrap">non-cash</FONT>
charges for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses of $9.2&nbsp;million and stock-based compensation of $0.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, net cash used in operating activities was $5.0&nbsp;million. This consisted primarily of a net loss of $6.5&nbsp;million and an
increase in our operating assets and liabilities of $0.3&nbsp;million, which was partially offset by the <FONT STYLE="white-space:nowrap">non-cash</FONT> charge for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses
of $2.7&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, net cash provided by investing activities was $8.1&nbsp;million, which was attributable to the $8.3&nbsp;million in cash acquired from
the Athenen Acquisition which was partially offset by the legal fees of $0.2&nbsp;million paid for such acquisition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2021, net cash provided by financing activities was $34.1 million, attributable to the proceeds from the
issuance of our Series A-1 redeemable convertible preferred stock, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, net cash provided by financing
activities was $4.9&nbsp;million, attributable to the proceeds from the issuance of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, net of issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, net cash provided by financing activities was $26.2&nbsp;million. This was attributable to the net proceeds of $16.3&nbsp;million and
$9.9&nbsp;million from the issuance of our Series&nbsp;A and <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> redeemable convertible preferred stock, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Commitments and Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, we enter into contracts with contract research organizations (CROs), contract development and manufacturing
organizations (CDMOs), and other third parties for preclinical studies and clinical trials, research and development supplies, and other testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and
generally provide us the option to cancel, reschedule and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. However, it is not possible to predict the maximum potential amount of future
payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease various operating spaces in the United Kingdom under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease
arrangements that expire on various dates through December&nbsp;31, 2021. As of December&nbsp;31, 2020, and March 31, 2021, our future minimum lease payments under noncancelable lease agreements were $47,000 and $37,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;86&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as of December&nbsp;31, 2020 and March 31, 2021.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we
believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in the notes to our
consolidated financial statements included elsewhere in this prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisitions of Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
evaluate acquisitions of assets and related liabilities and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if
substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the
screen test is not met, further determination is required as to whether we have acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for an asset acquisition by recognizing net assets based on the cost to the acquiring entity on a relative fair value basis, which
includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition; any excess consideration transferred over the fair value of the net assets acquired is allocated to
<FONT STYLE="white-space:nowrap">the&nbsp;non-monetary&nbsp;identifiable</FONT> assets and liabilities assumed based on relative fair values. <FONT STYLE="white-space:nowrap">In-process&nbsp;research</FONT> and development is expensed as incurred
provided there is no alternative future use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recording our research and development expenses involves estimating the level of service performed and the associated cost incurred for the
service when we have not yet been invoiced or otherwise notified of actual costs. We estimate accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. At each
end period, we confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vendors in connection with preclinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CROs in connection with preclinical studies and clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CDMOs in connection with the production of preclinical and clinical trial materials. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All research and development costs are expensed in the period incurred, based on our estimates of the services received and efforts expended
considering a number of factors, including our knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the CROs, CDMOs and other companies of
any actual costs incurred during the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;87&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period that have not yet been invoiced and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation and vary from contract to
contract, and may result in uneven payment flows. There may be instances in which advance payments are made or payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of
these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. We estimate the period over which such services will be performed and the level of effort to be expended in each period.
If actual timing of performance or the level of effort varies from the estimate, we will adjust the amounts recorded accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of
the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. We have not experienced any material
differences between accrued or prepaid costs and actual costs since our inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure stock-based awards granted to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, consultants and independent
advisors based on the estimated grant date fair value of the awards. For awards with only service conditions, including stock options and restricted stock awards, compensation expense is recognized over the requisite service period using the
straight-line method. For awards that include performance conditions, compensation expense is not recognized until the performance condition is probable to occur. We use the Black-Scholes option pricing model to estimate the fair value of its stock
option awards. The Black-Scholes option pricing model requires us to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of our common stock,
risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimating the fair value of equity-settled awards as of the grant date using the Black-Scholes option pricing model is affected by
assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation is recognized. These inputs are subjective and generally require significant
analysis and judgement to develop. These in are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Common Stock</I>&#151;See subsection titled &#147;Fair Value of Common Stock&#148; below.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Volatility</I>&#151;The expected stock price volatilities are estimated based on the historical and implied
volatilities of comparable publicly traded companies as we do not have sufficient history of trading our common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-free</I><I></I><I>&nbsp;Interest Rate</I><I></I><I>&#151;</I>The risk-free&nbsp;interest rates are based
on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I><I></I><I>&#151;</I>The expected term represents the period that our options are expected to
be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). We have very limited historical information to develop
reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend Yield</I><I></I>&#151;We have never paid dividends on our common stock and have no plans to pay
dividends on our common stock. Therefore, we used an expected dividend of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 8 to our consolidated
financial statements included elsewhere in this prospectus for further details. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to use judgment in evaluating the
expected volatility, expected terms, and interest rates utilized for our stock-based compensation calculations on a prospective basis. Assumptions we used in applying the Black- Scholes option-pricing model to determine the estimated fair value of
our stock options granted involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;88&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outcomes change and we use significantly different assumptions or estimates, our stock-based compensation recognized in future periods could be materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intrinsic value of all outstanding options as of March&nbsp;31, 2021 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, of which approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million related to
unvested options as of such date, based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on
the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur stock-based compensation of approximately $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million over the next
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;years as a result of all compensatory equity issuances made in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur stock-based compensation of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for 2022 as a result of all
compensatory equity issuances outstanding as of March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board
of directors as of the date of each option grant with input from management, considering our most recently available third-party valuation of common stock, and our board of directors&#146; assessment of additional objective and subjective factors
that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. We believe that the board of directors has the relevant experience and expertise to determine fair value of our
common stock. Third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities
Issued as Compensation</I>. Management has considered numerous factors in determining the best estimate of fair value of our common stock, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">valuations performed by independent third-party specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our operating results, financial position, and capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and material risks related to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business conditions and projects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of our common stock and our redeemable convertible preferred stock as a private
company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold shares of our redeemable convertible preferred stock to outside investors in
arms-length transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights, preferences, and privileges of our redeemable convertible preferred stock relative to those of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for our securityholders, such as an initial public offering or a
sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the hiring of key personnel and the experience of management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trends and developments in our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our valuations performed in 2019 and 2020, in accordance with the Practice Aid, we determined the option pricing method (OPM) was the most
appropriate method for determining the fair value of our common stock based on our stage of development and other relevant factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;89&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The OPM uses option theory to value the various classes of a company&#146;s securities in
light of their respective claims to the enterprise value. Total stockholders&#146; deficit value is allocated to the various share classes based upon their respective claims on a series of call options with strike prices at various value levels
depending upon the rights and preferences of each class. A Black-Scholes closed form option pricing model is employed in this analysis, with an option term assumption that is consistent with the expected time to a liquidity event and a volatility
assumption based on the estimated stock price volatility of a peer group of comparable public companies over a similar term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first
quarter of 2021, in accordance with the Practice Aid, we determined the Probability-Weighted Expected Return Method (PWERM) was the most appropriate method for determining the fair value of our common stock based on our stage of development and
other relevant factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PWERM values each class of equity based on an analysis of the range of potential future enterprise values of
the company and the manner in which those values would accrue to the owners of the different classes of equity. This method involves estimating the overall value of the subject company under various liquidity event scenarios and allocating the value
to the various share classes based on their respective claim on the proceeds as of the date of each event. These different scenarios typically include an initial public offering, an acquisition, or a liquidation of the business, each resulting in a
different value. For each scenario, the future value of each share class is calculated and discounted to a present value. The results of each scenario are then probability weighted in order to arrive at an estimate of fair value for each share class
as of a current date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#146;s best estimates, which involved inherent
uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially
different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of this offering, our board of directors will determine the fair market value of our common stock based
on its closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible
Preferred Stock Tranche Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible
preferred stock includes an obligation whereby the investors agree to buy, and the Company agrees to sell, additional shares at a fixed price if certain agreed upon milestones are achieved or at the election of investors. The first tranche was for
the purchase of additional shares of&nbsp;Series&nbsp;A and was based upon the passage of time. The second tranche was for the purchase of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;and</FONT> was based upon the Company achieving certain
future milestones. This obligation was determined to be a freestanding financial instrument that should be accounted for as a liability at fair value, and the redeemable convertible preferred stock tranche liability is revalued at each reporting
period through settlement with changes in the fair value recorded in other income (expense) in the consolidated statement of operations. The fair value at settlement is reclassified to redeemable convertible preferred stock at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilized the Black-Scholes option pricing model, which incorporated assumptions and estimates, to estimate the fair value of the
Series&nbsp;A redeemable convertible preferred stock tranche liability. We estimated the fair value of the Series&nbsp;A-1 redeemable convertible preferred stock tranche liability using a probability-weighted present value model that considered the
probability of triggering the Series&nbsp;A-1 Tranche Rights through achievement of the clinical development milestones specified in the Series&nbsp;A-1 Purchase Agreement. Significant estimates and assumptions impacting the fair value measurement
include the estimated fair value per share of the underlying Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, risk-free rate, expected dividend yield, time to liquidity, expected volatility of
the price of the underlying redeemable convertible preferred stock and determining the type of option (call option and/or forward contract) and associated probabilities. The most significant assumptions impacting the fair value of the redeemable
convertible preferred stock tranche feature </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;90&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include the estimated fair value of our Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock as of each respective valuation date, estimated time
to achieve the tranche milestone, and the determination of the type of option (call option and/or forward contract) and associated probability of success of completing the milestone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determine the estimated fair value per share of the underlying redeemable convertible preferred stock by taking into consideration the most
recent sales of our redeemable convertible preferred stock as well as additional factors that we deemed relevant. We assess these assumptions and estimates on a quarterly basis as additional information impacting the assumptions becomes available.
The risk-free rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the expected term of the preferred stock tranche feature. We estimated a 0% dividend yield based on the expected dividend yield
and the fact that we have never paid or declared dividends. We estimated the time to liquidity by weighting potential timelines associated with reaching various pipeline milestones. We historically have been a private company and lack
company-specific historical and implied volatility information of our stock. Therefore, we estimate our expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry for the
expected terms. The determination of the type of option is based on the payouts available to the holders of the tranche rights and the level of control the investors had over exercising these rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes
change and we use significantly different assumptions or estimates, our redeemable convertible preferred stock tranche liability could be materially different. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See
Note 2 to our consolidated financial statements included elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Controls over Financial Reporting
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our financial statements as of and for the years ended December 31, 2019 and 2020, we identified
material weaknesses in our internal control over financial reporting. See the section titled &#147;Risk Factors&#151;Risks Related to this Offering and Our Common Stock&#151;We have identified material weaknesses in our internal control over
financial reporting. If we are unable to remediate the material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or
timely report our financial condition or results of operations, which may adversely affect our business.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative
Disclosures About Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Exchange Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our employees and operations are located in the U.K., and a portion of our expenses and payment obligations are denominated in and have
been satisfied with the British Pound. There was no material foreign currency risk for the periods ended March 31, 2020 and 2021, and the years ended December&nbsp;31, 2019 or 2020. However, we have and will continue to enter into contracts with
vendors outside of the U.S. for research and development services. In the future, some of these contracts may continue to be denominated in foreign currencies and to the extent they are, we will be subject to foreign currency transaction gains or
losses. We incurred immaterial foreign currency transaction gains and losses for the periods ended March 31, 2020 and 2021. We incurred $0.3&nbsp;million in foreign currency transaction gains and losses for the year ended December&nbsp;31, 2020. We
have not had a formal hedging program with respect to foreign currency. We believe a hypothetical 100 basis point increase or decrease in exchange rates during any of the periods presented would have a material effect on our consolidated financial
statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;91&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act). Under the JOBS Act, emerging growth
companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act
for emerging growth companies include presentation of only two years audited consolidated financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor&#146;s report on
internal controls over financial reporting pursuant to the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive
disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date that (i)&nbsp;we are no longer an emerging growth company or (ii)&nbsp;we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. We will remain an emerging growth company under the JOBS Act until the earliest of (i)&nbsp;the last day of our first fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion
or more, (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt instruments during the previous three fiscal years, (iii)&nbsp;the date on which we are deemed a
&#147;large accelerated filer&#148; under the rules of the SEC with at least $700.0&nbsp;million of outstanding equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or (iv)&nbsp;the last day of the fiscal year following
the fifth anniversary of completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;92&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often
occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad
therapeutic potential to deliver improved therapeutics for patients with these disorders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our two lead clinical-stage candidates are <FONT
STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155.</FONT> <FONT STYLE="white-space:nowrap">ETX-810</FONT> is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic
peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP, commonly referred to as sciatica). <FONT STYLE="white-space:nowrap">ETX-810</FONT> is being evaluated in two Phase 2a clinical trials that are expected to
report topline data in the first half of 2022. <FONT STYLE="white-space:nowrap">ETX-155</FONT> is a neurosteroid GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor positive allosteric modulator (PAM) initially being developed for
major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS), the most common type of seizure in people with epilepsy. We plan to initiate two Phase 2a clinical trials for
<FONT STYLE="white-space:nowrap">ETX-155</FONT> in patients with MDD and PMD which are expected to report topline data in the first half of 2023 and a Phase 1b clinical trial in patients with photosensitive epilepsy that is expected to report
topline data by the first half of 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on the development of product candidates whose mechanisms of action have been clinically
validated. By clinically validated, we mean there are product candidates with these mechanisms of action that have demonstrated statistical significance on efficacy endpoints in published randomized, controlled clinical trials. We leverage the deep
expertise of our team to generate new chemical entities (NCEs) based on these clinically validated mechanisms of action that we believe have the potential to be clinically differentiated and enhance patient outcomes. Through this approach, we have
established a robust pipeline with two clinical product candidates and two preclinical programs, each with the potential to address multiple disorders. Our product candidates are focused on addressing neuronal excitability disorders with large,
well-defined markets, where clinical and regulatory endpoints are clearly established and development pathways are precedented, yet current therapies leave patients with efficacy, safety or tolerability challenges. Our strategy is to initially
pursue indications for each of our product candidates where the clinical translatability of the mechanism of action has been well established and, upon demonstrating clinical proof of concept, evaluate additional indications to maximize the value of
each program. We believe these principles favorably position us to bring novel therapeutics to patients living with challenging disorders while maximizing our probability of clinical development, regulatory and commercial success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead investigational program, <FONT STYLE="white-space:nowrap">ETX-810,</FONT> is a novel, oral, NCE prodrug of PEA in clinical
development for chronic pain conditions. Despite a large global prescription drug market for chronic pain therapeutics that is expected to reach approximately $27&nbsp;billion in the next decade, it has been shown that less than half of patients
achieve a 50&nbsp;percent reduction in their pain intensity with current first line therapies. In addition to suboptimal efficacy, current therapies are often hindered by dose-limiting side effects such as dizziness, sedation, cognitive impairments,
gastrointestinal disturbances and concerns over abuse liability. Despite these issues, drugs to treat chronic pain, such as Lyrica and Cymbalta, have achieved significant commercial success and have been among the
<FONT STYLE="white-space:nowrap">top-selling</FONT> pharmaceutical products globally with both achieving annual sales greater than $5&nbsp;billion before losing patent exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PEA pathway, which is believed to play an important role in the regulation of neuroinflammation and pain signaling, represents a promising
potential mechanism to treat multiple conditions of chronic pain. PEA is an endogenous bioactive lipid that has been evaluated in dietary supplement formulations in relation to various </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;93&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pain conditions in more than 30 clinical studies, with over 2,500 patients, including patients with pain related to LSR and DPNP, treated with PEA in these studies. Fifteen of these studies were
randomized, controlled trials (RCTs) in a total of approximately 1,500 patients, with thirteen RCTs demonstrating a statistically significant improvement in pain reduction endpoints. A peer-reviewed meta-analysis of eight RCTs conducted with PEA
demonstrated a weighted mean reduction in pain intensity score (based on a Visual Analog Scale (VAS)) of approximately two points compared to control, which compares favorably to the reductions in pain intensity reported from clinical trials with
currently approved chronic pain medications. In addition, few adverse events related to PEA treatment have been reported in these published clinical studies. Despite this promising precedent clinical data supporting the exploration of the potential
utility of PEA in chronic pain treatment, there are no PEA-based therapeutics approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or similar regulatory authority. Rather, PEA is only currently available as a
dietary supplement (nutraceutical), which has shown low bioavailability and overall poor drug-like properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a prodrug of PEA, <FONT
STYLE="white-space:nowrap">ETX-810</FONT> was designed to significantly improve the absorption and systemic exposure of PEA beyond what is achievable with currently available formulations, potentially maximizing the therapeutic effect. In our Phase
1 SAD and MAD clinical trials of ETX-810, which included a total of 80 healthy volunteers, ETX-810 demonstrated encouraging safety and tolerability. <FONT STYLE="white-space:nowrap">ETX-810</FONT> also demonstrated improved pharmacokinetics in a
group of healthy subjects relative to dietary supplement formulations of PEA, with approximately three times higher PEA exposure on a matched dose basis.&nbsp;We believe the optimized pharmacokinetics and favorable tolerability of <FONT
STYLE="white-space:nowrap">ETX-810,</FONT> combined with our development and manufacturing expertise, put us in position to progress a robust clinical development program and explore the full therapeutic effect of
<FONT STYLE="white-space:nowrap">ETX-810.</FONT> To date, we have not observed any clinically relevant drug-drug interactions with <FONT STYLE="white-space:nowrap">ETX-810,</FONT> and due to PEA&#146;s endogenous nature we believe there is a low
potential for liabilities related to addiction or abuse, positioning <FONT STYLE="white-space:nowrap">ETX-810</FONT> to potentially be used as a differentiated monotherapy or in combination with other medications for chronic pain. If approved, <FONT
STYLE="white-space:nowrap">ETX-810</FONT> may be the first <FONT STYLE="white-space:nowrap">PEA-based</FONT> therapeutic addressing the critical unmet need in chronic pain treatment for novel, <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT
STYLE="white-space:nowrap">non-addictive</FONT> therapeutic options. Our research suggests that a multi-billion dollar commercial opportunity is available for a new chronic pain agent with proven efficacy and a favorable safety and tolerability
profile. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have initiated two separate Phase 2a clinical trials of ETX-810 in the United States, one in patients with pain
associated with diabetic peripheral neuropathy (DPN) and another in patients with pain associated with lumbosacral radiculopathy (or lumbosacral radicular pain (LSRP)), to evaluate the efficacy and safety of
<FONT STYLE="white-space:nowrap">ETX-810</FONT> in these indications. We expect to report topline data from both trials in the first half of 2022. If these trials are successful, we plan to conduct further studies with a view to broaden <FONT
STYLE="white-space:nowrap">ETX-810&#146;s</FONT> clinical applications in peripheral neuropathic and other chronic pain conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
second clinical <FONT STYLE="white-space:nowrap">program,&nbsp;ETX-155,</FONT> is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator of the GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor (GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R) and that we are planning to evaluate in patients with depression and epilepsy. MDD affects approximately 35&nbsp;million
adults globally and approximately 19&nbsp;million adults in the United States, and causes significant impairment to daily life. While there are effective therapies available for individuals suffering from MDD, there is considerable variability in
patient responsiveness resulting in only 33% of patients benefiting from their first line therapy. There is a pressing need for safe, well-tolerated and rapidly acting antidepressants that reliably provide clinical improvement faster than the up to
six weeks associated with standard of care selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Epilepsy affects approximately 4.7&nbsp;million people in the major markets of the United States,
Europe, and Japan, with approximately 1&nbsp;million of these patients experiencing uncontrolled focal onset seizures (FOS) that are refractory to multiple <FONT STYLE="white-space:nowrap">anti-seizure</FONT> medications (ASMs). Despite the
existence of over 30 approved ASMs, approximately 30% of epilepsy patients fail to achieve adequate seizure control. FOS has a high prevalence of psychiatric <FONT STYLE="white-space:nowrap">co-morbidities</FONT> like depression, which can be
exacerbated by many of the currently prescribed ASMs.&nbsp;There is a pressing need for new ASMs to not only reduce the number of seizures but to also provide a positive effect on mood. The
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class has been clinically validated in certain depression and epilepsy indications, and we believe there is a clear opportunity for clinical differentiation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;94&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ETX-155 was designed to have dual potency at both synaptic and extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. <FONT STYLE="white-space:nowrap">ETX-155</FONT> has also shown differentiated pharmacokinetic properties, including no clinically meaningful food effect and an approximate 24-hour
half-life to enable once-a-day dosing. Results from our Phase 1 multiple ascending dose (MAD) clinical trial demonstrated favorable tolerability data at exposure levels that are consistent with dosing levels that achieved robust activity in
preclinical models of depression, anxiety and epilepsy. Based on our preclinical and clinical work to date, we plan to pursue clinical trials in FOS, MDD and PMD. In the second half of 2021, we intend to initiate a Phase 1b photosensitive epilepsy
trial, which if successful, would support initiating a Phase 2 clinical trial in FOS. We plan to announce topline data from the photosensitive epilepsy trial in the first half of 2022. In addition, we intend to initiate a Phase&nbsp;2 clinical trial
in patients with MDD in the second half of 2021 and expect to report topline data in the first half of 2023. Further, we intend to initiate a Phase&nbsp;2 clinical trial to support clinical efficacy in patients with PMD in the second half of 2021
and expect to report topline data in the first half of 2023. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our clinical candidates, we are progressing a
preclinical pipeline with two programs currently in discovery stage. Our preclinical programs apply our medicinal chemistry and biology expertise combined with our in-depth understanding of drug discovery and development processes to develop novel
product candidates based on clinically validated mechanisms of action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead preclinical program is a Kv7.2/3 potassium channel
opener. Kv7.2/3 has been clinically validated as a therapeutic target for both epilepsy and pain. The first generation Kv7 channel opener, ezogabine (Potiga), was approved for refractory focal onset seizures in 2011 in both the United States and in
Europe (where it was known as retigabine, or Trobalt). Flupirtine (Katadolon) was another first generation Kv7.2/3 opener that provided clinical validation and has been used in Europe as a treatment for pain since the 1980s. These molecules showed
clinical efficacy but subsequently had to be withdrawn from the market due to safety issues. We are developing an NCE that harnesses the efficacy of the Kv7.2/3 channel mechanism while attempting to improve the safety and tolerability relative to
earlier molecules, based on our insights into the mechanisms of toxicity. We expect to nominate a clinical candidate in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second preclinical program is focused on developing a novel, potent analog of an earlier approved 2,3-benzodiazepine for the potential
treatment of Generalized Anxiety Disorder (GAD). The aim of our program is to develop a rapidly acting, non-sedating, non-addictive anxiolytic that does not impair motor or cognitive performance, does not have any adverse drug-drug interactions, and
has the potential to be dosed once a day. We plan to nominate a clinical candidate for our GAD program in 2022. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own the rights to
our product candidates through both acquisitions and internal research and development efforts. With respect to ETX-810, in February 2019 we acquired in-process research and development (IPR&amp;D) related to the ETX-810 program from Carnot, LLC.
With respect to ETX-155, in October 2020, we acquired 100% of the share capital of Athenen Therapeutics Inc., which included IPR&amp;D related to the ETX-155 program. Following these acquisitions, we have continued the in-house clinical-stage
development of the ETX-155 and ETX-810 programs. Our preclinical Kv7 and GAD programs have been developed by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;95&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of our wholly owned pipeline. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g01b28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 1. Eliem Therapeutics&#146; pipeline of product candidates. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We follow several key
principles to guide our research and development efforts that we believe will enable us to efficiently bring clinically differentiated therapies to market to help millions of people suffering from central nervous system (CNS) disorders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Focus on clinically validated mechanisms of action.</I></B> We concentrate our research and development
efforts on opportunities within the broad range of neuronal excitability disorders, where there has been prior clinical validation for the mechanism of action or pathway and where significant unmet need exists due to efficacy and safety limitations
of existing therapies. By focusing on products with mechanisms of action that have clinical validation, we believe we can reduce the clinical translational risk of our product candidates while leveraging our extensive neuroscience drug development
expertise to develop products that have the potential to meaningfully improve clinical outcomes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Establish clinical differentiation for our product candidates. </I></B>We leverage the deep chemistry,
neuroscience and manufacturing expertise of our team to generate NCEs which we believe can be clinically differentiated and enhance patient outcomes. We intend to improve on efficacy, safety and tolerability limitations of existing therapies that
impact patient convenience, compliance and outcomes. We aim to deliver therapeutic candidates with optimal pharmacological properties that make them both clinically differentiated and commercially attractive. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Pursue CNS indications with well-defined regulatory pathways in large markets that are inadequately served
by current therapies. </I></B>The initial indications we are pursuing for <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155</FONT> are chronic pain, depression and epilepsy, all of which have
well-characterized, large patient populations and are insufficiently addressed by existing therapies. In these indications, clinical endpoints and regulatory pathways are well-defined and precedented. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Develop products that have broad therapeutic potential</I></B>. We believe that the biological pathways
that are involved in many neuronal excitability disorders are related, and therefore, therapies that effectively address these pathways may be applicable in multiple CNS disorders. Our strategy for each
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;96&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
product candidate is to initially pursue tractable indications where the clinical translatability of the mechanism of action has been validated. Upon positive results from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials, we intend to pursue additional indications where we believe our product candidates&#146; mechanisms may be relevant, to maximize the potential for
each product candidate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Maximize and protect value through a strong global intellectual property portfolio. </I></B>We have a
rigorous strategy to establish and protect the intellectual property rights for our programs, all of which are wholly owned, to allow us to maximize the therapeutic and commercial potential of our pipeline. This strategy includes seeking patent
protection in the United States and other jurisdictions for our product candidates, each of which is an NCE. Our portfolio includes numerous filings with multiple different sets of claims that cover proprietary aspects of our lead programs and their
use. For <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155,</FONT> we have issued patents in the United States with coverage to at least 2037 and 2039, respectively, as well as a wide variety of pending
applications for these programs in the United States and elsewhere. We continue to leverage new discoveries in the development of these programs to strengthen the breadth and depth of our intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To execute our approach, we
plan to implement the following key strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance <FONT STYLE="white-space:nowrap">ETX-810</FONT> through clinical trials for DPN and LSR chronic
pain and progress toward commercialization</I></B>. <FONT STYLE="white-space:nowrap">ETX-810</FONT> represents a compelling opportunity to develop a novel molecule for the treatment of chronic pain conditions, with a mechanism of action supported by
a robust body of precedent clinical research across multiple pain settings. We have completed a Phase 1 single ascending dose and multiple ascending dose trial for <FONT STYLE="white-space:nowrap">ETX-810</FONT> in healthy volunteers and are
currently executing two randomized placebo-controlled Phase 2a clinical trials aimed at establishing clear <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for
<FONT STYLE="white-space:nowrap">ETX-810</FONT> in chronic pain associated with DPN and LSR. We intend to announce topline data from both Phase 2a clinical trials in the first half of 2022. With positive results from these trials, we intend to
progress development of <FONT STYLE="white-space:nowrap">ETX-810</FONT> into later-stage trials in the United States and other countries to support filings for regulatory approval in key markets. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance <FONT STYLE="white-space:nowrap">ETX-155</FONT> through clinical trials in both depression and
epilepsy indications and progress toward commercialization. </I></B><FONT STYLE="white-space:nowrap">ETX-155</FONT> is a potentially differentiated GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM candidate with dual potency at
synaptic and extrasynaptic receptors, an approximate <FONT STYLE="white-space:nowrap">24-hour</FONT> half-life and no clinically meaningful food effect. We have completed a Phase 1 single and multiple ascending dose trial for <FONT
STYLE="white-space:nowrap">ETX-155</FONT> in healthy volunteers, and plan to initiate Phase 2a clinical trials in both MDD and PMD in the second half of 2021. In addition, we are planning to evaluate <FONT STYLE="white-space:nowrap">ETX-155</FONT>
in a Phase 1b photosensitive epilepsy <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial with data readout targeted for the first half of 2022. Assuming the results of this trial are positive, we
plan to initiate a Phase 2 clinical trial in patients with focal onset seizures in the first half of 2023. With positive results from these trials, we intend to progress development of <FONT STYLE="white-space:nowrap">ETX-155</FONT> into later-stage
trials in the United States and other countries to support applications for regulatory approval in key markets. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continue to innovate and advance our preclinical programs into clinical trials in multiple neuronal
excitability indications. </I></B>We are currently developing two preclinical-stage programs: (1)&nbsp;a novel Kv7.2/3 channel opener for potential treatment of pain and epilepsy; and (2)&nbsp;a novel
<FONT STYLE="white-space:nowrap">2,3-benzodiazepine</FONT> anxiolytic for the potential treatment of generalized anxiety disorder and depression. Both preclinical programs are based on clinically validated mechanisms of action with prior approved
molecules in the class. Our aim is to discover and develop proprietary NCEs that improve upon first-generation molecules based on our novel chemical insights and <FONT STYLE="white-space:nowrap">in-depth</FONT> understanding of the biology and
selectivity required to yield drugs with favorable safety and efficacy profiles. We anticipate nominating a clinical candidate selection for our Kv7.2/3 program by the end of 2021, and for our next-generation anxiolytic in 2022.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;97&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Apply our expertise to expand our lead programs into additional indications representing large markets.
</I></B>Our team includes established industry leaders in the fields of neuroscience and pain. Through our clinical trials, we intend to enhance our understanding of the mechanism of action for our specific product candidates, and in general our
understanding of the biological pathways leading to neuronal inhibition and excitation imbalances to maximize the value of our product candidates. Utilizing this enhanced understanding informed by our initial clinical trials, we plan to evaluate
additional potential indications for both <FONT STYLE="white-space:nowrap">ETX-810</FONT> and <FONT STYLE="white-space:nowrap">ETX-155.</FONT> For <FONT STYLE="white-space:nowrap">ETX-810,</FONT> we will explore additional pain indications, which
could enable a broad label in peripheral neuropathic pain and chronic pain. For <FONT STYLE="white-space:nowrap">ETX-155,</FONT> we intend to explore a wide-range of compelling opportunities in both psychiatry and neurology, including potentially
generalized anxiety disorder and bipolar disorder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Pursue regulatory approvals for our product candidates and commercialize them in key markets. </I></B>We
plan to build a fully integrated biotechnology company capable of executing registrational trials, obtaining regulatory approvals and commercializing our drugs globally. We expect to build a focused and efficient medical affairs and commercial
organization to help bring our product candidates to patients around the world. Given the potential broad applicability of our product candidates in large patient populations globally, we may also opportunistically enter strategic partnerships with
reputable biopharmaceutical companies, with established presence in key geographies, to address the unmet needs of patients worldwide and maximize the overall value of our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team and Investors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since commencing
operations in 2019, we have assembled a seasoned management team with expertise in neuroscience research and development, medicinal chemistry, clinical development, regulatory affairs, manufacturing and commercialization. Our team includes industry
veterans with leadership experience at leading biopharmaceutical companies such as Amgen, Biogen, GSK, Lilly, Novartis and Pfizer, as well as at successful small biotechnology companies such as Alder Biopharmaceuticals, Convergence Pharmaceuticals,
Exelixis and Juno Therapeutics. In addition, our team has collectively driven development and operational efforts supporting the approval of multiple drugs in chronic pain, depression and epilepsy, including Aptiom, Cymbalta, Lamictal, Lyrica and
Vyepti. Our leadership team&#146;s track record of success enables us to continue to recruit highly experienced personnel. Our board of directors is comprised of industry leaders with senior leadership experience at large pharmaceutical
organizations and public and private biotechnology companies, bringing significant expertise across neuroscience research and development, corporate governance, finance, organizational strategy and capital raising. Together, we bring years of
experience combined with the resilience needed to confront challenging diseases of the nervous system and we are supported by top tier investors including RA Capital Management, Access Biotechnology and Intermediate Capital Group plc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ETX-810</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">ETX-810,</FONT> a novel prodrug of PEA, as a treatment for patients suffering from chronic
pain. PEA, the active moiety of <FONT STYLE="white-space:nowrap">ETX-810,</FONT> is an endogenous bioactive lipid known to broadly modulate neuroinflammation and pain signaling. Dietary supplement PEA has shown activity in more than 30 clinical
studies across a variety of pain indications, including demonstrating statistically significant reductions in pain in 13&nbsp;randomized, controlled trials, along with favorable tolerability data. However, there are no FDA or EMA approved <FONT
STYLE="white-space:nowrap">PEA-based</FONT> therapeutics, as no agent has ever been taken through a rigorous clinical development program with a view to obtain regulatory approval. In addition, the only currently available versions of PEA are <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> dietary supplement formulations that, while demonstrating promising clinical activity and tolerability in prior studies, have low bioavailability and overall
poor drug-like properties. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ETX-810</FONT> was designed to significantly improve the systemic
exposure of PEA to explore its full therapeutic potential and to significantly reduce chronic pain. In our Phase 1 clinical trial, <FONT STYLE="white-space:nowrap">ETX-810</FONT> demonstrated encouraging safety and tolerability data with all adverse
events (AEs) being mild and transient. We believe the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;98&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
endogenous nature of PEA makes <FONT STYLE="white-space:nowrap">ETX-810</FONT> unlikely to have drug-drug interactions and limits the potential for abuse liability. We are currently conducting
Phase 2a clinical trials of <FONT STYLE="white-space:nowrap">ETX-810</FONT> in two chronic pain indications: DPNP and LSRP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview of Chronic
Pain and the Unmet Need </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chronic pain is one of the most common and complex conditions in the world and continues to be poorly
addressed by available therapeutic options. In the 2016 Global Burden of Disease Study, pain and pain-related conditions were confirmed to be the leading cause of disability and disease burden globally, and this burden is escalating. In patients who
are receiving a first line agent for chronic pain, currently approved medications, including Lyrica and Cymbalta, have demonstrated pain intensity reductions of 50% or more in less than 50% of patients. In addition to inadequate efficacy, the
current standard of care is hindered by dose-limiting side effects, including dizziness, sedation, gastrointestinal disturbances, as well as concerns over the abuse liability of the opioid class of pain treatments. These limitations of currently
approved therapies ultimately lead treating physicians to resort to polypharmacy, prescribing a combination of multiple drugs at once. Despite a massive global chronic pain prescription therapeutics market that was estimated at $20&nbsp;billion in
2018 and is forecasted to reach approximately $27&nbsp;billion in 2028, there is a high unmet need for safe, effective, <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies to treat chronic pain. A multi-billion-dollar commercial opportunity
is available for a new chronic pain agent with proven efficacy and a favorable safety and tolerability profile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PEA Proposed Mechanism of Action in
Neuroinflammation and Chronic Pain </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PEA is an endogenous bioactive lipid that was first described in 1957, but its mechanism of
action remained unclear until the 1990s, when the work of Nobel laureate Rita Levi-Montalcini was published describing PEA as part of a class of endogenous regulatory molecules called <FONT STYLE="white-space:nowrap">N-acylethanolamines,</FONT>
which control mast cell activation <I>in vivo</I>. Systemically administered <FONT STYLE="white-space:nowrap">N-acylethanolamines</FONT> were found to be effective in reducing mast cell degranulation and therefore have anti-inflammatory effects.
Subsequent preclinical studies have since evaluated these powerful anti-inflammatory effects and revealed analgesic effects of PEA. Evidence demonstrated that PEA acts as a modulator of neuroinflammatory processes. In pathological settings PEA
production may be insufficient to regulate the inflammatory cascade that downstream drives an increase in pain signaling, and exogenous administration of PEA might prove therapeutically beneficial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;99&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in Figure 2 below, PEA&#146;s mechanism is considered pleiotropic, as
literature supports that it acts through a series of direct and indirect actions involving several effector cells and molecular targets. It is believed that PEA plays a key role as a master regulator of neuroinflammatory processes, triggering
multiple signaling cascades to control downstream pain signaling and elicit its potent analgesic effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g57q01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 2. Potential pleiotropic mechanism of action of endogenous PEA for the control of neuroinflammation and neuronal
excitability, and therefore downstream pain signaling. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there are multiple aspects of PEA&#146;s potential pleiotropic
mechanism that remain to be elucidated, but several potentially important mechanisms that have been published include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inhibition of mast-cell activation and degranulation and downregulation of release of inflammatory mediators
from multiple immune cell types; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Agonism of the nuclear receptor PPAR-alpha, leading to regulation of expression of several genes, including an
inhibition of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> genes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Agonism of the orphan <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptor GPR55, potentially
playing a role in microglial cell migration, activation and increased phagocytosis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An &#147;entourage effect&#148; where PEA increases the level of other endocannabinoids with potential
anti-inflammatory and analgesic properties, such as <FONT STYLE="white-space:nowrap">2-AG,</FONT> anandamide, and OEA, by acting as a substrate for FAAH. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure&nbsp;3 describes our current understanding of how fluctuations in PEA levels may lead to dysregulation of neuroinflammation and pain
signaling. In chronic pain (center panel), evidence demonstrated that there may be both a decrease in PEA synthesis and an increase in PEA metabolism leading to a net decrease in PEA below the level needed to maintain control of neuroinflammation.
As a result, sensitization in both the peripheral and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;100&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
central nervous system lead to an increase of pain signaling and pain sensation, relative to a healthy physiological state (left panel of Figure 3).
<FONT STYLE="white-space:nowrap">ETX-810</FONT> is designed to deliver exogenous PEA and restore PEA to levels needed to reduce neuroinflammation and restore a healthy physiological state, where hyperexcitability of the pain signaling network is
dampened and chronic pain is reduced (right panel of Figure 3). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g59q01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 3. The potential role of PEA in controlling neuroinflammation and pain in normal physiology versus chronic pain
states, and therapeutic hypothesis. <FONT STYLE="white-space:nowrap">ETX-810</FONT> provides an exogenous source of PEA aimed at rebalancing the body&#146;s PEA levels that have been reduced due to an imbalance between synthesis and metabolism of
endogenous PEA. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;101&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the preclinical evidence of a decreased level of PEA in chronic pain, a
clinical publication further supports the finding in osteoarthritis and rheumatoid arthritis patients showing significantly lower PEA levels in the synovial fluid compared to healthy volunteer control subjects. This data is depicted in Figure 4
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g04e08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 4. Decreased levels of PEA in the synovial fluid of patients with osteoarthritis (OA), and rheumatoid arthritis
(RA) compared to healthy normal volunteers (control); (P &lt;0.005, and P&lt;0.01, respectively). Figure adapted from Richardson et al. Arthritis Res Ther, 2008;10(2):R43. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;102&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Experience with PEA in Pain </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pain-relieving properties of PEA in human diseases associated with chronic pain have been evaluated in multiple clinical studies since the
1990s using PEA in dietary supplement formulations. Over 30 clinical studies, including fifteen randomized, placebo-controlled studies, have been conducted with these dietary supplement formulations across multiple pain indications. Statistically
significant reductions in pain intensity were observed in nearly all of these studies with PEA treatment. These studies reported few dropouts and few reported AEs, suggesting that PEA was generally well tolerated. A summary of the fifteen published
randomized controlled clinical studies conducted with PEA in various pain conditions, including the PEA dose levels evaluated, is below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g14n52.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;103&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Meta-analyses demonstrated PEA&#146;s consistent therapeutic effects </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two meta-analyses have examined the effects of PEA on pain across clinical studies. The most recent meta-analysis of eight randomized,
controlled studies by Artukoglu and colleagues in 2017 included a total of 743 patients receiving PEA and 460 inactive controls. Doses used in these trials ranged from 300 to 1200 mg/day and trial durations from
<FONT STYLE="white-space:nowrap">15-180</FONT> days. The meta-analysis demonstrated that PEA was associated with a significantly greater pain reduction based on VAS scores compared to control conditions, with a weighted mean reduction in pain score
on a <FONT STYLE="white-space:nowrap">10-point</FONT> scale of 2.03 (95% CI: <FONT STYLE="white-space:nowrap">1.19-2.87).</FONT> A summary of these results is below in Figure 5: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g22x23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 5. Meta-analysis of randomized clinical trials of PEA in a dietary supplement formulation. Adapted from Artukoglu
et al. Pain Physician, <FONT STYLE="white-space:nowrap">2017;20:353-362.</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted mean difference in pain score for PEA vs
inactive control of 2.03 from this meta-analysis compares favorably to the standardized mean difference in pain score from meta-analyses conducted on randomized trials of pregabalin and duloxetine, as shown in Figure 6 below: </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g02i16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 6. Summary of mean pain score reduction from meta-analyses conducted for duloxetine and pregabalin in different
chronic pain indications. * shown as absolute value of weighted/standardized pain score reduction compared to placebo </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;104&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PEA&#146;s dose-dependent therapeutic effect and impact on neuropathic pain in clinical studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the most compelling clinical data for PEA in pain come from a multicenter, randomized controlled study that enrolled a total of 636
subjects with compressive-type lumbar sciatica who were treated with either 300 or 600 mg dietary supplement PEA (Normast, Epitech) per day, or placebo, for 21 days. The reduction in pain intensity was assessed based on VAS score, and the
improvement in health status of patients was evaluated by the Roland-Morris Disability Questionnaire (RMDQ). A dose-dependent effect on both VAS and RMDQ scores was observed. The effect size was statistically significant (p &lt;0.001) on both VAS
score (change versus baseline pain scores of 5.0 on 600 mg, 2.9 on 300 mg and 2.0 on placebo) and RMDQ score (change versus baseline of 9.2 on 600 mg, 5.0 on 300 mg and 3.0 on placebo). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cruccu et al. performed a <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis from the raw data associated with the aforementioned study
which was published in 2019. In this analysis additional measures of the clinical efficacy, such as 50% responder rate (VAS pain scores and disability RMDQ scores) and number needed to treat were conducted. In the 600 mg PEA cohort, 82% of patients
achieved a 50% or greater reduction in pain intensity as measured by the VAS, as compared to 33% of patients in the 300 mg cohort and 22% of patients in the placebo group. Of patients in the 600 mg PEA cohort, 88% achieved a 50% or greater
improvement in physical disability as measured by RMDQ, as compared to 38% in the 300 mg cohort and 23% of patients in the placebo group. In addition, the authors calculated the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Numbers-Needed-to-Treat</FONT></FONT> (NNT) to be 1.7 for the 600 mg dose (NNT in this case is defined as the number of patients needed to treat to find one patient who achieves a 50%
reduction in pain intensity). This compared very favorably to the NNT of pregabalin and duloxetine published in a meta-analysis of randomized controlled trials in neuropathic pain, where the NNT for 50% pain relief for these drugs was calculated to
be 7.7 and 6.4, respectively. Across all measures, 600 mg PEA performed better than 300 mg, suggesting a dose-dependent response and supporting our prodrug approach to increase PEA exposures. These results are summarized in Figure 7 below: </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g41r43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 7. Results of a <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis of the largest PEA clinical trial
conducted to date: a randomized, placebo-controlled trial by Guida et al. in 636 patients with chronic low back pain. Figure adapted from Cruccu et al. CNS&nbsp;&amp; Neurological Disorders &#150; Drug Targets, 2019;18(6):491 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cruccu et al. developed an ordinal scale to categorize each patient&#146;s pain into 5 different groups based on increasing
probability of the pain being neuropathic. A significant positive correlation was found between an improvement in pain score and an increasing probability of the pain being neuropathic in nature. This, together with the anti-neuroinflammatory
mechanism of action, further supports the hypothesis of using PEA in patients with neuropathic pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another clinical study of PEA as a
dietary supplement in osteoarthritis was published by Steels et al. in 2019. In this single site, randomized, controlled study, 111 subjects with osteoarthritis in one or both knees were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;105&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
randomized to receive either 300 mg PEA (n=36), 600 mg PEA (n=35), or matched placebo capsules (n=40), daily for 8 weeks. All participants were required to have a minimum pain level of 4 on the
Numerical Rating Scale (NRS) and were not allowed to take any pain concomitant therapies while on study other than paracetamol (acetaminophen) as a rescue therapy. The primary endpoint of the trial was the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC), which measures pain, stiffness and function. The secondary endpoint was pain intensity measured by the NRS pain scale. All 3 components of the WOMAC score were statistically significantly reduced for both 300 mg and 600
mg PEA groups compared to placebo at week 8. In addition, there was an apparent dose-dependent effect as the 600 mg PEA dose outperformed the 300 mg PEA dose across all metrics evaluated, although the study was not powered to show statistical
significance between these two dose levels (Figure 8). There were no SAEs reported in any of the study participants. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g37a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 8. Modified from Steels et al. study (Inflammopharmacology,
<FONT STYLE="white-space:nowrap">2019;27:475-485)&#151;Reduction</FONT> of WOMAC osteoarthritis total index score, WOMAC pain score and NRS average pain score and WOMAC over <FONT STYLE="white-space:nowrap">8-week</FONT> course of treatment with 300
mg/day PEA, 600 mg/day PEA, or placebo. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both the Guida and Steels studies suggest that an increase in PEA dose may lead to a
potential additional clinical benefit in terms of pain reduction, supporting our hypothesis for development of <FONT STYLE="white-space:nowrap">ETX-810</FONT> delivering around <FONT STYLE="white-space:nowrap">3-fold</FONT> higher PEA exposure than
PEA itself <FONT STYLE="white-space:nowrap">(over-the</FONT> counter formulation, Normast). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations of PEA pharmacokinetics and our solution
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite PEA&#146;s evaluation in pain indications in numerous clinical trials, there is minimal information available on the
pharmacokinetic profile of dietary supplement PEA formulations in humans. Given its lipidic nature and large particle size, PEA in its native state is expected to have limitations in terms of solubility, absorption and bioavailability. While
ultra-micronized formulations of PEA have aimed to improve the bioavailability compared to the native state by reducing the particle size, we are not aware of any published data demonstrating improvement in bioavailability or other pharmacokinetic
parameters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the dose-dependent clinical efficacy and limited number of treatment-related adverse events in precedent clinical
studies of PEA in chronic pain provides compelling evidence of the therapeutic potential of PEA. We also believe this supports our approach to develop <FONT STYLE="white-space:nowrap">ETX-810</FONT> as an NCE PEA prodrug with desirable
pharmacokinetics to explore the full therapeutic potential in patients with chronic pain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;106&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">ETX-810</FONT> Competitive Advantages </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">ETX-810</FONT> offers several key differentiating features compared to currently available
therapies for chronic pain. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Novel approach to chronic pain with demonstrated clinical proof of concept.
</I><FONT STYLE="white-space:nowrap">ETX-810</FONT> is believed to be the only PEA prodrug in clinical development and is being developed based on precedent clinical studies of dietary supplement formulations of PEA that demonstrated clinically
meaningful statistically significant reductions in pain intensity in over 12 randomized placebo clinical trials. These trials collectively included approximately 1,500 patients spanning multiple inflammatory and neuropathic chronic pain conditions.
In one study of over 600 chronic low back pain patients, PEA demonstrated statistically significant reductions in pain versus placebo including a greater than 50% reduction in pain intensity in 82% of patients. Published studies suggest that first
line agents for chronic pain, such as the currently approved medications Lyrica and Cymbalta, are able to provide substantial pain relief (a&nbsp;reduction in pain score of 50% or more) in less than 50% of patients. Building upon the strength of
these clinical data, we believe <FONT STYLE="white-space:nowrap">ETX-810</FONT> has the potential to be the first <FONT STYLE="white-space:nowrap">PEA-based</FONT> therapeutic to address the unmet need in the large chronic pain market, although
cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits that ETX-810 may have compared to other product candidates that may be approved or that are in development. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Designed for desirable pharmacokinetics. </I>Commercially available formulations of PEA are currently only
available as dietary supplements and have low bioavailability with overall poor drug-like properties, likely leading to suboptimal exposures. <FONT STYLE="white-space:nowrap">ETX-810</FONT> was designed to significantly improve the systemic exposure
of PEA in order to maximize the therapeutic effect. <FONT STYLE="white-space:nowrap">ETX-810</FONT> was observed, in preclinical studies, to be rapidly absorbed after oral administration and to undergo enzymatic hydrolysis during absorption and in
plasma to efficiently release high concentrations of free PEA. In clinical studies in a small number (80) of healthy volunteers, ETX-810 has demonstrated rapid absorption and efficient release of biologically active PEA, resulting in approximately
three times higher PEA exposure on a matched dose basis compared to a commercially available dietary supplement formulation of PEA, as well as an approximately three to six times longer half-life compared to the published estimated half-life of PEA
in rats. Precedent clinical data has demonstrated a clear dose response with respect to PEA&#146;s ability to reduce pain intensity in chronic pain settings, which we believe supports our approach to optimize the pharmacokinetic exposure of PEA with
ETX-810. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Well tolerated and no known abuse liability in clinical studies. </I>Phase 1 single- and multiple-ascending
dose clinical trials with <FONT STYLE="white-space:nowrap">ETX-810</FONT> suggest the potential for an encouraging tolerability profile, and clinical trials conducted to date have resulted in no SAEs, no discontinuations, and no clinically
meaningful differences from placebo. These findings are consistent with published results from clinical trials conducted with dietary supplement formulations of PEA. In contrast, existing chronic pain therapies are associated with a range of adverse
effects including GI problems, drowsiness, dizziness, nausea, somnolence and others. In addition, as an endogenous bioactive lipid, the potential for abuse is considered to be low, potentially addressing the critical unmet need in chronic pain
treatment for novel, <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT STYLE="white-space:nowrap">non-addictive</FONT> therapeutic options. Prior clinical studies of PEA have no reported adverse events related to abuse.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Potential to be used in chronic pain as a monotherapy or in combination with other analgesics. </I>In multiple
prior clinical trials with dietary supplement formulations of PEA, a reduction in pain intensity was observed with PEA in chronic pain both as a monotherapy and when used in combination with other pain therapies such as opioids, antidepressants and
anticonvulsants. Because polypharmacy is a common treatment strategy used by clinicians treating chronic pain, the market is in need of therapies that can safely and effectively be used in combination with others. We believe the favorable
tolerability data in clinical trials and the endogenous nature of PEA make <FONT STYLE="white-space:nowrap">ETX-810</FONT> unlikely to have <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-to-drug</FONT></FONT> interactions and
position it for the potential to be used in combination with other chronic pain medications, if approved. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;107&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chronic Pain Indication Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chronic pain, generally described as pain lasting more than three to six months, is one of the most common and complex conditions. It is
estimated to affect approximately 20% of adults in the United States and Europe. Despite the high prevalence worldwide, there are few approved medicines to treat chronic pain and the existing therapeutic options suffer from limited efficacy coupled
with a range of adverse effects which can limit their utility, reduce compliance and complicate their ability to combine with other drugs. The two initial chronic pain indications we plan to pursue for <FONT STYLE="white-space:nowrap">ETX-810</FONT>
are pain associated with diabetic peripheral neuropathy (DPNP) and lumbosacral radiculopathy (lumbosacral radicular pain (LSRP)). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Diabetic
Peripheral Neuropathy (DPN) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DPN is a common, late manifestation of diabetes, affecting more than one third of diabetic patients,
and characterized by damage to the sensory and autonomic nervous system caused by prolonged poor glycemic control and increased levels of triglycerides in the blood. Neuropathic pain is present in approximately
<FONT STYLE="white-space:nowrap">one-fourth</FONT> of individuals with DPN and may be accompanied by an exaggerated response to painful stimuli (hyperalgesia) and pain evoked by light contact, such as those with shoes or clothing (allodynia). This
pain can lead to interference with daily activities, disability, psychosocial impairment and reduced health-related quality of life. While DPN can be managed to slow further progression, its symptoms, including chronic neuropathic pain, are
generally not reversible once they emerge. There are significant direct and indirect costs associated with the effects of DPN, with approximately one quarter of health expenditure in diabetes spent on management of DPN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that 30% to 50% of people with diabetes will experience diabetic peripheral neuropathy, and
<FONT STYLE="white-space:nowrap">40-50%</FONT> of those with DPN will experience DPNP. This provides a prevalence estimate of approximately 5.0&nbsp;million to 7.0&nbsp;million DPNP patients in the United States and 9.0 million to 12.0&nbsp;million
in Europe. Of treated DPNP patients it is estimated that 50% to 70% have an inadequate response to first line therapy, leading to an estimated 1.5 million to 3.0&nbsp;million treatment-refractory DPNP patients in the United States and approximately
2.7 million to 5.0&nbsp;million DPNP patients in Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are currently several pharmacological treatments recommended for the
first-line treatment (both approved and <FONT STYLE="white-space:nowrap">off-label),</FONT> to reduce pain and improve quality of life in DPNP patients, including several antidepressants (<I>e.g.</I>, duloxetine, venlafaxine, amitriptyline and other
tricyclic drugs) and gabapentinoid <FONT STYLE="white-space:nowrap">anti-seizure</FONT> medications (<I>e.g.</I>,<I> </I>pregabalin and gabapentins). Available evidence suggests that all of these treatments are better than placebo in improving DPNP,
but few high-quality comparative trials have been carried out, and there are only three products approved by the FDA and EMA for DPNP: duloxetine (Cymbalta), pregabalin (Lyrica) and the opioid tapentadol (Nucynta). For patients with an inadequate
response to first line therapy, second line therapy generally consists of switching to a different first-line medication class or combining multiple first-line agents (polypharmacy), though this can be complicated by the risk of compounding adverse
effects. Opioids are recommended to help manage pain in DPN only after all other first/second-line approaches and combinations fail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DPNP
remains an unmet need and is a primary driver of physical and psychological comorbidity. Available therapies for DPNP have moderate efficacy with adverse effects limiting optimal dose titration. In registrational studies of pregabalin and
duloxetine, only 40% to 50% of patients achieve a clinically meaningful response of a 50% improvement in pain from baseline, with roughly one quarter of these patients reporting dizziness or nausea adverse events. There is a considerable need for
new therapies for the management of DPNP that provide improved efficacy with a more favorable safety profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that <FONT
STYLE="white-space:nowrap">ETX-810,</FONT> if approved, could potentially be positioned as the preferred second-line monotherapy or <FONT STYLE="white-space:nowrap">add-on</FONT> agent for the 50% to 70% of DPNP patients who fail to achieve adequate
pain relief from generic first-line treatment options, potentially providing improved efficacy versus alternative options and preventing unnecessary opioid usage in this patient group. This represents a target patient population of approximately 4
million to 8&nbsp;million patients in the United States and Europe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;108&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lumbosacral Radiculopathy (LSR) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSR is a neuropathic pain syndrome caused by compression, inflammation and or injury of spinal nerve roots in the lower back and is
characterized by lower back pain that radiates into the leg in predictable patterns. The leg pain is typically much worse than the lower back pain, and is described as being electric, burning or sharp. Additionally, affected people may experience
numbness, muscle weakness and loss of specific reflexes. The most common cause of LSR is nerve root compression caused by a disc herniation or spondylosis (narrowing of the intraspinal canal, the lateral recess, or the neural foramen) due to
degenerative arthritis affecting the spine. While LSR can occur at any age, it often effects men beginning in their 40s and women in their 50s and 60s. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multiple sources suggest that between 3% and 5% of the adult population is affected by the condition, with equal rates among men and women,
which corresponds to approximately 10 million to 16 million people in the United States and 15 million to 26&nbsp;million people in Europe. Approximately 30% of these patients see their condition progress to chronic, with pain progressing past the
three-month mark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patients diagnosed with LSR, the aim of treatment is to alleviate the pain, and if necessary, address the
underlying cause of nerve irritation/compression. Patients are initially treated with non-steroidal anti- inflammatory drugs (NSAIDs) or acetaminophen and modification to physical activity. For patients with continued pain after approximately six to
eight weeks of NSAID or acetaminophen treatment, some patients obtain epidural steroid injections, which has been demonstrated to provide short-term pain relief. Patients failing to achieve adequate pain relief may be prescribed gabapentinoids, such
as Neurontin and Lyrica. Studies with gabapentinoids in LSR have demonstrated varying results and a recent meta-analysis found that these agents do not provide effective treatment and are associated with an increased risk of adverse events.
Additionally, opioids are used in patients who have severe pain. Many physicians, however, oppose opioid use in LSR as there is a lack of high-quality data supporting their use for this condition. Furthermore, the use of opioids is associated with
adverse events and the potential for abuse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the limited efficacy and potential side effects of current treatments, there continues
to be a need for effective, non-opioid therapies for the treatment of LSR. We believe that ETX-810 could potentially be positioned as the preferred second line monotherapy or add-on agent over epidural steroid injections or opioids in those patients
who fail to achieve adequate relief with NSAIDs or acetaminophen. This represents an estimated target patient population of approximately 7.5 million to 12.5&nbsp;million LSR patients in the United States and Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ETX-810</FONT> Clinical Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated the safety and tolerability of <FONT STYLE="white-space:nowrap">ETX-810</FONT> in 68 individuals across two Phase&nbsp;1
clinical trials. <FONT STYLE="white-space:nowrap">ETX-810</FONT> was well tolerated and all AEs were mild and transient. We are currently enrolling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT>
Phase&nbsp;2a clinical trials in patients with pain associated with DPN and LSR. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1 SAD and MAD Clinical Trials in Healthy Volunteers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first clinical trial conducted with <FONT STYLE="white-space:nowrap">ETX-810</FONT> was a combined single ascending dose (SAD)
and multiple ascending dose (MAD) trial in healthy volunteers. Fifty subjects in the SAD portion of the trial received single doses of either placebo or <FONT STYLE="white-space:nowrap">ETX-810</FONT> ranging from 50 mg to 1200 mg and 20 subjects in
the MAD portion received repeated doses of either placebo or <FONT STYLE="white-space:nowrap">ETX-810</FONT> at 500 mg and 1000 mg administered twice daily for seven days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SAD portion of this trial enrolled five cohorts of 10 participants, who each received single doses of
<FONT STYLE="white-space:nowrap">ETX-810</FONT> ranging from 50 mg to 1200 mg; participants were randomized 4:1 <FONT STYLE="white-space:nowrap">ETX-810</FONT> to placebo. All cohorts were dosed in a fed state except the 50 mg and 150 mg fasted
cohorts. The participants in the 150 mg cohort were dosed in both a fed and a fasted state, 5 days apart, to assess the effect of food on absorption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no clinically significant changes nor trends across dose groups seen in vital signs, ECG, blood chemistry, hematology, nor
urinalysis; a single adverse event (AE) (headache) required treatment (ibuprofen). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;109&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
There was no difference in the incidence of AEs among dose groups and no trends toward an increase in incidence with increasing dose. With respect to pharmacokinetics, <FONT
STYLE="white-space:nowrap">ETX-810</FONT> was found to convert rapidly to its hydrolysis intermediates and to PEA, and was found to be more completely absorbed when administered with food. The results of the SAD portion of the trial justified the
selection of 500 mg and 1000 mg as the doses for the MAD portion of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAD portion of this trial enrolled two cohorts with 10
participants in each. In each cohort, eight participants were administered active investigational product and two were administered a placebo twice daily for six days with a single dose administered on Day 7. Participants in cohorts 1 and 2 received
500 mg and 1000 mg <FONT STYLE="white-space:nowrap">ETX-810,</FONT> respectively, or placebo following food. The interval between the two daily doses was 12 hours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treatment was well tolerated; there were no clinically significant changes nor trends across dose groups seen in vital signs, ECG, blood
chemistry, hematology, nor urinalysis. No AEs required treatment or led to interruption or discontinuation of treatment. A single AE (insomnia) was rated moderate; all others were mild. There was no difference in the incidence of AEs among groups,
and no trend to an increase in incidence with increasing dose. Figure 9 describes the percentage of subjects with adverse events from the ETX-810 SAD and MAD portions of the trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g06c15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 9. Percent of subjects reporting adverse events in the ETX-810 Phase 1 study, 011810-101, in the (a) SAD portion
of the trial and (b) MAD portion of the trial. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1 Pharmacokinetic Clinical Trial Evaluating a 500 mg Single-capsule Formulation and Effect
of Food </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 500 mg single-capsule formulation was developed to reduce capsule burden. With this formulation, we conducted a second
Phase 1 clinical trial (Study <FONT STYLE="white-space:nowrap">018810-102)</FONT> evaluating the pharmacokinetics of two dose levels with and without food. Each of the 12 participants received two dose levels of
<FONT STYLE="white-space:nowrap">ETX-810</FONT> (500 and 1000 mg) with and without food separated by 24 hours in this randomized <FONT STYLE="white-space:nowrap">4-way</FONT> crossover. Treatment was well tolerated with adverse events reported
consistent with the prior SAD and MAD clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this trial the administration of
<FONT STYLE="white-space:nowrap">ETX-810</FONT> with food was found to significantly increase the AUC<SUB STYLE="font-size:85%; vertical-align:bottom">0-24h </SUB>values for the metabolic intermediates and the active metabolite PEA. <FONT
STYLE="white-space:nowrap">ETX-810</FONT> concentrations were below measurable quantities at all time points, indicating rapid conversion to its metabolites upon administration. C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> for these
metabolites was not found to be increased when <FONT STYLE="white-space:nowrap">ETX-810</FONT> was administered with food compared to the fasted state. Based on these results and the SAD and MAD trials, in future trials <FONT
STYLE="white-space:nowrap">ETX-810</FONT> will be dosed with food. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;110&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Improvement in PEA Exposure from <FONT STYLE="white-space:nowrap">ETX-810</FONT> vs Dietary
Supplement PEA </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a clinical trial to evaluate a commercially available ultramicronized dietary supplement
formulation of PEA in a small number (8) of healthy volunteers in order to establish well-controlled pharmacokinetics to provide a baseline for comparison to <FONT STYLE="white-space:nowrap">ETX-810,</FONT> given the lack of availability of high
quality human pharmacokinetic data for PEA. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This trial evaluated a single dose of 300 mg or 600 mg of a dietary supplement
formulation of PEA (Normast) in eight subjects, with 300 mg tested in both a fasted and a fed state and 600 mg tested only in a fed state, in each case after a <FONT STYLE="white-space:nowrap">five-day</FONT> washout period between doses. Blood
samples were taken prior to and up to 12&nbsp;hours after each dose. Prior to dosing, endogenous PEA concentrations averaged approximately <FONT STYLE="white-space:nowrap">4-7</FONT> ng/mL and were consistent within and between subjects across
dosing periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administration of dietary supplement PEA increased PEA concentrations in all participants at all dosing periods, but
with high <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">subject-to-subject</FONT></FONT> variability, particularly with respect to C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> and T<SUB
STYLE="font-size:85%; vertical-align:bottom">max</SUB>. Administration of the 300 mg dose after a meal resulted in greater increases in PEA than did administrations in the fasted state, with approximately
<FONT STYLE="white-space:nowrap">2-fold</FONT> higher AUC<SUB STYLE="font-size:85%; vertical-align:bottom">0-12h</SUB> and <FONT STYLE="white-space:nowrap">3-fold</FONT> higher C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plot provided below highlights the comparison of PEA exposure (AUC<SUB STYLE="font-size:85%; vertical-align:bottom">0-12h</SUB>) between a
single 1000 mg dose of <FONT STYLE="white-space:nowrap">ETX-810</FONT> from Study <FONT STYLE="white-space:nowrap">018810-102</FONT> compared to the 600 mg dose of dietary supplement PEA, from Study
<FONT STYLE="white-space:nowrap">018875-101,</FONT> both in the fed state. Although this comparison was not based on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study, a single 1000&nbsp;mg dose of <FONT
STYLE="white-space:nowrap">ETX-810</FONT> prodrug (which delivers ~490 mg of PEA) achieved approximately three-fold higher PEA exposure than a 600&nbsp;mg dose of dietary supplement PEA, which has demonstrated a statistically significant reduction
in pain in multiple clinical studies. We believe the increased exposure is potentially driven by improved oral bioavailability, rapid absorption and a longer half-life of PEA when delivered via the ETX-810 prodrug. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g41a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 10. Comparison of exposure of PEA from <FONT STYLE="white-space:nowrap">ETX-810</FONT> compared to an
ultramicronized dietary supplement formulation of PEA from two different clinical studies. <FONT STYLE="white-space:nowrap">ETX-810</FONT> data was taken from the 1000 mg fed cohort of the <FONT STYLE="white-space:nowrap">ETX-810</FONT> <FONT
STYLE="white-space:nowrap">018810-102</FONT> PK trial. Ultramicronized PEA data was taken from the 600 mg fed cohort of the <FONT STYLE="white-space:nowrap">018875-101</FONT> PK trial of dietary supplement PEA. Each 1000 mg capsule of <FONT
STYLE="white-space:nowrap">ETX-810</FONT> corresponds to ~490 mg of PEA active ingredient. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;111&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our ongoing Phase 2a clinical trials, we are dosing 1000 mg <FONT
STYLE="white-space:nowrap">ETX-810</FONT> <I>bis in die</I> (BID, twice daily) with food, meaning in these trials we are theoretically achieving approximately six times the daily exposure as would be expected from the standard clinical dose
(<I>i.e.</I> 600 mg/day) of PEA from dietary supplements. Based on the dose response observed with dietary supplement formulations of PEA in multiple prior studies, we believe that the increased exposure provided by
<FONT STYLE="white-space:nowrap">ETX-810</FONT> provides us with the possibility to evaluate the full potential therapeutic effect of PEA in chronic pain indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ETX-810</FONT> is rapidly absorbed and undergoes a series of hydrolysis steps to be converted into the active
moiety PEA. Studies have shown that <FONT STYLE="white-space:nowrap">ETX-810</FONT> did not have any potential for either direct or time-dependent inhibition of the cytochrome P450 (CYP) isozymes. Because the majority of metabolism of PEA occurs
through esterases and lipases, and not through CYPs, there is little&nbsp;to no potential for drug-drug interactions. PEA is further degraded by <FONT STYLE="white-space:nowrap">N-acylethanolamine</FONT> acid amidase (NAAA) and to a lesser extent by
fatty acid amid hydrolase (FAAH) into palmitic acid and ethanolamine. We believe this supports <FONT STYLE="white-space:nowrap">ETX-810&#146;s</FONT> potential as a monotherapy or in combination with other pain drugs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2a Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the extensive clinical data on the efficacy of dietary supplement PEA and the findings on tolerability and exposure of our PEA
prodrug, <FONT STYLE="white-space:nowrap">ETX-810,</FONT> observed in our Phase 1 SAD/MAD and pharmacokinetic (PK) trials, we initiated Phase 2a clinical trials in pain associated with two chronic conditions: DPN and LSR. Our clinical development
team has significant experience designing and running clinical trials in chronic pain, allowing us to implement strategies that attempt to limit the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">patient-to-patient</FONT></FONT>
variability and placebo effect commonly observed in chronic pain studies. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2a DPNP clinical trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Phase 2a clinical trial is a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the
efficacy and safety of <FONT STYLE="white-space:nowrap">ETX-810</FONT> in adults with diabetic peripheral neuropathic pain. Patients will be instructed to take their study drug, either 1000 mg of <FONT STYLE="white-space:nowrap">ETX-810</FONT> or
placebo, twice per day, approximately twelve hours apart, with food. The primary endpoint of the trial is the change from baseline to week 4 in the weekly average of the daily pain score on the <FONT STYLE="white-space:nowrap">11-point</FONT> <FONT
STYLE="white-space:nowrap">PI-NRS.</FONT> Secondary endpoints include percent of patients with <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>30% reduction from baseline to Weeks 1, 2, 3 and 4 in
the weekly average of the daily pain score. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A trial schema of the Phase 2a DPNP clinical trial is provided below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g11x00.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;112&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 11. <FONT STYLE="white-space:nowrap">ETX-810</FONT> Phase 2a DPNP trial schema </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 162 subjects are planned to be randomized in a 1:1 ratio to the <FONT STYLE="white-space:nowrap">ETX-810</FONT> or placebo treatment
group. A sample size of 81 subjects per treatment group will provide 80% power to detect a <FONT STYLE="white-space:nowrap">1.0-point</FONT> change in the mean change from baseline to Week 4 in the weekly average daily pain score on the <FONT
STYLE="white-space:nowrap">PI-NRS.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are actively enrolling DPNP patients into this clinical trial and expect to have a topline
data readout during the first half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2a LSR pain clinical trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Phase&nbsp;2a clinical trial is a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group study designed
to evaluate the efficacy and safety of ETX-810 in adults with LSR. Patients will be instructed to take their study drug, either 1000 mg of ETX-810 or placebo, twice per day, approximately twelve hours apart, with food. The primary endpoint of the
trial is the change from baseline to week four in the weekly average of the daily pain score on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS). Secondary endpoints include percent of patients with greater than 50% and 30% reduction from
baseline to Weeks&nbsp;1, 2, 3 and 4 in the weekly average of the daily pain score. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A trial schema of the Phase&nbsp;2a LSR clinical
trial is provided below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g00q10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 12. ETX-810 Phase 2a LSR trial schema </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 122 subjects are planned to be randomized in a 1:1 ratio to the ETX-810 or placebo treatment group. A sample size of 61 subjects per
treatment group will provide 80% power to detect a 1.0-point change in the mean change from baseline to Week 4 in the weekly average daily pain score on the pain intensity (PI)-NRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are actively enrolling LSR patients with chronic pain into this clinical trial and expect to have a topline data readout during the first
half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Clinical Trials for <FONT STYLE="white-space:nowrap">ETX-810</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the results of our Phase 2a clinical trials, we intend to consult with the FDA about future Phase&nbsp;2b/3 clinical trials. Our
current plan is to initiate Phase 2b dose-range finding trials in both DPNP and LSR indications in the second half of 2022. Beyond these initial indications, we plan to evaluate other opportunities to potentially expand development of <FONT
STYLE="white-space:nowrap">ETX-810</FONT> through careful consideration of our clinical data, the market and competitive landscape, and correspondence with FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;113&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ETX-155</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">ETX-155,</FONT> a GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor
positive allosteric modulator, or GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM, for the treatment of patients suffering from MDD, PMD and FOS. The GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM class has been
clinically validated in both depression and epilepsy indications by a variety of different agents in the class. <FONT STYLE="white-space:nowrap">ETX-155</FONT> was designed to have broad potency across both synaptic and extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor subtypes. <FONT STYLE="white-space:nowrap">ETX-155</FONT> has also shown desirable pharmacokinetic properties, including no clinically meaningful food effect and an approximate <FONT
STYLE="white-space:nowrap">24-hour</FONT> half-life to enable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-day-dosing,</FONT></FONT></FONT> positioning it favorably within the GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class. We believe <FONT STYLE="white-space:nowrap">ETX-155&#146;s</FONT> potent activity across GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor subtypes and
efficacy in preclinical models of epilepsy, depression, and anxiety supports its application in multiple therapeutic settings. We intend to initiate a Phase&nbsp;1b photosensitive epilepsy trial, which if successful, would support initiating a
Phase&nbsp;2 clinical trial in FOS. We plan to announce topline data from the photosensitive epilepsy trial in the first half of 2022. In addition, in the second half of 2021 we intend to initiate both a Phase 2a clinical trial in patients with MDD
and a Phase 2a clinical trial in patients with PMD, with both trials expected to report topline data in the first half of 2023. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> Receptor as a Therapeutic Target for Neurological and Psychiatric Disorders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the central nervous system. Neuronal signaling by GABA via the
GABA type A receptor (GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R) plays a critical role in a wide range of processes within the CNS. Modulation of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs via small
molecules has been a highly active area of research since their initial discovery in the 1960s. GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R is a clinically validated target, with multiple classes of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB><FONT STYLE="white-space:nowrap">R-targeted</FONT> drugs on the market, including benzodiazepines, anesthetics, anticonvulsants, neuroactive steroids (neurosteroids) and barbiturates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs are ligand-gated chloride channels with a pentameric structure composed of
&#945;, &szlig;, <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> subunits in a 2:2:1 stoichiometry. GABA-induced chloride influx mediated through
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs leads to hyperpolarization of neurons, preventing action potentials and dampening down neuronal excitability. There are six &#945;, three <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>,
two <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> subunits (also rare <FONT STYLE="FONT-FAMILY:SYMBOL">&#101;</FONT>, <FONT STYLE="FONT-FAMILY:SYMBOL">&#113;</FONT> and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#112;</FONT> subunits) that assemble to form 19 GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R subtypes. The subunit structures, abundance, distribution and drug binding regions of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs are summarized below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;114&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g61q01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 13. Mechanism of action of neurosteroid positive allosteric modulators (PAMs) of synaptic and extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. Neurosteroid PAMs can bind to and activate both synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors via an allosteric site distinct from
the GABA and benzodiazepine binding sites. This potentiates the action of both phasic and tonic inhibitory neurotransmission mediated by GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, leading to decreased neuronal
excitability. <FONT STYLE="white-space:nowrap">ETX-155</FONT> is an investigational neurosteroid with dual potency at synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> Structure and Properties: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19 GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> subtypes are differentially expressed in the
brain with distinct regional and cellular distribution dependent on subunit compositions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Of the 19 subtypes, &#945;1 GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs are the most abundant
(60%), with &#945;2 and &#945;3 less abundant <FONT STYLE="white-space:nowrap">(10-20%)</FONT> and &#945;4 and &#945;5 GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs the least abundant (~5%) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#945;1&szlig;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2,
&#945;2&szlig;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2 and &#945;3&szlig;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2 subtypes are expressed predominantly in synapses while &#945;4 and &#945;5 GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs are primarily extrasynaptic </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> subunit preferentially pairs with &#945;4, &#945;6 and
&szlig;2/3 subunits and these GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs are also expressed at extrasynaptic sites </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Benzodiazepines act only on synaptic receptors, inducing short term effects </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neurosteroids bind to a distinct site on both <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs and regulate both synaptic and extrasynaptic neuron functions </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs are typically clustered opposite GABA-releasing neuronal terminals. The
synaptic &#945;1&szlig;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2, &#945;2&szlig;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2 and &#945;3&szlig;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2 subtypes mediate rapid phasic inhibition of nerve
action potentials. The extrasynaptic &#945;4, &#945;6 and &szlig;2/3 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> subunit-containing GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs mediate tonic inhibition, potentially
generating a more powerful and broader modulation of cortical neural-network activity that is relevant in multiple CNS disease states and disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Positive allosteric modulators, or PAMs, are substances that bind to a receptor at a distinct site from the primary endogenous ligand and
enhance the receptor&#146;s response to the ligand. GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs act by enhancing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;115&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
endogenous GABA&#146;s activity at these receptors. Allopregnanolone is an endogenous GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>PAM and fluctuations in allopregnanolone levels
are associated with the pathophysiology of mood, anxiety and other psychiatric disorders. Exogenous neuroactive steroids (neurosteroids) are an emerging class of PAMs with potential for treating complex CNS disorders. ZULRESSO (brexanolone /
exogenous allopregnanolone; Sage Therapeutics, Inc.) was approved in 2019 for the treatment of postpartum depression (PPD). Other neurosteroid molecules in clinical development include zuranolone <FONT STYLE="white-space:nowrap">(SAGE-217;</FONT>
Sage Therapeutics, Inc.) for PPD and MDD, ganaxolone (Marinus Pharmaceuticals, Inc) for rare epilepsies and <FONT STYLE="white-space:nowrap">PRAX-114</FONT> (Praxis Precision Medicines, Inc.) in MDD and PMD.
<FONT STYLE="white-space:nowrap">CVL-865</FONT> (Cerevel Therapeutics, Inc.) is also a GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM in clinical development for epilepsy, but unlike the neurosteroids, <FONT
STYLE="white-space:nowrap">CVL-865</FONT> binds to the benzodiazepine site of synaptic &#945;2/3/5 GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R subtypes. The clinical data generated from these candidates suggest that a GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor PAM may have potential therapeutic effect in depression and epilepsy. However, pharmacokinetic properties and/or tolerability concerns leave an opportunity for clinical differentiation
with <FONT STYLE="white-space:nowrap">ETX-155.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">ETX-155</FONT> and its Competitive Advantages</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ETX-155</FONT> is a neurosteroid GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM NCE
designed to have broad potency at synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors (EC50&#146;s of 95 &#150;330 nM). In preclinical studies, <FONT STYLE="white-space:nowrap">ETX-155</FONT> showed
favorable pharmacokinetic properties and potent activity across several animal models of CNS diseases. Based on these studies, we believe <FONT STYLE="white-space:nowrap">ETX-155</FONT> is a promising investigational therapy for treatment of
psychiatric mood disorders and focal onset seizures. We believe <FONT STYLE="white-space:nowrap">ETX-155</FONT> has several potential advantages that, collectively, differentiate it from other product candidates in the GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class and could represent a compelling clinical profile. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dual synaptic and extrasynaptic activity</I>. <FONT STYLE="white-space:nowrap">ETX-155&#146;s</FONT> design to
bind at the synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs is believed to cause enhanced phasic and tonic inhibition, which can lead to decreased neuronal excitability. We believe that both types of
inhibition are important for neurosteroid clinical efficacy in depression and epilepsy, as suggested by the positive clinical results of brexanolone and zuranolone in depression and ganaxolone in epilepsy, all of which have dual activity at synaptic
and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Consistency of effect</I>. Phase 1 clinical trials demonstrate that taking
<FONT STYLE="white-space:nowrap">ETX-155</FONT> with or without food does not result in a clinically meaningful difference in pharmacokinetics, specifically with the C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>, and the total drug
exposure (AUC). This is a unique characteristic in contrast to other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs such as ganaxolone, brexanolone and zuranolone which are reported to require administration timed with a meal to
achieve desired clinical outcomes. Given challenges with patient compliance, we believe the lack of a clinically meaningful food effect is an important patient-centric differentiation that should allow patients the flexibility to take therapy with
or without a meal<I> </I>while maintaining a consistent therapeutic exposure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Once a day dosing</I>. <FONT STYLE="white-space:nowrap">ETX-155</FONT> demonstrated a half-life of
approximately 24 to 26 hours which provides confidence the agent can be utilized in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-day</FONT></FONT> evening dosing regimen. We believe this will be a competitively
differentiated and favorable dosing regimen for patients. The pharmacokinetic data for <FONT STYLE="white-space:nowrap">ETX-155</FONT> compares favorably with other GABA PAM product candidates in development, which have demonstrated half-lives
ranging from approximately 2 hours to 18 hours. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Potential for favorable therapeutic window across a broad set of CNS indications</I>. To date, <FONT
STYLE="white-space:nowrap">ETX-155</FONT> has shown encouraging safety and tolerability data in its SAD and MAD Phase 1 clinical trials. The exposures attained from the 60 mg dose in our Phase 1 MAD cohorts are consistent with the exposures that led
to robust activity of <FONT STYLE="white-space:nowrap">ETX-155</FONT> in our preclinical models of depression, anxiety and epilepsy.&nbsp;This increases our confidence that 60 mg has the potential to be an efficacious dose in the indications we are
pursuing. Separately, we believe the favorable tolerability data demonstrated in our SAD and MAD clinical trials and the activity observed in preclinical models will support our evaluation of a range of doses to potentially offer physicians
different dose levels, allowing for patient-centric dosing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;116&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Major Depressive Disorder (MDD) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MDD is a long-term, sometimes lifelong mood disorder capable of causing severe impairments that interfere with the ability to carry out life
activities. MDD is a recurrent disease and follows a fluctuating course of depressive episodes over an individual&#146;s lifetime, with periods of remission and relapse. MDD episodes are characterized by periods of at least two weeks of persistent
depressed mood and/or the loss of interest in activities, accompanied by symptoms such as sleep and appetite disturbance, fatigue, concentration difficulty, cognitive impairment, feelings of guilt, agitation and suicidal ideation. The <FONT
STYLE="white-space:nowrap">12-month</FONT> prevalence of MDD in 2020 was estimated to be 35&nbsp;million across the major markets of the United States, Europe and Japan. It was also recently reported that serious depression symptoms have increased
by more than <FONT STYLE="white-space:nowrap">3-fold</FONT> overall during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, though the long-term impact of the pandemic on the prevalence of MDD remains to be determined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MDD is difficult to treat, with current approaches utilizing a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;trial-and-error&#148;</FONT></FONT> sequential treatment strategy because there are no consistently identified predictors of differential response across treatment modalities.
The most used current therapeutic treatments for MDD include mixed SNRIs and SSRIs, dopaminergic/noradrenergic agents and atypical antipsychotics. Nearly two thirds of treated MDD patients are unable to achieve an adequate response with first-line
therapy, and most of these initial failures also fail second-line treatment, according to results from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, the largest prospective clinical trial of MDD treatments, published in
2010. In the major markets of the United States, Europe and Japan there are estimated to be more than 13 million MDD patients who have failed one prior class of antidepressant therapy, and an estimated 3.4 million who have failed two prior classes
of antidepressants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even for patients deemed responsive, disease burden often persists through the presence of residual depression
symptoms that lead to an ongoing negative impact on home life and interpersonal functioning, as well as a significantly increased risk of relapse of the full depressive syndrome and worse comorbid outcomes, including suicide. All the currently
available classes of treatment have side effects that can negatively impact treatment outcomes, quality of life and adherence to medication, including weight gain, nausea, sexual dysfunction, fatigue, insomnia and numerous other adverse effects. In
addition, typically current therapeutic treatments take up to six weeks before efficacy is established, which exposes patients to additional potential side effects and an increased period of suffering, before it is established if a treatment is
working. In part because of the long time to achieve benefit from current antidepressant therapies, many people with MDD opt to stay on their treatment chronically, enduring longer periods of side effects, rather than opting for episodic treatment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because MDD is increasingly acknowledged as a fluid spectrum of mood disorders and the patient population is heterogeneous, polypharmacy
and treatment-switching strategies that consider a patient&#146;s dynamic course of disease and fluctuating symptoms are becoming more commonplace. There is a need both for novel treatments with alternative mechanisms of action as well as treatments
that improve upon liabilities of existing drugs. Importantly, because of patient heterogeneity, switching therapies within a class can lead to improvements in efficacy and tolerability which can be as impactful as switching to a medication in a
different class. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Perimenopausal Depression (PMD) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PMD describes the development of depressive symptoms and major depressive episodes in women during the approximately <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">four-to-eight-year</FONT></FONT> period of menopausal transition occurring in women between approximately <FONT STYLE="white-space:nowrap">45-55</FONT> years of age, with an estimated
50&nbsp;million women worldwide reaching menopause annually. The perimenopausal period is associated with multiple neurologic symptoms believed to be associated with a reduction of estrogen / progesterone production and consequently a disruption of
multiple estrogen/progesterone-regulated systems in neuronal circuits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various studies have found the prevalence of depression symptoms
in women during this perimenopausal period as between 15% and 50%. While women with a prior history of MDD are approximately <FONT STYLE="white-space:nowrap">2-3</FONT> times as likely to experience depressive episodes during the perimenopausal
period, this period is associated with a <FONT STYLE="white-space:nowrap">2-fold</FONT> increased risk in the development of significant depression symptoms in women with no prior history of MDD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;117&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proven therapies for MDD are recommended as frontline therapy for perimenopausal major
depressive episodes, and there is some evidence that estrogen therapy in perimenopausal patients may have antidepressant effects, though it is not approved to treat perimenopausal depression. As with MDD, currently available anti-depressant /
anti-psychotic therapies do not provide the desired efficacy in the majority of perimenopausal women, and these agents continue to have the same tolerability liabilities. Novel treatments, which are safe, well-tolerated and rapidly acting are
needed. Antidepressant therapies that can also address other symptoms of perimenopause such as hot flashes, insomnia, pain and decline in cognitive function, all of which may contribute to the development of depressive symptoms, are needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opportunity for GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs in the treatment of hormone-related depression has been
validated by the clinical success of brexanolone and <FONT STYLE="white-space:nowrap">SAGE-217</FONT> in women with PPD, which, like PMD, is also linked to dramatic fluctuations in estrogen / progesterone levels. Brexanolone received FDA approval
for the treatment of PPD in 2019 after demonstrating statistically significant and clinically meaningful reductions in the Hamilton Rating Scale for Depression <FONT STYLE="white-space:nowrap">(HAM-D)</FONT> score with a <FONT
STYLE="white-space:nowrap">60-hour</FONT> IV infusion of brexanolone compared to placebo in Phase 3 trials. Similarly, the orally administered GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM,
<FONT STYLE="white-space:nowrap">SAGE-217,</FONT> demonstrated statistically significant reductions in <FONT STYLE="white-space:nowrap">HAM-D</FONT> in a Phase 3 trial in women with PPD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MDD and PMD Unmet Need and Opportunity for <FONT STYLE="white-space:nowrap">ETX-155</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite numerous antidepressant treatment options, there continues to be an unmet need for antidepressants that provide rapid onset of effect,
higher remission rates, efficacy throughout the depressive episode, an improved tolerability profile and an episodic dosing schedule that is aligned with the episodic nature of the disease. A
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM that potentiates the activity of endogenous neuroactive steroids at GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors may offer broader and more rapid
therapeutic benefit compared to current standard of care antidepressants, potentially enabling effective episodic treatment of depressive episodes as they arise. Further, we believe a GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM
like <FONT STYLE="white-space:nowrap">ETX-155</FONT> with the potential differentiated ability to be dosed once a day in the evening with no clinically meaningful food effect could create an exciting commercial opportunity in an attractive,
expanding market. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Epilepsy and Focal Onset Seizure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Epilepsy is a chronic CNS condition characterized by recurring seizures arising from hyperexcitable neuronal circuits. The condition
encompasses multiple seizure types and syndromes, diverse etiologies and variable prognoses and as such, classification systems have been developed. Classification is made at three levels: seizure type, epilepsy type and syndrome. At each stage,
cause and comorbidities should be identified as these can have important therapeutic implications. Most seizures can be categorized as either &#147;focal&#148; or &#147;generalized&#148;, depending on whether the onset of electrical activity affects
one side (focal) or both sides (generalized) of the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Epilepsy is the most prevalent chronic brain disease and affects an estimated
50&nbsp;million people worldwide with over 4.7&nbsp;million cases in the major markets of the United States, Europe and Japan. FOS (also referred to as focal seizure, partial-onset seizure, or localization-related epilepsy) is a category of seizures
that originate from a localized region of the brain and represent the most common seizure disorder encountered in patients with epilepsy. According to the National Institute of Neurological Disorders and Stroke, about 60% of people with epilepsy
experience FOS / partial-onset seizures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aim of ASM therapy is to achieve a <FONT STYLE="white-space:nowrap">seizure-free</FONT>
status without debilitating adverse side effects. Current standard of care for epilepsy/FOS is treatment with one or more ASMs in continuous prophylactic schemes. There are approximately 30 ASMs currently approved in the United States, which act via
several different mechanisms including sodium/calcium channel inhibition, potassium channel activation and glutamate receptor antagonism, among others. Many approved ASMs have Black Box warnings and/or dose-limiting side effects that can limit the
ability to maintain therapeutic dose levels necessary for seizure control, with adverse effects </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;118&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including sedation, ataxia, cognitive impairment, weight gain and agitation. Because of the diversity of mechanisms, polypharmacy of ASMs is common if patients fail first-line therapy or have
tolerability issues, with the addition of new drugs to a regimen, or switching to alternative drugs, to provide better seizure control and/or improved tolerability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the range of treatment options available, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of epilepsy patients with
focal onset seizures are considered drug-resistant and are either unable to maintain seizure control after three prior ASM therapies, or are unable to tolerate such ASMs.&nbsp;The inability to control seizures may result in severe disability,
increased mortality rates and socioeconomic consequences such as lower levels of employment and income and increased direct and indirect healthcare costs. Although seizures are the most striking clinical manifestation of epilepsy, other effects on
quality of life arise from common <FONT STYLE="white-space:nowrap">co-morbidities</FONT> including cognitive dysfunction (<I>e.g.</I>, memory, attention, or processing difficulties), sleep disorders, migraines and mental health / mood disorders
(<I>e.g.</I>, depression and anxiety). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depression is the most common <FONT STYLE="white-space:nowrap">co-morbidity</FONT> of epilepsy,
with a reported lifetime prevalence of major depression in approximately 30% among individuals with epilepsy. This increased rate of depression may in part be due to the side effects of current ASMs, a comorbidity of epilepsy itself, or a
combination of the two. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Focal Onset Seizure Opportunity for <FONT STYLE="white-space:nowrap">ETX-155</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By acting as a positive allosteric modulator of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>Rs,
<FONT STYLE="white-space:nowrap">ETX-155</FONT> is designed to increase the effect of the inhibitory neurotransmitter GABA, potentially leading to anticonvulsant activity. As a result of its preclinical anti-convulsant activity and its potential
positive impact on mood, we believe that <FONT STYLE="white-space:nowrap">ETX-155</FONT> has the potential to be positioned as a differentiated treatment option in refractory focal onset seizure. A well-tolerated, novel ASM with a favorable efficacy
profile in refractory focal onset seizures combined with a positive impact on mood would be a clinically differentiated profile and an attractive alternative for patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">ETX-155</FONT> Preclinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ETX-155:</FONT> a potent positive allosteric modulator of synaptic and extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ETX-155</FONT> is designed as a
neurosteroid GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R positive allosteric modulator, and has dual potency at both synaptic and extrasynaptic receptors. Using automated patch clamp electrophysiology against 19 different synaptic
and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor subtypes, <FONT STYLE="white-space:nowrap">ETX-155</FONT> demonstrated approximately equal potency on all subtypes, with EC50 values ranging from 95 nM to 330
nM including 207 nM and 165 nM EC50 at the most predominant synaptic (&#945;1&szlig;2<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2) and extrasynaptic (&#945;4&szlig;3<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>) subtypes, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">High intrinsic activity, a measure of the potentiation of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> currents, was
demonstrated across GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor subtypes, with <FONT STYLE="white-space:nowrap">ETX-155</FONT> having an approximately 3 times higher intrinsic activity at extrasynaptic &#945;4&szlig;3<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> subtype (1530%) vs. synaptic &#945;1&szlig;2<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>2 (586%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our in vitro assessments, the potency and activity of <FONT STYLE="white-space:nowrap">ETX-155</FONT> across GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> subtypes was comparable to that of <FONT STYLE="white-space:nowrap">SAGE-217</FONT> and ganaxolone. In contrast, data publicly disclosed by Praxis Precision Medicines reported a selectivity for
extrasynaptic versus synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors for the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM, <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;119&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical anti-seizure activity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We investigated the preclinical activity of <FONT STYLE="white-space:nowrap">ETX-155</FONT> in a pentylenetetrazol&nbsp;(PTZ) induced seizure
model and a maximal electroshock (MES) model of epilepsy, which are well-established predictive models for clinical anti-convulsant activity. In these studies, <FONT STYLE="white-space:nowrap">ETX-155&#146;s</FONT> activity was evaluated in parallel
experiments with ganaxolone, another GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM in development for epilepsy indications, and valproate was used as a positive control. In both the PTZ and MES models, <FONT
STYLE="white-space:nowrap">ETX-155</FONT> and valproate demonstrated encouraging dose-dependent anticonvulsant activity. The GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM ganaxolone did not achieve statistically significant
efficacy in either model at matched doses up to 10mg/kg. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g11i11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 14. Activity of <FONT STYLE="white-space:nowrap">ETX-155,</FONT> ganaxolone and valproate (positive control) in
two preclinical seizure models. (a)&nbsp;Mice were pretreated with control or test article and then were given a bolus intraperitoneal injection of PTZ to induce acute seizures, followed by the observation of the seizure profile and latency times. <FONT
STYLE="white-space:nowrap">ETX-155</FONT> (at all doses tested) and valproate significantly increased the latency time to the first full tonic seizure. Ganaxolone did not achieve statistical significance in this experiment. (b)&nbsp;The MES model is
an electrically-induced acute seizure model of generalized tonic-clonic seizures. Mice were pretreated with control or test article and then were subjected to <FONT STYLE="white-space:nowrap">seizure-inducing</FONT> electric shock. The magnitude of
the resulting seizure was evaluated using a seizure severity ranking from 0 to 6. Valproate and 10 mg/kg of <FONT STYLE="white-space:nowrap">ETX-155</FONT> significantly decreased the seizure rank. Ganaxolone did not achieve statistical significance
in this experiment. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;120&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical anti-depressant and anxiolytic activity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity of <FONT STYLE="white-space:nowrap">ETX-155</FONT> was investigated in preclinical models of anxiety and depression. The anxiety
models included the elevated plus maze, social interaction and marble burying paradigms. <FONT STYLE="white-space:nowrap">ETX-155</FONT> and <FONT STYLE="white-space:nowrap">SAGE-217,</FONT> another GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM in development for mood disorder indications, showed a dose-dependent efficacy in all models. As shown in <B></B><I>Figure 15a</I> a, <FONT STYLE="white-space:nowrap">ETX-155</FONT> and <FONT
STYLE="white-space:nowrap">SAGE-217</FONT> dose-dependently improved the time spent in open arms (a measure hypothesized to reflect reduced levels of anxiety) in the rat elevated plus maze behavioral model. The forced swim model in rats was used to
assess to potential anti-depressant activity of <FONT STYLE="white-space:nowrap">ETX-155</FONT> and <FONT STYLE="white-space:nowrap">SAGE-217</FONT> (<B></B><I>Figure 15b</I>). Both compounds demonstrated a dose-dependent statistically significant
efficacy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g22i22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 15. Efficacy of <FONT STYLE="white-space:nowrap">ETX-155</FONT> and
<FONT STYLE="white-space:nowrap">SAGE-217</FONT> in (a)&nbsp;an anxiolytic (elevated plus maze) preclinical model in rats, where the anxiety level is evaluated by the amount of time animals spent in the open arms of a plus-shaped apparatus with two
open and two enclosed arms. (b)&nbsp;a depression (forced swim test) model in rats based on the animal&#146;s level of activity (climbing or swimming) when placed in an enclosed container filled with water, where the level of immobility of the
animal is hypothesized to indicate a depressive mood. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;121&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical EEG model as a biomarker of dose-dependent target engagement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We used electroencephalography (EEG) to investigate the effect of <FONT STYLE="white-space:nowrap">ETX-155</FONT> on brain activity in rats. In
this model, changes in the EEG spectral power, reflecting a change in cortical neuronal activity, serve as a robust pharmacodynamic biomarker for target engagement with strong translatability from rats to humans.
<FONT STYLE="white-space:nowrap">ETX-155</FONT> increased spectral power of the theta, alpha, beta, and low gamma frequencies, and decreased the power of the high gamma frequency. Figure&nbsp;16 below demonstrates the dose-dependent increase in beta
power during wake and <FONT STYLE="white-space:nowrap">non-rapid</FONT> eye movement (NREM) sleep. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g33i33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure&nbsp;16. Effect of <FONT STYLE="white-space:nowrap">ETX-155</FONT> (1, 3, 6, or 10 mg/kg) on sleep and cortical
activity in rats (n=12, cross-over study design). (a) change in beta spectral power over time during wake stage (b)&nbsp;change in beta spectral power over time during NREM sleep. Animals were dosed at 8pm and EEGs were recorded from 2 hours <FONT
STYLE="white-space:nowrap">pre-dose</FONT> to 22 hours post-dose. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ETX-155</FONT> MAD trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAD portion of our Phase&nbsp;1 trial enrolled two cohorts of subjects, with 12 participants in each cohort dosed for 7&nbsp;days. The
first cohort was dosed with 60&nbsp;mg of <FONT STYLE="white-space:nowrap">ETX-155</FONT> daily in the morning while fasted while the second cohort was dosed 60&nbsp;mg of <FONT STYLE="white-space:nowrap">ETX-155</FONT> daily in the evening (at
approximately 6 PM) after a meal. Both cohorts consisted of nine active subjects and three placebo subjects. In both cohorts, no significant adverse events were seen, there were no subject discontinuations nor were there any clinically significant
abnormal values in vital signs, ECGs and clinical labs. However, the 60&nbsp;mg cohort dosed in the evening experienced fewer adverse events. The advantage of dosing GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs in the evening
has also been demonstrated with other molecules in clinical development such as <FONT STYLE="white-space:nowrap">SAGE-217,</FONT> <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and ganaxolone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our MAD trial, <FONT STYLE="white-space:nowrap">ETX-155</FONT> was well tolerated with no dose limiting AEs, no discontinuations and no
abnormal clinical values. We believe the safety and tolerability data observed in the MAD trial compare favorably to other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs in clinical development. With respect to pharmacokinetics,
during this portion of the trial, ETX-155 did not reach steady-state at day seven and moderate accumulation was seen. Pharmacokinetic modeling suggested that steady-state was likely to be reached shortly after day seven. Therefore, we initiated an
additional randomized, placebo-controlled MAD trial in healthy volunteers to further evaluate the safety, tolerability and pharmacokinetics of 60&nbsp;mg per day of ETX-155 when dosed for 14&nbsp;consecutive days in the evening, including additional
pharmacokinetic sampling time points to determine when steady-state is reached. This 14-day MAD trial is expected to read out in the third quarter of 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;122&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 17 below summarizes the adverse events observed of
<FONT STYLE="white-space:nowrap">ETX-155&#146;s</FONT> <FONT STYLE="white-space:nowrap">7-day</FONT> MAD clinical trial in healthy volunteers. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g44i44.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure&nbsp;17. Summary of all treatment emergent adverse events from the MAD portion of the <FONT
STYLE="white-space:nowrap">ETX-155</FONT> Phase 1 healthy volunteer study evaluating 60 mg <FONT STYLE="white-space:nowrap">ETX-155</FONT> dosed either in the morning or in the evening for 7 days. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trials referred to in Figure 18 below describe the CNS AEs from the <FONT STYLE="white-space:nowrap">ETX-155</FONT> MAD clinical trial in
healthy volunteers (evening dose cohort only, compared to placebo from both cohorts), and the CNS AEs from the <FONT STYLE="white-space:nowrap">PRAX-114</FONT> open-label Phase 2a and the <FONT STYLE="white-space:nowrap">SAGE-217</FONT>
placebo-controlled Phase 3 clinical studies in MDD. The trials referenced in the figure below were conducted at different points in time using different trial designs, and accordingly, the trial results may not be indicative of the safety or
tolerability of these therapies. No <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trials have been conducted with <FONT STYLE="white-space:nowrap">ETX-155</FONT> and any other GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM. We are encouraged by initial tolerability data reported thus far in the Phase&nbsp;1 MAD trial as compared to other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs
currently in clinical development. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g08e09.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure&nbsp;18. (a) CNS AEs from ETX-155 Healthy Volunteer MAD trial, 60 mg evening dose compared to placebo. (b)
Publicly reported CNS AEs from SAGE-217 Phase 3 WATERFALL trial in MDD patients, 50 mg evening dose compared to placebo. (c) Publicly reported CNS AEs from PRAX-114 Phase 2a open-label trial in MDD patients, 45 mg, 60 mg, and 80 mg evening dose.
ETX-155 has not been assessed in a head-to-head study against either PRAX-114 or SAGE-217 and the trial designs for all three product candidates were different. As a result, such data may not be directly comparable. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;123&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our analysis of the plasma concentrations observed for the 60 mg dose of ETX-155 in the
7-day MAD trial found that the mean plasma exposure at day 7 was consistent with the range of exposures where robust activity was observed in our depression, anxiety, anticonvulsant and EEG preclinical models. In addition, the exposures achieved
with the 60&nbsp;mg dose of ETX-155 in the MAD in healthy volunteers are consistent with those modeled for another GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM, zuranolone (SAGE-217), at the 30 mg and 50 mg dose levels in its
MAD trial in healthy volunteers. This observation increases our confidence that the 60 mg dose achieves the necessary level of exposure to potentially be an efficacious dose in the indications we are pursuing. Combined with the favorable
tolerability data demonstrated by this dose level in the Phase 1 SAD and MAD, we intend to move forward with this dose into our future clinical trials in patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Future clinical trials for <FONT STYLE="white-space:nowrap">ETX-155</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to initiate a <FONT STYLE="white-space:nowrap">single-arm</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 1b Photosensitive Epilepsy (PSE) trial in the second half of 2021 with topline data by the first half of 2022. Pharmacological effects in
photosensitive epilepsy <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials are correlated with a higher likelihood that positive results will be observed in the clinical epilepsy population. As
such, it has historically been utilized as a tool to quantitatively predict efficacy at certain dose levels in epilepsy. Assuming the results of this trial are positive, we plan to initiate a Phase 2 clinical trial in patients with focal onset
seizures in the first half of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to initiate a randomized, placebo-controlled, Phase 2a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial of <FONT STYLE="white-space:nowrap">ETX-155</FONT> in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> MDD patients in the second half
of 2021 with topline data in the first half of 2023. Further, we expect to initiate a randomized, placebo-controlled, Phase 2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial of <FONT
STYLE="white-space:nowrap">ETX-155</FONT> in patients with PMD in the second half of 2021 with topline data in the first half of 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preclinical Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kv7.2/3 Program for Epilepsy
and Pain </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead preclinical program is a next-generation Kv7.2/3 channel opener being developed for epilepsy and neuropathic
pain. Kv7.2/3 is a heteromeric voltage-gated potassium channel comprised of Kv7.2 and Kv7.3 subunits (Kv7.2/3) that plays an important role in stabilizing the membrane potential of neuronal cells and controlling neuronal excitability. Kv7.2/3 has
genetic validation as a target for epilepsy, as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutations in the genes encoding for Kv7.2 and Kv7.3, KCNQ2 and KCNQ3, have been shown to be responsible
for a rare epilepsy disorder in newborns that leads to impaired gating of the Kv7.2/3 channel and hyperexcitation of neurons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition
to its genetic validation, Kv7.2/3 has been clinically validated as a therapeutic target for both epilepsy and pain. The first generation Kv7 channel opener, ezogabine (Potiga), was approved for refractory focal onset seizures in 2011 in both the
United States and in Europe (where it was known as retigabine, or Trobalt). Flupirtine (Katadolon) was another first generation Kv7.2/3 opener that provided clinical validation and has been used in Europe as a treatment for pain since the 1980s.
Despite demonstrating compelling efficacy in epilepsy and pain, ezogabine/retigabine and flupirtine were removed from the market in 2017 and 2018, respectively, due to emergent unexpected safety concerns. In the case of ezogabine, an accumulation of
blue pigment in the skin and eye was identified, raising concerns of potential vision loss, while flupirtine was associated with severe liver toxicity, including cases of acute liver failure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have used a combination of both ligand-based and structure-based design approaches to develop novel Kv7.2/3 opener compounds that
potentially eliminate the toxicity liabilities associated with the first generation Kv7.2/3 openers, while retaining strong activity and selectivity. We plan to nominate a clinical candidate from our Kv7.2/3 program in the second half of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Next-generation Anxiolytic for Generalized Anxiety Disorder (GAD) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second preclinical program is focused on developing a novel, potent analog of an earlier approved
<FONT STYLE="white-space:nowrap">2,3-benzodiazepine</FONT> for the potential treatment of GAD. The aim of our program is to develop a rapidly acting, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;124&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-sedating,</FONT> <FONT STYLE="white-space:nowrap">non-addictive</FONT> anxiolytic that does not impair motor or cognitive performance, does not have any
adverse drug-drug interactions, and has the potential to be dosed once a day. We plan to nominate a clinical candidate for our GAD program in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry
is characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. We face potential competition from many different sources, including major and specialty pharmaceutical, biopharmaceutical,
therapeutics and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with current therapies
and new therapies that may become available in the future. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective or more convenient or have fewer or less severe
side effects than any products that we may develop. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we do. We believe that the key competitive factors affecting the success of any of our
product candidates will include efficacy, safety profile, convenience, cost, the level of branded and generic competition, market access and reimbursement by payors, level of promotional activity devoted to them and intellectual property protection.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>DPNP and LSRP </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the field of
chronic pain associated with DPN and LSR, our principal competition is from existing therapies including NSAIDs, gabapentinoids, antidepressants, and opioids. Specifically, patients diagnosed with LSR are usually prescribed with NSAIDs,
gabapentinoids (<I>e.g.</I>, pregabalin, gabapentin), or opioids. DPN patients are often treated with antidepressants (<I>e.g.</I>, duloxetine, venlafaxine, amitriptyline and other tricyclic drugs), gabapentinoids, or opioids (<I>e.g.</I>,
tapentadol HCl). We are aware of a number of therapies that are approved to treat other types of neuropathic pain. We are also aware that various therapies are used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat neuropathic pain. Our
competition may also include other programs in clinical development targeting other mechanisms of actions for the treatment of DPNP and LSRP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Depression and Epilepsy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
field of neuroactive steroids focused on modulation of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, our principal competitors are Sage Therapeutics, Inc. developing zuranolone for PPD and MDD, Marinus Pharmaceuticals,
Inc. developing ganaxolone for rare epilepsies, and&nbsp;Praxis Precision Medicines, Inc. developing <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in MDD and PMD. Cerevel Therapeutics, Inc. is also developing a GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM, <FONT STYLE="white-space:nowrap">CVL-865,</FONT> for the treatment of epilepsy, but unlike the neurosteroids, <FONT STYLE="white-space:nowrap">CVL-865</FONT> reportedly binds to the
benzodiazepine site of synaptic &#945;2/3/5 GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>R subtypes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the treatment of
depressive disorders, we may also face competition from other programs in clinical development targeting other mechanisms of action and approved therapies for depressive disorders such as mixed serotonin modulators, SNRIs, SSRIs,
dopaminergic/noradrenergic agents, and atypical antipsychotics. Several biopharmaceutical companies have therapies in clinical development for depressive disorders targeting other mechanisms of action, including Janssen Pharmaceuticals, Axsome
Therapeutics and Compass Pathways. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the treatment of epilepsy, we may also face competition from a variety of currently marketed
therapies such as generic anticonvulsants, sodium channel modulators and benzodiazepines. Additionally, there are next-generation therapies in development harnessing the previously mentioned mechanisms of action, such as XEN901 being <FONT
STYLE="white-space:nowrap">co-developed</FONT> by Xenon Pharmaceuticals and Neurocrine Biosciences. Furthermore, there are multiple compounds that have been recently approved or are in late-stage development for focal onset seizures, including
cenobamate, which was developed by SK Life Sciences and was approved by the FDA in November 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to face competition from
existing products and products in development for each of our product candidates. In addition to those described above, there may be other earlier stage clinical programs that, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;125&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved, would compete with our product candidates. Many of our competitors have substantially greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we do. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of
technologies and greater availability of capital for investment in these fields. Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient
therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
commercial success will depend in part on our ability to obtain and maintain proprietary protection for our product candidates and any associated novel discoveries, drug development technologies and <FONT STYLE="white-space:nowrap">know-how;</FONT>
to operate without infringing on or otherwise violating the proprietary rights of others; and to prevent others from infringing or otherwise violating our proprietary rights. Our policy is to seek to protect our proprietary position for our product
candidates by, among other methods, filing and acquiring U.S. and foreign patents and patent applications related to our products and other proprietary technology, inventions and improvements that are important to the development and implementation
of our business. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop and maintain our
proprietary position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our intellectual property estate is designed to provide multiple layers of protection, including: (1)&nbsp;patents
and patent applications with claims directed to our product candidates; (2)&nbsp;patent applications with claims directed to methods of treatment using our product candidates; and (3)&nbsp;patent applications with claims directed to innovative
formulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we seek to cover our product candidates and their use in our issued patents and pending patent applications, there is
always a risk that a modification of the product or its use may allow a competitor to avoid infringement claims. In addition, patents, if granted, expire, and we cannot provide any assurance that any patents will be issued from our pending or any
future applications or that any issued patents will adequately protect our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ETX-810</FONT></I>. The compound in this product candidate is covered by a patent family that covers the
compound (both generically and specifically) and use of the compound to treat various pain conditions. This patent family includes an issued U.S. patent and pending patent applications in the United States, Australia, Canada, China, Europe, Hong
Kong and Japan. The European Patent Office recently confirmed that the European patent application will be considered allowable subject to minor modifications. The compound portfolio is expected to expire on October&nbsp;12, 2037, excluding any
patent term extension or adjustments that may be granted. We also filed a priority application in the United Kingdom covering a new process for preparing <FONT STYLE="white-space:nowrap">ETX-810.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will leverage new discoveries we are making in the research of <FONT STYLE="white-space:nowrap">ETX-810</FONT> by filing patent
applications thereon to strengthen the breadth and depth of our patent coverage for this product candidate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">ETX-155</FONT></I>. Our intellectual property portfolio covering <FONT STYLE="white-space:nowrap">ETX-155</FONT> includes an issued U.S. patent with method claims covering use of the composition of matter to treat an
anxiety disorder, depression, or a seizure disorder, a pending international patent application under the Paris Cooperation Treaty (PCT) that preserves our future right to file this PCT international application into individual foreign countries and
a pending U.S. patent application each having claims covering the composition of matter, and a pending U.S. application with method claims covering use of the composition of matter to treat sleep disorders. We have also received a notice of
allowance in the U.S. directed to a formulation of the ETX-155 composition of matter. The issued U.S. patent and any future patents claiming priority thereto are expected to expire in September 2039, excluding any patent term extensions or
adjustments that may be granted. Any foreign patents that issue claiming priority to the international application are expected to expire in September 2040. In the last year we also filed nine U.S. provisional applications covering methods of
treatment and formulations of <FONT STYLE="white-space:nowrap">ETX-155.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;126&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also working to develop new formulations of
<FONT STYLE="white-space:nowrap">ETX-155</FONT> and new uses for <FONT STYLE="white-space:nowrap">ETX-155,</FONT> which we intend to file patent applications on in order to expand the layers of protection provided by our intellectual property
estate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Protection and Terms </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the
legal term of patents in the countries in which they are obtained. Generally, patents issued from regularly filed applications in the United States are granted a term of 20 years from the earliest effective filing date. In addition, in certain
instances, a patent term can be adjusted to recapture a portion of the United States Patent and Trademark Office (USPTO), delay in issuing the patent, and extended to recapture a portion of the patent term effectively lost as a result of the FDA
regulatory review period of the drug covered by the patent. However, as to the FDA component, the restoration period cannot be longer than five years, the total patent term including the restoration period must not exceed 14 years following FDA
approval of the drug, and the extension may only apply to one patent that covers the approved drug (and to only those patent claims covering the approved drug, a method for using it, or a method for manufacturing it). There can be no assurance that
any such patent term adjustment or extension will be obtained. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual
protection afforded by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from country to country, and depends upon many factors, including the type of patent, the scope of
its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the patent positions of biotechnology and pharmaceutical products and processes like those we intend to develop and commercialize
are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in such patents has emerged to date in the United States. The patent situation outside the United States is even
more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries can diminish our ability to protect our inventions and enforce our intellectual property rights, can make it easier to
challenge the validity, enforceability or scope of any patents that may issue, and, more generally, could affect the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our
patents or in third-party patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-Party Patent Filings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are developing
products. In addition, because patent applications can take many years to issue, there may be applications unknown to us, which may later result in issued patents that our products or proprietary technologies may infringe. Moreover, we may be aware
of patent applications, but incorrectly predict the likelihood of those applications issuing with claims of relevance to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under U.S.
law, a person may be able to patent a discovery of a new way to use a previously known compound, even if such compound itself is patented, provided the newly discovered use is novel and <FONT STYLE="white-space:nowrap">non-obvious.</FONT> Such a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent, however, if valid, only protects the use of a claimed compound for the specified methods claimed in the patent. This type of patent does not prevent
persons from using the compound for any previously known use of the compound. Further, this type of patent does not prevent persons from making and marketing the compound for an indication that is outside the scope of the patented method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets and Other Protections </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protections afforded by patents and other regulatory protections, we may rely, in some circumstances, on trade secrets to
protect our technology. Trade secrets may be useful to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable or which we elect not to patent. Trade secrets may also be useful for processes or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;127&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improvements for which patents are difficult to enforce. We also protect our products and proprietary technology through confidentiality agreements with employees, consultants, advisors,
contractors and collaborators. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third
party. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners,
collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and
physical and electronic security of our information technology systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Infringement of Third-Party Proprietary Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on not infringing upon or otherwise violating the intellectual property and proprietary rights of
third parties. If we are found to infringe a third party&#146;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be
able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same
technologies licensed to us. We could also be forced, including by court order, to cease commercializing the infringing product or technology. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146;
fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our products or force us to cease some of our business operations. For more information regarding these risks, see the
section titled &#147;Risk Factors&#151;Risks Related to Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently source all of our nonclinical
and clinical compound supply through third-party contract development and manufacturing organizations (CDMOs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clinical supply, we
use CDMOs who are obligated to act in accordance with the FDA&#146;s current Good Manufacturing Practices (cGMPs), for the manufacture of drug substance and product. We expect to rely on third parties for our manufacturing processes and the
production of all clinical supply drug substance and drug product and currently expect to continue to do so for commercial supplies of our product candidates, if approved. We use additional contract manufacturers to fill, label, package, store and
distribute our investigational drug products and currently expect to continue to do so for commercial supplies of our product candidates, if approved. It is our intent to identify and qualify additional manufacturers to provide active pharmaceutical
ingredient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;fill-and-finish&nbsp;services</FONT></FONT> prior to submission of a new drug application (NDA) to the FDA for any product candidates that complete clinical
development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome
requirements upon companies involved in the clinical development, manufacture, marketing and distribution of prescription drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other
things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and
import of drug products and product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;128&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation of Drug Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (FDCA) and its implementing regulations. Failure to
comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to
approve pending NDAs withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
contracts, restitution, disgorgement or civil or criminal penalties brought by the FDA and the Department of Justice (DOJ) or other governmental entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#146;s good laboratory practice
(GLP) regulations; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an investigational new drug (IND) which must become effective before human clinical
trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval by an independent institutional review board (IRB) at each clinical site before each trial may be
initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice
(GCP), requirements to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is
produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of
the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Payment of user fees and securing FDA approval of the NDA, including agreement to compliance with any
post-approval requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical studies
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any drug or biological product candidate, including our product candidates, in humans, the product candidate must
undergo rigorous preclinical testing. Preclinical studies generally include laboratory evaluation of product chemistry, formulation and stability, as well as animal studies to assess potential toxicity, which support subsequent clinical testing.
Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central
focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. Some preclinical testing may continue even after the IND is submitted. The IND also includes results of animal and in vitro studies assessing
the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;129&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT
STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns
or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve
the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in
writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be
evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. An IRB is charged with protecting the welfare and rights of trial participants
and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each
clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the
subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as
a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an
unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. Information about certain
clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation,
study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the
results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically
conducted in three sequential phases, which may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or
condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety
risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed
clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate
information for the labeling of the product. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are
used to gain additional experience from the treatment of patients in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;130&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intended therapeutic indication, particularly for long-term safety follow up. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an
NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if
serious adverse events occur. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can
suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. In
addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move
forward at designated check points based on access to certain data from the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are
given opportunities to meet with the FDA at certain points. These points are generally prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an
opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor to obtain the FDA&#146;s feedback on the next phase of development. Sponsors typically use the meetings at the end
of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the
chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently
producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing application submission and FDA review and approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed
information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. Data may come
from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must
be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. In most cases, the submission of an NDA is subject to a substantial application user fee; a waiver of
such fees may be obtained under certain limited circumstances. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (PDUFA), the FDA has ten months from the date of &#147;filing&#148; of a standard NDA for a new
molecular entity in which to complete its initial review and respond to the applicant, and six months from the filing date for priority applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA does not always meet its PDUFA goal dates, and the review process can be extended by FDA requests for additional information or
clarification and a sponsor&#146;s process to respond to such inquiries. This FDA review typically takes twelve months from the date the NDA is submitted to FDA (for a standard review) because the FDA has approximately two months, or 60 days, after
submission to make a &#147;filing&#148; decision on whether to accept an NDA for review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of all
NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;131&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
informs the sponsor by the 74th day after the FDA&#146;s receipt of the submission whether an application is sufficiently complete to permit substantive review. The FDA may request additional
information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is
accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is
manufactured, processed, packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the
deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the FDA may refer any application to an advisory committee, including applications for novel drug
candidates that present difficult questions of safety or efficacy. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the
application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA also may require submission of a risk
evaluation and mitigation strategy, or REMS, plan, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug product. The REMS plan could include medication guides,
physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific
REMS provisions, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. If the FDA concludes a REMS plan is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the
NDA without a REMS, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized (PREA),
certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each
pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in
adults, or full or partial waivers from the pediatric data requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including
the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue either an approval letter or a complete response letter (CRL). An approval letter authorizes
commercial marketing of the drug with specific prescribing information and for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally
outlines the deficiencies in the submission and contains a statement of specific conditions that must be met in order to secure final approval of the NDA; it may require additional clinical or preclinical testing and/or other significant and
time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a CRL is issued, the applicant may choose to either resubmit the NDA, addressing all of the deficiencies
identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response to an
issued CRL in either two or six months depending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;132&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications,
warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to
monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product.
The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes
and additional labeling claims, are subject to further testing requirements and FDA review and approval. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may
change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fast track, breakthrough therapy and
priority review designations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is authorized to designate certain products for expedited development or review if they are
intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast-track designation, breakthrough-therapy designation and priority-review designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be eligible for a fast-track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a
serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for the condition. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite
development and review of the product. The FDA may also review sections of the NDA for a fast-track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the
application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. The sponsor can request the FDA to
designate the product for fast-track status any time before receiving NDA approval, but ideally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> meeting. Fast track designation may be withdrawn by the sponsor or rescinded by the FDA
if the designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, with the enactment of the Food and
Drug Administration Safety and Innovation Act (FDASIA) in 2012, Congress created a new regulatory program for product candidates designated by FDA as &#147;breakthrough therapies&#148; upon a request made by IND sponsors. A breakthrough therapy is
defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over
currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the
development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the
development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a
collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor;
and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less
efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast-track designation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;133&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which means that the sponsor may file sections of the NDA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for
submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. Finally, the FDA may designate a product for priority review if it is a drug that treats a serious condition and, if approved,
would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis,
whether the proposed drug represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or
substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation
is intended to direct overall attention and resources to the evaluation of such applications and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months for an NDA for a new molecular entity from the
date of filing. If criteria are not met for priority review, the application for a new molecular entity is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not
change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies
for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review
and breakthrough therapy designation do not change the standards for approval and may not ultimately expedite the development or approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. marketing and data exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain
<FONT STYLE="white-space:nowrap">follow-on</FONT> drug applications. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain approval of
an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the
exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application (ANDA) or a 505(b)(2) NDA submitted by another company for a generic or <FONT STYLE="white-space:nowrap">follow-on</FONT> version of the protected drug
product, respectively, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT
STYLE="white-space:nowrap">non-infringement.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA also provides three years of data exclusivity when an NDA or a supplement to
an existing NDA, includes new clinical investigations, other than bioavailability studies, conducted or sponsored by the applicant that are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages
or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs or <FONT STYLE="white-space:nowrap">follow-on</FONT>
505(b)(2) NDAs if the protected clinical data are not referenced. Five-year and three-year exclusivity will not delay the submission or approval of a stand-alone NDA submitted under section 505(b)(1) of the FDCA. However, an applicant submitting a
stand-alone NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six
months to existing regulatory exclusivity periods. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an
<FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a trial. The issuance of a written request does not require the sponsor to undertake the described clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;134&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-approval requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new prescription drug product, the manufacturer and the approved drug are subject to pervasive and continuing
regulation by the FDA, including, among other things, requirements relating to monitoring and recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs must be promoted by a manufacturer and any third parties acting on behalf of a manufacturer only for the approved indications and
in a manner consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses and a company that is found to
have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. After approval, most changes to the approved product, such as adding new indications or other labeling claims or changes to the
manufacturing processes or facilities, are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products and the establishments where such products are manufactured, as well as new application
fees for supplemental applications with clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to
the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation
requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not
maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other
restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or suspension or
revocation of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing
warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product.
Discovery of previously unknown problems with a product or the failure to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;135&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective
advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#146;s approved labeling, including the addition of new warnings
and contraindications, and also may require the implementation of other risk management measures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of
prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug
distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. From time to time, new legislation and regulations may
be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be
enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other healthcare laws and
regulations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, including physicians and third-party payors in the United States and elsewhere will play a primary
role in the recommendation and prescription of any drug products for which we obtain marketing approval. Our current and future arrangements with third-party payors, customers, healthcare providers, physicians and others, in connection with the
clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud and abuse and other healthcare laws and regulations. In particular, the
research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services and certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or
financial arrangements. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which makes it illegal for any person or entity, including a prescription
drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or
reward, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare
program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The term remuneration has been interpreted broadly
to include anything of value. Further, courts have found that if &#147;one purpose&#148; of renumeration is to induce referrals, the federal Anti-Kickback statute is violated. Violations are subject to significant civil and criminal fines and
penalties for each violation, plus up to three times the remuneration involved, imprisonment and exclusion from government healthcare programs. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical
manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution;
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal civil and criminal false claims laws, including the False Claims Act (FCA), which can be
enforced through &#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be
presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false, fictitious or fraudulent; knowingly making, using, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;136&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
causing to be made or used, a false record or statement material to a false, fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or
knowingly concealing or knowingly and improperly avoiding or decreasing or concealing such an obligation. to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to
government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. In addition, a claim submitted for payment to any federal healthcare program that includes items or services that were made as a result of a
violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus
treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created additional
federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses,
representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (<I>e.g.</I>, public or private) and knowingly and willfully falsifying, concealing or
covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or
fraudulent statement or entry in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of
violating HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Physician Payments Sunshine Act and its implementing regulations, which require certain
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services (CMS), an
agency within the U.S. Department of Health and Human Services (HHS), under the Open Payments Program, information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to
include transfers of value made during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal and state consumer protection and unfair competition laws, which broadly regulate marketplace
activities and activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state, local and foreign laws and regulations, such as U.S. state anti-kickback, false claims and
laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and other
relevant compliance guidance promulgated by the federal government that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states
regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of
pharmaceutical sales representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory
exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws
involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;137&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are
instituted against us and we are not successful in defending ourselves or asserting its rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties,
damages, disgorgement, imprisonment, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and oversight if we become subject to integrity and oversight agreements to
resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate
our business and the results of operations. In addition, commercialization of any drug product outside the United States will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Further, if
any of the physicians or other healthcare providers or entities with whom we expect to do business with are found to be not in compliance with applicable laws, they may be subject to similar penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data privacy and security laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous
state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United
States, numerous federal and state laws and regulations, including state data breach notification laws, health information privacy laws, including HIPAA, and federal and state consumer protection laws (<I>e.g.</I>, Section&nbsp;5 of the Federal
Trade Commission Act) that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, the California Consumer Protection Act
(CCPA) came into effect on January&nbsp;1, 2020 and provides data privacy rights for consumers and operational requirements for companies. The CCPA gives California residents expanded rights to access and delete their personal information, opt out
of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to
increase data breach litigation. Further, the California Privacy Rights Act (CPRA), was recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies
doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result
in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on January&nbsp;1, 2023, and become enforceable on
July&nbsp;1, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the
EEA, including personal health data, is subject to the European Union (EU) General Data Protection Regulation (GDPR), which became effective in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process
personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities,
implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR imposes strict rules on the transfer of personal
data to countries outside the European Economic Area (EEA), including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#128;20&nbsp;million or 4% of
annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages
resulting from violations of the GDPR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the exit of the United Kingdom (U.K.), from the EU, often referred to as Brexit, has
created uncertainty with regard to data protection regulation in the U.K. From January&nbsp;1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or the U.K. GDPR, which, together with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;138&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended U.K. Data Protection Act 2018, retains the GDPR in U.K. national law. The U.K. GDPR mirrors the fines under the GDPR, <I>i.e.</I>, fines up to the greater of &#128;20&nbsp;million
(&pound;17.5 million) or 4% of global turnover. The relationship between the U.K. and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how U.K. data protection laws and regulations will develop in the
medium to longer term, and how data transfers to and from the U.K. will be regulated in the long term. These changes will lead to additional costs and increase our overall risk exposure. Currently there is a four to
<FONT STYLE="white-space:nowrap">six-month</FONT> grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June&nbsp;30, 2021 at the latest, whilst the parties discuss an adequacy decision. The European Commission
published a draft adequacy decision on February&nbsp;19, 2021. If adopted, the decision will enable data transfers from EU member states to the U.K. for a four-year period, subject to subsequent extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current and future healthcare reform legislation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs
and devices and to spur innovation, but its ultimate implementation is uncertain. More recently, in August 2017, the FDA Reauthorization Act was signed into law to reauthorize the FDA&#146;s user fee programs and included additional drug and device
provisions that build on the Cures Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in both the United States and certain foreign jurisdictions, there have been, and
likely will continue to be, a number of legislative and regulatory changes regarding the health care system directed at broadening the availability of healthcare, improving the quality of healthcare and containing or lowering the cost of healthcare.
For example, in March 2010 the Patient Protection and Affordable Care Act (ACA) was enacted, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical
industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars; expanded the types of entities eligible for the 340B drug discount program; introduced a new methodology by which rebates owed
by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and
extended the rebate program to individuals enrolled in Medicaid managed care organizations; established annual fees and taxes on manufacturers of certain branded prescription drugs; and created a new Medicare Part D coverage gap discount program, in
which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018 (BBA), effective as of January 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts
off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, administrative, executive and legislative challenges to certain aspects of the ACA. On
June&nbsp;17, 2021, the U.S.&nbsp;Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s decision, President
Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February&nbsp;15, 2021 and will remain open through August&nbsp;15, 2021. The
executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform
measures of the Biden administration with impact the ACA and our business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed
and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, included </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;139&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013, and, due to subsequent legislative amendments, will remain in effect
through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2021, unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law,
which, among other things, further reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives.
For example, CMS may develop new payment and delivery models, such as bundled payment models. There also has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription
drugs and biologics. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of
prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. It is unclear whether the Biden administration will work to reverse
measures that were initiated by the former Trump administration or pursue similar policy initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures in
the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding
procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union and in other foreign jurisdictions, similar political, economic and regulatory developments may affect our ability to
profitably commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or EU member state level may result in significant additional requirements or obstacles
that may increase our operating costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals, and enactment of laws, at the foreign, federal and state
levels, directed at containing or lowering the cost of healthcare, will likely continue into the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rest of world regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the
requirements governing product development, the conduct of clinical trials, manufacturing, distribution, marketing approval, advertising and promotion, product licensing, pricing and reimbursement vary from country to country. Additionally, clinical
trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally,
to the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate
compliance programs and reporting of payments or other transfers of value to healthcare professionals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;140&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional laws and regulations governing international operations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and
regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to
any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose
securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries,
and to devise and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is
expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the
government, and doctors and other hospital employees are considered by U.S. authorities that enforce the FCPA, including DOJ, to be foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed
to be improper payments to government officials and have led to FCPA enforcement actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders
also restrict the use and dissemination outside of the United States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and
technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or
selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and
suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Coverage, pricing and reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage, pricing and reimbursement status of any products seeking regulatory approval. Successful
commercialization of new drug products depends in part on the extent to which coverage and reimbursement for those drug products will be available from government health administration authorities, private health insurers and other organizations.
The availability of coverage and extent of reimbursement depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by third-party payors, such as government health care programs (<I>e.g.</I>,
Medicare, Medicaid), health maintenance organizations, managed care providers, pharmacy benefit and similar healthcare management organizations, private health coverage insurers and other third-party payors. These third-party payors decide which
medications they will pay for and will establish reimbursement levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and
reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Third-party payors often follow Medicare coverage policy and payment limitations in
setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Factors payors consider in determining reimbursement are based on whether the product is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;141&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the process for determining whether a payor will provide coverage for a product may be separate from the process for setting the
reimbursement rate that the payor will pay for the product. One payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Third-party payors may also
limit coverage to specific products on an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to
limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be
approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals.
Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates, if approved, may nonetheless not be considered medically necessary or cost-effective. If third-party
payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company
to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries.
For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the
completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or
pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical
products and medical devices will likely continue as countries attempt to manage healthcare expenditures. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be
significantly lower. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 15, 2021, we had 13 full-time employees and 9 part-time employees. Of our 22 employees, seven have Ph.D. or M.D. degrees and 12 are
engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include meeting hiring goals, deepening our neurology research and development and public company
expertise, integrating new employees, and retaining, incentivizing and developing our existing employees. We have a cash-based performance bonus and, in addition, may utilize our equity incentive plan to attract, retain and motivate selected
employees, consultants and directors through the granting of stock-based compensation awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease various operating spaces in the United Kingdom under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease
arrangements. As of March&nbsp;31, 2021, our future minimum lease payments under noncancelable lease agreements were $37,000. We intend to lease operating space in the greater Seattle area in late 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;142&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we are not party to any material legal matters or claims. We may become party to legal matters and claims
arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs,
diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;143&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth certain information for our executive officers and directors as of July&nbsp;9, 2021: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Azelby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin M. Lavelle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Operating Officer and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James B. Bucher</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and General Counsel</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Morisset, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Research and Development and Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Levin, M.D., Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Judith Dunn, Ph.D (2).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leone Patterson (1) (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liam Ratcliffe, M.D., Ph.D (2).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adam Rosenberg (1) (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simon Tate (1) (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Robert Azelby </I>has
served as our Chief Executive Officer since October 2020. Prior to leading Eliem, Mr.&nbsp;Azelby served as the Chief Executive Officer of Alder Biopharmaceuticals, Inc. (Alder) from June 2018 until its acquisition by H. Lundbeck in 2019. From
November 2015 to May 2018, Mr.&nbsp;Azelby served as Executive Vice President, Chief Commercial Officer of Juno Therapeutics, Inc. From June 2012 to October 2015, Mr.&nbsp;Azelby served as Vice President and General Manager, Oncology at Amgen Inc.,
a biopharmaceutical company. From October 2010 to May 2012, he served as Amgen&#146;s Vice President, Amgen Oncology Sales. Prior to that, he served in various positions at Amgen, including periods as Vice President, Commercial Effectiveness Unit
and General Manager of Amgen Netherlands. Mr.&nbsp;Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Alder from June 2018 until November 2019, Cascadian Therapeutics,
Inc. from March 2017 to March 2018 until its acquisition by Seagen and Immunomedics Inc. from February 2020 to October 2020 until its acquisition by Gilead. Mr.&nbsp;Azelby holds a B.A. in Economics and Religious Studies from
the&nbsp;University&nbsp;of&nbsp;Virginia&nbsp;and an M.B.A. from Harvard Business School. We believe that Mr.&nbsp;Azelby is qualified to serve on our board of directors due to his daily insight into corporate matters as our Chief Executive Officer
and his extensive background in the biotechnology industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Erin M. Lavelle</I> has served as our Executive Vice President, Chief Operating Officer
and Chief Financial Officer since October 2020. Prior to joining Eliem, Ms.&nbsp;Lavelle served as the Chief Operating Officer of Alder from April 2018 until February 2020, after its acquisition by H. Lundbeck. From October 2017 to March 2018,
Ms.&nbsp;Lavelle served as the General Manager of the Taiwan affiliate of Amgen. From June 2016 to September 2017, Ms.&nbsp;Lavelle served as Executive Director, Japan and Asia-Pacific Commercial Excellence and Digital Health at Amgen. From July
2003 to June 2016, Ms.&nbsp;Lavelle served in roles of increasing responsibility at Amgen, including as Amgen&#146;s Executive Director in the areas of Global Marketing; Global Commercial Finance; and Strategy and Corporate Development. She began
her career in 1998 as an investment banker in the healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;144&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
group at Merrill Lynch&nbsp;&amp; Co. Ms.&nbsp;Lavelle currently serves on the board of directors of Neoleukin Therapeutics, Inc. Ms.&nbsp;Lavelle holds a B.A. in Economics from Yale University.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>James B. Bucher </I>has served as our Executive Vice President and General Counsel since October 2020. Prior to joining Eliem, Mr.&nbsp;Bucher served
as Executive Vice President and General Counsel of Alder from 2016 until its acquisition by H. Lundbeck in 2019. During 2015, Mr.&nbsp;Bucher served as a consultant providing legal services to several life sciences companies. From 2007 to 2014,
Mr.&nbsp;Bucher served as Vice President, Corporate Legal Affairs and Secretary, and as the Corporate Compliance Officer, of Exelixis, Inc., a biopharmaceutical company. Previously, Mr.&nbsp;Bucher was a partner at the international law firm of
Shearman and Sterling LLP, serving with the firm for 16 years. Mr.&nbsp;Bucher holds a J.D. with distinction from Emory University School of Law and a B.A. in Biology from Colgate University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Valerie Morisset, Ph.D.</I> has served as our Executive Vice President, Research and Development and Chief Scientific Officer since October 2020, and
previously as our President and Chief Scientific Officer since April 2019. Prior to joining Eliem, Dr.&nbsp;Morisset was a founding venture partner at Bridge Valley Ventures, where she served from January 2018 until March 2019. In October 2010, she <FONT
STYLE="white-space:nowrap">co-founded</FONT> Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team until Biogen&#146;s acquisition of Convergence in 2015. Dr.&nbsp;Morisset subsequently joined Biogen
in a senior leadership role. She has worked extensively in the field of drug development for pain and across a number of other therapeutic areas including neurology, psychiatry, gastrointestinal disorders and sensory biology, including during her
time at GlaxoSmithKline (GSK) from January 2001 to October 2010. Dr.&nbsp;Morisset holds a degree, a masters and a Ph.D. from the University of Bordeaux. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Andrew Levin, M.D., Ph.D.</I> is a <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Eliem, served as our Chief Executive Officer from October 2018 to
October 2020, and has served as the Chairman of our board of directors since February 2019. Since 2015, Dr.&nbsp;Levin has served as a Managing Director on the Investment Team at RA Capital Management, L.P. Previously, Dr.&nbsp;Levin was a Vice
President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. Dr.&nbsp;Levin holds a B.S. in mechanical engineering from Princeton University, a Ph.D. in biomedical
engineering from the Massachusetts Institute of Technology and an M.D. from Harvard Medical School. We believe that Dr.&nbsp;Levin is qualified to serve on our board of directors due to his substantial experience as an investor in early stage
biopharmaceutical and life sciences companies, as well as his experience of serving on the board of directors for several biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Judith Dunn, Ph.D.</I> has been a member of our board of directors since February 2021. Since April 2021, Dr.&nbsp;Dunn has served as President of R&amp;D
of Fulcrum Therapeutics, Inc. From March 2018 to April 2021, Dr.&nbsp;Dunn served as Entrepreneur in Residence at Atlas Ventures. From 2010 to 2018, Dr.&nbsp;Dunn served as Vice President of Clinical Development for F.
<FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche. Dr.&nbsp;Dunn led Psychiatry Clinical Development at Sepracor from 2005 to 2010 and held research and commercial positions at Pfizer from 1997 to 2005. Dr.&nbsp;Dunn holds a B.S. in
neurobiology from Wesleyan University and a Ph.D. in Neurobiology from the University of Rochester. We believe that Dr.&nbsp;Dunn is qualified to serve on our board of directors due to her experience in the biotechnology and biopharmaceutical
industries and her substantial professional experience. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leone Patterson</I> has been a member of our board of directors since March 2021.
Ms.&nbsp;Patterson currently serves as Chief Financial and Business Officer of Tenaya Therapeutics, Inc., where she leads corporate finance, investor relations, corporate communications, strategy and business development, as well as other
operational functions. Ms.&nbsp;Patterson joined Tenaya in June 2021. Prior to joining Tenaya, Ms.&nbsp;Patterson served as President and Chief Financial Officer of Adverum Biotechnologies, Inc., a public clinical-stage gene therapy company.
Ms.&nbsp;Patterson joined Adverum in June 2016 as Chief Financial Officer and served as Chief Executive Officer from May 2018 to June 2020, Director from October 2018 to June 2020, and President from December 2019 to June 2021. From 2015 to 2016,
Ms.&nbsp;Patterson served as the Chief Financial Officer of Diadexus, Inc., a diagnostics company. Prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;145&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to that, Ms.&nbsp;Patterson was Vice President and Chief Financial Officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until it was acquired by Paratek
Pharmaceuticals Inc. 2014. From 2010 to 2012, Ms.&nbsp;Patterson served as Vice President and Global Corporate Controller of NetApp, Inc., a data management and storage company. From 2007 to 2010, Ms.&nbsp;Patterson was Vice President of Finance at
Exelixis. Before Exelixis, Ms.&nbsp;Patterson served as Vice President of Global Business Planning and Analysis of the vaccines and diagnostics division of Novartis AG, a biopharmaceutical company, from 2006 to 2007. From 1999 to 2006, she held
several positions, including Vice President, Corporate Controller, at Chiron, a biotechnology company (now part of Novartis AG). From 1989 to 1999, Ms.&nbsp;Patterson worked in the audit practice of accounting firm KPMG, where she held various
positions including Senior Manager. Ms.&nbsp;Patterson currently serves on the board of directors of Nkarta, Inc. Ms.&nbsp;Patterson holds a B.S. in business administration and accounting from Chapman University and an executive M.B.A. from St.
Mary&#146;s College. Ms.&nbsp;Patterson is also a Certified Public Accountant (inactive status). We believe that Ms.&nbsp;Patterson is qualified to serve on our board of directors due to her experience in the biotechnology and biopharmaceutical
industries, her substantial professional experience and the fact that she is a qualified financial expert. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liam Ratcliffe, M.D., Ph.D.</I> has served
as a member of our board of directors since October 2019. Dr.&nbsp;Ratcliffe has also served as the Head of Biotechnology at Access Industries since April 2019. From September 2008 to April 2019, Dr.&nbsp;Ratcliffe served as Managing Director at New
Leaf Venture Partners, where he focused on investing in therapeutics and therapeutic platform companies. Prior to joining New Leaf, Dr.&nbsp;Ratcliffe held various positions of increasing responsibility at Pfizer Inc., a multinational pharmaceutical
corporation, including Senior Vice President and Development Head for Neuroscience, and Worldwide Head of Clinical Research and Development. Dr.&nbsp;Ratcliffe currently serves on the board of directors of Deciphera Pharmaceuticals, Inc. and
Arvinas, Inc., each a biopharmaceutical company. Dr.&nbsp;Ratcliffe previously served on the boards of directors of several biotechnology and biopharmaceutical companies, including Unum Therapeutics, Inc., from March 2018 to April 2019, Edge
Therapeutics, Inc., from October 2015 to November 2018, and Array Biopharmaceuticals, Inc., from April 2012 to April 2014. Dr.&nbsp;Ratcliffe holds an M.B.A. from the University of Michigan and an M.D. and Ph.D. in Immunology from the University of
Cape Town, and he completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa. We believe that Dr.&nbsp;Ratcliffe is qualified to serve on our board of
directors due to his extensive experience in the venture capital industry, medical and scientific background and training, and leadership at various biopharmaceutical and biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adam Rosenberg</I> was President, Chief Executive Officer and a member of the board of directors of Athenen from July 2020 through its merger with Eliem in
October 2020, and has been a member of our board of directors since October 2020. Since January 2020, Mr.&nbsp;Rosenberg has served as a Venture Partner at Carnot Pharma, LLC dba RA Ventures. From September 2015 until its acquisition by Alkermes plc
in November 2019, Mr.&nbsp;Rosenberg served as President, Chief Executive Officer and member of the board of directors of Rodin Therapeutics. Previously, Mr.&nbsp;Rosenberg served as Chief Executive Officer, member of the board of directors and <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as Chief Executive Officer, member of the board of directors and
<FONT STYLE="white-space:nowrap">co-founder</FONT> of Teleos Therapeutics, a neuroscience drug discovery platform company. Mr.&nbsp;Rosenberg is currently on the boards of directors of other private, venture-backed companies. Mr. Rosenberg holds a
J.D. from the University of Virginia School of Law, and a B.A. from Whittier College. We believe that Mr.&nbsp;Rosenberg is qualified to serve on our board of directors due to his experience in the biotechnology industry, particularly in
neuroscience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Simon Tate</I> has been a member of our board of directors since February 2019. Since January 2021, Mr. Tate has served as a managing
director at Intermediate Capital Group, plc. From December 2017 to January 2021, Mr.&nbsp;Tate served as a partner at Bridge Valley Ventures. Mr.&nbsp;Tate has spent most of his career working in the fields of pain and neuroscience. He was one of
the founders of Convergence Pharmaceuticals, founded in 2010, and served as Chief Scientific Officer and head of R&amp;D until its acquisition in 2015. Following this acquisition, Mr.&nbsp;Tate joined Biogen where he assumed the role of Vice
President and Head of the Pain Therapeutic Area. Prior to Convergence, Mr.&nbsp;Tate was Vice President and Head of Pain, Epilepsy, and Migraine Drug Discovery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;146&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Early Development at GSK. Mr. Tate holds a master&#146;s degree from the University of Dundee. We believe that Mr.&nbsp;Tate is qualified to serve on our board of directors due to his
experience and standing in the neuroscience, pharmaceutical and biotechnology sectors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain members of our board of directors were elected pursuant to the provisions of a voting agreement, as amended. Under the terms of this
voting agreement, the stockholders who are party to the voting agreement have agreed to vote their respective shares so as to elect: (1)&nbsp;one director designated by Intermediate Capital Group plc, currently Mr.&nbsp;Tate; (2)&nbsp;one director
designated by RA Capital Healthcare Fund, L.P., currently Dr.&nbsp;Levin; (3)&nbsp;one director designated by AI ETI LLC, currently Dr.&nbsp;Ratcliffe; (4)&nbsp;our Chief Executive Officer, currently Mr.&nbsp;Azelby; (5)&nbsp;one director designated
by the holders of a majority of the outstanding shares of the common stock and redeemable convertible preferred stock, voting together as a single class on an as converted basis, which majority must include the holders of a majority of the
outstanding shares of (i)&nbsp;Series A redeemable convertible preferred stock and (ii)&nbsp;Series redeemable convertible preferred stock, voting as separate classes, currently Mr.&nbsp;Rosenberg; and (6)&nbsp;two individuals designated by mutual
agreement of RA Capital Healthcare Fund, L.P., Intermediate Capital Group plc and AI ETI LLC, currently Dr.&nbsp;Dunn and Ms.&nbsp;Patterson. The voting agreement will terminate upon the closing of this offering and none of our stockholders will
have any special rights regarding the election or designation of members of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of our
board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required. Our board of directors currently consists of seven directors.
Our amended and restated certificate of incorporation, which will become effective upon the closing of this offering, will provide that the authorized number of directors may be changed only by a resolution approved by a majority of our board of
directors. In accordance with our amended and restated certificate of incorporation to be effective in connection with this offering, immediately after this offering, our board of directors will be divided into three classes with staggered
three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will
be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;their terms will expire at the annual meeting of
stockholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;their terms will expire at the annual meeting of
stockholders to be held in 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;their terms will expire at the annual meeting of
stockholders to be held in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional directorships resulting from an increase in the number of directors
will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered
three-year terms may delay or prevent a change of our management or a change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the listing requirements and rules of the Nasdaq Stock Market (Nasdaq), independent directors must comprise a majority of our board of
directors as a listed company within one year of the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has undertaken a review of its
composition, the composition of its committees and the independence of each director. Based upon information requested from and provided by each director </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;147&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that all of our directors except Mr.&nbsp;Azelby, who is our
Chief Executive Officer, do not have any relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is
defined under the applicable rules and regulations of the Securities and Exchange Commission (SEC) and the listing requirements and rules of Nasdaq. In making this determination, our board of directors considered the current and prior relationships
that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our
capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to appoint committees to perform certain management and administration functions. Upon the closing of
this offering, our board of directors will have an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described
below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit
committee consists of Leone Patterson, Adam Rosenberg and Simon Tate. Our board of directors has determined that each member of the audit committee satisfies the independence requirements under the Nasdaq listing standards and Rule <FONT
STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Securities Exchange Act of 1934, as amended (Exchange Act). The chairperson of our audit committee is Leone Patterson. Our board of directors has determined that Ms.&nbsp;Patterson is an
&#147;audit committee financial expert&#148; within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these
determinations, our board of directors has examined each audit committee member&#146;s scope of experience and the nature of their employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate
accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee our independent registered public accounting firm. Specific responsibilities of our audit committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with our management the adequacy and effectiveness of our disclosure controls and
procedures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting with design and implementation of our risk assessment functions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually that
describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;148&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee operates under a written charter, adopted by our board of directors on June 25, 2021, that satisfies the applicable
listing standards of the Nasdaq Global Market. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee currently consists of Liam&nbsp;Ratcliffe, Adam Rosenberg and Judith&nbsp;Dunn. The chairperson of our compensation
committee is Liam Ratcliffe. Our board of directors has determined that each member of the compensation committee is independent under the listing standards of the Nasdaq, and a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary
purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers,
directors and other senior management, as appropriate. Specific responsibilities of our compensation committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our chief executive officer and other
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements,
profit sharing plans, bonus plans, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements for our executive officers and other senior management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees, including our
overall compensation philosophy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating with the chief executive officer the succession plans for our executive officers.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee operates under a written charter, adopted by our board of directors on June 25, 2021,
that satisfies the applicable listing standards of the Nasdaq Global Market. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee consists of Andrew&nbsp;Levin, Leone&nbsp;Patterson and Simon&nbsp;Tate. The chairperson of
our nominating and corporate governance committee is Andrew&nbsp;Levin. Our board of directors has determined that each member of the nominating and corporate governance committee is independent under the listing standards of the Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and
nominees recommended by stockholders, to serve on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and making recommendations to our board of directors regarding the composition and chairmanship of
the committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with our chief executive officer the plans for succession to the offices of our executive officers and
make recommendations to our board of directors with respect to the selection of appropriate individuals to succeed to these positions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;149&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and
matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing periodic evaluations of the board of directors&#146; performance, including committees of the board of
directors. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee operates under a written charter, adopted by our board
of directors on June 25, 2021, that satisfies the applicable listing standards of the Nasdaq Global Market. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon the closing of this offering, our code of business conduct and ethics will be available under the Corporate
Governance section of our website at www.eliemtx.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of the Nasdaq concerning any amendments to, or waivers from, any provision of the
code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of the compensation committee is currently or has been during our last fiscal year, one of our officers or employees. None
of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or
compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, we did not have an equity-based plan or cash compensation for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors,
including those who are not affiliated with our large investors. No cash or equity compensation was paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during 2020. However, all of our independent directors are entitled to
reimbursement of direct expenses incurred in connection with attending meetings of the board or committees thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, in
connection with the Athenen Acquisition, Mr.&nbsp;Rosenberg had the vesting of restricted stock awards to purchase 331,266 shares of our common stock accelerated. In 2021, Mr.&nbsp;Rosenberg will be eligible for the non-employee director
compensation policy to become effective upon the closing of the initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, in connection with the
election of Dr.&nbsp;Dunn to the board of directors in February 2021, we entered into a letter agreement with Dr.&nbsp;Dunn, which governs the terms of her service as a director. Dr.&nbsp;Dunn&#146;s letter agreement provides that she will be
compensated $30,000 annually for her service as a director. Additionally, pursuant to the terms of her letter agreement, in March 2021, we granted to Dr.&nbsp;Dunn an option to purchase 78,397 shares of our common stock at an exercise price of $0.66
per share. Twenty-five percent of the shares subject this option will vest on March&nbsp;4, 2022, with 75% of the shares subject to the option vesting in equal monthly installments over the subsequent 36 months, subject to Dr.&nbsp;Dunn&#146;s
continued association with us as an employee, consultant, officer or director through each applicable vesting date. In April 2021, we granted to Dr.&nbsp;Dunn an option to purchase 30,767 shares of our common stock at an exercise price of $3.05 per
share. Twenty-five percent of the shares subject to this option will vest on April&nbsp;27, 2022, with 75% of the shares subject to the option vesting in equal monthly installments over the subsequent 36 months, subject to Dr.&nbsp;Dunn&#146;s
continued association with us as an employee, consultant, officer or director through each applicable vesting date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;150&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, in connection with the election of Ms.&nbsp;Patterson to the board of
directors in March 2021, we entered into a letter agreement with Ms.&nbsp;Patterson, which governs the terms of her service as a director. Ms.&nbsp;Patterson&#146;s letter agreement provides that she will be compensated $30,000 annually for her
service as a director, plus $12,000 annually for her planned service as the Chair of our board of directors&#146; Audit Committee (paid pro rata to account for Ms.&nbsp;Patterson&#146;s time in this role). Additionally, pursuant to the terms of her
letter agreement, in March 2021, we granted to Ms.&nbsp;Patterson an option to purchase 78,397 shares of our common stock at an exercise price of $0.66 per share. Twenty-five percent of the shares subject to this option will vest on March&nbsp;4,
2022, with 75% of the shares subject to the option vesting in equal monthly installments over the subsequent 36 months, subject to Ms.&nbsp;Patterson&#146;s continued association with us as an employee, consultant, officer or director through each
applicable vesting date. In April 2021, we granted to Ms.&nbsp;Patterson an option to purchase 30,767 shares of our common stock at an exercise price of $3.05 per share. Twenty-five percent of the shares subject to this option will vest on
April&nbsp;27, 2022, with 75% of the shares subject to the option vesting in equal monthly installments over the subsequent 36 months, subject to Ms.&nbsp;Patterson&#146;s continued association with us as an employee, consultant, officer or director
through each applicable vesting date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021, we adopted a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy which will become effective upon the closing of the initial public offering and pursuant to which our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
will be eligible to receive cash and equity compensation for service on our board of directors and committees of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing upon our initial public offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual cash
retainer of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for serving on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
chairperson of our board of directors will be entitled to a cash retainer of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in lieu of the annual retainer received by other
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for serving as our lead director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson and members of the
following three committees of our board of directors will be entitled to the following additional annual cash retainers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Board Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chairperson&nbsp;Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member&nbsp;Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual cash retainers will be payable in equal quarterly installments in arrears, on the last day of each
fiscal quarter for which the service occurred, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of days served in the applicable fiscal quarter, provided that for the fiscal quarter which includes the closing date of our initial
public offering, the cash compensation amounts will be <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of days served in such fiscal quarter commencing on the closing date of our initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each new <FONT STYLE="white-space:nowrap">non-employee</FONT> director who joins our board of directors after our initial public offering will
receive an option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock under our 2021 Equity Incentive Plan. The shares subject to this option will vest on a monthly basis over
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months commencing on the grant date, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service with us on each applicable vesting date. Such newly joining
director will also receive a prorated initial annual option grant consisting of an option to purchase a number of shares of our common stock determined by multiplying &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by the
percentage obtained by dividing the number of calendar days from the date such new director joins us to the date of the next scheduled annual stockholder meeting by the total number of calendar days scheduled to follow the date of the last annual
stockholder meeting through the date of the next annual stockholder meeting. Such prorated initial annual option will vest in full on the date immediately preceding the date of next annual stockholder meeting, subject to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service through such vesting date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;151&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the date of each annual meeting of our stockholders, each continuing <FONT
STYLE="white-space:nowrap">non-employee</FONT> director will receive an option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock under the 2021 Equity Incentive
Plan, vesting on the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant date or the date immediately prior to the next annual stockholder meeting date, subject to the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service with us on the applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
exercise price per share of each stock option granted under the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will be the closing price of our common stock as reported by the Nasdaq Global Market on the date of
grant. Each stock option will have a term of ten years from the date of grant, subject to earlier termination in connection with a termination of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service with us.
Each stock option and other equity award granted to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors is also entitled to immediate vesting acceleration upon a change in control if the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director remains in our continued services through the date of such change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director is subject to an annual director compensation limit. In any <FONT
STYLE="white-space:nowrap">one-year</FONT> period measured as commencing on the date of each annual meeting of shareholders that is held following the closing of our initial public offering and ending on the day immediately prior to the date of the
subsequent annual meeting of shareholders, the aggregate value of all compensation granted or paid to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director may not exceed (i)
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in total value or (ii)&nbsp;in the event such <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected during such annual period,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in total value, in each case calculating the value of any equity awards based on the grant date fair market value for financial reporting purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;152&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers for the year ended December&nbsp;31, 2020, consisting of all persons serving as our principal executive officer
in 2020 and our two other most highly compensated officers serving at the end of such year, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert Azelby, our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Erin M. Lavelle, our Executive Vice President, Chief Operating Officer and Chief Financial Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Valerie Morisset, Ph.D., our Executive Vice President, R&amp;D and Chief Scientific Officer; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew Levin, our former Chief Executive Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table presents all of the compensation awarded to, earned by or paid to our named executive officers during the year ended December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Azelby<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin M. Lavelle<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Morisset, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,458<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">905,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President, R&amp;D and Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Levin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Executive
Officer</I><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents discretionary bonus amounts earned in 2020, which were paid in 2021, based upon our board of
directors&#146; assessment of the achievement of 2020 corporate goals and other factors deemed relevant by our board of directors. Our board of directors determined that Mr.&nbsp;Azelby and Ms.&nbsp;Lavelle were each entitled to 100% of their target
bonuses, respectively, prorated to reflect a partial year of service. Dr.&nbsp;Morisset does not have a target bonus and her amount was determined at the discretion of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this column do not reflect dollar amounts actually received by the named executive
officer. Instead, the amounts reflect the aggregate grant date fair value which includes the incremental fair value of the stock option granted to Dr.&nbsp;Morisset including those deemed to have been modified during 2020, under our 2019 Equity
Incentive Plan, which is described in further detail below under &#147;Employee Benefit and Stock Plans&#151;2019 Equity Incentive Plan,&#148; computed in accordance with ASC 718. Assumptions used in the calculation of these amounts are included in
Note 8 to our financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Azelby joined us in October 2020, and the amount reflects payment for a partial year of service.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the amount of safe-harbor matching contributions under our 401(k) plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Lavelle joined us in October 2020, and the amount reflects payment for a partial year of service.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Morisset is employed and compensated by our wholly owned subsidiary, Eliem Therapeutics (UK) Ltd. The
dollar amounts shown in this table, except the amounts in the column titled &#147;Option Awards,&#148; reflect the US$ equivalent of the amounts paid to Dr.&nbsp;Morisset in British Pounds. The amounts were converted to U.S. dollars from British
Pound using the yearly average exchange rate. Applying this formula, &pound;1.00 was equal to US$1.284. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the amount of company contributions to a defined contribution pension plan maintained for our
employees in the United Kingdom. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;153&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Levin served as our Chief Executive Officer until October 2020, but he was not our employee during
this period and he did not receive any compensation from us during 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards as of December&nbsp;31, 2020
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December&nbsp;31,
2020. All awards were granted under our 2019 Equity Incentive Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Azelby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin M. Lavelle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Morisset, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,208</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Morisset&#146;s option award was granted with a per share exercise price equal to the par value of one
share of our common stock on the date of grant, as determined in good faith by our board of directors. Dr.&nbsp;Morisset was initially granted an option to purchase 136,384 shares of our common stock on September&nbsp;1, 2019 with an exercise price
of $0.0001 per share, but this option was subsequently cancelled and replaced with the option granted on February&nbsp;4, 2020 that is reflected on this table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Twenty-five percent of the shares subject to Dr.&nbsp;Morisset&#146;s option vested on April&nbsp;1, 2020, with
75% of the shares subject to the option vesting in equal monthly installments over the subsequent 36 months, subject to Dr.&nbsp;Morisset&#146;s continued service with us through each applicable vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). As an emerging growth company, we will be exempt from certain requirements related to executive compensation, including, but not limited to, the
requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees,
each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonqualified Deferred Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
named executive officers did not participate in, or earn any benefits under, any nonqualified deferred compensation plan sponsored by us during the year ended December&nbsp;31, 2020. Our board of directors may elect to provide our officers and other
employees with nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pension and Defined
Benefit Plan Retirement Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers did not participate in, or otherwise receive any benefits under, any
defined benefit retirement plan sponsored by us during 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Health and Welfare Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision,
life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers. We had no benefit
plans in place for our U.S.-based employees in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;154&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain
eligibility requirements. The 401(k) plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> plan under the Internal Revenue Code. Our named executive officers are eligible to participate in the 401(k) plan on the same
basis as our other employees. The Internal Revenue Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis through contributions to the 401(k)
plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pension Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently
maintain a pension plan for our U.K.-based employees. We have historically contributed 8% of each employee&#146;s annual basic salary as an employer contribution, and in April 2021, we increased this amount to 9%. Employees may choose to also make
additional contributions, which, if elected, are deducted from their salaries. We also give back the 13.8% employer National Insurance savings into each employee&#146;s pension plan as an additional contribution. The pension plan is subject to an
annual management charge of 0.36% and, in addition to our contributions and any employee contributions, accepts transfers from other schemes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment
agreements with our named executive officers generally provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment and set forth the named executive officer&#146;s initial base salary, annual target bonus and eligibility to participate in
our employee benefit plans. The key terms of these agreements are described below. In addition, each of our named executive officers has executed our standard confidential information, invention assignment,
<FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Robert Azelby </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, we entered into an employment agreement with Mr.&nbsp;Azelby, which governs the terms of his employment with us. For 2020,
Mr.&nbsp;Azelby was entitled to an annual base salary of $600,000, and was eligible to receive a discretionary annual performance bonus with a target amount of 50% of his annual base salary, payable based on the actual achievement of applicable
individual and corporate performance goals, as determined by our Board of Directors, and subject to his continued employment in good standing through the last day of the fiscal year. For 2020, Mr.&nbsp;Azelby was eligible for a <FONT
STYLE="white-space:nowrap">pro-rated</FONT> portion of the annual performance bonus, based on his partial year of service. There was no change to Mr.&nbsp;Azelby&#146;s salary for 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, pursuant to his employment agreement Mr.&nbsp;Azelby was granted an option to purchase 1,567,937 shares of our common stock
at an exercise price of $0.66 per share. This option vests over a four-year period with 25% of the shares subject to the option vesting in October 2021 and the remainder vesting monthly over the next 36&nbsp;months, subject in each case to
Mr.&nbsp;Azelby&#146;s continued employment with us. In April 2021, in accordance with his employment agreement, Mr.&nbsp;Azelby was granted an option to purchase 812,989 shares of our common stock at an exercise price of $3.05 per share. This
option vests over a four-year period with 25% of the shares subject to the option vesting in April 2022 and the remainder vesting monthly over the next 36&nbsp;months. In the event that our successor in a change of control does not assume or
continue the unvested portion of Mr.&nbsp;Azelby&#146;s equity awards and the unvested awards will otherwise terminate, then the unvested portion of Mr.&nbsp;Azelby&#146;s equity awards shall vest in full and become exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Azelby is also entitled to receive certain severance benefits under his employment agreement, subject to his execution of a release
of claims and continued compliance with the restrictive covenants to which he is bound. If we terminate Mr.&nbsp;Azelby&#146;s employment without cause (as defined in his employment agreement) and other than as a result of his death or disability or
if he resigns for good reason (as defined in his employment agreement), in each case, prior to our initial public offering and not in connection with a change in control (as defined in his employment agreement), then he will be eligible to receive
the following severance benefits: (1) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;155&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
12&nbsp;months of his base salary, paid in 12 equal installments over the 12 months following his separation from service; (2)&nbsp;an amount equal to his pro rata annual performance bonus, based
on the target amount, for the calendar year in which termination occurs, payable on the first regularly scheduled payroll date following the effectiveness of the release of claims; (3)&nbsp;up to 12 months of company paid premiums for continued
health benefits under the Consolidated Omnibus Budget Reconciliation Act, or COBRA; and (4)&nbsp;the vesting of the unvested portion of any time or service-based vesting equity awards held by Mr.&nbsp;Azelby that are scheduled to vest and become
exercisable in the 18-month period following the termination date will be accelerated and immediately vested as of the termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Mr.&nbsp;Azelby&#146;s employment without cause (as defined in his employment) and other than as a result of his death or
disability or if he resigns for good reason (as defined in his employment agreement), in each case, following our initial public offering and not in connection with a change in control, then he will be eligible to receive the following severance
benefits: (1) 24 months of his base salary, paid in 24 equal installments over the 24 months following his separation from service; (2)&nbsp;an amount equal to his pro rata annual performance bonus, based on the target amount, for the calendar year
in which termination occurs, payable on the first regularly scheduled payroll date following the effectiveness of the release of claims; (3)&nbsp;up to 24 months of company paid premiums for continued health benefits under COBRA; and (4)&nbsp;the
vesting of the unvested portion of any time or service-based vesting equity awards held by Mr.&nbsp;Azelby that are scheduled to vest and become exercisable in the 18-month period following the termination date will be accelerated and immediately
vested as of the termination date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Mr.&nbsp;Azelby&#146;s employment without cause (as defined in his employment) and
other than as a result of his death or disability or if he resigns for good reason (as defined in his employment agreement), in each case, in the period commencing three months prior to and ending 12 months following a change in control, then he
will be eligible to receive the following severance benefits: (1) 18 months of his base salary and annual bonus, based on the target amount, paid in a lump sum following the effectiveness of the release of claims; (2)&nbsp;up to 18 months of company
paid premiums for continued health benefits under COBRA; and (3)&nbsp;the vesting of the unvested portion of any time-based, performance-based or service-based equity awards held by Mr.&nbsp;Azelby will be accelerated and immediately vested as of
the termination date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Erin M. Lavelle </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, we entered into an employment agreement with Ms.&nbsp;Lavelle, which governs the terms of her employment with us. For 2020,
Ms.&nbsp;Lavelle was entitled to an annual base salary of $450,000, and is eligible to receive a discretionary annual performance bonus with a target amount of 45% of her annual base salary, payable based on the actual achievement of applicable
individual and corporate performance goals, as determined by our Board of Directors, and subject to her continued employment in good standing through the last day of the fiscal year. For 2020, Ms.&nbsp;Lavelle was eligible for a <FONT
STYLE="white-space:nowrap">pro-rated</FONT> portion of the annual performance bonus, based on her partial year of service. There was no change to Ms.&nbsp;Lavelle&#146;s salary for 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, pursuant to her employment agreement, Ms.&nbsp;Lavelle was granted an option to purchase 470,381 shares of our common stock
at an exercise price of $0.66 per share. This option vests over a four-year period with 25% of the shares subject to the option vesting in October 2021 and the remainder vesting monthly over the next 36&nbsp;months, subject in each case to
Ms.&nbsp;Lavelle&#146;s continued employment with us. In April 2021, in accordance with her employment agreement, Ms.&nbsp;Lavelle was granted an option to purchase 243,897 shares of our common stock at an exercise price of $3.05 per share. This
option vests over a four-year period with 25% of the shares subject to the option vesting in April 2022 and the remainder vesting monthly over the next 36&nbsp;months. In the event that our successor in a change of control does not assume or
continue the unvested portion of Ms.&nbsp;Lavelle&#146;s equity awards and the unvested awards will otherwise terminate, then the unvested portion of Ms.&nbsp;Lavelle&#146;s equity awards shall vest in full and become exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Lavelle is also entitled to receive certain severance benefits under her employment agreement, subject to her execution of a release
of claims and continued compliance with the restrictive covenants to which she is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;156&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bound. If we terminate Ms.&nbsp;Lavelle&#146;s employment without cause (as defined in her employment agreement) and other than as a result of her death or disability or if she resigns for good
reason (as defined in her employment agreement), in each case, prior to our initial public offering and not in connection with a change in control (as defined in her employment agreement), then she will be eligible to receive the following severance
benefits: (1)&nbsp;nine months of her base salary, paid in nine equal installments over the nine months following her separation from service; (2)&nbsp;an amount equal to her pro rata annual performance bonus, based on the target amount, for the
calendar year in which termination occurs, payable on the first regularly scheduled payroll date following the effectiveness of the release of claims; (3)&nbsp;up to nine months of company paid premiums for continued health benefits under COBRA; and
(4)&nbsp;the vesting of the unvested portion of any time or service-based equity awards held by Ms.&nbsp;Lavelle that are scheduled to vest and become exercisable in the nine-month period following the termination date will be accelerated and
immediately vested as of the termination date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Ms.&nbsp;Lavelle&#146;s employment without cause (as defined in her
employment) and other than as a result of her death or disability or if she resigns for good reason (as defined in her employment agreement), in each case, following our initial public offering and not in connection with a change in control, then
she will be eligible to receive the following severance benefits: (1) 18 months of her base salary, paid in 18 equal installments over the 18 months following her separation from service; (2)&nbsp;an amount equal to her pro rata annual performance
bonus, based on the target amount, for the calendar year in which termination occurs, payable on the first regularly scheduled payroll date following the effectiveness of the release of claims; (3)&nbsp;up to 18 months of company paid premiums for
continued health benefits under COBRA; and (4)&nbsp;the vesting of the unvested portion of any time or service-based equity awards held by Ms.&nbsp;Lavelle that are scheduled to vest and become exercisable in the 12-month period following the
termination date will be accelerated and immediately vested as of the termination date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Ms.&nbsp;Lavelle&#146;s
employment without cause (as defined in her employment) and other than as a result of her death or disability or if she resigns for good reason (as defined in her employment agreement), in each case, in the period commencing three months prior to
and ending 12 months following a change in control, then she will be eligible to receive the following severance benefits: (1) 18 months of her base salary and annual bonus, based on the target amount, paid in a lump sum following the effectiveness
of the release of claims; (2)&nbsp;up to 18 months of company paid premiums for continued health benefits under COBRA; and (3)&nbsp;the vesting of the unvested portion of any time-based, performance-based or service-based equity awards held by
Ms.&nbsp;Lavelle will be accelerated and immediately vested as of the termination date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Valerie Morisset, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2021, we entered into an employment agreement with Dr.&nbsp;Morisset, which governs the terms of her employment with us. For 2021,
Dr.&nbsp;Morisset is entitled to an annual base salary of &pound;252,350. We will also make annual contributions to the pension scheme offered by the Company for Dr.&nbsp;Morisset&#146;s benefit in an amount equal to 10% of her base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, Dr.&nbsp;Morisset was granted an option to purchase 244,762 shares of our common stock at an exercise price of $.0001 per
share. This option vests over a four-year period with 25% of the shares subject to the option vesting in February 2022 and the remainder vesting monthly over the next 36&nbsp;months, subject in each case to Dr.&nbsp;Morisset&#146;s continued
employment with us. In April 2021, Dr.&nbsp;Morisset was granted 300,645 shares of our common stock pursuant to a restricted stock award at a price of $.0001 per share. This grant vests over a four-year period with 25% of the shares subject to the
grant vesting in April 2022 and the remainder vesting monthly over the next 36&nbsp;months. In the event that our successor in a change of control does not assume or continue the unvested portion of Dr.&nbsp;Morisset&#146;s equity awards and the
unvested awards will otherwise terminate, then the unvested portion of Dr.&nbsp;Morisset&#146;s equity awards shall vest in full and become exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout the term of her employment, Dr.&nbsp;Morisset is also entitled to receive six months&#146; notice prior to the termination of her
employment. If we terminate Dr.&nbsp;Morisset&#146;s employment in our discretion with less than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;157&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
six months&#146; notice, Dr.&nbsp;Morisset is entitled to receive a sum equal to her basic salary, bonus (if awarded by the board of directors) and the cost to us of any benefits that she would
have received during the notice period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Dr.&nbsp;Morisset&#146;s employment without cause (as defined in her employment
agreement) and other than as a result of her death or disability or if she resigns for good reason (as defined in her employment agreement), in each case, prior to our initial public offering and not in connection with a change in control (as
defined in her employment agreement), then she will be eligible to receive the following severance benefits: (1)&nbsp;nine months of her base salary, paid in nine equal installments over the nine months following her separation from service;
(2)&nbsp;an amount equal to her pro rata annual performance bonus, based on the target amount, for the calendar year in which termination occurs, payable on the first regularly scheduled payroll date following the effectiveness of the release of
claims; and (3)&nbsp;the vesting of the unvested portion of any time or service-based equity awards held by Dr.&nbsp;Morisset that are scheduled to vest and become exercisable in the nine-month period following the termination date will be
accelerated and immediately vested as of the termination date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Dr.&nbsp;Morisset&#146;s employment without cause (as
defined in her employment) and other than as a result of her death or disability or if she resigns for good reason (as defined in her employment agreement), in each case, following our initial public offering and not in connection with a change in
control, then she will be eligible to receive the following severance benefits: (1) 18 months of her base salary, paid in 18 equal installments over the 18 months following her separation from service; (2)&nbsp;an amount equal to her pro rata annual
performance bonus, based on the target amount, for the calendar year in which termination occurs, payable on the first regularly scheduled payroll date following the effectiveness of the release of claims; and (3)&nbsp;the vesting of the unvested
portion of any time or service-based equity awards held by Dr.&nbsp;Morisset that are scheduled to vest and become exercisable in the <FONT STYLE="white-space:nowrap">12-month</FONT> period following the termination date will be accelerated and
immediately vested as of the termination date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Dr.&nbsp;Morisset&#146;s employment without cause (as defined in her
employment) and other than as a result of her death or disability or if she resigns for good reason (as defined in her employment agreement), in each case, in the period commencing three months prior to and ending 12 months following a change in
control, then she will be eligible to receive the following severance benefits: (1) 18 months of her base salary and annual bonus, based on the target amount, paid in a lump sum following the effectiveness of the release of claims; and (2)&nbsp;the
vesting of the unvested portion of any time-based, performance-based or service-based equity awards held by Dr.&nbsp;Morisset will be accelerated and immediately vested as of the termination date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Stock Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Equity
Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted the 2021 Equity Incentive Plan, or the 2021 Plan,
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021, and our stockholders approved the 2021 Plan
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2021. The 2021 Plan will become effective upon the execution of the underwriting agreement for this offering. The 2021 Plan will be the successor to
our 2019 Equity Incentive Plan, as amended, or the 2019 Plan, which is described below. Once the 2021 Plan becomes effective, no further grants will be made under the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. Our 2021 Plan provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, or NSOs, stock
appreciation rights, restricted stock awards, restricted stock unit awards, performance-based awards and other awards, or collectively, awards. ISOs may be granted only to our employees, including our officers, and the employees of our affiliates.
All other awards may be granted to our employees, including our officers, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants and the employees and consultants of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. The maximum number of shares of common stock that may be issued under our 2021 Plan is &nbsp;&nbsp;&nbsp;&nbsp;
shares. The number of shares of common stock reserved for issuance under our 2021 Plan will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;158&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2022, and continuing through and including January&nbsp;1, 2031,
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock outstanding on December&nbsp;31 of the immediately preceding calendar year, or a lesser number of shares determined by our board prior to the
applicable January 1st. The maximum number of shares that may be issued upon the exercise of ISOs under our 2021 Plan is three times the share reserve, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares issued under our 2021 Plan will be authorized but unissued or reacquired shares of common stock. Shares subject to awards granted under
our 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under our 2021 Plan. Additionally, shares issued pursuant to
awards under our 2021 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations related to an award, will become available for future grant under our
2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum number of shares of common stock subject to stock awards granted under the 2021 Plan or otherwise during any
period commencing on the date of the company&#146;s annual meeting of stockholders for a particular year and ending on the day immediately prior to the date of the company&#146;s annual meeting of stockholders for the next subsequent year to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, taken together with any cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director during such period for service on the board of directors, will not exceed
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in total value (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting
purposes), or, with respect to the period in which a <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to our board of directors,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board,
or a duly authorized committee of our board, may administer our 2021 Plan. Our board has delegated concurrent authority to administer our 2021 Plan to the compensation committee under the terms of the compensation committee&#146;s charter. We
sometimes refer to the board, or the applicable committee with the power to administer our equity incentive Plans, as the administrator. The administrator may also delegate to one or more of our officers the authority to (1)&nbsp;designate employees
(other than officers) to receive specified awards, and (2)&nbsp;determine the number of shares subject to such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator
has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of awards, if any, the number of shares subject to each award, the fair market value of a share of common stock, the vesting schedule
applicable to the awards, together with any vesting acceleration, and the form of consideration, if any, payable upon exercise or settlement of the award and the terms of the award agreements for use under our 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to the terms of the 2021 Plan, the administrator also has the power to modify outstanding awards under our 2021 Plan,
including the authority to reprice any outstanding option or stock appreciation right, cancel and <FONT STYLE="white-space:nowrap">re-grant</FONT> any outstanding option or stock appreciation right in exchange for new stock awards, cash or other
consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any materially adversely affected participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. ISOs and NSOs are granted pursuant to stock option agreements adopted by the administrator. The administrator determines
the exercise price for a stock option, within the terms and conditions of the 2021 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of common stock on the date of grant. Options
granted under the 2021 Plan vest at the rate specified in the stock option agreement by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator determines
the term of stock options granted under the 2021 Plan, up to a maximum of ten years. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise, if an optionholder&#146;s service relationship with us, or any of our
affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that
either an exercise of the option or an immediate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;159&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale of shares acquired upon exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#146;s
service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for
a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual for cause. In no event may an option be
exercised beyond the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a
stock option will be determined by the administrator and may include (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of common stock previously owned by the optionholder,
(4)&nbsp;a net exercise of the option if it is an NSO, and (5)&nbsp;other legal consideration approved by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options may
not be transferred to third-party financial institutions for value. Unless the administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order.
An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tax
Limitations on ISOs.</I> The aggregate fair market value, determined at the time of grant, of common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not
exceed $100,000. Options or portions thereof that exceed such limit will be treated as NSOs. No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting
power or that of any of our parent or subsidiary corporations, unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&nbsp;the term of the ISO does not
exceed five years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>. Restricted stock awards are granted pursuant to restricted
stock award agreements adopted by the administrator. Restricted stock awards may be granted in consideration for cash, check, bank draft or money order, services rendered to us or our affiliates or any other form of legal consideration. Common stock
acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the administrator. A restricted stock award may be transferred only upon such
terms and conditions as set by the administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested may be forfeited or repurchased by us upon the participant&#146;s cessation of continuous
service for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards are granted pursuant to restricted stock unit
award agreements adopted by the administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock
as deemed appropriate by the administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit
award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of continuous service for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted pursuant to stock appreciation right grant agreements adopted by the
administrator. The administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of common stock on the date of grant. Upon the exercise of a stock appreciation right, we
will pay the participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of common stock on the date of exercise over the strike price, multiplied by (2)&nbsp;the number of shares of common stock with respect
to which the stock appreciation right is exercised. A stock appreciation right granted under the 2021 Plan vests at the rate specified in the stock appreciation right agreement as determined by the administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;160&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator determines the term of stock appreciation rights granted under the 2021
Plan, up to a maximum of ten years. Unless the terms of a participant&#146;s stock appreciation right agreement provide otherwise, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause,
disability or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of
the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant
dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the
event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond
the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>. Our 2021 Plan permits the grant of performance-based stock and cash awards. The
compensation committee can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a
designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance goals may be based on any measure of performance selected by the board of directors. The compensation committee may establish
performance goals on a company-wide basis, with respect to one or more business units, divisions, affiliates or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of
one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, the compensation
committee will appropriately make adjustments in the method of calculating the attainment of the performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects;
(3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in
nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us achieved
performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock by reason of any stock dividend or split, stock
repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than
regular cash dividends; (9)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be
expensed under generally accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Awards</I>. The administrator may grant other awards based in whole or in part by reference to common stock. The administrator will
set the number of shares under the award and all other terms and conditions of such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the
event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under
the 2021 Plan; (2)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year; (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of ISOs and (4)&nbsp;the class and
number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate
Transactions</I>. The following applies to stock awards under the 2021 Plan in the event of a corporate transaction, unless otherwise provided in a participant&#146;s stock award agreement or other written
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;161&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant. Under the 2021 Plan, a corporate transaction is generally the
consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;a sale or other disposition of at least 50% of our outstanding securities, (3)&nbsp;a merger, consolidation or similar transaction following
which we are not the surviving corporation or (4)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of common stock outstanding immediately prior to such transaction are converted or
exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction, the administrator has the discretion
to take any of the following actions with respect to stock awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity or
parent company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring
entity or parent company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the vesting of the stock award and provide for its termination prior to the effective time of the
corporate transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the lapse of any reacquisition or repurchase right held by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as our
board of directors may deem appropriate; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make a payment equal to the excess of (A)&nbsp;the value of the property the participant would have received upon
exercise of the stock award over (B)&nbsp;the exercise price otherwise payable in connection with the stock award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a
change in control, as defined under our 2021 Plan, awards granted under our 2021 Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. A participant may not transfer awards under our 2021 Plan other than by will, the laws of descent and distribution or
as otherwise provided under our 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination</I>. Our board has the authority to amend, suspend or
terminate our 2021 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs
may be granted after the tenth anniversary of the date our board adopted our 2021 Plan. No awards may be granted under our 2021 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board and stockholders adopted the 2019 Plan in September 2019. The 2019 Plan provides for the grant of ISOs, NSOs, restricted stock awards and stock grants to our employees, consultants, officers or directors. ISOs may be granted only to our
employees or employees of our affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Plan will be terminated on the date the 2021 Plan becomes effective. However, any
outstanding awards granted under the 2019 Plan will remain outstanding, subject to the terms of our 2019 Plan and the applicable award agreements, until such outstanding options are exercised or until any awards terminate or expire by their terms.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;162&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. Upon the effective date of the 2021 Plan, we will no longer grant
awards under our 2019 Plan. As of March&nbsp;31, 2021, options to purchase 3,860,961 shares were outstanding and 2,284,148 shares of common stock remained available for future grants under our 2019 Plan. The options outstanding as of March&nbsp;31,
2021 had a weighted-average exercise price of $0.48 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan</I> <I>Administration</I>. Our board or a duly authorized
committee of our board administers our 2019 Plan and the awards granted under it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Acquisitions or Other Combinations of the
Company</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we are subject to a change of control, the committee has the discretion to provide for one or more of the
following treatments with respect to 2019 Plan awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption, continuation or substitution of the outstanding options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceleration, in whole or in part, of the vesting or exercisability of unvested options or lapse of the risk of
forfeiture with respect to awards of restricted stock, to become effective at the time of the transaction or at such time after that the participant&#146;s employment terminates, or at any other time determined by the committee; or
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">termination of options that remain outstanding at the time of the transaction; provided that, with respect to any
vested options, the committee must provide at least five (5)&nbsp;days written notice of such potential termination, or otherwise provide consideration to the holders of vested options equal to the consideration received in the transaction per share
over the exercise price of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Except as otherwise permitted by the administrator and the 2019 Plan
terms, a participant may not transfer awards under our 2019 Plan other than by will, the laws of descent and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan
Amendment or Termination</I>. The board of directors has the authority to terminate our 2019 Plan at any time, provided that outstanding awards will survive such termination unless the holder agrees in writing to terminate the award. The board of
directors also has the authority to amend our 2019 Plan, subject to certain limitations, and provided that certain material amendments require the approval of our stockholders. As described above, our 2019 Plan will be terminated upon the effective
date of the 2021 Plan so that no future awards will be granted under the 2019 Plan following the effectiveness of the 2021 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee
Stock Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our 2021 Employee Stock Purchase Plan (the ESPP),
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021, and our stockholders adopted the ESPP in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2021. The ESPP will become effective upon the execution
of the underwriting agreement for this offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees and to provide incentives for such individuals to exert maximum efforts toward our
success and that of our affiliates. The ESPP includes two components. One component is designed to allow our eligible U.S. employees to purchase common stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the
Code. In addition, purchase rights may be granted under a component that does not qualify for such favorable tax treatment when necessary or appropriate to permit participation by our eligible employees who are foreign nationals or employed outside
of the United States while complying with applicable foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. The maximum aggregate number of shares of
common stock that may be issued under our ESPP is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. The number of shares of common stock reserved for issuance under our ESPP will automatically increase on January&nbsp;1
of each calendar year, beginning on January&nbsp;1, 2022 and continuing through and including January&nbsp;1, 2031, by the lesser of (1)&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding on December&nbsp;31 of
the preceding calendar year, (2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, and (3)&nbsp;a number of shares determined by our board. Shares subject to purchase rights granted under our ESPP that terminate
without having been exercised in full will not reduce the number of shares available for issuance under our ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;163&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board, or a duly authorized committee thereof, will
administer our ESPP. Our board has delegated concurrent authority to administer our ESPP to the compensation committee under the terms of the compensation committee&#146;s charter. The ESPP is implemented through a series of offerings with specific
terms approved by the administrator and under which eligible employees are granted purchase rights to purchase shares of common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than
27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of common stock will be purchased for our eligible employees participating in the offering. An offering
under the ESPP may be terminated under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Payroll Deductions</I>. Generally, all regular employees, including
executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings (as defined in the ESPP) for the purchase of common stock
under the ESPP. Unless otherwise determined by the administrator, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share equal to the lower of (a) 85% of the fair market value of a share of common
stock on the first date of an offering or (b) 85% of the fair market value of a share of common stock on the date of purchase. For the initial offering, which we expect will commence upon the execution and delivery of the underwriting agreement
relating to this offering, the fair market value on the first day of the initial offering will be the price at which shares are first sold to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations</I>. Our employees, including executive officers, or any of our designated affiliates may have to satisfy one or more of the
following service requirements before participating in our ESPP, as determined by the administrator: (1)&nbsp;customary employment with us or one of our affiliates for more than 20 hours per week and more than five months per calendar year, or
(2)&nbsp;continuous employment with us or one of our affiliates for a minimum period of time, not to exceed two years, prior to the first date of an offering. An employee may not be granted rights to purchase stock under our ESPP if such employee
(1)&nbsp;immediately after the grant would own stock possessing 5% or more of the total combined voting power or value of common stock, or (2)&nbsp;holds rights to purchase stock under our ESPP that would accrue at a rate that exceeds $25,000 worth
of our stock for each calendar year that the rights remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event that there
occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend,
liquidating dividend, combination of shares, exchange of shares, change in corporate structure or similar transaction, the board of directors will make appropriate adjustments to (1)&nbsp;the number of shares reserved under the ESPP, (2)&nbsp;the
maximum number of shares by which the share reserve may increase automatically each year, (3)&nbsp;the number of shares and purchase price of all outstanding purchase rights and (4)&nbsp;the number of shares that are subject to purchase limits under
ongoing offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of certain corporate transactions, including: (1)&nbsp;a sale of all or
substantially all of our assets, (2)&nbsp;the sale or disposition of 50% of our outstanding securities, (3)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction, and (4)&nbsp;the consummation of a merger or
consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase
our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute for such
purchase rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of common stock within 10 business days prior to such corporate transaction, and such purchase rights will terminate immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>ESPP</I> <I>Amendment or Termination</I>. The administrator has the authority to amend or terminate our ESPP, provided that except in
certain circumstances such amendment or termination may not materially impair any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;164&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our amended and restated certificate of incorporation will contain provisions that limit the liability of
our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as
directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will be in effect
on the closing of this offering will authorize us to indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws that will be in effect upon the closing of this
offering will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. Our amended and restated bylaws that will be in effect on the
closing of this offering will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on
behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have
entered and expect to continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements provide for indemnification for related expenses, including attorneys&#146; fees, judgments, fines
and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. We believe that these amended and restated certificate of incorporation and amended and restated bylaw provisions and
indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if
successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these
indemnification provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors,
executive officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they
will contract with a broker to buy or sell shares of common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;165&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive
officer may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy. Prior to the end of the 180th day after the date of execution of the
underwriting agreement for this offering (subject to potential early release or termination without notice), the sale of any shares under such plan would be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that the director
or executive officer has entered into with SVB Leerink LLC and Evercore Group L.L.C. on behalf of the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;166&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2018, to which we have been a participant in which the amount involved
exceeded or will exceed $120,000, and in which any of our directors, executive officers or holders of more than five percent of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect
material interest, other than compensation arrangements which are described in &#147;Executive Compensation&#148; and <FONT STYLE="white-space:nowrap">&#147;Management&#151;Non-Employee</FONT> Director Compensation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below
were comparable to terms available or the amounts that would be paid or received, as applicable, in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February
2019, we issued an aggregate of 4,080,000 shares of Series A redeemable convertible preferred stock at a purchase price of $3.00 per share, for an aggregate purchase price of $12.2&nbsp;million. In October 2019, we issued an additional 1,354,167
shares of Series A redeemable convertible preferred stock at a purchase price of $3.00 per share, for aggregate purchase price of approximately $4.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2019, we issued 2,564,102 shares of Series A-1 redeemable convertible preferred stock for a purchase price of $3.90, for an
aggregate purchase price of $10.0 million. In October 2020, we issued an aggregate of 1,282,050 shares of our Series A-1 redeemable convertible preferred stock at a purchase price of $3.90 per share, for an aggregate purchase price of approximately
$5.0 million. In March 2021, we issued 8,717,947 shares of Series A-1 redeemable convertible preferred stock at a purchase price of $3.90 per share, for an aggregate purchase price of approximately $34.0 million. In May 2021, we issued 7,692,306
shares of Series B redeemable convertible preferred stock at a purchase price of $7.80 per share, for an aggregate purchase amount of approximately $60.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series&nbsp;A, <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> and Series&nbsp;B redeemable
convertible preferred stock purchased by holders of more than five percent of our capital stock, their affiliated entities and our directors. None of our executive officers purchased shares of redeemable convertible preferred stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT><BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AI ETI LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,136,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,833,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.
(RAH)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,072,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,346,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,254,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeArc<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICG Life Sciences SCSp<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,923,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Nexus Fund, L.P.
(RACN)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,541,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Nexus Fund II, L.P. (RACN
II)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">576,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC&#150;Series A
(BP)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,370,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liam Ratcliffe, a member of our board of directors, is an affiliate of AI ETI LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Andrew Levin, a member of our board of directors, is an affiliate of RA Capital Management, L.P. (RACM), the
investment manager for RAH, RACN and RACN II. RACM is also the investment manager for BP, a separately managed account. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Simon Tate, a member of our board of directors, is an affiliate of Intermediate Capital Group plc. Prior to his
affiliation with Intermediate Capital Group plc, Mr.&nbsp;Tate was an affiliate of LifeArc. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this
offering, each share of redeemable convertible preferred stock will convert into one share of common stock. For a description of the material rights and privileges of the redeemable convertible preferred stock, see Note&nbsp;5 to our audited
financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;167&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, we entered into an amended and restated investor rights agreement, or IRA, as amended in March 2021, with certain holders of
our redeemable convertible preferred stock and common stock, including entities affiliated with our directors. The IRA provides the holders of our redeemable convertible preferred stock with certain registration rights, including the right to demand
that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. Simon Tate, Andrew Levin and Liam Ratcliffe are affiliated with Intermediate Capital Group plc, RA Capital
Management, L.P. and AI ETI LLC, respectively. The IRA also provides these stockholders with information rights, which will terminate upon the closing of this offering, and a right of first refusal with regard to certain issuances of our capital
stock, which will not apply to, and will terminate upon, the closing of this offering. After the closing of this offering, the holders of 36,690,573 shares of common stock issuable on conversion of outstanding redeemable convertible preferred stock,
which includes the conversion of the 7,692,306 shares of Series B redeemable convertible preferred stock we issued and sold in May 2021, will be entitled to rights with respect to the registration of their shares of common stock under the Securities
Act under this agreement. For a description of these registration rights, see the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Carnot, LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October
2018, we entered into a services agreement with Carnot, LLC (along with its successor agreements, the Carnot Agreement). Under the terms of the Carnot Agreement, Carnot Pharma, LLC provides research and services related to our drug discovery,
research and development programs and we compensate Carnot Pharma, LLC for the time its personnel devote to such efforts. The Carnot Agreement is terminable by either party without cause on thirty days&#146; written notice. Carnot, LLC was
subsequently dissolved and the services agreement transitioned to its successor Carnot Pharma, LLC. During 2018, 2019, 2020 and the three months ended March&nbsp;31, 2021, we made payments to Carnot, LLC and Carnot Pharma, LLC of $0.6 million, $1.5
million, $0.6&nbsp;million and $0.4&nbsp;million, respectively, for research and development expenses. RACM is the manager of the members of Carnot Pharma, LLC and Andrew Levin, our former CEO and a member of our board of directors, is the President
of Carnot Pharma, LLC. Adam Rosenberg, a member of our board of directors, is a Venture Partner at Carnot Pharma, LLC, dba RA Ventures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset
Acquisitions with Related Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, we acquired 100% of the share capital of NeoKera, LLC for 166,667 shares of common
stock valued at $0.75 per share. In June 2020, we determined to discontinue further development and dissolve NeoKera, LLC. Concurrent with the acquisition of NeoKera in February 2019, we acquired in process research and development from Carnot, LLC
related to ETX-810. We issued 3.5&nbsp;million shares of common stock, valued at $0.75 per share, to acquire the assets. At the time of these acquisitions, RACM was a manager of the members of NeoKera, LLC and Carnot, LLC, and Andrew Levin, a member
of our board or directors, was our Chief Executive Officer and was the President of Carnot, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, we acquired 100% of the
share capital of Athenen Therapeutics Inc. for a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> exchange of outstanding preferred and common stock. As a result, we issued a total of 5&nbsp;million Series
A preferred shares and 3.1&nbsp;million shares of common stock, valued at $2.90 per share and $0.66 per share, respectively. The IPR&amp;D acquired in this transaction will enable us to develop <FONT STYLE="white-space:nowrap">ETX-155.</FONT> RAH,
RACN and BP were greater than 5% stockholders of Athenen prior to the acquisition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements and offer letters with certain of our executive officers. For more information regarding these
agreements with our executive officers, see the section titled &#147;Executive Compensation&#151;Employment Arrangements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted options to certain of our directors and executive officers. For more information regarding the options granted to our directors
and named executive officers, see the sections titled &#147;Executive Compensation&#148; and <FONT STYLE="white-space:nowrap">&#147;Management&#151;Non-Employee</FONT> Director Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;168&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will be in effect upon the closing of this offering will contain provisions limiting
the liability of directors, and our amended and restated bylaws that will be in effect on the closing of this offering will provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our
amended and restated certificate of incorporation and amended and restated bylaws that will be in effect on the closing of this offering will also provide our board of directors with discretion to indemnify our employees and other agents when
determined appropriate by the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have entered into an indemnification agreement with each of our directors and
executive officers, which requires us to indemnify them. For more information regarding these agreements, see the section titled &#147;Executive Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will adopt a related person transaction policy setting forth the policies and procedures for the identification, review
and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or
relationship, or any series of similar transactions, arrangements or relationships, in which we and a related person were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the
related person or entities in which the related person has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our audit committee will consider all relevant facts and circumstances as
appropriate, such as the purpose of the transaction, the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction,
management&#146;s recommendation with respect to the proposed related person transaction and the extent of the related person&#146;s interest in the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the transactions described in this section were entered into prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;169&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock as of May&nbsp;31, 2021, for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily
indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power
with respect to all shares that they beneficially own, subject to applicable community property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership
before the offering is based on 38,375,837 shares of common stock outstanding as of May&nbsp;31, 2021, assuming the conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock upon the closing of this
offering. Applicable percentage ownership after the offering is based on shares of common stock outstanding immediately after the closing of this offering, assuming no exercise by the underwriters of their option to purchase additional shares in
full. In computing the number of shares beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable within 60
days of May&nbsp;31, 2021. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person. The information contained in the following table is not necessarily
indicative of beneficial ownership for any other purpose, and the inclusion of any shares in the table does not constitute an admission of beneficial ownership of those shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;170&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed below is c/o Eliem
Therapeutics, 23515 NE Novelty Hill Road, Suite B221 #125, Redmond, WA 98053. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially
owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B><br><B>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares</B><br><B>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA
Capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,901,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeArc<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,923,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AI ETI LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,418,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICG Life Sciences SCSp<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,205,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Azelby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin M. Lavelle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Morisset, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">593,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Levin, M.D., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Judith Dunn, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leone Patterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liam Ratcliffe, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adam Rosenberg<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simon Tate<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (10&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Consists of: (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock held by RA Capital Healthcare Fund, L.P. (RA Healthcare); (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock held by RA Capital Nexus Fund, L.P. (Nexus Fund);
(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, held by Blackwell Partners LLC&#151;Series A (Blackwell) and
(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock held by RA Capital Nexus Fund II, L.P. (Nexus Fund II). RA&nbsp;Capital Management, L.P. (RACM) is the investment manager for
RA&nbsp;Healthcare, Nexus Fund, Blackwell, and Nexus Fund II. The general partner of RACM is RA Capital Management GP, LLC. The general partner of RA Healthcare is RA Capital Healthcare Fund GP, LLC. The general partner of Nexus Fund is
RA&nbsp;Capital Nexus Fund GP, LLC. The general partner of Nexus Fund II is RA Capital Nexus Fund II GP, LLC. Peter Kolchinsky and Rajeev Shah are the managing members of RA Capital Management GP, LLC, RA Capital Healthcare Fund GP, LLC,
RA&nbsp;Capital Nexus Fund GP, LLC, and RA&nbsp;Capital Nexus Fund II GP, LLC and have the power to vote or dispose of the shares held by RA Healthcare, Nexus Fund, Blackwell and Nexus Fund II. The address of the persons and entities listed above is
200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock held
by LifeArc. The board of trustees are responsible for the general control and management of the administration of LifeArc, including the exercise of any voting or other rights attaching to its shares in Eliem Therapeutics, Inc. The board of trustees
of LifeArc are John Stageman, Daniel Morgan, David Zahn, Paul Mussenden, Aisling Burnand, Mike Romanos, Melanie Lee, Les Hughes, Lynne Robb, Andrew Mercieca and Jo Pisani. The address of LifeArc is Lynton House,
<FONT STYLE="white-space:nowrap">7-12</FONT> Tavistock Square, London, WC1H 9LT United Kingdom. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
owned directly by AI ETI LLC and that may be deemed to be beneficially owned by Access Industries Holdings LLC (&#147;AIH&#148;), Access Industries Management, LLC (&#147;AIM&#148;) and Len Blavatnik because (i)&nbsp;AIH indirectly controls all of
the outstanding voting interests in AI ETI LLC, (ii)&nbsp;AIM controls AIH and (iii)&nbsp;Mr.&nbsp;Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. Liam Ratcliffe, a member of our board of directors, is Head of
Biotechnology at Access Industries, Inc., which is an affiliate of AI ETI LLC. Each of AIM, AIH, Mr.&nbsp;Blavatnik and Mr.&nbsp;Ratcliffe, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims
beneficial ownership of the shares held by AI ETI LLC. The address of AI ETI LLC is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of stock held by ICG
Life Sciences SCSp (ICG). ICG is indirectly, wholly owned by Intermediate Capital Group PLC which is deemed to have voting and investment power over the shares held of record of ICG. The address of the entities listed above is Procession House, 55
Ludgate Hill, London EC4M 7JW. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Consists of: (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock held directly, of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares were unvested and remained subject to a repurchase right in favor of us as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issuable pursuant to stock options exercisable within 60 days of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;171&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock held
directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Consists of: (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock directly or indirectly held by all current executive officers and directors as a group; and (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable pursuant to options exercisable
within 60&nbsp;days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;172&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The description below of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated
bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws to be in effect upon the closing of this offering, which are filed as exhibits to the registration
statement of which this prospectus is part, and by the applicable provisions of Delaware law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our amended and restated certificate of incorporation will authorize us to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, $0.0001 par value per share, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, there were 7,225,907 shares of common stock issued and outstanding, held by 21 stockholders of record. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, after giving effect to the conversion of all 30,690,573 outstanding shares of redeemable convertible preferred
stock, which includes the conversion of the 7,692,306 shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May 2021, into an equal number of shares of common stock, there would have been 37,916,480 shares of common
stock outstanding, held by 25 stockholders of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of
common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our amended and restated certificate of incorporation, our stockholders will not have cumulative
voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
preferences that may apply to any then-outstanding preferred stock, the holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.
We do not anticipate paying any cash dividends in the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable
to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;173&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, there were 30,690,573 shares of redeemable convertible preferred stock outstanding, which includes 7,692,306 shares
of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May&nbsp;2021. Upon the closing of this offering, each outstanding share of redeemable convertible preferred stock will convert into one share of common stock. Under our
amended and restated certificate of incorporation to be in effect upon the closing of this offering, our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an
aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include
dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.
Any issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders would receive dividend payments and payments on liquidation. In addition, the issuance of preferred stock could
have the effect of delaying, deterring or preventing a change of control or other corporate action. No shares of preferred stock will be outstanding immediately following the closing of this offering. We have no present plans to issue any shares of
preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of March&nbsp;31, 2021, options to purchase an aggregate of 3,860,961 shares of common stock were outstanding under our 2019 Equity Incentive Plan. As of March&nbsp;31, 2021, 2,284,148 shares of common stock were reserved for future issuance under
our 2019 Equity Incentive Plan. For additional information regarding the terms of this plan, see the section titled &#147;Executive Compensation&#151;Employee Benefit and Stock Plans.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the
IRA which provides various rights to certain holders of shares of common stock, including those shares of common stock that will be issued upon conversion of redeemable convertible preferred stock in connection with this offering. These shares are
referred to as registrable securities. The holders of these registrable securities possess registration rights pursuant to the terms of the IRA and are described in additional detail below. We, along with AI ETI LLC, RA Capital Healthcare Fund,
L.P., RA Capital Nexus Fund, L.P., Blackwell Partners LLC &#150; Series A and Intermediate Group PLC, as well as other stockholders, are parties to the IRA. We entered into the IRA in connection with the issuance of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock in October 2020. The following summary discusses certain material provisions of the IRA and is qualified by the full text of the agreement, which is filed as an exhibit to
the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain stockholders who are party to the IRA have waived their
registration rights and the registration rights of the other stockholders who are party to the IRA, in each case, with respect to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of shares of common stock pursuant to the exercise of registration rights described below would enable the holders to trade
these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses (other than underwriting discounts, selling commissions and stock transfer taxes) of
the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, if we determine in good faith in consultation with the underwriters, we have the right, subject to
specified conditions, to limit the number of shares the holders may include. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will terminate on the date five years following the closing
of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the holders of an aggregate of 36,690,573 shares of common stock, which includes the conversion of the 7,692,306
shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May 2021, including common stock issuable upon conversion of outstanding shares of redeemable convertible preferred
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;174&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock upon the closing of this offering will be entitled to certain demand registration rights. Beginning on the date 180 days following the effective date of the registration statement of which
this prospectus is a part, upon the written request of the holders of more than 75% of our registrable securities then outstanding that we file a registration statement under the Securities Act, if the anticipated aggregate offering price, net of
selling expenses, would exceed $15.0&nbsp;million we are obligated to register the sale of all registrable securities that the holders may request in writing to be registered. We are required to effect no more than two registration statements that
are declared or ordered effective. We may postpone the filing of a registration statement for up to 120 days twice in a <FONT STYLE="white-space:nowrap">12-month</FONT> period if in the good faith judgment of our board of directors such registration
would be materially detrimental to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the holders of an aggregate of 36,690,573 shares of common stock, which includes the conversion of the 7,692,306
shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May 2021, including common stock issuable upon conversion of outstanding shares of redeemable convertible preferred stock upon the closing of this offering will be
entitled to certain piggyback registration rights. If we register any of our securities for public sale, either for our own account or for the account of other security holders, we will also have to register all registrable securities that the
holders of such securities request in writing be registered. This piggyback registration right does not apply to a registration relating to any of our stock plans, stock purchase or similar plan, a transaction under Rule 145 of the Securities Act or
a registration related to stock issued upon conversion of debt securities. We, based on consultation with the underwriters of any underwritten offering will have the right to limit the number of shares registered by these holders if the underwriters
determine that including all registrable securities will jeopardize the success of the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT>
Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the holders of an aggregate of 36,690,573 shares of common stock, which includes
the conversion of the 7,692,306 shares of Series&nbsp;B redeemable convertible preferred stock we issued and sold in May 2021, including common stock issuable upon conversion of outstanding shares of redeemable convertible preferred stock upon the
closing of this offering will be entitled to certain registration rights on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> The holders of these shares, constituting more than 10% of our registrable securities then outstanding, can request that we
register all or a portion of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and the aggregate price to the public of the shares
offered is in excess of $5.0&nbsp;million. We are required to effect no more than two Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statements that are declared or ordered effective in any
<FONT STYLE="white-space:nowrap">12-month</FONT> period. We may postpone the filing of a registration statement for up to 120 days not more than twice in a <FONT STYLE="white-space:nowrap">12-month</FONT> period if in the good faith judgment of our
board of directors such registration would be materially detrimental to us. The foregoing <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> rights are subject to a number of additional exceptions and limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the
Delaware General Corporation Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which generally
prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following
exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (1)&nbsp;by persons </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;175&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
who are directors and also officers and (2)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will
be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested
stockholder&#148; as an entity or person who, together with the person&#146;s affiliates and associates, beneficially owns or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the
outstanding voting stock of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision
in its original certificate of incorporation or an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the
outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaws to Be in Effect upon the Closing of This Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other things, our amended and restated certificate of incorporation and amended and restated bylaws will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred
stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our board of directors will be classified into three classes of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be
removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66 2/3% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election
of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be
filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;176&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairperson of our board of
directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of these provisions would require approval by the holders of at least 66 2/3% of the voting power of all of our
then-outstanding capital stock entitled to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has
the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it
possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies
and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such
provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market
price of our stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exclusive Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation to be effective on the completion of this offering will provide that the Court of
Chancery of the State of Delaware be the exclusive forum for actions or proceedings brought under Delaware statutory or common law: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a breach of
fiduciary duty; (3)&nbsp;any action asserting a claim against us arising under the Delaware General Corporation Law; (4)&nbsp;any action regarding our amended and restated certificate of incorporation or our amended and restated bylaws; (5)&nbsp;any
action as to which the Delaware General Corporate Law confers jurisdiction to the Court of Chancery of the State of Delaware; or (6)&nbsp;any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and
restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Such
provision is intended to benefit and may be enforced by us, our officers and directors, employees and agents, including the underwriters and any other professional or entity who has prepared or certified any part of this prospectus. Although our
amended and restated certificate of incorporation contain the choice of forum provisions described above, it is possible that a court could find one or more of these provisions inapplicable for a particular claim or action or that such provision is
unenforceable. Further, notwithstanding anything in our amended and restated certificate of incorporation and amended and restated bylaws, investors cannot waive compliance with the federal securities laws and regulations thereunder. The choice of
forum provisions will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;177&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any action the subject matter of which is within the scope described above is filed in a
court other than a court located within the State of Delaware (a Foreign Action), in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the
State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated bylaws and having service of process made upon such
stockholder in any such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits
with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#147;Executive Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
currently not listed on any securities exchange. We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;ELYM.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock upon the closing of this offering will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent&#146;s address is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the telephone number is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;178&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock in the
public market, or the perception that such sales may occur, could adversely impact the market price of our common stock and impair our ability to raise equity capital in the future. Although we intend to apply to list our common stock on the Nasdaq
Global Market, we cannot assure you that there will be an active public market for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of this
offering, based on the number of shares of common stock outstanding as of March&nbsp;31, 2021 (including shares of redeemable convertible preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) and assuming no exercise of
the underwriters&#146; option to purchase additional shares, we will have an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of common stock outstanding. Of these shares, all
shares of common stock sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares of common stock purchased by our &#147;affiliates,&#148; as that term is defined in Rule
144 under the Securities Act, or subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters or market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions in agreements with us. Shares purchased by our
affiliates will be subject to the Rule 144 resale restrictions described below, other than the holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining
shares of common stock outstanding after this offering will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered
under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, each of which is summarized below. We expect that substantially all of these shares will be subject to a <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares of common stock from time to time as consideration for future acquisitions, investments or other corporate purposes. In
the event that any such acquisition, investment or other transaction is significant, the number of shares of common stock that we may issue may also be significant. We may also grant registration rights covering those shares of common stock issued
in connection with any such acquisition, investment or other transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, shares of common stock that are subject to
outstanding options or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements described below, and Rules 144 and 701 under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as
currently in effect, once we have been subject to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with
the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one of
our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our
affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying
with any of the requirements of Rule 144, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell
shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. Beginning 90 days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;179&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after the date of this prospectus, within any three-month period, such stockholders may sell a number of shares that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after this offering based on the number of shares of common stock outstanding as of March&nbsp;31, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock during the four calendar weeks preceding the filing of a
notice on Form 144 with respect to such sale; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provided in each case that we have been subject to the Exchange Act periodic reporting requirements for at least
90 days before the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates
are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to
have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance on Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of
Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait
until 90 days after the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and in &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register
all shares of common stock subject to outstanding stock options and common stock issued or issuable under the 2019 Plan, the 2021 Plan and the ESPP. We expect to file the registration statement covering shares offered pursuant to these stock plans
shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the public
market subject to compliance with the resale provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and Market <FONT
STYLE="white-space:nowrap">Stand-Off</FONT> Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our directors, executive officers and the holders of substantially all of
our equity securities have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, subject to specified exceptions as detailed further in &#147;Underwriting&#148; below, we or they will not, except with the
prior written consent of SVB Leerink LLC and Evercore Group L.L.C., offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of or otherwise
dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or enter into any
swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. All of our optionholders are subject to a market
<FONT STYLE="white-space:nowrap">stand-off</FONT> agreement with us which imposes similar restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and the section titled
&#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;180&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period,
substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> and market <FONT STYLE="white-space:nowrap">stand-off</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31,
2021, holders of an aggregate of 36,690,573 shares of our common stock, including the shares of common stock issuable upon the conversion of redeemable convertible preferred stock upon the closing of this offering, or their transferees, 6,000,000
shares of common stock already outstanding, are entitled to various rights with respect to the registration of these shares under the Securities Act upon the closing of this offering and the expiration of
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of
the registration, except for shares subsequently purchased by affiliates. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration statement will be
eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;181&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common
stock acquired in this offering by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below). This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, and does not address
foreign, state and local tax consequences that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their particular circumstances, nor does it address the potential application of the alternative minimum tax or
the Medicare contribution tax on net investment income, or the treatment of person subject to special tax accounting rules under Section&nbsp;451(b) of the Internal Revenue Code, or U.S. federal tax consequences (such as gift and estate taxes) other
than income taxes. Special rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are subject to special treatment under the Internal Revenue Code, such as financial
institutions, insurance companies, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, broker-dealers and traders in securities, U.S. expatriates, &#147;controlled foreign corporations,&#148; &#147;passive foreign investment
companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic security&#148; or
integrated investment or other risk reduction strategy, &#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Internal Revenue Code and entities all of the interests of which are held by qualified foreign pension
funds, partnerships and other pass-through entities or arrangements and investors in such pass-through entities or arrangements. Such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their own tax advisors to determine
the U.S. federal, state, local and other tax consequences that may be relevant to them. Furthermore, the discussion below is based upon the provisions of the Internal Revenue Code, and Treasury Regulations, rulings and judicial decisions thereunder
as of the date hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the U.S.
Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Internal Revenue Code (generally, property held for investment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is for informational purposes only and is not tax advice. Persons considering the purchase of our common stock pursuant to
this offering should consult their own tax advisors concerning the U.S. federal income, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences
arising under the laws of any other taxing jurisdiction, including any state, local or foreign tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this
discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is, for U.S. federal income tax purposes, a beneficial owner of common stock that is neither a U.S. Holder, nor a partnership (or other entity treated as a partnership
for U.S. federal income tax purposes regardless of its place of organization or formation). A &#147;U.S. Holder&#148; means a beneficial owner of common stock that is for U.S. federal income tax purposes any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized
in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more
U.S. persons have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;182&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions, if any, made on our common stock to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to the extent made out of our
current or accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S. tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding and foreign accounts. To obtain a reduced rate of withholding under an applicable income tax treaty, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be required to provide a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits under such treaty. This certification must
be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. In the case of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is an entity, Treasury Regulations and the relevant income tax
treaty provide rules to determine whether, for purposes of determining the applicability of an income tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to such agent. The <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s agent will then be required to provide certification to
us or our paying agent, either directly or through other intermediaries. If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and does not timely file
the required certification, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally are not required to withhold tax on dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are
effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment
or fixed base that such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains in the United States) if a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected, is furnished
to us (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends will be subject to U.S. federal income tax, on a <FONT STYLE="white-space:nowrap">net-income</FONT> basis at
the regular rates applicable to U.S. persons. A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under
certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on the corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected earnings and profits, subject
to certain adjustments. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted basis in our common stock, but not below zero, and then will be treated as capital gain to the extent of any excess amount distributed, and taxed in the same manner as gain realized
from a sale or other disposition of common stock as described in the next section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and foreign accounts, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively connected with a trade or business of such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
maintains in the United States), (b) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and is present in the United States for 183 days or more in the taxable year of the disposition and certain other
conditions are met or (c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of Code Section&nbsp;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or
such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. In general, we would be a United States real property holding corporation if the fair market value of our interests in U.S. real property interests comprise at least
half of the fair market value of our other trade or business assets and our worldwide real property interests. We believe that we have not been and we are not, and do not anticipate becoming, a United States real
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;183&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property holding corporation. Even if we are treated as a United States real property holding corporation, gain realized by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder on a
disposition of our common stock will not be subject to U.S. federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, directly and constructively, no more than 5% of our common stock at all times
within the shorter of (i)&nbsp;the five-year period preceding the disposition or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period and (2)&nbsp;our common stock is regularly traded on an established
securities market as defined for purposes of applicable Treasury Regulations. There can be no assurance that our common stock will qualify as regularly traded on an established securities market. If any gain on a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s disposition is taxable because we are a United States real property holding corporation and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s ownership of our common
stock exceeds 5%, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be taxed on such disposition generally in the manner as gain that is effectively connected with the conduct of a U.S. trade or business (subject to the relevant
provisions under any applicable income tax treaty), except that the branch profits tax generally will not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in (a)&nbsp;above will be required to pay tax on the net gain derived from the sale at regular U.S. federal income tax rates applicable to U.S. persons, and corporate <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in (a)&nbsp;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. Gain described in
(b)&nbsp;above will be subject to U.S. federal income tax at a flat 30% rate or such lower rate as may be specified by an applicable income tax treaty, which gain may be offset by certain U.S.-source capital losses (even though the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such
losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting Requirements and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we must report information to the IRS with respect to any distributions we pay on our common stock (even if the payments are exempt
from withholding), including the amount of any such distributions, the name and address of the recipient and the amount, if any, of tax withheld. A similar report is sent to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to whom any
such distributions are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid by us (or our paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject to U.S. backup
withholding (currently at a rate of 24%). U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS
Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-ECI</FONT> (as applicable), or otherwise establishes an exemption. Notwithstanding the foregoing, backup
withholding may apply if the payer has actual knowledge, or reason to know, that the beneficial owner is a U.S. person who is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock
effected by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and such requirements may be avoided if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or otherwise meets documentary evidence requirements for establishing
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> person status or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information
reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the beneficial owner is, in fact, a U.S. person. For information reporting purposes,
certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be credited against the tax liability of persons subject to backup withholding, provided that the required information is timely furnished to the IRS.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;184&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Internal Revenue Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or
FATCA) impose a U.S. federal withholding tax of 30% on certain payments made to a foreign financial institution (as specifically defined by applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on
certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that
are foreign entities with U.S. owners). FATCA also generally imposes a federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding
agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity. An intergovernmental agreement between the United
States and an applicable foreign country may modify those requirements. The withholding tax described above will not apply if the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise
qualifies for an exemption from the rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding provisions described above currently apply to payments of dividends. The U.S.
Treasury Department has released proposed Treasury Regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a disposition of our common stock. In its preamble to
such proposed Treasury Regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final Treasury Regulations are issued. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are
encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EACH
PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;185&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC, Evercore Group L.L.C., Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Guggenheim Securities LLC are acting as
representatives of each of the underwriters named below and as joint bookrunning managers for this offering. Subject to the terms and conditions set forth in the underwriting agreement among us and the underwriters, we have agreed to sell to the
underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus &amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of the shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and subject to other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers&#146; certificates and legal opinions. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discounts and Commissions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the initial public offering
price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial offering of the shares, the
public offering price, concession or any other term of this offering may be changed by the representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the
initial public offering price, underwriting discounts and commissions and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of our common
stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We also have agreed to reimburse the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;186&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underwriters for up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for their FINRA counsel fee. In accordance with
FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the initial public offering price, less underwriting discounts and commissions. If the underwriters exercise this option, each
underwriter will be obligated, subject to the conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors and all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this
prospectus without first obtaining the written consent of SVB Leerink LLC and Evercore Group L.L.C. on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise dispose of or transfer any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file a registration statement related to the common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic
consequence of ownership of any common stock, whether any such swap, agreement or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions apply to common stock and to securities convertible into or exchangeable or
exercisable for common stock. They also apply to common stock owned now or acquired later by the person executing the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement or for which the person executing the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement later acquires the power of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common stock on the Nasdaq Global Market, subject to notice of issuance, under the symbol &#147;ELYM.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the
factors to be considered in determining the initial public offering price are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;187&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after
this offering, our common stock will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters do
not expect to sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization,
Short Positions and Penalty Bids </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group
members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in this offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option to purchase additional shares granted to them under the underwriting agreement described above. &#147;Naked&#148; short sales are sales in excess of such
option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our
common stock in the open market after pricing that could adversely affect investors who purchase in this offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open
market prior to the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter
repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;188&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may in
the future engage in investment banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive customary fees, commissions and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each a Relevant State), no shares have been offered or will be offered pursuant
to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant
State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that the shares may be offered to the public in that Relevant State at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the
expression an &#147;offer to the public&#148; in relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an
investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a
prospectus in relation to the shares which has been approved by the Financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;189&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any
time:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&nbsp;2 of
the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000 (the
(FSMA), </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to
Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom
means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK
Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts <FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT
STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;190&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley LLP, Seattle, Washington.
Latham&nbsp;&amp; Watkins LLP, Menlo Park, California is representing the underwriters. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2020 and 2019 and for the years then ended included in this prospectus have been so included
in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered
public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_22"></A>WHERE YOU
CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have submitted with the SEC a registration statement on Form
<FONT STYLE="white-space:nowrap">S-1,</FONT> including exhibits and schedules, under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration
statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its
exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit
to the registration statement. Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports,
proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection at the web site of the SEC referred to above. We also maintain a website at www.eliemtx.com, at which,
following the closing of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. However, the information contained in or accessible through
our website is not part of this prospectus or the registration statement of which this prospectus forms a part, and investors should not rely on such information in making a decision to purchase our common stock in this offering. We have included
our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;191&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIEM THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc105292_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements as of and for the Years Ended December 31, 2019 and
2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_7">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_8">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_9">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_10">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_11">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_12">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Consolidated Financial Statements as of December 31, 2020 and March
31, 2021 and for the Three Months Ended March 31, 2020 and 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_3">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_2">Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_4">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and
Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_5">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin105292_6">Notes to the Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_7"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of Eliem Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Eliem Therapeutics, Inc. and its subsidiaries (the &#147;Company&#148;) as of December 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, of redeemable
convertible preferred stock and stockholders&#146; deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Substantial Doubt about the Company&#146;s Ability to Continue as a Going
Concern</I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As
discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring operating losses and negative cash flows from operations since inception that raise substantial doubt about its ability to continue as a going concern.
Management&#146;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB and in
accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the consolidated
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable
basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, Washington </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May 12, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_8"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock, and stockholders&#146;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.0001 par value per share, 7,998,269 and 25,818,779
shares authorized, 7,998,269 and 14,280,320 shares issued and outstanding with aggregate liquidation preference of $27,444 and $49,891 at December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value per share, 13,100,000 and 40,000,000 shares authorized and
3,705,610 and 6,837,540 shares issued and outstanding at December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_9"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred
stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,321,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,375,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_10"></A>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock, net of tranche liability of
$1,510</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,793</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred
stock, net of issuance costs of $59</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,564,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,941</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of redeemable convertible preferred stock tranche liability upon
settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock for the acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT>
research and development from a related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,998,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,174</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,705,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock and common stock for the acquisition
of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development from a related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,055,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred
stock, net of issuance costs of $75 and preferred stock tranche liability of $551</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,374</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,280,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,551</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,837,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_11"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> acquisition of
<FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency loss (gain) from remeasurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets acquired in asset acquisition including cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used for purchase of <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development from a related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable convertible preferred stock and related tranche rights, net
of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;21,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIEM THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_12"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. Nature of Operations and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eliem Therapeutics,
Inc. (the Company) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and
central nervous systems. Headquartered in Redmond, Washington, the Company was incorporated on October&nbsp;18, 2018 as a Delaware corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company and its wholly owned subsidiaries have been prepared in conformity with accounting
principles generally accepted in the United States (U.S. GAAP). All intercompany transactions and balances have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has incurred net losses. During the years ended December&nbsp;31, 2019 and 2020, the Company incurred net losses
of $6.5&nbsp;million and $20.7&nbsp;million, respectively. As of December&nbsp;31, 2019, and 2020, the Company had an accumulated deficit of $7.5&nbsp;million and $28.1&nbsp;million, respectively. To date, none of the Company&#146;s product
candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. The Company&#146;s operations have been funded primarily through issuance of redeemable convertible preferred stock, and the Company
has experienced negative cash flows. The Company will need to finance operations by obtaining additional capital through debt or equity financing or other capital sources, which could include income from collaborations, strategic partnerships or
other strategic arrangements. There can be no assurance that the Company will be able to obtain additional debt or equity financing or other capital sources on terms acceptable to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the
Company&#146;s ability to continue as a going concern within one year after May&nbsp;12, 2021, the date that the consolidated financial statements are available to be issued. Management believes the recurring operating losses and negative cash flows
from operations since inception, and the fact that Management&#146;s plans to obtain additional capital have not yet been completed, raise substantial doubt about the Company&#146;s ability to continue as a going concern. The accompanying
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a
going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the significant accounting policies followed by the Company in the preparation of the accompanying consolidated financial
statements follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that
affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the valuation of assets acquired, accrual of research and development expenses, the valuation
of stock-based awards, the valuation of common stock and redeemable convertible preferred stock, and the valuation of redeemable convertible preferred stock tranche liabilities. The Company evaluates its estimates and assumptions on an ongoing basis
using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash. The Company&#146;s cash
are held by one financial institution in the United States (U.S.) and one financial institution in the United Kingdom (U.K.). The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with
commercial banking relationships. The Company&#146;s deposits held in the U.S. and U.K. may exceed the Federal Depository Insurance Corporation and Financial Services Compensation Scheme, respectively, insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence
on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#146;s products and processes and clinical efficacy and safety of the Company&#146;s products under development,
compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive
preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for the
Company&#146;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#146;s product
development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and
biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which is impacting worldwide economic activity, poses risk
that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the <FONT STYLE="white-space:nowrap">start-up</FONT> and conduct of
the Company&#146;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#146;s existing cash reserves, and the Company may be
required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the
pandemic will impact the Company&#146;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are
identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the CODM). The Company&#146;s CODM is its chief executive officer who reviews financial
information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company&#146;s performance. Management has determined that the Company operates as a single operating and reportable
segment. The Company&#146;s CODM evaluates financial information on a consolidated basis. As the Company operates as one operating segment, all required segment financial information is found in the consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all
highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. All funds are held in cash accounts and the Company did not have any cash equivalents as of December&nbsp;31, 2019
and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Acquisitions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the guidance in Topic 805, Business Combinations, in the Financial Accounting Standards Board&#146;s (FASB) Accounting
Standards Codification (ASC), the Company evaluates acquisitions of assets and related liabilities and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by
first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is
accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for an asset acquisition by recognizing net assets based on the cost to the acquiring entity on a relative
fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition; any excess consideration transferred over the fair value of the net assets acquired is allocated to <FONT
STYLE="white-space:nowrap">the&nbsp;non-monetary&nbsp;identifiable</FONT> assets and liabilities assumed based on relative fair values. <FONT STYLE="white-space:nowrap">In-process&nbsp;research</FONT> and development acquired in an asset acquisition
is expensed provided there is no alternative future use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment
associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market
for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The
Company measures fair value based on a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Level&nbsp;1&#151;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Level 2&#151;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Inputs (other than quoted prices included in Level&nbsp;1) are either directly or indirectly observable for the assets or liabilities. These include quoted prices for similar assets or liabilities in active markets and quoted prices
for identical or similar assets or liabilities in markets that are not active.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Level 3&#151;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining fair value, the Company utilizes quoted market prices, or valuation techniques that maximize
the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers between Levels 1, 2 or 3 for any of the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s fair value measurements as of December 31, 2020 were as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs consist primarily of research and development services and, to a lesser extent, salaries, benefits, and other
personnel related costs, including stock-based compensation, professional service fees and facility and other related costs partially offset by fully refundable research and development tax credits and a federal grant received. The Company
recognizes the benefit of refundable research and development tax credits as a reduction of research and development expenses when there is reasonable assurance that the amount claimed will be recovered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses includes estimates of the level of service performed and the associated cost incurred for the service when
we have not yet been invoiced or otherwise notified of actual costs. Management estimates accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. At the end of each
period, the accuracy of these estimates is confirmed with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vendors in connection with preclinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Contract research organizations (CROs) in connection with preclinical studies and clinical trials; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Contract development and manufacturing organizations (CDMOs) in connection with the production of preclinical and
clinical trial materials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All research and development costs are expensed in the period incurred, based on the
estimates of the services received and efforts expended considering a number of factors, including, progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the
CROs, CDMOs and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary from
contract to contract and may result in uneven payment flows. There may be instances in which advance payments are made or payments made to vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under
some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General
and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative costs are expensed as incurred and include employee-related expenses
including salaries, benefits, travel, and stock-based compensation for the Company&#146;s personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, and consulting
fees not otherwise included in research and development expense. Legal costs include general corporate legal fees and patent costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accretion and
Classification of Redeemable Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redeemable convertible preferred stock is classified outside of
stockholders&#146; deficit on the consolidated balance sheets because the holders of such shares have liquidation rights in the event of a deemed liquidation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Company&#146;s redeemable convertible preferred stock had the option to redeem their shares beginning in October 2026. As a
result, these shares were considered probable of becoming redeemable since the redemption option depends solely on the passage of time. The Company accreted changes in the redemption value over the period from the date of issuance to the earliest
redemption date of October 2026. In October 2020, the Company amended the terms of its Certificate of Incorporation to remove the redemption option of their Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible
preferred stock, which was accounted for as a modification, and the Company ceased accretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Tranche
Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock
includes tranche rights that were determined to be freestanding financial instruments that should be accounted for as a liability at fair value (Note 6). This redeemable convertible preferred stock tranche liability is revalued at each reporting
period until settlement with changes in the fair value recorded as a change in redeemable convertible preferred stock tranche liability in the consolidated statements of operations and comprehensive loss. Upon the closing of the redeemable
convertible preferred stock, the redeemable convertible preferred stock purchase rights liability is extinguished, and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> fair value of the liability is
included in the carrying value of the redeemable convertible preferred stock issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures its stock-based awards granted to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, consultants
and independent advisors based on the estimated grant date fair value of the awards. For awards with only service conditions, including stock options and restricted stock awards, compensation expense is recognized over the requisite service period
using the straight-line method. For awards that include performance conditions, compensation expense is not recognized until the performance condition is probable to occur. The Company uses the Black-Scholes option pricing model to estimate the fair
value of its stock option awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected
volatility of the Company&#146;s common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they
occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for the Company&#146;s common stock to date, the estimated fair value of the Company&#146;s common stock has
been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock, and the board of directors&#146; assessment of additional
objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Management believes that the board of directors has the relevant experience and
expertise to determine fair value of the common stock. Third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</I>. Management has considered numerous factors in determining the best estimate of fair value of our common stock, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">valuations performed by independent third-party specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s operating results, financial position, and capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s stage of development and material risks related to its business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of the Company&#146;s research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business conditions and projects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of the Company&#146;s common stock and its redeemable convertible preferred stock as a
private company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which the Company sold shares of redeemable convertible preferred stock to outside investors in
arms-length transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights, preferences, and privileges of the Company&#146;s redeemable convertible preferred stock relative to
those of the Company&#146;s common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for securityholders, such as an initial public offering or a sale
of the Company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the hiring of key personnel and the experience of management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trends and developments in the industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For valuations performed in 2019 and 2020, in accordance with the Practice Aid, the Company determined that the option pricing method (OPM)
was the most appropriate method for determining the fair value of its common stock based on its stage of development and other relevant factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The OPM uses option theory to value the various classes of a company&#146;s securities in light of their respective claims to the enterprise
value. Total enterprise value is allocated to the various share classes based upon their respective claims on a series of call options with strike prices at various value levels depending upon the rights and preferences of each class. A
Black-Scholes closed form option pricing model is employed in this analysis, with an option term assumption that is consistent with the expected time to a liquidity event and a volatility assumption based on the estimated stock price volatility of a
peer group of comparable public companies over a similar term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#146;s
best estimates, which involved inherent uncertainties and the application of management&#146;s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of its common stock and stock-based
compensation expense could have been materially different. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The
Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the
deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the tax benefit from an uncertain tax position if it is more likely
than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or
penalties charged in relation to the unrecognized tax benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s reporting currency is the U.S. dollar. The functional currency of the Company and its subsidiaries is the U.S. dollar.
Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured in the functional currency at exchange rates prevailing at the balance sheet date, and income items and expenses
are translated into U.S. dollars at the average exchange rate in effect during the period. Exchange gains and losses resulting from remeasurement and foreign currency transactions are included in the determination of net loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss
per share attributable to common stockholders is computed using the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for multiple classes of common stock and participating securities based upon their respective rights to receive
dividends as if all income for the period has been distributed. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires loss available to common stockholders for the period to be allocated between common and participating securities
based upon their respective rights to share in undistributed earnings as if all loss for the period had been distributed. The Company&#146;s participating securities include the Company&#146;s redeemable convertible preferred stock, as the holders
are entitled to receive dividends on a <I>pari passu</I> basis in the event that a dividend is paid on common stock. The holders of redeemable convertible preferred stock do not have a contractual obligation to share in losses of the Company, and
therefore during periods of loss there is no allocation required under the <FONT STYLE="white-space:nowrap">two-class</FONT> method. Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to
common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive securities outstanding
for the period using the treasury stock method or the <FONT STYLE="white-space:nowrap">if-converted</FONT> method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per common share
attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act,
emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this
extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation-Stock Compensation (Topic 718):
Improvements to Nonemployee Share-Based Payment Accounting</I>. This standard is intended to reduce the cost and complexity and to improve financial reporting for nonemployee share-based payments. The standard expands
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the scope of Topic 718 to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees is
substantially aligned. The Company has issued stock options to both employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants. The standard was effective for fiscal years beginning after December&nbsp;15, 2019. Early adoption
was permitted, but no earlier than a company&#146;s adoption date of Topic 606, Revenue Recognition. The Company early adopted the standard on January&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT><I>&nbsp;Fair Value Measurement&#151;Disclosure Framework
(Topic 820)</I><I></I>&nbsp;(ASU <FONT STYLE="white-space:nowrap">2018-13).</FONT> The standard modifies the disclosure requirements for fair value measurements and is effective for all companies for annual and interim periods beginning after
December&nbsp;15, 2019. Early adoption is permitted for any removed or modified disclosures. Adoption of ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> on January&nbsp;1, 2019, did not have a material impact on the Company&#146;s consolidated
financial statement disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-02,</FONT> <I>Leases</I>
(<I>Topic</I><I></I><I>&nbsp;842</I>), related to leases to increase transparency and comparability among organizations by requiring the recognition of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
(ROU) assets obtained in exchange for lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under
the standard, disclosures are required to meet the objective of enabling users of consolidated financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The effective date of this update for nonpublic
companies is for fiscal years beginning after December&nbsp;15, 2021 and interim periods therein. The Company is currently assessing the impact of adopting this standard on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses</I>
(<I>Topic</I><I></I><I>&nbsp;326</I>): <I>Measurement of Credit Losses on Financial Instruments</I>. The standard changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will
replace today&#146;s &#147;incurred loss&#148; approach with an &#147;expected loss&#148; model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard&#146;s provisions as a
cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The effective date of this update for non-public companies is for fiscal years beginning after December&nbsp;15,
2022 and interim periods therein. The Company is currently assessing the impact of adopting this standard on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the
Accounting for Income Taxes</I>. The standard simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The
effective date of this update for non-public companies is for fiscal years beginning after December&nbsp;15, 2021 and interim periods within fiscal years beginning after December&nbsp;15, 2022. The Company is assessing the impact of this guidance
and is continuing to evaluate the impact on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2020-06,</FONT> <I>Debt&#151;Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic <FONT
STYLE="white-space:nowrap">815-40)&#151;Accounting</FONT> For Convertible Instruments and Contracts in an Entity&#146;s Own Equity</I>. The standard simplifies accounting for convertible instruments by removing major separation models required under
current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> removes certain
settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in
certain areas. The effective date of this update for non-public companies is for fiscal years beginning after December&nbsp;15, 2023, including interim </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
periods therein. Early adoption is permitted for fiscal years beginning after December&nbsp;15, 2020 and interim periods therein. The Company is currently evaluating the impact that this new
guidance will have on its consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Asset Acquisitions with Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company acquired 100% of the share capital of NeoKera, LLC (the NeoKera Acquisition) for 166,667 shares of common stock
valued at $0.1&nbsp;million, or $0.75 per share. The in-process research and development (IPR&amp;D) acquired in this acquisition was intended to continue the development of the compound acquired; however, in June 2020, the Company determined to
discontinue further development and dissolve NeoKera, LLC. The NeoKera acquisition was accounted for as an asset acquisition. Since the acquired IPR&amp;D did not have an alternative future use at the time of its acquisition, the Company recognized
a charge of $0.1&nbsp;million during the year ended December&nbsp;31, 2019 related to the acquisition which is included in <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expense on the consolidated statements of
operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the NeoKera Acquisition, the Company acquired IPR&amp;D from Carnot, LLC, a related
party, related to <FONT STYLE="white-space:nowrap">ETX-810.</FONT> The Company issued 3.5&nbsp;million shares of common stock, valued at $0.75 per share, to acquire the IPR&amp;D. Since the acquired IPR&amp;D did not have an alternative future use
at the time of its acquisition, the Company recognized a charge of $2.6&nbsp;million during the year ended December&nbsp;31, 2019, which is included in <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expense on the
consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of these acquisitions, RA Capital Management, L.P. was a
manager of the members of NeoKera, LLC and Carnot, LLC and Andrew Levin, our CEO and a member of our board of directors, was the President of Carnot Pharma, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, the Company acquired 100% of the share capital of Athenen Therapeutics Inc. (the Athenen Acquisition) for a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> exchange of outstanding preferred stock and common stock. As a result, the Company issued a total of 5&nbsp;million Series A preferred shares and 3.1&nbsp;million
shares of common stock, valued at $2.90 per share and $0.66 per share, respectively, for total purchase consideration of $16.5&nbsp;million. Additionally, the Company incurred $0.2&nbsp;million in legal fees related to the acquisition which was
included in the value of the IPR&amp;D asset acquired. The IPR&amp;D acquired in this acquisition will enable the Company to develop <FONT STYLE="white-space:nowrap">ETX-155.</FONT> The Athenen acquisition is accounted for as an asset acquisition,
as substantially all of the fair value of the gross assets acquired is concentrated in a single asset. Since the IPR&amp;D did not have an alternative future use at the time of its acquisition, the Company recognized a charge of $9.2&nbsp;million
during the year ended December&nbsp;31, 2020 which is included in <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expense on the consolidated statements of operations and comprehensive loss. RA Capital Healthcare Fund L.P
was a greater than 10% owner of the Company and Athenen prior to the acquisition. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets acquired and liabilities assumed in Athenen Acquisition (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets and liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. Other Financial Statement Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prepaid Expenses and Other Current Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accrued Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, and 2020, the Company&#146;s redeemable convertible preferred stock consisted of the following balances (in
thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issue<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,564,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,564,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,998,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,998,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,174</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issue<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A (Athenen Acquisition)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,384,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,846,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,818,779</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,280,320</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,551</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company issued 4,080,000 shares of Series A redeemable convertible preferred stock for a
purchase price of $3.00 per share. The fair value of the Series A redeemable convertible preferred stock was $2.63 and included a tranche liability valued at $0.37 per share (see Note 6). In conjunction with the issuance of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock in October 2019, the Series A preferred shareholders exercised their tranche rights. As a result, the Company issued an additional 1,354,167 shares of Series A redeemable
convertible preferred stock. Total gross proceeds to the Company for 2019 Series A redeemable convertible preferred stock issuances were $16.3&nbsp;million. In October 2020, the Company issued 5,000,001 shares of Series A redeemable convertible
preferred stock as part of the Athenen Acquisition (see Note 3). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2019, the Company issued 2,564,102 shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock for a purchase price of $3.90, payable in cash. Gross proceeds to the Company were $10.0&nbsp;million. In October 2020, the Company issued an additional 1,282,050 shares of
Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, payable in cash. The issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred shares included a tranche liability
valued at $0.43 per share (see Note 6). Gross proceeds to the Company were $5.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Series A and Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock have various rights, preferences, privileges, and restrictions, with respect to voting, dividends, liquidation, and conversion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any
liquidation event, either voluntarily or involuntary, the holders of the redeemable convertible preferred stock shall be entitled to receive, out of the assets of the Company, the applicable liquidation preference specified for each series of
redeemable convertible preferred stock before any payment shall be made or any assets distributed to the holders of common stock. Liquidation preference is $3.00 for Series&nbsp;A and $3.90 for
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1,</FONT> each adjusted for any stock splits, combinations, and reorganizations, plus all declared and unpaid dividends on each such share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If upon the liquidation event, the assets distributed among the holders of the redeemable convertible preferred stock are insufficient to
permit the payment to such holders of the full liquidation preference for their shares, then the holders of shares of the redeemable convertible preferred stock shall share ratably in any distribution of the assets available for distribution in
proportion to their respective amounts, which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid the full preferential amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment to the holders of the redeemable convertible preferred stock of the full preferential amount specified above, any remaining
assets of the Company shall be distributed pro rata among all shareholders of the preferred and common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A liquidation event
requires approval by the holders of at least a majority of the outstanding shares of redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Optional Conversion
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock is convertible into common stock at the stockholder&#146;s option. The
converted shares will be determined by dividing the original issue price for each series by the applicable conversion price for such series in effect at the date of conversion. The conversion price for each share of redeemable convertible preferred
stock is initially equal to the original issuance price applicable to such share, with the exception of the Series A redeemable convertible preferred stock issued related to the Athenen Acquisition, which are convertible at any time after the date
of issuance into common stock at the original issue price of the original Series A of $3.00. The conversion ratio shall be subject to appropriate adjustments for anti-dilution provisions, including stock splits, stock dividends, subdivisions,
combinations, recapitalization events or similar events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Automatic Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock is convertible into common stock at initial conversion rates described under the Optional
Conversion heading above, subject to adjustments based on certain antidilution provisions, including stock splits, stock dividends, subdivision, combinations, recapitalization or similar events, as provided by the Company&#146;s certificate of
incorporation. Further, all shares of redeemable convertible preferred stock automatically convert into common stock upon the vote or written consent of the holders of a majority of the shares of redeemable convertible preferred stock or upon the
closing of a firm-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commitment underwritten public offering of the Company&#146;s common stock with gross aggregate proceeds to the Company of at least $50.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of shares
of Series&nbsp;A and <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> redeemable convertible preferred stock shall be entitled to receive cumulative dividends of 8% per annum of the original issuance price on each share of redeemable
convertible preferred stock. The dividends are payable in cash, out of the assets at the time legally available thereof, when, as and if declared by the Board of Directors, on an equal basis according to the number of shares of redeemable
convertible preferred stock held by such holders, prior and in preference to the common stock. As of December&nbsp;31, 2020, the Company had total dividends in arrears for the Series A redeemable convertible preferred stock of $2.5&nbsp;million, or
$0.24 per share, and for Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock of $1.1&nbsp;million, or $0.28 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain
circumstances, subsequent to the occurrence of a deemed liquidation event, defined as a majority of the holders of the then outstanding redeemable convertible preferred stock can require the Company to redeem their shares at a price per share equal
to the liquidation amount, to the extent that sufficient funds are available. Additionally, holders of the Company&#146;s redeemable convertible preferred stock had the option to redeem their shares beginning in October 2026. As a result, these
shares were considered probable of becoming redeemable since redemption is solely dependent on the passage of time. As such, the Company adjusted the carrying value of the redeemable convertible preferred stock by accreting changes in the redemption
value over the period from the date of issuance to the earliest redemption date of October 2026. In October 2020, the Company amended the terms of their Certificate of Incorporation to remove the redemption option of their Series A and Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, as a result the Company ceased recording adjustments to the carrying value of its outstanding redeemable convertible preferred stock for accretion to redemption value.
There was no change in value as a result of this modification. As of December&nbsp;31, 2019 and 2020, accretion to redemption value was recorded in the amounts of $0.8&nbsp;million and $1.5&nbsp;million, respectively, as a deemed liquidation event
was considered probable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Company&#146;s Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock,
voting together as a class, shall be entitled to elect three (3)&nbsp;members of the Board of Directors (the Series directors), provided that the number of Series directors shall be reduced to the extent any holder loses its rights to designate a
Series director. The holders of the shares of common stock and of any other class or series of voting stock (including the preferred stock), voting together as a class, shall be entitled to elect the balance of the Company&#146;s directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of
the Company&#146;s redeemable convertible preferred stock have protective provisions that require preferred stockholders representing a majority of the outstanding redeemable convertible preferred stock, voting as a single class (on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis), to consent to specific actions including the following: changes in the corporation&#146;s certificate of incorporation or bylaws that would affect, alter or change the preference or rights of
the redeemable convertible preferred stock, changes in the authorized number of shares, declaration or payment of dividends, repurchase of shares, changes in the size of the Board of Directors, creation of a new class or series of stock, or taking
any action that would cause a liquidation event.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Redeemable Convertible Preferred Stock Tranche Liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchasers of Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock also received tranche rights,
which provided them the right to purchase additional shares of Series&nbsp;A and <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> redeemable convertible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preferred stock in two additional future tranches. The first tranche was for the purchase of additional shares of&nbsp;Series&nbsp;A and was valued based upon the Black-Scholes option pricing
model. The second tranche was for the purchase of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;and</FONT> was valued based upon the Company achieving certain future milestones and utilized a valuation model that reflected both potential
outcomes of success or failure to meet the milestone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance in October 2020, the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred tranche liability was valued at $0.43 per share. There was no change in value from the date of issuance and December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilized the Black-Scholes option pricing model, which incorporated assumptions and estimates, to estimate the fair value of the
Series A Tranche Rights. The Company estimated the fair value of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Tranche Rights using a probability-weighted present value model that considered the probability of triggering the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Tranche Rights through achievement of the clinical development milestones specified in the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement. These estimates were based, in part, on
subjective assumptions. Changes to these assumptions could have had a significant impact on the reported fair value of the Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Tranche Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following reflects the significant quantitative inputs used in the valuation of the redeemable convertible preferred stock tranche
liability: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Tranche Call<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT><BR>Tranche<BR>Call Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.63&#150;$3.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25&#150;0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of milestone achievement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Strike price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of each tranche feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37&#150;$0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A redeemable convertible preferred tranche liability was settled on October&nbsp;9, 2019 upon the
closing of the second tranche of Series A redeemable convertible preferred stock. The fair value of the liability was remeasured prior to settlement, resulting in the Company recognizing a loss in the consolidated statement of operations and
comprehensive loss of $0.9&nbsp;million during the year ended December&nbsp;31, 2019. Immediately thereafter, the balance of the redeemable convertible preferred stock tranche liability of $0.6&nbsp;million was reclassified to Series&nbsp;A
convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A rollforward of the redeemable convertible preferred stock tranche liability is as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement upon issuance of Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
leases office space under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases. Total rent expense for the years ended December&nbsp;31, 2019 and 2020 was $23,000 and $51,000, respectively. As of December&nbsp;31, 2020, future
minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases were $47,000, the terms of which all expire in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such
expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to
such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases,
the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs
to defend lawsuits or settle claims related to these indemnification provisions. The Company intends to enter into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers
against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#146; and officers&#146; insurance coverage that reduces
its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is immaterial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Stock-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
2019, the Company adopted the 2019 Equity Incentive Plan (the 2019 Plan). The 2019 Plan provides for the Company to grant qualified stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, and restricted stock awards to
employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants of the Company under terms and provisions established by the board of directors. Under the terms of the 2019 Plan, options are granted at an exercise price no
less than fair value of the Company&#146;s common stock on the grant date, except in certain cases related to employees outside of the U.S. However, for any employee who is a 10% or greater stockholder, options are granted at an exercise price no
less than 110% of the fair value of the Company&#146;s common stock on the grant date. Option awards granted typically have <FONT STYLE="white-space:nowrap">10-year</FONT> terms measured from the option grant date. However, if any employee is a 10%
or greater stockholder, the awards have <FONT STYLE="white-space:nowrap">5-year</FONT> terms measured from the option grant date. Awards with vesting conditions typically include vesting 25% on the first anniversary of the grant date with the
remainder vesting monthly over the following three years. As of December&nbsp;31, 2020, the total number of shares authorized for issuance under the 2019 Plan was 4,685,487. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, as part of the Athenen Acquisition, 459,630 restricted stock awards and 141,433 options were converted 1:1 to the Company&#146;s
restricted stock and options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes option activity under the 2019 Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contract<BR>Term<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic</B><br><B>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest, December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value disclosed in the above table is based on the difference between the exercise
price of the stock option and the estimated fair value of the Company&#146;s common stock as of the <FONT STYLE="white-space:nowrap">respective&nbsp;period-end&nbsp;dates.</FONT> There were no stock options exercised during the years ended
December&nbsp;31, 2019, and 2020. The weighted-average grant date fair value of stock options granted during the year ended December&nbsp;31, 2020, was $0.97 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, the Company granted 68,192 stock options with a performance condition which vest upon the Company&#146;s initiation of a
registrational clinical trial to study the efficacy of <FONT STYLE="white-space:nowrap">ETX-810</FONT> or another proprietary compound. The probability of achieving performance conditions was assessed at December&nbsp;31, 2019 and deemed not
probable. The Company has recognized no stock-based compensation expense relating to these performance awards. This award was cancelled in February 2020 and is no longer outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes&nbsp;option pricing model for employee and nonemployee stock options incorporates the following assumptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Common Stock</I>&#151;Described in Note 2 <I>Summary of Significant Accounting Policies - Fair
Value of Common Stock.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Volatility</I>&#151;The expected stock price volatilities are estimated based on the historical and implied
volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-free</I><I></I><I>&nbsp;Interest Rate</I>&#151;The risk-free&nbsp;interest rates are based on US Treasury
yields in effect at the grant date for notes with comparable terms as the awards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I>&#151;The expected term represents the period that the Company&#146;s stock options are
expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend Yield</I>&#151;The expected dividend yield assumption is based on the Company&#146;s current
expectations about its anticipated dividend policy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s stock option awards was
estimated at the date of grant using a Black-Scholes option pricing model with the following assumptions for the year ended December 31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.70&#150;6.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.58%&#150;78.53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.36%&#150;1.47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to 2019, the Company granted 447,000 restricted stock awards to its founders, of which 223,500 included a service condition and 223,500
included a performance condition. Awards with a service condition vest 25% on the first anniversary of the grant date and monthly thereafter. Awards with a performance condition will vest upon the Company&#146;s initiation of a registrational
clinical trial to study the efficacy of <FONT STYLE="white-space:nowrap">ETX-810.</FONT> The probability of achieving performance conditions is assessed each reporting period. As of December&nbsp;31, 2019 and 2020, this performance condition was
assessed and deemed not probable, and the Company has recognized no stock-based compensation expense relating to these performance awards. The Company also granted restricted stock awards to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> that are subject to repurchase by the Company at the original purchase price in the event that the award recipient&#146;s employment or relationship is terminated prior to the shares vesting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity for restricted stock awards is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,943</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31,
2019<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31,
2020<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 133,502 and 43,500 restricted stock awards granted in 2018 and still outstanding during the years
ended December&nbsp;31, 2019 and 2020, respectively, subject to only performance conditions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets
forth stock-based compensation for stock options, restricted stock awards, and performance awards included in the Company&#146;s consolidated statements of operations and comprehensive loss for the year ended December&nbsp;31, 2020 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation for the year ended December&nbsp;31, 2019 was not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was $0.5&nbsp;million of total unrecognized compensation cost related to unvested stock options and
unvested restricted stock awards granted, which is expected to be recognized over a weighted average period of 1.69 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred
stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,321,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,375,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the computation of the
diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,998,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,280,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,435,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total potentially dilutive shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,226,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,720,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of the Company&#146;s expected tax computed at the U.S. statutory federal income tax rate to the
total provision for income taxes (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal taxes at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credit addback</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refundable tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax effects of temporary differences that give rise to significant portions of deferred
tax assets and liabilities are presented below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain or loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain or loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation Allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than
not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become
deductible. Due to the uncertainty of the business in which the Company operates, projections of future profitability are difficult and past profitability is not necessarily indicative of future profitability. The Company does not believe it is more
likely than not that the deferred tax assets will be realized, and accordingly, the Company recorded a valuation allowance of $1.6&nbsp;million and $4.6&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively. As of
December&nbsp;31, 2020, the Company had net operating loss carryforward of approximately $8.7&nbsp;million for federal income tax purposes, $3.6&nbsp;million for foreign income tax purposes and $2.1&nbsp;million for state income tax purposes. These
may be used to offset future taxable income. The federal net operation loss carryforward can be carried forward indefinitely while the state net operating loss carryforward will begin to expire in varying amounts in 2038. The Company also has
research and development credits of approximately $0.4&nbsp;million and $0.1&nbsp;million for federal and state income taxes purposes, respectively. The federal credits may be used to offset future taxable income and will begin to expire in varying
amounts in 2038. The state credits may be used to offset future taxable income and will begin to expire in varying amounts in 2038. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> The CARES Act, among other things, permits net operating loss
carryforwards generated in taxable years beginning after December&nbsp;31, 2017, to offset 100% of taxable income for taxable years beginning before January&nbsp;1, 2021, and 80% of taxable income in taxable years beginning after December&nbsp;31,
2020. The CARES Act does not have a material impact on the Company&#146;s financial results for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the U.S., various state jurisdictions and the U.K., in conjunction with our transactions and activities.
Currently, no historical years are under examination. The Company&#146;s tax years starting in December&nbsp;31, 2018 through December&nbsp;31, 2020 are open and subject to examination by the U.S., state and the U.K. taxing authorities due to the
carryforward of utilized net operating losses and research and development credits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Uncertain tax positions are recorded when it is more likely than not that a given tax
position would not be sustained upon examination by taxing authorities. The Company&#146;s policy for recording interest and penalties related to income taxes, including uncertain tax positions, is to record such items as a component of the
provision for income taxes. As of December&nbsp;31, 2019 and 2020, the Company does not have any uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
not completed a Section&nbsp;382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#146;s formation. Pursuant to Internal Revenue Code Sections 382 and 383, annual use of
the Company&#146;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. If eliminated, the related asset would be
removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#146;s
effective tax rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Provided by Related Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a services agreement with Carnot, LLC. Carnot, LLC was subsequently dissolved and the services agreement transitioned to its
successor Carnot Pharma, LLC. The Company reimburses Carnot Pharma, LLC for research and development expenses incurred on its behalf. RA Capital Management, L.P. is the manager of the members of Carnot, LLC and Andrew Levin, a member of our board of
directors and former CEO, is the President of Carnot Pharma, LLC. Adam Rosenberg, a member of our board of directors, is a Venture Partner at Carnot Pharma, LLC dba RA Ventures. Amounts invoiced and reimbursed for the year ended December 31, 2019
and 2020 were approximately $1.5 million and $0.6 million, respectively. See Note 3 for assets acquired from related parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12. Defined
Contribution Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company began sponsoring a 401(k) defined contribution plan in 2020. Participation in the plan is available to
substantially all <FONT STYLE="white-space:nowrap">US-based</FONT> employees. Company contributions to the plan are discretionary. The Company made matching contributions of up to 4% of each participating employee&#146;s eligible compensation. Total
expense recognized from the 401(k) matching contributions for the year ended December&nbsp;31, 2020 was approximately $20,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company also has a workplace pension contribution scheme for U.K.-based employees. The Company made discretionary contributions of approximately $42,000 in excess of the minimum statutory requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of the consolidated financial statements as of December&nbsp;31, 2020 and the year then ended, the Company evaluated subsequent events for recognition and measurement purposes through May&nbsp;12, 2021, the date the consolidated financial statements
were available to be issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redeemable Convertible Preferred Stock&#151;Second Tranche
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued an additional 8.7&nbsp;million shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable
convertible preferred stock for $34.0&nbsp;million in proceeds. In connection with the issuance, the shareholders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock exercised their option to purchase
7.4&nbsp;million additional shares at $3.90 per share. The fair value of the redeemable convertible preferred stock liability was remeasured prior to settlement, resulting in the Company recognizing a loss in the consolidated statement of operations
and comprehensive loss of $11.7&nbsp;million during the quarter ended March&nbsp;31, 2021. The increase in valuation was driven primarily by the Phase 1 results of <FONT STYLE="white-space:nowrap">ETX-155,</FONT> as well as, an increased likelihood
of future financing events. Immediately thereafter, the balance of the redeemable convertible preferred stock tranche liability of $12.3&nbsp;million was reclassified to <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants of Stock Options and Restricted Stock Awards under 2019 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2021, the Company granted additional options for the purchase of an aggregate of 3,121,705 shares of common stock, at
an exercise price of $0.66 per share, to employees including executive management and directors. Additionally, the Company granted 52,351 restricted stock awards to employees. The fair market value of the grants on the grant dates was determined by
using straight-line interpolation between the value of common stock derived from valuations performed by independent third-party specialists on December&nbsp;31, 2020 and March&nbsp;9, 2021. The aggregate grant-date fair value of these awards was
$7.5&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 3.7 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on April&nbsp;27, 2021, the Company granted options for the purchase of an aggregate of 1,429,264 shares of common stock, at an
exercise price of $3.05, to employees including executive management and directors. The Company also granted 488,756 restricted stock awards to employees. The Company is evaluating the impact to the consolidated financial statements. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_3"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock, and Stockholders&#146;
Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.0001 par value, 25,818,779 and 25,818,779 shares
authorized, 14,280,230 and 22,998,267 shares issued and outstanding with aggregate liquidation preference of $49,891 and $84,968 at December&nbsp;31, 2020 and March&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value per share, 40,000,000 and 40,000,000 shares authorized; 6,837,540
and 6,965,604 shares issued and outstanding at December&nbsp;31, 2020 and March&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock, and stockholders&#146; deficit</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_2"></A>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(1,916)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(18,601)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred
stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,085)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(2,355)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(19,686)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(0.63)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$(2.85)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding used to compute net loss per share attributable to
common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,711,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,911,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_4"></A>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,998,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,174</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,705,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Release of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,998,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,613</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,713,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,783</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,280,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,551</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,837,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock Issuance (net of issuance costs
of $22)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,717,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,978</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of redeemable convertible preferred stock tranche liability upon
settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,269</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options and release of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,998,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,798</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,965,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_5"></A>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151; &nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency gain from remeasurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin105292_6"></A>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share and per share amounts) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(unaudited) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of
Organization and Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eliem Therapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal
excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Headquartered in Redmond, Washington, the Company was incorporated on October&nbsp;18, 2018
as a Delaware corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying interim condensed consolidated financial statements of the Company and its wholly owned subsidiaries have been prepared in
conformity with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;). All intercompany transactions and balances have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated balance sheet as of March&nbsp;31, 2021, and condensed consolidated statements of operations and
comprehensive loss, condensed consolidated statements of cash flows, and condensed consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit for the three months ended March&nbsp;31, 2020 and 2021, are
unaudited. The consolidated balance sheet as of December&nbsp;31, 2020 was derived from the audited financial statements as of and for the year ended December&nbsp;31, 2020, but does not include all disclosures required by U.S. GAAP. The unaudited
interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December&nbsp;31, 2020, and, in the opinion of management, reflect all adjustments, consisting
solely of normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position as of March&nbsp;31, 2021, and the condensed results of its operations and its cash flows for the three months ended March&nbsp;31,
2020 and 2021. The financial data and other information disclosed in these notes related to the three months ended March&nbsp;31, 2020 and 2021 are also unaudited. The condensed results of operations for the three months ended March&nbsp;31, 2021
are not necessarily indicative of the results to be expected for the full year ending December&nbsp;31, 2021 or any other period. These interim condensed consolidated financial statements should be read in conjunction with the Company&#146;s audited
financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the valuation of assets acquired, accrual of research and development
expenses, the valuation of stock-based awards, the valuation of common stock and redeemable convertible preferred stock, and the valuation of redeemable convertible preferred stock tranche liabilities. The Company evaluates its estimates and
assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash. The Company&#146;s cash
is held by one financial institution in the United States (U.S.) and one financial institution in the United Kingdom (U.K.). The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with
commercial banking relationships. The Company&#146;s deposits held in the U.S. and U.K. may exceed the Federal Depository Insurance Corporation and Financial Services Compensation Scheme, respectively, insured limits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to,
development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#146;s
products and processes and clinical efficacy and safety of the Company&#146;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under
development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts will require significant amounts of
additional capital, adequate personnel infrastructure and extensive compliance and reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the
Company&#146;s research and development will be successfully completed, that adequate protection for the Company&#146;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory
approval or that any approved products will be commercially viable. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in
an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which is impacting worldwide economic activity, poses risk
that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the <FONT STYLE="white-space:nowrap">start-up</FONT> and conduct of
the Company&#146;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#146;s existing cash reserves, and the Company may be
required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the
pandemic will impact the Company&#146;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Going Concern </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
disclosed in the audited financial statements included elsewhere within this prospectus, management concluded that there was substantial doubt existed about the Company&#146;s ability to continue as a going concern for one year from May&nbsp;12,
2021, the date the financial statements were issued. On May&nbsp;21, 2021, the Company received $60&nbsp;million in gross proceeds from the issuance of Series B redeemable convertible preferred stock. The Company estimates the available cash as of
March&nbsp;31, 2021, together with the proceeds received from the Series B redeemable convertible preferred stock issuance, will be sufficient to meet its projected operating requirements for at least the next twelve months from the filing date of
these unaudited condensed consolidated financial statements. As a result of these conditions and events, management has concluded the substantial doubt of the Company&#146;s ability to continue as a going concern no longer exists. The Company will
need to obtain substantial additional funding to develop and commercialize our clinical programs as currently contemplated. The Company expects to finance future cash needs through equity financings, debt financings, collaborations, strategic
alliances, licensing arrangements and other marketing and distribution arrangements, but there are no assurances that the Company will be able to raise sufficient amounts of funding in the future on acceptable terms, or at all.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which
contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are
identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the CODM). The Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the
Company&#146;s performance. Management has determined that the Company operates as a single operating and reportable segment. The Company&#146;s CODM evaluates financial information on a consolidated basis. As the Company operates as one operating
segment, all required segment financial information is found in the interim condensed consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of
judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The Company measures fair value based on a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Level&nbsp;1&#151; </I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Level 2&#151; </I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Inputs (other than quoted prices included in Level&nbsp;1) are either directly or indirectly observable for the assets or liabilities. These include quoted prices for similar assets or liabilities in active markets and quoted prices
for identical or similar assets or liabilities in markets that are not active.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Level 3&#151; </I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining fair value, the Company utilizes quoted market prices, or valuation techniques that maximize
the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers between Levels 1, 2 or 3 for any of the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s fair value measurements as of December&nbsp;31, 2020 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redeemable convertible preferred stock tranche liability was settled as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Significant Accounting Policies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
there has been no public market for the Company&#146;s common stock to date, the estimated fair value of the Company&#146;s common stock has been determined by the board of directors as of the date of each option grant with input from management,
considering the most recently available third-party valuation of common stock, and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors&#146; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the
date of the grant. Management believes that the board of directors has the relevant experience and expertise to determine fair value of the common stock. Third-party valuations were performed in accordance with the guidance outlined in the American
Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Management has considered numerous factors in determining the best estimate of fair
value of our common stock, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">valuations performed by independent third-party specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s operating results, financial position, and capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s stage of development and material risks related to its business; the progress of the
Company&#146;s research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business conditions and projects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of the Company&#146;s common stock and its redeemable convertible preferred stock as a
private company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which the Company sold shares of redeemable convertible preferred stock to outside investors in
arms-length transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights, preferences, and privileges of the Company&#146;s redeemable convertible preferred stock relative to
those of the Company&#146;s common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for securityholders, such as an initial public offering or a sale
of the Company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the hiring of key personnel and the experience of management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trends and developments in the industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For valuations performed in the first quarter of 2021, in accordance with the Practice Aid, the Company determined that the
Probability-Weighted Expected Return Method (PWERM) was the most appropriate method for determining the fair value of its common stock based on its stage of development and other relevant factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PWERM values each class of equity based on an analysis of the range of potential future enterprise values of the company and the manner in
which those values would accrue to the owners of the different classes of equity. This method involves estimating the overall value of the subject company under various liquidity event scenarios and allocating the value to the various share classes
based on their respective claim on the proceeds as of the date of each event. These different scenarios typically include an initial public offering, an acquisition, or a liquidation of the business, each resulting in a different value. For each
scenario, the future value of each share class is calculated and discounted to a present value. The results of each scenario are then probability weighted in order to arrive at an estimate of fair value for each share class as of a current date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#146;s best estimates, which involved inherent uncertainties and the
application of management&#146;s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of its common stock and stock-based compensation expense could have been materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have no been no other significant changes in the Company&#146;s accounting policies during the three months ended March&nbsp;31, 2021.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Certain Balance Sheet Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid Expenses and Other Current Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Recoverable research and development tax credits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Prepaid research and development expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Other assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Accrued research and development expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Accrued payroll</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Other accrued expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2020 and March 31, 2021, the Company&#146;s redeemable convertible preferred stock consisted of the following balance (in
thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issue<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A (Athenen Acquisition)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,384,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,846,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,818,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,280,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issue<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A (Athenen Acquisition)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,384,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,564,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,818,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,998,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, Series <FONT STYLE="white-space:nowrap">A-1</FONT>
preferred shareholders exercised their tranche rights in connection with milestone achievements related to Phase 1 results of <FONT STYLE="white-space:nowrap">ETX-155.</FONT> As a result, the Company issued an additional 8,717,947 shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred shares for proceeds of approximately $34.0&nbsp;million. Upon exercise of the tranche rights, the Company reclassified the $12.3&nbsp;million in preferred stock tranche liability
to Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock on the interim condensed consolidated balance sheet as of March&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT>
redeemable convertible preferred stock have various rights, preferences, privileges, and restrictions, with respect to voting, dividends, liquidation, and conversion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any
liquidation event, either voluntarily or involuntary, the holders of the redeemable convertible preferred stock shall be entitled to receive, out of the assets of the Company, the applicable liquidation preference specified for each series of
redeemable convertible preferred stock before any payment shall be made or any assets distributed to the holders of common stock. Liquidation preference is $3.00 for Series A and $3.90 for Series <FONT STYLE="white-space:nowrap">A-1,</FONT> each
adjusted for any stock splits, combinations, and reorganizations, plus all declared and unpaid dividends on each such share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If upon the
liquidation event, the assets distributed among the holders of the redeemable convertible preferred stock are insufficient to permit the payment to such holders of the full liquidation preference for their shares, then the holders of shares of the
redeemable convertible preferred stock shall share ratably in any distribution of the assets available for distribution in proportion to their respective amounts, which would otherwise be payable in respect of the shares held by them upon such
distribution if all amounts payable on or with respect to such shares were paid the full preferential amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment to the
holders of the redeemable convertible preferred stock of the full preferential amount specified above, any remaining assets of the Company shall be distributed pro rata among all shareholders of the preferred and common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A liquidation event requires approval by the holders of at least a majority of the outstanding shares of redeemable convertible preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Optional Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock is convertible into common stock at the stockholder&#146;s option. The converted shares
will be determined by dividing the original issue price for each series by the applicable conversion price for such series in effect at the date of conversion. The conversion price for each share of redeemable convertible preferred stock is
initially equal to the original issuance price applicable to such share, with the exception of the Series A redeemable convertible preferred stock issued related to the Athenen Acquisition, which are convertible at any time after the date of
issuance into common stock at the original issue price of the original Series A of $3.00. The conversion ratio shall be subject to appropriate adjustments for anti-dilution provisions, including stock splits, stock dividends, subdivisions,
combinations, recapitalization events or similar events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Automatic Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock is convertible into common stock at initial conversion rates described under the Optional
Conversion heading above, subject to adjustments based on certain antidilution provisions, including stock splits, stock dividends, subdivision, combinations, recapitalization or similar events, as provided by the Company&#146;s certificate of
incorporation. Further, all shares of redeemable convertible preferred stock automatically converts into common stock upon the vote or written consent of the holders of a majority of the shares of redeemable convertible preferred stock or upon the
closing of a firm-commitment underwritten public offering of the Company&#146;s common stock with gross aggregate proceeds to the Company of at least $50.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of shares
of Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock shall be entitled to receive cumulative dividends of 8% per annum of the original issuance price on each share of redeemable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible preferred stock. The dividends are payable in cash, out of the assets at the time legally available thereof, when, as and if declared by the Board of Directors, on an equal basis
according to the number of shares of redeemable convertible preferred stock held by such holders, prior and in preference to the common stock. As of December&nbsp;31, 2020 and March&nbsp;31, 2021, the Company had total dividends in arrears for the
Series A redeemable convertible preferred stock of $2.5&nbsp;million and $3.1&nbsp;million, or $0.24 and $0.30 per share, respectively, and for Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock of
$1.1&nbsp;million and $1.5&nbsp;million, or $0.28 and $0.12 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances, subsequent to the occurrence of a deemed liquidation event, defined as a majority of the holders of the then
outstanding redeemable convertible preferred stock can require the Company to redeem their shares at a price per share equal to the liquidation amount, to the extent that sufficient funds are available. Additionally, holders of the Company&#146;s
redeemable convertible preferred stock had the option to redeem their shares beginning in October 2026. As a result, these shares were considered probable of becoming redeemable since redemption is solely dependent on the passage of time. As such,
the Company adjusted the carrying value of the redeemable convertible preferred stock by accreting changes in the redemption value over the period from the date of issuance to the earliest redemption date of October 2026. In October 2020, the
Company amended the terms of their Certificate of Incorporation to remove the redemption option of their Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, as a result the Company ceased recording
adjustments to the carrying value of its outstanding redeemable convertible preferred stock for accretion to redemption value. There was no change in value as a result of this modification. As of December&nbsp;31, 2020, accretion to redemption value
was recorded in the amount of $1.5&nbsp;million as a deemed liquidation event was considered probable. As a result of the exercise of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, as mentioned above,
there was no accretion to redemption value recorded for the three months ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Company&#146;s Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock,
voting together as a class, shall be entitled to elect three (3)&nbsp;members of the Board of Directors (the Series directors), provided that the number of Series directors shall be reduced to the extent any holder loses its rights to designate a
Series director. The holders of the shares of common stock and of any other class or series of voting stock (including the preferred stock), voting together as a class, shall be entitled to elect the balance of the Company&#146;s directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of
the Company&#146;s redeemable convertible preferred stock have protective provisions that require preferred stockholders representing a majority of the outstanding redeemable convertible preferred stock, voting as a single class (on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis), to consent to specific actions including the following: changes in the corporation&#146;s certificate of incorporation or bylaws that would affect, alter or change the preference or rights of
the redeemable convertible preferred stock, changes in the authorized number of shares, declaration or payment of dividends, repurchase of shares, changes in the size of the Board of Directors, creation of a new class or series of stock, or taking
any action that would cause a liquidation event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Redeemable Convertible Preferred Stock Tranche Liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchasers of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock also received tranche rights, which
provided them the right to purchase additional shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock in an additional future tranche. This tranche was for the purchase of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> and was valued based upon the Company achieving certain future milestones and utilized a valuation model that reflected both potential outcomes of success or failure to meet the milestone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance in October 2020, the Series <FONT STYLE="white-space:nowrap">A-1</FONT>
redeemable convertible preferred tranche liability was valued at $0.43 per share. There was no change in value from the date of issuance and December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Tranche Rights using a probability-weighted
present value model that considered the probability of triggering the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Tranche Rights through achievement of the clinical development milestones specified in the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement. These estimates were based, in part, on subjective assumptions. Changes to these assumptions could have had a significant impact on the reported fair value of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Tranche Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following reflects the significant quantitative inputs used in the valuation of
the redeemable convertible preferred stock tranche liability: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT><BR>Tranche Call<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.47&#150;$5.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25&#150;0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of milestone achievement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80%&#150;100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Strike price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of each tranche feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.43&#150;$1.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred tranche liability was
settled on March&nbsp;9, 2021 with the achievement of milestones set forth in the Series <FONT STYLE="white-space:nowrap">A-1</FONT> stock purchase agreement. The fair value of the liability was remeasured prior to settlement, resulting in the
Company recognizing a loss in the consolidated statement of operations and comprehensive loss of $11.7&nbsp;million during the three months ended March&nbsp;31, 2021. Immediately thereafter, the balance of the redeemable convertible preferred stock
tranche liability of $12.3&nbsp;million was reclassified to Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A rollforward of the redeemable convertible preferred stock tranche liability is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement upon issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable
convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
leases office space under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases. Total rent expense for the three months ended March&nbsp;31, 2020 and 2021 was $13,000 and $14,000, respectively. As of March&nbsp;31, 2021, future
minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases were $37,000, the terms of which all expire in 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The
Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by
the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the
Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company intends to enter into
indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent
permitted by Delaware corporate law. The Company currently has directors&#146; and officers&#146; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the
estimated fair value of these indemnification agreements in excess of applicable insurance coverage is immaterial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Stock-Based Compensation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, the Company adopted the 2019 Equity Incentive Plan (the 2019 Plan). The 2019 Plan provides for the Company to grant qualified
stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, and restricted stock awards to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants of the Company under terms and provisions
established by the board of directors. Under the terms of the 2019 Plan, options are granted at an exercise price no less than fair value of the Company&#146;s common stock on the grant date, except in certain cases related to employees outside of
the U.S. However, for any employee who is a 10% or greater stockholder, options are granted at an exercise price no less than 110% of the fair value of the Company&#146;s common stock on the grant date. Option awards granted typically have <FONT
STYLE="white-space:nowrap">10-year</FONT> terms measured from the option grant date. However, if any employee is a 10% or greater stockholder, the awards have <FONT STYLE="white-space:nowrap">5-year</FONT> terms measured from the option grant date.
Awards with vesting conditions typically include vesting 25% on the first anniversary of the grant date with the remainder vesting monthly over the following three years. As of March&nbsp;31, 2021, the total number of shares authorized for issuance
under the 2019 Plan was 6,223,286. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contract<BR>Terms<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Values<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,121,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest, March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value disclosed in the above table is based on the difference
between the exercise price of the stock option and the estimated fair value of the Company&#146;s common stock as of the respective <FONT STYLE="white-space:nowrap">period-end</FONT> dates. The weighted-average grant date fair value of stock options
granted during the three months ended March&nbsp;31, 2021, was $2.37 per share. The aggregate intrinsic value of options exercised, determined as of the date of option exercise, for the three month period ended March&nbsp;31, 2021 was
$0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model for employee stock options incorporates the following assumptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Common Stock</I>&#151;Described in Note 1 to the condensed consolidated financial statements
<I>Summary of Significant Accounting Policies - Fair Value of Common Stock</I>. The fair market value of the grants for the quarter ended March&nbsp;31, 2021 was determined by using straight-line interpolation between the value of common stock
derived from valuations performed by independent third party specialists on December&nbsp;31, 2020 and March&nbsp;9, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Volatility</I>&#151;The expected stock price volatilities are estimated based on the historical and implied
volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-free Interest Rate</I>&#151;The risk-free interest rates are based on US Treasury yields in effect at the
grant date for notes with comparable terms as the awards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I>&#151;The expected term represents the period that the Company&#146;s stock options are
expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend Yield</I>&#151;The expected dividend yield assumption is based on the Company&#146;s current
expectations about its anticipated dividend policy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s stock option awards was estimated at the date
of grant using a Black- Scholes option pricing model with the following assumptions for the three months ended March 31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.95&#150;6.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.81%&#150;79.08%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94%&#150;1.05%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has restricted stock awards with service and performance conditions. Awards with a service condition vest 25% on the first
anniversary of the grant date and monthly thereafter. Awards with a performance condition will vest upon the Company&#146;s initiation of a registrational clinical trial to study the efficacy of <FONT STYLE="white-space:nowrap">ETX-810.</FONT> The
probability of achieving performance conditions is assessed each reporting period. As of March&nbsp;31, 2021, this performance condition was assessed and deemed not probable, and the Company has recognized no stock-based compensation expense
relating to these performance awards. The Company also granted restricted stock awards to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> that are subject to repurchase by the Company at the original purchase price in the event
that the award recipient&#146;s employment or relationship is terminated prior to the shares vesting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity for restricted stock awards is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 43,502 restricted stock awards granted in 2018 and still outstanding for the period ended
March&nbsp;31, 2021, subject to only performance conditions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth stock-based compensation
for stock options, restricted stock awards, and performance awards included in the Company&#146;s consolidated statements of operations and comprehensive loss for the three months ended March&nbsp;31 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, there was $7.7&nbsp;million of total unrecognized compensation cost related to
unvested stock options and unvested restricted stock awards granted, which is expected to be recognized over a weighted average period of 3.34 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred
stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used in computed net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,711,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,911,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the
computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,998,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,998,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total potentially dilutive shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,905,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,029,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Provided by Related Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a services agreement with Carnot, LLC. Carnot, LLC was subsequently dissolved and the services agreement transitioned to its
successor Carnot Pharma, LLC. The Company reimburses Carnot Pharma, LLC for research and development expenses incurred on its behalf. RA Capital Management, L.P. is the manager of the members of Carnot, LLC and Andrew Levin, a member of our board of
directors and former CEO, is the President of Carnot Pharma, LLC. Adam Rosenberg, a member of our board of directors, is a Venture Partner at Carnot Pharma, LLC dba RA Ventures. Amounts invoiced and reimbursed for the three months ended
March&nbsp;31, 2020 and 2021 were approximately $0.2&nbsp;million and $0.4&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the interim condensed consolidated financial statements as of March&nbsp;31, 2021 and the three months then ended, the Company
evaluated subsequent events for recognition and measurement purposes through June&nbsp;21, 2021, the date the interim condensed consolidated financial statements were available to be issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants of Stock Options and Restricted Stock Awards under 2019 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to March&nbsp;31, 2021, the Company granted options for the purchase of an aggregate of 1,435,786 shares of common stock, at an
exercise price of $3.05, to employees including executive management and directors. The Company also granted 543,107 restricted stock awards to employees. The Company is evaluating the impact to the consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of Series B Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;21, 2021, the Company issued 7.7&nbsp;million shares of Series B redeemable convertible preferred stock for $60.0&nbsp;million in
gross proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g105292g66i66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SVB Leerink </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Evercore
ISI </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Guggenheim Securities </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the exchange listing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be provided by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#146;s board of directors to grant,
indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. Our amended and restated
certificate of incorporation that will be in effect on the closing of this offering permits indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our
amended and restated bylaws that will be in effect on the closing of this offering provide that we will indemnify our directors and officers and permit us to indemnify our employees and other agents, in each case to the maximum extent permitted by
the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors and officers, whereby we have
agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a
party by reason of the fact that such director or officer is or was a director, officer, employee or agent of Eliem Therapeutics, Inc., provided that such director or officer acted in good faith and in a manner that the director or officer
reasonably believed to be in, or not opposed to, our best interests. At present, there is no pending litigation or proceeding involving any of our directors or officers regarding which indemnification is sought, nor are we aware of any threatened
litigation that may result in claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain insurance policies that indemnify our directors and officers
against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are obligated, under certain circumstances, pursuant to the underwriting agreement to be filed as Exhibit 1.1 hereto, to
indemnify us, our officers and our directors against liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recent Sales of Unregistered Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth information regarding all unregistered securities sold since January&nbsp;1, 2018. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In October 2018, we issued an aggregate of 447,000 shares of common stock to nine accredited investors at a
purchase price of $0.0001 per share, for an aggregate purchase price approximately $45. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In February 2019 and October 2019, we issued an aggregate of 10,434,168 shares of our Series&nbsp;A redeemable
convertible preferred stock to six accredited investors at a purchase price of $3.00 per share, for an aggregate purchase price approximately $16.3&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In February 2019, we issued an aggregate of 166,667 shares of common stock to two accredited investors as
consideration pursuant to an acquisition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In February 2019, we issued an aggregate of 3,500,000 shares of common stock to one accredited investor as
consideration pursuant to an acquisition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In October 2019, October 2020 and March 2021, we issued an aggregate of 12,564,099 shares of our <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> redeemable convertible preferred stock to five accredited investors at a purchase price of $3.90 per share, for an aggregate purchase price approximately $49.0&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In October 2020, we issued an aggregate of 5,000,001 shares of Series&nbsp;A redeemable convertible preferred
stock and 3,095,130 shares of common stock to one non-accredited and 12 accredited investors as consideration pursuant to an acquisition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In May 2021, we issued an aggregate of 7,692,306 shares of our Series&nbsp;B redeemable convertible preferred
stock to nine accredited investors at a purchase price of $7.80 per share, for an aggregate purchase price approximately $60.0&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From February 2020 through July&nbsp;9, 2021, we granted to certain employees, consultants, and directors
options to purchase an aggregate of 5,420,190 shares of our common stock under our 2019 Equity Incentive Plan at exercise prices ranging from $0.0001 to $3.05 per share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In October 2020, we assumed options to purchase an aggregate of 137,683 shares of our common stock which had
previously been granted under the Athenen Therapeutics, Inc. 2019 Equity Incentive Plan to certain employees and consultants, each with an exercise price of $0.93 per share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From February 2020 through July&nbsp;9, 2021, we issued and sold an aggregate of 746,467 shares of our common
stock pursuant to restricted stock purchase awards or upon the exercise of options under our 2019 Equity Incentive Plan or the Athenen Plan, at prices ranging from $0.0001 to $0.93 per share, for an aggregate exercise price of $110,671.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public
offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act (and Regulation&nbsp;D promulgated thereunder), or
Rule&nbsp;701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule&nbsp;701. The recipients of
the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share
certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits. </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description of
Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unit Transfer Agreement, dated February 4, 2019, by and between the Registrant and the Members of NeoKera, LLC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Asset Contribution Agreement, dated February 4, 2019, by and between the Registrant and Carnot, LLC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agreement and Plan of Merger and Reorganization, dated October 15, 2020, by and among the Registrant, Athena Merger Sub Inc., Athenen Therapeutics, Inc., AI ETI LLC, as Eliem Representative and Adam Rosenberg, as Athenen
Representative.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws of the Registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of the Registrant, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of common stock certificate of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Cooley LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investor Rights Agreement, dated October&nbsp;15, 2020, by and among the Registrant and the investors listed on Schedule A thereto, as amended by that certain Amendment No.&nbsp;1 dated March&nbsp;9,
2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2019 Equity Incentive Plan, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2019 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2021 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2021 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2021 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, by and between the Registrant and each of its directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Employment Agreement by and between the Registrant and Bob Azelby, effective October&nbsp;1, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Employment Agreement by and between the Registrant and Erin M. Lavelle, effective October&nbsp;1, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Employment Agreement by and between Eliem Therapeutics (UK) Ltd. and Valerie Morisset, Ph.D., effective January 1, 2021.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="93%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of subsidiaries.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Cooley LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (see signature page to this registration statement on Form <FONT STYLE="white-space:nowrap">S-1).</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the
financial statements or the notes thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form
of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part
of this Registration Statement as of the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;For the purpose of determining any
liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial <I>bona fide </I>offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Redmond, State of Washington, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ELIEM THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Azelby</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert Azelby and Erin M. Lavelle,
and each one of them, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her in their name, place
and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to
be effective on filing pursuant to Rule&nbsp;462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Robert Azelby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Erin M. Lavelle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Operating Officer and Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Financial and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Andrew Levin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Judith Dunn, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Leone Patterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Liam Ratcliffe, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adam Rosenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Simon Tate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">, 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g105292g00q10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g00q10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2ND4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
MIP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/=7
M1P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %
M)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V
M]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M!"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M       $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M!"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M    !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M  4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M           %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T
M!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$
M)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W
M!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24
MT#[0      $ $L     0 " 2P    !  (X0DE-!"8       X
M  /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M     )           ! #A"24TG$       "@ !          (X0DE- _4
M   $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M$ 6@    8       $ -0    $ +0    8       $X0DE- _@      '   /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H     /________
M____________________\#Z   .$))300(       0     0   D    )
M   #A"24T$'@      !      X0DE-!!H      S4    &
M-B   '90         !                          $             !V
M4   -B                      $                         $
M$       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F
M<   -B     %)G:'1L;VYG   '90    9S;&EC97-6;$QS     4]B:F,
M !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$
ME$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -87
M5T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M          3&5F=&QO;F<          $)T;VUL;VYG   #8@    !29VAT;&
M]N9P  !V4    #=7)L5$585     $       !N=6QL5$585     $
M!-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q497
MAT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&
MEG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$
M%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T
M-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
MET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F
M]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0D
ME-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M  !     4X0DE-! P     $)$    !    H    $D   '@  "(X   $'4 &
M !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,#
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M7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
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MF_K'YNY)-Q[%EU3+(K=%[*\8U%]H?5<YVTC=O8_'?4]OL_-_G$7&Q<^D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $5 EX# 1$  A$! Q$!_\0 'P !   ' 0$! 0
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MFN';<M+@"+Z@ZCJ6M5X?547-&H;&(Y7/:V6">GJXL\3FMFB,E+-+&)X,[3-
MZ1LT8?&Y[ V1A=A: ;I32KC+P?,N-'<3DF(3L($&&>'%)WN*8.5)]&JRL6,L
MI#L7!I0A)00>YH\EPVL26&!QYB.EDSKID=;6H6,8.7FW!V;-[JS",MB<UW6
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MBNB)^5W22L [PTAT7D]MH*5R[OCZG(R16;MS9-C<Y0[980R&U@TW ('.1WU
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M*Q[K:6 #FEHZ\S76))%SQ66GY1/?B,=14LAIX7XI1XC4F.*28%M)2R4TL#8
M1SC:J"26-S'.#7.DRO>UCG.;G%QM6C1/:]%MLY4DHY"BF&.;)"8<LFI)64DX
M=+HY.9$^+LGZ:C1[=.I"%?+'[7*-UJUIP@I5.Z^[L+J<Y:0R  7+B&\!<$ "
MUO<W%O O/&,SLQF;&(F!DKW5G,QA[VB".HIIJ6*.-[3G IH96MB(<"!&W718
MUSAL%Q_EZ1Q@R*,M,?BHE'HT#C\5#P&#$P,87B60*9)&&((U)B+[8$3-G+4!
MLZ?1>C$C*HRQ&B+7XE1DF^K>.=S!:U[DD]\X7S-RD&Q%Q8G<:\;C1;>'<IJV
M@CF:6FJEGFFFEJ)ZBIYZ;GZ/H3HZE[90:J*.(N?!',7,BE<YX:;D&:.;&8V=
M;99;K3DXWKEC'NY''Q"](>/N[TL]R.3G.3C9)GV=/V]W&G[J\8*27Y(NVEEB
MKODK6MM*ME(RW [UT;@=[\V-/+MOH%6+E'40F@<VF@O05>#5D??/[Z3!Z,T;
M&NZFS-.=]K',UH%A=;*95Q2RRK$8]$WY9V(1C^0\1Y#2=LD45U7#S$F2(KD@
M>-4L7Y66M3#Z*MQCY6W]M0:.UU4*56L3I6C7N9<@-)<Q[2#MW[2"=N%[A>51
M5KZ*:6=C&/=+2UU(6O+K!E=2S4DC@00<[(YG.;>X+@+@BZQ>ZVM!7,3 Q6DL
M.-D@.X6<;A$2#1-LV?*&IQ.\ASIR#35MMN[E:#G>0GC)B12I<]HF-9N;J56O
M5MU<2F[G$ ES&L/$6;E\M\MCQMH" MP8U,)YI^8A>Z7"J7"3&_,^,14M-1TS
M9+$@ETC:-ID:3E^FR 6T(P%C+AS1[%SU@5!9,(V&!4@PC)&C]C!(*"M?$\(5
MR&Q8/Y*W#"FMTH-S>/Y0E3.>2<TY<R,L;59GF9,:FS;B4\CJ@N%BT6L\'5QT
MDRWM=QL&Y1E L+ZVO?-Z%7RHFJVOC?2,R21XE$X.JJJ5P9B(I"YD9E>\0QT\
ME'"^GCB#&,9GB>V4/SC,F<MJ3[,\\(2MMF*78Z$2K$JN%,@@8D%C2Q"4P-X=
M(FR;$?)CC$F[B;PDF4>BEBHAG<2;,G"BXUTP(V-GK?$R3):S02'!S22="+VN
M.-K]8U TW6CA^,B@I6T[J&GJWQ5PQ"FEGDG AJ6Q,B:XPQ/9',QN0/YN6["[
M0C+<&Q!6P#',6ELSD4/4AXEE)UI67$M"V&<3RX_#Y++H\O'G[L/-9-%R,@=Q
MU+NIV53BQ=9\E>N_?A%25\/7LC:4F9QL3<D "Y<[4 6 T(M87 ML"; ;K9EY
M35U13P0SF8F(1,E=%7UU/'5115 G FIX9FP"5Q9$Q\T3&%W-,E+>?O(L=S3A
M_HCL45"1V5RZ52$%"I=%@0T/6/16YG;+\_XXSI9ZA+G#L<R@K:"O<?,0V/!8
MPX&5C@RQM8&E8 PR&GV%A.<P-FM MO?09"P[6%C?,[O3<C8BX.Q#RF>ZM;+-
M3T\,<E1%/*YW/SB1\6&3X:35#OWU)G9,]]0^1DO/.<_G8IHW/AD8HV+EB&+)
MB%R88=Q4W.,;2C$5[%C>S.F6T5(9AF&4F$PF)F\F:;'<I'G4K=.9N^:&"@M\
M667>ID7KE5PX4L9R"W*!WKQ)?;4-#  +"S<H%M+@]>ZM6<HPVMIY:-G/0TU1
M3UK1*'1L;4MPVGH98*9MFN90P\PUM*'-8\1L8"Q@ 8.G]M.QMI2O73W>?\O*
MGYM:RY%?6B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+7C ?U9W
M%?=$27XA8WT10<:?7!;FO?PS\2'VB+8W1$T1-$7YO..AOMW4[0<B[?@FWC*5
M^/A4VA4W*R=I;$8-);2;\.=",QZ_;9;&CKAI5!!ZNGV#)9LDI2ZM54[[Z6W6
M^E0P0S-E,K,Q:Y@:02",S7N.V^C+#8@F]]P?L/L8<D\#Y1TN+RXQ1FJ=23TK
M8;5%1!E;(R0O'TB6+,2<K@77MEMLXVX3>.PXF/G(J>BW#?S?ZWN@4MC]+=H;
M?5';^.WZ1U:KZB/8QY%:WPEW9:OQ+X_WYMZ^!X[#B8^<BIZ+<-_-_P"Q_P!O
MN:= I?O''8:2.W-]QN+6U^3<)]#'D5\$N_I^);V_'.OXD\=AQ,?.14]%V&_F
M^TZ!3#>-VNWTQQ^3AX+J/H8\B_@D]G[_ ,2_7$\=AQ,?.14]%V&_F^U!H*7\
M&XV_QWZ;_-OU;<"GT,.1?P2?Z=B7ZZGCL.)EY=R*G7[5N&_F_P"OW?Y-2,/I
MK?4R.SG':>0:?,I^AAR+V]J'7_'\2WX_=GQ?&GCL>)E3JW)*4_ZKL-_-]J#0
M4FEXR= =7NTOY?VC7@GT,.17P2[A?]_8D/CZ:?%^Q*\;'B9><BI^'%V&Z]'L
M?Q?:GVOI>$;NLV>[?]/7>UN.FJ?0QY%?!+OZ?B6G_K=?!IX4\=AQ,?.14]%N
M&_Y?W/O\E-.@4NO>.N+Z&1P.G$>$(?8QY%<,)=QO>OQ+Q?=OE4Q=QI>)W8V3
M>7[B'EC-52Y%)U=B?#]K956VG.Y)->N/*)7J6TZ;K+;JW4ITUI2FH%#2W(R.
MN!<CG'$[D;7VTW-M=.(5/H:<A\QC]K!SC0"YGMAB.=H<+@N;T[, YMG-) N-
M1<$%0/'7\3/R;D%?<_<MPWT5]'WL^]H:"EMJP[:_33\NVVNI"O\ 0PY%V!&$
M.(XGI^)6\1Z9U<5YX['B8]/^J14\M*_N78;\GDK^Y]Y/+J?:^FN!S3S?4'._
MQ$7MY;VUW0>Q?R+)TPAUNRNQ(G2]].F]8/'37J3QV'$R\Y%3I_M6X;]G_H^]
MGE^'4&@I/O#<7O>1PL1U';CKU>#5/H7\C#:V$.)/^?8GUY1;]^:]]<>'3=3Q
M/C.\40*_="C.X$D)*,5KF[T:3Q'B)@_9N+?WR#IFZQTDX;K6]'9)*IV7T\MM
M-3T"EOI&XBUR6R$V'EV%]]K:]:K'[&?(B5C9(L+YR)X!;(S$,1>QU]+M<VMR
MD7! (/ \0I'QV/$QZ*^N14Y>3]R[#?X.5?!]I[7THO:-VFI[]W5>YL3K\7&]
M@;6/L8<BAOA+@3M>NQ(7''[MUUZD\=AQ,?.14]%N&_F_]_\ 7K##Z8[1N[/I
MCM1U]83Z&/(K7^"7=G[_ ,2^/]^>#K3QV/$Q\Y%3T78;_#_8^\N@H*4CW!L.
M >Z^XV&Y X=O5NGT,>17'"7?T[$OUWQ_%VIX['B9><BIZ+L-]?L_Q?>_H</I
M;$\V[8[O=XQN>P]5M>&KZ&'(KAA+OZ=B7;_GO@U\.B\\=AQ,O.14]%N&_P /
M]C__ $>[IT"E&N1W;W[[CJTWUX7L/*GT,.17P2[C]WXEXONS7CU>+9>^.PXF
M/G(J>B[#?S?:'#Z46[PVX7D<#Y-^/"_;9/H8<BO@AW]/Q(<-/NP_M'4GCL.)
MEYR*GHMPW\W_ /HTZ!2G^3<>PO=UV.@OMQ'5;K3Z&'(KX)=XZ_$A\73#VW']
MR>.QXF/G(J>S_%=AOK]G^+[3VOI-+,-[;\XZW@!X^ !1]##D5\$F_P"/8E\O
M3?F2G&OXF=U:4IN44LKSI^RIBS#-:\JW4I6G*['UU.GGTUY<^75RKTZ=!I1_
M)..A'U1Q%[7!T.W'<$CLT4GV,.16O\$.TM]WXB=2X#6]61;772]MBTV(V/W<
M\4#B0[;=Q>3\("=V124CH 6%CVIXGB+"+!Z1M(QP,<O5<-&D!500O25*7M[+
M4U;Z7))6WW?L[J\L<-'32L8\Q%I<+D![S:W:3>QOM8ZZ7U7B<G.0W([&\%H,
M3EP,02U;)GNCCQ#$G1L$=1)" "ZJ#SI'>Y=QL02,RUP\=AQ,?.14]%V&_F^U
MD]KZ;<1N/^\=MPWMI^GPKVOH8\B_@D_T_$OUQ/'8<3+R;D5/1;AOYO\ 4=!I
M=3S;K"X^J.U/58Z_H4CV,>17'"7>*OQ+?^F:?&GCL.)CYR*GN_N78;^;[_MU
M/M?2WUC<-+D\X[37:_BOXO&GT,>17P2[^GXEU_CNNG@U3QV'$Q\Y%3T78;^;
M[3H%+I]+=<[#.Z]NW@.-^KRV?0QY%?!+OZ=B7Z[X?!VIX[#B8^<BIZ+<-_-]
MIT"E_!NVO8R.N=SH./;U'K3Z&/(J_P#%+K?C^)7_ +;\?Q)X['B8^<BIZ+L-
M^[_:^_7IT]KZ7?FSM?ZHXVOJ+^3Y-#HH^ACR+^"3_3\2_7$\=AQ,O.14Y?\
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MZ_)Q!(\FIVT1?=G[ZGOV_P#U4_RZ@[$6 U)N.-NRY(&_9MMNAV/^S_7:M_\
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MI?,!;<$G4'YK7X;*1X"?!ZE-0"-0"-1>^W';C:_Q$Z#4!0FI(O<6Z[;\+C0
M]9'AU)&R)I;;0 <0;]IX[;ZGK\B>OKZ^5-3;>UCH+>"Y/#6VNED352"+V.I<
M./#@#ZGR(FI[ZVMR=[ #<$6UL?#;PHFHO:QOJ1J-^LGMWOU]5V[HFIMH#I<6
M-SU;\ 1>]^OKO<HF@'VU^!)ML;WVO\GE1;!8GPE?D+&><\E+W&5V^+!N/0L=
M Q]NFY*2K).5IHA&(>#[7>W=*U8)#&$L-N4V2"K\@Z#, C6B%Y?NYEC?,&.B
M:<H#W/)<2;!L;<SMM=21?J!!O9KEXV)8J:*NPBB:V)HKI:J:JGG<&,@P^AIS
M-4R-<7, D<_F8HBXEC,\SGAWTL#*>YG:$^VNQ#;^8FI<F2DF2DYS7(X,<.JU
M'08M#CXD6ZAPDZ[0O:G#XUJ^<)G""5J@=,Z@['B;B@X;0P2QP5 G?.UH'TLM
M,;G.!O<.-W,:X&Q( N ;7N2"0%YN \I6<H*C&64C8Q!0BFZ \N<^6K944\L@
MJ9(QEYJ(R, CC<UDI8#FM)F;'MT<X7 .-,2T\*9++N<6@Y9D:6/'8]D-]5+G
M:RPQ(=R/AO,C9LK;>Q36RF?B,EQNSMNL6%V3"H9BC?55^FBK@Z:22VPSEK6@
M$')SV?*]IU![UI:3K;+F)!X<['R]GF(IF443:^2EHZ>-KN<,(Q]V(04>)8>X
M AQ91T]3'7!K7"5L)[]S\KPL8O\ A$;OAQ&*#' J+U7D+PBP.W66SVZS'KT5
M#'L]?-)#;6 T6EO:0 TA8D[PZEDYD[.,U(TT<+GU&H]QD%? 0;B0Y1KH+/O8
M M-QH2;92"=CMMZ#/9)Y,OCJI!+..9:QT M3CIHDJF4K1"!5OYAV=X?_  A)
M1 0WE> P9C\S;ADY/@&$<ES^2O&(LYAV:/JY D;QV9:XY:XV>XTQO,($['L7
M4-;SU.:3F0Y":QD8 -A1+]F_260D0>-MPT@)CS*MCY&M:"62,NT6M)G#W-()
M!# .]+O!<"[M712<O*&MQ3#Z6GCDEI\3I6BEA8R(UIQ!E?4T]4U[A4.IC34M
M)3/JG21R/;*UK70N=SC8W6>;X?TLQ[*)[CS)<H%6S('MI,;EXP\A"9\A&7T=
MA[]@3E818E*HM%V$D45@B4E+@Y'!2IZ)O"XP>P:G"*#]XN+L*IKPV6)G>B5L
M+A*X7N\/:TC+9X&< BX)TL='6.U%RRIZR"DK:&GD%-)C<>!U#*ML;)XZBH8Y
MM/(&P5-08F-J>99+%4LBG,,LCVQ!T0#L#;IX5MQ@F0Q@C;#E:0Y>@*T/".RL
MDD8&\"Z9S*R]X.D0QLBHU8*.!RC@>F<&J7,K>YAQIHPN>DUFBSU3)$Z9[?I[
M!&^Y :+V(/N2=]001OIE!L./L8!5XU64<LN.8=%AE4*J6.."*0R!T ;&^)Y)
M<[7+(&NMN]KSWM^;CUIUEL+7UN;.OP!'B-K=H/5NO<*:BQ)WZQU]>^UM] .&
MG!$U.I)WMPTXC6^P-A:UN)/'5$U!WMUZC2Q;J=AV<=B1V:@FI%[V.H /7KX;
M[G;:X -N(1--!K:]A;0:CJTO<7N0;ZW1-!8<"186TU-]>&GAT'"Y1-1J"#MJ
M0 0;:D?I).NXL- B:ML,NM]=O#ON3;7MV-PGQ)J!J-3:UN T(/5O?86TWTWL
M":C<:"W8[;4FUM.-[:$':Q1-21V&QM:Q'BUW'AU&I1=!=@7\!O?^]^;A_P##
M8)K5J+7IMK])BOXB1X>&QU"X_E=[KDO_ #LPO\U6+GUK8-CKIK:Y)M:_9PTT
MXZ6-]"5V)U)/64U?ONL=?$V-^'$ CPZ@[*%LM'L&Q]? <8S7,9C=%!\XW!KX
M8#OKQ[PH*CP2)0X1+<BS$Z.%,WQTHHQLFD+; 10=*Q5UVJ0U6[8I:PMKBS'G
M7,8PDMB$I-VB[I'AK& D@9=R7'47&H T\"HQ>H;C%1AM)3MJ31X-[931YPR:
M>>HJ7T]'3PO=]*C8!3SOG?("0'1AI"R%)]MF-87OC;;8)!D(XEC=7(4.@:^2
MUQXT449HS,.&O92<@,44(CQX]B7.-G)-G<Y=7-@Z+A*UZJYMH[K1DKG4W/-8
M!(62/#'7<V['VRZ6<;M)U%CN=5IP8WB-3R2./PTE/TX4E35]#S2OC/1YZACZ
M=I;=[W&*G>&/#FWF+!:SK#9-[PM94'B\>=D#Q!Y.9%"(K%484Q[VL51>[;(V
M4HF)A&#SCXHG8W%H>!6=1W+9Q=XNW(-F*)A&ER"3:ZYM@;7-+W -N ]QS $E
ML#(B2YNMB2\V%PX$WM<"Q\3N_ADJ)6QQPQ4L%945!J9!)()>3M'13R5>)1-8
MZ\C_ &PIYJ*G+1DOS0>'/S.=;%O"*W772>\#:I#;@Z<;2D2DXH+S#<#357E*
M\/1 *1BW$]<JIEE3#9=1-]?CRD7N!I72>V0W1^G?"MNGTQ;GL_5P;DTS[>[-
M[LM;OK6ZVZ$@K,?9)Y/"EYZU7SW/<UT;]XYRWHW23*)17&B+&L(:YHK.>;(X
M1&$3GFA0<O[%Y9MQQ'A[/\J>%XN,1/%8=D_L)+8V,.\Q1K/V9,>$X/APJ CI
M1F@0#P'%MDN>')"\O$L5G5KQL1?+$@T?7EE3SLDD5FO[W.SO3I'S3),S\UN]
MS:&UB<VX:%EPSE;3X]6XGA%.R*I=)")Z!KH+PLPZ?":"85&)MDD&9DM97]&9
M%"'27S9H[,YQ:A[C,.OL 9RR?AP@53.J0&6/PS4ZFG1"AL3=:D_!F+VU+U:-
M%B@9ZP>N&?;5>XUUE&U5E:I54NSQ2"6-DFP+0ZPOH07 M%[7MEWUOJ. MT^"
MXFS&,*H<29'S72X&R/BO?FI02R6,6 &2.5KV1FUW,:''4K"NK[@:"YUTN#KU
M::^$Z7W)7J+;OA__ %\^SW[I;"O\X0#\7O\ X/+K%.;P5'9#+;7AD/CX7]=>
M>Y6_8MRB_P!38A_9WK^EI;U4]ZGYM<POQ@O=$31$T1-$6N^ _JSN*^Z(DOQ"
MQO\ K_)HBA8T^N"W->_AGXD/M$6QNB)HB:(OR!_]TR_QM;5/^CG)7QGC&O8P
MOW,I_P I'^;G\/R+]">PI]8X_?WQ1_U'K\Q>O4%AMH238[V%OFN+Z^$Z67VV
MU_'\7EZODW347-Q<@V!.GC\&NVW[5":L2+FQ&H(U-K'7AX=[ZZW'%$TN.UW4
M;Z@:7N=+?%I:]KJ;=0*:CO1IFXG:^Q'A/7OJ>'#2/7U^)-3FOQV/4+$;W-[;
M ':VNR+,N.<TR'',+R9!AZ:BPG(M(.62<-WZPTA%YSC63IR2%302X135[-^*
ML<'PRC52VRQ8?(GBR2[9^U8.4,;XVO<PG,'-SBX-PYL@#7MU(%K7X$W)!%M%
MYE=A<5=54-3(1FI#51/8Y@>RHHZZG?!54KVW;9LCA3S!P-VOIVMME<Y;,QCB
M+YV:R]S*IW6(35/U)YQ8,HZTQQBJ'Q=WD#-V/B4%-9-G$8 0!*-9*/UM=,G9
MRDU#EE9*Q8J!73UJU?.5*X9*:,L#1F:0YHS&1SSS;77RM)U8!P#38&]@;!>#
M4<B<),(AI#44CNDX6]T[JROJ9V4F&UL=6RBI9I*MLU'&"PMAZ/)'S;BU]KA:
M^.=SF;'.; 6X:LN;M\JQ>X%9&R[*,11@"!#XP%;QL"!$P9D$;P@?&!D?;)!&
MT8:Q],%09VQLHQ4M67JIF$47-&(@NC<27 N[XDZD!YNXF]CF%B2 [0@+VFX#
MA4>%RX*RG<,/F$G.L,U09Y9)GB6:62I,W23++,!,9'32/:[O0ZPTN<_O)W 2
M2 ',8OY/&VD-D# F#=L &,L9QD@TB!>879 ?X_"2*/Q(;(X]CA6:772*S'X,
MJ/B")!12J0>Q!2]"ZH@B:YKVAX<W+WSGDC,T90[4D.=E%LVIZB+FVO#R7P2"
MLAK64\[ZB![)6.GK:RH8ZHC@Z,RLF@EJ'0S5K8 (NER,=,6V)<2T X_B.X+-
M,%B,L@,7R5+1T)FT-*0"01.XLY>QY>*FC0Z0%AS 2^O<L0JC\H+;JNB =!B1
M607),KW5618F@[N8XBX%S&$AV8.(U#@'"^NX(/$D7 X@+<JL%PNLJZ:NGHX7
M5=+5,K8JEL;&3FHCB? QTKP,T[6QN(:)7.#'-:YH#F-(HD/R]DN 1PS$H9,2
ML=CT@E<$G!8:/N133=2S&;HJ^@YNJER5RR;H ],OG;:U%1)!1Q<W6<IKJ,F5
MS>Y+'N:Y[ ][6O:'.=]K(+.83>V4W.HN[<$6*RU6&4%;/'4U-,V6:*GK*6-[
MB3DAKA&VJ:!< \ZR)C+G5C19A&8K([K=EG0G',BQ4_)0$J#Y1E\WGTGI,<=X
M[F!)I-<D-$V,YE,0-R6+E#4#-R5JBU3(O86_ *]FR'N&]470YDNABYF#,QV1
MP+ U@(D(#VMOE;(!H0+Z$@D@:WN2M#N:PAM115,4$M/+04U+20&GJJN!AIJ-
MQ?2PU$<4[&5D<#KN8*D.N7.!&4V-3.[R=P4D)"3Q641R^4"(U+(G68LL:8T%
MS8X'FV/7N*Y#;+IH+B+.43%^X@A!V%:EY06+%6%ZM"C-V@83L(6U$,#0YN1Y
M!()N\D=Z[,VP#K-&<"X &UQ>]EC9R5P.-DT3*>H$$TE/,*<UU9)31/IJR.OB
M%/32S/AIX^DL,CHX6M80[F\N313[[>AG61"YI'9A(!!H'E2R-#\MOF,%QN%R
M%D&/1U"&,ZABN4&\,7FEE";:!1ER37N(N$R1UBI(##0H5)&7!.>9BNTL!:YH
M?S??$L:7%[@0V^[<Y:T#9CK"QT56<E<(@D@GI89HYZ+GWX:R6KJYJ.BFGY\Y
MHJ0SB"T1JI1"6QAT3"V-@ 8S+AO,V59)G'*D\RW+Z-;)#/I(0D#YJPL43'C;
M'5]+&(<:FLHLLF,"CDF8D=8NLLO:Q9-[5EEE:7*76B:&1LC%SD !=Y23MJ27
M..K1<DFP)*];#*"'"J"EPZF<YT%)"R)CW@"1Y:._D> 7 .F=FD>T$@/<0"0-
M<9ZM:VQU-S>_#;6QZ[6)L"=#U+=34DC0GB 2.H=5Q8D[6!OUE/"FI!TWL+<#
M\0N=+7%SKJ=3HB:7O8Z[V[.O74WTV'#;<"Y-5!!).U@/%:VP\.POP[;$ONS]
M]3W[?_JMU+C?0'CO?QZ?)>PMKKJ4.Q_V?Z[5O_Q3_K_=R']\T;_F_B.L%+]0
MC[6D<.-MKKCN0/V)8)_H*G^VU"Y^ZSDC0W]SIIN;>$;>4?&5V/KNF@(MK;C?
M2Y).Q.FEKVO8C5$U!MMO:]KV&X'6-]2>'CT1-2#X[\"1N;DVWTUX^#>P3UZT
MT! U.NIX<>.NG \>H]B)J+C7AL>]UM8GP#3Y2#<IZ_-Z]J:MFMIH/#L. [#8
MZ$C6P[+I;U]?71-5X>$@V!ZR=QK>VF@'R(FIOOJ&VU\9!OH=[CR;6XI\2:?>
MV/':VM^/#@+7OO:Z)J>].E[6XWR^'Y+Z"U^I$U!L3J0!<Z]M^L=0MOY"1H68
M,<9D/8YB.5(4Q147#91#Q9%RJU(.!12/2J!RX;,H3,PC]LFHHB5"/F;\;<G=
M;R7#GBZ3=9D0O9$F-)(VO=&;G,PNMJ,I8]A:YI%[D$6O<6/&]K.\VMPR*NJ<
M.JG91)03RNRF-LK*FFJ8'4]532M?H6RL>'7U ?!$+97RW@S_ #ME[*D6@\-R
M-/Y%,P&.;I%?$4)"^4)O!ZDJ?HDC:BY5W54H34<.6Z-$%"CQY>R;66LV5S=I
M;1#1L<4;G.BC#'/RYK$  -O:S6D-&A/N0 !X2K4>$X=A\]7545)#2S5S:=M2
M86AC7MIHS'$UK  V-H;=SPP 22.<]]W$%59WN2SD^ $XN[R*:7 E\113!#X:
MI8RN1OQ1")6.FT6B"5W<U%6S(/)!;5ZW<-E$G]Z=SQBL\58$7[5Q.2$$$, (
M>9;AY!S.86.V)%G-)#M+FY %E@;@.$LF9.VBB;+'BE1C#'BYRXC50N@FJ;'0
MET3LHB)$;3'$\6>P$9!?;W-QI*8 Y^\E$06F0<>?$OI#=B+$="4Y&2H SB\D
M8Y57MA-OA:;&@3!NR()9(LD]KB^V]]=2A%99XIB;3TX:YA8XAX&\C@!8EP+!
MLS4WTZ@0"=#IMY)X$RGGI&4]2*69\#VP&OKW,I7T\CY8'4!-430&*1[GL-*&
M%N;(.\: J4/W@Y\$6'6H:4 08:3&)>:/14#CW'H&%E%9U V&-).P=0T1&6<8
MN"$(:+'L+0=@JT4T(-4C[)HV/T[YUET$)R]Z26L#0XR.<X6.:^8N!!))%[BS
M2+7L KOY+X.\QO?#/++##30PU$M9525$71:YU?#*V>21\S9V5+WOY\29W,<8
M''F'%@N1YO9S(9#'QD@7CSM9UAF58+B%(]$8;C\#!(9D*1C3N1G J*P*-1T,
M^/3)JQ=A219\E<O>T-$G2W=+VP:JP<S&US+9BULK)'#,YP>67RASB2\ &Y N
M<H]S?4G"SDKAL,D#H&RL:W%(<6JG3SSUD]94TD,D-$'S5,LCF14QD;*(V ->
MZ")ILRX6GU*4I2E*4I2E.JE.K6<NN7%UB3K>X/EWUV&UA8D<;]-\V@[!<FWE
M)/A)7N@(U[ZW5X+[W-]2/!K>XNB:@ZB^A<>HDWTUT&E]!?XM;(FAN-K#07L3
M?PFXT)O;6^]SM<$TLT@:@==KZ;#K.IZ]COVHFI! N>VU^SRVMH;> :;!$U!W
MM<&X!X#6]O'Q\ -[&R>'UZO7QIJ#EZ[V&P/SV(U[+:CB2B: VTX:'PZ:Z$<?
M%U[(FI)&MC8V\ ZCIU@6/$[61-1?OAK8#:^M[WN?'VD::HFITWX$6T[;VTU.
MEK=74. GQ>3C^U-1I8@F^O#LOIU=9&U_#<"/F];?+\:Z"[ OX'>]][\W#_X;
M ]:]1H:;7[IBTO?KUOVC;38#M7'\KO=<E_YV87P_R57Q^9<^M;%@+7N.OB!;
M3X^((.]M%V%K?)Y$U>X((O?O;WMIX[=O5MX466*99*K8-K@H@R3>@1^4[LL1
M@CW3<DY FBT53B,O85;]I43?,)./$Q%92MRK=8<ZC*54*JID7:=<=F\X9!HY
M\7-NL=\K@6O%W7#VF^7K-CH22/.]KF#%VXNQY$CL/]KYX2 63,CJ34TSBX=\
MWFG25#76^J,JGM)#8HP;?R%D>993G!O(\X+]]IC('#%T4+)-&0RJRXT>S&,U
M$VHMLS9M[D68]I92J""?.]+MMW-2Z^^Z6B-C&QL#@V,.' W!/A(OK:_4-3KI
MEH*"GPZBBP^D86TT#',C8][I"&O>^60.>\ESPZ1[GFY[VY:+-  RR2W>[DRQ
MI_(WF6I'<<)9IC^X=P123&(+6YBBPQP% S9O:@Q22;/AHES<.19H)IB[FEB#
M=1C<DV;VITYJGLUIB:X-C,0!<ZV4DW%S>P!<YPUZCO=>?'R:P..%M.W#X^99
MADN#AA<^QP^>832P.L07!SHXW%]P_,Z0W%PJXVWIYY920_)6KG%B%\J BX])
MXTC@#!2./Y$U"2!]*A! UCA/'=(*1D8P^3?OV,J=1]22M:.UF2)6P==W'JII
MX"-6R7#B0X2ESFW&4AKB<UB" 1L;D$+!W*8*:>*G=%6N%-*Z:GJ#BN)BLA<^
M%E.]D=8*KGV020L9$Z!CQ%9K2&YF@JWFFZ3+BT/98NDQ^T]B2@5G%"L!2#Q8
M:Q=Q9OE0WF&Y 4YI''=D?DC:8R>4. 4O8L[S0%A("0%FI=&7"X)>QBAS%X:Y
MKG:AP<;M<&9-+DG*6D%S; .RM%M+K,[D[AC:EU=3QO@Q 2NGBK3)-+(V8T,>
M'C.QTS1)!S$$'.4[WNCF?&V5X,C&.&.\P92D^;<HSS+,QO;W2.?R4E)223.R
M]-BRO?K5N0&#DU+U%$AHII:W&CDE%%5$F35"Q156^EU]UV,:R-D;1;*&V.@+
MAF)!TXV)OQ7H89018704>'4]^9HX(X(R=7/RB[Y7GC)+*7O<1I<@#LQOJ; ?
M;#8WMQ[.H=FE^KLW5MWP_P#Z^?9[]TMA7^<(!^OO_CUBF^MY]OJ$MA87MD.I
M/Q=MESW*W[%N47^IL0_,/7]+2WJI[U/S:YA?C!>Z(FB)HB:(M=\!_5G<5]T1
M)?B%C?\ RZ(H6-/K@MS7OX9^)#[1%L;HB:(FB+D=NAP9B+<'Q)=MD%S7C^.9
M*A[?:=G^0HQZ4L^[QB9H?DC$31D2M0[-/DY;MB3Y%._G7DFY5MY5I=K<B?)'
M2S.C>]A,T+26.+3;),=VD']"[K!<2Q#"N2.,56&U<]%4#'<(C,M.\L>Z-]'B
M>:-Q&["6M):;BX!MM;//BMN'EYHF%_@S3](UAZ34^^:CS\OIKS^[CE;\/XAY
MT>BGBMN'EYHF%_@S3](TZ34^^:CS\OIIW<<K?A_$/.CT4\5MP\O-$PO\&:?I
M&G2:GWS4>?E]-.[CE;\/XAYT>BGBMN'EYHF%_@S3](TZ34^^:CS\OIIW<<K?
MA_$/.CT4\5MP\O-$PO\ !FGZ1ITFI]\U'GY?33NXY6_#^(>='HIXK;AY>:)A
M?X,4_2-.DU/OFH\_+Z:=V_*WX?Q#SH]%/%;</+S1,+_!FGZ1ITFI]\U'GY?3
M3NXY6_#^(>='HIXK;AY>:)A?X,T_2-.DU/OFH\_+Z:=W'*WX?Q#SH]%/%;</
M+S1,+_!FGZ1ITFI]\U'GY?33NXY6_#^(>='HIXK;AY>:)A?X,T_2-.DU/OFH
M\_+Z:=W'*WX?Q#SH]%/%;</+S1,+_!FGZ1ITFI]\U'GY?33NXY6_#^(>='HI
MXK;AY>:)A?X,T_2-.DU/OFH\_+Z:=W'*WX?Q#SH]%/%;</+S1,+_  9I^D:=
M)J??-1Y^7TT[N.5OP_B'G1Z*T84X?.RCQE2&)Z;:<64QQ=L?6R%=#Z *4"UF
MMF>6T<MDE6O;NDI0'=491>MW0TK5/L>GG38Y^?HF?GYL_2,N;G7EV4QWMF+B
MX"X.EP-3;6ZZ0\KN4G<>VL]N:WI9Y2NIND<[:0TPPMDW,$@ &/G;26(/?"_@
MWG\5MP\O-$PO\&:?I&M?I-3[YJ//R^FN;[N.5OP_B'G1Z*>*VX>7FB87^#-/
MTC3I-3[YJ//R^FG=QRM^'\0\Z/13Q6W#R\T3"_P9I^D:=)J??-1Y^7TT[N.5
MOP_B'G1Z*>*VX>7FB87^#-/TC3I-3[YJ//R^FG=QRM^'\0\Z/13Q6W#R\T3"
M_P &:?I&G2:GWS4>?E]-.[CE;\/XAYT>BGBMN'EYHF%_@S3](TZ34^^:CS\O
MIIW<<K?A_$/.CT4\5MP\O-$PO\&:?I&G2:GWS4>?E]-.[CE;\/XAYT>BH2W"
MWX>EJ5]UNT;#%MUMO94NMC/*M*V]-*TK1S2M*TK2E>=*ZD5%03;I$YOH09I'
M"QT-P7$'QJ#RXY6[>W^(B^EQ, >O0AO9Z[+4G8CLMVK[F=J&'<Y;@<'P3+^7
M\@!#1";9%G0Y4Y*Y._'2Z0 F+LR5<N.WO%V@86.&(WJ=-C1D@E2E*6=.2:::
M.1[(Y98V @AL<CV-&9K2;!KA8'0V\&^Z]WE-RAQS L>Q#"L)Q6KH<.HGQQTM
M' YL<$#'P13O;&P-RMSRR22.R@!SGERV[\5MP\O-$PO\&:?I&L72:GWS4>?E
M]->'W<<K?A_$/.CT4\5MP\O-$PO\&:?I&G2:GWS4>?E]-.[CE;\/XAYT>BGB
MMN'EYHF%_@Q3](TZ34^^:CS\OIIW;\K?A_$/.CT4\5MP\O-$PO\ !FGZ1ITF
MI]\U'GY?33NXY6_#^(>='HIXK;AY>:)A?X,T_2-.DU/OFH\_+Z:=W'*WX?Q#
MSH]%/%;</+S1,+_!FGZ1ITFI]\U'GY?33NXY6_#^(>='HIXK;AY>:)A?X,T_
M2-.DU/OFH\_+Z:=W'*WX?Q#SH]%/%;</+S1,+_!FGZ1ITFI]\U'GY?33NXY6
M_#^(>='HIXK;AY>:)A?X,4_2-.DU/OFH\_+Z:=V_*WX?Q#SH]%/%;</+S1,+
M_!FGZ1ITFI]\U'GY?33NXY6_#^(>='HIXK;AY>:)A?X,T_2-.DU/OFH\_+Z:
M=W'*WX?Q#SH]%/%;</+S1,+_  9I^D:=)J??-1Y^7TT[N.5OP_B'G1Z*>*VX
M>7FB87^#-/TC3I-3[YJ//R^FG=QRM^'\0\Z/13Q6W#R\T3"_P8I^D:=)J??-
M1Y^7TT[M^5OP_B'G1Z*>*VX>7FB87^#-/TC3I-3[YJ//R^FG=QRM^'\0\Z/1
M3Q6W#R\T3"_P9I^D:=)J??-1Y^7TT[N.5OP_B'G1Z*>*VX>7FB87^#-/TC3I
M-3[YJ//R^FG=QRM^'\0\Z/13Q6W#R\T3"_P9I^D:=)J??-1Y^7TT[N.5OP_B
M'G1Z*>*VX>7FB87^#-/TC3I-3[YJ//R^FG=QRM^'\0\Z/13Q6W#R\T3"_P &
M:?I&G2:GWS4>?E]-.[CE;\/XAYT>BGBMN'EYHF%_@Q3](TZ34^^:CS\OIIW<
M<K?A_$/.CT4\5MP\O-$PO\&:?I&G2:GWS4>?E]-.[CE;\/XAYT>BGBMN'EYH
MF%_@S3](TZ34^^:CS\OIIW<<K?A_$/.CT4\5MP\O-$PO\&:?I&G2:GWS4>?E
M]-.[CE;\/XAYT>BGBMN'EYHF%_@S3](TZ34^^:CS\OIIW<<K?A_$/.CT4\5M
MP\O-$PO\&:?I&G2:GWS4>?E]-.[CE;\/XAYT>BGBMN'EYHF%_@S3](TZ34^^
M:CS\OIIW<<K?A_$/.CT4\5MP\O-$PO\ !FGZ1ITFI]\U'GY?33NXY6_#^(>=
M'HIXK;AY>:)A?X,T_2-.DU/OFH\_+Z:=W'*WX?Q#SH]%/%;</+S1,+_!FGZ1
MITFI]\U'GY?33NXY6_#^(>='HIXK;AY>:)A?X,T_2-.DU/OFH\_+Z:=W'*WX
M?Q#SH]%:A[M]EFU;!JFV)/#V#8)CBS,N[;$&"<JVQ,>N)I/L.SYO*%9GC>2]
MSNK:DHG)50HA0N*5K5%W<.:UOIS3MK3/!-,[G<\LK\D+WLSR/?DD;;*]H>7
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M+7U\>F@T/Q=MM58 $^Z &5QN<VI#20W1I.9Q :W[4.<,S@V[A=R>!N)Z8$#
M\DR.](@B[+)D=E,9D&1XB8[ ?(\$Q",72)U)P4+BSLB\=YJ9SN48_B[D(?C8
M6)R9N/D+>/+(BVL1A56[NSF [F<>O,IB,[F4#40O6@_@FK>4&+/0K-F#=LI)
M&V82/)V1X9$@MZ0-M%WB#4&:(6T(MSP5TZ&)2Z5D6\&B+G*I]EL;_>[7'^,H
MTUM_<)_&V_F7+K#]@S?YV.\?\#M6MF>=I^\%WO2RKN1P.VCR%Y2$N@D3*R:;
M, 0E9BXV^D8)WK:-HT,0R+65,LGU!2 2P.RMCBI-@S('5QZ$VL R$1K C+8_
M)<CP:[=?A\*Y2YM;AZ^OC*IS7$/%M3BW<EV5F#B0*8L2 DWI22@K:H&!&XVA
M=/U'VB+D$W,MEFW.Q:/E#<K69/!4DO95&9):N7+PJ(C3Y?DZO#QOM?390OB5
M[3-]ZMC27A)PW,9?0C;5VED%\2APHNA+Z[5LUXU8O[62C(P)826+Y#DD)'I2
M$5>H@6#O31-S>NU(&QM83U]?7P+-\>PYQ!A>?,97/<WD76WV*R.6=\+'SN+G
MY:8C:&7\D&Q+6>J*(Q^IU*1X??8UA8LDV;'CL;)"3!9=NP+TN,&)TMQO\7KV
M>._!/4+JEJ$31$T10'%]M$E:5K2E>QK3IZ.FM.C\]/QZD;B_6H.XVW^8CY=/
M&N=_">4LIP^=M=:W4Z8Q)^7*O/G2F1)?3G3ESZ*<Z<Z]5.=.?*G+6>J%JB0=
M1;?L.0?M\-EUO+I['<K,9+'-<TS0$%MB#^]*;46X:CP<3==%Z5YTYTZJ]--:
MZY--$31%\7*IV=-U]*4]FM>CKI3IKU4Z:TIU^S[%>47''3PZ)V>/73X]M> W
M*UZEFZ'$<<-/(F%-/LFSMC^Q=8_Q('(9(ES)6MU;*)FV<82>L8I9SI3LG<P(
M &"=*TN5=IVW6W:]"/#*N2-LKV-I8)+Y*BL>VGA<!NYADL^5H.AYADAO< $C
M*N4KN6F 4E1+0T]3+C.*0Z2X3@%/+C.(1.-P&U45$)8\/#B+"7$9:2 '1TK0
M;C'$R7W;9FBQT)$([&MM0TP'<I#I-,)"YE^66KZY&]9DHUC^/WR40B:M'*:%
MEY):>S2Y!.]6CB-.J=DTOV(AA-')&^=\N).8\%T4$?,4A <+M=+4-,LK2TN-
MA!!J!E>;@KR*]W+OE%0U--A]+1\BX:FED;#78C5NQ'E!#*]CN;<VBPF9N&T+
MFORWE]N,3+6DYZ)VK5^>OB60J:X_S1C&,Y%R(7RE-FF (DK(YD7;,&=[\FXG
M63%%VX]H.9,DVXAES[F&VN;5R"J"=%WSI9RJK6WZ)R7FAGHZR2FIVTE.[$).
M:@87.#6B"  E[B27:]]8AMSWK19?DWV:\/Q'"^4& T6+XM/C>)LY*43JS$IX
MX8N>F?BV-.='%'#'&UE/ 28X \.F='W\SW2$D<_$J5Z/>I3\=.OI_E]S71CM
MW)/RG33QFQ)[%\=;:^N]Q;R_MOXE5FWDY]71SYT][GY?^WR^SJQV/@\"ROV-
MNWUX6TOU?,JXWZO_ %?>Z;J5_!_HZ:]=:GR"V_4;BW41:WCT&ZF+6WC^?159
M+R?W/^6GZ_GUB.Y\)686N;=0^4W&GKHJLAU>[SY^]^QKS_/R\O7K"_?Q?I6R
MW8>NG#@/D5PC5;4%VJUW.MJ*Z"M_+IK6U-6E]W*E>7.ZMM*]CSY=/+JU#KF.
MPUNQP(N 2#8$ V(!ZM--MUMT[FL?$]P<6LD:]P;8.(:\.(:2Y@#B!8',+'7@
MMZY;FW&1+<W"\YB29)Z&'Y6;S,N%;XJC,**L :,G0/4M<$P\E>5G)^Y&Y=!4
MF:H/>+7I)WJNZVK5M2Y^&@JX\+GP]\;!(ZC-.U[JV:H#I',YO0/C#((M XMC
M<6CJ)U7UO%.5> 5/+?!^5-/5SRTU-C_3JJF;R<HL*FIJ1M;'5'-4TM;428O4
M$.D'/2LC<^P<YP<2'6SB++T)A4(R/#3-)6K7,;MZ'D;\51*U.'QIH((T!F@;
M2XDVL+R B<-+LI T=7-6U\,;D@B+V]61+W,LE;0U,U133QM@'0&QR0-?D?TF
M9SF"6*6["&Q,CC+XBX'Z?D+KBP/G<G.4N#X5A6,X;5/Q$]TU1-3UT],"UN%X
M='33,HZRDA$@%772U4QBJX91!FPADM-SSI*G6\, 9SQ_CLZ4)$HRA#KG 2%C
MD7,9!$9^P+KQF8C9.5>FHW.IX@V0.&DQC5,8=$OV5D6>MK'H82T=*W.D\6)X
M;5544<;)75-I)I',FEC@='SL!C8(YHH "R%SG.=$YKG2@AKG.#1?TN1O*_!,
M%K*F:HH(L)#Z;#86/PZ@J<5@JG4.)08A425=#B6)D-K*UE/''35D$K!A<PSQ
M0-S.+J$$S4/$@I6-33D#UFIFN Y+AL>,/[R;!F'C).=$BK @\7=*=@4)W'@J
M+UR@S7N**).5W:W-NC:I=^'RO? \<VQWM=54E1,UH83)-%!&PM;:^2[7N:">
M\O;L6E2<J::"EQ"G/3I8SRMPK'L+HJF4U#(Z:BJ,5J:R.661W-MJ*DU5/"Z4
MBTK\TSWEK&@S.8<BPJ2!6<;@[F2%62V1\CY0)E96)8B2+5_/Z1UNE'6R;$T<
ML>(BFD=L6?%E%VM2;]Y=<FP;I-K;EIP^FJ(9'35#8HW"EI:1D<3W/:YM*QWT
MXW8W+FYT-:,Q<T1NN7$$B>4N,X574L5%A;\1J&/QO&L>FJ,3@@@FCDQCH36T
M<0AJZP/C@BHV/DFSPB>60N%/$6EHO:/YSCRHC'X25/).[N98CRIBV5G:-T2Y
M(59-S1UT!(@T7Q9K4JV$CG8IBX8+O178C['8]I?1--"JFM/ATP=5/IVQ=]74
M-9!'F#6OYB-F=LEF682]SR"&GOP"0>^!]BCY5T?1\(IZ^6OE,?)OE#@.(5#(
MF3U%,,4JJIU%-3-J*FGCJ&4M/)!"Z!L\!="Z2-CXV1W641NX?&2#B+UOMF5K
M?%,FB<BA=Z8035S.Z13&$>@%K*4W4D2=(W5\2C+8A1=O626-@Y)\/JDJLFFH
MOJ/PJL#9<O1W.K8I8ZAKI7 4W/U)J1S)=$!(UK7Y'@%IYUN;,!<+VX>7& ,?
M09FXIDY.UN'U>%,;2T_/XOT'D[2X2&8B\UK(Z1[JBFSB435UJ>9\1;9I*^X]
MN!QP.*#Y*NWD;DE(/ JUEP%4")O"QUGB(#8&<+@7:AM>XY<=79L%FC-V+%)L
M&CHF@X47OJE<I,N$5+XGP#FN;C-<^GD+W&64U[VD,E C;S7--S<X<[KDC*
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MCTW_ "5(]ACV.AM@4OY8QK_J"C6\/#:3;^]QH\IR_P"?4^_^YM.Z7&??8/\
MX>F^:$*X]ASV/!M@<N]_XWQC?^GJ)3AZ[3:<Z4QL]Z>7/G.9[7J]^2ZD\I<8
M.AJF_P!'I_\ E*WT'O8^W]I)?RMC'9_G_8HE.'WM1MZL</:<^O\ JXGE?SR2
MNJ]T>+^^6_T>G_Y2R#V(N0  'M))8;7Q7&#;RUY7W;P_MJ=M>=,<//AO._\
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M4YI:+5:03 ;9W!1RKR!.X8XD2K:?S=7)=]T_8OF\V.#4Q#"+LY$T'W1!V";
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M)?:G1I:K1Q?5:MB?38-REEP>E?2MI&3M?,^;.9C&X%[(F9;<U(+#FSM8FXU
M!!^,^R'[#U/R_P ;IL:EQZ?#'4^&0X;S$>'QU8<V&JK*D2\X^JA +C5N86\V
M2,@(?J6K5FW@AA[>7^J)*5K3E3GX-67*O+W*S2M>FG7T]/L4UZPY<2<<.;XJ
MOCQ^Y?)\?6N#_P#IGHQMROJMP?XFAX;?X14VGP30Z?+EN%*?AQNTY>3R4FGN
M:@\N)3?^#F^#I5_+^]6GQ!S>N^FMC^YHHS?_ .[ZH#_4T/5;X14]9P6 R?+E
MN")5Y<J?Q;M:<NFG.O\ 7I[G\OOZ@\N)]O:Z*UO?#]QMKS=[^MT;^YII&_\
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M_EK!_P#[?GX>)?5O#2'6_P!EQ[7_ -#T*=/PAKJ#RIE.]'&?]\_YF>']BM]
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M_NK1>W<.4;RKRRN^KT=58@A3^6DB]CJ]BO3T\N6G=1-[RBW!TF?K8@@:LTU
M)/9:RD^PM3D$=T,]G-<T_P '-V<TM/W=U&XZB%$WV"^\0CA^!:+5<4#[^-L
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MR;!2K95*B-UB+EC1NY:WV66V=I7:K(KM[TTE&ZB2B2=]I%\1J'Q:&QR-Q&+
M!0*,P\:Q$1<(.9HMQX$:-9=[6+08A;;V+1-LPK<T3JEV-_:;U++KKJ*7]D15
M*T.(L[5V L=9VAXH01[%BVM[2_6I?15\ER2IVMXK12^BCFSDM?2^^EU]>RKS
M(O+ PA-"]JF*&V-56US-1M8Q:VH*-+U%E;FMZ-J5$[VURKA=2Y"ZVJ55%UKZ
MVUN4OK<1<_)OORPYCS-DDPD5PMDY>D3F &!'LB!0F+EH(Q(&4]ME%%;6JF0V
M>070\*_W/8('$*CX(Y=*.#*ZP=F3:1<DY9NKMV3UZEJ=B??9MBQE"(JSVO;4
MLD0=[E3),4+6C)A'XA"J%H].)MM[QV4R6B=/Y'</YDD5!9-A 2-M8H]DSP>0
MCC81*1T6BX)(A;8@]8VX$:6N;6&WR70BW'R$%93$\6'!(O!J&<Y-C*=H"FPR
M$.S;B-I8FH_*3*8XL$97F(Z*PXCE1KD1[2'P]XL5/$R<=9M2 P0^>A"4A%M+
M":\6-[<4W];*E1W?QBK'RJ426VV&HI'3,]W/LP\<$%,3%G<PR#C_ '0!\4$C
M*9<YD4#'HHK*BLZ,2P];DAY%>XG"JPR/$SS18 O)H.GQ?&+HMB<+[\L*YEK(
M2,2QMD<()"8QEN9@$B/1Z$L&LVC<*2 ^JRZ--!DQ)R(<<%W3\"U4:S$-%+GR
MQUW0<X>MD"#BT19/4>O!8GDW%1VOQ=X_0<8[R66'HW/6[ _'XS 2H*2RI2"P
MJ=(PN/O;)NE4I,3 G*7<M@RU*SM-X^:$B[EC&A!<XFLBOS+V\\+ \$P;-D5P
ML?;K3>#Y@G]\5GT>&1661N/80Q'.YD^L)B;R*;)Z35<1\6)$,&LD1:/XH6)'
MPA5XT:-FA(GKZ^ME%6WQX]=8RW2S2.X1ERS_ &YXTR7DB\%(DH $&96$0"29
M=QH<7C)8)(I8N,'.9A@N7@'=TO"AC=!#<62;Q\FU=-F]9MJ!IK;X^ORIZZ:+
M!4>XA^(<,D,Q!#^W+(D;<G<EO# !MCYM )NZR])38/;BTD[4@_89'>IK3>/$
M,XPL&]<DG#6#KQ$6,&021FT0[01:(MZ[>%/7U]?E6S<RWL8U@LCP/#Q^$<W2
M:99P@8O(48B\7QJ-0.0D 15%1\0C/69LV"5BI!,A(T0))LA0@C%DK2;B1N!
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M)I;K4=V>.W%WX:ZYU#L#P4@Z$Z@X?8@VU6D_#DX?&V[*FRW!,]ES;+MTBD0
M^Z)W =Q.>HJ)JJWFTF'I=QQ^,Y&$@AJ?<S1"EZ0\>V356HJY4MO<+K*J9:BH
MD$SP!&1WH[Z&)QT:-[LWU.MKVM?9=+RPY48S0\I<5I8):'FH9HVL,F#X3+)9
MU-3N(=++0ND=KIW[B; :Z+=OQ6NTO[6SM^53N7^=;6$54@V;#?77F8N/^S;X
MNS9<V>6>/'^5P_\ (F"_J"]\5KM*^U<Z_E4[F/G7U/2I1L(A_N(O']IQ4=V>
M/?A,._(F"_\ 3T\5KM+^U<[?E4[E_G6U'29/O8>'\A%P_P!CCQ4]VF/?A</_
M ")@WZ@GBM=I7VKG7\JG<Q\Z^AJI#NV'S$/H)W9X\-I</'_DF"_J">*UVE?:
MN=?RJ=R_X_XUO\WN:D54HX1>9B\GN-NQ1W98]^$P[K_B3!?U#BGBM=I7VKG7
M\JG<O^/^-;_-[FG2I;[1>#F8K?U.S??M3NRQ[\)AWY$P7R?6'K<K5C+?#AQL
M)W);2XY!0NXUQB.4/LVV9P?,L_[DRP@>V#8VO(8Y[_22[(SI:)V.I=R1&J-R
M(JIMY;0:K<\3_H:MVU#C',2(0[Z6&WBAOJ3FRMR:VL+V'>@KVZ'E=6OPC'I:
MJ?"1B$+,-.&,?@V"MDE,E:(ZP1LZ"!*13$&2X.5C<Q  N-I_%:[2_*USK7_^
M5.Y?YU^?\O\ +TZQ]*D^]A\Q%U6^\^/M/!>+W9X]^$P[AK[28+P_\!LO/%:[
M2_M;.WY5.Y?YUOUY>_J>E27OEA/^XBW''W&Z=V>/?A,.X_X$P7CP^L%[XK7:
M5]JYU_*IW+_.OITJ7[V'S$6W$:,X\4[L\>_"X=^1,%_4$\5KM*^U<Z_E4[E_
MQ_QK?YO<TZ5)KWL.I)^HQ7UTMJW9.[/'OPN'?D3!?U!/%:[2OM7.OY5.Y?YU
M].ER]47F(M?_ .BCNRQW\)AWY$P7]03Q6NTK[5SK^53N7^=?3I4O5#IM](BZ
MK?>=7R!3W9X]K],P[7_])@O7?WAZW3Q6NTK[5SK^53N8^=?4=*D^]A\Q#U6M
M[C:R=V>/?A</_(F"_J"\\5KM*Y<NY<[>_P"NJW+\_P"=;4]*D^]A\Q#Z"'EI
MCVI,N'6U_P "8-^H+3."[$<#F-].?<,D'N;U\=PK V"9I&PENY;<*BLPD4TD
MV5!\B?7ED<FV%GEKYG&PR-C5Z\<-&G<EU[1!!5PYO5RNJ'B"-P$68R2 GF8M
M0 T@>XO:[B2+D$^._0U7*3%(N3&$8DPX<*NJQ7%*>:3VFP@YXJ>*A,#0TT7-
MCF^=< \,YP@V+B UK=S?%:[2_M7.WY5.Y?YUM8NE2<6PGPP1<./N-];+GN[/
M'OPN'_D3!?U!/%:[2OM7.OY5.Y?YU].E2?>P^8B'"W!G#@G=GCWX7#OR)@OZ
M@GBM=I7VKG7\JG<Q\Z^HZ5)][#M;ZA#MK_B=J=V>/?A</Z_XDP7?K^L$\5KM
M*^U<Z_E4[F/G7U/2I>J+S$7H=JCNRQ[\)AWY$P7L_P P[$\5KM*^U<Z_E4[E
M_G6_7E[_ #CI4GWL/F(NS7W&YLI[L\>_"X?^1,%_4/6Z>*UVE?:N=?RJ=R_S
MKZGI4GWL(X_4(=^OW"=V>/?A</ZOXDP7;J^L%JSDSANXS&;IMK\7AX;<>XPM
M)H[GISF9^SW ;DB89B5!@8>OC*PS*KLB.%8NJZ)NSUHQLD3&4/JIN$%$R%&5
MJ:&5M4XQ2DMASCF\GTJ$&V8YK-++GA>VV^G'VZ+E;6.P/')JBHPEN)12X4,.
M8_"<&9*]DL\[:[F8A1 2AL8BYTEKLC2#QL=IO%:[2OM7.OY5.Y?YUM8C52'[
M6'S$6OA[S@O$[L\>'\KAWY$P73_T">*UVE?:N=?RJ=S'SKZCI4MK6B\S%\F2
MUNQ1W9X]OSF'7Z_:3!?^GIXK7:5]JYU_*JW,?.OITJ6][17_ -!#Z"GNSQ[\
M+AWY$P7]03Q6NTK[5SK^53N7^=?3I4GWL/F(?0];)W9X]^%P_P#(F"_J">*U
MVE?:N=?RJ=R_SKZ=*D^]AX_R$7&W^);@$[L\>_"X?^1,%_4%YXK7:7]K9V_*
MIW+]/_S6_-RU/2I!>S81?_(1:>#O>P)W9X\=Y<./_DF"_J"]\5KM*^U<Z_E4
M[E_G7TZ7+U1>8B]!1W98[^$P[\B8+_T]/%:[2OM7.OY5.Y?YU]1TJ3[V':WU
M"+;P9%/=GCWX7#OR)@N_7]8;K2'>OP]MML 5VBVQUMEVE)OO:P; #U#&XC/<
MAI=') WF%Y.P9W\R._[R%KJL4*-) ([B.#J56M8$&]JZU%,\%3(>>N(]('D6
MAA!NW+:YR:V\O405TO)OE3C%4,?YY]">C\FL4J8LN$X7%]-C-/E+^:HX^=80
MYP=#+GADN.<C>!9;N^*UVE?:N=?RJ=R]/P=&5N7+WM8352'[6'S$7EU8N:[L
M\>&TF'#JM@F"BW@M0?L7OBM=I?VKG;\JG<O\ZV@JI1]K#YB+T>&PX *.[/'O
MPF'?D3!?^GIXK7:5]JYU_*IW+_.MITJ7JB\/,Q7T((UR=BGNSQ[\)AP[/:3!
M?U#JT3Q6NTK[5SK^53N7Z/\ YK?GU'2I/O8?!S$7H>O"R=V>/?A</_(F"_J"
M>*UVE?:N=?RJ=R_SKZ=*EZHM[_4(M]?\3M3NSQX?RF'>'VDP6_#_ ##L]=$\
M5KM*^U<Z_E4[E^C_ .:WY^>I%5*/M8>WZ1%KX>\4=V>/?A,._(F"_P#3T\5K
MM*^U<Z_E4[E_G7TZ5+M:&VG\A%P_V.SU"GNSQ[?G,._(F"\?_ )XK7:5]JYU
M_*IW+_.OITJ7;+#;JYB*WDR63NSQZ]^=PZ_7[28+?^P)XK7:5]JYU_*IW,?.
MOJ.E2\1$?]Q%VZ^XWUW3NSQ[\+AWY$P7]06H^Z_9!@7 939_.\=H9/3D-=^.
MUD)6Z69RS-D 5W 0G%ZKFE $YG<A"4==FS1[2^H/[M;6]LM;KIVK*TOSPU#W
M\\'".QIY_<QQL/U,C=K0=+[7LO?P'E%BF)LY04U6^D=".2^-R6APW#J5^9E.
MVWTVEI89<O?&[<^4FQ() ([E4ZJ<O8IK07S9>Z(FB)HB:(M>,!_5G<5]T1)?
M=_WA8W_7W.K1%!QI]<%N:]_#/Q(?:(MC=$31%Y2ZE>?*O5U]?E]_1+\/7U[%
MJ_),"F3>[_%^Y)$\-0!0+!N3L3O8VHW<W%GY&>RZ!R-F5;.K?Z$39,$(@X;N
M4E?V]15VA<ESLL4Y91):%\5O=21OOU9 YI'C#SXP%[$6*,BP&MP?FGF2KQ*A
MKA,'-R,9205D3HRTC,7/=4M(<#8!I!%R"-H.=.KG3KI3\->FE/P^36)>/_?X
MNM>Z(FB)HB:(FB)HB:(FB)HB:(FB)S_7\?\ V:(M8+L"F+MYJ>Y[O\-[PV;9
M5,$5C/<[GOO4LIE-'('?WNKH9][J,T^X*M_]<]T_ME*52UEYWZ1S-OY7G2?
MS( /*2>O3J7L'$X^Y\8-S3^=&,G%.?S-YLQFA%)S.2V?.'#G,U\N73?4;/=E
M3GV//I]C^76+^_;Y]EXZ]T1-$31$T1-$31%\*6]G9?;2O[ZVMOX:TT4:$^ [
M;=A/Q[ZA:R;-<#F=LNVK%F#I =&R8QC\26'/3@ALY:#B%Y&3G#J:C5N\_HE.
MU-$JFWOHK3G<JE??;6MMUNLLT@ED=(T%H=;0FY%@!\R]GE!BC<9QFNQ1D3H&
M5;XWB)[FN<S)!%#8N;WIN8RX6M8. L++9[6)>.FB)HB:(O*UY4K7V*>QS_DT
M1::2G?-AJ(Y-*X>+MI@CD(3)F\6N!V"A/9/"!$KAP<!49NUSR#&K22-<V1X^
M&7=N6ERD?C<_?NTV:T2>-%<HA>YI> "T &XN=+.)X;MRD.&I&AV-U[</)_$9
MZ..OCY@TLD1FYWG"<K&MKB^[ TR$QOH)8'EK"!/)3LO]/C)J[/?3M.)I#.\^
M;H>8=&RZP$.P8K/.[2)>Q,%>T030<LT*-6AFZ519&/&2%S,%(5Y/'4@Q)[<:
M'=T08I 0"QPN=R+@;[D:: $D;V!L%5W)_&8P\RX?/&(V!\CGAK6L&:=KKW=<
MN8ZFJ!)& 98^9DSL;D*JU-V^)UMMI/=*,ODA_&P2)N9632C8!T=/)ICFB:IH
M6T;,+E!I!Y'7MSD5(B+(HM&@1$4;L+'6;8(6<LPC<9!'L20 7:#6^4GB+\-+
MG@"=%C&"UYQ:+!7,CAKIIV0,942-A9FD(YISW.U8V5KFR1@@/D8^-S&N$C;[
M,MUJ+HIK6TNMHI9;?2EW+G2EUM+J4KRK6G.E*\J\NCGSY='*NL?K^WQKRM>.
MA!((ZB#8]2C:(FB)HB:(G/\ EZ-$O;^XGY$K['/E6O5^OET1:OQ+ YB.[M,P
M;AUSPUP#R1B+$N.!\=2;.;"@U]CH[D L]).W-W-HJT(I3%JBU21_;4[V2]RO
M*E]E*Y"\&)D>75KWNS7WS!HM;_97L3XHV; L/P?FGM=15]?6&8N!8]M9'2M:
MP 7<',-.[,2<K@18=>T'.GLZQKQTT1-$31%\*75MLNNMMNOK2E:TMMK;2M:T
MI6O+G=6EM.?+ESK7ESK3GRISKHA]?6Q6B,?XB^W,Z0=#5W\FCKH$@R<SI*0B
MAS*[':+N*/)$O66T;&7MU5QI=$=CMZRCELA?W9%D<?CC!J_3>K$&N4P2C+=M
MLWN1<7<2X-L#L#>][D;$WMOT<O)7%XHV2\W%*V4O%/S+W.=4ADHCS0L+ _(Z
M+-5A\HB:VDC?-(8[!INH]OXVJ!V*+UGEV,2"]6V)N%&@IZDE>R'2J4@HOW<3
M>E[A8H4I'?5 VD,K"D2#:2 XLS(F5PMR+>EJD"&4FV1VMP#E)UN1I8&^HL+7
MU[%@BY-XU+*(^A2L)=.P9QJY]/#-*]C&MS/>'F%T,;V-=&^>T+7F0Y5DJ=;B
MH;!6&'33D3)S,>S7-(C!8P<%MPC!,>8G;AFWBUY<'*ST9E[A C5W>[7;1F-R
M0R)$CRYTR('A!!$BVJ&$YA< M!<0;W(&]K ZCMLM.GPVHJ7UL;711S4%/4U,
MT4A>264C7.G:U\4<D37,#':RR1,<ZS&N,CFL.?:5I6E*TZJTYT]ZNJ_$O/W3
M1$T1-$31$T1>5K2E>7/IT1:Q[F,$&,Z7[>[PYT:$\#6YG%^=BE"+=RX[\B($
MC(4G@)AW-T($G]3256KAQ_0J=$%*+5IV5NLD<@CYRX)SQ.C%N!=;7M  .@U*
M]G!\49A@Q7/$^7VQP:NPMF5P;S4E68LLKLP-VLYLYF@9C?39;.4K2O5K&O&7
MNB)HB:(FB)HB:(FB+SG3GRY]/Z]?L=?ET2ZUEW.X)+YY'819ASHX%=BO<KAK
M.1!0BW<N+2@G&)UP6?A&=&W2D0)6*VI-%UOZ&2OMK<M^QKK+%((\]Q?/&^,:
MVMGL"?$+^->S@V*,PMV).?$^;IV#XAAC QS6<V^MC;&V5V8&[([$N:VSG#W)
M"V:I6E*<N?52G/GT:Q+QK^IT^5>6W6W<^QKSY5Y5Z*TY5_#31%]:(FB)HBUW
MP']6=Q?W1$E^(>-]$4+&GUP6YKW\,_$A]HBV-T1-$7%@DIQ*\?#,@',38[G4
MO./)H;;) <H9*QR=&$ED\F9DD(B4PYH;G!-0)CAUCFN*(.^CB1N"E+7KRA$3
M'Q2H<V9*;=Z=V0.>P"Q<2T/N.]8 UQR$W+P_W(< -;\!WS!R/JI::.MJJ>FB
M;2PN=+0T55'(UPH\/AEIZAS((Q+6"K;7U3)G1U$3VED;I@V41LW@PG,]R,W"
M9J?FFT80?12>'<>8E6D@<J!"39A$SA.]7)!6C%M0LBP/#BHR,JLAJ-[!$_"3
M9$.JZ$&&CB[ YK&Y-3<MS/L02TN'>CJO:SC<_; $"Q"YO$:?"H)*!L+ZC)-2
MQ55:&/CFDIWS,;>DC!+&$Q%CY&R.<'F*HC;(&R1N"TES[&M]LB=YF;87C6?H
MQ1;+8%6(JVY.@2PHV!$P/)]CV5Q-V9RN/*1,!),I'84QI#;TQ(2*0R'Q29EH
M+D=R_P @8V*9HS  PN<QUV$GO7Z.);8$9""<MQ<7N[[8  CH,+EY,PC#_;&3
M#J@"BF-2&TE0)8I7U5)DIYBVB+)I8:.&9[96ND=-43RTXJJ-ABJH.SB';*H(
MU5MI8KVI/MEE+JWTM4["G9VTNK;96ZE+N=*75LMK6G*M;;:UY4UCN;=:X73@
M21P)&4GM+;FU^JYMUG=1=0B:(FB)HB:(FB)HB:(FB)HBY>YI'[SQ>=\E2["T
M8R,?%#VMA&+(O<C0YCBN1QA+!9H1ZC D0D<F?VCLA7YS<QF3(2%Y!Q3/O($.
MMW\M79$$ 13,SFRT!SF@WL18Y@2YISDAMLN4$6N3<>YUNNMP]W)]^'4T6(/I
M62O>8Y2*:K-;!+[8P2BI?-#$&/I#AK:FF,;9I)!+-&YE.'-,K;TVQ9%WC2G(
M3&'YZC@D T XR'R^>O&(EC8DRGIEWZEA&-F182]+1XG?1A&RV62Q(&8?*LD9
MI'H^Y1'MT$VUZ5D60ECB"7D-;<$\W8$.OH1U6+;DWL2!=8,8I<!AIW38742S
MNDK7P4X<]P:ZFC9S[ZLLDC9,UN>9E#&R4!SC323EQ+PT90#P3,AK<'!I=-'I
M8$#B.-SCV76PK(DS\%TXG)TT0!1./,X 2.VL:HPV(MR4BDA4K%FK@E(SL/J-
M+/$@+YJC6[0P@!MR0 2TY@!K?-MJ3:VNE]!HM%T]#'A=33Q!DD]15PB(S4T
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MFH#:96;LI@)<CACC(LH0(O1 XD(6#C :(L@/O70?6O:T<V-KXPTY@0PNOUN
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M"Y;O6,YPB13+47+1;&,F3DOJECR<6'NVHHXXP7MH.1ZBQ'P@G'44%CL@79S
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M7OXRT'VPU<BZ%EGI&-%S3]TP:VNCKAF*$F99W41=-TR-EC:X)7\YSA;;*UP
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M@HWF*E.05#()R6-:VHKC&Z1LC8F<VRMJII3E;,8G999'1P1-CZ*X=/X[)P8
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MBVG\HL8E>Q\U7SQ9,V=@FAIY6MG;SUI\LD3F\]>>5QEMG+G EQR,RW-(MG^
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M\,;\V9H*OAKM=PTQBYJ'L(Z2'!CU\/6>=[9;+1Y)!W 98YG,/?BC3,T@8#$
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M"R (0F[<I(WD3+IL\>MAK2VZZE57B[1@]<)(6_L[TFJ]]M*T3NY%"IAB=PL
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M.84*')&RJ)H^$&%1A:'A3$\C_JY%JP0],EKP)0SC:6LQ8UX@RFEZ0_OH^B;
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MFB)HBUXP']6=Q7/SAY+\0L;\OY-$4'&GUP6YKW\,_$A]HBV-T1-$31%B')&
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']U]]Q%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g105292g01b28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g01b28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '*:^<S0X0DE-!"4      !                      .$))300Z
M  $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $( <@!O '0 : !E '(
M( !- $8 0P M $P ,@ W #4 , !$ %< ( !S &4 <@!I &4 <P      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     [\   =D          $                          0
M   '9    [\                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   [\     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   ._     %)G
M:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MH=/ZAU$]1PP<S((.12"#=81K8P$$%ZW/_&NZ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<H6&D[+70T5(8G2"A)BEIBECB**UPL3&:'.#HZ>HQ?_$ !T! 0 " P$! 0$
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MGYQQ7SX?3#_*AUW2NP=NNST'8]]WF;W:]==E:8GWEP/Q9GXQ7?OQA]A[H/\
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M0FC.+\9IRB*:=00]B.A2H$IC#GZ6KAIM*+:4&VL!M&;,$L2Y2$J.(ERE!2E
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M.CR<5B\&O:<I&)P(Q9Q$M<O$)W?$91G8Q,M2I(1B)F'E)5,F2\.J;," 5!)
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MKPV7QU(V<SE?LF)5X?HLD4X^I=#UKNZ--=_5LV4U<%^M9/\ DG^<J//]%OV
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M)AA6*=3W71*D ->8+AM-)%5!G/ @W[FH]:$B]];BV4[!8I14R2I'C&(7N!2
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MO0O(\IQP@,I"98SM,*AR'7 2;+N6UE7%<+>(-]&4%HR:3FA4K1Q'%H=+-FE
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MT]G\/.X--572QS[O#Z].EH_OBVO^73SZ5P]',_\ 8ARN_P#NJ9>^G^YUY[_
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M)R_:3Y;OP5M?Y!AX]C/E,[\8KVP^OCIA^$FV/RZ=\Z'T+;DY?M)\MWX*VO\
M(,/'L9\IG?C%>V'U\=,/PDVQ^73OG0^A;<G+]I/EN_!6U_D&'CV,^4SOQBO;
M#Z^.F'X2;8_+IWSH?0MN3E^TGRW?@K:_R##Q[&?*9WXQ7MA]?'3#\)-L?ET[
MYT/H6W)R_:3Y;OP5M?Y!AX]C/E,[\8KVP^OCIA^$FV/RZ=\Z'T+;DY?M)\MW
MX*VO\@P\>QGRF=^,5[8?7QTP_"3;'Y=.^=#Z%MR<OVD^6[\%;7^08>/8SY3.
M_&*]L/KXZ8?A)MC\NG?.A]"VY.7[2?+=^"MK_(,/'L9\IG?C%>V'U\=,/PDV
MQ^73OG0^A;<G+]I/EN_!6U_D&'CV,^4SOQBO;#Z^.F'X2;8_+IWSH?0MN3E^
MTGRW?@K:_P @P\>QGRF=^,5[8?7QTP_"3;'Y=.^=#Z%MR<OVD^6[\%;7^08>
M/8SY3._&*]L/KXZ8?A)MC\NG?.A]"VY.7[2?+=^"MK_(,/'L9\IG?C%>V'U\
M=,/PDVQ^73OG0^A;<G+]I/EN_!6U_D&'CV,^4SOQBO;#Z^.F'X2;8_+IWSH?
M0MN3E^TGRW?@K:_R##Q[&?*9WXQ7MA]?'3#\)-L?ET[YT/H6W)R_:3Y;OP5M
M?Y!AX]C/E,[\8KVP^OCIA^$FV/RZ=\Z'T+;DY?M)\MWX*VO\@P\>QGRF=^,5
M[8?7QTP_"3;'Y=.^=#Z%MR<OVD^6[\%;7^08>/8SY3._&*]L/KXZ8?A)MC\N
MG?.A]"VY.7[2?+=^"MK_ "##Q[&?*9WXQ7MA]?'3#\)-L?ET[YT;00]!D.Y?
M&F,Q(/C1F12S3"P<< [98J$1;R**N*!<D4/*HA!/"! N/&BR<0 ',5L[8($4
M+V775H';2E$R;,FJWYJU+4P&\HDEA8.='CB;1VIM':V(&*VGC<1CL2):90GX
MJ:J;,$I!4I*-]1)W4E:B!8%1UCQ"<N=^V23+_:U$GA_6N:FGB_'C=P[^"',W
MLSU;Z<^$5R?@#F8Y$^.NS7CI373P5ITTIMV]6+NH5;)RS\P=":4XQ;$--FWQ
M4Z]FNM-_M;?!3$O6G6>%68V\].9A#?T;_;KKI3P;./EIMKA;6WF!#GG7+L-!
M"%::Z:<=WX^&NF_3Q[<'9WRO]&;/9^JD(;.GQ>[T[?>Z]F%=.OT:4]?"L(>/
M;K77SW;>G7X:NJC!N]Z:-[ B/AIQWUIIOZ:>"G3KOVUQ'(Y6!>VAYG1K4$(A
MY[>.NFN_93=U;-]:XGZ;9,[6J;\:V A#?[]/!QTV>[OUW:X6]1YY/7T6:[0A
MO\?EK7SKX^.%NKS#N.K*$*;*\*Z[./@X=.OAV>4:ZAJY<\]&Y5[$=">2E_;!
MLMG]L#S]J+'WXMF*YWW)=,N&H]/Z8KF_<U=7\X1[AL:/%SPT-7<@4%#4EKO1
MHH' GAQ<NY X&I+7>A9V)S8"I(>A/74V'.AHQ<1.; 5)#T)ZZFPYT-&+B'1Y
M^7R^UB*NP%!F"S@"@YA\R'ZXBKL!09@LX H.8?,A^N-;LVTIO:&('<;]CD-K
M7O8)XPNS4"][)*LO-8H/*DX1Q%)I35T9"<+35E0))3GL<5"Y(DXT>\P=)E@Q
M#EH%1;+Y8%P1UN^=B37J<MPI$D/1KT<%RU34D:BU6['U&;^?=WMMUNMDS*W&
MH7.Q 8S+H\@/%F<SH; D%6@]I08^4;O*59&EE($C-04T2;45*5D%Z7/%$HZK
M3*0'(B7:F"#GS5]3"Q)<'5ZYL]=&-?T$:J+@T-"VI%2= +:3^5)3%-SE725B
M)^WP6DQ$O/&5C?<3-#D"&W"TYX7(:=2L[2AB2@2+B9:11'M6+2D<D'@YC"8.
M*K6%Q! N9+!#YWJ*L_76U[:9"!KG>H8FK6K6SO;3(1..OE7F ,F2?;$43ON0
MUMB*) NWQC"K'R4VWPG@9@&#E]="@5-!/8XMM,8DXGXGJ352I#16<=>J53G)
M,H EEED^D&N+5R-J<F%&IE=W:);*@KD32G8'#!LKW:,NI.=Q:%D20HMOA*1W
M;)Z5+"JRFI$K5+Q8CN=-:S2@F"I9>CE=+U<DY5C97(IAN:FZ3*J*>N-P^9-N
MIOM@LTCPB.N.TPJ,Z5=QJ;^NS$7:(#ZTJ[ALS6U^!#,"[4CH+2M:TI6M*VUK
M2E:VUTK6E>BM;:W6UK3=7L;JTZ*UIMPS%LW;7AQJ;OG31I87=M?:'.N=-(U]
MKCYZ;?!YU<S2Q;-[<<[/GI=E4N+%GSLS5KH[,>UB!H^;7(+@,]ZNW6_"(&CY
MM<@N SWJ[=;\(KK8_5"B_P!D2O\ C;<"*&OWO"H9QP:XL#RSA7P7X#K#TTH*
MY ^OSB<OC;;=FRBWLJ4K_0[M_36E*_NDRCT]5:^WC[+[FH!V-C:#]DYEP_\
M<N$C^;WU8A(]T7HZQ(?H5A+%J^_FWLLV%KQQ&!#LK=2E0[:Z4W=C;IPUKNK3
M3?T8]XN@I2O7RRX1^5)))UN;G@.=G-VKYZL &'I7\Y9L_P#-MZ^&GN^YBD^D
M<>/>GI>.A()<WH!0VS]3,.<5TH$%I;6H8>G8Z;0[:;:[==VFW=3;PV4TQ2OX
M7?3S<BVKU:.K( 9-!<W%Q4N;UK2*\ "#6VS^=!5V5_\ !V\-:='5C6)-0Y/:
M1],=66E-]T6%P']9'>MXK98$&NE.TA4W_P#@[.%=>CCX/%LQ6MQ5S6]>_'7T
M1O(0DFJ4@C)A:HTXCM,7(3!![+^E!]']+MK3;2G5L\/BQ4HEC4V/HCIR4(8'
M<3=/WHX<'BZR@ %-/YR#39OH'9K7=IM['Q?CIKC6436I+-1SK4T-.=[Y1TT(
M2 &2D4%@+$$O0/2Y[O<A4$+6G\[#I6EM=O86Z[]*\*:^'R[\5K)!NU,B=3ZH
MW):$E0=(-10@5RMW\\7(4""TI_.P]_UEO3IT<-W@X8UG)HY-#Z[][6C?EI2Y
M\E-M!J.$7&4"#TI_.P^']3;T>#9C&-M"4L[!WH6#Y=D5X ,/78'932E-M+:;
M*:UW4I3=IPV=/AP4_$7+OH0* '2M6UN\;*4C=%!4:<32V79%>*!AZ_TNSA_4
M6_7>#!= ]B]Q0FA^G6F<;02D-Y(IP'HBX"X0>G]+#W?66]75OV[_  ].*E$L
M3FQ]$;*4IHZ1\).0/IOSX15[ @M*U[6'KKO["W7=3JQ@<B"?AMZCG9P?HSL0
M!H+#(9N=.,3X80>W^=V<*?I+?@\],0"=U1J=*E[5Y-]&D7H 8^2#4484XVT]
M'&)^P(/6G\[LX_U%NSVNC3R[MNN)KOD%VX.UN=/;VQGNI-TISR&K^Q]3$T&&
M'_P8>S_S;?)KIN\?3C $N*_?<> ]%NN! 8T%M /9&2HRDEV1&[DUZ,E0JG*Y
M"O8#!W6W7$%4@)=9<:25<I9>%0ZFFZ!V=M NNMO#$#!-%12YPL6, Z^+PLG&
M25X?$)"T*J"&"T+KNK06.ZM+FX/WP(()!ZNP]N[2Z.;2D[4V7/\ !8F0X4"'
MDXB2H@S,-B):2!-D30D;Z%$%*DIF2U(FHES$^@^ Y\:,^- ->0K[4]=(6@@.
MEK#C6B'T(_?;72M+NQ#J<2C=;!+TQ3#"L#,AVW@BV%SQ<V4+_-MI;-G[-GF5
M-&]+4YDS@"$S$ ]>ZL4WT.2DFY203^Q^A_3#9O3#9HQ>$(DXN2$HVAL]:@9V
M$G$&H+)\+AYA"C(Q"4A*P%(4$3I<V4C.N.='KH80AA"&$(80AA"&$(80AA"&
M$(80AA"&$(80CG9F8D_. S<R67J+8<>^7)%9&8-3?2 GWR1"LD/5T-%0C>,5
MN15E0.*K:GZ/TI=)K_,U4I-( H*.,C=T4-FCZQVKN<3( ,27HV>O48R #$EZ
M-GKU&+!OY5R,Q 2HR=!DZ*ECW,-D2!:@>A,5MS -]S9@&QEK+N9F"*,HDPVF
MG%)%>K1,&"DKW,%7N:KC35P%/$OL4B*<W>(XWI0FM.$0W$<;TH36G V>,6/W
ME1G-:>45)BL TWD%OQL='>S8>K82'%(,>2ZU<ZC4RI2$WG  AS"W&<O(+;,&
MU^VPRT7@I7'1[TUS)!Y?( WMXZW7;4D]C O;CZ*7B=UV&9?E0 C)ZO\ HC*#
MBY6>'F2EOAP/R(9I9S<0BLD"1ZNJ=(K,DIG/15F1;&5%VIC.M3)..CMD8&8W
MPS4PF;E(-A)XR"N7.4R;)I26J"E@23F,M<P^FD DEK>QP^FFCG*[16)"Y0>B
MQR?\MYP(6;5[?<4?* [9M;LJ(G?4FI3E3'^WF>K#F 8P=PY)^M^I!:HNH*@P
MGJ9++Y48D&7.@GZ'$XN J!K6F='H[<N!B '+"O(MQN;=<:R('*D3XQ1$IP3=
M 2H[(Q1XUS62:[7E&$>K43+JY%$!/> 4A*S#),7YBY$:[T:S"%09)>P"LP!:
M/1_+JLB(ZRTJFF\;K<*89'3C4@T<7YT$2PR.G&I!HXOSH(V'D#E8X98#VGMA
MWQE*CM5()3;5<RI,@S&+C;CK3$^36'%#V/ +I20NXF67B]QR,W#\EUD:YIB,
MUMV+2LL!%Q410) MTEJBM,\P^GHX1#$MQ+9W-LL^#\8N)A<J3!,C9AVIEW;C
M8>YY7<QINMX=ZI:G&+E9R"^G)$A29RC9.5:<AKKA6$8!J'T]/'E%IH3@B<=T
MJ)!&3GJ>#,4/VP4D>S-G9V/?SP(;OQ9^W*_"+^F&>IIC?-W D7I)^(%Z*92*
M/-3>#/O;[I+RJP(YCY@N=>>4]."1A7J QD!C(S]OC&.2+=46$8,+JB^:C@.T
MF*2'+%0%#?0<3HS:/G"C&[Y:<K<\XF<L.?N)LS<:3%*"<@NR/46#3H]'P$ZQ
MFBO!7MZC&3I&(O)MKD;N=[-QS-E4:RAW41.)*L8%'')&[0 !BEZ>=/B"&%"]
MO1G:!#,+OIV=L:7C\K]5IG)=>TD0&^VU&R*P\M#SB*/C"O#I*<WFA32V9[?:
MP\>;AII--M8(V,V*DI13V,DFRTA-^[GP9R(E$L RJ).6[9B*ORH6I2)W;,1<
MC-LFRXWM&6 .5&3BC9S&R$M06[[X]B66([C>+E1+>T2$EJ::R-$<:RTCED!
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MZ,C472@YI,(OMI*AUIM-KFNT.=P]KK>66RXG:1S+.+DQ=2ZJ*HA]IO.4%I>
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M" 'W>)U!R8&(WQ5P0Q8DAF=KUT()T%;",1J,#R6FRRU8,&1BXDJNY18B&GM
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MS)D+34DF$YET;(2F0?)I82&VVE%6'=Y]$N;Z0:'+(0*JL7&$_+P9W@7#!16
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M "GQG(])[.CH&%0)+M=;#!>M5<601&C<1J*X5Q"YMH1L9;EH9I;1&H:[KJ;
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MGWQ-ODH_YC3V\(M3]45-5_>BB[?LZK_I''Z8GP^5Z-WUT] $M3I^J>+73_Y
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MF;I5:4KU&\@KA0D0CL@X&D<60[S35*M4Z,V@P1$8\:*87X@^9N;U>N1?A9H
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MUP@(_E!Z58R5&)R.D-3.E$T1\2&V00;WDL+',N^A<6UM>L/)''M&1I;5LR_
M1DG+RD<IVNYN([<DU&Y*BR*2R,P3RC'0HC0E*-:L._+FD NIC/*0$Y_(UYJ5
M$Z>!UT=3>Y:-SKC4UA)2ADE2OC18.$24'=;4UK49THS6RRYP+-K>M07>F6F7
M.QC*V99@.=:S]P9(+2R=.9Q%(A05R1ALP;*08K2UB29A4V ^(KCF*WE(JRZ$
M1]-V(&.U7NZEYVF2Z8X@%)R*K,*E$88@VUNTX#,7-\NPNVN0=N<0+$/?*O/D
M]!YXFN3^#SY$8:S')L]%WM;(@MJ6Y8"NF,$G?8F+3ABDESHSA50.0I'6UAMM
M&6DQ2(CJ2\M$!U0F8O749"0FXLHZ22%J,>!OEG76!:C=?MZ],HYH4BKE+DY)
ME)S,%C9NT:49:9.5Q&>,KR [XW5I)3)/C&-<SZ@]"C:;S'E5FMM4BY2EQU,M
M 2 QW"E,EJDW$5<IMKKS/3ADJDTX4>E<VX'CJ1:AME2EF!.1X#0FM3FW#+-E
M[ S\M]KYC32$R\SI.5<Q<LP%(2B]$=V(QAN1XT5/+/& 3Y5&:RDF56 H&WRB
M3@TUF+UYCA.=I)B6R3:*NF%52:[<&*JL4I:G.M<Z9WMJ*4:''D\!6]3O'S,7
ML^4=L\JQV75#+/ !O, 3/$)T%AV.K9C*J0*6 ?#DX)J)8+YN-A(=XB):.,Y0
MU(83F>[FJZHG9IUMA2X&RV"SEK/3E$%G+6>G*,^8B(AA"&$(80CP7\N=^V23
M+_:U$F_JBYJ;*=?XL=##_<QS-N)N:\+D!FC;D_ ',QR)\.NM->NFSAQ]K9IX
M:UI=R9BW USR\]7?0 VQ#9LV]&O5T^?1B:UIJW'3OK"'"NE?#MI3KV4KMZ-O
MBTPS#CE0GA4BFM.MX0X[O%3;\/OZX97ZS3V>IH1'P:UK3;6NNNFW;L\-===:
M]/3B.; &@#,]*5Y!F8::0B&W?XOQ;>CVMG5B:6Z_IIKYZ\80X5Z_)OI6NG7N
M\7BPS'#ML0'X7Z^N$.-=N_9OZ>FNZOY=<,A2U;:<+C]#0AMIMT\'AIQVTU]S
M;X,*&C\^1RH6]-.<(=.FNG7QW;^&S7SV8:.S\,KVSJW>L(=/'S^#JKX,-,N_
MMXCG".A7)2_M@V6O9M[X7II7_!8^MFW9\'CV5SON:VT%*7*A7O0]5:YOW-75
M_.$>X7R?D\Z8T6=@YLY-C2V1%*7+YTJ]#.P<V<FQI;(BE+E\Z5=[>)-;Z9T)
MRM0U-P2!:)-;Z9T)RM0U-P2!:-"GCDT=2FSI1;K&FL9BJ<I9HE/,2O'RS;=A
M1/6D-6:Z:V#D4NZD?2M&CV64*E4M.7:JR%(#2%/J2*BIBLFGVQ:L(:R&519N
M;&_GMU/ 9,19N;9W/'M8Q@J,>3+<\8UBU&(SX@++,9"GE\=+F(JL,FA'BY'7
MEX@W^9_;MK>>(<L6%&BREEFER*PH-)0:SP&3G9<N**.NE"#@,IA<3YQ0CL'&
MCCMX/ YV!(+$-F> '"VKU:*TR.3A<C%B:0('3IS;QV+YDR^-6&I4'4X;-&9(
M%<+/RLHN5U+=D=O(.5BZ4SVR(DME!>0K"<#1?8A96JZ4U.=A,L[!3:6<]A>Y
MMFYK:HZJ5#1#T):H.M@:G(O5P<J4#M$X;R 2TM+#F?:SF?3T.6'6^Y$?!A[1
MI#BBS0&T:>V35*REI%[.2E:8'>I)2RTQ&\@R&67#3D/W'S()]%+DD88T37DV
M+FVC@N!<&M+N2SY5-#4U@ ]*N[?"?XHY!\B2U8NW+%D-5($E6V6'+*B7("G:
M)/!L-,*LIWIX9)3G8KE;#4#1-QR',$O/(>]"%RXJ=+32VXEE76RT@F C2F4H
MABT7)K[#>]'L-3H&%*.(GAU@WJ3>PU-;,'#UBG3_ )2)/GK,ZZ57OA;S-@9U
MP9EN:3T5C#6 =3V<JS$&826)>,-E@'[7TATCA4+6J34O.O)=9+X(CE%S1NEB
M2^A"&P#V%R" :\P_'EUY0)L!4BG 9.=3<M>A+L\6VT^3J>R9(Z](KUS(FY!4
M5AX0&XJFUEE.\TX3A" ,SQC,8WRJTK.6:'8E!*2J75%A@"V,9ML)C("?<E*S
M<CY/[D4TI:<19R>=.%>;@E^0,!J #4GM#/2K\P2_;&=\M.3P'+LKL55!?83G
MJSLLK(RZF 0FC8WJK5[-?CT>]KR%%M<*O4M<?%>1DE:@WV'*D[P1SU%HQ<?$
M+!*D<./807&M7;@6A4@V:IT%F(+CA=JLQ #1NKY^?G^-KF&.8XO<6)U-PS-#
M7,,<QQ>XL3J;AF:*ZV/U0HO]D2O^-M]W=B#\$OVT#Y=>0J ]QE$*^">8?+].
ME6U&4>=?E]OV34/?W"B?'^$![ZZ=/73C3=MQ]C]S3]BMH?QA_P#C28_G)]61
M^WOHM_Y33G5AMC:3MKQ&G%HX:@UVTK7;72GO>/?ICWJ[=[^QGC\ERBVESZ U
M@8JX&RFO@X]=?;KQVT\7"HZ4MEQ''N[Y1TI!\H\A:N? W/$AJ<!%?*\-*4U[
M'?OUZ^&SP5X5XXJ7?7AIPY_1'6D-NIK]\6Y%Z9]R:LQBN%]U/#7JX>#SWZXU
M#GE4\&CJRK=28KA;A3HUZ.G=3WJUV\=NS&"K9:::>L6T;2-^6*@6;L[UH3YW
M>+D)[+MG3[6GN4IKIUXI58\CZ(Z<FPT=/JX=]!%UE=U/#3KZ//3=X<:JK\&/
M.RG]5QGS?IH^#U6K;=/=CJP+1<977\[7HILKOUZ_+TTX8Q7<<O68VY?PT\QZ
M#WM%RE>'A]^W&MEW_P /7OE>.@B_7ZE=[_1<93=3\>S\[Y/)X\8QM(MU^R*X
M7T[*NO5MWZ4\>NOGOQ@0"[O95=&I9^%=7MIMHM7,&W$$Z#LI=JAXKY3?Y/\
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MYF<\!PM<MG!I1AE6N08DUMRL"YK?(JCDER]+&8!UYG"*R$2?+VO3AUD4-L0
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MDS9ZY^*5X.7.E8@S$3)R@5M+)4G<'-AJ9;YQ';;:D9V9&GC4XHS1F0D"6LM
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M?$6B;LY1;):+_2YY;MW@0WG[[:IC$]&]MB^ F?C)'];%R?=A]S57P>E>"/\
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M!PYJ(W]F]..BFV,9*V?L[;6&Q&,G!1DR-S$25S=P%2DRS/DRDJ6$@J"$J*R
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MT$;EE]&L=\AL!"/-7O6D012#>CTBX@IO!M-&T[8EB*"F1)#A!'K$NP2E@H@
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MN5X>G;<^]E2^=>$(=RO#T[;GWLJ7SKPA%8(6*(8-;5,R3-F.V75M%(DAB -
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M?DV08K.-P ++#LRU.&#VSEP06G*=KS0E-7$=YN0P'.F$D9CF6^B6*0*\623
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MJTV;,7.!9F&;AN.?MN#K%L0[6)_P=]/_ %;O;V>YY,3O#4'K'M]/;"':Q/\
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MH:HRHW>C:BD(Z$\E,'?3E!LME:V74IWP/3;V-=*?4M?=-M:4_+OXXJFD&4H
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M..[6O1QQ=NH(<(3_ "1[&?*[#7*+-Q'Q4_R1[(?S8>;C9_139C>OZM\F]?\
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M;.MP*UJ7&7HU8R;,!1ZLX%:U+C+N[5="4E$XLIA0X?.FRIHX 7,EC!H<<N8
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M+K>2TV'*XG*,$9RU# VKIYQ,MIKX*L$&&>35IO)*HECD3I,(:TU/N1R%%(%
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M:VCMI%5W&X51/0V^WTL^MKBTK&P""6CHZ44&/J:HI'S5X18DGIY( <V<-F!
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M+,,W L>L/>$;5N_)WF&;KG9#(M;1EU+T@1 ASP33D50#&L26LJVB%%FYT#J
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M.;9/6[N2#0$$7C'*EGMB$-VI" WJBNU#<R#EI6VF]$=0)A(3AKF7FA_0V@D
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MEH*8?OUO1+[J%#-]47M(B/XK;FQ!-"L9@T_;JJGR4AA-#EYLL-]TS6FGA&)
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M$)F3!XKNIQ/92E*6TI;;2E+:4I2E*4I2E*4II2E*4V4I2FRE*;*4QXB/TJ
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M, 3Y5P2?)34@.]M8&;,^-D,AF!PA]"TR):4^H@/OK^ZM-75_"-B!.FD!U74
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I"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g105292g02i16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g02i16.jpg
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M 0$! 0'_P  1" #W ET# 1$  A$! Q$!_\0 'P !  $$ P$! 0
M  <%!@@* P0) @$+_\0 ;A   00" 0$!"0<*# X0!0,%!0,$!@<! @ ($@D1
M$Q05%U25U1894E>7T]8A.%56D9*3E-'4"A@Q,S98=WBTM;:W(C(T-4%%4W-T
M=GFRL]<:(R1&47)UA(68IK'$Q=+8)DAAA\<E0G$I1&-D9?_$ !T! 0 " P$!
M 0$            ! @,$!08("0?_Q !L$0 ! @0"! 8&$ \-! D% 0$! @,
M! 41$B$&$S%1!Q0B09'1%E)A<932%1@R4U155H&2DY6AL=/4U2,S-4)B<W5V
MHK*TM<'B\ @7-#8W0W)T@Y;"UN$D1(+Q15=E=Z6SP^/E1X6&Q,8E8__:  P#
M 0 "$0,1 #\ ]$>HCNM/6Y7O4!><!B]AQMG&8/<5FP^.M%Z[A;Q9J"C,U-A1
M#99XY#J.7:J ]DW24<N%%%U]]<JJ[[*;[;9_MU*T(T>FJ739IZ6>4],R$F^Z
MH33Z07'I=MQPA(79(*E$@#(#(91^;6FW[H_A7HNF>EM&I];D6I"DZ3UZF2+2
MZ)2G5MR<A59N5EFU.N2JG'%(9:0E3BU%:R"I1*B3$.^_,]?/QF1;Y,H)[$YO
M]@.C7H5_PN8\>/,>6AX8_3ZG^X%'^20]^9Z^?C,BWR903V)QV Z->A7_  N8
M\>'EH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&/T^I_N!
M1_DD/?F>OGXS(M\F4$]B<=@.C7H5_P +F/'AY:'AC]/J?[@4?Y)#WYGKY^,R
M+?)E!/8G'8#HUZ%?\+F/'AY:'AC]/J?[@4?Y)#WYGKY^,R+?)E!/8G'8#HUZ
M%?\ "YCQX>6AX8_3ZG^X%'^20]^9Z^?C,BWR903V)QV Z->A7_"YCQX>6AX8
M_3ZG^X%'^21)U)]USZXIK<U1PV06+&G0&6V= HR;;)5S"6JK@0>E0H4202<M
MP^B[=15D[63T71WT51VVPHGMKOKKG&I4-!]'9>0G7VI9X.,2DR\V3-/D!;;*
MUH)!78@*2"0<CL,=[17]TGPM532?1NF3E;D').HUZCR$VVFATIM2Y:;J$O+O
MH2XB52M!4TXM(6@A22<22" 8LF0]V-Z\QY\XP:V5%]&S$P39M]-JT@V^VJ#9
MZLBCKMOL%SMOG5/37&=MLYVVSCOYSG.>9V= ]&UM-+5*OXEMH4;3<P!=203E
MCWF.5.?NG>&!F;FF6Z[3PAJ9?;0#0:02$(=4E(),J2; #,YGGBC^_,]?/QF1
M;Y,H)[$YD[ =&O0K_A<QX\:WEH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C
M7H5_PN8\>'EH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&
M/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&/T^I_N!1_DD/?F
M>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<
M=@.C7H5_PN8\>'EH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'
MEH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&/T^I_N!1_D
MD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&/T^I_N!1_DD/?F>OGXS(M\F4
M$]B<=@.C7H5_PN8\>'EH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN
M8\>'EH>&/T^I_N!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&/T^I_N
M!1_DD/?F>OGXS(M\F4$]B<=@.C7H5_PN8\>'EH>&/T^I_N!1_DD2S0?=;NM^
M>7K2T&DMB1IW')G;-<Q,^U1KJ%-%G(213$,'*MTG;8.FX:J+,7BZ>CA!319'
M;;"B6^N^NNV-*IZ$:/2U-J$RS+/)=EY&;?:49I]0#C3#CB"4E9! 4D$@BQV'
M*/1Z'?ND.%BL:7:+4F>K<BY(U32.ATZ<;31*4VIR5G:G*RTPA+B)5*VU*9=6
MD+00I!(4D@@&(Q?]V4Z]D'SU!*RHMJFB[<I)ZYK."YSC1-;?33&<Y"YSGO:Z
MXQW\YSG/ZN<]_FVC0+1M2$$RK]RE)/\ M<QM(!/U\<![]T_PPH>=0FO4\)0X
MM*1Y T@Y)40,^*9Y".I[\SU\_&9%ODR@GL3ENP'1KT*_X7,>/&/RT/#'Z?4_
MW H_R2'OS/7S\9D6^3*">Q..P'1KT*_X7,>/#RT/#'Z?4_W H_R2'OS/7S\9
MD6^3*">Q..P'1KT*_P"%S'CP\M#PQ^GU/]P*/\DA[\SU\_&9%ODR@GL3CL!T
M:]"O^%S'CP\M#PQ^GU/]P*/\DA[\SU\_&9%ODR@GL3CL!T:]"O\ A<QX\/+0
M\,?I]3_<"C_)(>_,]?/QF1;Y,H)[$X[ =&O0K_A<QX\/+0\,?I]3_<"C_)(>
M_,]?/QF1;Y,H)[$X[ =&O0K_ (7,>/#RT/#'Z?4_W H_R2'OS/7S\9D6^3*"
M>Q..P'1KT*_X7,>/#RT/#'Z?4_W H_R2'OS/7S\9D6^3*">Q..P'1KT*_P"%
MS'CP\M#PQ^GU/]P*/\DC5_IZCHGU(*VM9UI$Y45F)6X9IL4*-C.B.Y%R^R/.
MO'SW9RS>++O71$P]667W6[^^-],9U[^N=MO'Z*Z)4JM2<],39FDK8J<Q*-AE
MY*$ZIMIA:;A32R57=5=5\Q;+*Y^AN&_A[T[X.J]HS2J FB+EJGH51Z[-*J%.
M=F'C/SDY5)=\H4U-RR$,E$FT4MAODJ*SBLH!,R_I$Z/_ +I-/7[7V3ST_P"]
MUH_VU0\);^3Q_%_+=\+'G>BON-,_.</TB='_ -TFGK]K[)X_>ZT?[:H>$M_)
MX>6[X6/.]%?<:9^<X?I$Z/\ [I-/7[7V3Q^]UH_VU0\);^3P\MWPL>=Z*^XT
MS\YP_2)T?_=)IZ_:^R>/WNM'^VJ'A+?R>'EN^%CSO17W&F?G.'Z1.C_[I-/7
M[7V3Q^]UH_VU0\);^3P\MWPL>=Z*^XTS\YP_2)T?_=)IZ_:^R>/WNM'^VJ'A
M+?R>'EN^%CSO17W&F?G.'Z1.C_[I-/7[7V3Q^]UH_P!M4/"6_D\/+=\+'G>B
MON-,_.</TB='_P!TFGK]K[)X_>ZT?[:H>$M_)X>6[X6/.]%?<:9^<X?I$Z/_
M +I-/7[7V3Q^]UH_VU0\);^3P\MWPL>=Z*^XTS\YQ&DIJT)THVMTU6M39>3!
MIL#O2#%1!5Z42>98$ )L<8'.$4TV37&<ZO&R>%TE=E$7+?*C=9/=)3?7/F-)
M-$Z52'*,)7C2A.U-J5?2\\E8+2E)Q!)0VVI*B"1B!N.;/./[/P1\/6G>GDGP
MCJK7D*TO1K0>IUVEN4^G+84BH2[3I96\'YJ90\TE24JU10 HCE$BXC9F]^9Z
M^?C,BWR903V)SV'8#HUZ%?\ "YCQX^>O+0\,?I]3_<"C_)(>_,]?/QF1;Y,H
M)[$X[ =&O0K_ (7,>/#RT/#'Z?4_W H_R2'OS/7S\9D6^3*">Q..P'1KT*_X
M7,>/#RT/#'Z?4_W H_R2'OS/7S\9D6^3*">Q..P'1KT*_P"%S'CP\M#PQ^GU
M/]P*/\DA[\SU\_&9%ODR@GL3CL!T:]"O^%S'CP\M#PQ^GU/]P*/\DA[\SU\_
M&9%ODR@GL3CL!T:]"O\ A<QX\/+0\,?I]3_<"C_)(>_,]?/QF1;Y,H)[$X[
M=&O0K_A<QX\/+0\,?I]3_<"C_)(>_,]?/QF1;Y,H)[$X[ =&O0K_ (7,>/#R
MT/#'Z?4_W H_R2'OS/7S\9D6^3*">Q..P'1KT*_X7,>/#RT/#'Z?4_W H_R2
M'OS/7S\9D6^3*">Q..P'1KT*_P"%S'CP\M#PQ^GU/]P*/\DA[\SU\_&9%ODR
M@GL3CL!T:]"O^%S'CP\M#PQ^GU/]P*/\DA[\SU\_&9%ODR@GL3CL!T:]"O\
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M&9%ODR@GL3CL!T:]"O\ A<QX\/+0\,?I]3_<"C_)(>_,]?/QF1;Y,H)[$X[
M=&O0K_A<QX\/+0\,?I]3_<"C_)(>_,]?/QF1;Y,H)[$X[ =&O0K_ (7,>/#R
MT/#'Z?4_W H_R2'OS/7S\9D6^3*">Q..P'1KT*_X7,>/#RT/#'Z?4_W H_R2
M'OS/7S\9D6^3*">Q..P'1KT*_P"%S'CP\M#PQ^GU/]P*/\DA[\SU\_&9%ODR
M@GL3CL!T:]"O^%S'CP\M#PQ^GU/]P*/\DA[\SU\_&9%ODR@GL3CL!T:]"O\
MA<QX\/+0\,?I]3_<"C_)(]>NY4=<743U3>?CSS2D0?\ <+YK_<WY/BL?C_BG
MNG\XGECPWD9BT\;\/[GA?@_&?"> \#OX'L>&5[7AM--':71O(WB#3C?&>.:W
M&\X[BU/%=7;&3AMK5WM:]Q?8(^E?W/'"SIMP@]F'914):<\B.Q_B.IITE)ZO
MC_DWQG%Q5EK68^)2^''BP8#AMC5?6_ZOOKL^J']\3=G\Y4FY_5Z%]0Z-]RJ=
M^2,Q\.<)?\H_"!]^VE?Y]GXQVYU8\3#B$.(0XA#B$.(0XA$V]-'UQ_3_ /NV
MU3_+L#SGU;ZE5/[GSOY,['JM!?X[Z&_?5H]^=Y.(SEW[*Y/_ (PFOXR<\VI?
M^#L?:6OQ$QP:C]4)[^N37_GKCL0J%2>Q).+AL-%[&9*:V=:#!FKMBQRZV9,7
M))SC#HFZ9,4O!,F;E?.5W*6-\)>#TSLKMIILF)AF497,3"]6RWAQKPJ5AQ*2
MA/)0E2C=2@,@;7N<KF,E*I4_6Y^7I=+ES-3TT7!+RX<::+A::<?< <?<::3A
M::<7RUIOAL+J(!H*C!\DFW659.TTG>W8:JJ-EM$W.^-$E,ZM]]M,:K;>#70W
M[*>=L]A9+;O=Y33.<@6@D@*22D74 H$I&>9%\AD=NX[HTRTZE*%*:<2EPV;4
M4*"7" DD()%E$!:#9-\E).Q0O(LGIJQ8:":2.3 D! U\-B!=KHZ. -2J["=Z
M212-+( =2F3CCQE.)F=B&C<<KN SHP3D&!:Q<2F]U&:C*3#JF67"M:5S#9(;
M<P!4L6@\"[@U8L7D8"5 .\HM8PA93VY_1BMTR4;GI^41+,.L4R9;#DW)B86S
M5Q/*D%(DQ,&;7K$TZ:+P0PHR>%E,[Q=4S+)=L!0061PZRL+(I88K(MWN5&3G
M3#-PXSWD$'6=DL>+K+Y^HBDKV-U,_P!)KMS:#C9PV6@X@2FRDG$!M*<\P.<B
MX$<94O,)UF)AY.J4E#N)I8U:U^90Y=(P*5]:E5BKF!B[SU63Z*Z27,FCCF/.
M8@=!QJ0"33H>,/LS4B:EW@MFC'7CM$Z2QE &0R_<C!SQH'4PS0,+L%R@Q-Y@
M:GI5XLAEY+H?:<>:6@*4VIMHH2M1="2VC-Q.%*U)4L8B@*"%E/3G-'ZQ3Q/F
M?D5R2Z9.2DA.R\TXPQ.-3<ZW,NR[29%UU,X_=$H\7G)=AUJ5.J1-+97,2Z7;
M.R**:[NT]AK_ %4885R^3RS<8W980QC*V7>F4^TVPCC.,JY6QIA/&<9W[W?Y
MGUC=DG&BRK83B395]F$WSO8VM>]HY9EWP7$EAX*9"B\DMK!:"/-EP8;H"?KL
M5L//:.NLU=-TVZR[9P@D[3V6:JK(J)IN4M=]DME6^^^NNJR>JFFZ>VZ>=M<;
MZ[:9SVM<XQ8*220% E)LH @E)VV(&PVSL8JIMQ"4*6A:$N)*FU*2I*7$@E)4
M@D *2% I)3<7!%[@Q<B,%F;@$9DZ,7.;Q^.D@ <X6P-=89BR<I:EGL<8O%=D
M\>!<&F@(NY'I[8[[A$>X4T[^NN,YPF:E@ZVR7V@ZZAUQM&-.):&2A+JDYYAM
M3B O<5 &-U%)J:Y.:GT4^;,E)/R<M-S.H<U4N_4&YEV1:=44V2N::DYEQE)S
M6AE:AD+F@)#B"RJ2"+%XLNMNLFBBDV6456W;XSEQHDGIIG=3=#&,Y6UTUSE+
M&,YWQKWL\RE: "2M( L22H  *V$F_/S;^:--++RE)0EIQ2UE02E*%%2B@$K"
M4@$J* "5  E(!O:)$L&FK%J\\O%YF"18R!M(Y;$G <<; 2$BB>@Y+41)6:S*
M/$RCE!-F_P [(M7JR2; OHDNY#.2#5NLLGJ2M0E)QL/2[I4T6F'PXMMQI!:F
M4E;*@IU"$DJ2+E()4BX"PDD ]NLZ,5N@3BY"J2:69UN>J5-7+,S<G.OHG*2_
MQ:?:6U)3$PXA+3UTMNK2EF9"5KE7'FT+4FA1.OI?.&\H>1D,L19PR,E9A)7>
M5FS1L, AM4=G[K=9XLAHNOIX=+"(]KE<@Y[6VS=JHFDMNGE?FY>6+*7G E4P
M\VPRD J4MQTD(%D@D)-C=9L@<Y!(!U*=1JE545!R0E5/-TN0F*G/N8FVT2\G
M*A.N<*G5("UC&D)9;*WEW)0VH)44]+>'2+0&!D6K#1R-DSXR.#:L7XX@37=
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MK5Q<"[Z?N7PIEH/8ZUNR(R;"X;R]W]!KL/V,2'" A?(G2*04%$MS:<DEA*F
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MEYAGR2+*)=*C*/(GEM.*;F&I3$Z^RU@<"9$*]#DL?VA/(= YQ"7L1"R>J!$
MF<R).XRC8PWJ!&%CU(*AT$!91/0E+A0S+9^FY4:CP)G95L4?,VK1^Z9ZK>D;
M"9.6F)F7F$ON,SJYF7ET)>,JNF+;;J <)6@X&%K"DD J<;LI"5%20KMS/!-4
M7M(*Q2Z/5J4[396H:.RU&JE4?<D$UQC3.7F9W1-4LA$O,)#]3EI? \E:FV).
M:*FYAUI#;SC7Q5O0Y84M1J:72W*P2M;&L9O7) DQ8'&IX"7=MIDX9Z:8D,>'
M1XVD\]PQY/!&*EY./'*H(-S"H]X]9-G"<TCE63.L,6<FY25,VE"E-J:<;"F
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M>-7+5NKIJJX052TW3VT:G,.RE-GYIA(6]+2<R^RA22I*G665N(2I*2%*"E)
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M6U:Q/SFL93)HF6Y5#+A?*VFV&YM]*&T%*"%<M*B(]0_PLZ933KCDR]1'DO\
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M%PZ+ JY<.U);H=.:04(:<PJXMBQOO+4>)SSU1E[K6M2C@FWW7"225A00LJ0
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M'$(<0AQ"-A#N$'_S4?\ V/\ _P O\_E_"3_T+_\ <?\ ]"/M#]R%_P#4+_\
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MQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0C80[A!_\ -1_]C_\ \O\
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MZBB^^FNLUUUUUV5VVSKKKKKC&,XQC&,8[W/((TQTH2A"4SLL$I2E*095@D
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M/Z?_ -VVJ?Y=@><^K?4JI_<^=_)G8]5H+_'?0W[ZM'OSO)QM^/?ZL=_X2O\
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M'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ",C*
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M$1#M*BDHN8]3M2AA<R<;R8N?D!%"7Z'!$3CJB NJ2.C0Y)PT:Q>%.:22%7)
M !20,)!6FQSS-]FQ)S(LJ59+KIPN)0DLA*$J62H.)42XDHEW24\D!(*;%1S<
M&23?YOKXLR)O2Y:<[U3$TADGNN$RRFAL?-SRV:@:U)0,OM?6Y)._'67'V,T@
M161180,0%H1NOA)..V?7SEK98]XOLX+3K2";X18J!3F5)L@JN<P"+C<!8CE;
M8H)1M0 1K%72TM+I(0TYK'DMZM(+:BE82HFY4LA3:_H9 L*S275WU 7'.(W5
M[=]30@VTM6XX7-99B)9DK9Z!KFM:(LL3Y% 0+J$F<8#2)WI<+F*'%$K4FXMN
M[!J%4D&;S5U&$)2M2CAY(.)0)M?(!)&041?E6/*.SFV1#LLRVA3A#I!;;4A.
M+#8K<=;-RME*BD:O$/H:3G;/S40S&KXZER(*G9:RO2M)/8D9IOKZE4X8O('(
MEHNL[J28TL@*ALX@L=N49NVFPEYJ59,)$Z(,E(U'CCX8VB*KW=T6(T"UV2<0
M*@ETD6-KI*;!20H9C.VRP.R,I98!<1JEI0IV32@A8Q?1$.W6A:FSR2+$IL<2
MA?$!8"<2W47>$[C%@3A%]7L?KV(=3G1]58R(#P=D,YR0$VV6Z/),=)$K,C-N
MQ/5!=CO=Y\4@':Q#<$;%C&H^5LCH0F;!OKXU*!.0 6V+6(-E:L[0H=O;98VS
MR,80PTA2$$+4M3$RX5$H*06Q,I "%-J\Z!OBQ FZ2D@&+&&]0M\MHA 23^U*
M>FDS;=8'7)7+P8>TEM8CXEI6,"ZY3]4-+2*1NW%!K>$,\TV'W>,YS$BPM*"/
M0\@2:KS6$B;">P%*L.4DG6.CG3:P<*;V5LY(V@Y9[0#%RRSB6 VZE)EY58(P
MN%6L<E4N:L*:N5G6FQ0H'&"/,K*!GOTJ7"_N^GQ\P-E!964,)%*XC+MPD9:Q
M<2RDT5.NQ1(4P;#+*N  50'922;>Z&,V3* !Q311\Q<,-E%A _(A6)-[@FY!
ML+ $;1YI0/?!(C3F&M4Z4@$)(2I%U8B4J ())0VH$[E-I4-A!VG(_EXPPXA%
MPQ']E<8_QA"_QDVY1SZ6Y_05^*8S2_\ "&/MS7XZ8H:_Z^M_?5/\_;EXQ*VG
MOGX8XN(B'$(IIIH0?ARS$25W!%7HQ^T&&TV;4BH&(.&JJ+(JF/?:[LGVXYSN
MF[U9O--FKK9'"#C79+??&1V'.W=W=V)! ()%P""1<BXOF+C,7V7&8CR$>,S]
ML=*'3C'REK7JXZ@;>L2;5#"[!BM[6U6!QJAM8$Y+V':,F$5',('$I.^KBIX)
M(Y%&&<EC3V*-9,QCD-8C!@>29&K:^:FT<I6-1*00I0MF25$ @&P!M?*]ASQT
MKAN8?(;9#+:$.*0III8/(0$-I+B%J3K'%I2K"H**2I9)*;C)YN\=@NI3J0@U
ME7'*4Z99]*U%R1D@:FJT%'UDSD$TZA(;(B0N?B'X&6#C1$=# Y K81B7.)?@
MKIJY9GAS5F,9L;W.-:2HX=6D[;8;E0R.V^6V][]X1KG-EA2&TZTOO)-D!9<(
M2RI(*""D@%1 0$X;?6FYO6^@V5%9/3$D1,2=W+G$5NVYXDU+9GIJV@* 89.B
M;D "AMOR93>56I&(R$?L(ZA,Y1HU/KE1A<.0'C5 ^&#>6C=)SO92AM*AD<@%
M'-0&RYM<WR$1-I"719(2%--*(P!M5R@ E;:0$MJ405%";I (()O&:G,D:L.(
M0XA'@?\ H>SZVGJF_?V7)_(2H^:LI]+7]L/XB(Z]9_A+']49_&<CWPYM1R(<
M0AQ"/)^\[$/M.IJ2#$K-EH&R8K;_ $+1^DJK%V%(  6:539EGB&%]'756L3#
M2/V8@ZB"ENI'Y ? 2)6#C:Y:F0[F/.@:SQQ@43C(Q$*"FPE-S8@GE'#>RA;%
M<VRP[1'0:0DL).K2I"FIM3KA0%%+B&R61K""6^5J[)!3B*[$&XM?W6G;<#WK
M.N;.KFZQR)\98D3=1MS .H$T ?2:(L+9BD<LQ.%5A%I"G#.HN6)/&'F_90.;
M,W =L^/F62)-H74R!/V<4,(4E6=Q:RK7&( V3>RSE8 Y7V=VDJTO6+;6T<)0
MH*QL@A*BVHMXG%#&PG/&5H() !L1F(>Z2;1F$CZU[,'F;-+R>-2=3J]T!0_:
MSI-*RX32K>HR&PT<E:E0%3;Z+T&I"&*K^,4RZ@ QEK;$!..3MGI#9R,9($ZM
MJ)<-U7OK+#$HY)6!RDG)-MB;;1MSC+,MI3*H(;"5)XM=6!*0K&RM1+;@ 4]C
M(Q.XR=6M("+I)M[!\SQS8<0AQ"/ WNXW[)>YE_O[JW_AX?FO,?S7VP1V*3YB
MH?U-SX%1ZY=3Y^5QFFS1:(/38EQI*:N8R<]&F.Q&0QFL3%IPL/;\J"MM&1)3
M0C%ZK?3$^W?H#WSD1L.\KM6;QRQ2:K9EDA)(N,TW(S(3B&(\^Q-SLCFRX2IT
M!02>2YA2HV2IP-K+22;C)3@2FUQ>]KYQ@H(ZJ+(K4_*QK$T]LBB_*-P.J8E+
MZ'F+2N"8Q^%TL+G")733>>UFZ/UH%LX?8T-#SS+>6K2U(1&P1N41)B=$66_Q
M!9!(!Q)Y6$VQ*-D@[Q<8L0OGLL2+@QMF70XE)("'K-ZU(4&VDE;I1;S#@2X6
M\"BCDX<14$J(4V+JKSJQZCIJF@X4CE;:-H]+:MBLG<C8/,"#27H6AU-R2D$9
M-#2#&S2 P&(CT%TBMJ+=I[/V!L6NZW:'F($V+/#I"UG/DFQ -@<\2RFXY1R
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MNO&^C@3'CKEA92,F8J1'2H<6 ;@<D &X()-A=6W-(5<&PV F_-&1<JQ<$+4
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M54OJ\HTM$<>P\9"HK"-I3"X^AI6<PM,A<[Z8PDR&DN#;&3P7-9UQ&SQJ8CL
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MTJ4"M:4@J&V>YJYQNY<;^Z(/CMKJ[][*!?OX[2FV>]GO#\X[^._WL][.<?\
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MR<2$Y"^P7/<C8.\UCG[8PWX Q[.YEXP.T5TIZXY?$CY\UT._%P\UCG[8PWX
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M0[1P^Z;6F.%2#9Z%,Z1DFONRV&OG0(IJKK.:23*V:@\S(K::E:1Q\+?MK6W
M].L+Q,*<:#S:52:UM87&]<@!6-(=1;K2G!)2F9[1>1G])9:>FZWI[V+%BFEP
M2,U**IFC-4ERU5&Y6=XC..-Z0L2TZ792:33YA9:+#[DG,!<=QSH0EDU9P=*(
M6-"R$HER-+DR48?M)(*UB,=O$85)1LT3/+"%!I+4-H%?9D3(-JZ>(MMF2XU$
MBY7<L&.T[I*S+JF"_*3"&63/H0\E32]>[3EH2\VAL+"T8]8G5*<PI*L064I
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M:0:L(]%3KVH[WM^IWL'BNRDDD>9A,(V(J[$CF'DT@T>^1#H"7Z1,&),$!,5
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MV-NXK=W/6TX3$,WD5L+56!J$(CLV(QG8[.?,[/A]8[.]OSAI!L;+%PBZ,0Q
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MJ\^CJ$1Y"4;,?4JG\X]",Q^0W"6#^^-I_D?X[:5<Q]/9^,=_%W']P6_!;_\
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ML;_!V^]S^3B$.QO\';[W/Y.(0[&_P=OO<_DXA&1E Z[8]UG?UVQ_6']7&?\
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MK]>&H3T)7I44"<#YN=AVU@1/<T+ .':^$2+I9CX\F$/["UQ\/O;8:E>$*.$
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M>X\#8!J>6"\D5N#)>&@HRB:YLRO=:\UB58@*H;UQ!0L@GU?R&72>8C(6.?N
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M_CR)_P"TJMX9_P"W#LV'J1T(]P3\LA^F,U^(;IP^3)3V_P >1/\ VE5O#/\
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MSM*,%QC."F4T6&]LB[39[R:8F3SE.0MX:I%0: XT'>3<^#W ?1"0#;"0218
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M NDV2B^&09O79S;J:WL(K2V]O "]>UA%:\F*:U:.]J"E<:F]@%IC)%AE@28
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M%SS$GFC&Y,MK24<L L):Q!MM-UH>4XDZM*@E*"E6 @$E-K\J+!F?1O-ZNID
M_A20Z2VE6% 1"%5PSA4>=JNC/4)!;?&6O64C*;;>2D&\%6EK94;."!HD.10B
MDDF.Q5V@-)E-UJE"@D6VA(  'UX5B!V#*^TFP )WF+IF4..$+NEMQ]2UE:O,
ML+:+;B1M./#F@ 'E)38$@1.]MT7+HCTEU!4=?!VUCS&$6_TEFRNY3QIJPEQN
M+]2-7SNRYW*G#$87=#V)@@SD\YEY5N&(J,$7)0CH,<^!PUWLI)"$) Q$*03W
M;*!43W\R<M^48FG4*F'7%G A;4RD6M=(4PXAM"<P"0"E"02+FPOG>('D_0;>
M$@:;);3&N$6QR?D;A7B(<[/(=#JWL9Q>HZXLXCB$<":/;.$%AX0/'5_=OM'Q
M "7^7K7'0PB8/:QX74M*/.+7*K D **@K( 9@@6S(L>58F,R9QD'S+F2 UB(
M0I;B T6^5B)#9!)5R+E2;(*@!<WQ+.@J12,-? _$CA.'=HU5UIP2*NG0Q\IF
M+FNINW5++B9A3?#/=5!&*):LTC"@[/C>Q1HBY&X5U125UDMDX\QRDN =S&;C
MFYK"\43.)3J>2OZ&[*K58CE)8;P+&WZ[.U\K'./3OF:-"'$(N&(_LKC'^,(7
M^,FW*.?2W/Z"OQ3&:7_A#'VYK\=,4-?]?6_OJG^?MR\8E;3WS\,<7$1#B$.(
M0XA#B$.(0XA#B$.(1X'_ *'L^MIZIOW]ER?R$J/FK*?2U_;#^(B.O6?X2Q_5
M&?QG(]\.;4<B'$(<0AQ"'$(<0AQ"'$(<0CP-[N-^R7N9?[^ZM_X>'YKS'\U]
ML$=BD^8J']3<^!4>^7-B./#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0
MXA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(1D90'^^W_ *!_\YYIS?\
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MGQ0I?9D<^]LRSV[,QLO%%,%(*BM( P@7"L2BH*( 3AN#R2#BPVR.8(O9U?\
M= 0MW3JCXU6@)0(E)>I(A3MG,9"6KZ;=J-.ND&]NHB*GH1,JAL2>01^F3,5[
M&V2SU$\2V20:R0?D;A!V%/N%[VMOMS;B>8F++8+87B(-F\:;8AGK4-D*"D@C
M)1RMN[HCTFY,:\5 3_749_R@R_A*7(5L/>/P1=OZ8W_33^,(Z._]/M_QMO\
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M)2&4;NC;IP'#-,LWI0]L(U')R,^F36_;FZ-D0IQ2@ K"; #%A3BLD6 *K7(
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M(O>XJ&>L7J%,VW)*UAP:$/Q3J21.-Q.7&:>G0]Q'-D[DA%73@W*HJTN5^Z.
MR0>8XL" +N"];/UX@V&R-\.(1N1"B^ZYN;?!LS%[]-QLV;LXC5-A(42H&Q)
M6#?D%20#@ !!3A5DK,D7N+108?U;7?-+,H?SDJ":M 1N;;O+-@X:O;&:')Q"
MV_1);MBR*WM3+R2D&;6FV5N[-X0+@F\7DIQC/8*-W=S]\3<L RJYRY@-O-]:
M3<YY"^7?&V)4TA*5X;K*D\A6)) .N0D)MA!*RG,D$#"K9M,9$]8UFBQ$2I)_
M&K,E<(.V'8<5;P64QXN4%PT>%54'2N53JPF[-HJVD$<#5^+-,P$4D>BH"5S"
M41R./F&CHJR.1^3S=\<]OV[W/[\8V4DE=TA02A6($7-]@2G<2HBZAFE(40;
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M(42#B'))&5V5=3/4,A-Z0E]N1?J+F49IOJWL5_"7&DYL(/*1U261TXP!./R
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M)6$;)MP4;L-8Q#$XTOD!)!:3=-!B@L;<]^5;/NY?L<HA*VKHQ!L@ED+N@&R
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M[W7#B+G;H_"ZHN:.QQR&\<\.X05\9\7[/@L*?T/@?#]KM=O77]7PN.]WN_\
AJ9[_ /8Y52@JUKY7V^M&S+L+9QW*58L.PD6PXMX[L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g105292g03v00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g03v00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1VT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '9B^=78X0DE-! 0       \< 5H  QLE1QP"   "(   .$))300E
M   0MV9>?53;01#W5P=W'7#,93A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              00   'I          $
M                 0             !Z0   00
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   00     4F=H=&QO;F<   'I
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $$     %)G:'1L;VYG   !Z0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      3=@
M  $   "@    50   >   )]@   36@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MU< &[0&>UK6M1]/#UP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQU)M/V=U/MM:U8B+1"*06*89P8_F<B#<(4"R1%BBR.2H!B0AVOJN?\5NFO\
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M2LP^G(.$O^GY"5(6:?#421DLP%GI62WEY?S"5^;*KQU9&<R_D!F>EHUEUB+
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MJ\!V2ZX:S T[::OLBKTVTPM<DYMZLVRL6X:6&:>(AY>1DV 9Z&F1(UT20BU
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MWK[*7OK[(MOR4?(1TY(CQ)L5:XEIXPEX:8;0/,)R_AP9_*>.S9ISM+&X2:1
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M"S9L7)Y;5J>6S9G<R33SR-++*[>[R2.2S,?Q)/C ]AI%>LWBQZ8]1-T6'?\
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M7+5]YU^+?Q*U\V/D4-LN/.*6PDC#+V,XPZA>,8QS5!8EK2":%N$B@@-Q5O#
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;1HX:-'#1HX:-'#1HX:-'#1HX:-'#1HX:-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g105292g04e08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g04e08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5]2:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3 U+3 W5#$Y.C(X.C Y*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 U+3 W5#$Y.C(X.C$P*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP-2TP-U0Q.3HR.#HQ,"LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$S-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%I045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y1&%";TAL=V583DYM;3 R
M>G Y5"8C>$$[:&534C19=CDY2U-Z17)H47)73FHU2G8Q5G)/>G-*=S1:;#11
M>$=O46=-9G,O=T-535-#1TU-:UIC:F%);3!(>71#;V%85&)*1EIL4B8C>$$[
M4S!%47%Z1VEJ-U!C;D9K4T%O869P+VMZ54DO57-R1WAM4V=B:W1V2#EK:V=-
M2W%.:GA.1#-X24DU<UE:27E&9S)I+SA.95A0*W)66B8C>$$[+W=$4U!&+WI4
M9UIO85!3+THP<S97.%9J65-44U)T2VEP1$4Q55)G:DU#1G!S>'!H;W-2344Q
M84HO=T%.95A0*W)66B\Y23A8+TY/0B8C>$$[:V\S1VDK5DQB,"]8,#9Y:CEA
M4EEO<7=29D4W+T%'5DAW.3A)=&E:06,Q8B]!03$U8R\V=%9N+S!J>&8X,#1'
M4VIC-DPU5'1L4G Y3R8C>$$[<V]X3$EK35I-15<X:V@T;V\K2'%38TET:DM1
M2$Y!>DXK6'-%='A&3$1P>5,R<$%U27I$1GE5<WEQ3G5.5#A4<4YV15E2071:
M>C1W4R8C>$$[0U)S:7)85'9*;#!Y3&(R5FA).&MF<DEG9VDU1U!L>#552S%P
M>3)W149N1V-4>4MP8F%,-51U4DDP1VY756=I:V5'46E#3&%333A76"8C>$$[
M-U!52$4R;4UG95,K6'DO-5EI:6576%1,2DDT,4Q/-6=I;T955DI0=S1P2G!4
M+U$O;$E79C$P-F9:0S$Y4#%V5DU%45@P-F-U5S8K1R8C>$$[3D9(14MV;W)$
M>3,U8T\T,'%Z+S5%4F8X,#1'5&8K1W9,;B]6<7,O*VME3"]!2G!X5C,K1W9,
M;B]!1F%R4"]P2&DO-7!X5E1'9RM6;28C>$$[;F5!86):1UI&5C-4,$EQ:%A*
M0VXW4&9I8TM,1C!H6'102D-7-'5'<W)%=W1-8EI75S-J87-Y<U5+2T91:VM-
M<#9E1TAH3$1X63%D.28C>$$[82M+<6UM951N<U5V,7-B13)C:7)):R]O4D)3
M<C T;7!8=EA"4G5K:6-42&EV6F5U:2M5,G5P3%)D3W-J8WA)<W-K46=I<7%3
M1F=P4"8C>$$[=SEY:'AO<#1H9&16:C96-5%3.5-Y8E0W25A4;UI21CE8:DI#
M1&)K4T9O;RME3DAM<&U,<G%O45$K47)I,VMU25E.3F5#1C%J;&Q%528C>$$[
M4$978VA6<6%F=$9H43DX2FE707I127-%56U(*T=V3&XO5G%S+W=$<$AI+S5P
M>4QA;S-E:2M63%,S931U9$]S;V])-D8S84-+9W%A1"8C>$$[.6YX3T575TUP
M04-Y;T,P.&HO<$(Y3RMQ865,-DUC;F=-35%91&E(-W(O2V$O3$12<3)0:5(T
M=4<Y,%)B84@U5G5R94\U=#E/<UI92B8C>$$[;$1X4W!"159:5T9145%U03)'
M55I#47-C:75K,$1Y=D5!6DY.<U5$3455=$1#2W-X;W%I<3E396U+4U%';V1!
M.')Z2C9K5VTR5'!6;"8C>$$[-4Q"15)64U9B.6YS4E1&45%7+S!"-5@Y6#!F
M,&)9*W-&-6U0,%EE6$5M;DMN1W1+-')9-4E(>D8U9#AV<#5F,4XP,'DP5FQT
M2GER0R8C>$$[0TU%15)T46<X8T-58F]56'$K5F1/:2M(.359=W(X83@Q,VA!
M*TID<6HR=V])<TU/,78X04QJ5TAS54YR9D,T=55$4DQ!1DMO<U1/<B8C>$$[
M0D4Y85(O9U-H-'%X3DLQ2%%:9DA+3#5/<WDV1UIJ<V0O=T%D-5)T;"M7-WAI
M2U-7-U)736MC.#A#>&PQ-4I.-G9(:WIF1E)735E9:B8C>$$[<#DR4D]6<VIO
M=3@Y8BLR+S),<DPX='9Q8VQO.%8S0S8R.%9V2$IB>3(U848S:%%Q,'A54TPK
M.'$Q5DYD=F9%-7)2:C!(1%9%8D%D3R8C>$$[-W)Z-7%C4#5:,TMW<7-U<6E2
M,&QK;FI946Q1<VMV;S%:44I+2V%W13=D,G=N3C5,2%%%8S58,35E-WHX=G15
M-WHX=#=T3$]'2WIU528C>$$[13!):V=T,VAJ.41G:SAQ<S!J:W4O2FA(>519
M8C%(:&E-=2LV2F%%,$%$>79K2S5L4&17.&UW6#AV2DIZ8G%L:CE2=&5+:W1%
M82]B0B8C>$$[<4]Q9D%2-&0X:$A*5&LU3DU*9&$Y3DI&9&9L8DIC5U5D<612
M5D934# K6&]U>E(O1DMX.4%T2V5#=#8S>$$Q<GA'5$=A:GEC5V9:,28C>$$[
M>')I-F9,;GDS,C5O>B]!5CE*3$Y.4'%34$QC0UE-=V=A<TQ49C=S='%Y;C U
M0C U1W125$(T9S=M=S9/4C5Y-3,P-5@S8C=&4G-F>28C>$$[,6QT8FUZ;2MV
M;S97<S!5,W!'1GE&34UV<69U955R96XV9S)F<FA/83)-9$%146(U5C W:F4R
M*S$Y55IQ9FM',W4Q,4-9,T%&,V184R8C>$$[,U55<V=K36-32SA,=$@V66M5
M9D@V035/2T=N>7E-8W15>GDV25-S,W531#DS;C5+,FXK5F)P3F)T.61B56A)
M-GAR04E);S913F)#3"8C>$$[:455<S=V.$$S;G@Q3&ME,V9!6C=65$M';E!'
M2CA8;#566#8Y,$10*UAT=DQR4G4W;2\U4EA$,THK<F-74C94=$DW3$=W:W P
M;&\Q5B8C>$$[3E%-;#1U>D$V26-D:S@W*S(O4'I5:BM806YK:&PO4WI4>7AQ
M-EA5<DM73%1->FPS6&I);U5N:T9:5%@T5D%X.%AY4BM2<V<X5F\V,"8C>$$[
M.&I.0F\R<V%A8G1'+U-K46I745)%96UW:DMC>GED;5DQ,W!5061Q65!%,T(W
M;5DP;F]L1R]Q2#9&8E1F2V$R5GIQ42MU:#(Q4TMC4"8C>$$[0GA:86U395=1
M4TYX8TUE0WI,2%55-F129VQ/-CAK-#E.=VU7+W="5B]E5"MM:V]H+TQM-35V
M8G9C:&):3%I9,&M#:%9A-$QR>6M%4R8C>$$[;F%K2T-08S<Y8VXT<E9(4DAL
M93%F8B]:<VE,8CAT+U1N+V9A:3!T='=L:D-"0W-I<$ER<7-34'I93$5G8TU&
M-"]B545(=&=/6'E42"8C>$$[43<W>3(S+U1T-W8P:%-V9GDQ=DHT0W%A=5).
M27-,6$5R>&-J2E!',#=T3%5/<%5L-VEQ,$\Q2V(T4FU(8WAN;TI%9E8S9$]O
M-'0K9B8C>$$[;CEI8G0U3VEE,G1)2DIL9C9R<4TR;W%Z4F=K:5HU6#E-8C=5
M36\K3#(V6D1X4'5B>'!2448X<$=8>G8Y851R*U=L>7-%5G-.5%4R."8C>$$[
M4WA%2UE$>3E33T-'2&Q8,4M5+S!C34YU<#8U335V2F]H;T1%5GAB8F1/-$%D
M+VMI3&)Y2SEP0G%-56UP<#9M<'AW=TQ-26EJ<S!5<R8C>$$[:W1:87E(,5=K
M1#A8<%-O=TA,9&)C;6-D1UDX6'$K;T%C=31K-S<W,V4V33!J>5)$67EY4U,S
M06QA87EA>69G;D%Q2&QE42MM4U=+<28C>$$[;VM#274Y06\S>4US;',X5VM%
M5%I.-U8Y<%!Y-W9C9W)R.'9,:3AT+W$Y,7%D14M144U925%H359O:G)#2TUZ
M:FQY;$QS9EE5-#5)6B8C>$$[839.8W1#6D-J3'5'=S9#-BLY1S9Z-5,Q1%9,
M:E-P-4Y30U!P.&9'56E,95(R045J9V@Q241G9EI.8VI'648W3G545'EM66TO
M<#AK<B8C>$$[+W=#5EI3:4)91C%&5VE8:59J:VA:;%)V5&=6-4DQ.5%"6D=E
M0FE7,RLR9FYK+T<X;6=A06=6>&9:-41Z-3=F86U'<652-4QZ5F(S528C>$$[
M;V113G9.94%O4C9F34I'.75S1$9+<T%*4&@R96UW2D=2:FMO5E1B:S!N1DEY
M0G$O,58X+TY2=G9*9#<K9W)$4C=E9$QQ0S)V:DU'=28C>$$[67AX4S-:2E!G
M6D5+0BM,4V)5<'14=W=J24Q*67DP:#1"04=W2F1E-V1#:CAS-VXQ6&MK,4Y,
M<6=T=E17-&<U:&IA.$%N<6=/;V5Q<28C>$$[5E!1,%!81#0S:W<O24@K9&9,
M;4\W=C-A;"],0U)I,TA5>4%93&U#4#1(2'!E=C9T4%0T>4M!;SEB9%-$5VXS
M27IE4WDW4$HO:39%928C>$$[-C<X+TY5;"],5#1R<C!B=45*8WAT16]E,TQE
M:VXQ9WIO17!)=7=R>$E/>#A+8EE01U-D0GIO:F9Y.#<W,E)A,T-94$MD+T-7
M1$=+=R8C>$$[;5%S049"-'=K5D-J669,2W5R<T%+1DMV;'(O;$A.2R\U9S=F
M+VLP=4)+631Q-T9867$W1EA9<3=&6%EQ-T952G$Q<F185VY4=U=K-28C>$$[
M=')P;')B>D%K8UI&25I/5DXK3E(X43=J1$4P5T=32DU306%+4C9B;TAM1T=A
M-T8U96TV:'5,4#!Q>51335!R3&ER<VM:059%<514<28C>$$[865!,GE::T]J
M:C0X37=46G5X.7%6,B]L2'IL8DI95SEV<6AJ<S=5>&-O,75*2VIJ1$-R-W-J
M8VM$<$IX:D\Q1#)Y6GE23C=.161.;"8C>$$[:G=G4S)(;C5$.75Y1W5V2E!N
M2SES;S%V8C)+5S1H=4AN:B\P:69:2%=/<V%Y8T]90F%.<61A5CES27E20C)9
M;E,U<%(Y4C-U*UHX="8C>$$[=G98,UAL;GIH6DIC5&%F9'9(2F1Z>E-*8E%Z
M4WEQ2DHU=FA:=5%50E9I9"M49GI5-C1"3THU<&QP.'-B351Z2C<K<"]69GA4
M+U=T0B8C>$$[,38T83-';6%Q.7)';'4P535D;5IM:VI5;4-153)R-F@O969Z
M1&))4FM/;V-N3FAM831:5G0O6BLS=E-I2'EV-7=J=7)E+SA!<F%04"8C>$$[
M0E5,03%X2W@Y3#9X1DM91VY+8VU6;&IE<$LY-E5P:W5/4$IO1VYY,DI8=5!-
M.30R=79);V54>6(U,VUT1VIU3E4Y6FU#8S0R=7 K1"8C>$$[96UT=59!4$@T
M4UAJ;'$Q3S1Y6&E2-VU(-5A-4G9,-U0O4B]31#@Q5S8X<BMF6EIB;#0Y6%I%
M:VLU3$-T>DEO.4]P2WAQ,W!K>&Q.:"8C>$$[>49E9$XK=4%4:#--<&%F3U-F
M5CEV-TYQ*S%/3%11+TUC3VHV;$4K;W1*<71Y4TQA9#586D91055O0T%)>3-X
M5DMR-SES9UI#>'1S-28C>$$[16-5>$4W*V]P6E U8S@W=3AX=#E1*W)2=D5Y
M=V]B=659<%9!<7@X;5%%:U-!=C9V,G0K3DM:3&IJ,TY*=UIT-DYB9#4K6'HS
M=FXP828C>$$[:CAO95IX9G1+,2LO<%-'3TXU;'4U>$PY6&EV2DI/2%1D;70S
M5F5686=G+WI%-%1K:EA,.%5X:G!C=D9:;#EP-4-24"LU,F%U4$M8;28C>$$[
M-C1R-FUO:&I&4#9S4DTP:$I92D]O;%)M4G924$=61C1!34YQ-$)/4&-Y;'!S
M<#8Y92\S-SAT=5E:6F]L=&97,FLR,$8X-&MU-#!P328C>$$[-G4X9TQ6-C@U
M4&I0,#5826DY;DUX4DEI065A3GE,63=&6%EQ-T9867$W1EA9<3=&574X>2]W
M1$M/87(O04UW9'@O>6%B1EAE5W8X028C>$$[;$A.2R]W0UE/,R\U3DQI<5DT
M<3=&6%EQ-T95;6%#-79.6G99:F5Z=U)14G=E;DA#>4M+=4A,13%6=D1*.&<P
M,%1)-VYO<F9O5U@O<28C>$$[-3-V+T%!8V8O3D=$:3AK*T@U;#,V1FPO-G5D
M-R]W04A(+WI2:GAE4RM(-6PS-D9L+W=#<FYE+SA(2"]Z4FIX95,K2#5L,S9&
M;"\V=28C>$$[9#<O=V-F.$%Z4FIX95,K2#5L,S9&;"\V=60W+T%-2$@O=T$P
M63A8:W9H*UID*VA:9BMR;F4O.$%">"\X,%DX6&MV:"M:9"MH6F8X028C>$$[
M<34S=B]">"\X,%DX6&MV:"M:9"MH6F8K<FYE+SA(2"]!33!9.%AK=F@K6F0K
M:%IF*W)N92]W1$)X+SA!3D=01C5,-&9M6&9O5U@O<28C>$$[-3-V+T%!8V8O
M3D=01C5,-&9M6&9O5U@O04MU9#<O=V-F+TY'4$8U3#1F;5AF;U=8+W$U,W8O
M0G@O=T1.1U!&-4PT9FU89F]76"]Q-28C>$$[,W8X07=C9B]!1%)J>&53*T@U
M;#,V1FPO-G5D-R]W04A(+WI2:GAE4RM(-6PS-D9L+W=#<FYE+SA(2"]Z4FIX
M95,K2#5L,S9&;"\V=28C>$$[9#<O=V-F.$%Z4FIX95,K2#5L,S9&;"\V=60W
M+T%-2$@O=T$P63A8:W9H*UI32C5D9D=U:E1X<"MS=%EE<C9:,6-81F@V051G
M<D-49R8C>$$[6#EA;DEL86-+-U9X-'9*9D0X>6=.23@S86)Q4&PS5#EC8697
M<E=,57)A-'9,83-M4F95359S:&M9.&Q1>"]'9W)'3UAX1'!T5VIF:R8C>$$[
M=F@K6E-I-R]!1%4X=3(Q<%I82#%N5C5F<FQP2&4K;$4Y<5=J5U-A3T52=%5G
M8R\S;V)9,'!49C1L<3,U3#1F;5=7*U4W;4QZ3#5E<R8C>$$[.6)T8C=524EB
M>%=+=WEV1GI1;S=2<W)C54LW36@V2$AI.&PX4'I+96%&4$YC84IP.7A-,T]A
M83)H:VMC.5-Z4F=K-V5*3TUH=54T:28C>$$[5$%%.7=2=5)B2%EQ-T95=3AY
M+SAO-7%V+TU(8V8X;6UX5C-L<B]L2$Y++S5G-V8O04I.3&EQ631Q-T9867$W
M1E5S<W8K3SEQ9B]'3R8C>$$[,B]5*U-024Y59G)0=U1%>7AH=4IC0G8U86EU
M*U)B5C)+<$HU;SAU3G)N-DM8,4QD63E/,4-$54A3-70O<D)9,CE39VE94U%T
M0S19:"8C>$$[:$EP4%-H1$M757%S9'50>7EK=4Y/4WIK+U%95DQ-,G%Q;6DP
M:'%B<%HV96MB<&@V1D5".4=V.$%E+W9E6#=/2W!Z<%8S<4UF;F96="8C>$$[
M26QV2DQM=W0Y3C K-W0T-5)(5T]3-'5,,D]3:F]I37=+,C9F84HV935X5FMM
M2V]+9EA.1G0U;6AU3E%T;UIK,F5/4UI&660Y=U181B8C>$$[5DIF33-L=&A6
M9%9S>4MK5D4X4C-";V8R=DA&57A6;%I1>6M&4TMG:F-%2$97.%9D:7)S5F1I
M<G-69&ER<U9D:7)&=DU%6#5I45)A;"8C>$$[9&%,9#)6,GIQ<396<#!L<WE&
M2&0T5DQ45"MV4FQ24DEX;V<V*S%-5F0U;'8O4#A!83989"]O3%,W4S5V65ER
M63).6E!G;&Q:>4QH5R8C>$$[4FI&=U9&<'A023='=E55>%91<TQZ>GI,-71K
M:'5.270W9GEW2&DK<C-"0V973T)T;61U6$=29T]%,&-A+UHO059X5FPV27%+
M1E%"5B8C>$$[1W=50V='2W!F-6(O04]59#!R+VU$="\K5%,U2V9-=%=$-DDK
M-$IJ:U<Q,DMU>%9,=DUV+T%#:FUQ+SA!34AC9CAM;7A6,VQR+VQ(3B8C>$$[
M2R\U9S=F.$$U3DQI<5DT<3=&6%EQ-T95<W-V*T\Y<68O1T\R+U4K4U!)3E5F
M<E!W64XU9U,K=5!/3#9R9%,R,3-O,FDV=G Q:D1:6"8C>$$[3F@V<VM&,61I
M>D-Z475,>4=.;7)D<GAN:VE,>&9%155I=DM,83E->%8R2W5X5FI&:B\U33=7
M+RLR3'!0+U58<5=+<VYX5C)+;V)4=B8C>$$[.34S+T%/33 O=T1Y969&551I
M<G-69&ER<U9D:7)S5F1I<G-69&ER0SEB+TYN>7!O;6]8=&YQ8E-X3EIZ3&(Q
M4E)+>GEM151516%&<"8C>$$[1DA&,$%:9T%X3S-W<7A#<50S9B]!1&M&-41G
M,"LU=DEX9'I#0T9*,%%1,#E15'AV2D%O,TI(<6E.<59',U9Q1$95=S$O=T1/
M:GED;R8C>$$[;'AD,C%W=#5,3EI31TM9=S(W4$=(04A'<V<K14MX3D%3975'
M;%IZ1$Y(3D1(3D5E56-Q:#!B8U96:%5':'=+9V9,9B]!0VIU;&8X028C>$$[
M34AB+T%02G!C;%!M5W)".45F8T5X>4QA-T9867%L,VU8+VQ(3E8O-6<W:B]!
M2DY.:7)V3%@O2T]A5B]Z0C(O+T%#85A&57AX5C)+=28C>$$[>%8R2W!:6F8X
M9#=5+W=$:DAB9G%F2DAK1W%0,6XT364Y8E0W,WI4<59S*VPS5&963E-T4DQ-
M;'9"2F%Y5')B5W,X9'<W379,;D5(4B8C>$$[964W3'=(16EG041A>E1!<4AV
M8C9#>D5*;40P;FQ30D-I331$>4=I.&EO25)A+W1.461U<$%X5DM2-7=T9G%I
M6&)73C1S56M8<DE"1R8C>$$[:G54>C1E;'AJ9#(Y44M1-5@K6#-"06%60394
M8S(Q>"M:97500DMK<6I2=$I6:6I"9T=&,7%2;V%D1'9I<DQ-5F1I<4<P-R]E
M9"\X028C>$$[:DY0+T%-;FYX5D4T<3=&6%EQ-T9867$W1EA9<3=&6%EQ.'8Q
M82LX-&YZ3G%Y869R,FHK;F(S;'-O<S=M84E33$8V5'8Y6$DY1&Q%."8C>$$[
M:3%&5UHY=5(R-EE64FYM0S<X,#)T.6-U,G5A3'!7;%%#,FQM3312<#%J4T$O
M5TLX:'A5<U=Q:D944E(P,WA1;C-K-GHX,DQ$8W8U;"8C>$$[=7)3.6IN4S,K
M<&TQ6&)I<U%%<&M*5F529#9T6'!V<T)G4WEB1E5U.'0O.$%+3S96+W=!=V1V
M.$$X;6QY52M:87-(,%(Y=U1(271R<R8C>$$[5F1I<5AE6F8K56,Q6"]M1'50
M.$%K,#)+=3AT9CAO-7!8+TU(8B\X04IP8U942$9867$W1EA9<6QL;"]X,W14
M+T%/361T*W X:V51828C>$$[;R]79F=X;3EV8DXO>D)J=&AE>C,Y=WIE:TY'
M:VAU:D)%,$,R<SAK>7E2;C9O0D%T>$A,>FUI6GI)-%)*4CEG4F)5-C@R-C=R
M96DR528C>$$[*V]79&AA6$=N5TYV3&0V:&18;#-,8D-/3TI3-V5M:T9R979)
M47%K;C12,G!Y-TMP>$-F<F1P1$IC5WI1331J;&$Q;31-.&)I:FA7328C>$$[
M8E-2.&M99G-S4E5B131Q<V93<D-294UK9G%,>#0P9&UF871F,FEF06(O4FER
M1W1%,#=4-T@X>E!-27-R5TLQ1GAP3VQZ>FE'3EEX2B8C>$$[2SDS<5!+4BM)
M2$HR;TMS9#A69E S+T]4;FUR>E)P9C5K<&)A6G)&.5DR,S909V8P3&$U;6A4
M:UAK<3-&1U563DU5:#5,+WES1'HU+R8C>$$[,4UM<68Y2G1X+WI8:6QP9E S
M;G!24F9-97%+2VLP1C=C1&-M<% R*S5X5VTO=T1L64AN>B]Q6DY5+S948FHO
M;79&6#9&67-867$W1B8C>$$[6%EQ-T9867$W1EA9<7A855!Y=CAL6"MQ6$=Q
M6$YI>'9R;6%/-6UL5V%645HT4GAI;#1H9W9.1G%!861#4FER5W!F;&(U1S%,
M56(W528C>$$[<C-45FPQ1%5!;VYU:3AN<41J04Q91TTX=F<O9$1I95!8=FER
M2C=7,FAT8F%+,F=8:$)!:7AX2E5M:4E/2VEP<65G-S1Q<5EQ;#-L=B8C>$$[
M+VQ(9$LO-6<W9CA!-4Y,:W X>3%94&]J-V=M3U)B6%EQ-T95=3AY+SAO-7%V
M+TU(8V8X04IP<U9D-6$O-5)Z4W8K64\S+S5.3&EQ628C>$$[-'$W1EA9<3=&
M57-S=BM/.7%F.$%X:G1V,5!K:GE$5D@V>CA'251A8G!&=#4V=3E5,50V<&)8
M9'AQ3G9$<&,X=7%Z5W-S9VQT8E%'3B8C>$$[3%=0.3-),&MT=E0P,B]V3T%R
M<T)K5S%!+VUJ8C-6-7(Y<EE10G)Y3S=G:6AV=%!A4S=T649T2DI*5FUN96(Q
M-$Q/8G%&34@Y-%)V=28C>$$[2T%&6'%'0EA9<7AI>"\X04IN83,O=T)S6%-F
M*V]V57-69DU8+T]6,R]K,&LO=T,R8F(O.%1K>%-(:E=+6%EQ-T98-E4T<UA9
M<3=&6"8C>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<6PS;'8X0352,U-V*UE/
M,R\U3DQK<#AY,5E0;VHW9VU/4F)867$W1E5U.'DO.$%+3V%R+W=!=R8C>$$[
M9'@O>6%B1EAE5W8K56,P<B]M1'0O=T1K,'5+<&II<G-69&ER<U93>7DO-#<R
M<"\X63=B.50U23AG,5(K<R]"-78U9SAY-DYB9FUP2"8C>$$[8GDV-61,<6E8
M5G)B46%3,"MN=$%N2C='3VM533%T3&-2;61.5&M::D<T9#%J8V-G04]%5S%L
M9FXU<DM85'14<V)39&)(>D1C5U-P828C>$$[-FI(8T,P:VAL:V%28D5Z>DDV
M4W)%8FM%2T="5GI644=*2S1Q>6)52G)Y1TM*<E=-4VQP-%5L0C5%:4HU07)S
M;UAU;TYD.6@Q-UEQ>"8C>$$[:E9D8S@R5W5N3$Y"2D9*3CE73'-Y-E!Q13,W
M>C%O=T@Y0TMB,4MC2%I04W)Z2B]E5C1+5GA65#AT-FAC6#,U:RM9;6YS3&I4
M,F<P=B8C>$$[4S11;'HV6#<P2F1A:BLK:3E*-68S8E8K2&QX8F)D4FER-7<O
M-7EU+SAM:VXO8DYT+W=$:6-M2U$X87A3-T9867$O4VY&:3=&6%EQ-R8C>$$[
M1EA9<3=&6%EQ-T9867$W1EA9<3=&574X="\X04M/-E8O=T%W9'8X03AM;'E5
M*UIA<T@P4CEW5$A)=')S5F1I<5AE6F8K56,Q6"]M1"8C>$$[=5 X06LP,DMU
M.'1F.&\U<%@O34AB+SA!2G!C5E1(1EA9<3=&6%EQ;&QL+W@S=%0O04]-9'0K
M<#AK95%A;R]79F=W>E@Y9G9B4'IN2"8C>$$[;U1Y>E(R,G$V<EEZ5S$V53%H
M4VIX4G=S.6Y$-E9U,7!+:W%7-W,U1GEI3'IC=6@T3GII,F]B.#%,>EA)3E=H
M<S)6;3AS87)A9E9B-B8C>$$[,T8Q16XQ;&DW0U<R:G1O8D,K,48S949V:6%!
M-TIY4#=S<GIX5C9F:7)S5EEX62\K5$\Q=B]T:394+S%&-FQI<C5I+S5Y=2\X
M;6MN+R8C>$$[04=Z8F8O:6-M2U$X87A3-T9867$O4VY&:3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1E5U.'0O=T1+3S96+WI",B\O2G!C;%!M5R8C>$$[
M<D(Y169C17AY3&$W1EA9<6PS;5@O;$A.5B\U9S=J+VLP,DMU.'1F.&\U<%@O
M34AB+W=$2G!C5E1(1EA9<3=&6%EQ;&QL+W@S=%0O-"8C>$$[>#(S-FYY4C5"
M<6HY6BM$0S<V93!G+TUA-W5K;&=453)M<TQ0.49T3F5I+W4W6FI$+W!525=9
M4G)A=T<T:S52<&)01U=J:TQY2U=F:"8C>$$[1G11,S5I5VUH3C4Q<TQR571&
M=&1A:&AT0613:75X;W1)<DI28T@Q54XW3$)D:#%U1$A8-'92-&-Q9DAI<C Y
M2%(P5C!936I!37)+828C>$$[9V<W9V=J1E<X5EEX62\X06MZ=&(O=T,R3'!0
M+T%&1C9L:7(U:2\U>74O.$%*<$HO,GIB9B]I8VU+43AA>%,W1EA9<2]3;D9I
M-T98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T95=3AT+SAO-W!8+TU(
M8B\X04IP8VQ0;5=R0CE%9F-%>'E,83=&6%EQ;#-M6"]!2E)Z5F8X028C>$$[
M;41U4"M45%EQ-WDQ+W=!;S5P6"]!1$(R+W=$>6%81E5X>%8R2W5X5C)+<%I:
M9CA!2&4Q4"]J2&)F<69*2&M'<5 Q;C1*4'%7;&5A1R8C>$$[,4<T154X0S9D
M8S9P63-S9#%*9#--8S!%34%T,6UT;S1646]W;6$S655%<7%F5F)K<&]E8U<Q
M:W1Z6E=D>5EZ8W=2>FU&=6-2:U)8-"8C>$$[4# U3'E";V9C67%R67%W1UAY
M,RM93&%"0G T=3%E-VIT2F]P3#)85DQJ,6YK;&-O:71*8E=D<E@P-'E*0DUQ
M2R]*94A1=$II<4XP2R8C>$$[3%4T+WI-.'A#+W5)8F=T<%=L=&%M0T9O3T5"
M=3E2-$I*>6QM.5-18CAN2$5(*U59<2MB4"MC<G8O2G!*+W="<S(S+S1N2FEK
M4$=S528C>$$[=7A6,DMV,'!X675X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%9,=DQF.$%Y:G5L9CAW9'8O>6%82E0U;'%W9E)(,T)-8VDR=7A6,B8C>$$[
M2W!D-6PO-5)Z5F8K64\T+S5.3FER=DQ8+TM/858O>D(R+SA!>6%81E5X>%8R
M2W5X5C)+<%I:9CAD-U4O*TUD="MP.&ME46%O+U=F9R8C>$$[=VYZ2&9A8VYN
M;3)P3DY,8U)8,79Z<W(V0T\Y<S!D6'-,6G!R4&Q*2$QA>FQD6&EO>6MP.$QN
M,'EX<3!7,394:7)S5F1I<D=,2"]Y6B8C>$$[,G0O.7-84V8K;W95<U9F35@O
M3U8S+VLP:R\W6G1V.$$X5&MX4TAJ5TM867$W1E@V531S6%EQ-T972V%F*V%0
M:VI56DY,4WHQ07I.<B8C>$$[5#-C96PX65II2GI9:R]70W)C2U57;&%N<C)X
M5D]03%AM6%)V375J5RMS-DQ0.6$P,C8U96A0=V50;'=9;S-W=49B6FQ)-EEQ
M;65+=28C>$$[>%8R2W!8-6HQ1%A,1WAJ;3!B5$4Q5S9A84].-UHU+W%W5TYJ
M4C5/9G!Y,31$8VEL4T]L5%)3<3-O96\V>&4O6&8P;'!:,'HV=F13428C>$$[
M5W9+6DIV<D5+530S0SA0<W$Y9&QB-'9%67%M94MU>%9,=DQF+TM/-E8O>D(R
M+SA!>6%82E0U;'%W9E)(,T)-8VDR=7A6,DMP9#5L+R8C>$$[-5)Z5F8K64\T
M+S5.3FER=DQ8+TM/858O>D(R+R]*<&-65$A&6%EQ-T9867%L;&PO>#-T5"]W
M0TUD="MP.&ME46%O+U=F9VMW,&)Z528C>$$[=FYA9E5M4WEU9$5L2D5C8VMP
M5UI&.4\Q16)+9W1M*TM*-#=K+W="-SA8<4-P;W%H671R3$U69&EQ;F,S5G9B
M46UA-&M72TIA8VY9,"8C>$$[07)T:7)'-T%G+VUB<EI"<41O;6MK168X>&5P
M67$K62\K8W)V+TIP2B]W0G,R,R\T;DII:U!'<U5U>%8R2W8P<'A9<%HU:SAY
M-DPU828C>$$[,&$T,7)7-VXV<'!L<G<Y930T4U-C9E5D63 K0TI88S%D=TYH
M:7)#4"MH:B]!36U0*W!H+S9C-S<O<6AI;6YF.41(+VMX+S%-4"]4;B8C>$$[
M9F8X059$1F%D+S!-9BM42"]5=R\Y3V0Y+W="54U6<&QV;$1Z>#58.#1A9DQQ
M2&QY.2MV5V-%<'0U6F93;&AP2496>79'6DDR*WDT,R8C>$$[<%1&0V4T<3AC
M,3<O04IY:SAH-DQR;6\V4&1A9'%J,T]M,TTQ;D\X559U55HT2D1'>%%T3W T
M:W)T541&3DUC8B]N3511-FYJ-6)U:28C>$$[3WA.>$=0.$%J531R4S9,+T%*
M>D0X=FU60DXU9'4P:4Q$,4=394YM0S$S255Q;TIP,G%-5G!L,VMV+VY)+W=!
M;"MB=DTQ;#5D,#9W,28C>$$[2T<X=FI)27!,:4]"66@V8U13;FM5;61V<V]E
M:31R5#%B1D-895<O*U5D,'(O;41T+W=$:S!U4VYZ3%9G*VE0=4-9-49T9&ER
M<U93-R8C>$$[>DPO>6IM<2\X=V1X+W=!;6UX5C-L<B]L2$Y++S5G-V8O:S!U
M2W!J:7)S5F1I<G-64WEY+S0W,G O=T1'3S(O52M34$E.569R4'=44"8C>$$[
M271R<U9D:7%&,5146612<S)T6EAK:41%15-W='=K56<Y5F%H<%5B9DQ&54]0
M3&UI:35E-E<R0S--:4Q(2DUR3TA+4FQM4D-183A6328C>$$[:D92,$94-#1Q
M>$AZ4F]F:T4S9'AD-C4U42]32'!&8F5(57!O<F%C5'EU63%G=#1M:VTY44Y,
M3% V4V5O<7!Z0G%W2$5S<6MT;'!F-28C>$$[2C-0;6UB>7<O:S8Q=&17=#!"
M;5-E,'1H1TI(9&A&0C9I3S9M5U=&1&-)9S--5E<O6EE+<6AB>4@X;&)/,49X
M4#5(:%)N:W8T3&4S3B8C>$$[=G T;&UM,'DT1G).1D-P;DAQ4U!+94U583%:
M*W=X5DUP9DPO04]414TP355V:S8R:BMT5&TS=$AA>6A#>6QB*TA4;F1A;6]2
M6G)L1"8C>$$[5F=/4TAK;DE9<3E%+U%M;2]W0RLR+S5'4V8X04Y72V]F55!+
M9FPS56)2-U!53$I,>3!L<#9L=&-&<%DR-&M-=DI(2E4P64%J1E5N+R8C>$$[
M04]64F9L9B]!3E-T<&XO4TY(+U1&5TIZ860K4G1V<&\Q2S4X<%<P1F\X1G)E
M5S=V67A6;70W>#)#4WAQ=DEN9VE'4U94.&%*.%1+328C>$$[5EI94'EJ+TLT
M9T5E5CE-24\T271O+S99<6UM;"M3=DMU:W=.8C96<'-/;G=/,W%01F%G=V]8
M24$U1EEY;TIO04LT<6I0,$IP=BLK,B8C>$$[+W=#4FMN+TY72W!(8V9L5BM7
M.7IC4S-.>C5A,"MA-&UD<$IP<$E%9#-D>GE:;5IG4U=*3E-4:7%1*UE02G8U
M4#9*8U=D=&-E5710;28C>$$[=4PT=#E89VEH<WA+-&I:02]#2U8T<$I3;VLU
M1EEL6G%D0E=G2W%),%0X=B]!37%.5RMV96PU3G1,63)&,TQ:=4QM>FE4,41&
M42MR128C>$$[4GE$>$]'*T9V;TY#0TU65'%W+TQ,.'9T4'4T-WEW.'8R3G!D
M>%8Y2S1G:%=+4F512VYI-E595D))>%9024Y,<V]*5FQI4F<V,6]3-R8C>$$[
M=#%&3VA9:D961'DS+W=!;S=P6"]!1$(R+W=$>6%82E0U;'%W9E)(,T)-8VDR
M=7A6,DMP9#5L+S52>E9F*UE/-"]W0U1467%L+VPW>B8C>$$[1&]%96=A6DA*
M<61O:VE7:T-U:E1X9V=I3E%145=X5DU0.%,K6% X07$V,F8O4U)&+W=!,5EQ
M-R]!0DPU8R\V=71N+S!K4F8X,5EQ-R8C>$$[+T5V;'HO<38R9CA!,&M29C@Q
M67$W+T5V;'HO<38R9B]!16M29C@Q67%L:RMO-E@Y9FUU-U1Z1%I1975S87E2
M<S!-;CDS5VA".5)F-28C>$$[<VQE>E591S="9"MM278X07%A3E K-D@O04MQ
M-#=D>3A-=2\W2&9P:4PO<6%.4#A!=6@O-G$T-V1Y.$UU+W=#>#,V66DO=T-P
M;S O-R8C>$$[;V8X07%R:G0S3'=Y-R]S9"MM278K<&\P+W=#-D@O<7)J=#-,
M=WDW+T%,2&9P:4PO04MM:E0O=6@O=T-Q=4\S8W9$3'8K>$MR>E0O3"8C>$$[
M.3=F3F4S9FU+>G5*5T,P:FQL-7=O-F9:;&EG3G=96356-U-O9V8X07ES8DAC
M=D1,=BMX4G0Y13AQ=U,K<VUT-F4Y>69Q-64V;%E3>B8C>$$[=3%M>DY!-WI3
M6$1Y3S9'4FAY6FE31'A*23)X<V1Y.$UU+S=&4G1,.'-T13!483-P<%)Z9$4O
M67%'=G)G6%9W>6XQ-G%Z5&]S9TDS528C>$$[9V-A63)/-65'6&8Y:49U+TQ0
M;$,V935E8EAR4&YD3W-J1DQH-"]39%HP=5,Q='=U;"MR1C4T:VQK.4AH>F11
M>CAJ:EDW;#1:.2\R2B8C>$$[-6)A:&(R.79&8G@K86)*;S155TY':UI*6$E5
M54)A4U-D;F1T=#)9:VYV:G0S3'=Y-R]S5F8P>$8O=T)44G O,U$O.$%66$AB
M=5AH;"8C>$$[,R]9-SE-4F8Y5%)P+W=",% O5EA(8G58:&PS+T%'2D9:95@O
M04-F6FME;'$K;'9W9%AG12]#-$5)4DAJ4T]!5%1Y0T=+3DI85DEO*R8C>$$[
M2TE'4$92530R3S5E1UAF.6EB5U8U63)6;D):5W9M6%0T-V$R:E-'0U Y,&5+
M4G%&559A66LP03<T,D\U94=89CEI=BMM278K<&\P+R8C>$$[-V]F*W%U3S-C
M=D1,=BMX,S99:2\V;6I4+W5H+S9Q-#=D>3A-=2\W2&9P:4PO<6%.4"LV2"]Q
M<FIT,TQW>3<O<U%M;WEA6'%6=3%V928C>$$[*UET4&QI86TS-W13<DLV>4DV
M37-W6DA2,%9K6E-'5F=#0T1J63=L-%ID+S)+5VQX84IP93)N*UE.3W0Q.4=+
M,S1R-F9%<$)Y.4]Q;28C>$$[8VIL.%IQ+S)J,TIO36)(8W9$3'8K>$U0,'A&
M+S%.1VXO9$0O04Y68V1U-65'6&8Y:G8P>$8O,4Y';B]D1"\Q5G@R-VPT6F0O
M,DEV5"8C>$$[.5HX=%=6:&)7839V84]T=$5K2W5:-&=323%#,5!X93)!-VQN
M0U!$141U4D@K2F9,;B]6,7,O.$%P26DO-7%W36YF-&PX=68Y6%=Z+R8C>$$[
M04]K:4PO;7)&6&8T;#AU9CE85WHO=T-K:4PO;7)&578X=RM99$%K,$15-#0Y
M5'1(:V4P;E9%5V5-:VMX<T%!03)+=B\R43T]/"]X;7!'26UG.FEM86=E/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D
M9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB
M<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T
M<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y+:7)A
M($AA9&%L<VMI/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+61E9F%U;'0B/E-L:61E7S0\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z
M9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @
M(" @(" @(" @(" @(%-L:61E7S0N86DF(WA!.U5S97)N86UE.B @(" @(" @
M(" @(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# W
M+4UA>2TR,#(Q(#$U.C(T.C Y)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @
M(# W+4UA>2TR,#(Q(# U.C4T.C Y)B-X03M38W)I<'0@5F5R<VEO;CH@(" @
M(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C
M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[
MXH"B(#$@<F%S=&5R(&EM86=E<R!H879E(&$@<F5S;VQU=&EO;B!B96QO=R R
M-C4N)B-X03LF(WA!.R @(" @("#B@*(@,2!P871H(&]B:F5C=',@:&%V92!T
M;W1A;"!I;FL@8V]V97)A9V4@;W9E<B R.# N)B-X03LJ*BI&25@@04Y$(%)%
M4E5.(%!2149,24=(5"!30U))4%0J*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN
M9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @
M(" @(" @5')E8G5C:&5T35,F(WA!.R @(" @(" @("!4<F5B=6-H971-4RU"
M;VQD)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @
M(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @4VQI9&5?-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C(Y-C0Q.28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#<M36%Y
M+3(P,C$@,34Z,C0Z,S8F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#<M
M36%Y+3(P,C$@,#4Z-30Z,S8F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X03OB@*(@
M,2!R87-T97(@:6UA9V5S(&AA=F4@82!R97-O;'5T:6]N(&)E;&]W(#(V-2XF
M(WA!.R8C>$$[XH"B(#$@8FQA8VL@<G5L97,@8VAA;F=E9"!T;R!O=F5R<')I
M;G0N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%1R96)U8VAE=$U3)B-X
M03L@(" @(" @(" @5')E8G5C:&5T35,M0F]L9"8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B965N(&9L86=G960@9F]R($-3
M.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I<R!L;W<@<F5S)B-X03LM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF
M(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,#1E,#@N86DF(WA!.U5S
M97)N86UE.B @(" @(" @(" @(" @<G(Q,#DR,3DF(WA!.TQO8V%L(%1I;64Z
M(" @(" @(" @(" @(# W+4UA>2TR,#(Q(#$Y.C(X.C U)B-X03M%4U0@5&EM
M93H@(" @(" @(" @(" @(# W+4UA>2TR,#(Q(# Y.C4X.C U)B-X03M38W)I
M<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I
M;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@
M0VAA<G0F(WA!.R8C>$$[XH"B(#$@<F%S=&5R(&EM86=E<R!H879E(&$@<F5S
M;VQU=&EO;B!B96QO=R R-C4N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N
M=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @
M(%1R96)U8VAE=$U3)B-X03L@(" @(" @(" @5')E8G5C:&5T35,M0F]L9"8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @
M("!#35E+)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B965N
M(&9L86=G960@9F]R($-3.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I<R!L
M;W<@<F5S)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP
M1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @
M/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-3DU+C(W-3,Y,3PO
M<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#0Q+C@Y,#8R-3PO<W1$
M:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU
M;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @
M/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5')E8G5C:&5T35,\+W-T
M1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A
M;6EL>3Y4<F5B=6-H970@35,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@
M5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-2XQ-3PO<W1&;G0Z=F5R<VEO;E-T
M<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS
M93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9I;&5.86UE/G1R96)U8RYT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^5')E8G5C:&5T35,M0F]L9#PO<W1&;G0Z9F]N
M=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1R
M96)U8VAE="!-4SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N
M=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3
M=')I;F<^5F5R<VEO;B U+C$U/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC
M;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA
M;64^=')E8G5C8F0N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @
M(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M
M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E
M;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T
M94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG
M<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG
M<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @
M(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z0C<P0T1%-#$S0T%&
M14(Q,3@Q.3!"1$0R14(S-4$R1#0\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z0C<P0T1%-#$S0T%&14(Q
M,3@Q.3!"1$0R14(S-4$R1#0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HS.#DW149%-C$X
M049%0C$Q03DY1#DU0C8U,C U-C%#,CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO
M>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z0T0S,4%"1D(Q,T%&14(Q,3@Q.3!"
M1$0R14(S-4$R1#0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z0T0S,4%"1D(Q,T%&14(Q,3@Q.3!"
M1$0R14(S-4$R1#0\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HS.#DW149%-C$X049%
M0C$Q03DY1#DU0C8U,C U-C%#,CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO
M<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HS.#DW149%-C$X049%0C$Q03DY1#DU0C8U
M,C U-C%#,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,2TP-2TP-U0Q-3HR,SHP-2LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z0C<P0T1%-#$S0T%&14(Q,3@Q.3!"1$0R14(S-4$R1#0\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C$M,#4M,#=4,3DZ,C@Z,3 K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 4$"
M7@,!$0 "$0$#$0'_Q  ?  $  @(" P$!            " D'"@4& P0+ 0+_
MQ !G$   !@(! 0((!PP$!PD+#0$" P0%!@<  0@)$1(3%!DY6)BWU@H5(3A9
M=W@6,34W05%YEI>SM;87(G:1&B,D,F%QTQB!@Y25H=3P\2@V0D-3559UD['7
M)3,T1$=(8V9SAL?1TN'_Q  < 0$  @,! 0$              0($!08' PC_
MQ !C$0 ! P,! P0'$@D*! ,&!P$!  (#! 41!A(A,0<305$4,F%QD;&R%187
M(C,V5W)T=8&5EJ'!T]7P-#=2559V=[31""-"8H*2L[7"X213TO$E)T5#1D=F
MHK8U8V1E<X.%H__:  P# 0 "$0,1 #\ V3.G9T[> <ZZ?_!V:S7A)Q-ETQE_
M$+C=)Y9*Y+QYJ=\D<FDC]3L.='R0/[TYQ-2XN[T\.:I2X.CFO4J%J]<H/5*C
MC3S1C$5W$ASL$]L>GNE3'\F)TW?0#X9>K+3/N9A5R>L^$IY,3IN^@'PR]66F
M?<S"9/6?"4\F)TW?0#X9>K+3/N9A,GK/A*>3$Z;OH!\,O5EIGW,PF3UGPE/)
MB=-WT ^&7JRTS[F83)ZSX2GDQ.F[Z ?#+U9:9]S,)D]9\)3R8G3=] /AEZLM
M,^YF$R>L^$IY,3IN^@'PR]66F?<S"9/6?"4\F)TW?0#X9>K+3/N9A,GK/A*>
M3$Z;OH!\,O5EIGW,PF3UGPE/)B=-WT ^&7JRTS[F83)ZSX2GDQ.F[Z ?#+U9
M:9]S,)D]9\)3R8G3=] /AEZLM,^YF$R>L^$IY,3IN^@'PR]66F?<S"9/6?"4
M\F)TW?0#X9>K+3/N9A,GK/A*>3$Z;OH!\,O5EIGW,PF3UGPE/)B=-WT ^&7J
MRTS[F83)ZSX2GDQ.F[Z ?#+U9:9]S,)D]9\)3R8G3=] /AEZLM,^YF$R>L^$
MIY,3IN^@'PR]66F?<S"9/6?"4\F)TW?0#X9>K+3/N9A,GK/A*>3$Z;OH!\,O
M5EIGW,PF3UGPE/)B=-WT ^&7JRTS[F83)ZSX2GDQ.F[Z ?#+U9:9]S,)D]9\
M)3R8G3=] /AEZLM,^YF$R>L^$IY,3IN^@'PR]66F?<S"9/6?"4\F)TW?0#X9
M>K+3/N9A,GK/A*>3$Z;OH!\,O5EIGW,PF3UGPE/)B=-WT ^&7JRTS[F83)ZS
MX2GDQ.F[Z ?#+U9:9]S,)D]9\)3R8G3=] /AEZLM,^YF$R>L^$IY,3IN^@'P
MR]66F?<S"9/6?"4\F)TW?0#X9>K+3/N9A,GK/A*>3$Z;OH!\,O5EIGW,PF3U
MGPE/)B=-WT ^&7JRTS[F83)ZSX2GDQ.F[Z ?#+U9:9]S,)D]9\)3R8G3=] /
MAEZLM,^YF$R>L^$IY,3IN^@'PR]66F?<S"9/6?"4\F)TW?0#X9>K+3/N9A,G
MK/A*>3$Z;OH!\,O5EIGW,PF3UGPE/)B=-WT ^&7JRTS[F83)ZSX2GDQ.F[Z
M?#+U9:9]S,)D]9\)3R8G3=] /AEZLM,^YF$R>L^$IY,3IN^@'PR]66F?<S"9
M/6?"4\F)TW?0#X9>K+3/N9A,GK/A*>3$Z;OH!\,O5EIGW,PF3UGPE/)B=-WT
M ^&7JRTS[F83)ZSX2GDQ.F[Z ?#+U9:9]S,)D]9\)3R8G3=] /AEZLM,^YF$
MR>L^$IY,3IN^@'PR]66F?<S"9/6?"4\F)TW?0#X9>K+3/N9A,GK/A*>3$Z;O
MH!\,O5EIGW,PF3UGPE/)B=-WT ^&7JRTS[F83)ZSX2GDQ.F[Z ?#+U9:9]S,
M)D]9\)3R8G3=] /AEZLM,^YF$R>L^$IY,3IN^@'PR]66F?<S"9/6?"4\F)TW
M?0#X9>K+3/N9A,GK/A*>3$Z;OH!\,O5EIGW,PF3UGPE/)B=-WT ^&7JRTS[F
M83)ZSX2GDQ.F[Z ?#+U9:9]S,)D]9\)3R8G3=] /AEZLM,^YF$R>L^$IY,3I
MN^@'PR]66F?<S"9/6?"4\F)TW?0#X9>K+3/N9A,GK/A*>3$Z;OH!\,O5EIGW
M,PF3UGPE/)B=-WT ^&7JRTS[F83)ZSX2GDQ.F[Z ?#+U9:9]S,)D]9\)3R8G
M3=] /AEZLM,^YF$R>L^$IY,3IN^@'PR]66F?<S"9/6?"4\F)TW?0#X9>K+3/
MN9A,GK/A*>3$Z;OH!\,O5EIGW,PF3UGPE/)B=-WT ^&7JRTS[F83)ZSX2GDQ
M.F[Z ?#+U9:9]S,)D]9\)3R8G3=] /AEZLM,^YF$R>L^$IY,3IN^@'PR]66F
M?<S"9/6?"5KE?"=^'7$GCWP)J.9T-QBX_P!*R]SY>P*,.4IJFGX!7TB7QM;3
M-_.JR/K7F*,#4XJ654Z,K.XJ&PY0-$<N:FY682(]$F,+*["<G?G=T[^D=>5L
M:],+S;'3Z^Q-Q8]AT&PJO[=WMG>,J<N%5<6XO;*T#2%.SNUM9B\W9"$MQ<$B
M(:T_7=[24@%)Q0E)NN^#M+)T,>N\'MU_6UVW9'))M%C'O#1EQ8USMD=;L X'
M=. L>>KI*5T3:FJIZ=T[MB%L\T<3IG[O21"1S3([>/2LR=XW;U[HU24M00C,
M4D 5J2SS4R49Q85"@I-LK2DT@@0M&FEI]GD:/&6$02MG%:,V'P@.VN"07 $M
M! )P< G. 3P!.#C/'!QP7U,D;9&1.D8)9&O='&7M$CVQ[/..8PG:<UFVS;+0
M0W:;M$;0SY\A73"+P#5)2U!*,Q20!6I+/.3I1G%A4*"DVRM*322!"T::6GVH
M(T>,L(@E;.*T9L.S =Z=EQ!< 2T$ NP< NS@$\ 3@X!XX..!5#)&V1D3I&"6
M1KW1QE[1(]L>SSCF,)VG-9MLVRT$-VF[1&T,\29*(R2\CCILB8BI 6B$Y&,1
MCNW@>0-P [&->-L$HTM"B  (AB5"(T0$(=BV9K6M[RXAF,?.B*0Q%VP)1&[F
MR_AL[>-G:S_1SGN+&=<*!M4:%U=1MK1$9S1NJ815"  DS&G+Q*(@ 29"S8 !
M). N8(/)4DDJ4QQ2A.H*+/(/(, :2>2:#1A1Q)I>Q ,*, ((RS "$ 8!:$'>
M];UO*$$$@@@@D$$8((W$$'>"#N(/!93'LD:U['->Q[6O8]C@YKV. +7-<"0Y
MK@06N!((((.%Y<A63")A%X5*E.C3GJU9Y*5(E)-4*52DT!"=.G) (PX\\XT0
M2R222PB,--,$$!8 B&,6@ZWO4@%Q#6@EQ(  !)))P  -Y).X ;R5221D3'RR
MO9''&USY))'!C&,8"YSWO<0UK6M!+G.(  )) "\3>X('9"C=&M:D<FQQ2D+6
M]Q;U)*Q"N1*B@G)E:-6F&8G5)5!(P&D*"#!E'%#"86,0!:WN7-<QSF/:YCVD
MM<UP+7-<#@M<T@$$'<00"#N*K#-#4PQ5%/-%44\\;)89X9&2PS12-#XY8I6%
MS)(WM(<Q['%KFD%I((*]O*KZIA$PB81<:A>6AS4.*1M=6UP5,ZK2%W3(5R56
MH:UHBPG!1N))!IAB%5LD8#=)U(2C=EB"9H'=%K>[NC>P,<]CVA[=IA<TM#VY
M(VF$@!S<@C(R,@A?"*JIJA\\4%1!-)2R"*ICBFCD?3REH<(IV,<YT,A:0X,D
M#7;)!Q@Y7)91?=,(F$3"+C6IY:'U)X^QNK:\H?#J4OCK4N2N*3QI$>-,L3>,
MI#3B?#I%)1B=23W_  A!Y8RC0@, (.KOC?&[9D8^-V [9>TM=LN <TX< <.!
M!!Q@@@C<OA3U5-61\]25$%5#MR1\[3S1SQ\Y$\QRLYR)SF[<<C7,D;G:8]I:
MX!P(3XY:/'OBSXU;?C+M[/B_QY+X]V]G>[/%/"^'[>[\O9X/[WR_>QS;]G;V
M'['Y6R=G^]C'SIV53<[S'9$'/\.9YZ/G<XSCF]K;X;^UX+RJW-M0; %>X(40
MC-"V6%6K(3;,T'>M"V#1Q@-CT'>]:%L/;K6]Z[?OZR USNU:YV.. 3CP!6EJ
M((2!--%$79+1+(R,N XD;3AG&1G'#*_I(O0KPC&A6I%H"Q:"8)(I)4A +>NW
M01B)&/01;U\NM"WK>]?+KY,@M<WMFEN>&01GPJ8YH9@3#+'*&G!,<C7@$[P"
M6D@''05Y2%*94$P2900H"4><F-$0:6:$I2G,$4H3F;+$+0#R#0B+.*%V&%&!
M$ 80BUO6"",9!&0",@C((R",]!&\'@1P4LD9('&-['AKW1N+'!P:]CBU['%I
M.'L<"US3O:X$$ A>H[O#0P-RIX?G5M9&E"7X5:Z.ZY*VMR,K8@@T8J6K#24R
M<OOB"'OFF@#WA!#V]N]:RS(WRO;'&Q\CW'#6,:7O<>IK6@DGN %?.IJJ:B@D
MJJRH@I*:%NU-45,T<$$3<@;4DTKF1L;D@9<X#) SDKD?O_>RB^Z81,(F]ZUK
M>][UK6M=N][^36M:^_O>_P FM83AQ7'-+PT/R$MT8W1N>6TXQ222XM*Y,XH3
M3D2HY"L*+5HS3DYAB1:F4(U( F;$0J(.3FZ :4, ;OC?&XLD8^-X#26O:6.
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M[IA%PI,DCJE[51I._LI\C0IP*US 2ZH37M&D,T7LM2J:@'B7)TYFC2M@..(
M6/1A>PBWWP]OT,4HC;*8I!$X[+92QPC<X9R&O(V21@[@2=QZEB,KZ&2KDH&5
MM(^NA8)9:)E3"ZKBC.SB22F#S,QAVFX>Y@:=IN#O"Y!:M1-J4]<XJTJ!$F!L
MQ2L6J"DJ5.7K>M;,/4'C+)*!K>]:V,P80]N]:[?ERC6N>0UK2YQW!K022>H
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M5:H[K5PW:K94S20TU+9XX73-9$YS)*B>2H#F!G.,>QD;6ASG-!VL..QJ=?\
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M4<I(Q?G'.O.1$,HTN#<L6.9.-;K*C7SE1)("[12+(IE\2SE7*S MLCTH:G%
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MJ9F]G1WFIH;4]\ @CDEFDD$,;& G&9$_N)ZYC=.$WD/5=*%S*QJON:1-#M'
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M2V*>@4M:34;_ +CS0U6&K?R'=7'2 2$#D0X(P-)&VT;FYN:8L1AVU295K8-
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M1&Q^SEK8Y=L!QRYVRW,G<VW6_*90ZU\X6K*#1!NM^TK=+[I2XV%U\\S*:X4
M>P6Z^QUTAJZBG;( ^:JH13.,(:(HC).6TL2N'?(;F3#>!]G<@GU!$KY;(R19
M+K#FLYQL=]N1YF:>SPM;RKE[@X*EK:K@,6:37UY(0,G@7D#"RHT)9Z36C32=
MU?;78JC4E';(G36U\QI&3O#:6.@C@-'MQM@8UK7MJ9GB.,NDS'SLCG$.W ^;
M\F&MN5&U\C]_UI60VW6%/0,OE3:Z=\]]K-455T9?VT]5)<YII)8)+/;Z9U95
M,@I-FJ%'2Q0M?%Z9S;$^$M[3OD%7KG-IG87'"P233&430?Q[W-4NV 2UO,5N
MC#/V&=.3B],3^B/$G C(-\4&J2:-5&I"M#+UG+Z@MM-;*IE/3TMUI2!('BZ"
MG/.[+@UDM-)3L;'+$X9+B-H-=AH<<%>V\D^L+OK2RU%UNE[T->FN=2&F=HHW
M6,T1FA=+44=ZH[O/-54=9$XL$3'"(R1!TCHVY:II9H%ZJM73X6OYN.E?MLUQ
M[">2.%=G$][Z0KINF%YMCI]?8FXL>PZ#84/[=WMG>,J<N%50#Y$<9>45T/MB
M,,8Y=(H%1-J1T$4D=9*:1C$J=F1A6QXN.RM'&I@N>DK@$R6)A+SU"A467MH4
M.!AK:7HPDLS?2VN[V>@CI9)K&ZIN-'+S\56+C-"R25LIEA=+ V,MQ"[9  )Y
MP- ?N)7C6M] \H.JJN^4=!REQ6;2&HJ(6ZNL#])V^XU-)1RT+:&XQ4%TEJXY
M\W)AFD>^0--+).YU. 6M*Y1#PL8X?:'&"Q(E-')KC/%>E9=4;-%3X_\ 'S])
M$+W&0,*5\,?BUY)1+JA"3I<<A*B[B4ZK!B)(*1%# 3JCK_)/1WBEGIVOFO-P
M@KI)A+S<<+HYN<,8C+22QV=D.,S"QH!)<<E?>'DJI+7J'0%\MMUGIZ#D]TI<
MM-4MO?1=F5E=#54'8<=6ZK;,QC:B(-YYT+;?.VIE):QL32&"CKCC 7RI;SJ1
MZHM@F5G7$9;(&N>Q6V^#SS6TBB4*DC\Y"FLUDUJN$VD+%$G5L:U9Z1N61HMN
M* B4%IC4P"PJ&E;Z'=:F.MMU;'<9(*.@%#MTTU#J*.KBFJ(8F"GIX:)M/%)-
M&][07ME+SM NVLD/;^2M#6:KTWJ[3=7I&BNFH-3G48I[Q;=2<DM38JVVVFNK
M)W7:ZU^HIKM74EMJ:>GD?%!+0-A:V*1L98&A]-+=4R\&36?CYRXHK^DXM0/E
M):EQ647*/N-$4&$!M<AD)"S#9ONH,W(Q,/Q/L6W +JQ:<_&-!TB;_!=IGG\F
MH0^YV.X]AX\QJ.@I##S^>R.P2\\YSG,CFN=V^UV)-C';.SN_5=+R1NIM%<I.
MD/-]KSR@ZAU/?A</,LM%I&HFTC12FE\T'&N[#[%R9Q44?/[>.:AV?3=K:.'Y
MC5;_ !0M7=@@/#QDI)VIX;%]RHB]S43I%$49^Z$#E]T1FHZ$C:3QWXJV@?-F
M:,\7^,2^[X<7R?? ^AO5%V*1YKW".NYSGL]C[$[IN:V.:'.YVMG;VH\8SL'.
M!L:;DR=3ZGY.=1>;37C0.E*G3+J/S/+3=346V.W]FB?LT]A!G-\[V.8:O:SL
M<^,;9]*L^&AM=\;>1/'W=BENX[Z>;X=@2S43$@#%OZ:F92TA3B8]R19MZ^YO
M:CQ@1NG=I^-^YX+1;9WO":M67X55UM=S[%+/,V.VQ\SSVUSWF>\/SSG--YOG
ML8QL/YO.<O7RL')<ZR:%UOHLWQM2=8U6L*D7(6XPBW>>JE?3!AI.SI#5]@[>
MV7"IINR<;.S3YVAC);P ED;;.-4HIB^15S>O'2GF^D/N^65ZADT3LB!)DX?#
ML\E@J]_"- 5\9C6.K::D?UAK<>M-[?&U1+>N09;=30S/NT-PMHJK;=:YUP[%
M;5.AGI*DG=)#4MB],=C98\.B:'AH[5I<UV@EY&;E0T^@[AI76)L>K]#Z9ATG
MYLR66&OMM]L\;!MTM?:)JP&%O/F6H@='62NA=*X'G)&P30<G87#6^;"WQ^L1
MWY.LBWD1Q]EEC2&/3QPI)F' W-JLI @:W".JZY22E,629'T#>G(8)&%Z-<PZ
MT8>H*^,1)G%#2EOMMI?-.E9:)&VNZ04L4M,VX2"I8^D>Y[)6U3H79YQSB98N
M;##N ])ECLB]<EVL;UYS+W5:_I9M;:+N5\K:*\3:3I39YZ>_0PT\U%)8X[A&
MUKJ*&!C**M%4Z<>F>]HG,<\6+SNF9,W>!WW#)5R-3R-PO6ZJSO-SEAU4D-ZU
M!*XBLTYRQ+MG;YNG;AM,C6ED%,"1*8CW%T! 2#S'XS>S=9@U;3LJ;;/#:C$V
MW6^KMS(16%S703M+('<XZG+^<B:7&5Q#A,\Y B"Y]W(+=:FSZRM=QUQ'73ZO
MU58=75%R=IUD$L-QMLO9%RC[&@NS(#35TH8VCBC,7F?"P,>ZL=Z932E''0<C
MY7U?R<U+PHP5Q6$QKD4*VP[4#>!2Q;M7IXU(OCDG2#2#M\'M!MD6;4_Y_CB?
M_-S00W0166LM',;1JJR"J[(YS'-\PW9YOFN;.UM9SM<XW9X;)7JEPT.:[E&T
M_K[S3$3;'I^YV,VKL,O-4;C*9!5"M[*8(1#G9YGL27G./.LX*,U2\"[(J^J;
MMXX;Y#I7SCM8L"N6(P6)&U<WI)=!'&W3#MZ>W*8%R,PR3%1DEP>P :](FHEZ
M4NHUAAK8!,E1D[>MU)25=;;[KYENCNE)4T$]1.*QQ@J64('\VR#F@(3,6QY?
MM/,8C#0'ESG'@M-\CM]T_IW5FAO/M'5Z(OEFU3;+1;7:?@CN5GGU*YQ%7/<V
MUQ=<&T#9ZL"GYNG;5R5!D<ZG$<<3(Y\TZ4>F_AYQUX5LI,TM+DI%MUN73$UK
MROG]DC[.* NB"(+)+*I 0Y.Z*"-;97KFN3N+@O?^U<Y)B7H*-&1K93=M+!<&
M.OMTU!(8*.TS=EFX4]551222=DQOG;##$YL;JE[ZIC"QK8O2L<8RXG>[AN57
M2M7!R8Z(Y*J5MUU#KNW&Q#2UULEDK*2BIO,:HAMDM=<*UD]5%:(*>RU$S)YI
MJS^>GC95B*)GI8+=J9JYAI.IZ[J6, UIDKV(,<51G>#T48N$U(2DZQU4@#O>
MO'7A<%2Z+A]N]F+5AYF][V+>\XBOK);A6U5;,?YRJGDF<,Y#=MQ+6#^K&W#&
MCH:T#H7Z7TMI^CTIIRR:;H!_PEDMM);XG;(:Z8T\362U$@&[G:F425$QW[4L
MKW$DE8MKCCF. <FN1_(D4P Z@O\ :JD; 1'3#M"**?T7Q8R-".$^[>5>GOX[
MV9XYHO3.T_%VM>+[&N[?#:S*NZ]DVBU6OF-CS,?7/Y_G=KG^S)A+CFN;;S?-
MXV<\X_;XX;P7/6/0YLVO=<ZW-S%2-9T^FX!;.PS$;=YW[<Z@+S6=E2"K[+SS
MH:*6FYCM,S=NHUO7!2UHG9UMS3CAR(8*KC%Y2Q;/IM#IM1T7MGXBGCR'7W0R
MN$.KP]-0T)KT=VJSF9Q3*FXI2$&Q"4$%IDZ7;1ZBHIZ2BI[K:Y:R:W0-IJ:H
MI[C-1<Y31^I05#(XWAPC&X2-(?C/ DD\'5<D.HK;?]2770VMJ/3MOU=<IKS=
MK7==)6_4G8=XJA_QMQM-1555,8753R9'4LS)(&O R7L;&R/O]W\/9M,;.JV_
M:2NE/3%Y5S!5-9.CZ;7;5+(9.H.N6&NJME=H88ZM1+8$I]6.+PA&B7'Z3G*P
MEA!I0E1."7&M]\IX*.LMEPH#7VZJJ6U;(A5/@J*>H:W8;(RH#'E^8PUC@Y@R
M&YX.<T[G5G)C=;I?]/:RTGJIFEM76.SOL%16.LE-<K7=[3-*ZIDI:FUNJ*=E
M.&UDL]5$Z*5^PZ4- #XXIX\)^30D#I3=YP.6\ACGNQ[>OYJY(-MI-E9-\>*B
M]AM D)Y CH87*G%O=FXY20LV),0XM ""EA6@ ,&C[RC/\]D;*^W5,-K$=)0V
MQUI?1OJW2F:E?M@XJ.98YC\.;Z8L?DM).-K Y3T!:VHTOJZSW+6SZN^:FUG3
MZZ@U#3V"&A;;[W3&)[2^U-N,\%3 ][9<QLGIFL;*W9#C%E_=8UP4L>0W8ONG
MDGR$074<_P! S/CZ^PYHJ=!73*")30\P3@4TK6N5.1Q0!$JW/:L:Y"L7K%;B
M8:4M0(TR-O)^$VHZ2*WMH+3:W6\1W*GN<<\E:ZJDY^G V2]KX6@G(;L[+FM:
MUH!:YQ+CM:#DAOE;JR;56N]:PZK=6:-NFBZRUTVG(;)2BVW1[C,VGEI[C.YK
M2R6<R&6&2:66=SFRPQ,BA9V&@^*/)&BS8/7Z?EFCEO'2OCU"1HKU\I..BFKK
M#!)ER9O@KU/P2'?:WM05A0R'=$QD+C H$J0"9(V]B$OY7.]6FXBHJ397076J
M =)51W";L=E1M-+JB*F,?;/V3ECI2UNT3ES_ $YSM'<G6N](NM%F9RD17+1%
ME>^.FLE7I2A-UJ;463,@M%7>A6^HTW.M+*F&D9*X0LB$<=/B%O2*MX&6_13@
MBAE1<DHXU\>F^<&2MKKV94'$YQ,V5A72'[H7NOD%@KWU(><R/!IJY)MV4M7Q
MLVD.*@Y#H*T.E0\BLU)0W%IJ*ZTRR71U.('U4%RGIJ>21L7-1U+Z5L;@)(P&
MNV&O#'EH#O2^E6HT]R/:GTA-%:]-:[H:?14-W-RI[+<]&VV[72EHY:WLVKLL
M-ZFK(WOI*ISIHS4R4_9,#)WOAQ*.<=WR?<.;02<A9AR%XU\A2J->K8C\7CMO
M1IYK!GLN.R04-0 9XU(V9(O>V,+,]-#.4!$03L*E*<8)0>:8$I8M2J<:FOM&
MZUP6N[6PW&.BEFEH9HZR2DEB[(<9)HI'-CDYR.20[1.YPW #+6D;B\\E^H8M
M:W36N@]:MTC5ZCHK?1:EH*K3]+?J*N-KA;2T%=2QS5=(*6JIJ5HB:PB2-Y=(
M\N:V26.3,7#?C@;Q/H&*T@?,PS\V-.<L<ARD,?\ N7TO%*)0ZR39?Q-\</VD
MVT?QGXIL>G(X*C9.SPEI]&:(+P;[=1>KG/<13]C"9D#!#SO/;/,PQPYYSFXL
M[6QM=H,9QDXR>HY+]#.Y.=&V[2;[H+RZ@J+E.;@*+S/YXW"X5-=CL7LJLYLQ
M=D<V2)W!^SM@,#M@?S1_&T=-W'R>M@4R!(@\C9C$I6!A#']M(H?J+LKBT;0"
M<]O3EI^VNVO\8TITWLWBW@O!>+G]_P (!<;L*^@M%%S'->94$\/.\[M\_P ]
M(R3:V.;9S6SLXQM29SG(X*-):$=I?5'*!J,W05PUQ<[;<11BB-,;8+?2STW,
MFH[*G[,Y[GMOG!#2\WL[.P_.T,9\H.)%F71<U+7I4=_)*,G5+L4Z8VE<KJMK
ML\M<7/$A#:Y';1/4E9FPCP;7I8CT!0WN(MB5Z4DFICDY8MY=GO=)04%PMU=;
M'7&FN$E-(]K:U]&6&E<Y[!M1PR/.7EKMSF]K@@@K0<H/)M?]5:HTKJ[36LH]
M(W?2M'=Z2FFDT[3W\2B\1L@G=S5774U.S%/SL6)()SF42,=&]C2N@V!PFOV]
M:U9JJY%<M45HQ0%P0J?RTEMHIAKX^50:)]\]56(_N7F1)"-,^.0P.ALB4$.:
MM"K1-PDZ 04PPGY-+J"V6ZK?6VNR.I)^P:BF@+[E)4B&HGW-K!SM/EQC9E@B
M!8US7.R\$C&FO/)1K/5UAI=.ZWY28M06X:FM5YN38-(4=E?<;1;<NDL!\SKF
MQD4=7.14.KGLJ)898H"R$B-P?R9_39IJ$V_1ES<;DK+0$DJ>6N+G*$S,QNLA
M167#7YM"S/T/<P+96ATTG*&P:TAM>P <@MIC@H4#:EHPD:*J-65]107&WW4R
M7.*M@8R$R2,B=25$3^<BG86P.YP!X:7QDLVPP /:"<Y+^0G2]JU-I'5.A8Z3
M1E?IRY3U%PCI:2IK8;]:ZR 4M9;)Q+<8>QGOIS,RGJP)Q Z>1[J:8A@;G_F+
MQU_W5W':?T2"5?<4?,=QH]))A-6WPIM5QF6,<J(\.U:7M@U9"P;+X@;HM>G,
M("JVI!LT1.B#=98KKYBW2FN7,]D"#G@Z';YLO;-#)"</V7[);SFT,M();@XS
MD=ERGZ(]$71%YT@VX^93[H:!\5>:;LML$E!<J2XMVZ<34YD9*:7F7;,S',$G
M.#:+-AV [)X4V8X7";R#IN](Y7EIS"!Q:%7(GD].M-@P&PU<40)D#9+&V-NT
MC)7P]W2$IP)TQ!#T[ATW%)D(EFM:<3W794E_I&T(M=?;IJJC@J9JB@,->^EJ
M:5LSBY\#I60ED['$Y),<?IRYP;VH9QM]Y*;]-J=VM-+ZOH;)J&Z6>W6K5#*_
M2]->K->Y;=#'#!<H*&IKFS6RIC9&&,8RJJ1S+8X3*/\ B'U.:I]QDW;/%21<
M<[0EJ"4/TFB)C:Z60V0MJAQ9LV2* .D>G26',BL3<VJ65\1-#CIO1+P@4A;M
MI]J2BU M P*:[]A7J*ZT<#H8H9P]E(^H?.13N!9+3&>0![VR1ND;M.;NVLX.
M-_5WC0/GCY.J[0VH+G#<*ROMKH*B^T]JIK6UUVB>VHHKO':Z20P024E7#2S\
MQ%,!((-CG&AY(QG+^ -?R/B/6/%MFDKE#5%/*HC+*_LAI;$:MR9[3BPUJTV?
M*6)6<%$YC?G=YD*YY:359!9P7M46G6)32TZDK+@U-517NLO#XF3BO;/!4TDC
MW-9)13!K13"1HVF"*..)L;PTD<VTEK@2#H+GR,V6NY-M/\GU+7SVM^F)+;<K
M+?*:GBEGIM0V\S2NO,E'*X15!K:FKKIJJF=(QKQ5R-9+&YL;VY&H:E;RA*^2
M+KNNB#6H2YLB5E8F^&T9&JKVQG%"5A<7TUV;'AV7.*Y[3*@)UC>("9K2>*$C
M1% [YX3,6Y7"W5#8FVZWU-&62.DD=47&6MYT'9+(^;?'&UC8W-RUP)>[)VCN
M!&]T=I35MIFKYM6:JM&HF5%)'24D%KTC0:=-(YID$]8ZIIZFIFFFJXY R6$M
M93Q<VPQ 9>'8 KSA5?M/<9('QQKCD=7X&J(.ECIW<<TX^-TR89M#)T^*GY$Q
MOK&[3D[12]@<G1[5B6)5&D+N4XIFQ:V:(;!*7'95=_ME?=ZFZU=JJB^H92%@
M@NCX):>HIHA$Z2*1E,,LD8R)H:1M1EA>U^7[+.,LG)5K/3&@;/H:QZYLHI[9
M47UE2;IHJ"Z45VM=WJY*V*DK*.INSMF:CJ*BKE,L;^9J63LIY8-BGYR>4W$W
MCLV<4Z$@U&M4G<IB1$ /)RB1N:0IM,<W*0OSE(G,U(TD*%A#.VA7.AY;>V%J
MU>TR4!>CUBQ4(]4=I[W=7WJY5%Q?"R S\V!$QQ>&,BC9$P.>0TO?LL&T\M;D
M\&M& /0N3C1%/R=:.M&D:>OGNC+8*ISZZ>-L#JB>MK)ZZH='3-DE930":H>V
M&!LLI9&&[<LLA?(^-EA=/\Z=E<[2M6N6U_[M/=2[*%N$"6_T<?T7I-I1>$UJ
M6I?NM^.^WOZ[NXU\7?YN_'O\[-M2ZF%,=.'L(O\ ,#LW/_$;/9?9CMK_ )#N
M8YOA_P"VV_ZJX6]\C+[PWE?:-1MI_14.F]DFTF7S"\[\?-G:_P#$H_-+LOB,
M=@<QP_GN*S)-^+!DQLWAW8NIR!N#Q1+F99C1N-B5[G?W6P9GAFM@7_'J;49\
M0VU;<=Z$C?\ QK1_BG:GV5XR9@4]Y$%)?:7L;;\VC!B3G=GL;F*F2H[7FW<]
MM;>QVT6,;6_.!T]VY.W7._<F%[%W$ Y.6W1KJ;L$R&\>:-HI+6")NS&=@<R:
M;G]\59SFWS?I-GG'9FN6+VC+H4:T5!9+15LQTYMZL$C?H*BL1H5M:89FW%@7
MQU<ZLX/%GDL0$YZ\A8%8C*",24'AAA,+P*":C@J ^NI)*R#8<TQ15+J61KSC
M8E;*UDF^,Y(86[+CC:. NIU3;]0W.U.IM,WVFT]=.R(9175EGBO=-+3QEQGH
MIJ*:HI1S=4TACYF2B6)H=S8VG MK$G7&:%\6.&_)&!V2JE=SR;EA,Y6J$T5!
M3RM.WD6K*HXN<X8@@U:1<]\)C36QN\72N1+JO7Z1?&"1O+4#3!\11[ZZGN]1
M>;]:JFD$-!%98(6B2NKVEQHX96LG=4U<PC,KY8YG,+&MVMES\9],Y> 7?0-J
MY/.2_7=GOLMQU57\HUTN,G8NF=,2,A9J*X4,U3:H;18;>^K90T]'56^.=E1-
M,(1-% UY8.:B7=Z=X&OBGION7&.82-1#+1NY 9.K7E[FWBEKHAL"4R-GE3C\
M<H_CIM$].C4UM#1%%Y^GT&CU3::O"J4:%V&X]?J2,:K9=X(A44=O>*>B@8_F
M&.I8(GPLYMW-OYMCWO?,T<V<!X;LC&[;Z8Y'JN3D,J- W.M?:]0ZLA-WU'<Z
MB$W*HAO-PKJ6XS=E1=E0&JJ*:GIJ:W3/[+ ?) Z82/!PZ3TXXL#F=H</+&W-
MRT .*9,W)-911O:S[O-3&"L\+_JK_CU/J-:0?%6W$01(G_QO2CQ/_)_![4F:
MBGO/,4E]I>QRXWHTY#^>V>QN8J9*CM>;//;6WL=M%C&UOSLKT"[\GANFH.3&
M^^:S81R=,N['4AH.=\V!=+12VK(F[,8*#F>QN?(,59SH?S68]GG'1.5]-"=%
MPA^XX1_D^XL/#>2351*UM1$UJSJ)XW,BZ2%2QPKUDM$Q\"8DCBE]*TL+7'1T
M]>2$0TJ@I>4>MVLW0U;3FHCNLMH9)?H:=L+:XU<@IG2-B,+:J2CYO#IA&=DM
M$H83AP+2&[/G$O(-=Q::S0U%R@5%'R7UUUDN,VFFV*E?>(*2:N;<IK+2:A=5
M[4="^L:)6S/H7S-!,<C9VOFYV1_(C@M5O(29\:I4\ *9TG'J3)E6V1.A\823
M"#($R1:WP)R$)25O36EE#!%W &U85Y(6PE^;P)0GO.UB?56O459:Z>[0,S(;
MI"6\X78=!4.+FOJ6#!R]T,LS3C9.V8W;6(]D]SK;DBT_K6ZZ#N-4&TT>B;A'
M)V(R'G([G:(8XY8;/.3(W_AX[A1V^8&03-%.VLA$8?5<ZSO5H<;!61R6XV<A
M-S'XG*X_-UOMYL1"Q#5FRW5JP_44T:5(2WM$*/B8^S:[Y&AV$X=NB F(!:TH
MS&H[KV):;M;.8VS<WT#A/S@:(.PIS/@Q&-PEYS.SV[-CCA_!;?4&A#?=>:%U
MIYI]C-T9!J:%UM%(Z1UR&HK8+=M-K6U41HC2>K;J:I,W: PD;:@2#I<VT@JR
M+T2S\JVI-4%76JCMNKF!71[:<_?=$EEJR2DEV))T<V0+96F0E.[RE)TA+935
MBI0A5'F)T+4B9RNE.L*%];-<9+,\UU91.H:R5MQ>(^:,#82:6%U.YL)<61D[
M1D#6AP +GN>?'!_)\U)#IZWZ0I>46G9IG3VHHM2:>HI-)0.J^SH[C+7,%\N$
M5VAEN+(6U-5&WFFTKI9)(97%D--#2MG77G&UUK_EAR$Y')YRD7L5_P 8K)M=
MH&;&3"7!E?ZSCZ2,-CHCE(7T9)S:H:R5IBAK,8-'FK'( ].!)3;H"_G*JZLJ
M;+:[4:=S9;9-6/94B8%DD59*9GL=#S>0\/+0'B7 :PC8)?EGK]DT+467E&UK
MKF.[QS4>L[?8(*FSNH"V:EK;#116^GJ([B*PM= ^G9,7T[J(/=+4 B=C:<-F
MY"\..0[CMKC-: 9@&.AX[SB23(;()@VZ[EVI QIV;3<%QT\MNF':39'C&U>T
M+QH_O^"\6)[OA-TM]T%#17:DYCG?-2FBI^<YS8YCFI><V]CFW\YM=KL[4>..
M3P7VU;H=VJ-2:"U +F*(:)N]==#2&C-2;D*RD92\P)^RH.P^;V-OG##4[>=G
MFVXVEU%]XE#?.45@WV?.2PQ.T^.:F@)I7VX\,3F:G-<350) RRX#T26V& 2F
M!3B1J(^XZV+Q@>CNT\@2'[QWH1V>FMHIR9Z.ZBYT]3SOI 0P-,4D'-DO&1G:
M;*S=C=N.UK:ODV-9R@WK6+[NT6W4.AWZ,NME-$34.8Z=T@K*2YMJVM@(C<&&
M)]%/OVSM>G888D(.FG=YD)I6I)+S 3/50<?;2A]@U]$2:,9T#DN2P]Z6N;>W
M2>2D38+BJ5I4;@L:&U0FT!$F+4FK5S>YG%HB46\=JVWBIN%=#8S'77.CGI:J
M<W&1S&NGC:QSX8C3[#6ES6O>'9<X@-:Y@+B[S6'D'U:ZTZ4TW7\IL=7IG1>H
M;9>K-;&Z1I89YH[9535$,%?7LNPGDDCBGEIH'LQ%&V1TLL-0YL+8I'2O@E&I
M_8O,B5S29*7",<NH%6T(6QAN8PMSG!AUU&RF9$_(I"<[."=Z7#<TR1^1$'L"
M!,A4)2DRD+F3LS8M3!J.6EI;%!3T[6S62JJJELSY"]E1V5*9'1.B#&&-H83&
MXB5Q<'$C8.%W5RY(*"\WOE0N-UNDDUOY2[/8K3+004@@J+0ZQT+:6&LAK7U,
M\=7,:B.*LA8^CACBDC;'(*AFT3B:-<"^0)TLXUN=L<N6^R(GQ;F+>_P2/@HY
MLCSR\M;6UELR1+(I6DFYZHYT V)TJ(+@8B7Z$$DU6N Y+U6U).=-J2V"&[,H
MK&ZDGO$#HJF7S1?+'&][S(YT4+J< ,+R7; <SB&MV&M /-4'([K1URT'/J/E
M+AOMMY/;I!66BB&DJ>AJJJGIX&TT<=;<8KL^1U0*>..(3.BGR&NDF$\SS(V9
M'*/CK'>450NU6/SVZ114-T9)/%)BR%E'NT/F497 <6"0HDQXRR%GBQX3$RQ$
M8<G$K;E:Q.0L0*C"%R;0V>Z2V>N9611LF:&20SP2$AD]/,TLEB<0"6[0P6N
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MQQOC;+_.N:YS&.8QP,@+L,WY.-ZY!O<FYW2%+VI>B<T)_>\"M;U1"U(=W!;
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M+0"YVP[#0[@7'& #T9QGH5.S:/G(XNRZ7G9G/;#'V1%SDKH_5&QLV]J1T?\
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M1%Z5I0J6UU,;A*4YJXD6<Y3S2TUFT350T;J]T%RNNS3-:7&5[JD[#&X:_$I
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M*^T6]U-7U</-\S4UL#J<Q551%S47-33LDDCYN/9<-AN/8DE45;,72/ODNK6
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MF+5&)]':+$>!.2 >P[$$O6MZR2& D>F^;_9,O/  CH/ G?U9W>%9*\<Y\_\
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M5W%9TI=E]EQ:G(M&[++=)NP<E=50_.+G.T;R[+7TFIWUN<E)AJL1[ZI/T_*
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M_P!/>#<<[;M-5,VBK[EIF2U]/ZID+K%X<_2J0-R)V4M\"M./K5459G,_Q=7
ME+?W# HS7DS9G>$(&,@Y[GWP>@G>T#'2@P#T[@..1\V7# )P/3$Y(W#HN/RJ
MLG;K\^$7YW@]O=[==[[_ &=NNWL_/V??PB:WK>]ZUO6]Z^_K6]=NO]>OR81-
M;UOM[-ZWV;[-]F];[-_FWV?>WA%1!U-/.7]%+Z_+J]D#MD] [Y\359O"3VK/
M+*O@R%54.?"4_-#\A?[2TY[4XMDC@[O?2%9GJD?MO]+E\NK(6<F$3")A$PB8
M1,(F$7T-?@A7S#>1?VN7SV-T_D] [Y\35B3^J?V&^4];8>0ODF$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+&MS_B>M?ZM9U_*
M[KF70?AU%[KIO\9BT.JO6QJ/WAO'^7U"C3TV/F*<9OJW2?Q-SS;:L]<=W]UN
M\ABX/D)_%#H+WC9^\U"G!G/+UI,(F$3")A$PB81,(F$3"+5T^%K^;CI7[;-<
M>PGDCA79Q/>^D*Z;IA>;8Z?7V)N+'L.@V%#^W=[9WC*G+A53")A$PB81,(F$
M3")A$PB815J=2O\ !G"'](KQA_>S3.KTIV^H?U6O'DP+PCEW]0Y)OVWZ \JZ
MJRO.47NZ@-S[N=MJ1DXR,;W742LMBOCEW3M!/3/,F\AS;FMNL $DV=(4B-46
M<G-<VP32#27PQ8@:">;^7LR1QXD;CP[@RH<,CHW$<>Z0,<#UK"REVH,ZT.;E
M8(N,5-D&\5:;AMCM+N;"H\:&1KYA$;!D($2Q+INUHA.@.AI!.]EB[3@*S/O=
MS6\G)P#D]W?W3_#NJ,#J;OSC=OW8WGHZ>L?PDMT\[E<N0G"OCG=#O'8_$W&P
MZV9I"JC<52>(QUF&I\*#2%H2?^(1DA+#HHO_ ,'7;K79KLUD$Y.?&<_.I QD
M=1(/C^E8HOKGA:]-V<_U_&N!7)BYF=D"BVGL. FP(N+/6U:0E28%NT]2-"X;
M\4&:),?L]*5_CRAZ!K8>P6Y#01G('<W?20F=Q/#&=Q!Z!W 1CX>M0W(N7D+R
M[YY\"9&MX.\@*)@%%2B]I1.)Y9ZF$"9$Y<KH^5P]@1$D,,@<5PSUKNY%$Z,T
M1L!0A "/789L8)W '?GP=((ZSG>=Z9!Z1OP /3;\.:XG>T# QC?Q*OKRBE5<
M<L5EYQOF?P<<VJVE+534OM1XAKM5;6V$I0OBT-<RU[/=Y ]]HE:\DA0VHP(&
MO6BTA6]G'F=\W8.[<8P1C?@DD_-C[_0H.?G;CCUC/3CKZ.'P8@"MG-F,^X?S
ME2VO/E5FNW40/XX.M:"DBHVNW*GY#*9+5P8'N#"'ML3.,03^(V+MZ2$ ?-+(
MNI&I5C;SU1.20,EO$ 9/7G>!U<,YQT_"J@[@22,[M_0<YST;CC'4 2L0)+CN
MB@Z;XW\LXI;T]F%B\N.*')&X;2C\J?U$DAZ.8L%0++2B"R+1I2+Q*-H8*ZJB
MV).E:RTY2MG0%$.>E"KPBD4$YW  ;MKY@?\ ;JQT;@K8WXR>V#<]S:V<]\XR
M=^[.["EO4EDL?!^U:DE5C7M.7NGKMX*6ER9OYXL>1.\S1QN9U))*1!]WL?1E
ME+53$CD:&XGIL<V5D3 :C=1]F^+T!)Y*H9X[QPWCYMG&=W1G/ 8X!0!CPM&/
M;;>._C9 !/6>O="^_.HQP[YT=3[I!MG%RX$-H+8#>%L+Y82C89.S?%*5WJ=]
M3MQHQ2!G:P'^,&IC@A"FV:('<WLS0=;UVUZ,=T_1_!?8-<ULA<T@%K,$XXAW
M</=\:VO<A?-4.?"4_-#\A?[2TY[4XMDC@[O?2%9GJD?MO]+E\NK(6<F$3")A
M$PB81,(F$7T-?@A7S#>1?VN7SV-T_D] [Y\35B3^J?V&^4];8>0ODF$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+&MS_B>M?ZM
M9U_*[KF70?AU%[KIO\9BT.JO6QJ/WAO'^7U"C3TV/F*<9OJW2?Q-SS;:L]<=
MW]UN\ABX/D)_%#H+WC9^\U"G!G/+UI,(F$3")A$PB81,(F$3"+5T^%K^;CI7
M[;-<>PGDCA79Q/>^D*Z;IA>;8Z?7V)N+'L.@V%#^W=[9WC*G+A53")A$PB81
M,(F$3")A$PB815J=2O\ !G"'](KQA_>S3.KTIV^H?U6O'DP+PCEW]0Y)OVWZ
M \JZJRO.47NZK0ZJU&-EQ\<(]*''DLT<2#>-UP0;DJT7E(8ZSRI@B;U69;SX
M@-W87U>VMSDD.$\CUI(<I_RA2 @CP"K1@DQLC[_#]^XG2-V<[L9(SG>,8SO!
M (W'IW*G:Q>)_*BI([.N5M@=:I@CD'YE1.OX),)\NX904N-R"*NC XM,%V:,
MJ0:W$4@VJ7.0 NNOBSP9CMLUP4:-(2B36ZQU;L8&[>0,8=OWGN]U1D$- :3Q
MP[:.3P)!]*1T=0W#H6PIPGHAHXR<4*&H9AFG](K-65=,$;;9UHA.E#*TJ=-H
MTI\+3I3U2<HIPT=XP4 E2>#18P]AQG^?NA^^4!SD[O3'.[..]O/1]PJSWV'V
MCU(.:/)ZKY)R'N>D.,/#Y_A-;AJ^B9@.LY-;-B2"(()L\2B<3^.*_NU!&$"!
M]0-;1'FQ7'TQZA,H5J1K>Z'NR#C?W>@XX<>[P(&['S(>CAD@G>-H <-S2,9S
MDY.3PQA<S H/;'3SYM\=*58;_MB\^+',$%F19- [ZFBVQYU2MJ5]"UD_;7N"
MSI[V?*W& R2/,;FT/,<?5KD!F>0H7)"N+*7'I R3M#A]]YXG)(P.!)QT'>0G
M#HX8.[ !!.SO & 02"" ,@$')&5=WE5*QW-*J@U@R"O)1*V4#F]U9)%$M@ZT
M1QQ0V9^5-*UC/6EA*&$!VS&QP5IA%G!&#NG;WH.A:UO4@XSW1A01G'<.? HY
MI. 7&=%>Q?(0B*2#[L2)0Z3U'&C)U,C*I06,]M*UB=K)0U(-ZW7:2P'!H<G%
M$IEY$= ^F%."_8EO>6*=FLG&/O\ P[F<9QNRF/ON[^,XSC._!..YN"XRM>G1
MQ0JJ:R2;QF!.:M1(6N7L::,RF9R^70&',E@*%:N=,U>0.1O3E%("URY2O6G2
M!%%&IJ3N8E)VE(!A'O6YVC]_#PX<1DX"8^^ #X0 ?#PZ%RU$\!>,_'=YE;]!
M(D^.CC+8XC@YHK%F\PL]-'J];UZMU05Q"D<\>G]+#( E<5RA:7$(X4W,>U&R
MC!(Q"3D>#%Q/?ZQQ^_<& F/O@#X=P&3W3D]U5?\ 4/@,&AG4SZ+AL1AT8BYJ
MZ^;F+6F1]B;&<:LLJH7@10%(F]*GV>$L0A" $S8M V+>PZUO>\$D@9).\^(*
M[0 ),#'I6>6M@W*JJH<^$I^:'Y"_VEISVIQ;)'!W>^D*S/5(_;?Z7+Y=60LY
M,(F$3")A$PB81,(OH:_!"OF&\B_M<OGL;I_)Z!WSXFK$G]4_L-\IZVP\A?),
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6-;G_
M !/6O]6LZ_E=US+H/PZB]UTW^,Q:'57K8U'[PWC_ "^H4:>FQ\Q3C-]6Z3^)
MN>;;5GKCN_NMWD,7!\A/XH=!>\;/WFH4X,YY>M)A$PB81,(F$3")A$PB81:N
MGPM?S<=*_;9KCV$\D<*[.)[WTA73=,+S;'3Z^Q-Q8]AT&PH?V[O;.\94Y<*J
M81,(F$3")A$PB81,(F$3"*M3J5_@SA#^D5XP_O9IG5Z4[?4/ZK7CR8%X1R[^
MH<DW[;] >5=597G*+W=5)]8V'/;_ ,?*<EXX4\6;5--<KZ*M[D-7#$@7O;C*
M:1B3XLW*S@1EN1+SY<FBRM:TRY?&!)A$NB!C4]_Y2 !%9O'Z#T_!T]!QW$SC
M._!P0#U$CCG(QD9&>@D+'W)7J?\ 2_GW%*>Q%BNNH;S%8%:/<4@U"04PF7V%
M*WM]8%#=&8JW5JV(EDE:G/:\Y&0 "MF1FM!A?A1Z*&GUK0 D\0>OTPW]/1OW
M]Y,'=N<W&-Y! ;U$D[L ;^.\9XJ:?3?@=C5CP7XOP2V4RU#8,<J2+(I&VN*M
M4N<&E3XGHY.T+52TDA6:J:D1J9 ?M004:$Q.( RPB#O60>/@[O1]";N@Y![P
M[_#NJECGIR2XX<8^:MD3KCYU&X'Q5Y-/S9%&;D33<YJ:4VQ74W&SM@#8Z_O3
M;'V,\UFFB=A6H4FG) Y@4&-FDI:LD8?!=DC'3P\/3PZQGN80DX[4D \1NP3T
M9((Q\!WY/1O[+T[[XX^\H.9L/M*ZN?4;Y<\KV*'S2-4-6\#J2<5=5=6QUQ2G
M.,Y?8XT/3$0E63)Z8T@6UVD3RYF+=M"0+>W@*+//+,'&"!OZSP&,]7'B1O))
M^!1D](QG'$[R1PSP&.)  QDYXXSLN952F$3")A$PBH?ZFGG+^BE]?EU>R!VR
M>@=\^)JLWA)[5GEE7P9"JJ'/A*?FA^0O]I:<]J<6R1P=WOI"LSU2/VW^ER^7
M5D+.3")A$PB81,(F$3"+Z&OP0KYAO(O[7+Y[&Z?R>@=\^)JQ)_5/[#?*>ML/
M(7R3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%
MC6Y_Q/6O]6LZ_E=US+H/PZB]UTW^,Q:'57K8U'[PWC_+ZA1IZ;'S%.,WU;I/
MXFYYMM6>N.[^ZW>0Q<'R$_BAT%[QL_>:A3@SGEZTF$3")A$PB81,(F$3")A%
MJZ?"U_-QTK]MFN/83R1PKLXGO?2%=-TPO-L=/K[$W%CV'0;"A_;N]L[QE3EP
MJIA$PB81,(F$3")A$PB81,(JU.I7^#.$/Z17C#^]FF=7I3M]0_JM>/)@7A'+
MOZAR3?MOT!Y5U5E><HO=U&WE8T\HWJHW!OX@R.I8M<1KJV^)NMU,3U(X,%BT
M(W3RG5M; K1N!JM03LL"483O!%B[XC #UV:R1C^'<WCZ,ITC()&=X&,D8/7N
MXX6JG</(#JL47R#9*AIL?33Y \JY.Z%%/$1H7CE+ELBAJ4[PPCGNQID.0I6F
M')B@E'F]UX<25AN@"\&0+8@Z%/IL=MU9&3T]>>'AQ\RD"(Y):X  [\M.\= &
M-_1WM^5MRT09<!M.UP;?Y45(N@V)M!ME$0C2K44(EAB4 W8ABTM$-3I 2H$(
MLKPHQ[_J[[!C#V#W51_O_MTE4H]2N-]'TBVS)'>+J?%>9VR$^F9WXTNTC:^3
MQRDQ&2F;3#$T!4$K'?P:3:4)!$L)6MVDFBP&D"2[V$5QG=T9R!Q!QTC=W\[P
M1\"C!P<=KG?N!;D=)!W ]T8.2NF]-N0=19SY.MI3JW/KSP.^*9(6FE7*:,5U
M%N4Q#PG0.)3(%I*@GB:AP852D#:/QM_:2'$Y$:X"5" ,I.-5+LXZ<8W9SGB.
MVZ.OHW]:@;&!C<\N.0T9;LX'23D? 2.XMCG/FK)A$PB81,(J'^IIYR_HI?7Y
M=7L@=LGH'?/B:K-X2>U9Y95\&0JJASX2GYH?D+_:6G/:G%LD<'=[Z0K,]4C]
MM_I<OEU9"SDPB81,(F$3")A$PB^AK\$*^8;R+^UR^>QNG\GH'?/B:L2?U3^P
MWRGK;#R%\DPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB818UN?\ $]:_U:SK^5W7,N@_#J+W73?XS%H=5>MC4?O#>/\ +ZA1IZ;'
MS%.,WU;I/XFYYMM6>N.[^ZW>0Q<'R$_BAT%[QL_>:A3@SGEZTF$3")A$PB81
M,(F$3")A%JZ?"U_-QTK]MFN/83R1PKLXGO?2%=-TPO-L=/K[$W%CV'0;"A_;
MN]L[QE3EPJIA$PB81,(F$3")A$PB81,(JU.I7^#.$/Z17C#^]FF=7I3M]0_J
MM>/)@7A'+OZAR3?MOT!Y5U5E><HO=U";J"U1R(NKC1+:_P"-/(5EXP39V/)V
M_6T\LIKO\404I$X:DB5M/)<FLQA<5(!I3"Y !3WVY.G4^"T68: \F1Q\6[._
MN;QOZE&X$$C: .2W.-KN<#X.!Z5K<\'6RP^."S7'?B[U5.F$OL9\>U2=_6'U
M&O?K*L:8)M:0N*M_E*JR-'R>0[&CT0J"2I-$$1&PA)#H.]9? QCC@] WYX9Q
MMY^9022=K8>-W$N& "<@ EF -^/OA;<-6H;";:]B*"V)#'Y98Z5D1%3&1Q1G
M.8(X\O@2M>.KV=F4+%YS<A/,_KD)3%BD18=ZULT7W\H<9W</OW3XU(SC?Q6K
M1U":IX>S;F3R.L&-=.&R^4TII!FCDMYC79"+W:JMW!TIT/*="4,8CRU_2+9=
M*6V%-B1S<FT&V!,-$$G1:\\T6]:D;L=[J&>G!W\=^1T<!OX*03N <0"=PWXS
MD#HX;SN._>3D#HMKX-=/?@-$M4[S'XRQN9%F2B#I9?7[V]6/-7]+N/S^,"!H
MQ0SNSZX-AAYK.[F$B[Y9W@#1"&29W@A'D$][X /H^_PH=_'/'?WP>GIX^'NJ
MVK(1,(F$3")A%0_U-/.7]%+Z_+J]D#MD] [Y\359O"3VK/+*O@R%54.?"4_-
M#\A?[2TY[4XMDC@[O?2%9GJD?MO]+E\NK(6<F$3")A$PB81,(F$7T-?@A7S#
M>1?VN7SV-T_D] [Y\35B3^J?V&^4];8>0ODF$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3"+&MS_ (GK7^K6=?RNZYET'X=1>ZZ;
M_&8M#JKUL:C]X;Q_E]0HT]-CYBG&;ZMTG\3<\VVK/7'=_=;O(8N#Y"?Q0Z"]
MXV?O-0IP9SR]:3")A$PB81,(F$3")A$PBU=/A:_FXZ5^VS7'L)Y(X5V<3WOI
M"NFZ87FV.GU]B;BQ[#H-A0_MW>V=XRIRX54PB81,(F$3")A$PB81,(F$5:G4
MK_!G"'](KQA_>S3.KTIV^H?U6O'DP+PCEW]0Y)OVWZ \JZJRO.47NZI[ZU"X
MC?'&EXI-'M;&>/=C\N^/\ Y3/R98<V(4U$2"1J@2%LD[R2I1[9(9)'LB/1V5
MNAJDE,2T.9Y"H?BR@T(I'WSPQP.>YP'A3N](!V>D[71@<"<9('7A9 YB\5^!
M3=PCMA++ZUI6"59$JGDKQ&98T,,78!0U>VL*I;&I#$'U"6B-0OA#J6A4-*IM
M7$JEBX10 &C&?_6;^!S@='5\'7X/G48&01O/0>).>OCG/=S@+,O39D=BRW@A
MQ9D5KF.9\]=*>B1[XJ>2!IG==O2 );>O<B##3S"UJYL C5J-#.-%LTX0A#%O
M>]X/'[_Q._K[JGK[_>SW54A9O'?J=5ER1ZC[CQ5K'C=;-7<TGEG6+G6>V>OC
MDJA!P:;:JV5(#&1O2+"Q'E )-<RM+AE!/":0'1>BQ"%MPP>\>D<./'=N^'QI
MEK@ <@MRTXP<@DG.>(._YE(WIGQSJE4+&* XV<BZ,XZ1KCW459(X&YV5$;0=
MWV=G%1&+#01Y9MB.;TS7H3BX)$0'/83]%)4YIYA7;W ZQX. ^_?Z_A0XR2"X
MY)W$  9)/'CNX#HX*[A&M1N*8E:WJTRY&H#WR%:,\I2F/!V[UWRCR1#*,#VZ
MWKO %O7;K>NWY,A%[.$3")A$PBH?ZFGG+^BE]?EU>R!VR>@=\^)JLWA)[5GE
ME7P9"JJ'/A*?FA^0O]I:<]J<6R1P=WOI"LSU2/VW^ER^75D+.3")A$PB81,(
MF$3"+Z&OP0KYAO(O[7+Y[&Z?R>@=\^)JQ)_5/[#?*>ML/(7R3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%C6Y_P 3UK_5K.OY
M7=<RZ#\.HO==-_C,6AU5ZV-1^\-X_P OJ%&GIL?,4XS?5ND_B;GFVU9ZX[O[
MK=Y#%P?(3^*'07O&S]YJ%.#.>7K281,(F$3")A$PB81,(F$6KI\+7\W'2OVV
M:X]A/)'"NSB>]](5TW3"\VQT^OL3<6/8=!L*']N[VSO&5.7"JF$3")A$PB81
M,(F$3")A$PBK4ZE?X,X0_I%>,/[V:9U>E.WU#^JUX\F!>$<N_J')-^V_0'E7
M565YRB]W4'^H9=-)4OQHDIEZUM_3;'K1=V.F8O1)+6C>7"ZY]8:@;5%JV;&]
MP")"-2^J0F[,5K>XD;D:92O/, !/OMD<?O\ <YZO#NRF_B.C?G.,8WYST8X]
M?5O53%U=.'CGQIHJ#\FF+A1;EX;A9D<L2PN*<IY/3^3Q&IV':4#[,UD<@LEE
M;U7TL<*ZWXP8WQTE")N5:;M 9]I@@3B#;.\C=C. 3PQGC@DMX=  [AZ# R3O
M(&1U '/ 9<!M8/3OW=.<%7UT):M?WA2]96U59Y!]>3Z&L4CB/BQ19!1#,O0E
M&)47@"M:+(,0A[49I -=TDT@98?D#K*GB>GN\5/7W#@]]1HY&<#H_<\N,M>L
MKJNOBW=QI"5*MLZC94G;AR1&B*&2D036$R9OD4 F"4@ M )->XRJ<4@ !"@7
M)=]N]R';L$9ZNOYP1CCQ'2HQOSN[QSCYB",].",]*CLQ=,FZYBN1D<K.I!RM
MY#P1"L&>;5S=NOJ1ALG3;*-)+;YN?4$2BDJD2 .C.^H;1R-.U. @Z X(%!&M
MDB9&_ [V<#X=P'@)(ZP4QU@?!M$_!M.('?QGJ(5KL5BT?A$;8XA%&I(QQJ-M
MB-F8V= 7X)&VMB D"=(C3%]N^Z402 ( :WO>^S7R[WE5(&%S^$5:T ZAH;.Y
M16'0$-J/:Z(U9-9'!IE:JRTX W')7.),FG.0JFZLU"W[NG1L;EIA+2->F0;3
M#.&-4 W:4L1F6V1C.?@\73GN</FWJNT>K=QSOX<<\.D;^/SK&48ZM<.,3!F=
MFTE/*LI>8U]9UH4;:CF\1Y^27!$*M2J7-T6H8\R'GNT=42!C*3OT42.NMF.S
M8O2;WM.K,\4TV>Z,_P"Q/02>CJZ0@)ZCQQ\/#IQT[CU'N*07%GFH]WU/WNKK
M)H67\?IOJLXG=<$;)1(XU*$T_JB7.#@T$2!N7QH\XAN=V)V0EM\GCJW_ "QJ
M,<FDX)JE*X)SQ01NR#G?CH^@GJ*D'?@]WKZ/@&[J/ []Z@GU-/.7]%+Z_+J]
MD#MCH'?/B:KMX2>U9Y95\&0JJASX2GYH?D+_ &EISVIQ;)'!W>^D*S/5(_;?
MZ7+Y=60LY,(F$3")A$PB81,(OH:_!"OF&\B_M<OGL;I_)Z!WSXFK$G]4_L-\
MIZVP\A?),(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$6-;G_$]:_P!6LZ_E=US+H/PZB]UTW^,Q:'57K8U'[PWC_+ZA1IZ;'S%.
M,WU;I/XFYYMM6>N.[^ZW>0Q<'R$_BAT%[QL_>:A3@SGEZTF$3")A$PB81,(F
M$3")A%JZ?"U_-QTK]MFN/83R1PKLXGO?2%=-TPO-L=/K[$W%CV'0;"A_;N]L
M[QE3EPJIA$PB81,(F$3")A$PB81,(JU.I7^#.$/Z17C#^]FF=7I3M]0_JM>/
M)@7A'+OZAR3?MOT!Y5U5E><HO=U 'J+\<K-Y!4Y"'2C%D?3WKQ\NBON151-\
MO$H+B$HEE=*%VQPR3GI0&JD33*F5T=&@3FF).4-:I0F7E%&;3[ *6D Y/4<?
M?O9&>CBF[IS@[CCC@]7>(!QTXQTJ%<YYH]1FZH/(Z,A'3)L:K+0G+&^P5QM"
MS+*@JFF(0)V1*69;+B5;&<KD<F;R"#SES2@*9D2A4+Q8I9I/H1N@SCJ./A'T
M$G/P=[NQNZP1@9 !VCG@,$8&>G)./'9]P\H/?%[C'2M!&/(I"JK&",T;<7P1
M>B=.KJG)V:Z+2R=:UHHD]><H&27K6NX5L >SY,@G)_C]_OUE3O.\\3O/W_AW
MU)3(1,(F$3"*AR7\++>FW(^-ELG&>GJ=$Q<G5=U23E]!Y&,N8S2M1-3\4Y0A
M7'M,Q#NH?9]IT2QJ6DN3^JCQ33I6XI$NUY;?I)?:QU;QO&-Y/=W=9Z\$9Z53
M!X'/'KW 9SNWG'#O@D="Q$IZ?7+>Y:NIOC)/HK"J\B/$FB;=J>#6JGEALB_I
M8>7V)%PJMWK<:*9FTV-I"&UL:W64IE*U?VKCE2)'L1&@'; @8<#OX> 8ST8/
M>/<SQ(G>200<$Y.[&[.T<'?OZ.C ^%2B@/&_EO?$KF$LM4(N(SU%>(*;BC5T
MPK67(YM,PR-ZDJ213>V&TY4PM;:UI$XHS%$T4:5B9<> 6W10K,#X4LH,9 &-
MQWY^8CN?!WL](3B<D;ND'@<'(X'/?W_[5;6SPUN;BQU0ND:NM7FM=_+(B6W=
M:B1I0VZ2P%$0\YNJA_.4JV;XE2)M[-<@'@)4^'V/6@$%]WLWVY'1\)W>#_9?
M5I!;(-EK<-9VI<=VUN&\]"VY\A45#GPE/S0_(7^TM.>U.+9(X.[WTA69ZI'[
M;_2Y?+JR%G)A$PB81,(F$3")A%]#7X(5\PWD7]KE\]C=/Y/0.^?$U8D_JG]A
MOE/6V'D+Y)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PBQK<_XGK7^K6=?RNZYET'X=1>ZZ;_&8M#JKUL:C]X;Q_E]0HT]-CYBG
M&;ZMTG\3<\VVK/7'=_=;O(8N#Y"?Q0Z"]XV?O-0IP9SR]:3")A$PB81,(F$3
M")A$PBU=/A:_FXZ5^VS7'L)Y(X5V<3WOI"NFZ87FV.GU]B;BQ[#H-A0_MW>V
M=XRIRX54PB81,(F$3")A$PB81,(F$5:G4K_!G"'](KQA_>S3.KTIV^H?U6O'
MDP+PCEW]0Y)OVWZ \JZJRO.47NZ]98M1MR4Y:X*TR%&F+$:H5K#RDR8@H.NT
M1AQYP@%%@#KY=B&((=:^_O"*JNZ^L1Q/KR?(*3J19(N4G(!^&Y)H[4M$("Y.
MN7+6I-I4N MDIAR:,-R5$3L)C@J&YFA1%B"(\ =C $4XZ]W^PR>YNZ1G/<3?
MC./2C&2=P&3PW[\JR&L)+)YC7\2E$TABNNY2^LB)R>X0O<4;JMC*Y45HTUH5
MN*#8D2I0DV+19QJ80B=F:%H A:UV['CUJ!W>[]]Z[YD*4PB81,(F$3")A%0_
MU-/.7]%+Z_+J]D#MD] [Y\359O"3VK/+*O@R%54.?"4_-#\A?[2TY[4XMDC@
M[O?2%9GJD?MO]+E\NK(6<F$3")A$PB81,(F$7T-?@A7S#>1?VN7SV-T_D] [
MY\35B3^J?V&^4];8>0ODF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3"+&MS_B>M?ZM9U_*[KF70?AU%[KIO\9BT.JO6QJ/WAO'^
M7U"C3TV/F*<9OJW2?Q-SS;:L]<=W]UN\ABX/D)_%#H+WC9^\U"G!G/+UI,(F
M$3")A$PB81,(F$3"+5T^%K^;CI7[;-<>PGDCA79Q/>^D*Z;IA>;8Z?7V)N+'
ML.@V%#^W=[9WC*G+A53")A$PB81,(F$3")A$PB815J=2O\&<(?TBO&'][-,Z
MO2G;ZA_5:\>3 O".7?U#DF_;?H#RKJK*\Y1>[J%W/?AE'^>/'EYX_P DLFP:
MK1.;\Q2(B55P[ ;7<*U@/-/3MSDG4%G('IA7;.$6Y,[@2:F4=TD\&BU29.<6
M^_WZE(.-^[X1GX>X>Z"#W51N_<8N>?"KDKQ7O1QX\U3R>X^\5H]:#0K>>)4/
MCU87X^-4[BX6$QXE-7/K\BC,C<V<A"D6':A[N0I?UIYP"&5J"G*\-;CG?TY'
M7X,XWGJWD]&.%1@!W$$[/$Y9@')WX+ANW#(W=)Z5LLU58K7;==0ZRF5GE$?;
M)FQ(7U(QS5A61>6-!:XD)NVZ0Q]P"%6TNJ,>Q$+$9W>V4< 6@C,!W1B@C'WZ
MT!S]\K(&0I3")A$PB81,(F$5#_4T\Y?T4OK\NKV0.V3T#OGQ-5F\)/:L\LJ^
M#(550Y\)3\T/R%_M+3GM3BV2.#N]](5F>J1^V_TN7RZLA9R81,(F$3")A$PB
M81?0U^"%?,-Y%_:Y?/8W3^3T#OGQ-6)/ZI_8;Y3UMAY"^281,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB]5:N1MR8Q8X*TZ)(3W/"J59Q:<@OP@PE@[Y
MIH@@#WS!@ 'M%KO#$$.NW>]:PBQ#5O(:F[G02=SKB=LTA10V8S"!2,X!AB+X
MNE$!=U##+6\0' M*8:!F=DIZ-2L)"8CV86+99XP=@ML?/\/W[RC/'.1CKW9Z
M<CN8W]Y>>"W[45DRVPH-#)LTO,IJV4HX7-6HH1I)K7)5\=;I8E;"#%!91+F8
M9'G9O<MF-ABLD!*C6AF!, 8 $X(^_>\'$>%,C..G?\Q(\8/@68<A2F$3")A$
MPBQK<_XGK7^K6=?RNZYET'X=1>ZZ;_&8M#JKUL:C]X;Q_E]0HT]-CYBG&;ZM
MTG\3<\VVK/7'=_=;O(8N#Y"?Q0Z"]XV?O-0IP9SR]:3")A$PB81,(F$3")A$
MPBU=/A:_FXZ5^VS7'L)Y(X5V<3WOI"NFZ87FV.GU]B;BQ[#H-A0_MW>V=XRI
MRX54PB81,(F$3")A$PB81,(F$5:G4K_!G"'](KQA_>S3.KTIV^H?U6O'DP+P
MCEW]0Y)OVWZ \JZJRO.47NZJLZJ-IR"IVG@P\,TW50-L?^HEQNB,T<BG@+*@
M<88^!F07AD?59AI*<3*X"(2^.$*C-$&"**V/Y0ZR6\?@/P[C@=W?T(1D'=G&
M#WMXR?@&5ALSEPSN?(+JFQ0^_P")J(C >.=9JZU;"Y_'-M[#)G6M[:7R$R.B
M*<NW3NH4$1U2N+3F&'EB"V#V OPQ6S9P<#=O&.CNGCX!Q4;MQ_*VAQW'&S@#
MHZ3PZ25)[I'R9\F73<X?RB2O3A(GU\IR/N#F^.JPUP<'-2>)0(:M4M/&8:I-
M-UV;V:,8MBUV;[=Y4G.\J>EPZ <#N# 5C.$3")A$PB81,(F$5#_4T\Y?T4OK
M\NKV0.V3T#OGQ-5F\)/:L\LJ^#(550Y\)3\T/R%_M+3GM3BV2.#N]](5F>J1
M^V_TN7RZLA9R81,(F$3")A$PB81?0U^"%?,-Y%_:Y?/8W3^3T#OGQ-6)/ZI_
M8;Y3UMAY"^281,(F$3")A%1;UO>1?-J@:HB"?B-'$TL7V,X%1O3/&VZ4J;4)
M?FI8"4J72.K6=.I943(FC+(Z$/.GK1(E 5.BD1@U @%"LT;B<9(QNX_?N]SA
M@[T :7 .<6MQQR!O[N\'JX#IW[N&%N0G,_J(BZ5<2Y 5_&((JN6ZF]3 FV(1
M..V.3.FQQM4!<-@)D43.*,I:W3F%N2Y2_/*R3I43&,QH%L9J8D>A[$ '=O.X
MXQEN_JQ@D9(P%#>VPYV&@D$G&=V">'<SP.?APNV<;^8W4$=>F%,N1<ZBM>--
MOU,@5,AL(ES#8QLI5CJ_;C&ILAE9"1*-R7323NK44L9UC"E4M'?<@CT,XD/?
MTQDC=O.T<;^C./AR#N'4."KN!P'$-S@'TO3OXG'1\.3U!<GT-.2'/*\X784;
MYC1C445U<X&-HTDP;9(GM%U=948GF3.[K5ZXHM@5Q@,<?$S4W%-8C5)!K<,*
MS99FA%Z$;@2,'AW]V\\.L_1C<K'9#MECMIH''YL=8WYSGN=85_F54IA$PB81
M,(F$3")A$PBP?R3IUIOZB;0J)X:VIY(FT0=VI$@?#G%.T#>MI3#F(YQ.:5"1
MR+2I'@I$J-&B4DJ0A)[Q)@#-!%J0<'/A[WW^=01GN=W[^!4G],[H=D\)G6XE
M=KS1HO;^E>M&YC$YNQTG(<VB225O4BMIJ  UY.1J8W)7L1"TER,(!(3B@["N
M5F&ZV8.0<;P23G)S\&>DC?NWXSN1^7] & <8QO/!O0#D#CT?.N,Z>/0\<N'/
M+0KDI-9K'+"3.#%+GPJ-A4S+9=86BXNZMH8UE>_&3\K)6,0JP<E,5=C9,4XN
M^A(F_P 15$)]'%8R-_')\'@[Q(Z>YQW3DD-&  .D  D=1P,[G .XXR2-^ MC
M/*HF$3")A$PBQK<_XGK7^K6=?RNZYET'X=1>ZZ;_ !F+0ZJ];&H_>&\?Y?4*
M-/38^8IQF^K=)_$W/-MJSUQW?W6[R&+@^0G\4.@O>-G[S4*<&<\O6DPB81,(
MF$3")A$PB81,(M73X6OYN.E?MLUQ[">2.%=G$][Z0KINF%YMCI]?8FXL>PZ#
M84/[=WMG>,J<N%5,(F$3")A$PB81,(F$3")A%6IU*_P9PA_2*\8?WLTSJ]*=
MOJ']5KQY,"\(Y=_4.2;]M^@/*NJLKSE%[NJO.K9**CC_ !JB#19_'**<JG^Q
MK[JJK:.IR:FZ0QQYN^=+G%HA[HZOFT#EN.-[&A&^."]["E&-*C+/* ,L2C0]
M2WCT?"/OCNGH&>\F_?@D;MY!Q@? 1GO=)QG WBNKAYP[X>6%?-R<5.6/33XN
MU'R$K^#P^T2E58N*N;P>RJQF*IR8DK\A7.C6QO")4SOC4M87)M=4YHN\$H].
M,28X';)/5CP-/T _-XPHR[<-IY&_BYPP=W0'$;\\0=YR,;EL05M6L#IZ"1>L
M:PBK-"(!"FE,Q12)Q]&6@96%G1AV%,WMR,K6BTZ8D.]Z 6#79KMWE5/?)/=.
M\GNGNKO&$3")A$PB81,(F$5#_4T\Y?T4OK\NKV0.V3T#OGQ-5F\)/:L\LJ^#
M(550Y\)3\T/R%_M+3GM3BV2.#N]](5F>J1^V_P!+E\NK(6<F$3")A$PB81,(
MF$7T-?@A7S#>1?VN7SV-T_D] [Y\35B3^J?V&^4];8>0ODF$3")A$PB81>JH
M0HU8B1JDB92-.(8R!GDEFB)$86(H8BA#"+98AEC&6+8-ZV( A!WVA%O6R8'4
MO%\5-GBY"3XN0^*I32STR;Q4CP"<\H6QE'$D]SP91I8][& P 0B"+>]AWK>^
MW"+]TUMNDQZ/3>BTD5&&FJ4NDI&DZ@P\>S#C#B= \&:,XS>QFB&$6QCWL0M[
MWOMPF!U+R)T*)(,XU*D3)C%'@]GF$$%%#.V46$HK9HBPA$9X,H(2P=_>^Z .
M@A[-:UK"8''&_K7M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%C6Y_P 3
MUK_5K.OY7=<RZ#\.HO==-_C,6AU5ZV-1^\-X_P OJ%&GIL?,4XS?5ND_B;GF
MVU9ZX[O[K=Y#%P?(3^*'07O&S]YJ%.#.>7K281,(F$3")A$PB81,(F$6KI\+
M7\W'2OVV:X]A/)'"NSB>]](5TW3"\VQT^OL3<6/8=!L*']N[VSO&5.7"JF$3
M")A$PB81,(F$3")A$PBK4ZE?X,X0_I%>,/[V:9U>E.WU#^JUX\F!>$<N_J')
M-^V_0'E7565YRB]W5=O4CXJW)RKK2EV^A)W#:]L^D>2E8<A(X]3QE7O\;5*Z
MY(D6B6E:VMRA*H-"L4/)&Q[\+H.B23@_(,0-Z#<IR!G()R,;B!@\0=^>! 5>
M*'A+UBF_E._<MR>2?$/=CR&FF>D%B$=32_<?!$F64KI<D/)1Z?=&:=!.B\[1
MJG9N]"3Z 7H&NS>]SGN#'5D_Q_V[B'9(&YV0<YVAX,;*OBJY+8J.O8BEMQSC
MKU91#(B+FCK$D"ELC:Y^"7K2Y0S-ZPY0J2(##>T1!!YYI@ _((>]X.,[A@*H
MST_?Q>(+OV0I3")A$PB81,(N.0.[2Z"5 ;'1N<1H3]IEH4"U,L$C4A_SDZH*
M<TS:<\/Y2C= ,U^4.201Q!'?49!X$%48=33SE_12^ORZO9 [8Z!WSXFJ[>$G
MM6>65?!D*JH<^$I^:'Y"_P!I:<]J<6R1P=WOI"LSU2/VW^ER^75D+.3")A$P
MB81,(F$3"+Z&OP0KYAO(O[7+Y[&Z?R>@=\^)JQ)_5/[#?*>ML/(7R3")A%'R
M\N5_&OC,%C%R!NZN:@U)MJ0Q_P"[V2H&#;QM'H&U>F_2PP&U'B^C ;-V7K>@
M=[7>[.W) )_W('CPGA^ $^)1[\K!TU_3;XZ??WK\9#'_ *?_ ,?[WR?^[&R>
MY_>;T?#_ -^A1D=WP'^"X9\ZOW3'CJ+2]RYLT,-/LP)78URT#ZIT,?;V=J)C
M3N*S0-=G]8W9&BP_)WAZ[=8P>Y_>;_%,YX G^R[^"Z;Y;KI4>FI5/_LI;[M8
MP>YX1_%3O_)=_==_!/+==*CTU*I_]E+?=K&#W/"/XIO_ "7?W7?P3RW72H]-
M2J?_ &4M]VL8/<\(_BF_\EW]UW\%^ZZW/2HWO6M<U*H[=[UK7:7+-:[=_)\N
M]QO6M:_T[WK6OR[Q@]SPC^*;^IW]UW\%D<OJR=-4TLLT'-OCOW3 A&'OV*S%
MCT$0>]KOEF&@,+%V?? ,(1!W\@@ZWVZQLGN?WF_Q49[_ /=/\%_7E8>FOZ;7
M'7[^M?C'8_R_\/\ >U^7_3C![G]YO\4R.[X#_!37K^PH/:T.8;"K:5,DV@\H
M1!<8[*HXO)<V1Z0#&,L*MN7IQ")4D;&6,&C"Q;#W@"#]_6]8((."I^_4?A!7
M<<A$PB81:IW5A^$/V1T\.8TJXP0^A(=/&Z+1&#2 ^22%Z=T:M4KF#"0^B(+3
MH#RB@$)"E)1&A"UL8QA&+>^SLR=V!QR>Z!TD=1ZE=D;G@D. P[&_O-/4>M5K
M_P"%_P!Z>BG6'ZQR7_I>-W4?"/X*W,/_ "F]'^_]'I4=;R^%6<T+$4L9U906
M%U"4W$J2W,AI6NCF%W&<, B33?'S3?!"3Z"((>YV=[0M]OY.R<@<&CX=Y^C=
M\"D4Y/;//]GYLY ^'&.A8#_PF/J2?^EK%_Q4S_\ SC:_JM\"GL9OY;_"N/5_
M"6NID>H0FI9^RHB$YPS%J4+64?IP*$7L("!''EB-2Z+'V&>$3;"8+>NZ+?=W
MO&UW&^#BI[&'Y;_F^Y^'*Y#_  F/J2?^EK%_Q8S_ /K&U_5;X%'8P_+?W\_?
M^*[7!_A/G4'CTM87N3*8U+V!M7EJ72-*@JDJ=Y2A"/0D9JA/L!Q01B$$6QEB
MUO\ J]GY<;7]5O@_W0TV[=([/1G>/A4V]?"_[TUKYJ=8;_T[D<E[?]__ "O(
MW=1\(_@J\P_\IOBZ=W0>C=TKL\)^%S7/(IG$8^Y<6:X3MS[)V!F7GHY%(MJR
M$3FZI$2HY+HU5LK:@L@\P9&C-;+V:$.AZV'MUDC!(&#O..(_@H="\ NVFX )
M/P#/Y/0MZE$HVK1I%6PZ!M2E3J-AUOMT'9Q0#-AUO\N@][L[?]&5X+Y\5[.$
M6-;G_$]:_P!6LZ_E=US+H/PZB]UTW^,Q:'57K8U'[PWC_+ZA1IZ;'S%.,WU;
MI/XFYYMM6>N.[^ZW>0Q<'R$_BAT%[QL_>:A3@SGEZTF$3")A$PB81,(F$3")
MA%JZ?"U_-QTK]MFN/83R1PKLXGO?2%=-TPO-L=/K[$W%CV'0;"A_;N]L[QE3
MEPJIA$PB81,(F$3")A$PB81,(JU.I7^#.$/Z17C#^]FF=7I3M]0_JM>/)@7A
M'+OZAR3?MOT!Y5U5E><HO=TPB81,(F$3")A$PB811HYG/LPB_$?DU(Z_/6I9
MLQT3:;K%U;:$0W%&](86\*$*QO  (QB7)#@!4(]  ,6U!9?= +?8'9,9P,XR
M1D]S._YNGH5,E,/-9\6[?I6=<48&X645*^F[8]J\@ZWIQ2A>9):4YB$RI/=4
MR!Y3GN!2(ZRGQ3+KA;$;LZJTKF_IR%J9P/4DL:+2.YR0<@#YB2,8W=.[/A.<
M8"J,='Y0 X[@0_:W$=&&DCHZ <J&_++F1RGY"<K^!'()AZ6_-=C8>(]CSV;2
MMC=XW#1.\H1RZ$+8LD1QX2*5J40%252I"I4;<E*,K9 =Z*&,SL!N,'&,'CG.
M.O'1\'6OJ-@!XYQF7-:!O./2G.\[/^ZL5\LM>_T1?/S]7JZ]^,C!ZCX"JX;_
M ,R/PNZO:_?O[E71U5^8_*CJ <)[+XNP/I;\UH1)9R[09P1R.71N'#8T145E
M[1)%0%(&:5.*\1BDAM&G(\$E&'1Q@-F" #6]Y.#OW'?NX=&0<_-P^=69LA[2
M9(\ Y.\YX'=O:!T\<]S"U$O)+]2?T,+U_5(S_;Y&#U'P%9'/1?ECY_X)Y)?J
M3^AA>OZI&?[?&#U'P%.>B_+'S_P3R2_4G]#"]?U2,_V^,'J/@*GGHORVK]\D
MOU*/0PO3]4C/^D8P>H^ IST7Y;?"OSR2_4G]#"]?U2,_+_P__9^7&#U'P%1S
MT7Y8^?I^#_MTIY)?J3^AA>OZI&?E_P"'_P"S\N,'J/@*<]%^6/GZ?@_[=*>2
M7ZD^_P#[F%Z_JD9K_P!Y^,'J/@*GGHC_ $V^+QIY)?J3^AA>OY_^](S_ &__
M #??Q@]1\!4<]%^6.OI_A\W%;-G1+N?E[TN>.EH4O9?3,YC6,\3RZW"ST+M!
M8S%RFU$VK(+"(H!N5A?Y*U*MK@*HLI4B$208G\ I(UHW9NC  G!Q@AW$]&>.
M.Z.I?"5S'.VFR,QL@8)<#N)/0T]?P%7,>66O?Z(OGY^KU=>_&1LGJ/@5,-_Y
MD?1TNZ?[/WZ<+\\LO>_T1?/S]7JZ]^/D_P!_)V>X[^[_ +INW?SD>_\ K._Z
M/'A?OEEKW^B+Y^?J]77OQC9/4[^[_OU_Q[B8'_,C_O.'3C\C_MWMZUXNN =S
M9ZITBHMUK+IP<L:W1U0T2M"Z@G<:8CE+DI?U;<<G$W@C[XZE:()+1F:.$H-*
M'WQ T6 8=B$&,'J/@/WZU](BQCG.,C-X P,]!XG=O[A'0J&?)+]2CT,+T_5(
MS_I&,'J/@*^_/1?EM\*_/)+]2?T,+U_5(S_;XP>H^ J.>B_+'S_P3R2_4G]#
M"]?U2,_+_P /_P!GY<8/4? 5//1?EM_[_?X.E/)+]2?T,+U_5(S_ %?^7_Z_
M?^]C!ZCX"HYZ+\L?/WNK[\>">27ZD_H87K^J1G^WQ@]1\!4\]%^6U/)+]2?T
M,+U_5(S_ &^,'J/@*<]%^6U/)+]2?T,+U_5(S_;XP>H^ IST7Y;4\DOU)_0P
MO7]4C/\ ;XP>H^ J.>B_+'S_ ,%N9]/'GWR;X;<,Z&XSR_I6\X)7(ZEA^HVZ
MR&-QN$ELCHHTY+EGC#>!TER)>$GN*P [%*4DSO %ON]WLWD[/#<[N[O%\RQG
M%KG.(?'@DD9+AQ.-_I3OZ3XL;U-#RR][_1%\_/U>KK_5_P"G'_7[_P![&R>I
MW@\/WZ>XHPW_ )D?3TN[P_H?QZ]X7[Y9:]_HB^??YO\ O>KGWX_Y_O9&R>H^
M#I^_3\R8;_S(^..V=_T_['K7YY9>]_HB^?GZO5U^3_\ ?'_;^3&R>H^!,-_Y
MD?A=T#VO_?H/0M27JT<=^>_4/YK3KD_!.G_R9@D8E$7K^/(([+8NWG/Q!D0B
MB!B6*%>V9T<&\(%2Q,>:F"2K-%I-LH1O@S1"+!)!W;CN&.'=)^E?:)\;&D&1
MN2<[LGH Z@?Z/5]"K6\DOU)_0PO7]4C/]OD8/4? 5].>B_+'S_P3R2_4G]#"
M]?U2,_U?^7_Z_?\ O8P>H^ IST7Y8^?O=7WX\$\DOU)_0PO7]4C/R?\ #_\
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M'E'R1;'FA*@4.G@#5!R<@XTD 1!1ISE2DU.B+V!*08H.&42 1H]BDDGB>"@
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MPB81,(F$3"*FJ_6"/VEU>^-E;7.0D?*RBG%2?6=4D(D:0M9$)#<?W>$L,FD
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MR<])&]/R>GM@#U ='< W =&"<=S:@J$6A536F^WMWN Q#>]]O;O?:P-_R_\
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M$\DOO@ /03!Z%)TG4'=YM:;^-V_3&H]'NUYSZ&_+%GCZPY1Q[U<%-SRFL/\
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*1,(F$3")A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g105292g06c15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g06c15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &-:^8U@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             $)@
M">8    & &< ,  V &, ,0 U     0                         !
M          GF   $)@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   $)@    !29VAT;&]N9P  ">8    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !"8
M    4F=H=&QO;F<   GF     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      YQ     0   *    !#   !X
M?:    Y5 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MZ3O:_P#.3^$?R+=&##0\OWGK\K_&1T6\L<QG4:-H,^FRG75KM=V0YO\ @_\
M,WJ ^OW2VV-KK_:9LK;Z<-94_<6E^Y^Q]]F[VG_THN0MZ9UJRK8.CV5<'=7C
M/:[2?SCN^E/N2'2.MLRS9]@S0W>[<:ZWM<6DD.V/C\YA1H*/+<N=;U_OO7,_
MQB=)%8:3U)P:_=O].F8(_FW.-[O\(U[O=_Q?YBDS_&%T<6FZ>I.#' ECFTP0
M=K=NUE[6^[8N9=5]8',M;]DZIN>"&D[G:D!@]1K65M^BW9]'Z"I,Z)UH,?\
MY-R="R&FE\&#]'A*@@<M@ZZ?X;Z(S_&-TE](O;B99807 10'0"YCCM.5^\QR
M;(_QC=)QH];#S!+G,T%#O<SZ?\WE.7#CIO5+"RZWIQJ<#M-?V*QWMD?I';/:
MY/D]-ZD"]M/23<'M+!:W#LI<WZ/Z5@W.^E]%F]-H)]G#>_X_M?6>F=0IZGT_
M'ZA0US*LE@L8VP . /[X:Y[?^DI=0S:NGX.1G7-<ZK%K=0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQP UZDKD<04D]=@6-45,SM*FLPJOIJ=A<U@=-/2R11MSO+6,#GN:"7N#1N2
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MCO.DOT?;?3Z]>7.Y-M;=R_U:_7/_ ,7OA'_0US#_ *D(_/@YORLO\8_^L5_
M6,?LMBG^\:W_ )F53+YK7.3PB>$3PB>$7\?'[*:_\*?2G^\'?/\ WCR'SZ'
MMJKQA^J5?T9\@WY+B?\ C,)_J8CZ/7HOY-O.^OZ#]?3]?,DV]Y UMZT1_1BW
M>Q^J/J]TRHIK=%UKM?4^>IW^;&G:*^; T+V6M;?GOKT:%:-P-ULA(+_GQSV[
M[ 2L# $?:N8;DBQ?:!-">=Y>UM1.QQ;V<4;RVQ&8OA =*#K^V#LK;V%XW=]O
MSD\>4T'$..T%5)3G#<,H:M\/8R1R5CZO!8&5>+-?#G[0-?%5-BILX8UTN&UN
M5QLZV28?1R5'HW/N1*?6CI0G3.N/YNKR,,FUVSU2#I4=.[5S/E!\%75/"B-D
MPW.Q+K+=&91 <)+BCB6"Q'P+9*_.O'Q%<]CGNGCR1^98!S7%F:)\C;D 7,F4
M-L2,KB +@W.IG&]515N(RXY0NHL.B&'AC63P5)H75.&5N(1F>2%H[9U:ZF\G
M8T.RQ51AA:7]J'G2#?HS64?.8>B+O8/EIHEAB>67G01><)_P_P":INNM>1BV
M=5,:X^U1V*S$HG5PJ]+A6'_>-4!QJ180;*1%7?,Q7@R=F8)!8 /(-\CRP/RG
MS=A<-<ZXL[D1JO6SCQGEIHWX+7L,/90UKFD2FDKI<.9B!@D#8K&&!LD=-/5.
M>P,G=I$Z$&5:Y9OH_P!<)/['I^?=V5=6N/K98CZ=:*15J"V%M+)X@;6E3;;"
M*D:/AV\/)JN37A!7'3X%S%>J-<P;6!2B20Z/BJ*T_@3)"8V3 .:]S[M#2&D"
MX9;.;W#+@D"X)/FK?#QE*1@TM9A#\/I<;A94P5<]=$Z!D4T<$E/$Z5D+HSB$
MS97.CH7/C<]D?X&2:4F)FG^WOHJ[]1E:\EUUGGEY=BWMYS"[5>NFPP/*Q<Z\
MOC,83 +Y&!3![2\EQ-TL%I* KY.KE-.*<@!B-5$'9TM6*DNM$]@RA['&Y#FD
MD"YL ';'*"X6.CC9>KAOBV+B*1[(L-K*2,TL5=2U$HS15%-+)E8U[Q'&R&JR
MEDKJ</F;V<EV3/+9 VRG=?4#@VW1N7>MO%_P41]<OE H]G5N3.HW>WVEE=G/
MKI7^I@\UM5",I".LU$WK%TLHE8YXU16NUZPE;IX&HH4;$O<3SQU4X9)/)F=$
MQ[FEHC:UH8)2S.UX>7.[-HS/!8W2^NBX.$<38QY'78YB9J)L.I:NI@EB;A]+
M34\=+'C$U ZNIZQE3+/4LP^GA=-61R4\!+<^1SRQN;6$/T5%R8J;&<^[CR^E
MFHK''S'86SS84@"=L4\IJ'3^B<ZM#ADT AKHG-RKW6N>6&T0CNO_ *]3LA=4
M<*50:ZTR.(C,T"&1P<"^[3<]D9',8]K0#F+\KG9"6V;;SB2 O3-\H=.R2%D6
M$5U2V:$UV: ]H]V%RU]10T5;3Q-C>9GUC:6:LBIR8_\ )@QW:F25L:R?*?HS
M*Q:NA<2K=H[T,2#;;UZ8H^N(*M3W"^RTA![J<^ST7FTE;?.M#:[86V@L7X.O
M9]1-PJ^>Q6M\#O XV0(<?B#@R1S8;69.Z)SG@AQ@?E?G:+.:!<$"YS:MN#JM
M>(<>5$%%BDU/A#FOIZ7B27#IZBJB?#52\-5@HZ[MX(PR:&,$]M$"[/,UCX\T
M3BU[O+2XK*^EM+U55;!-:ZZ QG&46(A//7YVX<>V,1F2I223)UV^^?FUR/(5
M-MK\OS?/G&V,8Z$;G.8USFY7$ EH.:U^5["_J7W]))--302U4(IYY(P^6 2B
M9L;G W E :UXMS#0!>Q%[*9O5O\ JFV3_P!';W _[)';O,)_Q&_QU/\ \Q$N
M9Q%^Q\/^^>'=.X<088KN>EGK%ZP=*]<G/5_8@L&LJ(^^,.9V/HS#NE:Y8=SV
MCC\H@N&+%2*/80&I'9KF.]EUQ!S^OJF+EV+O@.+*R/?+47R54\\<S60W<3$'
MB,1&3.[M,MG.!'9MRWNZXMOKJOEN*,>QZAQR+#\%#II/FF.M@H685+7MK*IU
M>:8PU-5$Z,8;3&('-5RR,CB<,Q#R.S=S5CZ-^/N#_G*/F=AAYWK8O7+UQM6K
MRZ?+-4K7VOL=(L%GUJ>]B:V)7LH9OYT!>4E<K"NV.]@HB"PZU, L9G1XFN,3
M7E[>T(GF;9ILYL49:,U@UUP,VI<6B^A<M4O'#\*BKI:^$UIBQO&:<Q4YRU%+
MA>&U,$)G$,<+^UCA$X$DTSZ>+.6M=,'2,:H:J7H05;;QQ3CXW9*L%V?K-!KW
M8G%/*K5@CKO/./V#D#CO&MH<7N7:%>X?+N8+0G!]44KMM-6+P!- ]F(%;R+M
MKJW*R67LG&&-QC:_,W-)()!'E#-PTO.CB=@26[7ZU1QB*>EQ/$CA<[\+H*N?
M#H:IM1#VU;B,.(187V$=( 7Q0OK9'QMJ)'GS(G2F(!S ^PPOT;O,5]%LB2Q]
MYJ<=XM';/5*C<>Z*J7N+,DB_'Q6O8H:;GG1ZG36S_P# RP2W+FB:5NTT)MNZ
M!(L&8*]&0EFTCWTFNE+VD0'*V*9\L9<&G\$Z/SXWN#<[0UQ %FYG$C]K=<5W
M'%>^KIYH<(J#2P89CU5B=&^2*"6V$SX.\5M%45,47E,(IJR01Q9:<RRO<QY8
MZ',JT]%]"K/S/FERLCWI%6EZAS?EU1[=?N2!*G4V4G+KOU%7R9"T"ON(_P &
MW5CQ8+%5F;*M"QQZ"H'T1(K@]DN:J0M\=:V21C1&X1R/=&R0D7+VQ]H06;AM
MK@&^XU %BNY1<808A74L$5#.,/KZZ?"Z3$72QCM:^FH9,0EC?2:3Q0&&*9C)
MW.NZ6(M,36/9([)T'TPK]SY+QRVM;[K2C^A<K]DO8NSV4Y6PL2RO\EX):-J)
M$A55I/B$]A;F[NL7UK).0?H$2/O5%VF$^D;9F5)*I[)96AF<,?!"QH(:723-
M+\Q<;V: 6BUNIUT"UUG%-12XEB=-%1^5QT5?@N#4\#)60/GQ#%J<U9FDJ)<[
M64\<<U+&&AI<#VSR9"6,;EL?1H]4:6SI:&I7559$W/EG/K$+9E?'/:NWB66K
M=2Y96NPTMK_]C_ .KJZD853;8HV9I+J\0GK6>2X=/MBX;+7=Y>P-C+F%I>7M
M+>TA&5S)#&X>?(PN&9IL6BQ'?HL?N[P]D%#+4TDD$M6^KA=!)B6 P&"HH:^?
M#JF.^(8K025#&U-._)+312L>S*?->>S&ZP>A"[FWIVB]E^Q([ZQ=-.Q^N$S1
M"@UU6UE%P/K0?292M9+5D<X<GI#N2NU<F> : M900[/4 6VY]H=V"N5C6:TO
MJ701EK6MCF <=2Z6,-L0-L@N;:W?9Q&EBO&[C&2NXDFP3#):6.*+#<9$4TPS
MSSXOAYH\I; 2TMHHQ-.P$N#ZHPU#V98(HIIH'><@*]?^U^[G#C6FCN?DE5Z]
MSW[[CBQ!HYAJ?2ZPF%;X'QO)]ERS&$A.V$SOOL+M/D??;.T>V?-XD[:&EEM;
MM'POMTS DCT+LQ8BW&,+X4Q5K#$,0J<-K.R)OV1J*&HD='>PN&.)8'6L0VXW
M-Z0^>M?5^K;3XZ;:B_L7ICQW@OKQVCU1::4@ZO%^U=34V2]=*%LK_IZ8BK<T
M Z=3*H#9*L()69.6O9P5%FT);)7%I!:S@RD%K])&(<(1//EGGBJ"7W%.2UL=
MA&0YYB+B'F_:-&86! L+ZZ:KX+$\8QO"^(VFJ$S>'IY*>EH3##02-J*Q]!45
M#H9WNE\OB:Z:)S8Y8X7,#FAK[,<7BU+WT;]7_K^Z6574[TK1>GO3_<7E]MJ#
M"_SDM/8;3UGYH)9ZQ8I&7W+!/16#FR9()Z0!5H)5X-+*'AKNJ=N+LZ-T>5U(
M[)I>PFICIY&O#+-A[9^5P_&\ZPT:7:YA<W!L.!%Q7CX&%4[ZFEDEXCH>':ZG
MJ&4C6LP;YZK703PAG:D5;(X<K:)T[@YU0"9C*QW9MCYQ]&CSV^66K/J9UX;C
M-3ZRAX^RH]%M2"Q]&:5RU=,]65_LLXK#FR*,KR(JVD!A?@)G1JTQ\2!/5LE+
MF$IK)F+D*][&N:^,3.C,@>]C@P%K)^P#@VQ!<26FP(&^H"]D7'5=1P3PU6''
M$Y\/EQ%M75T\T-&R:GHL>?@L<[(9,[3/*\PNDB9(V)KA/E>P,8TZU0?HICK]
MDU\L[P"1SF:I<XO**W)^669RP#JG1>9W;IH]FZF@^^P .0U56)07M8FM=BM!
MM?*M>X ,3",.4L\'-V(Y-#"<X<YI:9&@%S7M81&ZQ[1WG!U@ ;7TVOOK/E"%
M'EBDPAXK145E--3R5\$<9J*.NI:(PT$W9/DQ&>1U7'.((86RM@#R8R0UKN+Z
M/+U7]<>]\W?->WYC@<O?9+D' ZB5M>;-3W$DO3Z5TQF,KY] KK%CJC?IK2QU
M=$)5Q.GD5GGLNLAH]@M*326$S173SPN9V)-A%)(X!C7CS',%W7LX, <2XLN[
M30$K+C3B#&\(K:>/"B3%'@N(XM4M\DIZF.U#4T4;I*LR2PU$=%'!/*9W439J
ML#*8H)'"RV#'JYZY\IXZ=TKI7)+WT5NMXEZF/FM,4]'84YO'>.T]2[K2;U.I
M-"2V"#5@*%SM' @4E*VBR!II/M,.9$3O%G6*F>20L9*V-O:U #G1AP#(HXWL
MS V-KN.8@@V/4+S?=#C>(8EY%18E2T<3L4Q^*.IDHHZF(TN&8?AE72B1KWQ'
M(Y]7*996OCD+"+.:6BWGC[6\;5>O7LGV_B"-Z394W+NDVBG*W1\8\+,P!.RF
M'$U<0B?\$B=B0XT"=Q"XU&C;#F:01QQ8TTUZ%/*9H(I2 TO8'$ W%SO;G8G4
M7UMNOM^'L3EQG!,+Q2:)L$M?105,D3"[(U[VC-V1=YQB<07QEQ+C&]F:YO?D
MX_\ U*?:_P#Z'*3_ -I'AGF,OY:E_C)/^!(M>*:8EPV/_P"9U?\ _I<4M[/3
MUW4&I8E$[E3!8#6"U!,S B>,5*X=NU7IY"XM&9RQ24R3"M& @6TY 2XENJ@.
M)CC%F9 QR[%1;W7L<H!=8Y038$VT!(!(!.YL;#D5V)C(V*5T#&23"-[H62O,
M<;Y0T]FU\@9(Z-A=E#I&QO+6DN#7'0^N%D]4_6CF/1O8^P35;H'3>6\B4>BZ
MVF4)O<M*M:'9WMCS:K6][;+18*TL)SH37<:6'1:E30P*H[)8Z[&5,Q2JIU3C
MF"IJ'LA;G9%)(:HN?DS- @<0&,#B!8\RZYR@G?5?FT/$6.UU#@T(J:/#Z_$)
M>*9*FLCI1/3Q,X?JYX8J:GAF>T$2VBSRRN=(8892&MD>'QR5>/H]. T=Q>.&
M:%V)Q>":-[M]/JG<S;9J(EJ(GJG[ =/Y)5J>WJ@:S1(T'N"?DC">WLIR8F8E
MBNZ'1!("&GE$?8-K9GM;-YH8'T\;H<MW.,T3)'.#B;W!?9H ME:2==5XJ;C/
M&:J*EQ8B".E95\,T%1A+*?--5.Q[!Z+$)ZJ.H=)VK'4\E<T4S&@L=#32]J'.
M?GCP?3/H_P#AMEDZDLYPS?\ %8O6OO'M#Q?H%IN9S/HDO1J?ZT<B(ZDTZ6/6
M Q$\RFV,X:W889Z\B)TKGU%AIX\6H,L)K)EG'5S-+"_+-V\4,K&LLSLW32B,
M1YM;M&8:N&:[7:E;Z'C#%Z<4,E<R+%3C>%8%B='3T[8Z(453C>(-H8J$SN=(
M)*=CIH7">5O;7AJ"XONUK(ZF^BN(/M(-<I?L(@N6T#]4HM$8/,KF-8AH;;ZT
MV#VLH$-'JGVDMAT>V7'FM;/4ATQ5,M8PW^8&MPE'@D[/HK\Y6:2^!S=+M_"-
M(TF$+L[K ,:UY_&-P6ZV&R]@^4(,@DFJ<&FILT3WTY=7TSH7.@QJ+ JMU54$
M,914]/6S-D=4/#VFD#IB&.:(SK7-/3'F]2][[5ZU=9L@]YI] XATWISUNUBL
M_, H7E9]3W?? 4]S"KN;=>*H/3['$)7N@*P@C;@#LE>@?<([N/*B+*2JD=1M
MGB'9O?(QC1YLFAF[(EI(#79A<M/XIN#>VJ]-?Q/75/",&.8=":.JJL4HJ&*.
M,P5[C'-C\>$ODIGS"GIIS40ETM+(YS:=W:QN$QC(E5M4_P!'QZQ%='631*;,
M\YI:NP^N<51G77XPE-9>:]2],.[]OM>*I8LIT[\NMS=5YE$MJ#RS5VNW@:KK
M=P[-7U[L@^+3SFLJ,AU D:R0/NP7:]M3%$"YNP<&/U )9F.A.B^;EXRQX43V
MF6"*MI\,Q@U =2,;+#74/$N%87 :B$OEA;.,/K7.J(H)IJ1U1)FAF?&&%>8G
ML[R_F=>HOK=VGEE>L?/T7L)0[G83>86>R?A@15&]!Z38^>%M:Y9Y5*-DUI-L
MPEC/2ZN%\S):V$L:F1PY'!'+\]]/)(Y\\4CFO,+F@2-;E#@YN:Q%R ]NSK&V
MHT"^]P#$*^>JQO#,0GAK)<'JJ6%M?##Y,VHCJZ.*K$<U.))(XZJGSY9>R<&/
M8^&3LXRYS5[O?L7#^K![:_\ 1MS3_K19/.9CGY.G_P#&_P#JM7Y3\N_^@</?
M^;KN_P#U,/Q]2D3]E-_]_P#2;^Y>P/\ [?&_->!;U7A#]<J\?R#?_$WCA/U8
MC\:_79?R1BE$ E#&B3;CEASPE"D1;?+) 0/)K+#-'M_^SO%)IKOIM_Q;:XSY
M]"0""#J"+$=05_0SF->'-<T.:]I:YIV<UP(<#I?4$BU]CR4OJ?8KO2*RV:Y)
M>Q=)4VVZ7=1TJV61?<'@CNQ=!0LFS=+<V[* W0LZRJV+YV4$WGEW-'W;L]8Y
ML1G$Z2:C!"6M:8HRUK2QK<HL&N !:!:UB +CN!W"YDF"8/+#!32X9124]+2R
MT5/"^GB='#22QQQS4S&%N5D,C(XPY@&1V1A.K6V_-S]A^Z]%>MK->>N= M5@
M?4O/.'#=U:&IIS'G^6^'WX$DSR$YVDJN'&NK#5!^19H1KKMJ-C&NN,&P0L :
MR-C0']H &@ /MES ?NK:7W5IL$PFBBC@I,-HZ>&*J%;''% QK8ZP1F+RI@#=
M*CLSD[;\<C4F^^4@]HO8T:O<]J<';^G15SDSE38.9I];BZ^Q45T@T8Q(6%8C
MR7G*F=%$W:Q),B;1Z*(F1\2[4:,N?62>3P%SW=E'FD!#SE%W VN'::WL+];+
M6< P1T]94.PJ@,^(120U\GD\=ZJ.;LS*R?S?P@F,;#)>_:%C2\DM;;7T7=^T
M5>A$\NK74[W7N>F6(.VE5!)9FJI)/9%YRIH"YD$!)@UV-#:HDC4:3.?A"U3*
MF<>NIR\0B'(PQ.?VCHV%^7+F+03E(((UTV)'@2-M%NEP?"JBJ;73T%)-5B!U
M,*B6!DD@@>R2-T0+VNLPQRRQD$:LD?'?(]S7<'2^V]>[+:%UVZMTBX]!MRD$
M9:LL5K>G.6X (C QL.,*:7+)-#IHU8L&FV=-L;2L3BSI=MRB9I=S(8HVN8R-
MK6N_&:T  W%M>NFG@LJ'"<-PRGDI,/H::DIYG.?+#!$V.)[W,;&2]K=[QL9&
M-[,:UHL&A;U=_;SVDZ2^J%HO_L#UNX62@'LVE)>V"\OV;:JL740\#<U$>2;N
M2N)9P"#0GRCR:;%Q0Z1SYWTQ\OF#*:GC:YK(F-:\ / ;HX"]@1W7-NB\E)PW
M@%%#404>#X?3P5C8V54,5)"R.=D1<Z)LK W*\1N<XM!OE)N+:E:6J[MV='S%
MSQ91U&\KN2V R1@YYR+9&<=0/,GG7DDSRH\$?8==S"5*J<[$44>ITRT&4O6;
M<2#:/,PQ&02F-AD;H'Y1F%A8:]P-@=P-EZ9,(PR:OCQ.3#Z1^(PM#(JUT+?*
M&L:'-:!+;.<C)'M83^*'N#+!SKYE?[,>PBJT;W5;VCI(5MEOK;J,UC&MKB)O
M/T1^H(K[VYD&ZE8F(L#M"86D;L)MMYF2DLI<;F8,B:'?$T\);E,3,N01Y;"V
M0.S!MMK!P!MU6I^ X-)3^2OPNB?3"DCH! ZGCR"CAE;-'3!I;E$,<S62QM;8
M1R-#V6<T%1"Y<-;$X;6!Z>4U=O69[ERT.EVG-9-6A4IS%@9/OG.\Q1AD\Q)$
MN^<[22R;[[9^.<^;0 T!H%@   -@ + #P"Z<444$<4$+&QQ0L;%%&P6;'&QH
M:UC0+ -:VP &@   T4[<V_J!^RO]SX]_UX)\U/\ RT'_ *G]4+D5^F,8%;KB
MAM_](#[=OUJN_FY=L>G7;4>.GP;VZ 7>$^K773>_QR]=]+I>AR]"7V>WL&&D
M$UKJOKE[/7;D8Q&--_K.R4[A%\L//"@89/Z&=XD<K];'68=?C-M94ZC(^NY&
ML4>WEJ[F)H_:NFA;)N/P;I&AX)&P(-G=Q*^6XO?,S"Z9C+BGJ,;P.EQ$@D6P
MVIQ6EBK&N(M:*6-W8S$Z=C)(#IM8^XUGTDQRY<$-6>7(W5&I'T?MS:7.M]*O
MS>Z7]MU&D+Y_:BM/T,W0K$G)Q6&\\I+%/SZH5VP4)H!*!)F+)<P7GF:ZK[3\
M:0A[ZMH:YC0U@8;PN!+!HX: N<0[7>PMP:6HXJ%>YW;U\L574\7TT=+-0TD=
M-1LH)WC IX9?(XG@SL:&LDK*B6*JCD#@'!H<LIZX]"]5N;>_'K2_Y/%SD;F<
M[9:IOC_I8+HY!4IRGOV@FSAF=@^46NO %@< Z^S18^1'H:28MG!=ZC,0TL=3
M)23"7M,X\YC6%EW6%LI[(:MN;EIW(')3&:+B&OX2QJ/$C6FM8UTE)#0OA$M2
MT1Y1 ]F&7=-$Y[W%\!UD+&M>UT69CL7ZX,KZE]!?:*?7K_/G%=MP#VA5'UKL
MW=.2U+1=H1-7+ITKV!9\OM]S06"W6E0IIJFE<>"KZA];CK2Y9,4@48R4>!XF
M:TU=..R>"W*]\XBD=<CS60A[6D!I)+I"2  T \U<9CI9>+>'Q\VUD4M-Y/55
M6-085B-07EK9::CPB.NIZ:6&G@E?42U&(OEDAIVP,:R5V:0NCK=[SKT0G3N8
M,@(QX;5;/5KU>NO5HH-=(Y9.I6KBU2;V9HSAT^'U3^RCD*K79=I-(R"K$]:'
M%Z?:RI]L^BC)[-X_:-GG9%_%MD(: >8!NT=  .2[O"4DSJ"O8\DT]/CV.TV'
MDG3R"#$JB.*.,G>& B2&&UFMBB8QOF-"I?YZU]5_CZR=#N0._P"P63PG2POK
MU&EM+\]?;U5A^F?U"/6C_P PZW_\0I?-$?Y:H\8OZBXE ?\ /&/:C5^'>KR(
M=-#;3T76@<LZE9N168NRUG 1&6]4N=#L:9K$1.GLE+Z#5VE.M]=:PB$A%9%:
M(G!D41(98AZP_4-LL+$9 "$Q9R1ME;E=<6<U[7"UVO8X.:X7!%P1S!!%P="O
M9B.'P8G3L@G+F]G44U7!+$0)(*JCGCJ*>:,N:YEV2QMN',>U["]CVECG@[(R
M]E/81PBYM66G;>IFU_CIRIIRM1/>;'L!SUHA@A%0LZA!AAC1$Q1"#CA(SE_U
M)2<&&();*,+'I#B"G@!>X11WDOVA+02_,;N#K@W!.I&Q.I6F/ L&CEK9V850
M-FQ)DD>(2BEASUC)7.=,RH.0]I',\E\C'7$CCF>";E.JL.\].,K'6NP-[Q?&
M_2EQ4=5M-O<%V)]8D5299JN9%T1913;2NKG4!E=5D:C0)R&RQVK523FJ&\(L
MB$,8='$&,$9&=K1E <X9M3:Q<18G4D"U[ A3#FX-0"HP[#8Z2CCH7L=404\;
M8889JEAGL][0(C.Z(MED;F,K8WQ/D 9+&78FI=S[-0'% ?4OJ%ZJCSDX+U7S
M-JBLC58PH"^S'NV=B"J1(Q,<R =RRLE@.9Q+MA]2RW+.>;&TAD^V^3HHGAX<
MQCA+E,@(!#\MLN;K8 6\ ME3A.%UD=9%54%+40XB^&2NCEAC>RL? R)D#YVN
M![4Q,AB9'FN6B-C1YK0!;.CV;Z2/KDH=[I_1N^.Y/96S9X#%;2.G,$D?4756
MKI3 BJL'3JQ*X3%51K#QALP>LR(4%95M6HQC<"$EC#MYGMH8KL>R(=@WM<N3
M-V8<0T$  ZN<&@- NXV.4Z%?.U<' ^'=I1U-%A,?S) <8=3MH6RF@BJ)F1B=
MD<<,A$M1/%&&0L!EF>R,MC=E85F=^1?205NDV"J O>F3<T]3%%"]@QQ:EUY9
M:.=TE6[(&M?.^C\[:U2VMZFXU^6QD7&O,*<>PRMAGL#@3[*3HVSYCVE"YX=9
MF>H+XKF-S7.(T>UX+06[979K7OK<+4,2X'GJH:A\-$*WB"2KP=SZC#I(:RID
MB!IZRCK63P1U$1_!-IYHZEC,Y$3"'-+%6MITKV+XQ;EU>LUMNRQE64RJ&*N%
MVYULG84>UW!-[ A+ASJV]&^VTF[VLE+U& NNN8173 X*VJF6#91&>N\1T\S"
MYK6$.)\[*+AS6&&]G--G-;=GG-T L1;1=N.@P/%:9\U/34KV5#Y"9VTT?:QU
M4%/+A+WN941NRU5+ )*%S)HG.B:UT$C,MV*;>[?2)=B[MLXW85JE5$AUS%QR
M$ELF8].MEI_ FTW==?K@MWNW6>B]&N9>EA:J%R?Z@Y^2O1U##.MUX%8/8[),
MVU0T,4.7SG.RR"2Q#&MS,:6L.5C6M!:"3<"Y=8G0 #EX1P5AN$F$-GJJEL-=
M'B+8I64,$!JJ>E?24[_)J"DI*9I@9*^3,V(/EJ#'-*^1T,(CH)Y[5]ET)T/C
MUM<>SETUT)7^K7ZY_P#B]\(_Z&N8?]2$?GP<WY67^,?_ %BOX!QC]EL4_P!X
MUO\ S,JF7S6N<GA$\(GA$\(OX^/V4U_X4^E/]X.^?^\>0^?0X%M5>,/U2K^C
M/D&_)<3?QF$_U,1^.?@OY-O.^OZ#/+GN.NMCR'IO;P4[0^SOL".Z<V$7K5S$
M<OJQ2:8R.$:;"[[UGFI-/,YZJ$C'TB@61THR@4LRKSJX@RTA=;6%+R()X/K-
MM)IX2 TQ,(!<X7%]7AP<23J<P<X.O>X)NN.[ ,&=%%$[#:9T4,U34L8Z/-^'
MK14-JWNN7.?Y2VKJ6SM>7"1LSVO!!LLY:_;_ -EKK9D%QL77[019ZLNOBJNN
M%_W8A*4!=06%I^B:!X0+UD,<US /.CL)F8MC6,YA1TY&QT\I.T;2T[6E@B;E
M<6%P-W7,9NR^8D^;86&P MMHM5/PU@=+!-30X9 VGG?22S1N,DS9'T$C9*3-
MVTDA(IW,9V3+Y&-:&#S&@+61/8WMH7.$W)(>@MM^>UPZ%A7*^4,I/_!R6"S1
M730:OMCEY#Q(JWMT.EFG1JV8B4IYF5H2!*9/--)D8(2\R9!G((+@2+W:6DD
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M6S?.JFM%-V'W+$S7F]G?LE)HLT+$,UJ41$7K)MIMIDZEIWWS1--W.>;WL7.
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M2.4^Z%FK$[*33V3]X.<])Y;7[6=@ZZJUM#IG93.GWAN',ZL1]=$L3/KM27J
M3';;$T!):09V^WIAYT>R"&1DM*UP ["ED;(YOXISO8(V @ .(#'$Z#KE;F 7
MMP3",2HL2X9@G;&#@G"];1XA-3L+*5[ZNIP]M!2QO$4+)W0LP^H=(]L3+%K9
M3%#Y0UA\MO.@OO\ D.7>/ ZZ"WU#GT3PIRN-;W-QR\!]GC>YWL+Q_P#J4^U_
M_0Y2?^TCPSSSR_EJ7^,D_P"!(N'BEOG+AO\ WG5W[C\RXG??U^U5Z\]"[M]?
M=<[GGRY>C7TO";[@>&YZ?:+GQ\5<3TDN-6J?3NBK[,:N4%=(]9?9WD5*?-BH
M %Z?H73.)W*JT[4IF3)$,IBLC4_2D;M2YAP%VEHV+9DBK8BRH?+5M<Z-A:"0
MR>&1X N2QD@+B!SRCS[;G+8:V7S'%=-43T%%) Q\C*'',#Q&JAC#GOEHZ+$Z
M>>I(C:"Z0P,;Y5D8"]Y@RM:YY:TVFO'O?SNR40>FE"6>UUZAJ/H]C^54UDBJ
M8RM!;N \D&I_L7.GGL:2[H4,]^=QRP;,VE/M2^XA1KRK776(RT55IH;1O:_,
M"&%YJQ*\%Q);*]SH= 6DY!;3,+;"VI7S]+PE70U9J6N@IYJR3B]M?5,EG=)+
M3XO7NGP82,@EII9121EKNSCJ('4SB]L$S#(^1;YZ_P#TAG&*[V&Y]$<5QUQH
MQIS&BTRN-"N><;[?6,2U;ME9ZE8A;+R_GO.?5VHN);"JKXJZKV-LI?6&D6(
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M6#VU_P"C;FG_ %HLGG"QS\G3_P#C?_5:OP3Y=_\ 0>'_ /SE;_P(/CTKW_\
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MZ2K/[Y/Q*\7_ #-\D_R94?\ W%X[:7Z63^6[WI\_8[^>L6_I*L_OD_$KQ?\
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MJ0NB>^*6)SF&_FET4DD;B-VO<W8E:5^TE]0O[6SCGZ#IOU?R^5U7[XF_2/\
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M=B7@;[2M_ASZ?7Z>ZR6/QXV^M7"];?8.E>T?':UVOGX%C4URQL;BD^Y[<$N
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M2>A7M?SBL%6EFCN=B&%G$&^Z:#3;#>K&1(9/K!IL.BK0# _[+!C;:<T^:.$
M$:/>8HF+7Y?F(HCYW[:\-ZQ94U4Y]:#;&UL2*I6E']17GH8S*KW2@C=+36*"
M5D 'M&GTJC%'*S-)C@T5-K'7J^=]2\;B@;MD5DO")X1/")X18*L_P"M_N&?\
M[)X19WPB>$3PB>$3PBJ![P'=#6>IWN(RY'+;(.K+_4?MAO,YZ%HTWO,/0!>>
M7F>G2TW1)KNZWM4=AC7;U_51INSV;8$P!KL5F+&:-Q?J%1N-M^>WI[EYAJ_8
M_P!M.)!-,\@5=+Z7P[KW?5GKGZR'^U-?ZF1U='TKH_)>>&5[H3DCJ)U3ZY8O
M6ZF=:4=6 ?RWJ&>X-864957M U$1J2B+8'T"YM:Q\+::W ]>A*;_  !Z!U/Z
M]"LW>/<[Z1$--VY?2:!76ENY5:?:)@M>1^K7:G'/+I5^2\KL?1N24>G3&= J
M%F=VVZ-TBJA6YONJ'%'L[@A?10;7$8A;9EAIKO;Q'7]7B.A332^Q]FNO7XL>
MY?NU>Y/TE-<O-/YH#R:@-9\]3Z%3I^GM^$]O44CIF4SWCV:971AZY8;MMRJ-
MQ7K];]9KPY969*PFJ\CU9%J#4;HMF:<[\OMN>_PT\4T^/CXVN%GB/;_Z0!,,
M298J%7Q*];'LFT5L ]9>QM)> TA+[:7+BCJPV>J*^@,G'6R3^3JJQT,*)/K3
M-E6C@J[D@,Z$-O!"T^/#W^ONYSX^-U\JGM%])3>.?O[C)2*;SUP&]],:)7*T
M[]9>LFEN)>_]AHU+Z?V)@N/ZHD=+JO1^=.&?0B^:RPC/.=_:IUO0KMIO6S]M
MUA]?,<AI\<^2OZ_U?'/N6GVKO?TCGKTQ]CFU;K)OL. PZEW)=34#CBW5B"ZT
M51>5<#8)N@UDM5?'&6/*&#!CT-BIY!64HI3MBL/25*ZEV+8_<Q8:>&OK/MMZ
M/1JFFGM]9^RW=U6=0^]?O5#:_4]"_P"1)W*KH_1E*_I]J1<-[@)6W7*+IW"3
ME"BP(3BHYIN>7SGJ:&:W]#!NT4%-EK\E=MR!TP4W->F5 !KK;3J.E_;T%R.?
M>T^/#T;G;_"_NGY%$\(GA$\(GA$\(GA%5SW 8V59R 2=&3>0$LW4N- =+9\T
MVM<-Z6<D8=0JP?2#D)M$^%U4Q1UF8W2QOJGN/8:[49+ ]4'JS5T+0,/?OX?%
MN]%07UU?^Q==Z?R,OH+KV!N=&N$><;*'@5\"G0:9; TSDJ2WDV!LQE:MP>4O
ME?;.I N*S0GYA1EA<W2U7*P4&>GCD7L[X1/")X1/")X1/")X157[-GH87=_6
M)DBLM]BYR0^ZDLZ74:TKT(K)@$7&>@-TK^TFJD95IP4%80$P%:!A>A)IFY<6
M<J&UBW0$+"+S,'L'<EB!O9ZC</9AW0:9[$]%3I$<TW>F!=O]=[)4>/+Y7J2[
M=0-VZB3FMV2]L*[*WO:J^62L="&O]HY!.HH?-<"RT\MMOB_>GQ\?J7ND$3DP
M,0O(Y(F2AH"<B&QXB,%S/%I+D<N+7>36,F#YOJIX]9-\:2Z[ZXWVQCYLQ%V?
M")X1/")X1/")X1>>WT@;>^+*M1HJ\?V915S!^NY8L>%?C$CNFW30N26<OAZD
MXKEVDEFCKC.[:29P$7C6JV"Y"4JLV?!Z]S]R-R+4_5AUW5#W:S4WL#3J5W#>
M*FED26(T2P@49186Y&8NB*XX&#E\K-34VT4C:D5F0#>HJDN3('E1I1%>ZQ]]
MAD7IKX1/")X188G^'U/]ZW?^D(__ %__ #_S>$^/CU*"?9CB4/LGQCO? "+!
MBIP=BXXRYW-9<I]+#A%':1K0JV9[(I&*C1OJ)@C,NR[=HOU+UUS#DN#&_P!9
MK0;$'H;HJ063Z-&[60*GKH.V\AH:M/54_/;)6>5>K.U&I)E#K'>J9["UQ=1:
MM%W1F/07V;C66PEE>$%VY>]6V2642N(V@'W@=;CH>?/J+&^FO^*H-C?GR^/U
MA1OZY?16V)2-RFZ=TN=+BME =<^)@Y[4>8*XZ_-6><=-ZWT0)1?7TUR>Z]&M
M[AGTS;>*[ZA(5U?7 X !IDAY[5H3+^/KZ[^BWZR5/CX^/U<>GT,ZN&I"\_'[
MW%#4].?+Z\27KQU=B]PVY!ZN="]4JV=7KII?-)*[RT2EWZ5^WY+ J*D;6($R
M(>\J45D>*2 -OCOOR[_9ITM;[]_HYWY6_P -.EK!].^C@5VN[U#HM"Z!6**^
MYU5?6A)2ZZYX^ON7,MFWKD1[(Z"L;G1PKE3=K.GLRSV1<9'1 .ZT95++4*Q:
M5]A.('P#"OR(TU\=;>[ZT'Q^I;S[*^B"7V>%I>MUMZ(,NI^OG2^(;Z"<T7%H
MI&72K;Z_VLR[HD)UCETK6B63ADBM36X36&T2ZWS0_?\ KJG^5L!^L'OTO[U%
M7YG]$PB+NS!^#V+196K3T^&_6U##R\'-@5*J[[J7OW:H]=XU<8KB-GD!XMUO
MA=*O=F#0666[5%4FF7*J8\7!,1E^[E;UBQO]8[SS5OZ_LM;X]._+15/T.LR!
M16-E??:O):J"@Y;SNF2MO7M>?SLGFG)^1=ZXRB)Z)SD;IZW\-NX,*[["VULV
M[2#:*IMO8$U8D I0"@5DG:7->]^>_76WN%M-M$)N=M]??^J][+UNXMSB/CO'
M.3<CA;R/X>6<SHG.(GTH6JV5W'2*LJK.C>1=J4;J!(RU68,W"U-+U%VFS!@H
MC$>)=\5%)?A$\(GA$\(GA$\(GA%YPLOH_<OLW%78>L#'U-ACL*OGZ^#FX<-@
MHM7[OVB7O?1%IM@.M;0"RN=[P!4DM9L0M;K$J*@U\Q/* SM#R2Z@OU>Q/U>Q
M7>Y;3W-!HB.IO[:?>6JO9KL39&66^Q!4;%TQ:!@Q[6"P6M_N B"-'0JMWMGL
M+K=6L#W:NF9^2#)B*0/")X1/")X1/")X1/"*$O8KF-P[-QZX<OI70X.7LKH,
M(E:6R:LGVK?%3)/&_"] ."JN%#:@S6VMZLJOL_46=6[KXS<ANA+#>"+CQ ^/
MBQ3XWM]A41*O59Z%U;GG6\=(3UYS3JZHISI!S.@L>?T^QU%*IKL(B*!!'T)X
M.*+EJJ:0?56;>[""4TY!7U8:ZPTBN7> BN5X1/")X1/"+!5G^ 5O]PS_ )V3
MPBSOA$\(GA$\(GA%A-/_  C)_O(%_IY_A%U6M,I[U_6+6[JE;<6FD;MY:996
MJ)6P?U&6P ZK'TE8<%BS,4$CM;IHO;[JB1-F0.NHAF9A\8C\(ME\(GA$\(GA
M$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA
M$\(GA$\(GA$\(GA$\(GA%AB?X?4_WL=_Z0D_]?\ \_\ -X3G;Q]EO>JQ>YO7
M[9Z_^M?L]VZB0J"+GRK@EAO57@?+3'"65Y7%]J8KM&BE>P5',@LDP1_7@B,@
M2"=/C#$5#OOC?%&I ZD(-Q?;FJ,T?Z3#H_/WU0YG[*\D<G6^UW5@M56>M<]N
M?)VL/-K)+:E_$NC]'X]:2^@_B?TZA9.?]#K"Y%=NKKK0TVIYUDKU1- ^\UB(
M1ZO'_"_H_6GU?'@MJU^EBK*"'@C+I7$K74E'<>=4WJT^E==E]&=\RHW4JS<;
M-R9K?XZ[3HZ<J)O4-"M:T%))>HW\K).?I7U=F&6MR5JQUVT-O$CHBY.??2K1
M7M#SFT%^K/;>?U'H/2.>TS/0>CJ7M2YF@1=45I3Z)8F%R84_728MN>]"JVT<
M2S6@:6S890)U [2QTDNU+;]WQ\?XJVWYV42<\^E([:<=R:Y]*X,C7<SN7'DU
MXO -)N:UDYIN;7[.J. HK@).YR)+8 1"'06&=,'A$9Z0"N7<;66;"JO$+7V]
M&F^_BFG7XU_5ZUO*KZ7]"_J5AZ*I]7>\C\M4/5F\?7;17+%6>6+>;D-;ZH;=
M*O%O)J!4-:55\BBZ3.<(A+JA1 V^L,[9:ZRK OYU&6Y:7Z>K3V^L$);XWOZO
M'X*VFD_2;K\="Y]RNZTLUW9;[[$];XTZ+IH#7,7*!EGLKU_@/)#;?J,+8JO*
MDM+WECE$+:VMYI[.WDHW3RLT+?(;5 F$=.@/L!/QT0Z>H>T77K/Y%$\(GA$\
M(GA$\(GA$\(GA%XW7#W=]CD!-BLRR/E;:F[3^QUA@08KIJ^P<^KOKC["-/79
M=6WKP^_X!M3OKEL-IY)DHJBOL:J,OZ&%65-N:#I!AWQ\?',(O4ODMNWO7.ZQ
M9R&8+9D>*4.^(6J7B$$:SJ6)B:TIATUG!6619K7[$O:(=@[ N!=0[K=M6@L!
MN)X]2*1O")X1/")X1/")X1/"*#/9*ZMN<<8NM[3WE)SPBK P-)+"ZH1O3=IX
M]"X8(:W7Z2ON%(+L%PMQ\X=7J"P=S*2QL39<N"5LSBQ1=R*KG//8WOHG>*-R
M/OZ[GE$(M?.N=7 X2M .G, 5I94A0HME&'>B,7@0&3>S.S@D;BT2IQXDM>25
M\/9\ZZ A8Y(O1;PB>$3PB>$6"K/\ K?[AG_.R>$6=\(GA$\(GA$\(JA>[M7O
M-W]4?<2E\P ;->E6[U'[;6.>K$!&1'K&[ON=7E55 4I>)Q<C-BWI0 ZXC!0V
M83)(9,3PYU^LUHW%]KBZ*A5V+^DT48Z.PKMZZ8"K=[>RZ^K+8N1\CMXW.5G/
M>V\2C]?2:8&EH)%R9,NH<H;]<2L7-OSU7"X$06XP4ED[K$2>Q-/CGIK[;=^N
M_,%H3[H_TMK.%\=7:AUZH6HOF#,Y=2757]=+;2*NED]2*PYJSV*^JZ@I,MWL
MYK[?$O*A:ZQ$$NY?-316;$#ER)%$A=&733GKWC8\^@(Z7-U=-/MOUV-CM;72
MY[UNDX?TI%>LKZL ]1[#;ZS8+Y8ZHON[OG7K/J]I-&KGNOZPU*M7>OX0\E0H
M3'=N]5+M["6AU):J[8U&^M% <*:^A9KMAFTTZ6]?0_;;U\TT^/ _;;U^E:+9
M9/I+Z_!9+*.LZ^^O+"AZ\?#Z/7JKPJ"UH *A[F]Z75OI\E=VY78TEH:V_@*[
MESVU5D"I0))LW/-A0"<_CB:DK6G3Z^8&FXVU33Q^!IZ-?%>Q7K8\ZG9O7CA5
MA[DFWKO:G?(.<,^O(=P8%NR;IQM143WQ;]WBR3"!:AVG=K!H,)-,)%IIKH+-
M*/B.3:'<VVY*'<VVY*:_")X1/")X1/")X1/")X1/"*K7N'7+!:..CK%%:>W9
M%%U#C;/IE)K4.QCNW\D5=0JS#I*,95'.//809*L.>98:D+O.7<ZR&YJ(JUS.
M[T3,"*@_KKQ;NG,.F\CL[>A=(=(6D&-+ DM5C$V$H\Y#D!!S2O287JCS21.(
M^O;K=AMO:K:^ILG05EZKU8.#Z >DD<D7L[X1/")X1/")X1/")X157[-2+:T[
MMZQWI)^&S.M5)[U$:^(E#XV"HZ(FW&>@"+6#FK:'A*G3@VTSH$Z9DS@/+42$
M?9U,JD=J\E.(O,D'@W5%U;9V*D<EZD$AJWL3TE_0.>R@R\WK+CUXO-2Y%7+1
M6!^:ZQV^Z<YUF=OK?7C*RC+ *Z4#3.C]AS$I,MM/4"4\O#[3Z_=IR1>ZH4L\
MX8DY0FP!4PL$I(.TT1&P4\D6F\PFT\&<P3[#R9VAS-#G,4F=/GCSG3;&?(B[
M/A$\(GA$\(GA$\(O/+Z0>@W2^U6BA)J!<^HU2&'K@S*GT63&K<?I;KDMG5</
MN)FF&J?>);6;R1]0(]W+R)2+:ZJG0#\JA:IO:*[1[OC8_'(HM8]6>8]?Y3W>
MS!V^NW&U5FT*FCO'1;,V&S$NNC:?(_6688*^MIQ,BVBW4FL0U^.PL7-K:44F
MF6%07H'K>@0HB]-/")X1/"+#$_P\I_O8[_TA)X18-_7:Y;M[35[>C2V:KOZJ
MN5/Z]8UH3A"Y5&E6" Q:W5,H2 & !<.^T1(AD$H\\>V8Y(]M<YQDBUNW\+X;
MT:W)KW?.0<KO-[JD 8%?N-LH53LELK@P3'#X -18&RHQNI@#:R?? < 98^@Y
M\NQ\&FD\NTNQ%TSO7/U]:/:1:&7#./L++S-,AKO.;";S6FE/*"@JQ6IU91TM
MK.FW.K"BNFZX+1+4DX0:DCXS 0CR;;;9MSU.N^J+"*?4[U;0A(EJ/UNX,F75
M>[2=+K0"KD5 7A5_HLL0$,E\2"B5^*!7<=X52N+-E!T@<?5K%VGVSY01<1+G
MJ>F_+HK<]2LPH]</7I!J\T1<)XZFTLYT[.R:*N:4U?H_9%6("W$GNM1$T.K,
MPBUJE=FF)-Q--*_7 N-]\L!("(XHL*9ZF>K#".RPG^M?!#8;E;@+_;XB^0<_
M)BM-Z5Y;Y6W*Q1S5_?1U:0,OWV0W[+4EH-EXXS$5IEF;]?;GJ468.];?7=I9
MTEV9<'XVPN5:=&62N6PWF5+*LJ&Q,;C/T1@^3/9TN[-8Y.OY15W+9A%0&D6T
MHFQ2S[MR)B]USU**:O(B>$3PB>$3PB>$3PB>$7S.<:XSMMG&-<8SG.<YQC&,
M8Q\<YSG/Y,8QC\N<Y_)C'A%$<'*>#*WUM>#<XY*OL]Q80O+TVAJ50%>6EH&$
MT%@;6LW0",YT<*O>NH8C6\A,T(SAIKK)K&P+^N(I#KJ&NU=0)7JHG35]$JQ*
M.$E0 !*U2[ZR;<J>$9>OB@%%S(01*3-I'%IG>:>2:3&9)=MMB+->$3PB>$3P
MB>$3PB>$6F7[GG/>HUHFH]0I%/Z%4""06!E9O5<36JN3EJ2HF"TTE.^#.6RD
M+38(3@B)1]I RH8B8-XYH]-]2+!I>3\9KLM>TKO-^:HYZC-%+5=$]2K*Z6M3
MRH%M=AW0ZA@0[IY9*O7E"6+*_ ^VZ-&M7Z?$%8-% 12?X1/")X1/"+!5G^ 5
MO]PS_G9/"+.^$3PB>$3PB>$6M%G!+&[1BR,%7KP*W":>><1$($$&*4RG)++*
MGWC@&&'ATWFGGFDTBABTWDDWUTUSG!%FH#P22"A!C1""P<#Y-%@)AE(#P7'F
M87)4,>^T@^"8<9E'S+KIB:/&=X_FUQG/A%V_"+HKV:UO!(4J8@LQH36*V4A>
M6.;!$Q3GDJFP$DPTDL>AJMH$8M8B[;8G"/$)#)CB(@ECT(F[-;&R'32, =&Y
M8)C,55N7!JR)6KYP13V X.TF"I@02F:T8PN.+: :=@##-)I(7!K(1=[PB>$3
MPB>$3PB>$3PB>$3PB>$6).?HEC%2H9.E*]L^D)B1K#F08C%S*'%B<R-2%/-&
M2QD%@VUF)T#BFV@BSB27&NF<9\(L4!>Z.UVUT5W*J,M]V<B330"Q*#-MW,(L
MYTJC74<R3.S.((4DR0#&,EZ"CSD;18AADWU(MF@G@*@A*%FB)&)BCG'(@DTF
M@G@FTQ)%-#+'MM'+%+'MKO')IMMIOIMC;7;.N<9\(N7PB>$3PB>$3PB>$6-<
M.4]>7$N'[9:C4!:Z;&-7!PJQ<)K++'!'L2<;+ -!K)/+%#IF673&\LD<>N<[
M[ZXR1?B!ZD**G!&<*B31BH@20X& DQ0YTZ[[WA#G'CFVFB*F4_\ TI$/)IK-
M(N_X;IID;^F^$65\(GA$\(GA$\(GA$\(NJ4>"#K)N:8('I$*4=+N41"/K&$#
MB/8TR3:7?3&@H>LT62B-LXA'Q+'F7?3&^OQ(L,+<:B=$#.%:JX9 T6R.EDPK
MQ81$Q3Q$0"2M@9(2M]"UL910HTAX^9!=""8(=I<231Z[$6Q^$3PB>$6&)_AY
M3_>QW_I"3PBJG[P<UNW9/5SVIY3S9<2VO_0O7ZQ5*GK0W 5>+,L+H"TA*X!7
MK(]6 G)V*EC^H9%,@80Y<:3[%0_)C? ;C[=O2B\G;;Z^_2M<<_'$#R,QMTRS
MVGV'BOM?[;6[-SM=9KQ1^8>O7K=S/D@?4*A=NH<U0DM+D+2KLCZO8"XK4#K;
M:IJX4\L8J+\N;56Z&W*W+TGGKUZ;:;[W3X^/3ZQ?K*E_1?2F. +[7DBCMJ:6
MGY]CYZ_9JW;O70]?V(FP>[*:_P# *^AT.[?1K;6*T!ZK9GYW9[.V,Y[;::)E
MO$C!M;H $*P73NY==-#?EUM_@FGQX>GG\!<6:Q]+;O:N^V=IO;,Q&U-L-SWF
M*9MR4WGQ*6QR<U5UY;3.E1][HEW'ZYRE9/?;*:6WYIRU-TI^I>(S^M*E=@H#
M9#--/;O?GW6Z==KVY(+<_M[^[PUUMR!U"],_2T3V 7>MG/EGM!]\;]K5$WA7
M92[!+497;),OZ%:Q>?M&VU&M-VK>K)ESN*J&'QBVVQ&1ES3:-W#%OJ<9.-N2
MBM+Y$3PB>$3PB>$3PB>$3PB>$3PBK5[D\L==K]4_8;EM7$:L;=<^/=!3TM8G
MM1M+):76:KL\T];.^#=5^*%:=9-5@S4)RTAK+5=(2LM$1=?+9"34&Q!^M%5S
MM7I=7^L=JZQU,WA-%$:+N2UBF\PMB9/S5?;^B]-MMG2/KK>.@.2E[$PZMT0*
M@<KJRS\*ACV^M8W[ O3U]V&^3"LI?2US\=WK16B]2ZM?Z-QE)3NCUB"M/J\5
M*-M)HR@:'6:8X)<ZL-J<DC6.U1[M6MV:6F.4O#>/5R,(+88T53A;Q5-(166\
M(GA$\(GA$\(GA$\(J@^\G->@==]?V=!H&+23AU=N:[WY)1I*%'<K3RI?>4;'
MHE6K\?4B!.=,)'E<%*";H;I/FNVBM[NJPS$:#N-U)Q%6#C/$O8U!W#E/:+OS
M1;)8;-2*>O[IO,VI@ZQ1TA50:Q6#+NF65>RQ" [JJ>P>U-5$N&O8 5G&Z/7Z
MZN0T:YUR[Z73KS]G5%ZN^1$\(GA$\(L%6?X!6_W#/^=D\(L[X1/")X1/")X1
M5)]U.9V[M/JU[=<=H  [2]]6]4.R\WI:PL\56*QMEXH%VK-=!)9G3#A+ARV[
M,."8XN>$42.3:>>6.*/??%&A'B$&XYKRS[#Z;?2*5JY],:\?[5TR\H;Y=.5G
M6>VY=<JIO9;4EJG#;'55,2W/+++ZEUH-#SSH92Z<M039:[/9@_L!K<+HJI<R
MK#AIKRZ;V'?O?ZTZ^SUC[+K8;?Q_Z5G?J/7B4]CM+&EM:+7JO(>AZNKJ0_1H
M*?TKUJF8ON:+7?4[4+Q#KG5.*HO9-&:RJ=(Y14J5T"X5Z35I8]ERWI8=N.G7
MOMO;EJ-NNW>0K?N^/BV_3O*C/FWK1])]SACRU/RU8]Y954=Z]G;=MO9.X#=
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M@=5"5+]]^366R%4:TU;H7(^@5PCIHW2:%TS7GHEGY?ORVD<^Z0W)L ]1Z%<
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M[Z;I HACAN,Q9=!N2RYW]JCT?5.:+/U%>E8\=JLB@6@6;5%5:7:'%H(3F/\
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M5N2WH\NUD2C9K3(IJY']Z'$7,) .FAE'C=2KYRAHI2*3";Q2@EDKLRX5<1-
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M+"EQ)C9NIDWU-6::3R'0P:#D;1K'H5;'H5F:O[2^M-W,I"^F^P'&;6?TLNR
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M;]=]?<K?X^/C4KT&^_$O]F%?^,!/]MY%$^_$O]F%?^,!/]MX1/OQ+_9A7_C
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MODB*JS$@&LN<<MA"WEWHST'>RFSVDYU8(6A%?C[\2_V85_XP$_VWA$^_$O\
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M^K0.Z-V$NBXDX+;[N0(J0Q/+EC(G;,9IX@TJ4_?3&\V+8RYH(<+EQ;8WW\T
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M=VI7UYLW-55-M=?K?M)YWW5"GEKJ4]GEI">5\8AY@112WNFJ>0(B7Y,S>5W
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M)6Q6#N-$JJFL-[&CM*;6V*V3)8N-K&VC>*11N- <L/7:2[SB,=2SEX8_Q^<
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B>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g105292g08e09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g08e09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %HR^5W(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             ##P
M"=H    & &< ,  X &4 ,  Y     0                         !
M          G:   ##P                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ##P    !29VAT;&]N9P  "=H    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   P\
M    4F=H=&QO;F<   G:     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    *.$))300,      PG     0   *     R   !X
M7<    P+ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M ),N+RT;5N;DTAL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME]F9_25O^M/,M(_^<U_Q/ ?F$]'K7\OR/S!6OL[CRM+[,S^DK?\ 6GF6D?\
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MHV?;_P#D:![,?#_UG_?ZN^?@X\QI^N_\GHGFK/6=X=%K^%0ZN?5_?ZC?Z*-
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M-/UW_D]$\U9ZSO#HF?=3^KG'_P!>HWT&@?Z?_P"Y[?B[=\X[]_Q\>8T_7?\
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M .5HW^@-+YFM^YX7_8._O.(7BX#]^:;_ )RH?X/HI8CA>@W6C<$I7SQ&TLA
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M>,)4K'R+75RTBG2-457L#EUM)_2GV@TKA,50Q& T!3QF,;I=E73&&P.*I:3
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MGM\'K]??O^;O[>_P^K'"+7.<=O5C^+/P=\]OA_'\.<]^^,X]O")ZL^O/;/\
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M5('7J,:[J^?*?\AO_$Q3_D\OD<5]L/XO27'^$=!_Z.C^ML;_ -*>?*?\AO\
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M')3K;*EVEULI;YD6;;(+QT62A5E]]S7<J5 EP5!1T>8[)7Q"B0&^E<"#-@;
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M+I.P^&JU'UJF.+A0?3/E:-:J.KNE4CE,HK=+,4Q*JX*Z)KP2V4"OE!T2QSA
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MX6!4$"HK,MVKU8MMDC3YWB<-R[#2WM4X(V*4VMTB,E:\Q&*R$2:QY/"MXB3
MV2;3\#/BK?Y^>/BHF<W3T&&BVT-F2*UKR1?.GPU>]@2D$(5#'6LM-KK-3FF-
MDTYPP='@9<<D4*U#$.XGBX-H6>(!C)^?7%$(Q9X)XW@? 3R*>'3+KO4JW$UT
M-&<7^I7R;H6:NNDK'>MC [$[5WG8)RV!6-=VXR90^I?E1HJ$V# H5APRY*FJ
MBW,359[:<6 9 EK\>&??]_BGS\1[I]BL2F7[W/BK6AQVK)U153FHYE>2'+*"
MMBFQ1+:U3?."G*?)DQD^5E2]2/D\R7Q+:R$(41L<5Y;$-9Y"1!B3<'VR,K^&
M:?%9?*U)K)5M'7QRB5AVZARQTZ,M3XF*\?@F;,('U\Z1CE'4+F(ED00@4$>=
M\;X2!(V"-9\7#B,,HDGCNSM&8]_-%1G- Z1=LECN#NJ*$NT6^4+FV8\JLBLE
M#4P,<!68?*G2\QO&N2&K'5ZT>=>QE+DPQ7@9*:J1+%07F$[/G;]_,\44N\?-
M_F_SM1> ]/-T6N;UE'-AC7RM?&7:=*5%1$9)0$RF[.C.91D4\MM1<7#A>72E
M"VUY3-FLP69<4D.S-&3O;(<:0#3!+ )_]NSC,>R<C!7JD.+ &D EHGE>-W3<
M;B_FKIILF-J_II%"&G0K;8Z&'@-;(@CV0:;)K" J78HT:6*8:MSM2BWV9)<J
M4U0.3+;9=E8E%UP<R)JU 3JS!)))+;$M>?1S]'6+;$:T6L)60UX)B;W)]$WA
MQALC(&,[]PE="2,T^9U;<[&"#5\9:(<$6EF(X1N#&($_QM2;D9 9+'I$?+OB
MV+$IV 60>4=<-/J$/ADUUAJ39J![09+3-Q!)S^M ' VU8BX(=*LO#@"21)W2
M1>"8'=E$ 7!FU+BD^GID?58DZN9D*57H,BPF(AJY+L35A%BA9<P-GAGX,&N)
M:M-C'$:H") S<Y@+6SSI@M$27BQ,P'[9+KG.P(;JP3 @CTK-.L00)<(!C-Z<
MF^VTANK$P+CTK"YD"XC)5A@QTV-/UWPZF-?B>;*UYW<?+[+?F+ERBVO6K:DJ
M.CH$Q8<T<,3L"2$? '# Y]+Z&GV7)3(9G BKZ7I7$Q 9!LXM()FQ)8#(!$$Q
MF$BI>^^T-@_6B#?_ %9D;/:M0Y+0AB=5AA0-#?>G*H(\I.=D7B*_%S &Z0&F
M(C;B"S(]N'.?9V[B>]F.IQ"5M+$S!K6*\MJ'RH#B#$:Q'U=IJP?&F<]AD$R#
M#K@$@P!K&(!VO(.4S]2+[Y!NH>VX+!AK^8&5MH4T(BPZXEC 63/DP')+E9#.
M$Y*$E)I(D.?EE%S)4T'-(3I->G/R 3DJ1D?EU?(R2T$S)G, ',P+  VBX%Q?
M:ML)+03G?.,I,9  VR,"1>+J1]/6+3XBN*C;!C(5+1>01XKA,";.*F:\#?$/
MC (=I N8)<&R)2[(NYP"Y4$@A#6#?@N$R N+'C8>'D^C/U2!< !Q!!<9,R+:
ML P9RE9>'D^CN(%[ F9)N#,1JD3$GVUZ?;]+OQ!KEC'U[8-OCP'XI^T.1-AB
M81N5#?H.0\F)%%RZ<YAK J1=14Z01$L$9<D,Q+>RE,@<[+@%2\$M%B!Z!-RZ
M<];_ %2()$>V( ^\2T9@>B?6D'//T=NV<Y72NX+30V!J4F)CL9K9*RMJN3PT
MB:S;9%89P 000J,5(/0Y3KJ&S<V%/%# ;8N7/17"#,]\:T3D4&H=<;0#JR!J
MSLR$C<9)!B1$P#2\ZP.8%K>C-XO X;3.<C);$ENG!PRS@G5FXD"(<KD5_P!%
MCE])B3(@F0@.6<JA^R0@1T6W6@X=Z##&X&R)Q$G;21%J7)BB1<&.BK!AT$@P
M'!H((F/JES3),SD  (DDJQ4BQN1M#9! @"T@R;SPB N\.L/3S%,#GWJP&BH9
MLXJ;*DCBFSRL9D<,*ZE<7D6].37IGDA4>UM%<^--"K)1I2\-C9K+::\YR$52
M##OXI@$,!)(J9Q(L?)Q! BY!AR$/@WF0;0T&X=Q(L=7;$#;=5W74#0%J-0!L
MH("2^/ AWI+I@E>AP\S/\WZJ<L634S!Z.T/4HRK90U@I \D% H,OT@EBB\ 6
M.;R>:@!()N76 :2!Z>K @S_%)!EQB)!)*RXU!OS-_1)S=  B]M4\<I%UAQV[
M=\9SCOCU9SC.,ISG\>/7GOA6<9SW^%.,8QW[^OF7,LT >QM6QZ/3 S)X&!M(
M<#&C1CTFJFR+HHK(-T<G9%G&&JQ-CQ,OBQ%KK8E-6588MGC&O.5NP#(29;N>
M M>7.,.()N X"P#PW5N#F6N,P1$-)A<):\N<3)!)M,6](#^-W$Y1LN%;BS?3
MD7+18C5,'08! B*6N0F=?()5EEX)1ILZ&N2HU* P\KL_IF$>EL!5Q(HS*),)
MI+:!LWEBJ!.L;:UO1(@$@'+6/HP<Y)L8NJ14 F;B=Q&9C8";1[R)LNB7&Z>K
M6UCD(N/K\JL,4P.H#&CDKO!K<FU+:K^9\D\@6[;KL!Q*A8LC[85$@NN ==$L
MO2&PRENLV:A8")G6O9I.K>PG5:;P)(%IVB]!>6@@F9O9LQ?*8:;Q>UIVV0$8
MZ;UOHDD*EXMV0(DR_,YD_>F@0\G%.5\1$"N'J[ ('9SI*L"[!:9!9FOQX23=
MH:&-Q148/&;0(JQ9P,',!LF1G!($ D")G5;,DE#Y3?;*8;-P3,$Q ,")FTWS
M6\*=Z>D9'QYX-F%$=B5. :6V[>WY<Z+DCI(E:5S74$/$9E-JA;:AX<$PQL=R
M,MM4"(B1FO/MPBK>\_6U?JV/[:&YC*#3S)N+[5"*E[SF1]6Q]("T;06YFQF9
M%EL)C-1EM.VFT 0]?'VR.D"SY(HE;&'QT]QK5Z">:X@L<EQ)R$S5WAIX3/8*
M2YT4M.-#BD0?4V(+MEXJ-:22TSL;>SS> "-E["P!!))0%X> 38S&67I9P!PY
M1>25['>X\?N>=C?IL+_T!U[SS<7^[N[F_P!D+I8C]V?_ .W^RU3KM^.F7L*^
M15./,IDO"XZG8SN6)+27J=7V\N1WD_KF7D85E33J?6VYA*\>M/,5OJ8;_8.[
MOWSB?D\(7C8#]]::_G.E_@VB5Y3:8]SP#:JM^IKB2N]:L<S4):E9"0Q&IX53
MA%@.O-*;3T_7)IMM5PL67MI&']E1KEL#947R9BUDZ34X,.GUY N%-A\1=,\?
M>2#;<)R&R<UZDYVS]\@[LK9;%=MVZ,K"<W%>MPTS:%6I$^SW;4^QA=>?U:;L
MP95WUBR%'KL5[S(VV+E6*6: BLUY$>A.ZE',#\#)AR%:3PK!F6FPME-]L'9E
M[YX0F[.W=EPMWYS\%#E2]ST*ZF?K5HB6>L;;?U^'!OCZNG60REW*[G@?3D8Z
M;U5\ALHSL Z+#ZP/![*8MI^D+JTI<HRR*:</S(D"1!+TNG>)F;["[6RC.8O.
MS+<-Y^=LWWD$""K8K7N54%P.TJY;+;4<(Z$IFN9;XX?=YI&IW8'TW5;IU,2
M!-.S 5*LNKB ,(3E2J';-32"151\FERU#V5CXPIK96VSLRDG=/CEL2=HL9]F
M<VV@[C/L*F>X=")"Z9.3B=AT)#*6O4U:UK8(U?Z=;15JS!(T;<-JV[3+C0H%
M7ZA@MJI1&$2M*LG(Z+P7=.6(%7[,R1$LQ)0":D<8!)%QM $91>!LOE"3[[7V
M1<'9?NRL05G90*V0IU$I-1*GWK64JM2K=<)6E\6."/V4@##0QDP^\%$-M"1#
MIB3%<(N"Q;38\>N1F)"0F,RVG&?GY^]1?/Y[K'^Z9KOZ&ZKV^EM_Y]K^CK^
ML1_.>(_NV#7^;?ZKO_Q0T9_N3HG_ !KM&O,?G[U?RVI9T@*,F-E!8X*R&ZE,
M@C;;8Y)VM%9(2P10M0IQ^VV*.%)Q5)=BE"($(2&CUYPXTN7+9;?8?96XRYTM
M(O93PE0U*5.NUSZ%(4ZS ^D:E?$4J%(U&.LYC*E1CW#/5:8(,$?H^R>'Q.)T
M]A&83'XS1M6C1TECWXS1^(J83'4L+HO1>-TGCF83$4B'TL37P6$KT*+O2;Y2
MJT/8]A<QTD$NG4G-:"%5[+K#I2Q1Z\6L4JTIL Z,,GWG7-8VL':=,-P#<LW,
MF!K2J,2DX@L89-CIJ/&2XK\:>_U&Z58PU*?F=<4Z)JTZ0H>2>7-P^*K8)Y%,
MOIMIM#Z$L&L9IN;8.!:/<K=B,16;@\1^'M'NQ./9A,3CGZ1&-H,P]?2N@]'=
MH\.UV*;0Q=3%U:N%TFUF(J>29JXNE5:#5IN96?)5>Z8]=VFLZQ0(N+K]FN>X
M*9I*66C6.!+$RKI<7=A#R:H%4>JL \+#4"8(UV1GD)A4@W9@5Q;D1E YA&'$
M&]2KIC%4:V,+\/%&A@:^D6L=2<UXP] 89S-:L*[J3ZF):_%-:QK&FC5HZI\H
MUKG/][!=@=":0T?H#S72A?C]*=I]%=DJN)IXZE4P]32VE'::H5_(Z-=HZCC<
M-A=#5L-H2O6K5L16&D,'I,5&'!5:]&E0P3QGOC&<?#CO_KY^C7R$&0",B >:
MKX6U6BMLE8]=LAX!'/05BSC 4P1%,F1CF%8<'%FH,EA!&"O"UX7$F)>CJ\-7
M=O/A9[\=2C1JEAJTJ=0TG:],U*;7FF\9/87 ECAZS8/%=W"Z1TA@6XEF!QV,
MP3,91.'QC,)BJ^&;B\.9FAB6T:C!7HF3-*J'TS)EMU0><BZ:<(I#U11T;'V'
M6*:]*7!AEIDATG+:RC$E@.)@2S1E<+#J'&ED/-0Z8D<VZA33L[,=MW&&UJSC
MJXW$^:86MB T.<QH#&G(U'N;3IZT$$,UWMUR""&R0O;[-Z(&G=-Z/T6^H:5+
M$U7NKU&EHJ-PV&HU<5BC2UP6&N</0JB@' M=6+&N$$J4\].,B0-#S8=_JL23
M-9H;YEBP,&A8X![Y6M<[1JD?SM$'EG"CS@.//A$<L#([<,FQ';;7)8EJ>C=,
MZ5#:E1CL+7<UIQ(IFB:=1]3S/%#!USY-SZ88!5<PMEY+F.)@%L'] .PU2KA\
M+5I:9T;3J56:'?BV8UN+P]#!#3V@G:?T8SSFGA\0<2]^$I8BE7\GAV-HUZ;&
MAU1E769(0_I2%28.FXJ+J-,G=@WP/6[:X"GSO):J$O&R;5J>BF1L0E4HL0[&
M</T<\<)NM65LN[!FBPSU7 J9DV!_J/TT\.Q[O-WTZ6%PM2M0\JQNM6J8?"4<
M;B:;RRNYU)PIXBG38/)%@<'U!6J@BD/;H_1SAWTNRU(:5H8G&:;TSA='Z2.#
MK5C3T=A-+Z>TCV;T/BZ%/$:,ITL93=C-$8W%XAS<>,2:-3#X1^C\$YM3&NPN
ME1G(<J3$>\#+L5]Z,[EM6%HRXPXII?@+QZEH\).?!5CU*QVSCU9Y^@:X.:UP
MF' .$B#!$B1L.\+Y948ZE4?3=&M3>YCM4AS=9CBTZKA8B08(L1=<'*L+ZK?<
M"_W/NZOQ>_#'_H8"_P#XY\<^DC^$\#_Z(_\ .>O]"_U'G_<SM3_O*S_#,(O>
M/GSI?UZG"+R'P&8L5HZJZ_*=6Q%.[LV$'D/MQ!,]QB.4J56A/.MP3HXP#FK;
M;?4M,0R(*BI"L89(C9T-;T5VG9Q'Q*+%0;[GCK 4U7HL3:&ZT#@WH5YR$Y)Z
MS\UVAO6VT]C;<U[!(1$ZL3BM J78-IVL/7:QK5=$K0ZGI!5IH3Y'7QBF1=G8
M;=^T1ON;<3*3?9&Z]K 6OP!N#>=Y5'_4"!Q\77],BW4[<:' G5AK8QC8\D0[
M?"U&U=J*S:BU;K&J-:\J>OZN-"01-TL,PW9R$*1:G'W'ENRC$LFS,!"[/W"=
MX,[3-K92J3,G?W_$GX;-RN_7G05K35"J61UW>M@5"WTARPPX5\ 5W0@BRG*E
M:!5'$F:1;(XS2,2JV,3(;UW5IK5AGUI>Q(I&&\[%NS,66]"4+B9G+=<WO?,G
MV>])^9.=^/$VRVD$W5TUOHXI58L^M++#V!LM_P!Z2X[$ME)%/XUC&3!@[*FD
MB9B@R[0(UD+V(0UW$)%I9"/6I5U7@Q+:%.W*9:<@0F!Z;$6@Q.[=EE)G=M,1
M*GSMV>WOV'.T++OD1.$7BE[NA^YCU;^GD/\ [/=B\+;,SW?$+Y9.%RK):@5?
M4;FJ$VVZ^5SR;%IV(R5&CCS  AE-=J^NYVM0C).2*.,06KO/L&S<R&_-;LPF
MBD)Q D15CGW,%#,\+;)SF_@-NU2;0JQH0+N2&-K5EK5G#5VS7CTED;6,4%-0
MMU"JL\E)'#:Q+N0>MU:%:]C#1HZN@#*[#*0)FV3)^,Z)8'K)C2AG<1$97N>[
M8-VU33JNL]*0PAJPH<DZ[DM0J2Q#LM>.W+6)+-KM9$Q0I]^-/S;*2=%5/T)6
M:NE."B;LXA-YHM-P<U%+CW<_ N^2&=G>)GC;(1;/C )(6!NU %9!Q-7NU^1&
M>GG-<N%K8W#1*8C-&8^Q]B5X')9A3\)G0D']=@:-:\-3&VWY/I!YR4A&)R4X
M*CYR^%K&VSXF)>%4X17GK@563NPZ$$NA50.G&;I5A5M-H6AM8:LD3D&(>*I6
MY_:T*'"GI<Q*E_K$Y9QE7JQGA#D8SV+)JPT?II@AT33AD^!ML0_76K96PUH&
M.XC.V5&YU600*"YII8@&8UZ3I&O1[_E#IIQ2+SE$UV/XT8J.4DSE/AN]FT[L
MN4DZ\KNC'P.ML77.K##BQ>U"5:S!O6HJH88<G3A%:H-=VJ^5DPW'+"!&C[EN
M')'9(ANNDWWZ508TEQTF3I#10S>,[;#!M/<-WO,D1TS([IBL=1JP !D:X6#4
M??KTTK"$C +C<?66D2.*7;CIR.3E&2D_<N]:TS9:X M[ NQU86?D4&-#DU8O
M3R)0@G,P)]Y.6RX$#_)>>O"TO:?W +_M'Z?^B3;?_I0OA8?D._X%?>3PN).$
M6#6^/VZF/T7 _P"EELX^?=\^T>V;3W"W/W_!>:]IZ"]>6>Q7>U-[-V]5SEXN
M=@N<EZI.:G$#@LBVTW8E!M@\+75ZFEUIQ=GJ^RS,&PW$^'.[.-OAZF1*7R61
MK\:4Y=;9 RX\-L\+;,X&:OL]_.Q\,N&:L2Y>Y\BFJ-L6OZXV#9Y9:[TS:-$!
M0]G2J]-I>NV-Y5RMT;9=U"PJ71ZW:[!9\5*M#T!!%FM<P#B6S)88R"25ED&@
M,189@\3'^?B@L0=RO-[W/71^;!?+5"(VD58;I<FMC#CH\1J?TCU]?T;*J^WG
M[-2[?/U?/N3Z9NPJ@(/2ZO>K%=J0XC#PC%82$1!'06LZVX=]]@G986WWB;7L
MG><HS.P1SBT[1FJY>.B>K;"@WZ%9-O[@?7LV)257$BS%TBDK*M5##I !-C@9
M[^EI#M'V"T)9AM13]%]&VZ_.@0C=2@UXZTLDZG*PM.<[=F>6_P!@RLD^'?EN
MSRSYW69K3>&6FFL+<7AIM#>%O.+>>7A"<)PIUUQ2ENN*[>$MQ><K6K.5*SE6
M<YY%%R<(G)U[N[HB^;BZ>NXVS'?/KLQ[OC'?/;L4E?#\/J[?!G/^OMGWV?4;
M_P#U;[@O7;]5O</<K9]N/9G\:O7V[]_7CUY]7;^/&?S>WOS2JR$@5?5BJA5Y
MAR=(CE2U:96V]%-1!O@&993<S4XG/CS!Q!R6P%=JVOQ>1K#XQMR,6;E9>9>-
M1WT\9+Y,"0'',9 "E $0;ZSS)!$B-A"P2Z3 D [CE#+;,Y<9O'L5OMHU=&@7
M>.,3YP6]06'@<^PS969T"V-6T"F0T%;8A@8;[TD$[/PI$V 3PU&1+=CN-/XP
MXS3K^C:/2]*(C5U3<Y[8R(0Z_H[/2N!$%L'//;N*NN^BJA(KL\BE%6CGQM'H
MCI%VIR 3\#T\D6RQ#9P;Q]4DO5%U12G(](LM@VT>*B"1;!=2K,Q9)$S+-:?X
MVJ7/C6GZNJ"/K>E =:^^1Z,!1NL"!<C6=G.4"]Q.=O=98XYSW_6_CSZ\>OV^
MW/LQG^+U>KOZ\8QCV\JY%IG/^GVYSCM[.^/7GOVS[<Y]6<>KV9^'A%KG.?AS
MG'?./A^#\?J]7L_UY]GLSCA%N;PA3B,+6I#>5IPXXE.7,MMJ5V6O"<9[JRC&
M59\'&<95VQG&?AR19,W6I:3$&#D%),C%4//&E?WO/0G64B(M^OE;%B88[($A
M,S(<JPNGV3)5V407+CDG9*HV62#$F-Q-<\@'5%P/[+29,Q]8N$0,N?&'/(!@
M&8V?ZK2;SOD0=RMH.JE);JC5>A5QXE%V/9$RI5F) &Y1>FI$!GX'GA=[5&I,
M1+2%%V!#TT0/C/ELX\I:ER4166J0Z22706BS03#IV:H+C/"2!WH9O)/U1D#
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M_P"+3/\ \6GX!OJJ_*+I'YZN/W-X_7(T5]ATARPWY]/V'?;C_2CLG_Q:9_\
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M5)/^00O]_%MQYCHEMQYCHGZGH=\J2?\ ((7^_BVX\QT2VX\QT3]3T.^5)/\
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MQ-K=UU,UK]TAZHZ2Y9RMDZ?Z+"#^7W&G#0,>9<3!?6MGI4?ISG6:Z;)M-?\
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MAE?@)8-6HG9BUB*4VKU+R>Z*F3!6O;+8W&Y*8QC-MY2T /ALM ;JNO,D WR
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MR!%BQ6B=4I[@M.NEPM<"K%/I1*V^B<$QKPNP1D6R30*_@JY?\7=$-G!!BNM
MVR#Z<Z#H$0")DYWSB8(RDY1QE4&!$ B9.=XF)@[).4*S9_2E395#J&NX=TV.
M' :^CU1FB>1SZB1>JS]8JUJI<F;$C66EG@Q1^U5NXFA]CC6,4;&-J\WS*T/K
MDX9!DLW7,ET"3,YWN#L.P@1'MF5=:\P+F=N\'80=F]7#3NFW7M&ME;N0.395
M%:M7AU5&))E8Y-I($)7%5,"+5*ECG"S$ 2#6MKR& 3A039/+5BM,8]9(<$O%
M%Y((,023MS)DG.)GPL+(7$SE<S[=OSL%A 60',+*<(G"+K3(<4A$E0)S#<J%
M.C/PYD9Y.%LR(LEI3,AAU&?4IMYI:VUISZE)5G'P\(L0)'0MHALI-)5J$;HS
M14@ZHN'J#M?@AB56EB-2"B>OO(Y]<)K%5 HO25!*/JK[X>TPR,&?@/9Q@XG*
M'*Y/*OVF8RF<_2OG!^L1!D1F%K7/"VV+[=NW,YRI,*:'R5O-&V _MS:J#- C
MW"&)BYSK.<*EQ;N>\\ET3XI;6A%YF2Q 9'5(64"2@YB!4AC8ML@I\I8YQO.M
M8C5;!CUM@@?QN\WVGNA-B(%XWS;V^TS:=EA%>U;I.GZAD6:35'S;JK8X,>*>
M>9S!!Q<D:HH^J:Y,3"CD290E.,DIQ4P>F%R\I;T:"F<T'%!Q@\YQ=$[,N0'P
M'OS*A)/L^?GK*E[F5$X1.$5$LE; 7$ 8JMJ$#[!6[".E"#@,K&;F#"PN<TIB
M8/GQ'DJ:DQ)3"ULOL.I4VZVI2%IRE6<9 P9&8N$!@R,Q<+'*M=)5'I%RK%OH
M]NOU19JQ/816%41:J',J4B3M&THM%Q4_&/T(R9ANSE1A@"-/!G!!6!61<<5$
M(->6FI!39>2"" 9B]P;"!D0+9W!$^Q:UB00;S%S,V$#;[>]7@3Z>J>=.U.W'
MS%I-7>DZY+:[KUYDR $2VPTGQJA!RY^=Q%=&+]." YZ9&;)(;;$A4E#*ZX##
M.FBKDR:QN($$R1LWQW>^TFR:QN+03)&S?$;E=6JM25+3@8U7Z8B:P(-6:?:%
M0I2H.6!LB="&#DCAC<"! ;9&0X0F&S'Q)3+(O+2]+)$9\V0])6<XN@G,"/$F
M_-0DDR=T?/-2=S*BB#77[/-^_I)K?^Q?5?"*JAHYAZR[%4/)PH3.+2,PMN0*
M<G+4YZ!TW.5X=22AX2G*<I3AOQ2LXRE2LKSX6$I[%6/)X60?W!VV/_N<1P*\
MO ?OO3?\Y4?\'T4KH\BL_P ?B_HZ]]N\X+;CS'1>HGD5G^/Q?T=>^W>+;CS'
M1+?)^Y/(K/\ 'XOZ.O?;O%MQYCHB>16?X_%_1U[[=XMN/,=$3R*S_'XOZ.O?
M;O%MQYCHEOD_<GD5G^/Q?T=>^W>+;CS'1+?)^Y/(K/\ 'XOZ.O?;O%MQYCHB
M>16?X_%_1U[[=XMN/,=$3R*S_'XOZ.O?;O%MQYCHB>16?X_%_1U[[=XMN/,=
M%;<>-_NMXIY%9_C\7]'7OMWBVX\QT43R*S_'XOZ.O?;O%MQYCHK;<>?W)Y%9
M_C\7]'7OMWBVX\QT4M\G;R\/%/(K/\?B_HZ]]N\6W'F.B)Y%9_C\7]'7OMWB
MVX\QT5MQY_<GD5G^/Q?T=>^W>+;CS'12WR?NW].*>16?X_%_1U[[=XMN/,=$
M3R*S_'XOZ.O?;O%MQYCHEOD\MG^?!/(K/\?B_HZ]]N\6W'F.B6^3]V_IQ3R*
MS_'XOZ.O?;O%MQYCHBH(%J<U>[:DA+CS7_1>CY2['AJ@HPWDG?,)1EE<N9E2
M\*PO.7,.IPK"DI\7C*<J5SOCS:C C]OQ&V?_ *>%[EYE+^&=(1_Y;HGC_P#<
MZ8[O=[3LD#G77IIPBQ0Z>A$&62ZD),ETBVK'4O?\*S'-&(#"4(KE(SX6684^
M-'3G&.^5.>+PK.,=UJSVQVLD;N0/P5D\.0Z>]9%-! KR&G69I-UM]2DLN-6N
MP.(>4G"U*2TM!?*7%)2VYE6$9SG&&UYSCLE79)X<AT23PY#HN?T;&_OQKZ2V
M/[6XD\.0Z))X<AT6U%>%N(2XW(,+0M*5H6BSV)2%H5C"DJ2I);.%)5C.,I5C
M.<9QG&<9[9XD\.0Z))X<AT6[T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V
M3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0
MZ))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT6F:X,QC.<O&<8QCOG.;-8\8QC\>
M<Y+=L8XD\.0Z))X<AT6Q $0XMQ#<HLM;*L(>0BT6%2VEJ3A:4N)27SE"E(4E
M>$JQC.4JPK&.V<9XD\.0Z))X<AT6W 0*I64IFE,JP]F/E.+58,JQ(PCQN6,X
MP7[X>PW_ &S+6<>'A'Z_P?!]?$GAR'1)/#D.BY$UT6M*5H?,+0M.%(6FSV-2
M5)5CNE258+9PI*L9QG&<9SC.,]\9[<2>'(=$D\.0Z+=Z-C?WTU]);)]K<2>'
M(=$D\.0Z)Z-C?WTU]);)]K<2>'(=$D\.0Z)Z-C?WTU]);)]K<2>'(=$D\.0Z
M+CR!$)<0RJ462\XE:VVLVBPX<<0WX/C%(1DOX2DH\-/AJ3C.$^$GPLX[X[I/
M#D.B2>'(=%M6#"MK6AR840MMG,AQ"[58$K1'3G.%/K3DOC*6<93G&7<XPC&<
M9QE7?&>)/#D.B2>'(=%R)KPI??P)!A7@YQA7@V>Q*\'.4I7C&>Q;/;.4+0O&
M,^O*5)5CU*QG*3PY#HDGAR'1;O1L;^^FOI+9/M;B3PY#HDGAR'18[[-%1(&_
M.E1R.L@I2[1ME"L2RQ4@CP?>ALRNZ6I\V2VA7?&/UZ$)7V[I\+P<YQE,[N0'
MN"3.[D![@LIN11.$4+J'1R&]3N)"YJ<-:FI^4^1DB([.<JN%YQGP\CY47+N/
M5CP<.Y7A/K\'&.^>]F-WM /O4!@G+(; =IWJ0DA@:_'^!/)*\E5E,GP;6?5Y
M.K&,YRE_L8SXE6,8SG.'/!SC&,YSZL<2>'(=%J3PY#HNQZ-C?WTU]);)]K<2
M>'(=$D\.0Z+:FO"U95A,@PK*%> O";/8\Y2OMA7@J[%L^"KP5)SX.>V>V<9[
M=LXXD\.0Z))X<AT6[T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.
M0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT
M3T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIK
MZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD
M\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<
MAT3T;&_OIKZ2V3[6XD\.0Z))X<AT3T;&_OIKZ2V3[6XD\.0Z))X<AT7 D*$4
MAMQ,XFI#SN66EIM=@RAU[&5IRTVK!C.%NXRVYC+:<Y5C*%XSCNE79)X<AT23
MPY#HMZ@(A"VVERBR''O#\4VJT6%*W?%I\)SQ:,E\*7X"?UR_!QGP4^M7;'KX
MD\.0Z))X<AT1L"(=QA34HLZE2$.)4W:+"O"FW,9RVYC*2^<90YC&<H7C]:O&
M,Y3G/;/$GAR'1)/#D.BY/1L;^^FOI+9/M;B3PY#HDGAR'1/1L;^^FOI+9/M;
MB3PY#HDGAR'1/1L;^^FOI+9/M;B3PY#HDGAR'1;5UX6A*EK?,(0A.5+6NSV-
M*4I3C.5*4K);&$I3C&<YSG.,8QC.<Y[<2>'(=$D\.0Z+J)'5Q2F4I*S5*D9Q
MAA*;@<RI_.5Y;QAG&#/=S.7$Y;QX'A=UXRC'Z[&<<2>'(=$D\/\ A'1=I=?%
M-I4IR27;2E"W%*79[$E*6T8QE:U946QC"$8SC*U9SA*<9QG.<<2>'(=$D\.0
MZ+5->%K\+P)!A7@YQA7@V>Q*\'.4I7C"NQ;/;.4+0O&,^O*5)5CU*QG*3PY#
MHDGAR'1;O1L;^^FOI+9/M;B3PY#HDGAR'11KJ^*U"NV^X[*I"FT[*KN<9DRY
M4UWNK3.K%9[R)KTA]6.^?UJ5.Y2G'ZU.,)QC'(HKNKRE(,[-6C/92;1!4G..
MV<X4G7U,SC/;U]_7V]N.V?S\YZO[GA?]@[^\XA>7@/WYIO\ G*A_@^BEX ].
MG67U2%:YI<AC==CV[4[+!Z2B.Y]@[!IM+KXO5FY-D#MRO[?TTQ8:?K.L"C%/
MKC59H=AN0)<>3>=;07WQ\_8<61:Q$47QD"]AMVFXM!VW.S8?8O6(%[;XN<A<
M'VY#89V1>8:-[J'L^Y#M!2T7+HYCR=W[XM^OV84DK=Q;U=U55'0CGO@VK!"V
MI32[>=$S$$*SJLZX[<BTV\ZV D1M=GXOZZ;"(FQL-VWOW3MM-[VO(SSMG;;N
MY[>_A*@>Z)]4-?J5;*V+4$3:HT*)K0VTPH39UC;=WNMVUOU [ %,U/ :M#:D
MS!@&].":>T/<JZB$^-<H+RI#103A%D0"3!XWV"V9GCX<50)-B,I]EL^?&_-:
MZ^]U,WS8Q&F#]IU'IT$ VGL2U46&6%[.JUIFER<:I:N+UT;&J=+V);SM8%@K
M1>CU:VQ=EYNI#78VO +?:]8UH%9;,YK=J[B8B<CE?NO MD#O4C<9VY<3\!//
MV^E717U F.IOIZJ>V+(.%BK.0*6T#98%>C8]%F#=5M!4!,15#4:S7,+<*[C$
M%OS=<ZW:SE?L:<+GCY$3PW1D"$08465G(B<(G")PBQ4O%HV]"V/ND$ M8J )
M%=/X2ZZ_;?I."3%?LZS%R@F)!-S)J._:B4Q %AR"QY4)%C&'1[;H0@XS/DFM
M@-U6D@DEY!$Y@0;;L_O$VT (&_6B)S^?DY1#]*VYM!C9^G(-NMAHQ5;]KS7A
MTI$%5X&C$"WFJA3Q2*L4<6P)D,2)%B.F-C61(!TT<BU^:&<EUT'2@A$TK1:V
M'0!(+HN<@29VS80)@3-R2J0(= R)@SLD_ 1<"\Q<PO0OG$L)PB<(G")PBX)3
MSD>-(?9BOSG66'GFH4949$F8XVVI:(L=<R1$AH?D*3AII4J5&C)<6G+\AEK"
MW$D73#3I9,2.(S@I*N3)L1B3) F'A$@H(>=1A;D @^ *G CLN,K.6WG!1@E!
M4M.<QYC[?@N9'OGB)^(!\$53X1.$5ECOVP;7_DG1?_5;]SG=^]J/^WQ'_+PJ
M\RC_  QI#^;M$_WG3"O3G O33A%@U5JZ8M^JNN>IUZ/B8?M&S]]UT'$5(8B)
ME&#>M*X-&1U2I3K,:-A^;)8:S(DO-,,X5XQYUMM*EX(O,W5?15U-Z\10[E3=
M%$M/U*M3ZOY3TYZ]V%I '8X]EJ/0[U':PO6[JV4BE"^K]>;,W%N*XZLJ0<[3
M[+*,-!1DJX; 6S&L=O'PM2-IGB9C,6WP+_("U,YF\9F=XM[+^WV*2*+JSKZ(
M2>F<'?XW6K AH#7B5U'VE6[.EF4.=M-@(%V:=4(U?@;E+37-:5!5E<(D[P+;
MLM_,U37]0">A#Y^VVE\,M!N)V6/Q]V\S(@*6O[(S]I_SW[(5KU307NK%&U#5
MH&O;;+J%Y"ZO"ZJ&T:59-0+U/3 @'W.C7@@>6KE2$Q\AAUF'];H2PB0TN"MX
M1$@/9EN",:RD^5N4EI.5KGB9<;&_JQN[R5?1G_._I=.ZZN0;JCW3N"'H:7=D
M=0AM92H]1@@]&EQ.G&J'-3)L-/L\;5IYI_\ 5/[*@[4V>"N$45)I0.XFK12"
M(FRA/2;86IIM,./V.6OEF-]]^RVTV [C:);Q&_+;LV?,KU3Z66-O1= ZVB;Y
M$R FV8@HA%MT";96;;/R[&/%F!$\@:CG+2QDB7K[8DL0%,VVXM5V;.?KK=RM
MR16+(4AS,?/S[.X*+(#D1.$3A%"/4)0BVQM;/  +4Z0:C6NA'X$:$?EU]N1@
M#=01(@DBZP1&Q28]H0P1DN!RJY0Z;(8C*S"?FLPO TTP9X$&TYCP]BK2 ;Y0
M9Y*-JY4[76.HK:FR NHR<*M6VOZZJ$Q]J3J\-(L!J!?3F"M[&- K1B6;"PJ[
M9YEELDS8S,.^(P*8"TP:140E"T4D%C07202=I@0($G*X@ 6VE6T $WN=MK6&
M6TC9:]UA*#Z1]SMHVA+=H\X6;,W</;0Y#TEH\1+A&+>=JW:V1P+5>L:)QJNS
MXDVC!:1<K@=I>\'B)\Y"MUK&48! "9Y34;:\B""()BS0#,"#F2 "+2!)D:UA
MOM$;=P FT"+Y"(&1*]:Z4DNFG5--@#C:Z>36@230 -EK(@&62+BX(AQ>6'I#
M'FX;+P]#A>(D2&<1F6\-/O(\%U7 8DQ)$F)SCCQ6#F=MU<W(HG")PBQ/VQ2C
M5AZAM$V*%IZ69!4MTE83VW03FM&+! )I'GJS5Z/,D6*V KLS1HK%QM5QM&*T
M.+.S)\:N"8< C&*65F/MI&HX:T$Q#3,;R<B)L /;,66@8:Z^=HOWDY1-@!/>
MHPV-KJS[-VT*M!+IPL02 G3)1<BT"C6CXUC+;(LH=>&J/?CN;D2+R*U1H@>&
M#A0XP"^TFR6JT8)DH6*[38\TU00 !K3#@0(=  )N! N9FQ!@9@F%1 'U@;[C
M8;Q89Y[#W$J<^E^DW77&MWJ1=Q4&%+K=BGBPQ:(^F1(MP") %,PK.15FPV1]
M#DE]$L:*C2Y8^3"K@L)!R !,QF!K$>03(VB8B(,FWQ[R5'$$R/\ +A\\UD9S
M"RL:]L_M\]*/^56V?]C]FX19*<(G"*)8?[>UA_1+3?Z8WKA3:>X>]R\.;OT'
M=2M@M74F5H&E1&MK!9+AUEV0ELM-HU,J9U3@=P[+"V71^NS8-@F<09JU9@CW
MRIM_=T:OO5AM'HI51DF'9CTV%J<KVM[(S,[/9GMNM$Y7-HCA\QL]MU)FP-?>
MZ$D8O4*BK >M<62M.^:K!T])"[]Z5)(V@:-'O'(=LO=?;-[A#OV:UV&-,)'!
M^N[C$J(4%+<U6"S/*Q:S?BE@>C:XXYY[OO[^ 2UKC*^><?.4[3N [SG3W[H&
M(MNR3NMS>Q*4 DW#9NV:4'=O6EV"MPN!>Q=(B*,(V^H<\1AVM+%'"=0U>*^7
MDY,5<8="COG)2LTF4ZD6D"PB.???*^_A*6W7CCQ[^'W!6K(U9[K@U7=NFB>Q
M=F6&ZM;,'DZGKJM,:/K.OKU#B6C:4V&U7-H/]1D:[4/4TNKRZ$%L+B:!3+J#
MF0JL83JS;'F[9(JY/1M:VTW)Y$1/,3M&:6ME?=-K<MG=?,6CT@Z0@O4D (]0
M4'?_ *5DA,G<M@,ZBM%V.U"4>+T8O)F2V14>KT:V7.OUNKU5.806K3L3JJ7M
M0MM)8_K.C&436BD.SN'SD/CWH?A\Y_>LT.11.$3A$X1.$5"CQK,FQ$94HP#>
MJCHZ"T)",5V=&L$$LVX_DE.(6=RS2AY,?+:5&1"&1ZF)D#W&GW7RQ),A#,:V
MC;.^;<H^*MHVSOFW*/BJ[R*)PB<(G"+17J2K.$Y5VQG];CMW5ZO_ (<>%G">
M^?9Z\XQZ_7G&.$7D//Z8MK$C%JE"=,^8ZG:;'L]S7-?(3]2BI^E+-<(?3*FH
M[6?KM1L\NC"6J)(UKL>*'(ZXD$[\Y#4)(3P\VRWB[FW></%I<; :Q&L=8#7]
M&][R)F!G$0%R:PB"9,B3?T@-:1<3>1G:_ !2WO\ TQLO<VZ-37;.LSD6MUMC
M 4@QZ0:\2^R,QL0I'M\H\5]*O2:L.S]?Q!MEU?)U))61/GC#E2W2F-5XF1T7
M+7!K7"1?;Z5C%HM!O(=K; "T2H" ")F9V<!PO>QF,N*G+I9U_L'6XJZ@KS7A
MPQ$ZP9L8PM&GC)TH@\=F&)DP-E0>2T,2)J@_((:.\VU2@BO+7C+0RIMQ6$&S
M67D$@@S;<1L%S-Y)FY+C$2=@CB#!!V?/S)[UE9S"RG")PBL7:%6A7G6>Q*43
MA&2(VX46W58@/KLH5!L$^%8 ! 3+A IQUUD)#,RF);C R49>:%1YKC#Q!UN(
MAY>*#!!W$&^5CM5!@@[B#R6$6N.F@I-,:1D7K454&B=6V_9U_$G"U;TU#V2.
MA";)(=T?KXJ_K&#%KL=],RV6'9)>34'&P[!NI5=LJ1)%RIUV5R%_UH<3K #,
MQ,#6-QPU1P)R$!:+OK0XF8!N2#:YO?8 )O!]BE386L;3?[Y5=DN4RRQ&B'2_
MN&GVFH2[L#\H$W>PVO0UMHM2S >+6.@8)9?K-XA&[&.%G:V0:'M0K)(.A7 T
M"1D$ $2/KM,P;@!P)M!BXM,W,7E0$ $3_&:08.0UI.P[1:Q[E?'2_2;KKG6:
MJ3>1 ^!/KA^:+%E(<A$I^V@XH\2U#LQ%W!L\_AU]]$P6,8F28,F)7!(.'D($
M9CL#8\>03(FXV[#R".()D?Y7/#Y,W*R+YE940:Z_9YOW])-;_P!B^J^$51BF
MDUVQWA,\19GD%#XXC!D"ZP=+Q)$1-/JXU:TRQD"5'PM$T?+86TIS#J%,YRI&
M$J0I7;-,U:>'+7T1J4G,<'UJ5-P=Y>L^-5[VGZKVD&(,YYKP:>*&"QNE16PV
M/<,1C:->B^A@,7B:;Z8T9H^@2*E"C49(JT:K"TNU@6R0 035_3T9\2W?Z!V[
M['YCS9_KX?\ &</^<79_"]#[+I7^J-(_HR>GHSXEN_T#MWV/QYL_U\/^,X?\
MXGX7H?9=*_U1I']&3T]&?$MW^@=N^Q^/-G^OA_QG#_G$_"]#[+I7^J-(_HR>
MG@OXDN_M[_L#MWMSW[Y_^3^W/?/^O/'FS_7P_P",X?\ .)^%Z'V72O\ 5&D?
MT9/3P9CV!+O] [=]C\>;/]?#_C.'_.)^%Z'V72O]4:1_1D]/1GQ+=_H';OL?
MCS9_KX?\9P_YQ/PO0^RZ5_JC2/Z,GIZ,^);O] [=]C\>;/\ 7P_XSA_SB?A>
MA]ETK_5&D?T9/3T9\2W?Z!V[['X\V?Z^'_&</^<3\+T/LNE?ZHTC^C)Z>C/B
M6[_0.W?8_'FS_7P_XSA_SB?A>A]ETK_5&D?T9/3T9\2W?Z!V[['X\V?Z^'_&
M</\ G$_"]#[+I7^J-(_HR>G@SXDN_P"/]@=N]O;MW_\ D_XO5_%QYL_U\/\
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M@+DP"TE N2X$$+>BK4.AY9OIC+6%YVYB8/>)-^)WJP[<[Q7%$ZA/<\Q[(.-
MW+TA0H]9=%/UN/$O.H8[-?> HE(!NA&F22&Q3@=$Z;@6N"EA0_RR5F)EK,AW
M*WIW^M?/._?O3TO];Q]ON\%?7ZM3H]_QI^GG^>/7WW@Y(.X\BI!W'D4_5J='
MO^-/T\_SQZ^^\'$'<>12#N/)/U:G1[_C3]//\\>OOO!Q!W'D4@[CR*?JU.CW
M_&GZ>?YX]??>#B#N/(I!S@QOA6L5ZFN@@[805M-[WZ43%JJ[<QJM64IL75,\
M_7FB+>62#80Q**ND!2)S*E-2T09#"9#:E(=PM*LXS?2 (&L <Q>#WA(=E!C:
M+KB_5*= 7F('5_?RZ3<5JL0,"ZW7L;"U1@)7QF!#]?P."BO.OD(N#@#*DA/)
M(+##'FB0^-\7Y&\XRIZ=SZ4FYSN9F3OO?O2'3D9SVSGGS\550W5CT.UQ!%NO
M=173""08+33Y9 ?:.LAJ2ATEEO)$R03#-,XFE9^6FLS"$C#DN3XMOQSJ_ 3V
M$..8<8$"9L-W<D':#X^Q5G]6IT>_XT_3S_/'K[[P<D'<>12#N/(J+BN]]);>
MZB.F05JG;VM-E$PIO:Q4P/H=WK=MFBA:]5'X"")&,")3GH4%<Z5&AIE2$-L*
ME2&6,+RZZA*D$9@CV)!W%9U\BB<(H645&#-ZG<DB4 ?A[4U/PUF=,CQ,.Y1<
M+SE>&\ON-X7E.%)\+">_@]\=^W?'+!.0)0 DF 38;.)6RP:_Z<[96B5,M-+T
MM9:@9M$F\&*J?KU'+UPK=)A59V7;B00A$D#9UFEFG72\H[)C.E)!)QR<]*7)
M<6YE#MQY%6';CR*M-W0_2.J/(9BZNT&*>?K=?J*" :I:^%E(5=J MX+318XC
M#'M2H$6F#'W(519C.-M5N/X+(A$1I"48L.W.\4AVX[\CGO4+Z@Z$>AC3U/C4
MR+K_ %9L*#!NI38(N=M@5KN\3@-I+@J?6IL^J1I0.*"I:) 2@4Z-+CT\*"9*
M303!\PDC9)) Q+>E_K<B/G-(=N/(K*"FU#06N3%QL.OJSJ*BG]AE$&[\;IX>
MG5HM=S+;T^2@M;2(:/"F6(DB25*R4SB[TR3B23(R,.>.G2ENR';CR*0[<>14
M@^E=6^4H#YX'?6>(.X\BD'<>13TKJWRE ?/([ZSQ!W'D4@[CR*>E=6^4H#YY
M'?6>(.X\BD'<>13TKJWRE ?/ [ZSQ!W'D4@[CR*>E=6^4H#YY'?6>(.X\BD'
M<>145$M:]-)DK93Q>B:0*'+FRW'MYHA6J+-+6EAIP6\TS8B,B&Y,--M/ PKS
M2"+TE+;H<6XC"5CXBF=2^UWVRSMGENS/,J^D,M8<U<<8)I6%#(CH8K6$0>7"
M!JT5@QH558ADZY7&),6O@"$5IM#$P*"BS)D8.+D(<@C&)4AF$PRV\XE4]/\
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MDMZREOLV U$U?;-<R!3$,O?BP]C3T^?9XU]E:L-Q+(MZV5L/*E6R5E/CF ?
MU8, V]*(&L';!,YC6!&>2:UH@Q-KY"0=V=HD1:;*>='ZIDZ:J$NE9M,RSAXY
MZ9+JR)D>0RY7:VY#'185>PN22)*E*9?ARR<J6SF!$>GE9>8@N!'PVSC+G:QD
MB#MX_.7<%DF3,1:ZF/F5%$&NOV>;]_236_\ 8OJSA%+CCC;+;CKJT---(4XZ
MXXK"&VVT)RI:UK5G"4H0G&5*4K.,)3C.<YQC'"*.(FX=9S%LM(N N-(??CL(
MBE,2@TQ"ID-!"$Z_#+1X4J+$G078\N#.DLLPYL>7!=BONHG0\OZ+'C^*?9<9
MQ (D$S(@7L=RUJN&SC:_#9QS&8VJZV+75I3DMF+90$EV!'E2YS3!D<\Y#B07
M/%394M#<E2H\>&[_ &N4\]A#<=S]8ZI"O5R:KO5-S L;DY#O*D'<>2Z3U]HT
M="G'[G4V&T>2>&X]8@[2$><&/*H'A*7,2E/EL;^Z(G?./*6/[<SX;?Z[EU7>
MJ[;L.S/EM2#N/([,US9NM-QXSO;:QCQ+DQE[N>%8\4Z/CKF3VG.\O]8Y!B-N
M2IB%=E1H[:WWL(:2I6)JN]4WRL4@[CR*[*+16783I)JQ G![$5N<]/;+0%PV
M83V>S,MV4F1EAN*[G/9I]2\-.9]2%YSQ!F(,[H,\D@S$&=T75$B[,U[-CP93
M%TK7B"(QPQ%6\7A15*',LB9#\A]N4ZR[$RPR>#N/LRT,2&$D8OC6D9<QCE+'
MB?1-C&1SO;CD<MRNJZ]C8P;;;]%79=FK8^0B)/L 2%*<7!;1&EE8$:0MPGE]
M(U"&7I"'%+(*C2<04X3E4O,=_#&',M.>#()$@$C?!A2"<@2N!5OJ:'F8RK17
M4R)&8^(["C8W#S^9:GT1,,M9DX6[F4N+*1'PA*O'JC/I:\+++F$M5WJGD4@[
MCR5/<V)16\O8]+ +N(U=+VV0Y%)1IC,>M G8S!8T^]$6\RS!AO2V6U.N+3XU
M7CL,8=\ED^)NJ[U3F&Y;3D.](.XY@>TY!;VM@45V/F5BX5IIE#&9+WE1H?#=
MBM(<98=S.CRY#,B"MB1(9C269C3#T64ZB-(;:D*PWQJN]4YQD<TU3N/)5+TI
MK/D+)/TB!>;9#4E]@AYW'^0O,0Y+<.6\S+\H\G<:BRWFHLEQ#BD,276V'5)=
M6E.9!R@S:T';<<Q<;T@S$&=T75/]/J1Y0W%Q;JXIYQA,E/@F8"VL,NY'^3Y<
MD)?S':7+P5'K@M.NH=G-2D.PT/M)<6AJNW&UC8\>AG<FJXY \CQZ%5!-IK*\
MR\)L0)61XU)B?A)<?G,(0N.W+05EXQ(SY,-7%>:DIG/>!%5'=;>P[EM:590=
MQSC(Y[N_@D'<<XRV[N]4^1?:3%<$-/6L!A1^<T,#Y04ANH(3Y Y9:-%8=9=<
M:R[*'H\IB84M.)278Z(^7'949#K5<=AM?(I!O8VN>%X]ZU$7NFGHB)PNR"9$
M9P;DRE2Y;<1S E+#,APDN/,\GD-P6&GV_*93C2&8SF5L2%M/M.MHI:X&"#,Q
MEMF([T((S!7(B\4IQQMINWU=QUWP?%-HL E3CGALID(\6A,O*E^''6A]/@XS
MX3*TNX[H5A69JN]4VSL;)JN]4\BNJK8M 2^S&5=ZGA^1&=F,H](16?#BLXC*
M<D>%B7E"6L)EQE86I6,+2\A2/"3GOBZKO5=F!D<S,<X35=N/(_.Q=J3=JA"D
MJA3+*&B2TSV1GDTJ?'COKG2)#$-EAIIY:%O>'-DLP?&LX6RF=E4)3B933K2)
MJN.0)F38$Y7/(7[KY)!W'Y^>5UPM; HKZG4M7*KN997%:<RD\,\##DV.Y*B(
M2YF5AMQ4B,R\^SAM2LK;9=4GOAM?@W5</XIY'Y_S&](.X\BMZ+Y1W&L/MW.J
M.,97,:P\BQ"%M9<'QFYL]O#B9F497!ANM2YB,*\*-&=;?>PAI:5YFJ[U3;.Q
M[O>"/8D'<>178%7"J')3D(-90168WWRJ*/*P9<C*<0X!#+B&F'UK=9Q"*C96
M7FTK:PS/BN97X+[?A"UPN00.(/$? H01F".\*X^11.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X11I9-<OF[/BW![]=*06< Q*Y
M,Q68]#F12 Z 0($X>9+-SH]N4U(CR2DWL[ <AX<;<2A]#N6VU))\_/-='WN;
MA^7S;/S-HO\ J6X1/>YN'Y?-L_,VB_ZEN$3WN;A^7S;/S-HO^I;A$][FX?E\
MVS\S:+_J6X1/>YN'Y?-L_,VB_P"I;A$][FX?E\VS\S:+_J6X1/>YN'Y?-L_,
MVB_ZEN$3WN;A^7S;/S-HO^I;A$][FX?E\VS\S:+_ *EN$3WN;A^7S;/S-HO^
MI;A$][FX?E\VS\S:+_J6X1/>YN'Y?-L_,VB_ZEN$3WN;A^7S;/S-HO\ J6X1
M/>YN'Y?-L_,VB_ZEN$3WN;A^7S;/S-HO^I;A$][FX?E\VS\S:+_J6X1/>YN'
MY?-L_,VB_P"I;A$][FX?E\VS\S:+_J6X1/>YN'Y?-L_,VB_ZEN$3WN;A^7S;
M/S-HO^I;A$][FX?E\VS\S:+_ *EN$3WN;A^7S;/S-HO^I;A$][FX?E\VS\S:
M+_J6X1/>YN'Y?-L_,VB_ZEN$3WN;A^7S;/S-HO\ J6X1/>YN'Y?-L_,VB_ZE
MN$3WN;A^7S;/S-HO^I;A%7:/1$TM=HE.V>R6XI;SK%@,&+.BLLS%RXM>!UB,
MQ'CU.MU82Q$8%U^ E*<#52%OY?>>DN>,2E!%>!#+&($[,IG$B+B')S)85A*D
MOL897EYE25=DJPXWX2,X5G"<X5VSZN_"+"IB7KB%64VDKK.TPJ_+J FQ3WIU
MU-/EGA=ECXUV'CSH)N= FR)D()X(^(N2\WB&.=4_"?D/.HD/=DA[G:H>"0X@
M0T"[9<<IB3)-KW'!<OI$QK"03 U1$@ZQRD9W]]E>Y9G56M0]I#BZ 2=#V*G.
M-7)X5)GJ'M5D-/(UXRW)E07Y1YKT8BDIOE96$,\>H<F$M@C(S$2N%@&H\M.O
M</\ 1D"=9T$$6BY ,$YS;-0:SB"7"0;3$S8C.!>=IWRN@Y[TS"1EOL=1L\0D
M2OT"M%,$RMDDD*X5KX^1L2$6,Q9,B.TQ&SYFAF2KL!N3$E9F-R%R",92\*H+
MY(:X0&DB&B""=2! .^!.5P(5].X!$:LBP@CZI MQ('<<E10-<Z<#P>209AV<
MQ$#0R$N.J9-M#3F11RY6,4@4&AMD&6B<08:G%AT.=!9DH;9++<P5>64E+<$U
M00+ RT6 S#0072+$B"0<]6X]$1"7@[/9&8 OP) G?P"N:CS-+GC9(%5HEFGK
MV4Z!N*IF&2 R*.C4]6) "6P0=D02;+<*T5XMXM/]URD'XT^++0@1Y EPX5&@
M%Q:-36;%I.M9TCBUPR@:L$7NAUQ<D6ENPYYB+C(\C(O*C<?,Z7F@C;3X*Z"W
M#%9K#)<+Y1>ITMD=:I(:;5@!29'GR&78YZ7'$MBW7I7F]V-#ABYDJ%$<8&O:
M/EI-VG5<Z##!!;]8B0+B3-IDDB2)&B*I.<P3!D"XS,;Q-]O?=268FZ#-BB-N
M,13V(-1\T5R8E_-J$2)$ 8^:!Q4/",28,H[!;RU9(4F/-BRY3C,,OX$-6'UY
MF8 J@AH(].2/JD7@F,PTY7$1:%F'@B,SZ4B-L'/9LX9*AL$.G."@=7$C[;XZ
M5*R'BCU)N\\S/:>5< )(?)C-RY1J8,CL^D, ]#DM.-05N,BYK+)F"F#!O[:9
M=(L))] "VJX'("3Z)!&=R+$S8J9R+7)M L".'=X6,G:-LO38 \Y1X<(] P;J
M=E:+#V(EHD877# BL2+68>&#GI.&%2FXE;$D#<6,F1@F/DL-2,*&GI$=JUG:
MN1&L-4DB)!(:+[KD-.PFUTBH8VP01E,@F(VVDF.,G-5$Q,TGX($K9JQ8H.;$
MFZ%V8RI)Z0MAZBVZQG#4V?!'3W&6I0R39;:94OMER..(31C6)*<1(C4 J7 <
M/1U<X%WM$"2-NJT7M(!,7*#7,@&8U1LBX  GV- WV.]7.=:T^F,:J" )$K*U
MP5A1I T9)*((PW=W%)8F9YN)HG-KEXGR#Q&1*&.3,9AR8D)],:*Y&#240&I9
MT@:XL2!!\D!&R+0!.VX,W"R-8F9C6!N<O1O&7 <XR)4:Q2W2M)"@(42*:R"$
M0[=!K[[;=V9:4+76XP2V,QG%/MS9\5X0!8J<M*D/OQY#L:)VC.'QLLCL"L";
MB9;,EIN'2WA9SM;=OF"!K]LOE< GZN^1W&\CN.XA5)G.EQ8:=F*&NX*3?J%8
MJT0=BS2YB<+#PG*528XI]B43FI\[QF"E88KZFXDYH9'9(Y5+A9D$LD(?*.-R
MUVHX'8 2=9YR )!+73M*2^1E9P(M DR9L!:QG?QBW6,XZ;@)I&9X^SR%38H^
MUCIL*?=RD:QS2+DNK3HK,)B<XN61EQXF734)V/A)>,MR<\B0XTM>:!5<)EMB
M6WU1JBSA<Y S /&-J /(L0(,1:V1!-LKPKBJ<W1SII=%IHVP2U69EW5ME:20
ML61<<0*IUH*!U$I,T@MB1Y<$&%V I" XZ0<Q+?=EOLR(^$MQPJQK.($?M@F)
M)+FM)$#>1(-K" H=>-8Q:' P)S \"1(.V+05;T]'3H0-G"9,6>%1%-26[(IY
M!0= ,R[!<)DA48MY),Q88TH+9*(1*+$SD#FAKI!:G8N'<JBPK^VZH$@Y1$$P
M&;+09:\"1)]'<)5_;( %]P$$QJBXV$0Z)$Y9[ZR 3HBQ"+(PH78 ^$-;!O-A
M:+$K#"(RAB24(-8;*0FR"*<1VSDZMP"$-I^3&=CD@\B5&;ARA\Q:834!:9:?
MJ-;8$"VL&@1FT.@[8/$(=<1<'ZK1E8FX'>)(VV/<ND4OW3T36[/6W9LS(# M
M/APEV<1.\INA1V\PX[F6)L0AF=(/J0W*=<0KS1)-,QU.Q1Y%;N8&U1Z-C.M;
MT3]4:I.1V3$9ZMI(35>+6O-K;+>X6WP<\E1D1^FEYN );J5C(K>-R0$,<X@Y
MEI90U;1@0B] <*DH<%;CIPJU,2^/<3/Q!K3T\8RF*'CX<U-;U@ !,B+ -)$@
M F  0)$>D <TFH+S%@<AN)$VW;]IXE5ZV,]/PJU$X\NG'#EB'6&8))+@QS3[
M23-T@2+=-CQ9LZ;&%.2\I\5.PB/+8<'JD83!6C+;\?$:*I:/2 :6@B2T2&^@
M+9Q%IB\70!Y%C B8ML(%]L2>.Y<E2O.C@Y8,0$";>/LS<89":$,QK.4R-7:!
M%?&!84I3;SXQ4>PP((?R!Z0]D5(G16),MR,95"4L6U7 @EI;<SZ(D-+I(MF#
M,Q< C9*A:\B\$;["PF;VRV[=UE>]OZ@QU/LI&NRJ9;)[8ZS":NLS BMK%.D"
M=/C7/Q"93F4,-RTC92&6([KR6E/M2'B,L5 :3,<PVF7"9 ]$N@D6 =J]^?"=
MP)4#) ,BX)[A.KRG<.:J=?W]2+*9BB!BWG4R9MKB*G^4#W(L=-2=_NQ]W#$M
MYU6"4"=73(2*RAV<0$G')F(K2 %BP,&FYHDYVM!_C1&S?()R!$3=LBP@7SM:
M#M^2#Q'$+<=WO6:T()FS0@_!A#!VPIRLN)#J7)?UY<!]*F#&,-%W$IFERA2"
M^,=DJCCF8#WE!>>,RS);8"FXD $7+!M'UVEP-QE ,[9R!L@820 1<M'_ !#6
M%XBPF1G-@"JO8]U4.K%FP9:=-\Y. ,V9+$ ?())\T-(P],D*<A8>0VJ#%6U-
M?:=RVZ[#=0]"1*QAQ+<#'.$@6G5O:Y[^-N]0-)$@6F/;LYY#BNNQN0+-'OF(
M8LHH+&O BGOF);68<"-",UH-9XMMF+6AQV'7GXQR!#BR9++?C)DN%F7F!$D.
MRHU\F9B1.J7 7DD$@M&\B#,;C$E74BQ(G5)C,R"1J]]E9+/4]328IDU7QI(R
M/D1XN(RFG8J94LJ2*6@<+#0X$54^;*ER6J><).X:8RM,%N/B"R2EJF18.O(N
M!AQ@R<KB &DDFP ])HN=MX%R\F9@V,Q[I,Y6D*0#.TXP/'>0 )S5QZB:M)2.
M,?A+ECLUYD>\7@.QR+HO/:)@E&;S,=5'2\^\RS&8?<Q+Q#QJ<0)<!)F+Y&TY
MP;"8B^8F:O$9P,[YWV[OG:F[9#@A%RL%JA2 86GV1==7/;>;*H+>*BPIDB<-
M9B(2_(;@MRW62,5AM^7%F#"\-+;T@>ZC+4)+0+ES9B+BY$'E(.4$')-4D@"\
MB=T9Y\L\K@Y+K!]V5"PV )7 ;9B;.+$6H,A;HR3"8$-SJB;N869-=EH;2MD\
M(!R7!B(V7G58RO,I,5;*FE4TW!I<8B)%\X<&F.XD3*NH0"3$1(XW#3R)NJ'$
MZBZ(ZD7DA#LXAVP.P6Z[#D@I,V:83+K(6V2/)V0^2*,/C YN+*G1?'+=4UX.
M(.)DAU$;%-)PF(.K]8@B =8M$S&9%O&!=/)NV08S@Y7(V["18_"ZN,SN*L R
MA840AFV'0IR&&G3'83:!:$2541+I7SAB0MEH=%5L2OM.*EXC25N^7*;C*APG
MYB,BFX@$1<$@3>VM:-YU#&^VU0-)$C=/]JW?#2?\PJ.G?50?I=MO$.*8ECJN
M7G@406X2TE2Q<76H5D(PHT1>,9CK@MOSHLMR0K$=O(B=+;>>B>(<=ODG!S6F
M!K .G8 20">^T#.X&=E=0ZS6F 2 >X$P.=N:VJZAM=^22)[;QM<*+EQ;DUP"
M3C1'X<<J&%2IPMZ1';4;88<.07EX#-SG&FW&TRT1')$=+KR3O]6\;1:9L2+-
M-C]:.$WAJ.X<QN)]F1%XO89%=\)O6@GB,$9">,MR")$8*C.RPLR- 5,+#\$H
M:?.:T^;E,NL/0&FI#<E;$N85&0X#DN1+2A(TW"28$ DWO8QEWJ%C@)M%]NXQ
MUY=RXAN\JG.*K!O0SL,PJQ&JW$@9&O27)4L+9Y-7=SX^/A4-E3TB-@IAI<C.
M8X:3&FRELJR^S'&F0)L1 )V1+=;;PYG)"PQ.R =FT3E,Y+F<W75EWB)1(#4V
M>4<(E1<Y]M*&HL"2*(5X:[G#J\Y1,:7+.KCY5&6I<>4)(Q)+;3[:4Y>3=JEQ
M@" 1O,@D> GN((D75U#JZUHB><]/%3%SC6$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1<3_ (7B'O ;2\KQ3G@LKSV0ZKP,^"VO/@.=DN9[)5GP%]L9SGP%>S)%B57=
MB6 =7Y:4=/<:-%'P8A,:'K8PB-C)9<J\RQE1S42938F,DX5D1+&LH8CLXFND
M<NY9CSV\QR7.YH+KU3,Q)(/\8-DG6F(N<X %R)(Y"T6.O?>8F9@;=T'.VU7;
M&V$LZ$/R[/IE86+6FJ*P,CV?,*5"GRS\T7AEB+B*%)/LP@1!Z'*CR1H\H\XB
M.TO$ >89R*9A86D:M22[7G5F8 .9M<W!$[=H,J1! :^9F=61E-LQF.X7VBZH
MT?:,Z.,!MXT 3'C3#TN>P/R+)(P(ESHQ-4XJ<'Q*0\@4RS)3,19)>$OE4PC$
M"2/''IA&8,A@P$DFJ)%@9!F(@"7 R?XHRL9+85U1)],6S,YP1E>YW;+7(5(K
M>QY,<-AH;H%(2QO42.:+(Q5C=? 23T=LT0AU*.[$I4^9(G29K#!@9!DM^!#A
ME93LR9%+,,12U+!-ZH(UB!!!.J8!<?2@ Y&]R-HF!:)N^1,"X,@Q)N;;B=I&
MT97I:;G!ICRIPO3Z3<B((KMF:> A"/E\R=*C2@Z\!'X]+=BN20E?;DCV7"1(
M,9<3*A 6Q4:.39=SD-UK&I%W""182#>79%QDP"+%TDB% )L7QF+FP$S>^1-S
M$C:K'FW*0EZMBH73K 8BSGP[)6.]5Y4YMFMW& Z=(1QJ6JF.'MRQTK ]-OC$
MY46)#.NL#_%D\ON%Q^@VSB:N0,>D/K-( _C&Q$ZL3($VR.@,_P!L-IB]I!@&
M9VW(B\2;;>*/MDL4C^:B73\[)@D$,F9C3E=-I%I@-[ CAHXV1$*4QG$ZR,P"
M,BRQLO-1(JI<<FXYYOA,K+.C3 ,^5 (G^,V9U29$.L# &<Y"YL&J,P\3EF))
M@S<&PV3RDF%<]6LXTH',F)W3U@ \"!P+>P+9 PYY0FN(9/J=CB6FJW$0NPCF
M,2RPH<XZR6G$#+\2-'C..2YJHX$$ 5=:21,D-&4$DF(.TY  &2(4.P>4F21,
MF!81MF#EE:.Y4P9;U/D4C6NEV0)PR/<D*S.&@8V69$9F2 ECV$P0LV)(\,/"
MEBQLN),=A$(V(D!3L0.0B3G*6D7\L";9$G.^<V,W(,7DYRKJ@#]T&>0.=P9S
MWWO$1ORJQ2]E(M$I!(7I),8B4\OB,5N4*>GPJT)\_BPI& TD$!?<CRCX0A))
MQ84N*#A)&CR[Q1U3@YL63@:"YP-2P@S(&L8)!,G^*;',R0 +R( "XR^V^;N,
M$C,\(FY!(M>U)B;#O<$_)FDM'PYK=B-BH*YH(;,A&',1+5?10XI8R18:U'?4
M+$48(5@-K7XM+]G#-M$8,?(^21NHPB!5B 3!,B-5I( &TEQ!WZIM8Q2UL0'W
M .<D1 )B)VDSW%<+=R=DRLQ7NF-EM>9M9CNRGH$-Z-_A,'A)G2L834/*W&Q,
M14,9,<=C,,.M09<.5)@*'M1GA;M\M/UHON=E];:?2]LWF5  ,JD9Y;P;;<B;
MS.>PYJ]39V O4HDXSJB$>-Q8 6'&U^W424V*-F%80PF9$CV)-:CR&H$$<IWP
MY2!<:&Y.@M#9&&YS:HS>0#KD:\"3Z6L+@2 203\3!) (4@ZQ&O$GZTB^XF_Q
M,"]URS[O$.#J](*ZCFE\62]XHTR%/!2IN1H%HVF/"M,W,^M8CNBD)6/./0G5
ML-CV?.&<S%S0)-J/-6Y >(#=>9B3&0$YY@';:T$%(S]+)LR-Y D6.^T\!L*M
MLA>7*W9);L#IY<<<&S3)"/:!<&.W)4B;=9U**%&$QZODL^4)C@^;$0A!4E2,
M\.0K3;>2*2N78.@W6$&KF!8FUFAP!ET 2=63D0[*%0T$?7B8$;+-F][ 7 )X
MY0NF*N@N<?B.3]+#J]5!J:U.?-&Z:3B30DV36KQ=3LR%_@HIIYRO'HS0=S*$
MCU,&BI";B:])-P8RZ6P+5=9QUA <#(#FL:/K3Z3;@7L -B$6/IR9(@$08+6C
M;M!MP&X%7'8;$&U_8R0(5IDB3'S1E>!>/K 25*&3QY-RSSG17FJ$$="#X<28
M_-7-\HE18TZ0:6]/6VAI;N,@%S034O+C!(D$:HF2X7(B-M@!FI=PDOO,P3ML
M)F=P%]BMBL.!\S+M9Y6BQB%)"/6$2L>)/3')KU&K-6DP <498*H-\@)NR[:4
M@A9 ,1"?FR!AV)@3(DBU3R==-AY0Y@&X_C%TF0XR!J@W)S!D PM'8!4SL;B+
MD@DP2(L)DY$>REM;+F2E2U%= 1'WQ:IS$@AZ-GLPR ^8#M]FQ&"9D4-^>\F0
M4KU9'2GWF$1)LX_%E/,023;8A-U!%JMC$ N;L+6B0'V@.,;0,K)JBP%0WBTC
M/T1>'$9$QW$=]_EK<J1' E_>2R5S=0 (E;TSQSF"PY,T*?\ * I*/BJ3U&IP
M4=!(A7(A&0-_MQ@>,RF-'+.K:R&BX\I&J2&W$$@B"/2$ F\B<I$Q;(&?IQ!,
M;LQ<7M)@V!RG9:D538T&RMDIR](2!)^KTLO<(D*6*:010W GO"J\'A^45Z&8
MA$;/FK>4"FD#,91 %P5(0^_';BQZ61 \H(<X--["P+B2"1#=:]\SWJEL 0^0
MXQGS)O$"=IV[%5ANQR]@LT.ND=02!T27:E!K"6*Q2LB TIRG'691EA]VHL1"
M,*>\/C5@02<DI;(B93L<SZ//.014R%C0"14!M+0(D^D+9V(!DC8<M;-2 !.M
MLL!&\6^M((-S;B)S'5H]_*$K4) R=+20[CI I FV^*-4+#P(U;"92%?CX+!Q
MTR0M$6>[7\QXTAV*.\>^P((%HBIS<2.: "0^;"&YF2;Y'V\=H!0@03KSE FY
MDWR)W3QS("H\';=ME,'9KNCYS\)H<]-@CT#S,$@N&7"&+!8!4Y1"L81+,/DP
M\$>7'QHC<9XQ-PPJ237%B22>C3:(BJ)F),18@ V<2&P20;VO O%+6C^/>;Y;
M+ B#EN,^P)+V"9*2QA=>D840E)4,"%91P64+G1XF8V-ES&4O#JBJ%+$.#III
M^%EBP.L8CPW7"T(:7\96G!9 (\I87@$02#'K6(MF,S8QZ20!;7M<B( F2 8+
MK9 Y;MEU6,W )+I(,[$TRS.@GIMFLR@:0J)F$G *'6')#;0JM%F95KL<M,I%
M=G/L0X)8:P_.=L49;T.#,:IUB#5@C5;,[#Q+A#6C,9@VU;$A%XUXB #EGWD>
MB,SMDY9D6R:V,Q(D.D3_ $^PI,+"B(=RP%X,EYMQ"A<=;TC*YM 5*S5S:UPH
M,&4ZE! C'[(D@&)K"12@;$ 52#8P+9';Z0AP,F,AF"095#=U3C L1[)S[I[U
MRQ-FK(2WW&>G>:P]6Z0/<'SR@6? PV))#V(RZ:*<7179<)4>=,6/F"W&80Z.
M!PL[+S'@J<C(:N0\K8NDP0;@GTHUO2)&T7FW%2/]?,F;C/.3Z7CG-A-IIF=Q
MV,N&?;+]/Y,H%?C%#&0$FN$VVWRI"_C(8&$707!Y@#3,,1*+6ZSNHBF6'FTP
MC42;%4]/A0[Y-H((JB; &03]0R1!F) :W(Y@BU[J $0\ FTR+#5O$&X_BBXO
M(@BZR>$B:W,R/.L5@</*0L2HL=Y\)$BE1+K;:0Y")'D^3I=;;PU 0/\ *(+R
MX!"!%C+A2)8U41U?"2;B3&<28/&/;WW*XR3OGVY[?GJN=52JBFD,*K%>4PW,
M=(MLJ"C<M((/RF)S\Y#>8W@)F/38T:6[*3C#[DJ.Q(6M3K3:TM9TSK&8B9,Q
M$1W1:-UDD[SS/SM/-=QP"#>D2Y;H84[*G^(\NDN#H:Y$WR;,;,;RMY3.7)/D
M^84/+'CE+\5F)&RWX.6&O 2;7-LKY=W,I)WGFNABFU# QX)BJ5O :1EC+XC
M(7@8_F*_F5%R] Q%\E=S&DYS(8\-I7B7\Y=;\%S.5<:SIG6,WO)F^=^.U),S
M)G?-UL=I-/=Q.SFK@&W";<YN?(CBH467)P3?9E$%.3(S+4KQLN7&C3'WTO)>
M7,C1I>7/*([+B&L[>=EI,6$"W $CN,))M<VRONM[K=RX1%#I@&&)@BJP%C,
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%")PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g105292g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g11i11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2VV4&AO=&]S:&]P(#,N,  X0DE-! 0
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M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     %RP  !V0          0                         !
M    =D   %RP                     !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   %RP    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !<L     4F
M=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    ).$))300,     !J@     0   *    !]   !X   ZF   !
MJ$ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,"
M@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,#
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M1X_8R/U5!!'VQ^NGT&JJ/J+0 !]MMT_D,_\BK'[2^H_P#Y8X'P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MIXCGG29 _A:G3R-*9QKESK_N=6=X?2\GO?CAWMH/!V>4\ZZGBLQ$E_43.?\
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M*=0U&<MNBBDNF'39$N8F:K2:2M?)F:)AAC5"42KJIE3/KTI^:.X;?!D-EG)
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M 89YFB?S:>-C<[>J9C5+=_W7/_?WO*UB=^J+O'W)9U^5]^9/'CBOP##(K_\
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M*D_F+4CJCAI>K2F@(AL1/65R3C1YHZ0?!%#!&)*BG(YS$0-A##!!"%C8X0U
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M[EW6-GSH'-I:_P!CP1=96RXM;=%!,5+:4X%EP6U<JJ; #!\2A[#I09FHY-9
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MO]'I]*+(N B.G7QL-G?;=G74=ZXS'%<PPR6 ]4V[CS?)QJUK^+]F!#QECO\
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MB:&(/0,J@A4%8\=_:,:P;UO_  52")!$@B01((D$2"+4;+/^$8N=MU:7?_\
M);S]?L>KO01;<P1((D$2")!$@B01((D$2")!$@B01((D$6H>?:C;I(PMR:5+
MN-YTNVV:?9]WFWLV&0MA-IW+[? 3ZQ#R2W7",,6#1%4]13( HJ3,EZB(E<C
M8X(@=(E/&^:=L.7S;T1=,.7K;T0RHNF';33P9/\ :BP&ADVU6K!X667;QIN;
M#+#;38A'VC+)::E;[4&5M2@TPFOMB8NYE8_-UE8;Y$M.Y:ZZ'N08[ZN/E\Z;
MM-EF*(5I[A*#G7##1<ETG,2-&1V*2=B.5,!(QH[0,JR#+U%ZAJC 7A<5<9,3
ML,T]]1\7J&*/3&*&V_>-][6*'^3!ZX=M,=T9))B\>.CW,UY,?[,_.X'PM@.G
MTEMU@QP73]EPT\::-$9H\70;=,M#+9)+1RFV#DFZ,5*1DL\,;E*])XL^L=DJ
MZ%3!/6N:]VKCK#M8S*1$H\XS8SJMLRC2.\7.W ;T*B-RWGS!9]0*I2@A'2QM
M*!-+!N:?'OEZ0UU&5V?-GLSBR$59JF_M%O:ZY+N5S+)DDW2;SM'2S@9&RMZE
M1T*ZJYS-XU$R.PTDDT#IAUM0TJ WM,5J;(**+/*+!IVB4F #RK56;)(>FJH5
M5Z@,V@%=I(GHK$!VM).166TD\[1;%&>C&6RUOKDTL8_;Q,MY;Y+F9;#HFBU,
MA7K(VFG;J;S()Q\TKAV^3$8R[P)HB'6(2*2KF:ATV 5SAZ%_>\%P-&RFB".=
M?9#=?+E(VI>KK;P*:SG4(DJS6/I]VC:8D\] B> PD8Y< $&[@=FN>163A' 2
M4W0>MN(,EJHY@T2(GZ03*NVNHBN!@(6+^U5T]&>U'<XWB<:R6DW!3W PS2B,
M1M?<A=4C[Z,W 8;8()C %0VXIIKR<J-=E;8"!<(K;>I7&3GT*AT/RD-3  $"
M)[6N<IQG=Z!"&8R$U>5EW9HZ:[HV7)6<36\FO]78Y"JU1A.:+^1DHLGF$!XJ
M*4V%$^HI95KI%R@&E)_&$YGNP8K<A/;5#FH+II=,I-T05E'/V,?OOE%6K>97
MQ63!UE4>=DGA=E#<.8+3M5R1=.%4F<E7*N4Y+3V\>JVI'.;"24GL L[U!LTN
M="<)DV4<[T15,)'05!2+F:@B7PC?QBN<= A(67PQT#D1@6F.1?;3XLD:8B2F
M*9I.M,X2C0/W%KNG2P[PW8('3329K%).QQDSB%=]/N6IDD=>0.34Z#HJO2&,
M4-U% 2DIRE"TQJG,&8A%6#:);T4%B+3/5Q4N=7?;4?BX-6Z5]T6MN(IJ'.PF
MLBTSX3CQ1MMFW28.CV72F,TK0K:,\PT2EGB$RS;#!<@]-9$B$5D2,T8>NK5
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M^O\ 7CN<SEC'N\KC--NXKR%="4$OM9]6%(H:P2!,E A"9XD2=C@*2%!%II%
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M)!$@B01((D$2")!$@B01((M!=*9YW9F+Z1;S]QTQVJ%[Z<_K'ZK2]3B3^=N
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MZ8XVZ\_:N5V>73R+L1C5(V1K,83C9*=1AIDB1.,PGH,*H>B7'H)&5<I0A(
M\8A"$9F$JIA%@58\L"]7W$T7W_S%7'X?V1QTKWH_^0>?4,N*I8//<WGZC7U2
MI<H\@M$D$2")!%";DAYII;]."['P3L"XUN.'YL4+]J,?8T]=;#?P51_G;'V5
M(5!CY2O()!$@B011\W&\EK+U[GV/+MZ_5SZS7Z\O#<VQM?9)_-_$.[O;28Q%
M[C!FC2;>-<^-7P;BY\V?_9T-6U.<I3U<$N'5O=?9KGZNO<GLUSCX^2 87"^%
MF>43QQJ,HE>(2>Y/5U]4Y3X>&<]NO7JW)_MM>R4]R!J,,\"#?>3.,85'VT9
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MKJ>+(V4,(59A.HI.%1MZ9KT"P1((OS)D'^+ 9_\ C"A^-1->'!O[T%Q-UPO
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MBJ3/)J6$84DE6+ +$DY2)%AQT!9+\L(B]ND>XT3Y)K[1I>LQA^!L3OV+2O\
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M #7^MI"U&/WYWX8O_(?^WT3-ZHUPC6J;'J%X^V,)C9?=HVI!(7BVS0*[:]4
M;$@G;MHV#1:"_P"2BVN[_&5ZN#B<Y0>K_7JZ\>*Q^_-]KY[1>EM?0/8RAX5,
MP^+:<3_]G9VFM<6MY&&U_-Y$]ZRL?2W?N;OY-CZH7Q5_[L^^5>U?KM=CG5=C
M)<201((I"-$]YOEN=K#D-^43&./E?LI^],"?.J=]C1E]R]A#W]C'\SP;]O2U
MZH(^-K]#)!$@B01((D$6$L@,C;)XM6\,74OY<!(MRQ@%5,0@U=4"43QA27ED
M6L)*0D-$122FO.!;4*@QJRJ2B)A]0%!+F3%)?F<L.*&18!OA<)CW99V&-S+:
M.E%>[ ?.3ME',T':W3P*BB.%!54-XFD]333H,Z@QBY@&NFJ4_P!K6'5*L(6B
M@6BNBDI=7T:UO7!5((OS)D&>I+"_TA0V2E_Y1-;DMOZ-R6N"XVQ%H:*]?:_,
MJQ^;@X=N[+>EP:_T06'KONE4;3?#:D]G]FOP\)04$_QA;VZ4UZI;\_4G^/5+
M9ZT%81-@XQZ(F>M;@X/>63DA_P VWGCO:O\ <E;KUY<$^""Y&;= MC?7<;Q>
MO004_@I;_1P?]73'$W79GOJ ["=IJ*S[=K?25V(AU SM$(ZY0C57=  (D.BT
MB%T+JS9&$-))1(6WBVO,3?(&O3H@6!%CRP+U_<31??\ S%7)&%*]Z/[?Z!OC
M]H9S_%8//<WGZC705+G'D%HD@B01((H3<D/--+?IP78^"=@7&MQO_-BA?M1C
M[&G+K8;^"J/\[8L_])_I@J#'RE>02")!$@BCZN-Y+F7O_N>W;EN;T\^\UY;G
MX]4;7V2?S?Q#M_JVD"?R&#!/I*Y\:O@W%SYL_P#LZ$K9V;-L]DIZMV6S7+@U
M3V<$OQ;(^/UVDF!G,6SJ@8BX>B2\0FR>K5KGZVV?K:Y[VN<]FY.>O;$D80B=
M4SJB;(DRJ)C-%QP;-6K7KU;."<ISURU2GLEKEV)[D+I0A&,)7$$Q$ 9"(T&I
M%95S=7V,[E2U:I_8]?,]N_K:RMN;>O/AEN[DY[-G@:'?G! A ]]L&F=L::YJ
MF;SFT$R[%#]^4/YY1/\ 4.U^@ QO(2S_ .:S?]Z2D?MIJLZ3TK] *Z8B)!%H
M+I3/.[,Q?2+>?N.GPEUX[5"]].?UC]5I>IQ)_.W '[1<_O+>-O\ \0HGW(3?
M<0,=9JLZ3TKS3[W5[\HW]8JKQ%QJ-;1.^9&.]M/G1\-"^_MQ6J^(= 63?E'B
MZ!/CK7<LGYYYGKVNV"WOEE)"P:3T,J&H:3QU?AQ*1V(HHK;!!6Y4;O:5YM77
M.MLJPGKD@TV6Y"SK522.CK"2YL0;)I:HB#FSQHF'/Q23!S@$P@QZ1Z@IBU!:
MIT3JI[=(]QHGR3?VA7K,8/@?$[]BTK_O.$5@ECVQQ'QYTC.(S=L04Y^W%=:R
M-Z4 ZXCE_P!V7"(L,.R-MK0M,@[";''<"RWA[BW 9R0W&>\+C*803D641JDR
MPQLU76;JKZB\E"?IX_N$9534Y$%4@B010 H&CLR@,YO#*+CH:S>QH;V8.3N:
MB!>MDW(/)=U5=2R)L-19Y.M.4902'(VW%ME*JDMN$V^:EX=+-$2+?FE%*5*D
MR "4A.VZ1EIK$ZJA?$U*0%H:/AHLDT]3:)DCF6$*_7H>?:].>0BZ#RU=4$="
M0S LJB:85K'E,DWB%/+CU1L[.=,Z*S=8(8 0)57GT&:=QELRN^+=7Q>"+"5Z
M-%%CQD47;12]]R,IKE%F<>4%-KA.+(E\U4HA]5)23E$T3F1%)52%-D:9%A>6
MU"4S#E^UIIJ_;02'X+!?2"='Y]JY ]\1<KY4@I 7#4$Z03H_/M7('OB+E?*D
M$@+AJ"=()T?GVKD#WQ%ROE2"0%PU!.D$:/S[5R![X>Y7RI!("X:@LGLK0XXH
MVY+$B;&=V339*IR:HHY$!-R(?U-!9,5W8NOI2)!\O-#3Y2<=[G<"^-R4ZJYG
MU4U.FJD&8809(<6B'K!5^=+!LGU6\L.^*>WZT%4Z6#9/JMY8=\4]OUH(G2PK
M)]5O+#OBGM^O!%TE+186%6$U11U2Z659Y,5T\ZE*9(?(I[S!.)RB6%)GB@TJ
M!*:IA&BHXP LJ:J:N0$JY&JF>J<B+IU:*#'>I35%J=R,IO%5:#0PE4]+(E\R
M&/!MINI320:!]0TJ)R2VTAI*.6Y"BC_8A #EG+!>3$K[U%PG3Z$P75$I;UP[
M:;[HTPQDP+9#+):,628Y++(KJ$EK*;@;!6$7K+ZG4%S2GK#L.F6WN7E!V&FF
MPP,EMD9(:;:,(5M&R"_MTJC'[JFY4]\4^?\ [L=GO_AKXRI.MCJ+I^"V+OQ1
M1-3S^(G2J,?NJ;E3WQ3Y_P#NP[_X:^,J3K8ZB>"V+OQ11-3S^(G2J,?NJ;E3
MWQ3Y_P#NP[_X:^,J3K8ZB>"V+OQ11-3S^(NBI:)3&Y7+4$U.X64ATJ$H(ZK0
M /D2^IATJ+?6"#@13<I4CTSY:FK:6G*1;7.=,C),&==-=$JJ*N-]AG"M(=-N
M'].?O'3UG(>.VBQDMLRB#!D&<+"%S4?%[ E%?.Z31L&49R_<M9;IZP&\MAJ!
M&4S%LB,"15:J</H?\7#*@M*HSVR>K47&X%YU+AN>1#[Y:I.)T*YQ?<*N8U&.
M1YJ5EE0.J)KE=(87-!D2808='(T4\E&P]AFAN&*-1<(TAPX=Y0=NF"QDL9;;
M3;4,I@F;;335=9E 0"XJ9BQB_A"DO*93<$T6DTI[D%X^>!X6VR[=LNF"U!X!
M[5VPRQ5,"<3$GYZ3YBWZ-LGN^(??QB.?PHQA^-J5_P#:_AKK>!>*OQ'0M3[^
M*G2?,6_1MD]WQ#[^,0\*,8?C:E?_ &OX:>!>*OQ'0M3[^*G2?,6_1MD]WQ#[
M^,0\*,8?C:E?_:_AIX%XJ_$="U/?XJZAC0W8GFQR)DT[<FAQTP14%3Q:\B'[
MR101;;*\S5:L+D35,N2/-9T.%$'Y*54N8E8UR$J!N5"A]6F8;PM3W.YZ;3W]
M(<9;+SN;SN>3EL1R6O:L,F+,3":[M Q<P%@ND;KP?@RC42D]S;==V=!YE]S>
M9);8]LVT(-9+,91E",(QHH&A*PR*@ %BZUDB$7+ !%BX5&0UP.0"  #I"!"I
ME,Y.?(AAT4T4ZYSGR-,I3G..^,;\9@ !AJF    1=2 $ /<K!):IK$'$QIII
MIK%W!Y::)::.2^F6B23[M:22OZ=)1PW_ ./LD^^'N!\<B^&&,_QU3-;K^$IX
MO\2_T=P?J??QDZ2CAQ_Q]DGWP]P/CGAZLX>&&,_QU3-;K^$GB_Q+_1W!^I]_
M&3I*.&__ !]DGWP]P/CD/##&?XZIFMU_"3Q?XE_H[@_4^_C*\;?:)'&JU3M
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MO0_KSF% V 8)*+]1;7HII$!!!J#$))X=L;?L D.7-"52'&K52JB:I$HII ,
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MYY]V7Z+VO[/I7QOKR]>&0WO6N2=B;EI/!W_,O.JN.?=E^B]K\/\ 'Z3N</\
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M@J6'</<V ;BR.*H3KLC,PBG,Q;[7 ^]!_J]:7K1("X:@IW-B,F'=LLADVPE
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M'$4SZ/2H,IGM1=="X5FII9@HH$^7A)884Q2ALJ-3375R!@*?[:,6SDLM-1A
M2SDR'I(/$M;A6DM42@TA^[.2\88@R8!H=T;:#MF (:C!MXRU P R9Q)@91V7
MH8$H!FZ9LX[$0XJK&* RTVL6ABRN9*C**F@@AWG$729($],)=",V<-,\C70H
M"*A<,H[3XU= 2L4!-@8EN;$!Y5<90B) FSVQ CF,K%K6\,--/,$,L2%+.52
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M@(@F,;ESTJDTIW2W5%;IPH;O<[LNJ4W1V"S2G]3>4TV673HLD1#&4S7&)RV
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MD%!;&JL1-<8Q!LLB184@LJ[#FL,[+-$,T38D%+#62*R!"H6S$;Y&KBB@EQF
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M)4- [@0/:E@7CVUMD"(BH&(%1(,X\3C CQPVRY+J@OJ*'C37='K+X4@NRT2
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MG%>R>C99+PO+<=\W+M%<>PUEG,L(=R;DM^USL3"B>]J1RX]J0W,$S58FGES
M",D*3B0#BW6EHJ((;,4FB):18H3"&<PKJUPCZZX6*96"J01((D$2")!$@B01
M((D$2")!$@B01((O&+EW@'CR]+^92*JMI4<8[:S?EVKQK;E9[FM2MK;@MVH.
MUQ+AYR-E:7B-[$1*,*+3.'SI X8K2$ZD$4E52=* "!#42+$B8(K$KO4;UZ5\
MBK+VDOQ9FU6,KMNXM,=8=X+=5;8/!AGR:2\%JNV"0G*+G%:!TZ452 8:^PS*
MRDK8--0AV;1<2T.G#2$+5'2Q+A62*X1!OUQ[5'49]82X1.]1?F505V$=LV[<
MJ$2N :44Y%99HNW)M!%9=L:WBV5]70CSD1FE0TK;)+7I3$0$F0&J%4#%*B;(
M'Z4Z96N%DZM!NKL,-<)+*131ZVT;UPU2\+,R&=[7N,#<DZ^4!PU38*R1:*ZX
MEW*%064BA%5DP5//A*"%E3<)"3BRKRP=/%1&TL@TF#))3 4B0[9M-:[#&T<5
MB+?WF9E^YW&,N-:8[G4%92,O!*MTJF55\5.&Y2FBF^> 5$"K:*FE&+KKI$P6
M:Y=(45 0!-H",IH8ZP46":2(3NAGOZ;XRD)"FU<NW[Q'7BK7>#?6S+8>2M;Q
M? (J1<05,?""7+FUEJF YUTU>+286- #G"(<JQ@0Q.2JIE*FJ=)7U(Y[E,)E
MTN01V.Q$;P#.9INX3L-*QT,F4;;)(UG:##F6S8TZ2R8E4U)JGRLR;%"D8DF*
M51>0M) W,$BQC7EEC>$L&$(:\;)+J12W\KI&J#*GS,5*L3G>!=TUTRHF @TX
M"5#2,EG4*FBFJ%<)M& %T0A2E#!FZBD1",95]ME:OYB7@ME<QM)[N9#T0UM
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M+6W)7+[&W#UNMYVY*W80;3-QUK([?;RJOE%PV IK!4@*IF"(-*&E*PP8@1
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MSTV44B7B@DJ*17>RYSM;UIZ2RV83THK;,)K7)37><;I?E95)O:PR3ME)92G
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M1-FDOJXEE$=/;[3J3EZSK)>@#.#<XCA0WLX%\1QG1#*:9.(;D06[4'0K TE
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MQ!"7]PCNKL*@(^)N,#>0#[50L?;.H[:54M715-!3;>-<FDJ"0OED@FN)IT@
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M;?D=0/N*E>X0(Q:K.D]*Z#?EM?K-=)5:B+%1K:)WS(QWMI\Z/AH7WBFOB9Z
MLFO*/%T!=RR?GGF>O:[8+>^.4D+!I/J0^2SI/J[6J1V(L5&/@QYJO2P]N%;;
MX'N.T9M>2QQ^I;&F^]L&_-F_MWBDXC!:Y>=/26OC%MK:0%J(&1SMN[8(-Z87
MIHK3R/M,4>;H-([[MSDRBW+MHFG6TAVON BHK@9#D;*@[F@XU02E/6BRHZVD
MOI!\B?)45E"(G-"%5\8P,=$9*7[!EJ648^(U@VGCFXW"\+)H3 3R-OG6[0U@
M%S.1(I,FQ!UM<!7DE"50%)35!#YPT 814J@ 0:810@5)T%P:"O;MH6B>F_4E
M*G&:TS5 R:;V(R"]<E;>);RO*[S5TT5HEFXDH;Q<LV@Y'=:=3;2TT$QX*Z,E
M)@BLHO9DIIFN5"12X0#RB4!&*1TSNAZ[;;:C)8ML+>:Z%S\3M%"JK-C7 V6N
M[;A6#755]*ER3CC#35<J'<-/(D^8+D*Q^\;@*NHDG)SD2%UP"*!J26XR%*@H
M&!"A@>HGWZQV*GL@JFYNP1:"G-*AHXR!PVGG,U<= #A T9(G"]=RV_RPN;)C
MB%C1<3D354I" #A"!"2E.?(UT54Z]<H(K4=NELT?2.VUA3:N6V.3Q<),G6,D
M-F=Y&FWI+1N55%-!.:VI#"$4VFJ555=1DP'713*B=,J*JJJ:9DCV@>VRU:F%
M].M8<PYE9M3E8<#Q*1D-8FO&,PK0AMM1\6SBZ3FEI2K,ER!Q92/$+FI;(2#H
MJ(%%=#'JKKDH4RH*1S'L(_=I6YQ72O:.$8L7%,YIXYE# H (@Y2=T&X/,L-7
M134*7F.$9F$-,$2=04Q0IS#$G3R5$^1G*"JO9@:1S ^ZCU;5N+;Y9V,>S]>2
ME)':C1;;]1E1?<*I,N.;Y@24TL/69.F:2A4T;$#!HJF&5+&#(G(@@"UT$6ZD
M$2")!$@B01((D$2")!%C1YVE9SV.!K9DN?0'>5 D73WTT#XS<>1 *GDYA@4K
M1#D:U @'5777-'6@E1$&G772931Z!!*:NW1Z:_H[)=LEEXX:,6J._9#UPT;3
MW-J3+1A[H[+#P6-A:#"N+>#,+/&:4\8?4+";MC(<87P8^:H.%'+(B6612G,"
M^<LEHM;EI3-(HC9)#QPV&F@;1#4;R6Y#KDO$:;TM@"?]R6&R4((%RR)6@.4^
M25FT.9*MEV"RG35,4XW3C<.5SJ##+-8U7RP:.;(H-*([FUN!Z:W;YIIY1"U'
M^P^ +UR*H,O67K(G%\! +6A_C1@-DBF.1C5@]CR:50';FAX>=.PS72: V\=T
M#"30():?4)[07K460Q@]LY38R R;DLFXA8T.TUT!0,)XE("ND&0#:2XD(S5*
M4^9%]MJQ<BNHAN6YS.J)Y42<Y5<C35*4YQUJ11*112 ^=ED-38;!9;=/!OG;
MU@M.WC.=AIH+=8)P]@G#C#QK!M,8?MN"&:316V'E&IU#;-3NFT"DL.J91'DC
M[2D.7;4C 25\QUUMT@B01((D$2")!$@B01((D$2")!$@B\LMFKN/M*TVESQ"
MUW2^0ZG<2\&1MOJ\;TE[7Z:CRQ9:-HK"-=19[F<3#=+D2K.FK>7'7$@NAI;N
M-6[DE&7;<,BM-BX2T7K%)DBQXK2 )3G&-]D3HJB%-)A*NNIR/7.59>K&-6W<
MAO+%&\4&<=<*$Z3*5('$C%D M,1;;1@TC')'2H8)ZF14>NHO28D7'E2.$)3(
MJ*S? 1&M;[052")!%ANX>0]B;2*H*'<^[UO& L&$ZE7!3':ZT=".B)=0HX%*
MC2 H&@!.8YC%C <C$Y2"Y( 67)?M*M12(C",^VQ=BW5_+)W>/GTNUMU6%<!1
M3"(:DHDFBYDI=,DD\8:DN$=, IYD>L(J*/52%0/5*0=5=5-,JISJEK*Q%ZRY
M!$@B01((D$2")!$@BU^=N5V,[#75-KO6_-J6HXD4V$GJR*OO=!2U)./#S!I
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MB@LI""2E2IK<I2E75*4I26E#<U3U:MO8V2U07$W7I$>UU6FM5/EPVW^ZB?\
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M-'C@O)[FL3:U92+4"6+2#+030$FT AMAGOL>):?36FIS9#-6P7'*P!"Y D4
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MJB@X%0])<>8A<,@$R;X>B(U77S6^<%5YU/V1GY2>(FS7_A0+'9\SO>S<EO\
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MKAEBH#M0"BD.FC<U(RL'4.GN!OG94U4TJ#=<2<*46T$_13773(XE'R@\Z*Q
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M@PJL592P5I[KWQ3FA<)JX[V#K7VR:9UQE$TG!+5IVJJ)0U9E%9ZDG# GR U
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M;;X'N.T9'R6>/I[>I;&F^]L&_-F_MWBDXC%:Y0)9>-(![9/.2\CDT?><]TW
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M +5%;5.78GP:M?M;+ WPQ@B$?A7!HKB"-V.#&>>4H>I=BA^_*'\\HG^H=K]
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MS&*MN\M4,D-MTNEKJC>(+8I@ DH'TZ1<-3, &#J86K/4$S!D(*5=(U8=9(+
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MH>LFWM=9V(6\?0]WZX]E^^YIB=]7N"J=#W?J>N4\[+]SE/9JG;3$[ZO<$44
M/['-QT+T5!A9398TTU#&!YRG7CI/^Z&C IH:>N>/VO54,,).FG<IIG*F6R4H
M+&$:X$V2^_T7S7]?&Z>/'&GRQ]?'/ZOT%8"X5Q$M';5*2>-T\=^-/EAZ^.?6
MV^9^ZT$AHJA5ISRK3QNGCOQI\L?7QS^K]!( =HZ)FP7+(=H=!+:FQEUF%>FW
M66F4R;<"VBFL+#143Y+&Q5(DCZZSW*Q5(4TEFL?IE3] C<=JX6#",2JH!,&
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M];1VJXGHLMGFR<CY3X>=#%CZO'Z8>%F&I_TSC,-S.9?]/$G@+B[P>D1^>/\
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M&A1Z3$$$?ECZP@BVJ2#%_!@(/<WLC'W=YUE:+IT(MNGDLDE]P9:Y/FE-/8[
MMV5&"2\:BX=#6MBW@VNT"DP0\?\ E=1DDC!T@&CLY<N/"ZQQ]=>K5V,/8GX
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M 9P?0!"!S:QM2!S:QM3II.,'H5S"[P#.#Z (0.;6-J0.;6-J=-)Q@]"N87>
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#%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g105292g11x00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g11x00.jpg
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M0QB)2 LHSR4-1;_T=)O'0;.67($E2&A@=*&MRV +A;*[,T C4!KNN:+V#NN
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M--4U$%9-/42R3SRR0RNDEFE>9))'N+;N>][G.<3J7$DJ]_&/7GY>0S]* ?\
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MY%6=B5/B)?,3XQZ\_+R&?I0#_MW&1_L7>"?(G(JSL2I\1+YB?&/7GY>0S]*
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MPP<*)*:).-]M-L8N[^"V;?19;EN;>,MF&I%[VN!J1Q6S&,X08M^,5PTP&5T
MF%=2F(S,%WP[S>Y-ZT$%T=\[0;D *TXIBX=GL'&ZU196Q&S6GK];,,0649>V
M$Q]'JKZ[!VN!7IY8T]%OHIZR!3?H^CWUW\_S=L9S.^BL\[V.T?XPYVV9_OF_
M6_\ %97.J>&Y:I_5"AR4+LE:_E=/EHWW(RU3MY:G=<$99BPW!%E]6-)7.33D
MRPVHK/((PI<XVF2K& RMVG$G,81;.)*WDRB E34"O'F[UFN<2*Y:*"47;95_
MJWT72VW&:(9;RQC.&EMWMZX.N&ENNH<00TB][&UU#L5PQA@#\1H&&I;$ZF#J
MRG::AM07-@= #(#*V9S'MB,>82%K@S,6FV5/>LUW:N S:.5Y++!R9A$(GNJU
M=1>3S%N-$6!$EIN!:%U1053# OB.,R+]ZRWQMHDB**.$'#EHP<.=*!40]=F>
MV.SWQVD<UA)8[(2 3J,Q !YR1TA6&XYA>65T]93T>ZJJJDM6SP4SGR4=0*65
M\8DE&>(S.8QCQJ3)&TAKGAIP/6J[/WAF+&TKB>[U[LF\6UGFL/D.T,V2'%&(
M,@KB48'9"938FB8T0\WP^\UJ4(,1Z^=';MNBI<WL>?=[QF\T&3.W/<@D#+?-
MJ 2--0"> *R^J% *KD1K:05@+0:3E,/*@7QNE8.3Y][=\3'R-&2[HV.>+M:2
M,"Y6LM.$3A$X1.$3A$X1.$4@GB45W!JROF Q^OHJ$AX0AU5ZF2Q\+ ,4A[-U
M)9?04%D,H.+HHXUU4)'3C]Z4)N=L>D=/7*RZF<[[YSS"H)'R0/<]Q>145+07
M&Y#6S/:T=QH  ', N/V)K*NNPFKFK*B6IE9C^T-.R29Y>YL%-B]5#!$"=0R*
M)C8V-X-:T <%'WS-78)PB<(G")PB<(G")PB<(G"++H'$MIW+P41UDD1B&QUW
MEIB2SPXG&H@(SA!9?UDZ=51<)C6F?0^APONBIC*ZJ*?D\N^,XI>_(QS\KWY1
M?*QN9Y[36CB5C5=3R2FFJ=Q4U.Z;FW%)$9ZF74#+%$"W.[6]LPT!-]%T_P!@
MNB%[]=RKP,;0B]D/ 8K4W-MJ4*$K-9UL+<1H7,Q3RQ2 8)HRB*!Z(E4Y,$5*
M+IIO@C,F1QLFW8+[XQH*V&< C-&";,WP$>\.8M(C!=U^5PRNMP-AQ*T.#;6X
M3C4;98C44+99-U2C%(XZ%U<\3R4TC:)DDQ=4F*HC,$HC!+)71LL2]M]')]?[
MY6ES: (TE;BL\>@=)4SA*=;3)27.XPI_T)&VC>H7)E<#O_\ N&$F6X_;_ XS
MR]OX<N??19+Y<^\9ES>QS7M?M7NML<8P@4[JPXIAPI&R\G=5&NIA3MG]I=/O
M=T)?_#+@_P#[JRISU.[)-H77=@:TM8;Z,VL]F+"!N!$8*FGQQQ B[,!)\>R!
M+9Z5'^HFWF!B6I-FS4>NFSSU--=)OLKFGE5/GD9OHPZ(-+[N#0T/!<W4V!N!
M?0FVE[76.W:'!'55;1]4Z-D^'MIG58DGCB9$*R)TT%I)'-C?GB;O"8W.#6N;
MF()LL-(T7=P<A'A1>G+4%E):<)QB*#2->RUB0DTD"O/9QF/1YFY$).#1P20S
MAB3$C4W+]@\SZJZ;I+_W'*Q-"0XB6(AH#G$2-(:TBX<X@Z C4$V!'!9+,6PN
M1DTD>)8?)'3Q1SU#V5E,]D$$K<\4TSFR%L44C"'QR/+6/:<S21JO+2BKO(.)
M*T84W:KUW"UR;:8M6E>2YRXB;D(T3?F6\E11$;J EQ#%5)Z32*:M5&#11-RZ
MU21WUWR,T(RDRQ@/L6$R-ZX$V!;KUUSH+7N=$=BV%,; Y^)X>QM4(W4SG5E,
MUM0V5Q9$Z F0"82/!;&8RX/<"UMR++-WO5"]PTXZ_5])H.]B<@[.L8 5IWX1
M*I,1TC$69(4XW$2BK]/+A%@W>/5VKEV@X\A 8.>LG;]DWP[0TWH%3"YD[VO#
MFTY>)<MR6F-N9PMI>P!L1H2" 38K%9M#A,M+C%9!5-J(<"?61XEN07/ADH83
M/4QAAREY:T.:UPZR1[7-8]V4E;0MOP^^Q55XC2@X9%KL;2B;SZLF:_7>1IW&
MLPLBL&0HI.H(<$19HM( \ECP@V+,.F3T0FGN*=>NMUU445]DK45=!+FN70EK
M&2'?MW0,<A(8\.<<I:X@@$.XZ+ PW;'!<0WX>^HPIU/2TE<YN-0]30^BKW2,
MI*N*2=XAE@FDBDC:YDA(>W*X D7TM7G6ZYK*?M$ L#DPX.Z>F!:DRD$<D@V$
MCBH1B:>O!).3:!G3!D3SO'R@Y%@IMZSN5;[L=TTU$ULI7GSQ1@W>TD '(US2
M\@D $-O<CK@2>%M5LZW&\,H6.=+5P/D:V*04T,\#ZI\<SXF,D9 96O<RTS'E
MXZW=G,"01?!W%76:TCT8ESJNIVVBDW(^QX9)W$1D",>EQ;TNZ'LN,&E!^HT^
M1],GNCZB*<NW/I=-T_1>?KG&*]['F<W>,S,%WMSMS,'&[A>[1;6Y 66VOH73
M3TS:VD=44K-[50-J83-31V!WD\0?GA98@YY&M;8@WU6<6YUQMVBHW5TDM6*/
MH7BW!,L,QF/GVA /+6+2&3$I!S&DFC95DQ) '6QD0Y58-W:7GO!BC5_IY$G&
MF.415$4SI6QN#]T6ASFD%I+VAXRN!(=H;&W W',L7#L;P[%IZ^##ZAE5U.DI
MXIYH7,DIWNJJ:.JB,$\;GLF;NI&A[FFS7AS#JTK1G+RVJ<(G")PB<(G")PB<
M(G")PB<(I!/$TKN#5=V@;Q6NXJ$AL<WZ_P#5:1;!8^Q2'CLG)9UQK*2R4KEL
MCC5/UTX?*$2Y%?R><Y?O7#C?.=U-LYPL/D?)3ETCB]V_J6W<;G*V>1K1?H#0
M .@"RX_86MJZ_ G5%;42U,_5C'H=[,\O?NJ?&:V""/,=<D4,;(V#@UC0!H%'
MWS-78+I#K_U@F_8IC:!F-RFLX1&:=C0*5S^6VK,T(1&0HF32T1!@>VY1PS>:
M;N"$H/"12"'F:YV7>HXQM_=>3F//4LIS&',D>Z5SFL;$S.XEK2\Z7!T:TGN
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MIB'#9R[=9HRQU*^-TSH[V=)5R3NW3<^9CVA[2TG,VXO>X7,2^A]B\DW4TU%
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M<0G")PB<(G")PB<(G"*,KPG_ ,&^ROSR^Z_]9BQ^;#$ORB/]5I/H\:[?;_\
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MZ<(G")PB<(G")PB<(G"*,KP__P"_;XH7Y^+[^KM0G,^L_$8?^J'Z1.NXVO\
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M6-%5AUGB;X4C%[,+ZBX.I$#$9(NW(O8I#CS#73IY@;GCSZD\VI7:/1RD>J=
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M9*@[FHJ(JJOK::KG:(;F.&>N:YU(#:7D[0Z8-D>T9:?[02<U*/ANE&(@E*9
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M6F:L>%"V]IULI<;<S5A(D*D3_;<@"9U2/GQQV.RHS(5I9-=GXD].NY'JQ:%
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M3B2$J>!YO,%GUC3Q?X=S1@?FJ?PN/II'TT23E/<ES]_OI_RZ NK.%"C*\/\
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M<->1'QLQ\<C6_P C(+@_.WHH?P;]C_1&KYL=IJJHV7VBJ=:ROH:>.JHL1DL
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MG;YXLN]>+KNUUEM_+JBHGJYY:FIE?-/,\OEED.9SW'G)Y@!8-:+-:T!K0&@
M?5F$81AF X918/@U%!AV%X= RFHJ*F9DA@A9<AK1<N<YSBZ265[G2S2N?+*]
M\CWO=E?+*V*LDBC,;F =Y'I;'PDH $4\HD <B%,#8=\EG[Z3P:20<LG*>?\
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MMY/+;2N?[KR?_0NNOO?<_P 41Y6W ,()%Z,>MO\ CJCC>WMRM#T7/1#)'_\
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M-_4WM:#0K6-.AS%<=GK0KA$:X.RN3-)16]:=::.OX1#1!C5:&94OFUL6ZJ+
MJ-Q3R-1A80^&MXU8/LO)XP4Y1H;Z$7[EW%O;!%QTC3N+N>SN[D>KB_376WXN
MY(:LD=5I*[AV53\2C$5)U*)A-D&"<Y<RR3%1P:/A1%C0,544@<FW#1".2"Q8
M-(#:S*+%-R214@$Z\U[7[?1W>>W/8]"Q/M/XC%9=2+<"UA8L&GQ$>1JB26L\
MFD:8($Q;5N! V<>:Q)LW3VSI\+SJ%5'6P,5(B$6^$KM\P:PE26NALP;Q8I#2
M>'3;YN/0.WVEJ[/BNUVR.0".F*O,:DY0^@+.39BUKTA/VD6^-BXA5'UU@.K$
M)Z3<SXBO+S0\A/8Y'66)-643WS(9,'U0=A42Y,IXBY%B>!YA<W^#GU"KNOWB
MEP^][7H:I/B)MN$&+\JB#6Z"*%M09H)'([:5<6/;U<ZR4K'G;X4V4.0"LRCD
MAZN177$20T#C:;0GNVEK^*D+;<X_Y6OWK_6M>RGQ32TKLB'T_155>9*)+V2C
M]2JR6P"$</!FU?#+FM"F+,E)")12?AI+$I6C)ZD/HPJ+S1Z%($@A8?*]AS]P
M%DL.'DRBUR>;Y2+@<.X3WNVLGLSO_9X:?]F:IA(.CF;VH6B:L'M.?S=&+!S,
MPS(HP,TI5]4MERBE#$OL ZB;5$0>:PBT=:;/RU<>%DLX@;[9(<1(!P.NO:^O
M7HUYQT%2%=>K1Q>%!4A=.$![;%NU#6UG>K"=BNXIOF>PT-*<H#%#HT.:4'HY
M*Y39*%Q LGNVU2W?CF3K*K9,H.A(Z"5N#A0G"*,IE_3*2/\ [LJ%?UIY_P V
M!_-3?Z0=]&8NW?\ [-X/VWJ_W#1+&^QOB5J=;+.O2&DJJ+6<PJB,%IUAM&'
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MB01+"B&PK 7%9NUSWU-^CCI<\ 1J+:]*N4=\*<#6\^@DACMR0)D C%@?#0+
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M=6EIR$BT4MFPH_5<<1GTG:QTN'A,4LNSG8"&,-)"^9"SIIKE9ZG[- D2(TI
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M'/ZY2?X>O;'A5];L>3R'K:^YY/\ ZS1K_!_[E\GTQU_L*;Q<GVJ@^@GL@?\
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M5I(^T,KHZ,6M&D19JNLV3.!<6..V0J6-)#&G&0CPV-1EXP'8<>&G(<W.CS3
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MK:_ GBL!FWBC=GC8:RV]<=3S<5F,*;-S<1;&7$@FPZ3,RG7R[K(%L9BP"0-
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MNEED\V"BDJ(S(QS1;>BSK@E\;6.$8XW<]CRYO3D>!<A=A@NQM=CN'NKZ.H@
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MG")PB<(N9^I?733JU4*M4IR_:<:J67<EB^W=P.(WMKM;=J2ZS=@_LS4R=QG
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MKFULP#K6X9@#;B+KSBIW?*:C=;O=;^7=;G>[G=[QV3=;\-GW>6V3?-$N6V\
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MY9AV4S13N-<V,4K-%1@AXL)%@#<&Q3,(N-'.C1UH39]?/7Y#-&N_7O8C"T-
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M8S2*/4;#!S<>4VNAE.077]-L]K5VWK4=J4GY&0(Q!-Y'&D<K:,.862$M<W?
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MF,>VO'=/.LX@BW*C:AC31^UDZDP;KIJE\ZI'U#D>DN'.J&Y+9OZFB>B,4*M
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M-W"NN==MB+YA9U"I)H_4C\NC1K06J70)["S8U][/5 '"T8-ZO<-W*F6OLJ1
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M<GA6/9_I'23'3U[RN_\ Y)Y[U=%GIZ?T?G.EDF^/*LIIIDB]%YQ#FSE1DI*
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M&BV6!)MLLQ=JM'S=!QNX8/$D"+"X[=E32U>.MHS/XV=6ESLLRC&!C_1WH==
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M38ZJ6S&54,K0+X(Z++HJ$OP/1W=>V>>ZO[7I)78 H/,0J22N,N63*NAVS'3
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M@.XK!7'3&FJGE824PC>;L-8T6:%X['R<Q)24(%4:5N;J_5BQ5DV"\AU%J 9
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MN=S[\P6#QOPZJ%C&(7NT+6:_>0>3R*9,"AN6,BQ4K(Y@%C3"7D3Q!T!V<O\
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MK^AHGAFSD:7JP900Q27*H.$F^VU[+=AL$U'2;!L>5,[3A=4<Y-)G&YQQ%%G
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M$][6F3QRDFEHPA3%L&T4X32W;OKW.CG^;3MK633L!WR:9 +J]>F190XP-E#
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M\\_XE?O)?J>H/^5G")\\_P")7[R7ZGJ#_E9PB?//^)7[R7ZGJ#_E9PB?//\
MB5^\E^IZ@_Y6<(GSS_B5^\E^IZ@_Y6<(GSS_ (E?O)?J>H/^5G")\\_XE?O)
M?J>H/^5G")\\_P")7[R7ZGJ#_E9PB?//^)7[R7ZGJ#_E9PB?//\ B5^\E^IZ
M@_Y6<(GSS_B5^\E^IZ@_Y6<(GSS_ (E?O)?J>H/^5G")\\_XE?O)?J>H/^5G
M")\\_P")7[R7ZGJ#_E9PB?//^)7[R7ZGJ#_E9PB?//\ B5^\E^IZ@_Y6<(GS
MS_B5^\E^IZ@_Y6<(GSS_ (E?O)?J>H/^5G")\\_XE?O)?J>H/^5G")\\_P")
M7[R7ZGJ#_E9PB?//^)7[R7ZGJ#_E9PB?//\ B5^\E^IZ@_Y6<(GSS_B5^\E^
MIZ@_Y6<(GSS_ (E?O)?J>H/^5G")\\_XE?O)?J>H/^5G")\\_P")7[R7ZGJ#
M_E9PB?//^)7[R7ZGJ#_E9PB?//\ B5^\E^IZ@_Y6<(GSS_B5^\E^IZ@_Y6<(
MGSS_ (E?O)?J>H/^5G")\\_XE?O)?J>H/^5G")\\_P")7[R7ZGJ#_E9PB?//
M^)7[R7ZGJ#_E9PB?//\ B5^\E^IZ@_Y6<(GSS_B5^\E^IZ@_Y6<(GSS_ (E?
MO)?J>H/^5G")\\_XE?O)?J>H/^5G"+C+O+XF_>"]:FCT1M2[?A3'AUB"9&S'
M_%M403T)EI&I<,;O/6XY 1#Y3T;$N10]75<[M=_6/2;H;+(H*)%6SB>Y]87_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g105292g14n52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g14n52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2,Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (QZ^B9 X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             &0@
M"=L          0                         !              G;   &
M0@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   &
M0@    !29VAT;&]N9P  "=L    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !D(     4F=H=&QO;F<
M  G;     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MNN9;LKQ'Y38DO!K !/MV?I7-=_620P/229_6\H3_ ,,=/^BKI;+=I:".#/\
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MJ K]$O:&>J1M]0Z5P7?GJQ&UFUK0UH$ #@ ?)"R2\!FROUR7 %LM&T=[/?\
MNHIB#[OR)(?_T>S-S?M%P9ETAYM>RMK\O(T>7;&L?3N:VO\ 2';Z3';/]!_-
MHV.^I[GMMRFG'=367&N^US^/LS'?I/\ !/>V[W?3ML_26(-V>RC(N MWGU'@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-$5T=8&T)$*1\1DS-D9B@K+!Q2924X5D=H/_Q  : 0$! 0$! 0$
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M\-?(^KE.>O8BZO$DV.$UZM>IXY\6JDL/#9K5_;.[(@Q=U[5>*MXY7X>N7_\
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M(8!Z9L->H1,DD=\;'?\ 2Q*_W%;Y&%"1=/=R3OIJQKI:/3ASH_\ C?A(T_\
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MBYJ.];&.G(I>KBR?IF :6L4JE_T@.TFVH#*#%/\ =_#DUN;'K'_VNN*M[O\
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M+JPG+7CX"$]+2\%K?T3P_P#6-&6MIQ\:?A>*36GH&G^//2U)PELU38LOV_\
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MAI:9J:TR6KJ&G#?.6PJP>L9XW[Z]NGIW^O3IR'3#^G)Z\=?R_7G&H3^=:?\
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ME:<*I>O?E?W]_P"<I(X&(G>N&E%II!XH=K5\B<9(&[MT7']$U*D.#GLLE+J
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M?-?./E?61HI?%\UQHZM!A;^7%-=ZK^+^.3<\UY242,B*A(-KYN>;E$DCQN+
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MP+:T6Z&FE>_+PJEBY*S!0$Y++.2>'Y5' [# 3C7/"=*OW]>"[.1XS$B(M1G
M2+&,TD@D45(PLE%W12!P@;O[LWSVU[;O[STFD[.+": ,N>Q8*!@:*OPDQ<)A
M3:CB<5F&7:]F]!*.ND %F]1QB($L(*MF*OB4)\1>OV)TZYE&*Q1$41$1.$1Y
M$>*:?4,O/IDQ/5_GLM_W,1_^HETQCCIC#IC#IC#IC#IC*MN[-U\B8:] .;@
M6"[_ '8P"91-D(1\C&:YGHU(A8S*QEA%->LW2@L=3K\R8R729,:-J8S7[]2O
M,YKGY^EY:44%#JUP7=6]KI^CZ9#\.[#MGDJ17X][:MSI3.."!%:Q<@N4$C=+
M7K7(@^,G%OG'G.6C<ID(KGE\.E'7*9".WE3M5YY&2GTZ],T%TQD?96Q931\!
M9L/B%P;:+! %6Z9OUA]>T=9"M0$O!JLEF2/BP4.&K](4)H0^?:OD+=>I5BEF
MEPPY8RIS7=%VZ+LCO"<W7K<9/K<A0%/4%IJ%86%DD3N7AU.B2@XL92X6<R(H
ML.EBBPERJD YBC:X@M"2,59BGT^SKEW4;U(G2IDAMNJ0'$*M>]0OTK$5JE>I
M6XL)ZMNI:@SD@LU;,$D<U>Q#GG%-%GA)'GEAEQSRQG5TQATQB9@_F>]_H1_[
M>+IC'/3&):S$"N'RRM5*TIV,","&3(:.;'(@-%,E@W5 D+=?C^7%5+65L]#1
MER_DSR";V./UP9^2UQ?94^E7QU[GQ[='-,4C&?&V4I1/-&[@097&]P5.-20C
M)LBK&0.NIF<.F,C]%K62=V@.&GQ!&X4%73HV&A?K7.;P<;=IC;Y*KG6DECGI
MU"!"G3GGCSRPPL6(XN>?/YYXXM-730@O86Z+]6FO6GTS1";&4R,F$91A*9%V
MQG,FPC*542F:<V,5N1":"1:D'4S.)2S$#!6E^B8*4QUMJ-<KJY7M2\1RF3F(
M8NPY"Z&//USW. @ T4YBQ^OBF,MR_P#1BYZ906T[%O)TL/GRG!;WZ#G!;>$Z
M@8%K]MF"0G#3-*F#!/)&MF0M-D"9?V)*N<58Y,Y8C."&,O-_(^?&*SRO0>*X
MQ\TY(99+3S[%_*ZX]>7M[O0<I"22D'$8[VTC<6<=.XBC/SR"H$D"4DVQDDIZ
MF9PZ8Q;0,BBLY>J.(5;M@"2X#&H:TN,L@PKR-'&.!]S''GGF&UR++C+WHL_)
MEZM>K2>3R28]*>..O)[EI9\Q/B.:8RB191D$X[H*(3B2E!E%>)1)QE&RS=&4
M>HAPM36MHZ\5;&\T/7EP)6];*&"<^->G4AYDC@BXRSR\N4DUFQ+#4IU8<9+-
MVY/!3J0S69X8LW7(#) ZJ!:!:T6M!\5 [XYJV8;E:O<KY99U[4$-F#/*.2++
M*&>/&6++**;".6/++#+'GF.7#"3#GGG'/#'+CGC@E*>G&$8K%JQ1I$L::11/
M<4>HUGOZ9,.F,4!O^KV__%S/^\K/_']/_E^+B'?XOW]U\^JQOU<8=,8=,8=,
M8=,8=,8=,8G&?]<8/_&(O]Q!>F,<=,8=,8=,8E&_SDP_^(4_]S#>H=_C^Q]\
M?K>,==7&'3&'3&'3&1)H_'0_LM_XUNF,S5N+>;?KLBFHB$)5)#9/66W]T,+(
M\\.%L  U[IHH@BV* >O(00VV-#08*;-7H!] 57QQ&BZQDM+&5OPAUPZRA\^0
MXZ\W[/IB%B[ZM7TJ25,O46$UP[-5D)0+X#AV*]7#KN_-":(:V&S/;8!A'@;F
M9[@5$@O9UZ-J_8&XWR%\37RH<CK6@.\JXOHO.U0Z'5 6Z+LL'.L-."N_5(GX
M<I#&$Y+/\+4G"%) J6I".E.=I#?OB:D8IE;8?23(8[DJSM.O7<)K6X)U2RHI
M6:YK&%L.H6QUYE:L]HV%*SM+ S92J:X'H'L@X(<1VD)&V['+'KH7:A]7XG''
MK]\=.O?JG)T1S#$VQIN3NOK1T"%,3S\*I*44E$*D2,T/M?NRU_J7:*YJ @O/
M#4YL(U2+25D^@O7(0%!_;2B*CVC$!AG"&;55A: 9NE-;5P[)64QP@BS/<JLK
M5^364_+[]LR%H6 M,FZ/5:%X.4!:.!:%!8[PEX%VL:V[HG+7C<#H;$5%%GK:
MYJL.K[+C#[6KV;-6I";1Y^5EIGFQ#06"],>*,^U1 1'Z;V6JDH"0@<RH;D&P
M6E$4/4-U-=2T/5ZMG:$W)#N]?;FBC6JPA!6P3BTMVJWK6.1==IC@A,08MPV\
M<9:UR_5,8YSUO,PQA\W''S,<_/XXK_WS?/M[?7XXEM-NT3RFZY$KES:5&.T[
M$7<E+N;HQULWOS<-9.YFOEKU2;T=CW.;[<].P#&8L&=3&VA$2(LU+KAZR'*A
MA^M2>Y6^75IIJ&1RW4@CBO7+ =EY8<ZHJ9*]ZXOY=?7T[=<G^M^[1UN;=?-/
M;.64BM:U$,W(7V,[H1<Y?7_4-=)G:\\@I X@O2P)5K!6CW#'092E<O7,H"VK
MRTU2;+$IS1%,5W^'7CEO\N.N9TV3]([LW5H9;)NZ%KE7QV<@:^V^GV*\^S-A
M<ZQU\UU7UH-Q[A H2J08"10#KG7+.W2%T>K(!PE7W.K-EX"G3MA=E YL>B%(
M>;@Y7BK>ASV]\^FB0R;%:=-*S<=21:+M=@UP(8">O#9^:\%5'TFN0$+"F791
M@R2S8&!SLV0L@8HAY;.56":U7'23>;7R9GO[>N875>^#9IS)1GEU^BVPD1_5
M-1N/C3A^O5?$[?W=0T]K^F]AZ<@O4,^/ #V2M-M>SBR7+<%Y.+KU0 4(1&JS
M%@^.6CW[\5Z \_I\NG6O=QWT;"MC5PECJ=: SC&O;E7:H JX7BM\8MZP[NH.
MU/BDDDQ06$>;;;\\E]UL<6HXP\$XNDI59+>+/7: U^'/WS\OVS4B(H*@%-<+
M5KT&KNA+KEY$=+;WW,]Z[T ;W"K)XL0?!02WI47:]N6H8)S<37!B^DA:Z!9;
M("3WL=KR6DY)'42EO"6^V4;'$!0I7A5B<_/,AS_'Z\UQW_CJ4H4[P']&V \)
MVU-;5TZQ9+( 31X:6$I+GL#)\VKI?2'!^PZ5;1 %D%6MF[P4!3'7A##BL R[
M 6%0&:W-C*M2N[W.G*'=JR_;GXI9FHQ@L=TI$6028Q),8=9)&4H$I!S&+* H
MC(L<L##NI(##&P:CDAQ+@Y&[N]==K_$U9AC-WB5/;:7JHKKYURBKCZ]6I.8;
M-P*(J\ XM6?!PLUJ_.3GOU9!_"CU[64=[.&ZZ%\E\E=.<I&%2N2OX9*&PN+/
M='=&;)BA&'XEL25ZD8Q!A)F1_<'<INA'*I%10TUP3O;4T[LQC1]?-V5D,]5-
MN(J"8?!>NC9P+?/:T)'&&(?@)A2%UMLM&=,>W.@RZ35D\[/2=K]_;^;]>U>_
MIG:;=U\[J3C@0I/-N>;'R@>7S*T?JKWR:P5M&V-E;58@H9P"YLX<XF>K2I5K
M-U7MIFM/9I]?AS+9"A=WA_%9+-LP5:>5:KC#=<+!^!%@D/POT]?U^^OMACSP
M-- IU0&70]QKJ"7SGJ[;>ZETWPRZLRY7M>RI.TNUQ2[A+%E):"[(8UB19ZR)
M6#J[I>F%4P5WAU8R>VQBAD.YJ7(Z>E#]R_%9LDK0]<GW]>F246*B(\/)5B6/
M/9$3LC8UUVB?_FN;_7T/]X5>F3,=[?[S0FHVMRIDU@L03M:L'*Z[G!<-.Z3A
M)B^VG:/= QT1XRX:"^=E"A*"G"$NQ9D82!QAOBK\ BO2Q,8T!#FFZI.*XILO
MWL0HJKM#I&$)1'\3;-E3&4);=JQ(RC..Y46>^+&.V,8[):DI,(<Y;O<%SU=K
MAE+4&T;FQ-.J#DS;'7#7&MJ8_6. .D?F5;CP7J;.LT"HMXS7K]P-#K&X^G81
M=2WF;%@[\>%+-0//(+R66'HI9?:X\6688PCJ(S-33C)\^FSB:L8J7INII;X[
MP\CJ:0QL9P.3&-WOAUN%'C8RBV\D&<@<K)5,"O# ,F1Y^M2Z-%CUP#9+M(NE
M%BP,G<$A PA%@O!A=>7DQ=8R ,2,Y)6)]_?WW^.9KB[+XXYM/-;TJH[>;;Y*
M'FJ96/I&JT=0_,_:@?(2@D,5.X*J;$BWS,0T$S]V$1R[;OF=GT%Z;@,H]L!R
M0C2IE<K4K/#>J@/:$63!6\M4?^T>B_\ +J=O[.LJN/8$W)SG=T=+MXG1_LU&
MD\2K/3=I 3PQYM>M^C9LA"48ZVKIS)!I;2/=KKO?S[LY!1@K=#9U=Q)R4/&H
M5>(,6]"\OVNYN*-,4U%VH++[2:V9LJ=-Z6D\@9!X#V0'4) B54AGG//7%V=:
MKF^EWTKV>;'J=,IQ>^D(U[#I/7>S'A9;,3[0*UW3-@D\8+N5(G9T[5>.Z^<<
M"G.,HSTH6%-@O"*=TG:JS^T/JE&UAA1SF,Q:8_\ R.CQ4KXEMKB*6]>M5WW<
M9U-*+UU]**P9$9&LNXU?PS3=NC*.]C_O7?X?X8CJ&K6D\EWO]POG%);4M";:
MF936T"2%95&"QJ*F;.P+!K=Z,\<)5X=N"\J<F5+8^E2H"YPY,:N)*#[4)=;O
M':=F"?%1R*=%'D!+J_*KN#BJ/,+(IJD-(E*,M6$KA-AJ1=6,(SC)8[HOAY3F
M:L8IIQC& 2U=.6IJ:9#4B,:OTC^CR9 8/!+&S&+-D5M3M*=*%IH%GAJ_# U:
M'30"WA5EV)7))[<&-=R&J\F8!LRDC6: DQ,=H9% V%.]>D04&1$>LI;J/CMC
M*7T'K\<FEI1U-2$)Z^EH1E>[5U37=/2HD^<T-'6U6]M'X6GJ<I=>;;O>C8FM
MTJ=JQ1M#)[-6O8G&W<Z4ET?--#A)+1MR#;9 =):J9Y95[&="_=I92QYY5;=F
M#F.;.?G]^^<DI01!02Z:[E@T]2P?4'C*RV4QE5!6V*UARB2!LK:U0.6C^QKI
M >D+X87G?NL)]CLB\>;OJ 0!"2*<P134<+<U2*I8*"JT\Q*JR94>I>X)_=VW
M2:B\:CRU[:VIVQWMZDY+C!+.27FT*5U0,8->RK=L,/*U, _X4*F<Y(WD-)^N
M5I1DP&M-5LS95KUOG\O\_EFD"-[K=U47P<\O%<]J7HWVRKF[OX +#\2&0ZW;
MR^OA8':L-%EC*ZO!E-BONK=UH.D#R[K2DX[16(;L AP8V4/>B;^%$NP$@$&6
MOZ3;1NUK%MQ77GY\5Z\=^U/'-Y0CMZ^=D5YD(QI7='8WO6.UC,V[9$H.Z+'J
M)?2,Z-J+D3*+7MFL=7PR@?)PC@ZD(P5U8R)TRQ@6]T-N;NJJ:6I'%?>R2RTF
M)I8A(NN+K-6!6P-)+!,?%/O[K]LA%6E#FK;HZ^@O9Z"^@YO>.3"6..6/+'..
M7#&3#/'+'/'+#/'C+'+'/#G+#+'+'GCGC+#++'+CGCG'GGCGCGIF<_?3&90W
MGJ1WW,M:@6EF\OA@2]LW6^R68Z4.,U<G0XUP\+3;4J"D\50F67SDU0&G!$5)
MWOTAB@PVUG9 .*TV)@+*N.#Y=^OWZY1J_<KH/<>%Y.G4Y2XO"YB(=]'9N:N'
M'TK;]K#.WGVK9]BICFI3:(:<>C<U)'5Y=LB8\J>4G&WI9%,@3@2IO0JM& S2
M#>W%W@%D4,,N[]=WP;_/CX?ESH3N5[1MC[HV:2;U=W7EZH51EE:$,I*8_P .
MVK+*U7VKBPT-?PCJ^8[,'NN-^7@FS)LR8.[&#3H.):S;8]FL5"C2<I3=G4]S
MDY.W)SW,NG+;.$MTH;9QEO@7.-([H>:'FC5Q\\>:+CRYT=Q'9R:V#IG2^O-0
MGJ&O36F399A V!C7L#75*!H/:JV+KW)[KL&M;E)JF95UDV%9V/C7O2SU7DG6
M*"&>Y4D8[#"/6]7E]^>GW7/;(R9+*2R6K9-K55:W? '/0^%944?8YO(-L%&V
M:*?-8G6+1COO%BU;7/U60;1?J/<6R;J//$^U.1@V[X"75<-NU(EJ%9KL% W;
M5B5R[(O1.?-)7F2^ON!Z]*Z=^V?1K4.OX-3:GUAJNJ2F,UM::[2M?UR]F'&O
M8*P)JT,7(B4\&,DN,$UZ,;C:EAQEEQCSERPXDSXQ\[ED>5?7+#Z8PZ8Q,P?S
M/>_T(_\ ;Q=,9\[]O]E6Q=F;?>72H\+ H&VMHAFX/2RLW+[.FU4#7:/<[>",
M-;# 9CJ#@^H&]Q5LZI?+&38!_C#E0J6?&FDY1]TX>3KW^'7H]>/7IFXRVHDI
M02,C='K:-'6/$KVRYXBK4O[6LW+LEW*JCV6'5;17J%6QN K* 34<N1&6F-=F
MMV]T\C'Z6B3)!QLZHA=LW<Q?7T@,'DFE7]AH*?P 6R0Z 3R+'?FO;GGGIQ\G
MT]QK*(DUFBA<>:U"Q1D7SO(RJ12"[B1$EJ+<_;.RN[BKDTZVGP+X74Q/5RUF
MSR%_'=#'9[''ANZM,X5AQ:E:V)4&<UQ6>)*PL7HHP ',<X4JDAT:6F9&E;1I
MZ=>1.7T;J1W%O,X+GT?;U%9\6*L6NE?D==Y-HR,F<-9!,U<UU;W:QS$V)5@O
M -LTSQWC16R&0X1JB!5V,WNEC'RVC>9%P9VZCPEI=6'1.>O)T:HKNME<[C*)
M&46>I E*&Z,8DHSB;U9?[D+E&6S;%$;E+?!B$VJW]'S?'Y:G"7(=3"D37-8H
MJ,RPN!K> K;*9QMQ;V ,L. 'P06)\0*A:#"+8EV_DQB,;AR[C@6*4"9##B[G
M_P!I6C?QEU[])'5[]$<OXTUMUM96.I=R5):C(F6SY-2+_N209,I#%JV(6NP?
MN,F0QFO.-VKN8X0+UY?L')[[7:+.1E7T]VXZS;45DHF!1L1@@ODVC&CD\4)0
M-LI(/MDM 72".0<C6<:2"GF5/$40E&UYJ0CR\#QVE?.;-33BQE<]:.G.HZ&K
M&4='4T34=0A-TO$1U($V4MT-*46+)E#6).XGVM>QMU2=M:8>"%Y%,AM;,,39
M5MF#)@^ZZXJSH^\%DUJ+5MB)'6%R#5Q YM@<Q4(1HC7=4+37X%:!0M!!"?"N
M9450(W_Q+H/_ -F3]5SGJSAJ3G..E#0))MT='\1TH'<):VKJZM%%;YS559%
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M+JZNN\Q9&G/1X/+*3*H[B[6K&X9](*6.^:[#AL^G991QT@U9)<9UBJ#V@Q4
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M58PQ$Z0V@PM89/K+ ZP!A7GR#E]?IRO!V[^JX97TC&/*\;NB41\TI>6)8/\
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M$S&2WIC#IC$S!_,][_0C_P!O%TQE7Y]P^G<'D]K7EU'\O*L\+&O&-<Q@N\D
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M#SV.9'"U;?'H]]0AI-_B3U(5"=;-*.HNJ<:<$=;3K3DL=^H,I0%8Z6I02^J
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MJ_SBDX$$QC)LL*%?'+B:EQY>,/)SY,KU;'+C\?\ 3CSSQS_GXY\G3%?'ZO\
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MA,6,4W4Q$Y[H>^?MXN <FD>KNTRU=7)SZF>+#5%)%N]@;;UP/85@'9V&[*'
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M"-4@Q54D0:!I-0&L,8!*U94Q!U;%D:8-DX('Z!(M?P_QZ^GO^?:^G&>:2+P
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M,V,I0C(+\TB)EC:B1>U4-L-;VCJM]2B]NTGW]/ZV'A'!8/CJU/8!8MW M5
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M^O3.:(TB-72(TEC\$YOTYRPH=U:NMF$<(,=5\S:V+Q0]D)P96@9I%>32>P;
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M:U8P[;FQ%9]:AKDUX?>]8%T:^O@2S/Q)CS<]G^;$%6W6N<PW(;;^OY]<NZ2
MJA="J&[K1VOJUU>N9^8?H^=%N8YZ%NQC<;+68A#H!1,N+Y)9LZ=$/9;:1LQ6
M2K28*7)B^>%S;S30K2/V3=AFM5 2_>ANUJY>4W,EU];_ (^F;W%61X<6-$5*
MK#G5%T*8ZMG=HG"%S.O1KQUH<K=^]'8NW;.4<6/,]NY//:LR\YS6)I)<\\\G
MWZ?IA;5:M5: .>>  #T  Z &=_C5?W,Q\F)?LW3)AXU7]S,?)B7[-TQAXU7]
MS,?)B7[-TQAXU7]S,?)B7[-TQAXU7]S,?)B7[-TQAXU7]S,?)B7[-TQAXU7]
MS,?)B7[-TQAXU7]S,?)B7[-TQAXU7]S,?)B7[-TQAXU7]S,?)B7[-TQAXU7]
MS,?)B7[-TQBDX8@D&S8\5"N//,U+GRYB".&/\F]6R^O+*OCQQSSY/)QQSS]>
M7/&/''///'',?O[^_EC,@NW9UKE[V :=B[3M2(>7V.*V_@EU! ?$"/V30%ZT
M7;C!!>G4)F2S4*+.K0P>8!?-VP]?DPPWZU;"W("R 7%_?[?7G)QO;MY5M]-^
MK6X^S;'"9:I80#2& B@E"\OW3ZOL5 V8",V![$M&.*!JH9U[0"YG0L@TWDHG
M6I?K$*D9J6Q&]?NOOZ?.JT2HD;1W%"[KCR-E(6@E2)1I6MQ%(/GV?(42UJE0
M&MVT1B]K#5VK]324H08:?-O7=/N"H\I%LU9M*4LU M5/*N&9&<!D*K$JA6_7
MEJ8<QT9:C\OOWR+:H$;5HNB^Q:M'0M7W7G"QV>:]Y#;2$C6S:HK+;#6):F*S
M *&V(LO"]X[0WM(M61MM6E&FT\P=VPQK1Y=/5B5$NHQ4QMO&2?,A;O,I+D=H
MUZ[N> II*JNL:>>O2LVO'T>DX5<UVOZ3;6>SPKVTZB1YV(1MKH?)?3]2ZHT[
M!7.AD'4\US9ZL<7-(ZUNN^GB+ A)SF6 Y6LC8#SQ^(I]]/W[=OSY]5G*K?8
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MX[$,/Q#9J[!RZFJ99Z&UM4>6;'T/';=?M9ZS*6-@SYZ],9,7;@'*BCQ&H[W
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MK.LCT>1H#@U+TY) ?A>PPH]I5I"(?%G42IE5H#&U;\8$9GENV4%1E1LEO"[
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MSDH:*YU]251^(P:.7S?SQ??IW^=O/Y]/US3>Q^TY4V7N.#;ITE3GGKQ:<AP
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M7?'I]\9'G/Z/5GR7&NLJ;*CS<=I'E>1G:! 7A XUU+=WGO[9>S6_5V$1AIL
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M]3KR#3Q=T5QA$5$!-%ZB&K:YK-W&"ZVY"8PL<I8'0$+T^N54H%#RL$LRN"I
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MO[ISZGT_SC%(*(YR''<QWQ6.'JV'FXYB+<F7''^;+/$W'QES^/Z^,,>/ZO\
M.Y]OI[?'U_CWQC;T)_XB'^37?W]TY]OI_G&'H3WQ$1\FN_OWISZGT?YQGCT)
M_P"(A_DUW\?S[^[^_J\_9V^OY_EC//,)_P#H(A__ ##7>?\ ]_<=3GO7TK]W
M&'H3_P 1#_)KO[^_L_XY^IS[?3_/Q^SEAZ$_\1#_ ":[^_NG/M]/\XP]"?\
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M;QYPQ]'SACSCEE)SSGCEGY_&.7$>%Y^S_/P^^C&WH3_Q$1\FN_O[J<^I]/\
M.,/0GOB(CY-=_?W3GU/I]._W[8P]"?\ B(CY-=_'\^_N_OZ<^I].WU_/\L8G
M'1&_$#WFWQ7&7%ZIQ)SD(MY8Y9>$#N<<L,>#>/,>/&'../..64G/.7'.?&?'
M&7&&+GFJZ^GL>_PY_+&./0G_ (B'^37?W]TY]OI_G&'H3_Q$/\FN_P";_P >
M_P _]WU?U].?;Z>_Q]/SY]L8>A/_ !$1\FN_C^??W?W].?4^G;Z_G^6,\>A/
M_$0_R:[^+Y]_?_=U>?L[_7\OSQD</8$L)*?-VU1GCYPM<88U:$]3/'/RU?+S
MGG,1NXYX^3R\>;QAASQSY.?.YX^KEC(2Z:YL;!J:<NP%JXK#6^UA&R;6-BMG
M8\3JB S>%D%PY831<59YLV*.QC:DXECPPJYX919<R8Y8,HU?N)]<Q2@?1ZDQ
MVV[K]LQEUL\JY/<H?<)Q'KZZI"UYH9 JEW;*W#,86(,85+%J*1]P6NK5N_D'
MO7/3:;%WR9EA/6J9L?;*XODY^M\5U*#AZ-N=&42$2#J$F#'5M-K_ +FZ)&N6
M&V,+C(XF,A1"-<%OHW]@U0FK12ZT:O C=):T+Z^4L->(O"8Z7ZU\/M%:8S%1
MH&WUTM29=F GP#?-TK#A36@C:H6;M.22=TOLB^N[M>JEM\J6ORZO5XR;F:DY
MRYFRN2RB2FFZ<RI*T7)C%E*@IHQ?V_\ 89LR%*I3N8Y:U44P>4-J(@R"X@<6
MY"&L>Y'4>^A;(&7=0%9-9H58P*571"]G %XKG!'PN-]TKX@99@D95555ZJVO
MQ]<C.;*<F4EG9.3)6=\K)>96A+GN#VR\]6]CCVC]NW<?I,EM)<'E-[9XEH&1
M&4<5<($9K2 KIK63G3P\@,-7%/Q)4X8V0"L1KM>&FSF5FG9SSHP,A!?(]>[?
M(OO[?KEW1)PD1W;6+*.IR21MBU2P>G+=6+TR7]N_9C!HC9J_L8>/UE%/)J\P
M@L(\4&O<VU7.78S@_CL-8%;,%?@,L%)G.]795N 8"$\D*>)451AR(VJD-E(D
MKMVV'$>(V5V?F_%/>^FMKQUIZDS2CH$XQK2T+CI$C9N6+;4DE(&2DF/+2L 0
M^R'8Z+NZYNG)^0B%K\-%?<,RZ$2<5V)GOQI_=HA$B)"B)N@@5-O-*O<DN5;!
M;T$]@C-J<9@S'C-E@G.AYUK\_OGM7[9RLEM+3@C*4E0Y JAEM(D> 6[HJC-+
M;8UGN7=.I%+6QX_KE7@>%L.#[CH*(9D(RW:ESA;LO(75ES)@@BH#S5.JY*47
MM15,RQC&(:<RLR3+]L.R&N:YYX>EG/;WX[\?HD0C*9!9A-(3YB2@,@DP3<,O
M+(\PQ+$5&,/W1V<B-X[(?]A,3HQB+134FO$'6\"X?:PU5(<]?MNRGT5L8X'"
ML0D,\W@[JU(S0N!6&M8'"C6NA=_''FQ8YDBF9OIQWY]STOKZ_7,H#_HPKE->
M0U_QK5MJA'?H$]DC3:F2/"8C\+WJ:X?=]8BH9@0!<>FW5&KH]:7F*9>A*CIR
MMQI\2+&#3Q*Y7CGKT*Y.O%WQTZU\NN;6%RV[SRQV_P!IY_+NW4?V7OVTW_;?
M?/84^C4=2& 2A^$36=BL(3W2I1.%M>DB!]9:7?3>^DLN.3*OCD 4)KVUM;=U
MG;AD5%7P*,<@D6KE+7(Y?!3PK3I9R/7N/"^Y@U)1*C*4?-&7$D-T'R2XZRB6
M#VM3E<V7HWMD :B/M3O$M:QIMUU51TA"IJBW@-$ZV2%1'#5+J.OWI*_!&N ,
M[(D<&XC(/JB\BM8L*\5I620O&QS/AT[9B56[;VVU?6KXNN+JAKCC,;$/HX=H
MQSM!3#=R5L<AL&XONFR@VWM;UR20V[8C7.XP87:"ZRN7!5<ZM@6+<R0RZZ46
M_-DS 5-0*:SXY'B%3S:C2N?3\_;G]>.EYHE&^1JD\KS[=;[]?47OCQ*^C>.*
M!%8FQ?E&>)"+)-407KJQ2LU/Z$L;WT+MD:G[.+<EY.+8_7"?HD5J?58VCA8$
M#0A<J6(5,;!"U1Y<=[Z/UYKY=+^>-PO-G$N@/.U#CR]6MS?!S309RJ_T;1T)
M@OD"CJG,3[!OE-VBW[+/+TIP@X!D0JSW*%HRD$*O*2<>V(9L79PD@Q--(^?6
M+[0!95APCM:[2QPUQ[]']_\ 'YX6%<$B7%\E?\QIK=TV<+R[[ZE;A[6M+7M"
MZB!H!N!#LM%'&MRUN*."NA)]FGZ@D8(O;+>I"EH@7,[$<\QOC#67*E3%R6Y8
MPJYER>-3&]8GV_XS+357TYNNMM55<57SOM1FB^F3#IC$Q_\ FN;_ %]#_>%7
MIC/GX_\ >>[:KVGLCEH4U]@TPD[I(:3\.4*17+;]6<%V<A.[L[L#C@@>]G6H
M+2"RL0"VJ#A@(W2@H4C%(F?M3Y@\GW]_E]N:HHJ[JVTK^Y.."N*ZKW;Y E=K
MO_UW&<LA:6M]J$H[=\4*13&$>NQ8C;%XWW$#>VJAEK.<_L(1,SBN',P'8")^
M*O %#)!M>.E[U*5D7J)2A:>8+[MT<6W0O'3@;>EYHTQG&+J0B28;M1-39I[H
MDI,PTW4K3M)[(35C+\,U"EATGTEB!"-&\R:*[A9FTX/ 'E_7@D%KMD;C:N<H
M;.L\L-+A:V48!85J!#4+F!G'VS5<S,5X Y5AT@PQR1I*Z<G/Y<]&_K?2GK=A
M&'2I1;NPW>1))4KB%H$C:R*D%[KB2^CW]I98Z%6 ^G]T76%W9G-3U8)L4M=A
M;>RBVMW9[2=@XCHSNQ!N2?$I6->'S%^+9>*60MB<:\(F@0.29!L%=.3GX\?'
MC]+QL/)YXU(&3Y_]NU*GY.6@G_M[S;(YW;HG8E]]BGLC--F1-1;</"-@OB/K
MI1-9_@S$U"1]V[:,.Z[B::J5V/5)CQ2UJR3'%AMW*44F;-QD$7:S!Y/6N:1O
MK(.O6WHA_P 1.;X^#=67J&E&?]VMI:7]U[S6:VL0O\+2U/[V3MJZV2W;;AOI
MM+^DY 6$'7,[IH[<U[;C3K%0V:50-9K*XVRW%$VAKK<3?U.N/?2LTRIS?8*H
M$*N$K^&QIR5NA5LK&,4DQ"*=^.E\6]/2V@^='PS$@92VB1MHDBQ+:)2(Q%#J
MD8B] Z9KK2G<ZE;S>=MH2T#:19+45@)G>*&(U^PNMH-C9-C*(EC33*ZP':Q(
M?(Q:I=A=ZO;\/*"+@OU$K1J$\;E&E,B5W$]2^M"G(-ET]KZ*<YI'IDPZ8RM7
MM@.*:]L5F6@E!E/@%'@N) E#4BZ-)W!]8O9BJD#D(HY.*I9<Q\Y6KE8*6LPP
M8YY5AUV?T=>05SV^7M^?IE*7EH]0OX<6=_?,=ZR[OG[8&SM6AI5E.HH[H=1-
M9':L7)J1PI[!<^SLCWA9M8N_D0R$8H8\-2@U[$$N!Y3-TY:L'/:.M6'8AB#[
M_/[Z7^M*_GU[U]]>V>EM[^Z2YL&\-I:L<3J!3";>H!+U&=$A;=I;$U/O%#T<
M<":R#D=B4)K5(2S&G"I=HLPT PGLE^N34:983EG-8O%>]^O0[V5S=E(\4V-B
M:".QZNHRC22J,( [M\?PW<S9082CJ&PA,G"6^$H]%_Z2'4<2W[2!-?;=9Z]8
M$,;C]88'4*6:<DGPNF6A<>'0@>=1 194#:KN]=8HV$D4B%BQZUL+QVT*F2C,
M<,S--U\:]Z],^@\$T5F&&Q!)'-!/%'-#+%GA+%+%+AQG')'+'EG')'GAEQEA
MG'GEAGCSQECEECSQSRR9[>F,P_W'=X*IVQT]*KUV :3:-H/.OE_BF5,5@5 $
MCG=EI*(V-\UNWEAP1)"L7*KX KT.9"QJWQ;)<PQ+*VU%13G[]<T1DT@TJ'"[
MI!>T]7DX[6>I>2Z7TB>Z;(6.[DGZHYN\=K&7?5)ZOBUS4;&DHU%,:9=+4\^#
MW$N>X^,F[ ?7V%Y9%2S5KU#/.MZ_B> JJR5UYZ->W?G\LW%MGNP&ZNV;5U33
MU+L_8K'9'(-S*RG6-941-:SLSC<'L@,GG>MBIUKFU<RTBY8W9J]*Q1'\2!^9
MK67KLN-70"6RB<U3NOI=\12KXZW;TJTZPTHRCN=?2TW?MV3-9EMVLOQ/]O1G
M'9=0K=^)ND.S82G&KU/Z134SW*]<*B@^6JJ5IJ[N+UR][&PS%:GLWJ]D7%7)
M<'MI5R7F1YBVROT42)K7 =)UMC&292MFQHKB_8E<'):I7-G3EXJF^.;X; J^
M>TV1EOBK*473\V^($4G)8D-LU2.V<I#"3.,!@SYGCO>O:\=0Z@:0;!.HJ7CB
M=M]P'7%44N7]J!M*+^U/8'5<;,_BC=DA<LMZO1HV6@57$DI"G*\*+7V2+"":
MT4\^E=JYJTI[=ANTZEYO;I[=1\ST--O:@SYE..R8FT3;'4BQDB,P1L74W>OK
MG;[&FIP-0V.$;G''"]BM,P<+0*@%V$=L:,TUL$55AOQUE]=>]7,VJ#-BG+>M
M5WZ<!5CIR@SU Y)/F=/?UJNG7OZ5WOC,;2KWQZ77FM=VW;_;5UY[O;MXW;_)
MFQNIF<.F,3,'\SWO]"/_ &\73&8_V7WRH6JW1M4&'7>S[==9V+1TW2: \*%9
M"MFX#.F5G>B_KL#5N/E!BKD#R4S11TF%C" 4JH;&D*!EE%PY4+=ZUTY/ASQ\
M>*^BOSS;$VQD3@JRN!O)0"J9+ @DK\I"4WAW$>+A%7Z0=*HLFQ[;LL,";K?7
M()5JM90E4$V#2"^9/?=ZB.E%UM"6@J!M+DC!VT!E9'OJDQ>8NTO86K9R]7*^
M4&0Y+Y+YMI.*HJSN\UQQ0E.F,00;E&4_.,MFI#_;(?AP=.,XO,YKJ)N@ALA*
M*37$/I!HJ[4.RKZ9V!PCVU3;L=&O>EUY5?G?:FJ]UZDT@<1D0/GLS&.:RLNK
MFZ+AZ@=JC2;$668+B!RPALX[11176V^UU1?9._%<\4V<\3; C+S#+=0C(CMC
M&3;%T[?Q';^&[H[:E^)$)$H\7/TC 6TK,.RZ>KG.OJL"U(D-%JR]DR1!H3G+
MM!%]VWK."[([@B2RQ50)FBO>KVHS@_B_:'9^EFCM&9%B@5>XZ6B/6P 03H[K
M:Z)UV[M_AZ>S=^-%D:;)TV.I&6_\0@1A(TYPD$4U%DZ8D=2 [C3=30%KNZ1@
M^IMK;5:UEM2^-0M\:"R)['*I>/3MY44FF5$53*@FDXF1UVNAL),EA-WV>F"7
M<"UFPW$0-$*9N4I7/'/N7^X/Y9R8TH2)G4E$EM3_ -C=&,J^,1]LSAVS=]#U
MW $]-GI%K78U#V4PK^JBXL"4,'F,/LTMVG<=V!)@%M'-BL%)(8<;YVL?"YUJ
MH;MLD-IBS-4JT'LY),LH[5X3@D$NNU_M[%V(]#ARQI._]*KMA5?LZ>W3@"#N
M5E,M/5>KK4B"DLP;Z;^V>$E3!C=E6W^[2O[@3[0&E5KITAF0>0'FY!<5+*QZ
M"U]_(>]>OS[7D8UW'@>+[Q))R')>U[,NBE*XU?WJKF\%5-8]>*Y45BW;7K(M
M?)HO*AZAPL!]8B=TO#C7*ZT;7 %;'BTZY,DX3TSEK@-MN:JJGZT4U:W7S4#U
MOCJ#UJZYIX>'CLU93FF,(RJ4]\73W$M,E_?+3LA(U(Z:;-1V:J"7&3INI';.
M52Q_24+@[(HSLVJ7^CK\B"U4X(T-'V O/UO6[^N'FLEM<VN5-E7)N4D.!IA2
MMZL,K9M2W7O25V4%5N6!L%AQQZ_?'3KWZIR=$<,3;&K9>;<W84U&-,1)<*I*
M0DHUM21FP=.]P:GNTHW"54,S4IT+B <WSFJHR"J$=(VQ\3V'7=F2B6(99-ZC
M?0IR!^"*/,7P#9D\L+*$JQOCFO'J\W[ET^_(/U!]LS*)&4@D3!0G$D1F#1.)
M.,);9=3=&,J_NC%XR^.F9PZ8PZ8PZ8PZ8S/&U=WU]+#57+V"=-BF'Y]<E< N
MI$Z74(YVEY+V'M$I:M7'QO2@5>I&LZ^.10<Y%\I[!68=4XAPKSSW*@#GD.KS
M?+?0H>;OK1ZM]=PB2W7.,-L61N)NY*"$=D)^:5\,ML.'=(XO,BU](WKV02G'
MV4$;NK^R=O'4=5.IU$?/&NIEO9"AK;73D_KI9DA<!X]C//JJ*(EQ("\+'%+V
M=:U'1L94Z5J\=N/CSS\CO7!^;RY9$4&%QJ,-Q*6Y9,5E**0B$;.(MR+#=/F1
M-+G?DLT(=3R6-%[_ )YMQ!.7A7' UQ+;"M35N=E#JT]D&QZD^G)Z(JY)L$;E
M@O1<6G.*(,QY3KL<E83$:5S7'UX^O3Y]/>LP15HHY"U MX+5 /=:#E0YRM4K
MZ2,/-KY)N[ TWLJOM$SH1/[@S2FIQZ\E%$=8F=?-+H9V4I$2FT/4XU:O;1&P
M*-5F0S0V7E=P#XW%?"A?S+PBE>:.:N^W0X.KT&@OE0YS>R,I2\T=.!^(Q=1E
M+^T6,%A!6<Z(1ELC#=(9NG#=*/TMH7JI.C2)4I/34B%2M>J3>9G'Z6K;APL5
MY/1RXX28>DBDPR\R3##/'R^;GCCEQSQQ,YYU],8=,8=,9G'N V U:KU3LW8*
M>13AQ98OUR&/MH#8&:F7SR"!JPU4!KRP:7S)EP=#\X=04Q]0IA-.;-U,:U$S
M<XK!2#&9T=NZ'?*F\W$;E<U9F1,PZ#!Q21UF@B/T?L+>;ZKI(=9V48@8:=+9
MMV4?;=7.H(4L=>7JM!>4Q12U%5V2!:*[+7[T^M??K\,UUH+8Q/;>G4+89L;1
M$&V,-S(:H"Y;$XB,P.NVQ!68+-<XXMR!+E\?8NAL[?G6<A=BIS8SSE\_/)D>
M/\9;_3&4!O;8['I[3>_]KJ2T,<6#6Z8?>*"V9.3+@HGPKIT!FW'>,UA9FS4K
MPTJ=FUGC6&6K-KF'BG!Q%+8PFB'5O@?3EZ'N=SZ>^4I>5"GD+YIKBSA:%[#=
M-4TMMWNCV$@MIQ0&)*A%C:4^W>5&9S)XG>@MM?<#OA7T1A=9%NC2&9TU='*M
M58UG1ILV9EOCH71L=M5XDI$[+[^_OUXR^6BK9<KT #L=;XYNSN;>BZ![?]CF
M]J:O&MC+1$T&.LS[)1F#%?RM\KU\YJS9;?K L=7L"$MB]  9+Z?88 E2Y;O6
MJ0HG4J6"!"6'.[89E^_O]<N?IC#IC(DT?CH?V6_\:W3&8D[KT'8;O#K7D/I/
M_E$Z\&(V[8R.JKDVNKZK+NPE"FX:,=-C).SWW7"T^Z^5X*NRJ1,+FP6[8X\Q
M+3#1!R7Q--B6'Q_S^_Z.:C0EW5ETT[?^0--*=%$/1Z-%:]S[T-AMY]#J&R"M
MK34&RPVNS3)K'V.6@[!0, U]_P!A"4G!CJ7+%(#I"ZK?\GM7Q$9W[?%O:)Z:
MW;FOZYP8!]'K=+[W\.WQOJ=/A>XR DR(2E(NIDE5=O"<DDDSME'F)RM15RHI
M?2=8BR!=Y;7G(L!2M"@)%15J]O\ E(XCR('2%+?)-2:BS]P'@VZ M0[Q,"+K
M:E+:W;;K86N&:;J31&#C#[KZ]/8]V_VS4:6R]U;?-NI)5+^W;0T/GM4J*74B
MV%K?O0?>7I,R%;,FUL?I0HAD,W.VF+@MFTBV?@A6R@D/X2PRL4VX1*X0W&RO
M3,R$0X>^6'RJ"L39@9I9(CETB/(V(IR/"=$]N^4DZ6H2TYN[3ENT]739Q2<)
M7#4TVH3CY@E%2,H\+M;#76_+K#L[MTVS37^W//;++@:/J*MJ;9-'74X)M++#
MOR "OMT8Z-8M0+I%&X/BV./'&C@<L=!C(*=>M0-7:D>#F+UIHZ/9+[>SR?)Y
MQ4]*0;MJPBK"0^35@2I8+UA()1>16$P1#%FK^T[9-/9@B(AKK8ZR"$ 1@6ON
M9CV0F4MGW=&C>S;7VD1W;Z58]9[#)N8EHXWT$,[C*1+-SC7%(I6G=@;IFY,4
M]6*9FZZ)WX2Q>>?,)T>KS8>@GI#=NFT=<,FCMG5]>[)A=U/L^6=>;[=:47;8
MRVQ(]"[=-AB8%G03&5\<W$-WUQM\DL?^U9S<Z29 '):0W*9M<#\>KRO7E>[5
MKW5X]+5]\W#?J3V$KGJSC'SSV$Y2F<ZDYRC BRIE*<H@A*2 N:?[H4-AV+-V
MNRB]!,6QK"]LM0=F78$$FG8-EZ8!IY-6>9J@.P\/J5S08=BM*RLJ;I?1+1'.
MNB5WJ."/.].N52#L_IS[\WVJ_7GT2ZR?VR\T?[H^6I7+B?F$C1&/1&0K*-1D
M$F&%=2]OG=GJS$M'65ID.P_;UO-I(@7LH]P5D_%-&=T$2W?MQH+"V\-NLEW?
M170-M;V?M2G3WB[D,J/.SQ7HDX#)R.])P/6BSIQ??GH<]:S<"4M[!!CIR97*
M,5AP2($Y&Z3%79#<[;HHDEJ:FU[W.(*9K%(MKVUAUU4$=Q0^IA3)Z7K[V/:O
M*:;3K\A!@9QK$<T7+NQG[K;\QE-9V@];G.A8:K3L.Y.6M;$O2N:>E66<7=-4
M=:.;HHLOJ9#=^'.I0V;]-D+ DSK5V,8M:K",=^^4!A%8$TE/2&;;*T)WPM&]
M-IM:]L=2&J3SJTDC+!.(VR"9D91P=U>_&FKHH?;YY7MDM*Y28ISVVAU:];KE
MBL<E E2JK"*+ 3,"!3=;A3UH0XZ-6]>EH=7/?VT=I3HH&4[9QS6FI-6;LU]V
MIZ9TX/?;">N.1)NV/=657/=K6\WDUG7&=RA#T$]*ULG6"[H/NCK8_8!$9.15
MV.ED2MG%V_.N.U6-??3*2C=2WR@=B1&2!Y06,R-/*4CTXZE(/':5L6IL_8UU
M<[<S6R=%,&Z3FS=E:^=(^UFBV;R9W 7W;RS70AH2; 2MVJTU_P!I:@<% +W&
M-'MBF5@=6\I483:G@)LOR^OW?0XKH?'*RN,2ZVC5,JM8^:E0DAM=H"1+%Y?K
MCJ)=9E#4^L%-T+^T#BKZ\2EUM/>LV+GC;,$6Q@T\7]<MXX6K7B12M:N>LV<<
M;$_IO2S8\29Y<<3.>6'TQATQATQATQB8_P#S7-_KZ'XO_$*O_'/]71_CK\?N
MO?&5H7T#J8BR.3\/2%99VH\@R $SMT"IJ/.RN*I$$+6IIX6(V -<3SXA 0$=
MZ,I3(T+-($&I7Z5RF-JUXU_]91I+Y!.&Z:[-(UUZ(\M)BM:[8>WY3I(-(1J1
M&YRU@G(B"BD""^/*&%U6UG=7"B*-H%B$%B_%[.%U%8,#[/$_%J,L!%$>9N;5
M"M+%;:"VCH=B^M?'*SFQC%G)C#=MBR6,=S<MHM&YYE06\N,3/;IH1BJ5:)S3
M>M2M2CB&CI07DT%/C3C7LV[()'4YSI<Y5HQG&P'N*K'#EAA'6<VJKYO-9@*Q
M6I;Z].3V?7(*(BB-B*(G(B<C8-G.=3%H'1[;1S&LVI->':.=HW>]7)J06WAA
M>96^1_8;T/,M/+."Z;>)IFTI;@RCL76&:8M8DDNRYS9,F2 1JS6B_P BN02
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ML0Y.KA"-/,?)"Z2BEOB*,HR$9S(2\0JW\>[S;\<K)ER\JK*2R925NY*HO+R
MMMVY=W4S.'3&)F#^9[W^A'_MXNF,I+GM5T+;>MJ['8M<*[HV;BM^E;B+H!!L
M?. N37*/JZZLB/7QF<E%:*K2 %R*C))+7KQ"R4EFGYJ6HJ59EO\ +_/\YZ6/
MM/T,P 1JS#KQ96@5.\FRD:"JNK8K%F"HNQ)MM U!DGR"VK5Y6RV78LNQ&C!/
M3N7SU\Q:F(>:PL49:W]\\=/V*^'RQ?6R[*%6SDM*0M#:V)2\72."O;%VZ'#3
M QE]'ZM(GVNUG>9#-M)7YB1J[*3#FY[E^YE1YGGM6C"\$*W+&6?I;A$73NVL
MYK,.,G2TZ+UOY^OQP2D(BB(B*(G1$Z)V3DSWQ=M?;Y!4D'PZ6UE$/E!AEJ4=
M&F <!\@!<6;B4 $YT<:7%3*D&3;]M2&0\P\XTEF7P&OZ,5'%4PEO2^'J>M=,
M6TEM**6TI=*=%+:7I;75RTPZVOKTQJP"""P\[&5P.'YAM&O3D-&8@XE>C*E,
MZ\<>5XA@" A ^-NQS)/B-$CJ?&?J]."/!DR"+NC-,*+,-=%;56OUUM#*]5)$
ML@53"#30U1HQ104UVB1J4HK-436KP0U8:<,F$4=2&*KCCQ7CPBQ9;?5SHFTQ
MJ:;&UQSKA*PSN7N2D\V*P%YES*^WU_:V!3+TE*3"2_'LXH1V%A8EPDSX<KMI
MAR\XG/+8S6^N!1'T;ZI^E/TYR!Z"[8=:=NP7,.F1WBDOB!>Y3*G:"C2M!:IT
M2E!BH-:%I*LG*JN (UM>JELF+7ET9":-CI&(YR2/WKQ*Q;Z^[?W]7*R6^6I.
MY+44NEM53=*E5Y>>7/7QV?\ :MP/F$X]NVFL1EB6268?AKQ8PIR>EJYTLH<J
M^ WB+U3&IGQ6BI<8\4X(8:F$$$>-*IQ MN^_\]?KW]<1E*+NBH\\CV>$?411
M'A%&QRQ-;ZK5M78.V:]C:G);&?CFRW4T0Q&X$F!L-U!8GF[<Q$#A(['$8N %
MU8'<0#X9O!P [(C.0*<WB=V9F[_3+)Z8PZ8PZ8PZ8PZ8RA=CZ$U=OFJHU-K+
M-%Q"H.PFAQ&K1BK1(KA8H25WO7EBNQBB%.W 6&> O)O+BESZ##.[Q4RL9SU8
M[%.S#O\ %J[]?L.I7/7I1J^!LJ^;CR-E)SQ7-E+Q=)VW^VOM\)G*S+?TIJ^T
MP4F*NW5#$J2O\D*S34M+-^FPPV>*'$D9FF02U(C4(XY<6JI%;#$()8[@^M/'
M;>>>O#[EW3\P?B8)2"020D;9 H2C9+;*NINC&5-E@]0STBNV/MV!YKLH;2.K
MQ4B@<L,BIF.2P-/);-6N0'-BZ#YKTH^1?I>515RYKTO0U.,EA<RQ@XR!"^:E
MM]7Z^U?IQ\,$I%I)%$44L1$?411.XIT<68]I/:]BOYJG';[I[):D(U2L@//7
MRS(-DO4@]U>JRR59!V46<<2^3* >*V6/-7((5*"<X<AY*]7GF+?5S0W'''''
M'''''''''DXXX^KCCCC\7''']'''3)ATQATQATQE7MVL]>[8&'579B6M/BW&
MV"#D8)K$4C8K R&%!+8@IC2OQ30<7Q=O'&V/M<8>FIVL([$&<<T>&>+&1'_D
MJ]M?I&2;G16K.9G"D%'M,W*6#RF8*BW&LQ+F!:7FGS)=D7L$I/Q!6)LLK(?V
M67N1TM;D./YKVWU>H_,NGXEM?%S1*0,24B*BQ%I8DB*G10G('J$I5U;N@  !
MJH,,L+ <6O+:Z+H!   )0JBPP0,+JQ41@H4-I104QXX?3@AJ4J56&*O6KQ1P
MPQX1X8X\3,XVZ8R(V@89FK/*VQ"Z!Q?8(Y 9T*5J0WQ9@,66Z= F+)4;.$E>
MY0(4K$]2Y4L1R0V*\TD,N&6&>6/,._Q_8QG SZLUJZ5RE1N0U%FK&UVJHEX#
M@ 83C(K% CR8H ;>-NM+Z470+^0K1J9>6*F2QPOUL8K6&$N-QDA6EE=3%\.J
M*((2LK"\/K"@2^"'U10<0-IQ\15:(X=2BAJTZL$>/&,<,$6&&/'XN/+SSSRQ
MCSIC#IC(DT?CH?V6_P#&MTQ@&"#+ VM-+6YRDD]-GGEQ8M8>=EE8EYYY\W";
M''C^SCCCCC^CCIC&?L\(]UR^U6_U_3&'L\(]UR^U7/VCIC#V>$>ZY?:KG[1T
MQA[/"/=<OM5S]HZ8P]GA'NN7VJY^T=,8>SPCW7+[5<_:.F,/9X1[KE]JN?M'
M3&'L\(]UR^U7/VCIC//L\(]UR^K_ /R;?]_^7^O_ ,^F,\>SPCW7+[5<_:.E
M'IC#V>$>ZY?:KG[1TQA[/"/=<OM5O]?TQA[/"/=<OM5O^W_^O_Q^+\73&>?9
M\1[KS]IM_K^F,\>SPCW7+[5<_:.F,/9X1[KE]JN?M'3&'L\(]UR^U6_U_3&*
M3@$5&-FSPK<\9<34N..>;%KGZLK];'GCR<S<\?7QSSQQSY/+QY?JYX\G'/#&
M8-.=YH97W]N#5)K6%"PF:>NE:3(W ]AW9FP15%Z.UQN:)L;5<^LK:$H(INQL
M*/784^7W!'<LN%*MSF&Q#VBI-=4/Z\^I]E=.?KFR(U4@N,EW5&(QW<#;:A&N
M!W2JJ-SUX]^.AY(.3--6>#:S?351J7)5VC9+LAC(H*[BF!NKR".+M<)6H(X7
MMJV#S:*56LEF;+"2(T/0FBS5;S=2);R""\W=G;IU].WJF6.GNN]2$*A.7FW\
ML?\ _&;82N<N-O\ PY+E%O+AV?W Z[U<SH08BMG#@K82-9;%Z\O<DKI8P1N[
M6T3J%27@@>7BO3L3GF??2OC>O&3@"$)!+3LY1WZ,IFXO 'O3?H]*Y6K?3L]^
ME<H0C.AU(P61&YDMD2E93E$DA8 1C)?,NT#<QEW[JCE&TV]#5]V.4]Z'L5A(
M""Q4GM!$:A4F]U,U6.N0,CQP#!: H39*?N72G%.K9$25:UBY-8I\6)]_MF M
MZATM;HY"^!>+MH7T%R@U/OZ[>]B$:=A J7SB?"D/VPSS#9*4AN4*BJJE)N7C
M8GF0Y($XA;AF9++@8UG%-C5\A^&+B#7\K</'+% -W=\%6=[MOA.* ;'MQ;ZA
MWU]MA(118Z0G9%Y7E""2QID$+-IB$JUY@V!M+4Z\LELEHX9N$S[!LW3SHC@\
M4^FT!BAS 'Q3,2T&0+>NO\?G^7'?OS\:NWB[+LHYM*53BJ"KM'S%#YJY..^+
M3?%K&7%)="0DH@H#PJ1+4M%K9&*%Q&=QS(1QAK 3EU*Q% %7MI=RO!>EL G*
M3N5K8F(96L< I&2UVL./D<773KVX[YO\/D-\"X,U=U"0WD&HKO>( #'>D61R
MEA:^[M.V[9+8:5PA>X,K"LHX:+<U30K"FS7I7N_K&,6N6RQRN5LE9W\075Z
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M9:/##CBS:X\F/(4/)SQY>)^.>?Y>>?/ER\O/U^3CGR<<<<,8U]GA'NN7^?\
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M7!M\NW38Q(8K-O>P[F].W'R;=J(HG-K:AM[3K+VN%,:60V/#7O< ?V9K$-!
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MWW]_1R4HH-""TT**"]!2,D.X+V<A:[WF]L;6X+:2 W(C7R[?8;Q:S+DQ":-
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M5%7B,22RJ[D!)"C;%6,6T!E)E6*UV+[%1^Z#5^X1+L";U@.6:&_9UYK,$@A
MZZ-#+W*,^9E=U:JIT*YXHO9]Q# MJ1P[L:Q@(6"1:*XOE2]*B4O+X].M_#CO
M;?3IV^?!E%C04[I<4H1=C$W,VZ27&PKKNENJ%W-_:/<=+.SQ=K8&8)/V+O\
M5][S0C%P(39Z=T F:I!X4 APW3LSIS&-8]7^.KSX DS+"Z+-='U*5,@*%FHW
M%=.>[]>G-4V79=G#2F%ALB1B[W^^4EX1GQ"I!ME&421.,I$H7&028XVUKVA
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MJ4_SQEM@C'GO W9JR/7MFGKCB(QJ'5(GNV.WX]61J2T%:Z;]5&Z47(@U+8#
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M342IVN-/LQL6"=B%WI)6&:YAC(SKV (39L\JOJMMEJ+)@B-!VV*].?3Y_?\
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MBS.>JK_/9;_N8C_]1+_C^GI]_?V8QQTQATQATQATQATQB=?_ )E&_P#=8_\
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MKN4)5R]JGLWHJK^*1G4_1GUZT*.XV%J56MD*OH9Q"ZP"6J;VOW\:I<DV%6M
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M=K5@5T_N'D0>]VJ->C9P7F_]/JL/Q @PM+-72D[HSAIIM)LMS+4BQC5R@NI
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MW4?&P:4KJ:-(ZR:MX "+A-[SKW?;""*E2J]+^_OZ9HDT%M"H"@+Q)KI: +Z
M-T5Q8_1L9U9JS!1V0A2-6)8D?NA#>C\2VFKA!@8>ZLR6%2:PBV0.M9IXF#NI
M-<)"].X3SKYM+!';Y8[F0(T>+9[]7OV:XZ=>MO?C@KFLK"M]W)5G8DHQ*#;9
M)J6^6Y)#$VQVK+TR?1EPT2PFT#VT*N#:IO7MZ]@_ZLQ=&""GK^MVO9<$%4_6
M?%O!=?6\GVT5+CHYS"B\1N-I@PE 86E2O<,K^_6KZ^OMZ5D92;Y>:'W#L^H<
M4= #C+7"=HQI.[66[0"\X+)>Y1>5IU2A2\O7DM46JJ2TH3XNZLQC,-NPVS)>
M)2IV ZT3;6]F*TPS1(,IYQ+ D"&I.+]"_BA^5_E>7R.I_P H:;)+D_B2A"2E
MM&F3E&+S1#<EA&Z*]V[V$NV]A6SX73=FMF:'9>V.-AP\E=(M%L?BHT$)]UTC
MZW8L1?<&.S/A=7#G 8ZZ_NJ]M"BI;: 7MB$QQ0JUE<(7WVZ?3KUYOV^+=$C$
M(NX6UD,4\K&H[1$26Y92W18@18K*5/O9:S7U/N$'K>RXIK^^]&->FF*GFNTU
M^G<,LRVP) _83'.,*1#BE^B/9<6]ML6@%YF+,]$S95BX$2TD%*QT9C",$0C=
M/]SSRM-<KQY6)MJR4C<^V?C8ZOAO#^$GIL8>'YAJ$C5G<EGJRVS(U*<T@&G/
M2@:,-*&I#6U=,UI6]NS76T=IZ(V;KF.RB%SIER7<4*&W0L6Q>".MO2;?B]OJ
M=QACC927$0(_<-UQY,!7,TI*P:/ 22RLRX\VN*5X+LKGN? Z7WZ\=,\;LBQV
M2D^0W*$7?*/G(TOE%8B\R"Z+HSAG]&@!MINQQ1)X79FW8/&OKV)<5KF^LKBS
M>2>Z+;7=%>65\2O[#H-PG5C&>VCBGSIP38 8S2 K\9'AQN&;^-@<O]OT#[X^
M-YG=;;SUZ\O('+7/3TREN?HX]@AMNVA"-:5EK5Q/6V0>ZQ3+-@F&!LA($%HM
MMI7L,>YV[>ER!RS7ZBE9UX4:!2>E*!*X[(#T'VL(H$B)?OTY>/?K=Y92LH7;
MUVK=<O' 16@Y(CS70R> _HOS((7"(H;L4A^5 $9'@&JGI*<B]*MW@9O8*G5%
MYB<-JMF/".$$[MR&L"<P4F&5Q%*_A-\_5HL=_"F:[7\V_P!C$Y15VQE&+)0E
M/<[>-I)(P)(',@CN>0C59+$/Z-O),$^"?A6$SBLW;7+SQ1KH#'9Q$W];=UXC
MNG%T5\BW;9;SM>J1(6'M.*W#1<\4L0L@AAPN13!2XAJ?7MW^O;UJO3WZXW1Y
MHD6 >82MJ2L(EW*I'3:"))219JMV-#4;MOW=H!9<:M6/<';T!TKF8&*T"O6'
M'0>A\-*6=@34!Q*_ZP68<:U$\0\N>5ROC3JC<[Y/BK%;Y7=6ON]>/8?3GO\
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MLZ5W""!V!@R^))%EK5<L9RV?U4L[M60="N$VB9O5R['J]JH--#QBJ*&4\:Q
M*>)!V*&$185[GY\=/;Y<7T>U*81&)^+IMH-&H;+C%66[3.!DP=NYW0D@Q82G
M8:#W?Z@>7 .BV]3;&16,^WL*.(JN +74L%P\G$-W G2/&XF; <*T=55:.W[8
M*P0LS21X$2. 0@N<'%HM@>AGW\/OVS"4#8V/2^&TIL.:J7%E(+N)!%5KOQT
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M&N]N;#.:R.R0; SO<G:-#1NS:=HJ$K%4N2^KRU:;?-R;6)32O>OK\GIW[92
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M6T?119Y\\124=?@ BO1GC\V>F.%4>:TD5FM%/C/OT_3.:VJU:JT <\\  'H
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M;93S>:8&0#@0%U: 3=]77^MD_5PPS8V"0IBV>R9F:;#FE8U3^Q]_/K\\.UY
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M MG'L>2T*&\EE&&U<.CH19-%#YGS2C$ %K=)B70@<*T1%0S.EH/B-66GI.G
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M8XM4RN%\H*M+S+6$>O,*<>C1Z=;Y1.+].[>=*G&4HG6-QF0VRBFFBWLN$XC
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M^)A_D=W^(>G/M]/\XP]">^)"/DEW^(.G/J?1_G&'H3WQ(1\DN_Q!TY]3Z/\
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MP*RF6*<+I 43(Q:"TYO TJGK(%E,9#'<11V84QD@H0$U"T)7>+%%OM%+7(O
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M?YQA[/!?AM;\GG[W2CW^K_.,/9X+\-K?D\_>Z4>_U?YQA[/!?AM;\G+^O_\
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M;MH(#NK$:#15N9G*%TJ%UE5[7AO;2Z(8I%O*=IZ8X5UX/=P$BCM$WKPM*T-
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MJ(;^*LFU(:4:TQZF/+SUM#5$[6,@MWUQC:!JNIZT;G]F5F 'L%,SI%U.58Q
MOA:*<+1T DKZA9R'(EC:=KH+5 #KF]..G..K;4HZ6[3\T(C.$H[B3.<!):;-
MC&!/4EJ$(QB#)R7T6WOE(QZ(JT2>VQ-LSG:RW&7=M3ZXRH@-L8V-3<2H&016
M1,Y\^WNO4N[.S%.@<_B8O3#K?%C>67-13A:)Q]_/CIUZ<_9R"/\ ['(O?BMU
M1_MZRHKBBXVGFJGTLM](,DZ>3%1?J;PE$J^F4 1X@8U]J@IM*CW"A]3N=:?6
M=2J:"0#SO;U.Z#-:4BFS&"C;;8R9DWC:VM" Q*L:L?D=/?L<]^O<[-E'3-3
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M#47.%D7;+%8:@K*[2L42,$%V7,<3&7N*Y"L#E/5[H'0.K0'Q??IFHBRB&VU
MW2(QM:-TI,8Q/5DD0Y4+RFT9$>5SO3.-@X6[%59SUU9SV(;<06-963[XI/TD
M"2 .K6G$OS*8X/7U]P)MH#(1;B'EX2I.:R!DFHY.+[_7KA4B%\/*%]1D&XZ6
M"TE\2ZW8;XZ9G#IC#IC(DT?CH?V6_P#&MTQE![(U1)M,QI8_[?OBE6T\W$G2
M%9!J 8\LN!^6G:"#[C)&P+)GFU[/BR![%>R'V:T8XH:]HXL<F$&LDPS*-(H/
M/1NGV:1I]D?1,KE'[0$!,7(EV1PVJR<#"O;3"MDS( ="07M=]I6P8MBZ7UC!
MX.H#*I$*'*RFZI<\5KVVTY682&=HUC/ .DIL6W]?S*<EJEV[INL-AO6R]513
M);-M[9RVX[6MC=9 !\!M061K1E71:5$4ETH^>"30U'FHNW7[$SX08&MD*76R
MW2X&+U>E<W?3BO6SK[5?SK-185/?O796GM0">Z/,K'RD-_$>66WD+SL8-*DS
M&Y''<E#;FR@Y%FUO2UD+6\];IQ\ F@J<EHC/RN^T2,3(Q<L##:Q.-\%B[-&T
MY#5X<4YD'JRW"*F9OBJ.M]_Y^[:S/?\ R M?01UAU5H<9JM1-T^+&&3"*",V
MP;9I'9N\-B*Q*DE$4BSK6RK$X^XK8*U(F<+0X"G+XA2&IU&EE1J7 U_7[_,^
M=_+FW';WW;GWBQ3GO8Q0K^XE?.W;YK=U7VWPZC)93);T]KX\0B:0U&O\0JM$
M\1,:TT1JYV3U*FX3,*?:KX&Y&_8QMN($%:$+-<]FU<=E;C#76('<<>G;GGO?
M4Z5Q13?=[@)2$C1(0=RR$9,EN  QCMVQ8R9+(E*PD1/;JWMA7]?A-3@6'8.T
M]EU=/G=BMJ_88U@:&(F'79(&ZOFGEI(J*J"NFG3B%JV@2E9))XB),[M%G,E)
M;=ZJ"E%S(2I$#BFD)#3?)*Q+"Q$3A$O(A'V0ZJ#"R:JCLNUTE"-[7UYM0FFU
M:5EGKU+>KE?52PFAE(\]!&=G18!-?5 S*N:5"XUAKU#QL94)5ZU)2Y6-RG*3
M;M.*=L(QN@.2("\"M<RN3YE7T:WBM77ENF:,79'330\-X?PL91A#3@$X>&TM
M*$U-*$YRG%EJ:I+6FRUM34G.TRNA@DFVM9;,5VIT2Q&KZC?@)UF)0PMY+NF=
M@%>"#JVS>,JM\U1;3M+'(!P>%E*E\4"(,8\/+0B;6;@IC.#);9+):M57CW7]
M<B1GM12CNN-3ZC)-VR+*!KXNNL[@.G4 4YK<+>M[%7]P1M3HTRIF1T668=I@
M.7)R]CK:]69;1@S4LP106HN:[&[V+N[YNJK;5[:__6_>LL/M[TP"T #*BZ[3
ML;81,K"HBI&5S7JL):%8U\GB$9)7(XE=77QF=<0%$<W+=Z6CF0*GS!TI9GPA
MMU!]!DOITX^^<T)X[5]S-?(C'[%TR8>.U?<S7R(Q^Q=,8>.U?<S7R(Q^Q=,8
M>.U?<S7R(Q^Q=,8>.U?<S7R(Q^Q=,8>.U?<S7R(Q^Q=,8>.U?<S7R(Q^Q=,8
MI-FJT@V;#BJ7QYYFI<^7,*5CQ_DWJV7DYSSJ8X\<\^3R8\<\^7++GC'CRY<\
M<<Q^^OSZ8S"F^NSL?MHOLDN+:G$5GN)DU?FTT:HZVIC5((IST!KJVK4*VF37
M&7:KCKFL6U/[3LA"H4C1FBR%ML5@&O 0,=_;^?OI_G-;CCRA1U-S:*VW+CK_
M ,:.#B[N0&.S5 LE4YC6W+9Z<S:\=]NOZ05%*PB[4"G-Q[BBV^P5Y@190NB"
M0<?-R04 ]"U6\^FO$I+D5F-FHBCM%DM_3\BOTQ:J]DJ(B(BTIINPMN!3J<\*
M.P%E[S5ETH;H'E;M5#=GTV5D421["P2@-:J'7[5J*T&RXIM1B4F/]7H4J8J.
ME=R_WRDN;D6<V6EVKU.>'GY4]\]P'L;TXL!%9;"&=I5@B=0(B0=28=S:EB&W
MMA=O&PXJUBW*M^L6,Z5[MO41<-G+/&>4>88))\Y+T@^U0E_GSDM?J-_#IEK]
MM7;Z@]L2Y96%#DZ7J8B594$DB6OPXQBJ(J)5(4DE6,'UI5#$6W%=@+%>:Y5B
MENWY;)(C=RRPNDB5B[64I5NDRVA&-JU$Z!?0.P<&==;Q&OXC\/\ 'UM76_!T
MXZ6D:NI/4-+2C>W2T]\I;-.-U&$*C'L9I;QVK[F:^1&/V+J9QP\=J^YFOD1C
M]BZ8P\=J^YFOD1C]BZ8P\=J^YFOD1C]BZ8Q56-5N#!3/U4OSQG4%\<<<!2O.
M?'.&1#R\YX<4_/PXY\[CS.<N..,_)EYO//FY>1Z_?_?WZ.,:^.U?<S7R(Q^Q
M=,8>.U?<S7R(Q^Q=,9XX.5./+Y*1GCR\^7GR 2_'EY_S\_\ L7U\_5Q]?]73
M&>?':ON9KY$8_8NF,/':ON9KY$8_8NF,5 S5:,0/PYJ&,N<:V''/. 0K)AS^
M/_HYX5,L,N/Z\>>>/Z^F,:^.U?<S7R(Q^Q=,8>.U?<S7R(Q^Q=,9^<S5.3'+
M#.B8SPSXYQRPS %\L<L>>/)SCECS2YXRXYX^KGCGCGCGCZN>F,_7CM7W,U\B
M,?L73&>.3E3+CG'*D9RQYX\G/'($OSQSQ_FYXYI>3GC^WIC//CM7W,U\B,?L
M73&'CM7W,U\B,?L73&*3IJM()N8<52^/.6$?DYD"E8\./)-'S]>>=3'''\7U
M>7GCR\^3C\?/3&-O':ON9KY$8_8NF,/':ON9KY$8_8NF,/':ON9KY$8_8NF,
M/':ON9KY$8_8NF,/':ON9KY$8_8NF,/':ON9KY$8_8NF,/':ON9KY$8_8NF,
M/':ON9KY$8_8NF,/':ON9KY$8_8NF,/':ON9KY$8_8NF,/':ON9KY$8_8NF,
M/':ON9KY$8_8NF,/':ON9KY$8_8NF,/':ON9KY$8_8NF,/':ON9KY$8_8NF,
M4"B]/B*?G.D5SRP+%Y8\N 123F/*6]:X\O&6-/+S)/1R91Y\>7'/'C+*//CC
MGSN.H=_B_EQ^WUYQC?QVK[F:^1&/V+JXP\=J^YFOD1C]BZ8P\=J^YFOD1C]B
MZ8P\=J^YFOD1C]BZ8P\=J^YFOD1C]BZ8P\=J^YFOD1C]BZ8P\=J^YFOD1C]B
MZ8Q4.-5L;9W+FH7YXD*Q9\<8A2N7./' 41'Y),<:G/,>?EPYYXPSXQSYPYPD
M\GF9X9<L8U\=J^YFOD1C]BZ8P\=J^YFOD1C]BZ8P\=J^YFOD1C]BZ8Q0/-5L
M2!W+FJ7YXDO5<N.,0I7++'C$2/PYXDQQJ<Y1Y<\X\\\8Y\8Y98<XY\<<XY8\
M\P[_ !_8^^?TK&-_':ON9KY$8_8NKC#QVK[F:^1&/V+IC#QVK[F:^1&/V+IC
M#QVK[F:^1&/V+IC(Z=(PW9*>$<%^+G#"UESS;'7J6'/'G5>/)AG:@AQSR^OR
M^;CSSEY/+SY/)QY>F,R1W#WG8&]=KYQ3FV6R5>7"=;*:K2:NYA00QPT/6N!^
M6T&=WUC7R3:L>G0V)T_+KW>-JOKO9"J1<*F$]$L%@O1/O_'S^TRE<WTXOI??
M@Z]?4Z=^,RBJ=POT@H\%JL(+3JCRQ".WP$?:N-GZ:W0EF]I[PI5-C8;*UUXT
MNH-Q'22*=:6$RF!/,AM,5G4BS\D!)(T'+U,P#X??Z97;;2D5XY)(=E0+XZT'
MRZ/ZYW;WPUP?.PBN-:R7YUX[Q*V2UHSNAE6KWJ6P^V^<E0:M:E]5AV03MG(.
M3V^(UK?M*ME5\,KT+)0O?JB-A7JMKX=+ZGO[^W3K[<EZV%#9S%E__9IW1O$_
MNXDL>(H33:D4G#=J7?.XNZ,.=[<Z.G4L0+$;# 3&'<ML="V@;S&MW)'7D(36
MC)2U&L[*DUUF5$L+G<,,)Z6!?"W5O'+VOQJB;U0],Q1SST]._KS^G6_3$Z[M
M#N&7>SYC8S$CFT[[#;(+)-NR3TNS5[@/F[MZNMQ&)$X.%G(M:2O*).%@E=$4
M&WCY%V.8N&%M' F<=9H"E\"EO"A=72Q+#LL;ZV#>=(1@ZFD3DPTYRCOE'9J2
MC!FDI$'4TH[B)QIZFKIDD%U(0D2.GM(W1L@IF;L]Q8AX4'O<#;IC)06"*/LN
MDK#3A7M$1F%\ *N)P19A45\;L76&[LR \U?I9"#E:.(Y+B8<EV5B)\ZY>C^B
MG<^#QDEIHR(^8A'=*46,@BR(QE)A*<8VRA%-R$I$5O(7MI_[OP6RNX.SJ48=
MD'4(6:YKZJS:^8W)4,\:RU1H&PK+JU7IEP581)M+;VXW86;8(9;EBPLZO;)Z
M,.-@#"2&4.#I3TYB/-G-MUY7AJN'C<7N.FRC&W3IY/\ =T82&6\\VYW4&B^6
M6W:RB\.M#?4@S8_<2.)8[K73NR-BAGEC[IS0[*LL[(===JZL-[GM-]O6EB\2
M$EW[-0V$2='W]B;UE3UZ($P[)QHD2-.>V5JVSE&?S[??;W/WYO3_ (A&K_M)
M+(M_^;S&NC&-\[=SN\P]P/T@!I1M,H@)=&5A-G95'"F;[67J)P/"%O6N^]HK
M+),N76@)8HGBT0/M^UO !J#>:UK8;0[T:U:[/P.$! ?=A['7WY?;T.<U&,6Q
M.4L_W81"W87N'I-))8_AB\1?Q(SJ7</T@?M!7*Q*P&0)$ZU!Q%(ATPT86)@M
M7NO5M)RQC7"XWQ1\5CNK(=H[>S/6*&5<2LT-<'>,.0]\K8/./R]3KU_3BKN^
M?;)4>E-[+O\ $BQW?WW_ &]-E1V;MQ._-?DRJ+7>-WH3RAEX<MYU6]ZU:Y;!
M1AY#M9W# 0N[14U[6>)#1TRN0,BS(%%H;#V<O*F>]G;)>6):E)V]:*4,PD!F
ML^^OW].OZ9D#F^>PB'?K5-\7P(VCR",CRWAWJZUQ:)"BTZ&U)T<7UKHF:>B]
MD;(<-6@F#9?=291%4""%7[%MOM%TO5FKDFE6OA@837)'9Z,;,U;HF[C1+*Z?
M,ZG4YZ=BDJ^K=/4-,1C%*%6/,X-RC2K$J4(U..V4KC-)[9*2C&4G=P?2!3:J
ML.(80'I..6&S)JRG!H1MOY<4M/:+,RR9Q5[[;5)RD-Q=QU(6/0X+<=/'\&I+
MC@=6,$,,F'!QT[W5V![=OJW7PS48P?+7GW[=SK:<8)+RQZQH(MRGJ?B.GMH\
MG$GT,7<;WPK#7;3\T"XS7 >PA$:V67^W[8.(/<RO+M.\MNX>RP1F2ZYJ"FFJ
M*JPW@#*PD[LCEEL#4ABG)F.&-6+"K]+ZGQZ^M?!OBKS+"Y(;3R,R]2%!L_$!
ME9%GMHV%3=2],@3J.2 3W%=UETAJRN,"'&GD^-U,X&XI>UC;B+39<&K8Y<%O
MA%QN.%T;AJ3#0FNU@@V+MM\M66'9QMQ2!8; OQ1MT&DU]M_MZ<?$>G3)(B5_
M];?/&7*J)MZ<4,6T15! J]7WWWN*R&HAQBL9,'U+5RI:;H]F:DV1):98S/;$
M*V0;VC6V"<*+(@P^9]R;-1T6I]NT-D:V$90#'P3G$U;58NHSO_G]^GSR46QX
MNZ/-&KW56ZV-)SNO;WNLD6CN]K<K"<##]A3!KB8/U08[J'O8 O7!Z*XN]OH<
MQO!?P3"BX!OG98][\D5C5N1Q8"5C$>7..S8%&N<CH@K>=KFNK=%/%WZ]S*P1
MVA<MVSA)7(0\M6(O1%'AOU^O,4F$T4<V'G>9+'A)AY\<D6?F28\98^?%+CA+
M'EY.>/.CDPPDPY\N.>..7'/'$S&*C_\ -<W^OH?[PJ],97'&_-1\O)/6W+G2
MP=0IPNOF LM$O#D+O@4M V 8F(7Y1^ RH'H+.U-<RS,,]W !XPY@%C EFSWH
MP_2OO\OLS6U:JFRP$5N6T*N]RG]M;J\U;><FE)]1B4J_ .=%._.V4+915AI,
M0>U*S#!^'$E\BOQP7),S-"E'ECG;MCN+->MAEQE-)AQSQSTS.>^DYIY%<F<!
M[6M7U*M!>M6&FD=%VER"L+SFC)6)C<%J09% .DKV,+TN=K&.IG!-C8RCRBSX
MQ8R*LF[-/)XZ$LS[100@VQ IVX;A!L"0P2T7L_15TXGAES=Y\HED8"5$4)*^
M3PZW:L8XQVN<<9,L*"]"\U&$Y7MBM=?0:6E>+2+M.LDJ(O&/KFQ-?CHV&8@]
M)U")1S'1-<MQG"58UB0QQ'D(C8<Y[V&(7,KC-#D.P)<ULKW$L?-;B7C/'RS,
MY^[.P$.E*>@N.RC4F58AD[/#99 T$JY":\SD/,>CENX9AXBW$D?ADA#BOA?\
M_#U7F7SL?*QE;B^YO0)QF!*(7;"46,LMYZ$A\1QNI;'VCFN#ZDKMR]D7ADR%
MP,5 Z\+0^H"GMQE#$E_.0/5O0U+<D%I^_E_)]<TPD%HU0WU*D"-GQ/@H-/&,
M&7N(T<GV^*;)M)-%98YP0V[DQFO()$VKC(F*%"@>-U^9@Z^2*,.P5(>)&F[P
M^^6\4DMCJ]FB,+6:*GCCKT]_AZ_+&R:#M:DU'C^YY/*=94B.VP:&E+EJ_LQ"
M:+\@H&U"+97$BR#(A4ECU(G>L*!'@2RS"A]_&M<,#1!+GBE;,"H;@GB?GC#"
M[GSSQT1/H/KP@G3XGP>'G$H2BTA_;";M8R",XQE%6*@U*(BDHR=L@D(+G9_5
M-7"VYZ=B,XM:!T5OU^W5%%SMW*8F4F#BZ0\(OT"APN2*%B%$8-&"1UTA?O6Z
M]6K6EFEQPYF9SM3MH(3XH+3TM,=2=9;Q5@R N$XKB[<M4*4<DA+FP%8JPHV,
MMB.(9\#8XH.I$ LU>Q 5JU)H)8\&,<\N2AP8K+O+4M\,%WDIQ3!<G!?!BWR$
MXCR-<5AGK7KL_(CB6+DIZ*#/U#B2/FWZ+C/'RL9%AVYM7&#T"\)>%XG=MK]=
MGIVQY&O<!7!-IDLJ$&=-BKYR K5R1DJ6!' R A(1]<CYBYJ^7R>5EI^^OTZY
M. 9X&S"JAU;,BF (0PSDH& 9&F6%78XY9(),ZA"A-8J6<(YXI8<\H9L\<)8Y
M(\N>,\,L>&1$ZE='GT2Q^9R>V->F,PUW.D6V@.[=.=<<[0D?LMR:T]7HHE?;
MLB^10\]@I=;9]9UF3:\^IX:&"E8L69LMWX^'8*T#G,BS#FZ* P-'3I]>OUZ_
MGRU=UFAXE%#GD:C8QNN494BC&,HB[65[0SYLBC7=U97!>6<O>%%*0T'S)0R(
M4=VP%X?I(\$K7_. HWCQ5]-2[?N6>TS\7*E_"/M%P+4SL$.> >K0CX8HYZ?4
MYCS?M?3W[^N?2/=KCW68[OJ)NI)AB]KO@5J.O;8R.H3+WA(2?O\ E$8NA*,W
M$UKXR'A%XUSJ[/U'F&:*EF\19'<IHC06*.E<V/MR'[-\UTKB_B6)';)14MXG
M&/%5T8R9.Z46A';&17.Z.7M8=X?=2^/.P41D3N%)WRT,/,)")8U8T :W&T6X
M#VWUQ)$(Q%B!,FS -8MNX6"'?=0N*6^==U.%C"C[2THCA^"\%66V-7VY7V+L
MKJ\=K+V$8D=T8R61)-[&7X<14W?V'XH@5NF2AP&X)L=P[3[HDC;V:\J4=M7U
MC4'!I;5Z [4&S76DYK-G0JM@ W-L'9U+UU<V#/#LU@9ZIM.&U2+:*X2I3=-4
M83\?%$^X57CNU1U3^TX..>.E<<=<@PG*4YE#+=(TR,=NZ3?X</+&HV) HK@8
M!N+1[>>XCN;?-EZTUILM4"!+!E,/;2;C>*6UJO."FD''_3YA=Q7FS(:RK3 V
M/L.J-I*-YC"#XS"">=!=$5',!PMUY(!05+:4!3LH,@4ZA*0/%O7&M"$-35CI
MSE/2C.4=*<HPC.<+N$IPT]77TX3E"F<(:VJ0FL34F&Y^D_4SEATQB9@_F>]_
MH1_[>+IC*]YWMJ3AR+Z]]MQ>3LONR[KLVMQQWI"8EN;4&;9ZT.OPQU,N*M4V
MCU;AL>:ERQ!S\T2 S$EXO0N4(%?SU/6OLZUSTS6UJ^*V[O[HW6[;TN[O_C6[
M;YJV\Y**6Q]>$L 4HY\3+\;19SIK4E)H!VL&*W'G=CDJ@LX+TF):SA(-(X9P
M4.;$N.="[CECQE5GXC9FGT]/SZ?7MCH*QKS)#<L+IT,?KCB5P,0G"E*)6&B7
M'9\1D!5R6C//A5)49,L8[E&?+"U5SYXPGBPRYXXZ8QSTQATQATQATQATQATQ
MATQATQATQATQATQATQD)LM:LGBYB+8R@%<=88B="O?8S X)3GO6"5SF"E#:)
M6:T$MN?B.3F&OAGS-)QAGYF&7&'/DAW]GW]J^';IQ>6ENA:+?8L+?0M#XH=\
M7+^W-<,MV4:,;A&)3%Q;T*N*)6. Y0HU(=J2FV"P8XKZG=.<AI8\\K-D3!<J
M<U^.+4<^=;+&7FY*K]<:1;&U[/G7C@?$R:2VR3IM3")H"29VF^MAZ2RJ5\<+
MV64S)7C_ )<X./C(I%A_*DJXX_7TQD;3-Z:A?D-<V8L;$5+:4U1K_A!JV9I"
MH\KK2/H% 0._6*34[8EEO4RE#/%:)P5#L4EJ*O,/CGR]'TRHC24^_OR?4Y/4
MRU^F3#IC#IC#IC*N=]EH>GE38&R-F- M.2%:W@0.L!:23"K3@X"@XH\,(H(Y
MK=VY:GDBK41]"O9OD+<T-2E6L69HXLA;=#Q^GK\,L8RDI&+)!DD14C$62AV
M5>@"O&)6CN-T:EV]LT6G9BP&M:*4UIWV[':MR>1"77+$UDJ6#LD4,D4)!AP
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M^FZ[5VA3S/U*,=C@@04>$E:M<3PUQR6&IT*E?!]O^../A_UD4:J^C=HW)54
M**HJWD6^:-:],SATQATQATQATQATQATQATQATQATQATQATQF+^YC13MO2KJ
M<F7D 7&H[@V,>:".QDKG9 *FML>D]Y:PEDA2.&90P/$Y"K^+AK0SG8*=..6<
MA=J%*M289;#U^9Z>YU^5^O-5VU%"]PHQ2HI%OK&U)<$@4KD*&*[B@[?T:MGS
M-? AN_#<21KC9P?8P(:35S=EMYD$[$U+LO..XV@=EJX\N?*F-<%@Y$\R*)\9
M"NM%;D*K"&L%9;6'0T2/4KMU[/(^YQ32ETH]-/5V1U8HR-73(?\ "HR)$HSJ
M>G--M)>FZ6IME*/XIISU(3:X?1T0$(M&4FQZ1CHC2(65"K!0^L]@Z_&-.N<;
M6J+E*4S50NX0!%)MN*QJ8/G??[>!-*)^EI\YZA@S7PV=><>C]>_/M\./9YYX
MP2@=8S?*W4PN=2VRY@^46+*'+()!..X80K'Z+J7):'"YMO)>1@9J #H"&Q'H
M:+A1NZS#ZYV%KF5E,I=O:5W@IOVV.V2;SPVU(>C#U:-4>!RUO:%9E8B<^_Y[
M?0[?GDE(7HU1=MMT73118[2G:-6O.?6$?2C'4*(^*6Q/%0IUJ4<UN;*S;FCJ
MPX082V;&?\N>Q)CAQG--G_*EDYRSR^O+GIF<Z^F,.F,.F,IK:^MH=R:IWKJ.
MP6D P;/4F_7\IV*E@2E"QN.OZR]F5B'YV:>%V0?@1RM85,K=7&QE%Q#S8AXS
MYDQ?'[_7+%"0HH(H-*#R"B"G1IKK3TR,O_;Y4>S>^C,K/,-YWEV[KV@+-; /
M':X7( %S=EO!JAER(0>*6+/.Y)L.1,D='"'V=@RX(R>(Y8TGQ^_UP)98L1M!
MI3BP4D#1P[6GFGIE\A1W <.)$8S<V.!8R@.XGYPXBYGXHU8JW$W,?&6?$?,G
M$7G\X<9Y\8>=YO&67D\O+)C+IC*<V?K^SM9#VKK2!EO*,+W5B5BY\7#)*6JK
M1D4(I-=8/-%>'3##)59F+"!!Z"SS.N$KU4]#6O2C<*-B'?X_L?7'3.L9J@8'
MVO\ A+&6XJ-6+5 75-%4IC(:P^@.!L9$]3N5;,4^.,4<<5[ 9"-CHX0P058\
MX['/'/$.%R\5WNVV^*XKBN$YMMNS@KFV.F3#IC#IC(DT?CH?V6_\:W3&5<;6
M=:-I[7P5\"ZI97&&JS-.N*+JD#&1B'5%DHO<,9I9L%+$LU#,3?+J?)&\,XIR
M1V;0C/+^7C!S@Y_/_KZ>OZ7FAE$6,F(2B\2IW&[:T(J>:D/+?4LMP2"H6M T
ML]T=K%1!LFQE2W9QJH<%&D9VFZN:\"4S-VN/M\87&XR\6UJ"F?M19D,3' ZY
M-?BRJX6869Y^_3O^^/K^NA)209)<$)\G(=PPV!1PB7+-:'%VCK7*L;/:@JFX
M82!B/"]/-'<(1VI,+V-4CCSP0HTK-=?7WXZ'K?'ITZG-6=%S49RB3#;YX[);
MHQD[=T9>5D+"5Q#=!C+;NA>V4HL:(:RU@:>290JI:3+;**K<D9DB0U^OWW@D
MH$*\BW+&3N6;LIZXMWJD$H&3"W)(,LUX9!>7&<4>4'#%2V[JEMO;=.V^NV^E
MTW77F\X=@HVLC+$"QV8)UP>+;*R@UD,%M2=F='.LRY1:-J"0! /?)71!6PKT
M5MV:EZ<O5SS <9LN8BQ5G-W8KR^*^?W^_KQ?0QN=K'BK)/ECN$&/$ZW@WS$E
MM6E%B)^6VCK'4D)K:;Q=UVLQV&-;)3L["$GGGA:(P<&M5"@KXVC-JW5,VQE[
M-56EY5@PO$[S&6I"A]HHT$\2-ZU['8#NO-=>KRVU1T #)D1*C4(L3;&,5-TI
MK-B#J2N3YILI$2,!V0A&/Y6WS69]BIV%PTCSM1,A7$PVHD0O1.^*.VOQVS?#
M;MJU+5O4+QW7RN#8B=0A)6GSH!@$)2/"W7$5>)S]_?O^>19("J1*!7REK0/0
MN2T=U>[CV2LAZ$1S!7"35FI->B+%DX9F'*U)/6JU\M<ABGOSUQQ2C2E+&B4]
M:MCSA#(1,$[-:K%C:NV(8LV%5555M5M7U5Y7$*;0U)MZB!V>H4-1.48P@ZT@
M+7'KZI,87C5\P3&;'&13$+$1M:/6CT9<>\BI\!Q64MB1JL%;FYQ8PZ9.?T_Q
M^73),GU5%-NS:B0<->J4JNOBVR1$4DSA?&@UYM,,=(66C%B+],32KG3:VT8Q
M>AQPEMVQ9*;./+G#.3)C)*L,/MFN 6]49UD^L- @<?7C@T=;L#C(4O4AO"R@
M^QB<\RQ2OTK$%JI/AY<)H)HY<.><,\>>7WZ_IE1BHU8HTB6--(HGHBCU%,>^
MB/\ Q /\HN_T?C_[<_HZ9,BI!S'B[5NA<<U' B.(J@HD-@IV;A(;?>2<890A
M)#J9VQ='8L)*7BN,GNP05['&$\_$O%>O8FB8R5>B/_$ _P HN_OSIC* *=T6
MF0E9JME]S:_'8)1R!=98;8TS#>H$[.++)!S$-S(\$20V6NE.US$X+JW0GJ"0
MZD.2/%)18IQK*B-(CZ(CZ]_9/KC'GN.U''7?;EG=.L*%#6%"L5>B)3.42, B
M+E^^(J&)"1([5HW@UHV)*@*Y878O#IF(817X[.1FE9HQ/OZ],(G"(H((EB"/
MP1$]1$X3+&8W$>H9UXVEU35_.V./EZN)>O+1YL#%4=R79+T7K!_#SZP,5QR1
M)RX^7&I2QSLS<XQ899<4%Z>WY],L82G_ &E\QCU#F;43E.KWZ'>L?TYRA&G5
M(43(&W1O5H+E.W7%VY:]FI:BPGK6(9<#O.,D,\.>$L4F//..>&6.6///'/'4
MS.<1N(YX;-S)>$YX>FI>7B,5<PR\OKU;S>>,N3.?'''&7FY9<>;SYV/'/''.
M///&7!^G3]?WZ8QMZ$_\0#_)[O[\Z8P]"?\ B ?Y/=_?G3&'H3_Q /\ )[O[
M\Z8P]"?^(!_D]W]^=,8>A/\ Q /\GN_OSIC#T)_X@'^3W?WYTQAZ$_\ $ _R
M>[^_.F,/0G_B ?Y/=_?G3&'H3_Q /\GN_OSIC%5:(YXP4XXO">).*@OS\N1-
MOG#+'G(AYG&./!GC+'GC^5YW.6>?&7EQ\G&'F\^<Y^7;]\8U]"?^(!_D]W]^
M=,8>A/\ Q /\GN_OSIC#T)_X@'^3W?WYTQAZ$_\ $ _R>[^_.F,/0G_B ?Y/
M=_?G3&0;V)&M%5.)L(-&/WE*W&<4KQ].KF2"N9XBS@X+@+MZ_),'*\0YYP\$
M1G-2WZ++*/B3C#GG'EC.:/3R1##4K0H.I8J]!QDV)1@CUH(PAI; FDRFE>:D
M6-KC"LXRRY92R,T..!K.3++/*]SESSSRQ;Z^WR],E5A7XMD/%[5).LE?(/X\
M3L*GIB'D$<E>17'KLA7*SY!G)TWR/X]+Y*7)DKS6]%XC;],_?KE%+I2RFFK+
M&GU+!I[@]LI%=[4=4JVV3.[ RLO0/YH'36Y+<M=AM!!@:A(BSU*0)6L-$BV$
MCJ6=9H=H?R.%P9"+*U2F#<C\YK_-M?\ 'IC<^M<5QQPE/2NIQ+_V[WEC&]0)
M3,8),+(AZG8#YD'(LF#AO6HDJ8*K<L,]>5>)$[]JQ=O Y:]JS!()M3RT,X;$
M\65?G":3')DSB7-+JZBV\NJT&60IJ)5S2AL0T02I U]9LG96<L-65JL?B7UW
MAC8I(3+3;#C:=YFOCP\QRS>Y#"^*B\TR9 -.TH:-U4 ,JW2  B24B%1HXRS?
M0G_B ?Y/=_?G3,X>A/\ Q /\GN_OSIC%)V(YP)N<R7A.6'F1^=C@*N89<_Y:
M/R>3+(S)QQ]?D\OEPR^KR\?5Y?+PQC;T)_X@'^3W?WYTQAZ$_P#$ _R>[^_.
MF,/0G_B ?Y/=_?G3&'H3_P 0#_)[O[\Z8P]"?^(!_D]W]^=,8>A/_$ _R>[^
M_.F,/0G_ (@'^3W?WYTQAZ$_\0#_ ">[^_.F,/0G_B ?Y/=_?G3&'H3_ ,0#
M_)[O[\Z8P]"?^(!_D]W]^=,8>A/_ ! /\GN_OSIC#T)_X@'^3W?WYTQAZ$_\
M0#_)[O[\Z8P]"?\ B ?Y/=_?G3&*A$1SF"UYEX5CQP5+<9<9BKF?/.?!&QY^
M7'/!G#R899>7+#'R<\XX\\8\Y9\\<Y<P[_%]/V_.^;O&-?0G_B ?Y/=_?G5Q
MAZ$_\0#_ ">[^_.F,/0G_B ?Y/=_?G3&'H3_ ,0#_)[O[\Z8P]"?^(!_D]W]
M^=,8>A/_ ! /\GN_OSIC#T)_X@'^3W?WYTQBD=$<];.^9>$\9<%HN).<A5S+
MC+/P4/SQEAQP9QYPQ]'SACSCESGSY^.>?G^;EQA@QC;T)_X@'^3W?WYTQAZ$
M_P#$ _R>[^_.F,/0G_B ?Y/=_?G3&*!\1SQ ]YMX5QGQ?J^DYR%7,L<LO"!_
M./.&/!G'G#CC#S<><<LI.><N,L^,N.,N,,9Z_?[_  XX]>^,;^A/_$ _R>[^
M_.KC#T)_X@'^3W?WYTQAZ$_\0#_)[O[\Z8P]"?\ B ?Y/=_?G3&1P]@2QDI\
MWK-&?#G"UQAC5HV*N>.?G5?+SEG,0N<98^3R\>;QAASY?)SYWDX\G+&96[D>
MURWW%CU2U 0 \0@==[(4. ;!XA!1)%'#8>D78.4GN4JY*OE4 V=/9Y6 QD R
MKK#(0K#6A>/J^9L"5=OI^^4JF[NRBN$J5VW8C5 <B\E%T.*^CZV14: K82V;
MKNXR+Y=(:[[4*0+ZV7V@;6MO]MNV8 +S0&F,A@I*1?P"ET_5(H/XC$J+KY!
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MVE>Y7\YS%/I%$1<D/U7#3.YDVZ%MDQL,;%=T= /)$@C]IE -0YLE+=-Y76Z
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MC"4C7SPM1816:<.!.>T?^QTOOZ''3KRGI8\]+Z?AQJ_QM.]A(C6M:I!_#/\
M:V[_ #O*D/\ ;GY^=/?QZN[[%7<MS$)K[3>YRC4/A,W718(0ZO W=?B1UD7
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MR[S@?7N\QY+M?%*D]WY!:233NTZ;E.JGAJ^Z>-,$&#& '4+F4X2U]\^M??\
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M.F,.F,7E/^I2?ZRM_P"JAZ8QATQATQATQATQATQATQATQATQATQB^#^<K_\
MW>A_C<Z8QATQATQATQATQATQG +_ )NI_P"HP_PZAT^<OU<9W]7&'3&'3&'3
M&'3&'3&'3&+RO\WV?]'#_:8=,8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8P
MZ8PZ8PZ8PZ8S@'?_ %5C_OY#_P!9-U#I\Y?JXSOZN,.F,.F,.F,.F,.F,.F,
M7TO^L%?_ !##_=H[J'67Q_8QC#JXPZ8PZ8Q=3_ZX6_[W7_W=3ZAUE\?V,8QZ
<N,.F,.F,.F,Y)O\ K,'^HL_[2IU.Y\']8XS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g105292g22i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g22i22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2X"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +>:^$74#A"24T$!       )QP!6@ #&R5'' (   (_^QP"-P (,C R,3
M U,3$< CP !C$S,SDQ-0 X0DE-!"4      !!7Y-7!CO]L+LN^>["SCU_9.$
M))300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'
M-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%
M-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<'
M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     $^P  !P@          0                         !
M    <(   $^P                     !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   $^P    !29VAT;&]N9P  !P@    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !/L     4F
M=H=&QO;F<   <(     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    -.$))300,     !KK     0   *    !Q   !X   T^   !
MK/ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,"
M@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,#
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M:U_P#+3&K9[M%V=CAUK6X-;_1@NC+IT:?SW;K6[&^YNW>M-M/1W.#6NJ<XQ
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MOE#OSMR\UZ2 <QP(D&B\$'@@L73WXF(T%S**FN:]A:YK&@@A[-0X-5?FY5D
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M_T-Z-GNBH[<(U1NPOJZ\-#L*UP;(;-SC$G>[;^L?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU>$D,D5'2%5"1E)49Y*4IZBS0TE3969IAHB)DZ7_Q  < 0$   <!
M         0,$!08'" +_Q !S$0 ! P(" P4-$0D*"@@% P4!  (#!!$%(082
M,1-!46'P!Q05(C4V5'&!D;&RTQ8R,S15<W1UDY25H;.TP='4(U)35F)REM7A
M%Q@D0G:#DK72\0@E-SA#=X6DX^1$15=D982EXB8G1F."9J*C*$?"Q.7_V@ ,
M P$  A$#$0 _ +?^L#U@MK=%-K6FE:6:*>70]=4$0G1Q\[B$A?7K#T^O\Q;%
MI8%K7-&!,%"%.PHLD$90B-+-$>(2@P)@0%WK#L.@JX'2R.E#A*YG2.:!8-81
MD6.-[N-S?@RX=X\SGF<8#I9@,N)8G-B,=0S$9Z4-I)X8HMRCAIWM);)33.+R
MZ5]SK 6L-46N:KOU2AU"?J;UK^#>9?G/Y7]!:3[^?^FSR:S[]Q+1'LG&_?E+
M]A3]4H=0GZF]:_@WF7YS^.@M)]_/_39Y-/W$M$>R<;]^4OV%/U2AU"?J;UK^
M#>9?G/XZ"TGW\_\ 39Y-/W$M$>R<;]^4OV%/U2AU"?J;UK^#>9?G/XZ"TGW\
M_P#39Y-/W$M$>R<;]^4OV%/U2AU"?J;UK^#>9?G/XZ"TGW\_]-GDT_<2T1[)
MQOWY2_84_5*'4)^IO6OX-YE^<_CH+2??S_TV>33]Q+1'LG&_?E+]A3]4H=0G
MZF]:_@WF7YS^.@M)]_/_ $V>33]Q+1'LG&_?E+]A3]4H=0GZF]:_@WF7YS^.
M@M)]_/\ TV>33]Q+1'LG&_?E+]A3]4H=0GZF]:_@WF7YS^.@M)]_/_39Y-/W
M$M$>R<;]^4OV%/U2AU"?J;UK^#>9?G/XZ"TGW\_]-GDT_<2T1[)QOWY2_84_
M5*'4)^IO6OX-YE^<_CH+2??S_P!-GDT_<2T1[)QOWY2_84_5*'4)^IO6OX-Y
ME^<_CH+2??S_ --GDT_<2T1[)QOWY2_84_5*'4)^IO6OX-YE^<_CH+2??S_T
MV>33]Q+1'LG&_?E+]A3]4H=0GZF]:_@WF7YS^.@M)]_/_39Y-/W$M$>R<;]^
M4OV%/U2AU"?J;UK^#>9?G/XZ"TGW\_\ 39Y-/W$M$>R<;]^4OV%/U2AU"?J;
MUK^#>9?G/XZ"TGW\_P#39Y-/W$M$>R<;]^4OV%9RUEZ]W4'V%V&I2BQDZUQ<
M%N6;#J]%(\5+,W?+'B5O:-GRZ>A>+=;,N'@?A7?_  3#@BR?W'>\*2NZ[O$F
MHPJD@AEE!G=N;"[5W1@O;>ON1MWE:L=YDFB.#8-B>+!^-U!PZBJ*P0&OI8Q+
MN$;I-SW3H<_4UK6UM1UMMBMH/U/-_?.DUL_!%FWRJN6/7IOP,OOANSWO\?Q+
M1'/>BOJ)C/Z04OZA3U/-_?.DUL_!%FWRJ>->F_ R^^&^03GO17U$QG](*7]0
MIZGF_OG2:V?@BS;Y5/&O3?@9??#?()SWHKZB8S^D%+^H4]3S?WSI-;/P19M\
MJGC7IOP,OOAOD$Y[T5]1,9_2"E_4*>IYO[YTFMGX(LV^53QKT_X&7W=OD$Y[
MT5]1,9_2"E_4*>IYO[YTFMGX(LV^53QKTWX&7WPW[.G/>BOJ)C/Z04OZA3U/
M-_?.DUL_!%FWRJN1UZ;\!-[X;]G3GO17U$QG](*7]0IZGF_OG2:V?@BS;Y5/
M(:]-^!E]\-^SISWHKZB8S^D%+^H4]3S?WSI-;/P19M\JGC7IOP,OOAOV=.>]
M%?43&?T@I?U"GJ>;^^=)K9^"+-OE4\:]-^!E]\-^SISWHKZB8S^D%+^H4]3S
M?WSI-;/P19M\JGC7IOP,OOAOD$Y[T5]1,9_2"E_4*>IWO]YTFM?X(LW^[_[5
M7^SZ_(Z]-^ FW_\ I#>Y_P!'[_#Q)SWHKZB8S^D%+^H4]3S?WSI-;/P19M\J
MKD->F_ R^^&_9TY[T5]1,9_2"E_4*>IYO[YTFMGX(LV^53QKTWX&7WPWR"<]
MZ*^HF,_I!2_J%/4\W]\Z36S\$6;?*IXUZ?\  R^[M\@G/>BOJ)C/Z04OZA3U
M/-_?.DUL_!%FWRJ>->G_  ,ON[?()SWHKZB8S^D%+^H4]3S?WSI-;/P19M\J
MGC7IOP,OOAOD$Y[T5]1,9_2"E_4*>IYO[YTFMGX(LV^53QKT_P"!E]W;Y!.>
M]%?43&?T@I?U"GJ>;^^=)K9^"+-OE4\:]-^!E]\-\@G/>BOJ)C/Z04OZA3U/
M-_?.DUL_!%FWRJ>->F_ R^^&_9TY[T5]1,9_2"E_4*>IYO[YTFMGX(LV^53Q
MKT_X&7W=OD$Y[T5]1,9_2"E_4*>IYO[YTFMGX(LV^53QKTWX&7WPWR"<]Z*^
MHF,_I!2_J%/4\W]\Z36S\$6;?*IXUZ;\#+[X;Y!.>]%?43&?T@I?U"GJ>;^^
M=)K9^"+-OE4\:]-^!E]\-^SISWHKZB8S^D%+^H4]3S?[SI-;/P19O]W_ -JK
M_9]?D=>F_ 3;_P#TAO<_Z/W^'B3GO17U$QG](*7]0IZGF_OG2:V?@BS;Y5/(
M:]-^!E]\-\@G/>BOJ)C/Z04OZA3U/-_?.DUL_!%FWRJ>->F_ R^^&^03GO17
MU$QG](*7]0IZGF_OG2:V?@BS;Y5/&O3?@9??#?()SWHKZB8S^D%+^H4]3S?W
MSI-;/P19M\JGC7IOP,OOAOD$Y[T5]1,9_2"E_4*>IYO[YTFMGX(LV^53QKTW
MX&7WPWR"<]Z*^HF,_I!2_J%/4\W]\Z36S\$6;?*IXUZ;\#+[X;Y!.>]%?43&
M?T@I?U"GJ>;^^=)K9^"+-OE5<:]-^!E]\-^SISWHKZB8S^D%+^H4]3S?WSI-
M;/P19M\JGC7I_P #+[NWR"<]Z*^HF,_I!2_J%/4\W]\Z36S\$6;?*JXUZ;\#
M+[X;]G3GO17U$QG](*7]0IZGF_OG2:V?@BS;Y57&O3?@9??#?LZ<]Z*^HF,_
MI!2_J%/4\W]\Z36S\$6;?*IXUZ;\#+[X;Y!.>]%?43&?T@I?U"GJ>;^^=)K9
M^"+-OE4\:]-^!E]\-\@G/>BOJ)C/Z04OZA3U/-_?.DUL_!%FWRJ>->F_ R^^
M&^03GO17U$QG](*7]0IZGF_OG2:V?@BS;Y5/&O3_ (&7W=OD$Y[T5]1,9_2"
ME_4*>IYO[YTFMGX(LV^53QKTWX&7WPW[.G/>BOJ)C/Z04OZA3U/-_?.DUL_!
M%FWRJ>->F_ R^^&^03GO17U$QG](*7]0IZGF_OG2:V?@BS;Y5/&O3?@9??#?
MLZ<]Z*^HF,_I!2_J%/4\W]\Z36S\$6;?*IXUZ?\  R^[M\@G/>BOJ)C/Z04O
MZA3U/-_?.DUL_!%FWRJ>->F_ R^^&^03GO17U$QG](*7]0IZGF_OG2:V?@BS
M;Y5/&O3?@9??#?()SWHKZB8S^D%+^H4]3S?[SI-;/P19O\JK['Z9\37IOP,O
MOAOV?M\AFY[T5]1,9_2"E_4*>IYO]YTFMGX(LW^55R.O3?@)O?#?LZ<]Z*^H
MF,_I!2_J%/4\W]\Z36S\$6;?*IY#7I_P,ON[?()SWHKZB8S^D%+^H4]3S?WS
MI-;/P19M\JGC7IOP,OOAOD$Y[T5]1,9_2"E_4*>IYO[YTFMGX(LV^55QKTWX
M&7WPW[.G/>BOJ)C/Z04OZA3U/-_?.DUL_!%FWRJ>->F_ R^^&^03GO17U$QG
M](*7]0IZGF_OG2:V?@BS;Y57&O3?@9??#?LZ<]Z*^HF,_I!2_J%/4\W]\Z36
MS\$6;?*IXUZ?\#+[NWR"<]Z*^HF,_I!2_J%=?@,XVAAFUT&H^Z+)J&RXI/Z(
MM^S4:R!4W(ZN>61]K6<TM&DJ<]2[6_9*9T;G)#9CD8<2!&WGD*$"485!@!&%
MY].;"Z%\D;)&.;(QO32->"'M>=@B8006C.YV[%-JZ;!*C ZC$L.H\0HIZ7%*
M"C<VJQ&&NCDBK*7$9G$-CPZB<Q['T; "7O!#G#5WQJ4?-)_LA4>][;6WXWV;
MS(,%]*/]??XD:Z(YB76A4>W59\VHE7]L72\9HR@-*(6I2L;=/-BH)G:&QIZY
MMPU;@SQ*=2)TAM1QQ(N2I5;JCBC'#V%WFCTVM28Q2]/DJ.,5DN66..DHJN&5
MTLU4\7+(7;@Q@(L7- =(X@V&L7$-!)  &W,K+,%Q.HQ7&=*:QIFDI,%J>@5#
M1QR!K):BEB;48A,6.<V-U1-42QT\;Y' 110@-+-UFUN8GFC%;"I"U[HUUVSB
M.Q)-#E1QQMF,IZILBKEB2-222HH:1+H&XS5/X)/(^WR5S;D+J846RKT2946O
M.0A+,3E'P;5OW6.*:!T)EN&'=&2=, 7:KPW-A+1<;1?+A(ET>EU:<5P_"\:T
M?GP8XL9F8?.<0HZYKIX875'.]7'3'6I97PL>Y@<9&N< P.OK:O6Y)4+#.^GE
M"-F61F;6B8TY?[IK;91K0A3H<2V*2R*XLNL9B^%IBRBU4B95XI=!U[P9C*MR
M9"H>E5#--:L'&^FR%E8^ NNV2(3L!N2UP=J/:"?XKLG@; =:VVRGP8E+1Z:5
M>!RRODI<3PF/&J(2/+N=JF";G.NIXBXDMAE:(*ED8Z5LIJ'-MKD"!'*M9BG"
M)PB<(G")PB<(G")PB<(G")PB<(IO=-+V0?2[WRU/_CJT<I*[TG4^M/\  L5T
MYZSM)O:7$/F[U]/+F%+AE.$4"-S^H_KAHGE.FNDV=KW4^J+0N@QI@4/4R<YL
M@56%,Z-P=I O&J;F6.@E,TD\/K*$#>7-&G?K!E[ RB/1ICU;BC6OX$65]1-K
MH/N-4.+8A<5L2O5#9+Y974ZK&W(T"(V=6EAPARRVR2&S5@(7NJ-$[(^[1.)(
MD+HX)534YMRL!X1G&)R2*4'")PB<(G")PBP3:&TFLE(/J.+W1L71-0R9P:B7
MU!';0MVOX ^KF10K6("'E&T2N0M+@I:CUS<X(R7 E.-(:K0K$X#A')CP (NP
M5[>]'VY%WN<51<M4V="HTJ6(9'+Z]L.(S2+Q]:W-R=W<$;W((V\.32U*D+2L
M2.BQ.O5D&IFY4G6G  F/*-$1=Y32F,K5K0VHY&Q*W&0,2J4,"!,[MYZU\C2(
MUI(62)H2E*!GN3$D.?V(E4[HBSV].:]-)9J@ W)'@XB]51-H8D32E8KET83)
M(,K"@FRI0_M1*:'+AL[5(0(I2>8K"5'E8F!]9'P*=V$D.$SO#4YX!E$X)#S@
M!)L!<G( ;2>!1:USW-8QI<YQ#6M:"YSG.-@UH%R220  "238+E%;TSMZ]I:E
M[LV(G1_.5IV)M5KTJ9>]*$"(YQ7$-*,XT"AQ.1-Z<]>K*1EG#3(B#E1P0$%C
M,"4%R?")PB<(G")PB<(L'VALWK;2#NWQ^Z=A*/J!_=FW#RU,=H6Q H [N;1E
M4H18=6]MEC^TK5K;E:E5),+DQ!B7*I,H3]][Z28 )%V&K;NI>\6QS>Z4MZK[
M@9F5P"TO+O5L_BE@-C2ZC3%+0-CFOB;L[I$#@-&>2K"C5&E*1)CBC\%Y*, /
M)%BW.[^EN"I"=G;W5[!,2$ ,K-S?U48*C(C7(MF*#(3/39W#*(QX.*:@8<LI
MLC<C2T(<95#"5DB[_$-B-?[!8%DK@5YT[-XNW^A'A\DB%FPJ2L"'TP/BV,,/
MACPS/:UN3>C<E;7&/-'?E(/1)\0+6E%WY>E/3ED63UKTS-JUG;7%V;$#C(5:
MEO8$"U>E2K7Q>C;5KRK1,Z4\TL]S5I6AM<752F1%GG$-J!:N- %*E/-+(L"A
MW#U''%2YT#:77(4).EWJ?DS$-WUF**FSST."\>DDN0XD^6@<N]"1!=/2V%9E
MY]#A!6^!>#9P;PBSVJ>6A"L3MZUU;4:]6A<G1*A5+DJ=8I;&82$#NXITQQH#
MCD+4-S;0N2LL DZ$3@A"J,*RK(P81?JVN3<\MR!X9UZ)U:75$E<FMT;51"YN
M<FY<06J0KT"Y*8:F6(EB8TI0E5)S3"%!!A9Q)@RQA%DB_EU=6MB:W)[?') S
M,K.@6.KN[NJQ.W-;4V-Z<Q6O<7)P5F$I$*!"E)-4K%BHXI.F3E&''& + (6"
M+\F1\99,T-LAC;PUR!@>42=R9WQD<$CJT.K<K+"<E7MKD@.4(ER)24()J=4E
M/-(.+$$99@@YQGA%^S<Z-CN0:J:7% Z)B%[FUG*&Y6G6D$N;(XJF=Y;C3DQA
MI9:]I=T*UK<T@Q84('%&J0JBRE*<XH!%[W")PB<(G")PBCW9VW&J5)R4,,N;
M9S7NHY@-M2O((I9UT5O I*-H7&*"43J%BE4E:703:L-2*RDJ["7*508E4 )-
M&(DS 2+O]87!4MVQLR94Q:-=6[$"G-4RFRJL)M&I]&RGE$2E4+6DQ\BCF[-@
M'-(G6HCU2 2K"I.2K2FFE  H*$,BXQEOJC))%YI-X[=%3O\ "ZW-=2+$ES+8
ML/=(O CF),-:]DS1_0O![5%C6=&6-6ZEOBM"-O3 &>KP24'(\$7*36WJGK9Q
MBS/8MH5W 7:<N6&:%-<UFL:BSC,'<0BPA:HLB?7- ID#D(1Q(<(6DI6JR(TO
M&"NT8<9(NNL>QVO4GLAQIN-WQ3,AMYG4.R-WJICM"$.UD-2M@P/+ZE<8,@?%
M$G0J&7!9F78A2UE&MV"QY6!)[D781=J;[3K%VELK@+78T#<IW!$"-UG$*;Y?
M'UDMAK8X$A4('*5QQ,XF/$=0+DXP'HUCNC1IU)(@FDF# + LD74O7):[>GY@
MJKU?*6]5"6(6YSBU;^JG!O3])6UX:AOS0X,$/]'?3"\H75C*,>6Y6W-RE.N:
MBQN*8PU& 1V"+)"R6Q1N-5D.$GCR$] YQYE7$K'IM2FHWF7+4;9%&E66>I -
M.YR=Q<$#?'D!V *GI:N1I&TI2>I)+&1=AX1==DTOB<+1)W.8RB.Q-M6."9I2
M.$F>VUA1*G5;@S*-L3JW12E(/<%>"3LID11@E)^"C,E%C[@781<NX."!I0+7
M5U6I&QL;$BEP<G)P4DHT#>@1DC4K%JU8I&6G2)$B<LP]2I/,+)()+&::,  "
M%@B]@LP!H &E# 848 )A9A8L# 8 >," , PYR$0!!S@01!SG L9QG&<XSPB_
MOA$X1.$3A$X10CF?LBFO7O0=K/C;U*Y4-]*R^O0^),LBI^M3%/;[!/F&.+4/
M^:3_ &0J/>]MK;Q?_P!7V;_?_P W,AP7TH_U]_B1KH[F)=:%1[=5GS:B6&-C
M;*J>5+.CO?\ 93"9.:-B>N]/TK<,7;P%*CW#.L%IN;+9T-4I!'IBAN#E$79C
M=PM*E4A$XL\F;#,J$R9R*5!F0QR-Z)0L.K*Z:26-QV?=V7C(X@X%I-B 0=MK
M*OP2AQ"!G-)P:AF%+BU1C&(8EAT[B6AHQNB9+15#76<0QE0R6+= UVYR1/%G
M%A"DO:>X=<OE=[Z5],NHH3=,?ORJ'E-K=5<:K>ZHS358IHG/H[.XE"QQIWAS
M"P5Y,7F-,H(-'&V*1EVC*<\M4;,)XVX&E-7R(Z:1KZ21M&8S$^T[R^-TDA<T
ML<^^N2YH<2\ZQ!MYUM@K#AVC=?#6Z)5E-H6[#)<(KXW8U73UN'38A7NJ*:2F
MGJ1*RIFEJJ>&:0U4KYYF3$$""F?8ZL#VJ7(H#T?91#W XLJ0;#;P-J^,MAH@
MA5*X52M6H#91)$Q6<]\$A3RV5QY@PIP'O1BO*Y. 8C4B@)=66%^(M>,VPTQ#
MCGD^1YU1P7+03GO<=K9?)3.K>:5!4L!,."Z,.;/(/.MJ<2K7B"$G9KF"*64M
M.8;JD[6E5=\KUL!.$3A$X1.$3A$X1.$3A$X1.$3A$X13>Z:7L@^EWOEJ?_'5
MHY25WI.I]:?X%BNG/6=I-[2XA\W>OIY<PI<,IPBUU.LO6T-N?974ZM6'4;8G
M;.[@P&>6$[5]4&P%;Z\5Y.-?JYMBEI,_0*Z7JST2]JG44-MU%5CZ&(L V20I
M3D8' M\3%GE!R16,]+^L)?5>L1K98M%V;0EDRNV;4L6PV&Y;JA6P%G3.83F3
M&OCK8\MLNOB$L8<U4C[^0D;FY&D3&LK(SMC:I+,.($H.(K W5U:V)K<GM[<D
M#,RLR!8ZN[NZK$[>UM36WIS%:]R<EZLPE(A0(4A)JI8L5&E)TR<HPXXP!8!"
MP1= <KLIIF2UXN>+;K%J16Z:V$5.L<I[%4*6SSGI&G<6<FO%"IU*)FIKLWJT
MJYL+C8W,:]&I3JDN#2#BQB(N5]5"M/3_ )J?U1(-ZJ>&3TRYK7TVL'I_Q'.[
M[WZ8,PWT0],7H)WS]9Z*^AO@'=_K>_\ =>+A%WGA$X1:Y_55Z;NV.U&U[3<=
M'L%>/<-+H*O:Y5YE%@^E-V322*3ZXI&X8"@''W0![>:VSQFRF6 58&)06M)&
M0#!(!FEY<TFVS([XY=[85+WI":=7?I]3UXQ&_FJ(-S[8UW"G3,W1638EZ#,:
MQ5-:PK.'%9EJ:BBE9SK%7;ND6"#@81"3&"-R(X118_5X/I41EMX3OWRWEC62
M]/?: VH5L+C%H)&-TKV7P^HZI(B-CNT,>9+H[5BNQUU?U\_S];7,P,B5@K5<
MZAYD]"GBTE89HDHZ&-3DY)R'M:K:BBO1;.GMMM'(O*WICN=U#>$P/1M<EGBF
M_K24"DL;1Z$5G1Q:F0&-\=C#"\3/&Q=?-\O/G^("S2YT86MLD*A:D7&G1<AR
M\.U%^$RT,W1DS0L2L\_:(G/4"N3J%ES)]FKO>Y3:3J\M\_;G*3MT=D,+=XMK
M@MF49D+3#3RZV:Y%F%)U1I384^1ZNX,W+29_5V^5E9CIQ5=E4O0$4KVV)0\R
MN7M+K,58EC]/,V:XMK$\2YZ=XS'1344%K@3L0P,"QO;$R<,41I&,D@$?:U+B
MT-2!<>12AX1.$3A$X1.$51>YFLFQE@;,EVS4L%BLUBJ^BH#7:S#M82*'.;=(
M(E/[;DJO.4:YE< *T"IMGC5A,I)4!'A0G6%&DAP L9F1:/XS!A!JC-%+**@0
MANY:G2[ENMR==S=NZ"UN K$]*='JG'FT(IZB&#G5U07F7=.F$PA #=1KMFY&
M]^$6NLL=/V@[GIA3?[Y<D9CT35V5+H0XQQH8I<1,!A;(Q"$C L4N"Y*V-J=,
M:>X -\'2@"<+O ,&F##D> 8I,;Q&/%*TU44;XV;E''JR:NM=FM<]*2+&^6:K
MM',)EP7#1132QS/$\LI?%K:I$A;8=.&FXMF;+%^M&J^RM=T!8=$6#@9H7+7N
M7UC%W1;L ;/H*7)W!K6M#-EB@?J+0]Q@[(<6O$<8I.E$J4MB),!N"D7F&86
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M;&A&6$M,C(5/;R[O*[)1035[LYKW):8H6*CSQ^6L:TN+0 7G6<=]QL!<G:;
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MP;82+7F'#UXA$R2LC,]U4P$/\E>K)MUD>G4U18,1D*U::2UQF.H^\H%)"5(
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MLZ!PP[NB..H5+Z\+5:MS=7%2\*U*K/HTY%J9[(FPRX7*PO#YVVF<7N.O>)A
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M@6IB4C0D+6IQIW#O1XU>3SJENJVLI! 06"BD+-5Q<US[RW%R3?I[Y9D$6M8
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M6<!"'&<YSC&,YX )-@+DY #:3P*#G-:USG.#6M!<YSB UK0+ESB;   $DDV
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M<:Q %WO<611,O)-)'$USQP93"O?C2ULO[SE*68 Y%$TQG?VE,,L834ZAZ.R
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M%\:Q'#.:E-5.Q"L;A5)B>!4531FIFYR9!BV'&!\SX#)N+6Q2ALI.YFTAU_/
M _UN;KI4U3='>.U6PU) 2]@ZMQJ8BLB;MT.CV;(-LB[0GV)(H@KDQ34"2J!(
MRI&UHB"CW$>%+:K0(PDEIDY)7%-/))B6Z&1^XR&HU&EQU-SC:6@VN6_Q;Y#(
MB^^FC6-XAB'-(EQ";$:OH17.T@DI*9]3,*(4.&@TD,[8#)N+0[<7N/2#5>US
MBXN)*@P+HW0_$\%JH#<Z!#Z@@8)Z=?6V^IY* PO+GB)^G<5=!NS*[T"S,O2O
M_NOC'H+A)E)_)\@PC[5N*WHD_4W?G9_.FOJB;7&O;6U=?<K7U;Y;=N6U98.:
M;5\ZC'SHS5#1 UG.@QGGR$U09N_.W/9P[5U]PW:\>4M]<:E];(XBJ'IUUTT4
MS05[;.[,L-"/NQ-C.<=H>L'2LY'. R$N#RXF-/SK9SNU*R?2'&C7\!;4>K]!
M9!X&B<4#HH3J"C5:)'[EK7E\T4$#IA#'>602-9JZS=8:@()>X#.P(N00+9$W
M'$]-:V7$L7PG <#EQ>'!Z%LV*U[*V*E,//5,9HV4,;VGGJ81'7:T21%SV/8T
MBS7.G!N?TXHC<6_._P#/37YIUPU;UL#1)4A.K6HU,S=5$DGU2UYAFB5=U/!_
M00M8N<G-0H<GM86:C2-XW I>L <%8L5I*6GKG14M*RQFGFW35UY T ->Z[GR
M/N-F31?.UKC*^*:,Z;U&%:):*T@B?C..XR_%3"*_$131-@I:^J$D]7B%5NFJ
MUK0&1-))?JEK2-5K3^>F^@#'KKN/8<0G!L*O^JK*Z<5PW[2DQD5?"1%.C(Y8
MCI+([N<"G"-:O@\^CBPA80K0'B-<F?P@DP"P@Y6H2)H5589J9CV:\,C*R.*1
MH?L(#R0'M(UF.R(.PVV9 F.DVF$N.:,T=32"IPG$*+3'#\*Q*G@K-?4D:V<R
M,CJZ5S65-),W5+7#[G)JG)P:''6OQY,?8QR^+>0V#M!>>%%.$3A$X13>Z:7L
M@^EWOEJ?_'5HY25WI.I]:?X%BNG/6=I-[2XA\W>OIY<PI<,IPBJ+ZD!?1D@4
MFKVPNIC$]4 3F2$*VN /]R5VV2R<R%HC(TYJQ"4!MCKW)WB*LA[JEP:0Z$*8
MVA5N1!.0EJ5@ &1%\[7X[7^-%.+4Z^]9=BZ4CDYU$E4.EM%M)RN"Q55 6%7&
M(DT>D_!#8?&V5A5LS!AK0L1>$Z).C2-:= G)"64DQWH&,8@BDEPBI_WTZJ*7
M4/8"O]<HE%:4E5@/T$CMI/Z"[MF(7K6%]C<LG[C7L6@5..$U:7%CFMNR5PCT
MM=4;3)G>#0YK:HX'#O+TZU\:TV2+]"^J!)![2@KD5&-!>L@]S?G>?JUCLL>;
M(+VEQ4?JK"P949<.&T^I8%5@5>9DA=BCD'IG#Z*8C>6'.#^$NNV:\6M5UP=3
M[;>2U+9,!M&.(-)=)6!=(*ZF,=FS(B?45V;SK%C*K=8TXN:!.[)$C@@5*6XX
M\"PA.N1GFD@*4DB&16H<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+K
M\GE3!#6DU[DCD4V-Q9R=*6,19ZE4M7K30IV]J:FY&4H<7AY<U0RT;4S-218Z
MNBTTI&WHU*HTLH4R**29X9$TO<02=@#6M%W/>YQ#6,:,WO>6L: 2X@ E4==7
MTF&T[JJMG;!"',C:2'ODEFE<&0T]/#$U\U34SR$1T]-3QRU%1*YL4,;Y'-:<
M998I9:N.^S,A?"J\-QVE5^0K"3*9:F$$P.<6(ZMJ@P#0R*L"",<&CRTPY>G+
M+(EK^J0.#O"R*K=(:3* MFJ>R"+Q0FX]+,< 7R"UA42-Z4DF&-KVLG5D-)B&
M/]-B;)L,P=PRP</:VNQ%A#A_CB>%[VP4D@()PJCE+IFM:W$*N2&:HPP9A2MS
M>A3(42)"C1HVL@I,V)$J4A.F;DQ!'@I*="04 !20@E+_ .3%%)P%EED?R$ <
M%_K>49<YQ<YSG$O)+R227$FY+B3=Q)S)-R3GM61QPPQ,BCBBCCC@:UD$<<;6
M,A8UFYM9$QH#8VM9TC6L  9TH &2P=.=EZHKJZJIH"4N;TEL>YT+ZO@J)+&7
MQ>U+RH_DK"TI0])$1J A1W(CCC"@&G^AB-,-P?A-#>I;U2V%LK\"F+/O((G"
M+Y\5I?1OV4^MM;MA[OD]<C:7;[?9C'^GR>WCK/03K0P+V(_YS.N#N:G_ )0=
M*/9M/_5U%RW_ *%TW].W[OE\G;];Q]O,M6 )X_O=OC]W[F?+CW?%XL9\?BX1
M$W[8(!]M:HOC0B/B^M[OV/;\?9S&--.M3'O:Z?P!9IS.NOG1;VXI?&*^B?SD
M9=^)PB<(G")PBZ@MD*I:K4,\4)3KW!*:).Y.JK!@V%A.#W/=DK#"!E&.;J6$
M>!X8D!Q9P.P&'1:SEJ$QYT]L36M$DQ+6D78QMMUD'"T&X8P[-T<"#GJ->00+
M;+6R2ROIL.8R::-Q9/4R:QHZ-XM=DI8YKIZEH(=SI"YK@+<\34H?&]_XB#%X
M(F&_R>0($:ER<&)A52N5N;>W"7.LC?$,?C$>3*E0T:!'EYDKPVL<;CC:%.6X
M/KJD1H4BMZ=,B5^9)7/LT ,C:26QMOJMX7&]RYY&U[B7$6%PT "=2T4=.Y\I
M>^HJI0!-5S:KII&M)(C;JM:R&!A)+*>%D<+7%S]4R/DD?W7DI5B<(G"*+<DU
MF=9#('M^*V=VDCI;TZKW0#!&YY#44?90+E1JD+4R(U==+U25J08,PF0)U"Y8
M<2E**+-4G##DP11)N;V R:+ 6'2M OVS:[CON).6Q18T^INP+HU6UUMV;[=;
M8'S"R::KN;R@UNG,$;VXY]D<8;75T,1H 5D,*1*8K4FB*3 ,$$D&<%A%V!QP
M,CP\1V=U ;$&P-B#8Y@V-[$ C([#F,M]6CE R4467DPPW)98 9--S@1IF0!P
M'OA@@A"$1@^SNAYP$.,BSG. XQXL%!?IPB<(G")PB<(H1S/V137KWH.UGQMZ
ME<J&^E9?7H?$F614_6GBGM]@G;](8[R[RU$/FD_V0J.^]NK?\;[,YD."^E'^
MOO\ $C71O,2ZT:CVYJ_F]'W>7;6OUR[K<*<(G")PB<(KJ]:.JG$]?H#T\XB&
MNI<[*M0;"V$?K($0N9 M=APV]@2-"K86-.H/[LM8WMD@R(T+R64B-7)"1 %D
MO&!8M4V'OEDK'Z[ *AL0CO>['1ZF;LCD=4BXN;'>6J\<YGU5B]=IC5<^4S&Z
M0TF%1T (EUZ2IPQU.]LLQ:VVJY\) W/6=JO.0*X_8SJH-5YUQN3&TL+ES'+]
MB=L:VONO7T]<S'H(1#ZJ8XY&(G'7DD!HS3GY*S19JQD;>2<UA4 %C!@R\]N?
M45 8WTKBYI;#3R12-%[O=)K%Q&0Z6[SF;.L .U[P;F?2X77:-3OJ*66FPC *
MW"JZ("77J:BODJ)JB6(EH B=)42#IR'ZMLEFDSJRZIYO,W?PC5JQBNH".!9C
MX,BL)H,UF+GXH+ZG&;1] ? PSX2W$5_W.]*V5V&D2/\ D0EF'K.9/F7T/J=R
MYT-0SG0/OYPB8LUM?4OYWSV=^'/9TJMHYGFD70MNB+L=HCH@*S=S_!)!C1I!
M4\^<XB6YI0WGB[]VU2_7Z?5W/[@H_P 2Z@6N,[UOH:L-NZ.LZS[-U-FLSEM+
M2FO9PPQ*.SINFLF!-7"&7(6Z-;BYDL(Y(6G"M5PY.4\*V=$E2(%;*I&N5K9K
MJ.=DTTE-+&QE0QC)&O:7%FJ-4&,@C,-O8.R!)O<6M=JG0S'*3&<6K=&\4H*&
M@T@I::FQ*"LII9YZ1U/#SLVHPXQN:PRB$N+!.[<VR.)>R1H8ULE5/6BA$@OC
M=MX=HIL' J.W %4;RB>:0LENKW8RI9E5$)B<43O<9E*,_P! U:*18CQR9Z:C
MU91*EI&G3&C-*.<$1\GH8\14P#H72T^N"V5A?#(U[BZQ!%[B^1MMX+ JQMYE
M]9#A.C+(ZC!ZK%='SB$;X<3HGUF#5]-7U4\^Y30/;N@=#NVM&_4-GW<-4M8X
M8PCW57K"+;32NWD$(V(DM;CU"G6LT53VU>TIN>U'.03(+.8LL>4O=AR5V9(Z
M%U6MPU3O%("6VQXA1@*IO0=]4G!)].P^1U.V+7A#^>6SNU(FQ1@-#AJ-#&@N
MM?(OSME<65?/S/<0GT?I\.=4X-#7>:*FQNH-!A<&&T$<-.)6MHX(Z.GCDG,;
M7AL<]7KRD7:YU@":->79;:3A$X1.$3A%-[II>R#Z7>^6I_\ '5H_3^]RDKO2
M=3ZT_P "Q73GK.TF]I<0^;O7T\N84N&4X1:R'5$VIII@V8I._J<WST=U_LFH
M6S9C5J9XV<J6T+4]'79HE]5N-A01 BC*8M$TJ(!(VN/GN+DD\!=O#74M(B?%
M;(M=VU1$=HGM?W%%;5TRKO=M@]66BQGJ]=>]BEJJ:3)IS96L<$EE<U6J*:EQ
M));.DC,T/4/A3VTX'DEY6&&>#*SQ@&F"$&,XY!%8+PBJ6WWZ8CAN+.)9-(;=
M#/4)MT:T..G6P1+Y4;9:"R34*X3!PFQ9U:.:J418ZN+/:'1[?R6N4K2Y>PY)
M<TJI9$U#BPM2LMRY=Y%PS#TISH]L8T35#>YYNL;)MBCWL14$M@!:R;BV?0T\
M73Z=T5W8=*Q'K*Y[T6&>&Q4Z#B?CYCD0#9<-D$)NR4+?7W=G@63:6AT1A'5*
MVR:H7%8Y$&M3HYI"Y*&V+L;8P(#W%1>&]A)Z\Y&U)4B<U:>2F3%'*AEB/,*3
MD%C,$ HO 2BK->$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6-93886UUS
M#XBU"F4_,3D*1,*=5X$UQU$K[X%(]3I_PG6$QAF/&49E(7A*XR)["0KS&X^]
M80N&4E5%3:S-VF?N-."1NA&L^1PVL@CNTRO&^;MBCN-UD9K-UK+7XP(:CH=A
MT'1+%W,:_G1DFYP4<<FL(ZG%:L,D;0TSBUVYC<YJRJ#).<J.J,4VY_S&*\$D
M=RIE-77$RGH23BDKH8DRA88FF5E +5M4#CPCU8&!$IP'(5[HJ5N<J>@"PG>7
M]8W)FQN;DM1=AA@9N-.;:S0=:28M)+7U$EANC@<VL 9"PB[(VN+G.A0X.8ZA
MF)8G4#$L6:US8Z@Q[E24#)&ALL&$T9?(*.*0 B:=\D]?4@AE35R0L@AAR9RE
M5[3A%!BV-J66OK7BT1?=0MBIG*G:3O$3K"9QV'4DZ-TI=F>)R"7NN8:\OMQL
MSXW)BXHS25P$<[M\>&:G2+4V"A*%)2=213.CCL>_QYB?5+&\QA2],[8ZJ(W(
MRVXJ0Q\YQ1$JS61]*:'%X:BWAJ&<)"YEMCLZ-X%I!P4;@M3X+4F$7,\(OGQ6
ME]'#9/WUVV&.SW?YI&TL_<]K'\/;Y>=9Z"=:&!>Q'_.9UP=S4Q;F@Z3^S:<_
M^GT:Z;_>\7;^GCSV?8_T<RU8 G][/Z?7\GB\7E[.SR=O"+PF_;# ,>+Z*U1>
M/_K0B/\ H\7V>8QIIUJ8][73^ +-.9UU\Z+>W%)XQ7T4.<C+OQ.$3A%Z;@XH
M6I&>X.2LA"A2@P,]4I,"426'(L #W0Q9QC(AC$$LL&.T9IHP%EA$8,(<^FM<
M]P:QI<YQL !<GEM/ ,SDI4T\--$^:>1D448N^21P:UHO87)WR2 T"Y<XAK02
M0%U/N'J69[3O#XU&<Y[0IPB.;Y.^%]N<8RI,!D"J--IP.P84Q0B)(:$1?A)K
M$84>B/G79#LU991OY/AC._8$$2O&RYO$,["0%KA;M6JQ+SV[4% =C 70XA5M
MS'W0BTE! \6<&-+:YP(UW4;FOB?^DJED!J.%.,JF#Y'8! (FB(,<WIW5(V..
M,* :@A"G$I4FY)1HDXE2E.F+[K( 9..+!C]</&,R'.<]Q<XESG&Y<XDDGA).
M95RBBB@C9##''##$T-CCC:V.-C1L:UC0&M:.  !5T;(; ]*':*$-5:W_ +%:
MY2^*@DZ=]8FQ?;3&U*"Y6E9'YO2*VE8A>$:[#B2SNCWV$)3LX4)!*P*B%"'"
MDD<+D;#9>[C.Q''GX5,"K-L-7;@D)4$IZ]*HGTE):E#@1%X5+F1X<BF=L\')
M4*BFUN4&&%H4.#TQ8Q@+P43@PH/ZW&0XX2X.P@]U2+X45CUVMRJ6!Q5L[[9U
M>LKN@,P4N:W::1MN<49H@ -P4K0K'(E2G,R68 S #B@"R 8!XQW(L9R1<=ZN
M=)_\<56?"#$O^]^$4.^GI<M0->BFH+<YVK6S<X(M<ZB3+4"Z<QA(L2*282S@
M.3JDJAT+/3GE#QD!A1H & %C(1!QG&<<(IB8O.D\Y[,7#5F<Y\6,8L&)=N<^
MY^R_"+*?")PB<(G")PBA',_9%->O>@[6?&WJ5RH;Z5E]>A\299%3]:F*>WV"
M?,,=6HA\TG^R$QWWMU;_ (WV9S(<%]*/]??XD:Z.YB76A4>W59\VHEK]<NZW
M IE033"9S*G*;N%?*&2*(;_V59M;JF87="X&N,G6'>!IY98>#D_863"H6[NS
M,P+SR"EJQ<]K%"),27E <,5+)5-9)+&&EVXP.GD(( : "6LL=KG $C> VK%J
MW2FFI<3Q+#8Z>2I=@^"2XUB,T;VAE.!K&GH[';4U+&/E:"6M9&T.).N+36L;
MI(5[4<UD-<67U+=*H5.XHL @D<5?G2>(GAF6F)2%I:5<E%&\Y).&E5)SPASG
MQEG %V^/E,S$7R-#V452]C@2'-#2"!D;&^>>7;OP+%Z/FC5^(4T-;0Z$:255
M+4-+X9X64SXY&AQ87,<);$!S7-[8*@E8.H\MKS4JAMNG"51MPB%^S.Q(7'HN
MA*<\2)D65R[N30XK7<X],6V#2N!K:8<APB4GFA*-!A0$L6!8Q5LJ&OJ)J<-<
M'0M8YSC;5.N 0!8WN <][;W<MH=)*>MTBQ;1QM-/'48334E3+.\LW*05<;)&
ML8 XO#F"0!Q< +@VN,U%D]M<4N4@53>M3"7DEJ$(3TIY.5J<W/<E'I,&%ARI
M),SXBS2>[ //B"+.>3[C/,9;<QEV^#NK(&RQ.#BV6-P82'EKVD,(VAUB=4C?
M!M9?@%,I&:,@*<\1Q?==V2$HS)H.XSV#[LO <C#W.?$+MQCN<^7LXN+7N+'8
M;Y&^S/C7HO8&AQ>T--K.+@&F^RQ)L;[UCFO9"TN@V\QW VN VHHW!!KF%&H$
MWEGYR'&"3%N"\I@&YR(.,%B-P/.1!Q@/CQQ<7M<7X+B_>VKR9HA((C+&)2+B
M,O;NA'"&7UB,CO+.\OU@MB":\U/LY)VUM05C=LFF<9KLP+F4J?'<4"/(0R!X
M5-B4!P6EH ZFFM*$3FI3."Y4C4GDMWH:)&N5RFU$;YI(&DF2)K7/RZ4:V8;>
M]RZV9L"!OF^2M%-I!AU7C>(8# ][Z[#(()ZR[-6)G//31Q->X@R2!EI'ZC7,
M:T@%^N'-;@0] O3)TBQ2B5ITB\(QH51Z8XI.M 4+N#!)#S !*4!+'^M&(D0\
M %^M%G&?%R;<$D @D;1?,=L*\-EC<YS&R,<]GGVM>TN;?9K-!);?C 4A]3]9
M)AMI?584-%'1NBCE:;T\,3/+9(C=#(RB7,L9>90I+5G-J52H-&)&S&DX)2EF
MG -/)&8 )7="Q)J)V4\3Y7 N$8!+6D:Q#G-:-I&^X*RZ18]3:.X378M.QU2V
M@CBDDIH7QB=S99XX&D![@  Z0&[K"P-C?)8E7P9:WV2MK0:U(8Y(IPI@PW$
M3L(1KDS\-@$M" 0,*,)!'@R>$.2^_=YSC&0=WXN3 \&,26(!8'VW[:NM;@OO
M*X,K6/P]F(ACA&^C;6B,D:X8Z 3ZA/G=8 ZMP=6^8-E<^_=#&7(;7>=>8_NS
MI_(-D&MN-6I:+52B7QR<O"@,=*EJ=L0)7&+F%"6K(X<6\$!R+(0-PA+U.4Z
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M(0A"$(<!"'& A"'&,!"'&.S 0XQV8QC&,8QC&,=F,>+'/.W:IH  L!8#( ;
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MB$C)9(XV0W@8UTNZRB,O<6AQ9"">F< ;#;<@@ Y7E8WS1JZAQ3$,.H:3!=?
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M3_%Y3SR_SCOS7> KP_SCOS7> JF$_P#GYW_.F?X8N<OL\XW\UO@"U0W8.T/
MORYZ44X19BT!]E%KKWCNU/QW:;\VGS-_0\7_ #Z'Q:I9=HQYRM_.@\$JK!V9
M^GLZ@_OL7'[WJ)TG]S^]XLY]SQ:SYKW77#[2T7>YZQ#N>#(G@RQ#3;JRSV!3
M_+5*QCV^YV>//B[?L?YA>7'V?;SS5U^"V9ROVOH=M';WRL03W?K>[X^S&.WL
M[/'CQY[,9\>?N^+CAXN'.P%[6S&9L#F>[DBP/M%C'K;[TQ[M4SKZW;VQY?\
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M[Q"W=X-N?QXAIMU:9[ I_EJI8Q\79];'9V>YC./)GM^][?UNWQ\U=E;B%K<
M(V&_>W^*^:Q!.WQ]GM]F>SR?6[?+[?D\6>WQ=F?;SQ?.V_8VV<5]N_LR-\K'
M?*+ ^T?9ZV^]<]OEJF=>7^QUP^QVX\N<8S[7,DT.MYJM'C?;C%#M]D,[XVD
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MUO=[/+Y>WQXX1>$_[8(!G_Z5JBQV_8M"(]GB]SL[/NY\ODYC&FG6ICWM=/X
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M6FYR:K<7-P4J%JU29G)AZ@XPP><B%G/!W[<=K;.^IJ_'DG@MO6.SMWMELO8
M;+]]$X(OP7-SD=IN1WOH%[Y$(G(V_C7N-A.TYC9O<-KWW]ZV12/Z?WTPFTOV
MI-5?QLVMY[;YT=WPE%5#KI] BH_[ (S_ (L(YNG".I6'>PJ;Y%BYVQ_JWB^=
MO\8U>7\^_+*X69^7%6A.$[2_!']$*@_?.ZR_'O /T]OE@TGZB5EN&G^=0W^)
M93H9UR8?VJKN_P #J./Z_I7;NIM]/$#WJ5/?&]L=REYF^W%^U0^&J5RYK6W
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MT^=-V9_3+=L/@LTJ^3'R%AML+\-D788%TQ;JK&0RB50?J>[9L;],VB*L4E7
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MHW=+),]ANQ[AFTVOE8@+VK+Z0<\N"<8L>Q.I/MG(9GB*,\)]&15IIFW9]+#
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MPYWOVO\ M2M70+"^QC[M/Y1>/G*[Y_3%MK_@YTZ^3=QYBM&O4]WOVO\ M2=
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MDA07W7=%&@'@(L5-'S/M$L/JZ:NI,*,5323,J().?\2>&31N#V/+)*Q['V<
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M8ZVZL.E3-;5 DL=6MBEU:LK&Q@/M$E2_G.5L^_W>WPY#)1L-4'6%R7#5&M<
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M8TPD$4%AQ>'PUA(035>O<CW+M<?=XKGA"]$#5!UA<D@M&MK #5(<38-LZY
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MQ(;\J<-A'@WHB)*-<A IA<7M<7M>V_92]VB,I@$C3,&;H8P07B.X;K$;P)(
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M@;"SNW.<G-+JA4@R(62S@9$+.2+![OT^=/GW8>+[4.5+M)EV0\<75LLB3O\
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MAED+J[5G9[6N#/%XUO;:F.H&ULE3GMK'RX^Q.+(PO)2UR2OR1M=)PD)4)52
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M*2."U,6<$A4>6/?4>B>CKHXW'#(B7,:3]UJ=I:"?],N8I--M*P]X&-U( >X
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M8IB<JERXTA*GP:H.)(*R::#!AQI90>T8PASJGFC>GL.]B2_++=W,GZG8OO\
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M:^X41+P"  7$M#A;?!/+;Q<*F38JUD[:>"GFJGR4[*F/<=75=$]Q <2XC5
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M[$N6TS>MJ+UM,=KQ_0J;$;R+C]/BX: QNKH[)*58X1_(%J7*Q>ARI/<CVXD
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MP+&L_3D*ZVW-2JB"5*536>A!"A.H+ <0>0=U$J\+.)/*,P(LTHTL60&%C (
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MPHJ0>].\VH]Q:RW#"(4Y3BQ)FK089(V!GUDV)?TRIQ:YDT@>"F*3ET^H8%!
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MOIPA R!3;!D'!;3&*JV9T."N.6*LNS@YY H CRE2I\E&A+B0#B(X/2IWR?\
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M(=[^_N+C95^SU'>^MU"_*>J;ANWM#N;W;SX<]EN.S+Z?VJ--$?0N8?ZXR_\
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M'))-&JLC1TF=8_#RF<Z3O!):I*B*;V0N0/$?9,KE"E8265ET>FQ$#&1#/6%
M#D7,0702U5;EZEG3_N:_8)<DLZ8%O24!1,Z,MHV3P[41Q?K 7NL>C[+"ECB,
MW8120]F1OT(/P6:\+"3$*<9.$&#A"& !0N+[1MM;AXN^>6:G!8F_]=[Z5_KT
M[U_55J5(75>[\:C+DPVH570%ZL+UIYM<YMBQF%6T_L)IRW 3ICDHRU;DB6E'
M$YQX%W@19PQ&6R]P>[M" @[%D[DJYMD+VMGD;6 XB!;A.=NUE%0_1?LS3_\
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MO;QBNJ!0M":ZV'")K"[+CEHQ8F2F&@%Z6+"A!KVPA/"Y1Y0>CB+\!.W9QBW
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MCN6!=@_Z.NWWFBC\N72;F)Z2=5='_90^<TJSK0_J)I5;L(V]Z5RY/FVEI/\
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MS:G@N0)I+@<.^>^M.5?IJI]D3?*.5PW0K^G6V\\?;VZNZVY_^];8;R?6\?\
M>YT%S'.MW$L[_P".YOCH,/\ BX.);+T%ZEU7L]_S>F6T]S;BS5:</75]D(0>
M/./YDBDOL?19V8^YG/\ HQR.]W1]/[5X?O97V_0J3[*^AQ8/MY])$LS_ /\
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M&8K/+(.&42,)0\AK,/IZBIJX&4\$T[VR1R.;#$^5S6-D8'/<UC7$,:2 7$
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MMW9)AHOJ(ZUVMLK8FP,.5:B]-W:UL7V8QU^!QA=GV;MA &J9H(2AKR&0PA!
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M/^ G[XO [7_<[YKOZ%&_]9<MFU8EVQW@I?:.@+%I9[U:W:3'REF&9&7A5KT
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MQ($ %J@.!CP$Y2$PP.!B[!8[K/:1>ZC@D(;P,I:"&Q5"7&EJ]RCI:./-"8#
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M<9/+)ZQJ3>?IOQ\*%2?F*XU_R&=X]_;^SB3GYO8-![C)Y9>/6-2;S]=^,?\
M6A4G^>BN-<?>,[Q^M.?F]@T'N,GED]8U)O/UWX^%"I/S%<:X^\9WC_:3GYO8
M-![C)Y9>?6-2;S]-]_A0J3\Q?(:WY+>\?K3GYO8-![C)Y9/6-2;S]-]_A0J3
M\Q?&M^2WMV/UV^).?F]@T'N,GED]8U)O/TWX^%"I/S%?IV_8[(Z_Y#.\?K3G
MYO8-![C)Y9/6-2;S]-^/A0J3\Q7&O^0SO'ZTY^;V#0>XR>63UC4E\_3??X4*
ME_,7R&M^2T]P_04Y^;V#0>XR>63UC4F\_3??X4*D_,7R.O\ D,[Q^M.?F]@T
M'N,GED]8U)O/TWX^%"I/S%<:_P"0SO'ZTY^;V#0>XR>67CUC4F\_7?CX4*D_
M,5^G;]CL:X^\9WC_ &DY^;V#0>XR>63UC4F\_7?CX4*D_,5QK_D,[Q^M.?F]
M@T'N,GED]8U)O/UWX^%"I/S%<:_Y#.\?K3GYO8-![C)Y9/6-2;S]=^/L^JA4
MGYBNS^#C7_(9WC]:<_-[!H/<9/++SZQJ3>?IOQ\*%2?F*_3MS];L:_Y#.\?K
M3GYO8-![C)Y9/6-2;S]-^/A0J3\Q7&N/O&=X_6G/S>P:#W&3RR>L:DWGZ;[_
M  H5)^8OC7_(9WC]:<_-[!H/<9/++QZQJ3>?KOQC_K0J3_/17&N/O&=X_P!I
M.?F]@T'N,GED]8U)O/UWX^%"I/S%<:X^\9WC]:<_-[!H/<9/+)ZQJ3>?KOQ\
M*%2?F*_3L^SVM<?>,[Q^M.?F]@T'N,GED]8U)O/UWX^%"I/S%<:_Y#.\?K3G
MYO8-![C)Y9/6-2;S]=^/A0J3\Q7&O^0SO'ZTY^;V#0>XR>67GUC4F\_3?CX4
M*D_,5QK_ )#.\>]M_;QIS\WL&@]QD\LGK&I-Y^F^_P *%2?F+^Y_X^/C7_(9
MVK'Z[_&G/S>P:#W&3RR>L:DWGZ;\?"A4GYBN-?\ (9WC]=TY^;V#0>XR>63.
MC4F\_3?C'_6A4G^>BL\:VWI6=XY?'X;IS\WL&@]QD\LGK&I-Y^F^_P *%2?F
M+Y#6_);WOVIS\WL&@]QD\LO'K&I-Y^N_'PH5)^8KD=?\AG>/UIS\WL&@]QD\
MLO/K&I-Y^F^_PH5)^8OD-;\EO>_:G/S>P:#W&3RR>L:DWGZ;[_"A4GYB^1U_
MR&=X_6G/S>P:#W&3RR>L:DWGZ;[_  H5)^8OC6_)9WC]:<_-[!H/<9/+)ZQJ
M2^?IOO\ "A4OYB^-;\EG>/UIS\WL&@]QD\LO'K&9-Y^N_'PH5)^8KC7_ "&=
MX_6G/S>P:#W&3RR\^L:DWGZ;\>3_ (T*D^_] KR_P?6XUQ]XSO'ZTY^;V#0>
MXR>67CUC4F\_7?CX4*D_,5QKC[QG>/UIS\WL&@]QD\LGK&I-Y^N_'PH5)^8K
MC7'WC.\?K3GYO8-![C)Y9/6-2;S]=^/A0J3\Q7&O^0SO'ZTY^;V#0>XR>67G
MUC4F\_3??X4*D_,7QK_D,[Q^M.?F]@T'N,GEEVNI-+V6K[E;KU>[[V/NR<,E
M<S"KH_BZ9E#)"SL$8G<B@TGDWH6BC%=0X\MP7N==QCM4J%JDH"=*<7A-D9N#
M"X%UQ;5:!<'('>!&^3PE>)JUTL)@$%-"QTC)7;C&YA<Z-KVMN72.R D=E;?V
MJ9G/*HTX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$72+(03AU@\B;*W
M>&N/35P181L;Z\)C%:%H.4GDDJ7+*<L!O?%2)"-4H;PF$*$_AY:;PE.>G[X6
M+TPM#@7@EH-R!:YX!G;*]KY[+VS46V!%\Q?,!=1EDWF-<UC&GQ]:&*33Q<\U
MA#G)N;G)6P1LZ4V!,8U"#3DKF>W/2Y*S-[G(?"@G&-BE4>C2]N4Q9IO>R_36
MA[W $M: ]V8N=5K2[9< D@<('&H@!SB!<"SCPFS07;+[;"VW:L>BV:(8VU^2
M36''M<VC=B!K%R:VA]0JH7A^5QB.S!H<#+(DQ$08&=D=&*4M B,R(MI>U#IE
M:S,[(].*<DE5ZW*Y&J;M+=>Y'3  EIZ47)(+3?5N-A) *]!ER+&X(ULQG:Y!
MZ47)-P=E][A70GVQK(.FDMEB>7KV9JKS8&C:7Q6S>ECZ^,R!EL=/4X9.ZNS@
MM8O3*J>0J;54*6!>UN[,B(31AK[XUF!7.V%7H,9J@:MRZ*237SN"S7L,G:MK
M,L18YNVFPM'5;8"P.LQSM;.X+=:PR-L@W,&^WB!65K9<I<^61!ZLC<Y>JW2O
M$"LNP'*3QQ)'%3R>JAB^"L;,T ]-+'(&PIJ\*FIKP[A+0!6*\-2)$!6G1GK@
M'^&!H8Z1S0^SV-#22!F'.)R(-[-L-X7OF;+RVP:YQ:'6+18WMGK$[",^EL.V
M3M 4=ZYM&XG9UIRUK'6SMNKFVD-)HH^@BBZMBX:7)YY6K2K< R*/N,=6V!EF
M<IRH7)DZQND:$U"(UOSX*<V9.4XFN8P![&:A<S="XD/UK->;6-PVX;;*QOGQ
M*86M >UNKK-+[W#M8AKMH-[9 ;+<*L6Y2J0G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(L86]7>;1B":)^B1S44&:UO)E:M,J<D"W*"$V#&IBO2-[DS+&]U:
MG)>C8CD+<[-ZU,K:UJ@A>0< Q.$6/<;]1Q-KW:]N\?/-+1D<B 2"00;BX7IK
MM4WXG#A\\TMV'+?7,0ZN8A!65Q88^V'> O;BO>'\YZ<W63NLB=G,HE.O<I$]
MR1:ZN[XL4I4R9$,YT6JA 0)4C>5WM$E3IRH.<YQ!)V  6   &P    7-\AMS
M4"22"=[(6 %NT!8!=>44A62F:))\..F%/Z-2SN "$CV_HHTH=HZW#9X\^.$,
M2.A$1<GU@:AX;V5Z<&12Y-B4A&6C4E>AZ#*:(D>&EM\B"-@O8FY%[7 )S(!L
M5'7=:U\L^"^9N1?;8G:+Y[Z]%YH"L7]G:V1Q;)!E,S.4L<FY:BG<[;'\@4Z6
MJU\O;A29MD:20GL3^<M- X,"AS-9C$Y2-.%" EO0A3A(\$D$9AH-VM(Z6VJ;
M$$7%MMK[<\S<'N!)!&=MYO\ %M;*U@1;:,^^5R!E*UV;)F"4F-3H-5%1MA\;
M9!2N69A+&M96@3"T.;77_HWZ2$;HV,XQ(4+B0P 5I@9[\4:%3C!^&Z.U2VXL
M;@G5;K$$W(+[:Q!.T7L4UG6(OMO<V%S<W-W6UC?C*RMSPO*<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(OQ,4IRL]AAQ0,]F<]@AAQGLQ];M[?X.>@
MUQV-)'" ;=]>2]K=KFCMD;Z] YZ0$@[K!N3?'G'87C.>S..WQ"R+N<!\GM\F
M""0[P';(^*U][->-V9O7/:[7'^SC7$GR<&,YP01VX_\ EFC[ X\7;Y 8%V]G
M[K^]R8*<"^L_O"_&-_,'N6N%X,YODT6RS)/=X-G[5QICZO.P 0%1!0>[P 6"
M2_=\GZX?=Y[?:]K&<^3DP0,&QI=QN/%GD+ VX!<Y':I9ED).=AO:N7AO]!WN
#-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g105292g22x23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g22x23.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $U EX# 1$  A$! Q$!_\0
M'@ !  (#  ,! 0            8'!0@) P0* @'_Q !7$  !! ("   '!Q$&
M P8% P4% P0&!P " 0@)$A,4%5;6$1875UB8U0H8&1HX:'B2DY25EI>HM]?H
M(354=K;3(B0Q(S=!=;72)30V0E$F)[0S@861P?_$ !P! 0$  @,! 0
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M"7.\\Y3['AT ^0UT\^;-2OL3A+G>><I]CPZ ?(:Z>?-FI7V)PESO/.4^QX=
M/D-=//FS4K[$X2YWGG*?8\.@'R&NGGS9J5]B<)<[SSE/L>'0#Y#73SYLU*^Q
M.$N=YYRGV/#H!\AKIY\V:E?8G"7.\\Y3['AT ^0UT\^;-2OL3A+G>><I]CPZ
M ?(:Z>?-FI7V)PESO/.5\_'U2)U+ZK4ST=JN44_UGZ_53)7_ &M@X%](JVIF
MN8*=>@G50WF0<A79>+QL60<"7! 6,?+CEG&[-9X.8.5$=EF;?=,MT))<;DGX
M)VGE"^@SP>_W _1_\$'K5_!B%86I_?N^<[SE;?86*81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81?-M]5&_< 5!^&'7_\%>P6%N@[\_-/G"[%^#W^X'Z/
M_@@]:OX,0K"UO[]WSG><K;["Q3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3"+YMOJHW[@"H/PPZ__ (*]@L+=!WY^:?.%V+\'O]P/T?\ P0>M7\&(5A:W
M]^[YSO.5M]A8IA$PB81,(F$6(D!IE&@)N1D]MM!H 02-$-]./&WT9"F:SYWM
MKK_]VVJ""G.O'_CSQQQF<4;I9(XF9OD>R-H_ZSW!K>DA<:MJXJ"CJZZ<D04=
M-/5S$9D14\3YI"!QD,8XA<3^K%O=IN;2ZS";AU.-XF(Y*Q.:F'2Y!5M,3W:J
MO9+V&K?RW"N^VKOX*&L.#UB[7=)I\C2Y_5FTYWT77VY]_C%#@_:>+OH>#,S]
M2>G8 T.@CP:JBPNK L!J]NNJ'UC0.^CBN[,!?E+L>Z3=D+W0:!4VDXJV8;3&
M?#L5J9'SNCQ2L[(F"5^FN!:VL2)?<Y'AE-@$KY .UZFM$41(>XFZJN+Q9[WU
MOEE.IX!2/C;=9L:UB1BU;5&3%1#FBZP?(HQJMV4C;5D7A^SUW*72JY$&\(;&
MN"ZGN[>9MMD>!6,F;HWAKJ:FD,;Z%SJN9E'1O@![I5C29JIT1JV3ZK80 R1K
M>#U!_O&_J\ J<.E[,6F$6+XQ1MK(-)(H<"PVITCTBI\3<WW(X!,UE#@,-='@
M%5AAEEQ"1SYZ26<U8J2;\%&66P7I:'.^] /97>P/1KZEY3;3P<C;%M-XZI8H
MBV(*U&%>0;::) DFZ+%^_;^]E)BG&G#595)P%62UUUUX4>(3MT=D [6UFU\-
M$UQHJ(RBEDHZESV<(:<R$ES6DS%QF#@") 5Z*IT5PN7LNTFL[&N FT5Q'226
M!FDFDD=$['*;2/"(Z>I[4CQ5M&V-D,TS.T&PB@?&]S7TCFBPK9IV!GZG>-21
M[,IUQUY>R9SU(;O=AO\ ^W/OZ'-N#K><:/=77+CWQKVQH<IS;GS+D>JQX8..
M7>JNO"?'+.&4PT>X+6INZC81C9;K_P!J[6<XQ&FU;6X(4?!U_?:P=KML5T<>
MF>,GLM&O,6+^XF6OD[&S)33_ /(@QB!@JV8L)1+K]O/TD%7HN3P)A=#P+^$#
MAJKHLQ/S%2:R,.4A+<5!18UF["3_ )E8YWL?>*(,U7[%:+:,TGX1,>HL]2\^
M=OET7.K'A;31/5SIQIY9T4 IXGLJ"^I>]S9*;@7-X)H+@UPF+BV0O :=5K01
MK6)-BOMT59B;L5KJ6HPEE-A%/!'+28R<1@D-9*YD3IHG8>(FS4C8'.F:9I97
M->(=8 "06YU]4;]L.7]C)L2F@^>,JP[-,Y!+Z)4DPO9G%V"%3DE8Z*91!;5T
MLISK9%2;1RRB+=XU9>3+BY!NWV<\*[;YZC&<-I8,+IVT[Z9U9A)C@Q$1/UIG
M&L:)7F<:H']DK>&I&D.==CXKVLOB78YTRQK$]-\6J,5AQB' -/HZW$]$#B%.
M8J"%FCD[J&GBPQW".=_R[HV:''9V2QQ:M33UAC,@==5?'I=V1:W;%195_(91
M2LC\(7;#<2>;/""!"MD(NM;8E:N)/KPOSR7KF8>?AI!#55?^1"G@Y4(Y1\@[
MBW"7,EAPIV'S/8V*'$(M&*,R1D-+:LS=I/%5#E^SJH-62*<=])$]D@-VS7\]
M1XEIU'I7A]/435N(:*UW9KTB935D<D[)\"9A[M(Z9^!U]GGMG!,3$U+688YU
MH:6KIJBED;J28>!9MP]@; !]Q8](@C&=*T/2)N'4K:9 6-\M '!F]&Z3F4FI
M$2U=I[:/*S)D.OKIDJBP(ZL&1:P6SE8=MLKRIPZ'#*:3 I8I'4PQ+$(YZ^C:
M]]JD1X<2(8XF:I^#5L;B8<"YFLYE*X:U@%W^DVF>,TG9/H:ZDBQ=VA^B=7AF
MBFD4U/3Z^#/JM+F-?B%56SB0$28#43:%R1.;#.(8JC&HWN@).M<IVZH=6G=^
M6Q^QK&81(-)NM]()0P-(3:C(46E;BU[V9%>0C!=7ADH;<->8^U?JMDN'BS?0
M4BXWV22;:Z\&/#YZO1^GDI:5T[XL4Q$U$D48<]D(H\.<SA' :PC!X4M!-@=<
M@7+EZBKTKPO >RSB=%CF.0X;2U^@VB;<*I:VK=%35.(OTBTOBJ.U(7NX)U6^
M/M*.9S&\*]@IVO):V,##V?$)TIVWKR B9V>'U'=K-[<M@QY%^9U>M3_7):'C
M]8_&2J#U-..QBT7DRKIQ-PK?31N5:UZ<;ZZ:[30ZHKG23TXP2JJ7TT3JV@<*
M"FE+6%KH\5$[C+,PM/"S4;8*H4\AS8ZIC/\ [O&N-I!AF+GLE8)@U-B]7!HW
MI9%+I3C5$V:J$T=9H,[#(114%0R5HHL/T@DQ3 Y,6I& ,J&8)5L _P"5JPNC
MUP2(9#>[M6O7LJTL-],$J_AXFG!\\G4=FU4;O7TS1<VR!A@ EI#K @99-UQI
M:",J%IO(^Q "S"19VT;M@_.VAB?4:/U;6P]JL@-5.^N?34TM/6ZK8"VBDGE;
MP]-4L+?[&87D2NE>S4:XEYX>DU=3X7V6-'I9<1&-S8FW!<-IM&(<8Q>AQ;1P
MRRXJR322BPNCG&&8U@]2U^KI W$*<2T4-'3U3:F2)D=*K1!/39"Z.\PAY,CL
M6$,H9428*0:KNG2$&V(UA*=R<DC[%=39F@Z'.=4C#C1KHGPZ>,T=G/C;\:\\
M<.1L;*#1Y[8(YGNGK3)%8 U&K60AD4K@-8A[;QC6O9KC;)>@I):J;2GLMTTN
M*5>'4T6%:-"DK0^21F$&? ,1,]?10O=P;9() VI>(PWA)8FZ]R 5&O!_R863
MKV;Q44NSE.D%EPP2]MR-6!.[&@-OD7<-CKIQ+HP5L D6*@"O&G"+6=0MB1(B
M@$MU(*HDR#DFZ7S=I+"]E53SO#H>V8'O;134U/2U-"QM1*UL$S*9C&2Q[335
M#FM?)!J@L8UC0NO[#%?3SX+BV'4[HL0&$8E3TTNDM!C6,8Y@VDTTF%T,C\3P
M^IQF>HJ*.IL&Q8QA4,T]/18F)W-J)Y)Y'K,=RS(\6_H%K8DC-1#KR6L@ZUNZ
M1"9 =B+!!!"O90\KT;,I7&GHTL A)2<(#TRCKTB/&.RR( 47=\,2"C=SKP*-
M[VXD:6*.?%&4L1P^)\44[B350MJGP0S->R2H93EQ8-1SVL,KXQKM!'*[*-5!
M3S:&QXY756&Z$U..UD>EE;3UM9AL+&,P3$),%@Q/$:"6"IH\*J<6; VHDX>&
MGEJ&T=-52B&=S)-:C)>;/O!]W8M'Y!-G0'>X"0:AY*>/3%&5$Z8<WM%A<.<J
M2E9XE/G0)R.<E!X(ZZ?[''\&X%.]'KA)9!PKVS&4[=)L/$D5.V44+),2BBC@
M,#*\8?,^?]B&FF;('!CY8VMX-E1PC=4$$#P=54XM+V%]*WT-;BTE&=)IZ70^
MOK*S%&8C/HL_2_#Z?"WG$'2-QB2C? ^HAHZN28U<V$"GD$KVN8]W0VAJS6JJ
MOV\=?MF;0T[*DS)Q(9-;(G@CSYRIHR:["C-J'#TJ1;[!1XKSD?L[1'(D^'Z[
M-KKYRJLOYC$JL5M496ESHPQD<9?3TE-)J@%QUV4<<4)/".?9^J7EFJ'$ZH ^
MV:'8 [1W!F44T<<57+43U58V#%L=QFFX9[A%&:>KTBJZS$6L-)#3:\)D9 R?
MAGQ1CA'/?H%X2!E9I><U(-K87(Y [94=VGE:PB.6'8$ (,R,=5I!,3, >M?N
MF+J6S.&I%"92*P\F_&LCZNQ :F01<N4T'7I=%74C*>M?5/BB:[$,'A$DM+35
M+'-E&(%\$AJ6N;!!.6,9-.QCW1?!>6$ D?&>SG%C]3B^C<&!4]=621:)=D+$
MG4U#C>-8--'/0NT3%/B=(,%EADQ/%,+;43U&'X743015KC-3B9CY&MDG?:JQ
MID7Z]4K6M(2V;3&>WH.!.A%D5^+27EJL*@\<'S&16,W9+.635IR=+)1( 3:.
M5T>6Z$W>):Z^<-N$N>-@U)!'B=?5XA#3P4^'.D:^DJ7EL/;%3*Z"*E+@"7<%
M&9Y6. .L:=O$Y=SV1,<Q2IT*T5P'1+$L5Q3&-+X*.6EQW!J=KL2=A6$T,&*5
MN.,A?)%''VY4MPVCJ(Y'M+&8M*T O9JK\W!:MHW'UMZN3ZH3SBK[0G=S5DP>
M:O&KY8;'IBV92X5,X1,A:"J3DA%VDO$DHM)F>^W.R[!!9=O_ ,UJUWU4-'1T
M&+8O35T8K*.GH:QS2US0Z6!QA?3U$#R+-E="]DT+AL<0#E<+'2;2+2#2?03L
M?8SHU6/P#2#%]*< AD$T<SH*+%(X\2IL5PG%*=CF234$>)4U1A]?$3=\+'N9
M\,1E5._G5E&.BW;&5V$SF-;332]I6F8!.)&6X+P9AO84"T(A@<C'.6[O6-MA
M[I]R#*!EFC1]'W2))CJBW><<9S6TU)'I%@L-*Z"KI^YT!9(V%FI4.[6J2V22
M)P<.%+@WA&2!SFR-+'7+5YR7&,>JNQ'V1\1QN+%,"Q5NF&(-JJ-]=4]LX1 <
M:P85%+25T$D<HH(X))NU*BE=%%-12-GA#8Y0K2J\_.4ZE[M/.NY::R^!@11I
M7J<4DY&4S%R1F2%.I/3C&"G)VN2D<IAC6RN6[:.;NWI(-L;Y.C CM42W221X
M=9%3FNT?;BC*>"HD?&,:;"V& ,@-<6QNJ8Z<,BAJ#27,NJUDG!B-TC1(23Z+
M1^MQ=NC?97ET)J<5Q+!Z.FJG=CBHQ"?$,4DGQ1FC#9:N'"*O%WSU^(X7'CVH
MRA,LL]*:LU=/22NIF-:S&=2SL.(7A&FU!SR=3ZMW/7%V3OEU)II.IP.&W3S)
MX1I#%"[F9DBO$:M4J+6LOF91H=N+739L&6YH0UW9B.,V8U%.S#ICB=-3TU6W
M%6LPT0P4U.Y]!P-1VP&-IV,,M&QXI. E?KB[CP;R'2+C=C>LPN;2VA9H=C&,
M8S@<F@\E1I@_$,5Q?%H(-*CB&%#"W5+\4J*CM'2*HIW8\,4H833O;%!$:JFC
M,5,M9(E?/9AS9\++$_3W%1;=H'U]K2'98CLRUHF[[7?]7:MKES[BFWG*8EX8
MD]FO6+A+4</%L0I+1#A9NQ52[:;#L)%)41L$7;W<=N&MB^!K=T</HFXQ650R
MR+VLAI&N!UW/>]A-BX'P6&Z8:>/T@PNIJ#6>YHZ?S:8OKB^?@AHAI9I'+V/]
M'L#DLX\(VGEJ<0QZ6%[>!AIX:6=K ^.)S>DL3(.77:/MD)D14GI#&-.]<5DV
M[DL19B!29+X?-9*]'*)ND$Q#ERT9L=R9 <HU=^*S8K*N-=VK;=/RD[0,'P5\
M3&&=U=BH):QKI'EG<TQ-<+$O <YVHQP<V[G #X1O]UPV:23L@]DBFKJFH&%P
MZ,:#.:R2IGBIJ9LXTQ%?+ YLC!3/DCBB-1/ Z.6T43G/!CC+:*\'^=JJ4L+N
MFM>3M^45F<FW? ZV)V1,YT5K.KH[Z0C<$W+MIK(9$5"2.=K,S,\/H[/-%&VY
M\='54].8VGIKV.DT=;"Z@IZJG:P00ZLE4REIZ=E762ZLM1J&GBB9)%3AT=-$
M=6Q$3Y03PI)\?V&:S1W$8=+,5P3&)JA^*5[IJ3 :C'<5QBIP#1^AX>AP@U+,
M5KJZII:[&'15.,5C3*'1FL@HG-;VB&B->"V+Q0U50D@XG8"66L\KZ%.IBS8V
MK:DYD[%-9EIN\6G<<GLC+ XQ)=S/*J3O2*#F#/RO"S;CGA%--+C=I@R9E8]H
MIY(:-M34-@<ZCHZ>%UG6:*:6FB9+-%P=B.&<X[#F3=<'_9\J<.J]':>=^,4>
M):12X+A4F)Q1:1Z18OB$+7Q RNQ>AQFNJ:3#Z\U6LV48;!#%K!T8.H&M$!\'
ME)7)@O1/$ E]A2\:0ZTG2O:;WR2N=3&)![?X.P1*O_-'4N(E!L=L1^W4L70\
M C#ADDL!9-'1@7KNU$N,Y.E$+8V8EVS!2P/9BT3,'X&&F@FDH>"J35:S8&,?
M)2L<*4Q23!Q$CG-C?8O"Z;L)UTE34:'C!L3QK$X)M ZNH[(?;^(XQBF&TNDW
M;>#MP;@Y<3GJ*>BQR9CL;%;14#X6NHXHI*JG!CIGCH3VU+6"#ZW7"6JW<VC-
MV4.>*BW49:[/I.P9\N&R<A)QEFFFLLYD@N-[ER(!)NBNYW+M6?#5!9QY-/;S
M&"LII,5H65@C-.Z=H>V8ZL+G6/!,F=< 1/EU&R$D-U"[6(%ROM79(J<:I-!=
M)ZG1XU;<6APR5U/)A\9FQ"&+7C%;44$0#G25U/0FIGHV,:][JF.(,8]^JTT6
M&/UPUZN=A'O1Z8E+"EHBO982!/DYO.K0)?"5[Q':H#1NZG1<_OQ*EEVK-=T!
M:[([;GN=-#8U-^Y6T4[%\=4[&,+;I# RE@?50,D:::GHV=J"I:);MIXXOV(!
M<&R$$<'?@WEH%O(TM9@4?8^TUE[$V*5&-8C38)B4]),W%L6Q^<8[W'E=1B.7
M%ZFL(Q%SXXI):.,L)K"!5P-FD>'0;J<;A+Z]T&G7V=S>?4^KUW3(V\^D4TG,
M[&L+OVET93B6SXA-B9?8#91:,J6 K/8Z-6'N$N!X54Z):N$Q_._(QJ.H;AQ.
M)T]/35PQ0LH6Q4]/3/?A_ 3&?5;3L9PM(R84HI97AX.O((GEI<NH['%7A,NE
M[(M"\8Q;&=&7Z$-J-)9J[%<6QB"'2PXG0-PTS38K45)H\>J:!V,NQBBIW0/:
M(*1U731/;#K4QUYE_9':W>L@B>OY#)ZLE5R]LBT7FO#PCHH+:@FEXQ[6H[!2
MW7V]*:"W $=,*Y)O_*:+B7#\.V11]Y;157GXG!A/:.+OIFQ0UL-!@K):?5:=
M<R.PZ0UM*;? +Q(^"K8VQ#PUY)$[@/+:$XGIT=)- J;&):VOT=Q'2GLCU.'X
MJ)9PZGCHX]+J(:-XTUSSVPV!]'!BF!U$UVOII)J6-K>Y4;W;+;4O#]^]O*NV
M]@>CN*=2N/@?Q;%M:QSX2]+?\74MZ!UFG #EIYMIJAM%/,/>ILRX\UV \M.>
M4N>I&(5 T=M_9M;M[M'6[2HN%[4-"?@<+VOPNM<WX;6X;6^%PFL 5[PZ*X8>
MR]K$XUP'N8;I0(!I)I(*'N\-)K=L]IC%11<%P8##AO ]SC%\ T9C):=:K,<6
M Q[UR>6[E9)'*UC%\]9X\=L)E/K U:0X/(*M9NMH<1K)DZ:P%] K5E&P^&R.
M8&-W:L6-2!@2W&<>[Z59=K2"F=H[% &12U<N'8M+%2NIJ8F>2.K(X=E6YKJE
MM31PA\\4#-431Q.8'9ECO!X\_&H>R]B&)&IKZ' :#3'0*AK,:BQG&1%AE+6Z
M/0R'"Y\ BDCP>;!](L0X#"Z[$ZHR.PZJK8IS +FIBF7;:31]I:]Z,+=G5APU
M\*H.)D>GPZ'2Z>Q520V:Z^$/B2NH2.A9%DVG5IMY:T@(WB/%&YEPV JBN-!'
M 4P96<Z,%BE=18<ZAIJ6H:_$IV8XZ>"FF$5(.U>!;4NG:YU/1F U+^%8Z-ID
M#[OX2..W:]DBNHH](]+HM)<7QO"YJ;0[#9^QE3X7B6,8<ZMQ^3NWV]+A,&%3
MQ,QC2)F)1X/ **H9521T;J<"F-+553GW!95N.*LLKI#(+QFK6OVQ.L[<2LY8
MF5Y#Q=:=[0NL%/-2::"F@I9=N<6,:B-5=-]4-]W'F/.G&^_C<*DHA64FD$6'
MP&I<RKH32!C->84W#UF;"1K@&,1\)8B]FZVP+TV.Z2OT>Q[L3UNEN*QX-'48
M!I*W'WU%1VMA[\8.%Z/G@ZAK7"G>]E6ZJ%,' AA,G!6N;R&][KAT O;J1,Y%
M8S"+57)(G>SIV<>&U6$1-<OH]7+N)+O=^%=&#W=71TX7";NM%-M/.%]VG.G*
MJG.VK#L/GJ<.QJ"*E=-613X<&QMC#IXPV6K;.&@C6;8AHD#;;!K; N;IAI7A
M>#:7]C;%:['(</T=KL-TODDJY:MT.&59EHL#DPU\K@X0S%PDD?2.D#B-=YCM
MK.O3G>N5 7TZZENWD]C8"M)2,N N_+26R;(KJ#&VVP2NWL;<NI!5QL$9=/-T
M'CEQ'$'#S9@MNX7Y4TYUWV]WG:.PR-IL:#::62KA?0L:R*EI*FHC/"5390(J
MR.6,-NUHE(;K"PML7E^R]B-'-B_8XDEQF@H\!Q&GTFJ9JFNQ['<#PBK8:7 Y
M:&22MT>JZ.JDE+)9'T+'2F%Y>_6%G%2#M<8J9A(.GC:8SJ21ZB"3*S.5C,<L
M*Q0*I5DSJ]@ZK]?B2PTXUEYTDH[\R<@=]R! F6)J);\:OGKG;A77@T=:Z+'#
M!312XDQ]):.6EI9=1SJMXJ1P-1&Z&-H&L)0&-8Q@-]5HRYO9&J='(:WL8QXI
MB]?1:(3Q8_KU5#C6.4;JB*+1^&3!7BOPNKCQ.KJ#+P4E&3--/45!:ZTLKSK;
M4=4'MC$>N=1/K8Y/;3QU$6JIA25-^6DK6:[.77O?<2MMLFBJA*7$;X$+R--P
MBD[U-*/N'B2;KRVFO38RVE9BE<VCX/M=L[@P0G6A!L.%$)N;PB77$1!+3&&Z
MI+;+Z'V.9<<GT'T:FTC[<.,28;&ZJ.(LX+$71E\G:;\1C+6N9B#Z'M9]<U[6
MR"K,W"M;)K :OWA):Y9]IB WLY.9-":P&U) RU#L6DUGL$BDIG[F635.S'.K
MR#%@SB46.&:LJ]9@XRX=/WS8&5<O H910B0<[=OA\54[!V/PBGBJ*Q]=4QXD
MYU/35,T-,(*<T@U:B.00TDA=5.DF :PR,#9'C5:%\_TMK\#C[(4T&GV+XAA.
M 4^C>#U.A\,6*XS@^&XAC,F(XLW'GB7"*BE?B..4L<6"QTE ^2::.DJ)):6E
M<9YI%.[/NJ'5#W%BBMF6,P@L'+]:)2FSUD9M09&W\KTM**;-]DT%E=1ZIS00
MF_X16Y3Y>:L.'6FF_"'*FO/'HZ">NP*84E*ZIJ&8M$7<%&'RMA-'+>Y UA&7
MZMQ?5UK7SLNXT@TKPO1GLGX<['\<APC":G0/$!$*ZK=!0S8B-(<.+"UCG"%U
M6*9LVJ[5X40B0 ZFL%83LD9X[LQX3J_)\1U3JQ,"2HS5T[X"[F4K:@S9N_49
M<*>8[$TV*SENBZV2Y=Z-%5TM%.$=U->>*UD?N?E?JLX7NQ P/U6\)P9HJDEH
M=;6U"X-);?5U@"1>R[J2HJO?7HJ833]I.['F)U#J<22=JFJ;I)A,;)G1:W!&
M=L3I&,D+>$$;GM#M4N!T)H27]D>;BZU"9N_D,GJ>7=A>WY.-3'5Z1T5!M(PT
M[&QC2H9^GNMMP68M5P :;5J1?\J)[,=B85N@BG#1:JGI<1@PKM#%GP-BAK8,
M+P)DM.6M_:.F=A4QKJ8V^ YPDDIZMC;'6#9#?AW@?'M#<3TY.D^@E-BTU;7Z
M.XEIIV2ZB@Q02SAU)'01Z<4 T:QEI<>V8HWT=+BN!33%S3"9Z5C&-PNG<=DN
M9';;6'>$M>UVN;+6%&; E.M1L5.7)59D6;]5:9*!F47&N_+H;<^^1T\?,!39
M'ED\.N5^%6ZJSQSY3J3%0F?1)M4(V4LM+":YPU6:S'8U7LD=,X6.<+6M<]QU
MFQ@6-FBWNNWM)&87V=Y<$?5U.-T&-8@-&XB7U#X:AG8\T6J*6'#X)==A/;TD
MLT--&S@I:R1VLQSI9-:6]:ISU@CM:3:5U399Z:L8I#0LNM\[)9Y8$\.,' \(
M;)O'\E0F1@JC'IDNFP..9."%MQ))%RDT0+C&Z*(1+33BU/B\M73PUM)' Z:H
MD@H8XJ:FIHWATD;&MB=!&PRP NC;#(\O8028WDF0GLM!,7T H<!Q;$M'<>K,
M5AP["Z7$])JNNQC&<8JX7PTE7/+-7LQ2IJ&T6*.;!5OQ"CIV4T['LB94T[&-
MI&BK.AUN6N?E-DQ&ZQ$["G+*:H]E:_:3@?PSX&1J9D?1<GKZ,J:.G6JL;K=?
MWF:C]G'*#Y7F6K[K-4M4^.=N9I'0T4<-+/A[Z:2.D<<)J33OUM>6G8'0U4PU
M6VEJQPY> "T&$6)NO.]B#272*LQ''<-TKIL7I*O'HV:=X+%BT(B$%!BDW:^(
M8-AY$DFM08&_N6("_4F/=%Y?&T $V/T0NJ'3BH(Q 5;&82BV8VC.7TPCKPVJ
M3F IDWL@\S0<F47:JK]-%% @';([N-N>$T7+)+3W$^4]>.'I%A\]/6S5/:KH
M:*4P-@E;&&0/<:6-Q$9: VY+7D@<8<3G==[V(-*L+Q?1F@P=V.0XAI'0LQ:;
M$Z*6K=48G3Q,QRLC8^J;(YTS6M9-3,:7GX+7Q-%FZH4Z[NQ$?).K]W&%EI*U
M/0&IK0G4,?Q:72^)$1LN 5_(W01_Y6(&PJQ;5H[U363%%>2 I=?1/9=@MMII
M[G'T?G?#B^'L B,=36T=/.V:""=CX):J(2-M/'(&:S<B]FJ\"]G $KM^RQAL
M%=V/]+*I[Z^*LP;1S2#%\+FP_$\3PR>#$Z/!:Z2DFUL,JZ5U2(Y0US::IX>F
M>\-+X7D"U%=D()S NE@>,5GS)DWLELCK9HX1+6992C\JYF5RU:+D XC.G!:1
MS<$"-LG+@>7W#++<#1CI\JP&[[[;H+=EA53VSC\LU7P);#28L064E)JL%/05
MCXGMI@R*GDDC<UKHQ(!KO:T.?QCR&G.#]Q^Q734& ]OB6OQS04/;4X]CSIJB
M3%-*-'Z>MAGQ>2IKL6I*2KBD?!4FE>[@*>29T,!)+'5@/-3@-X/&_6;V0RX7
M94*F=@A"<76DTK.22GW*5D,EQ%=BIN=(O99*@8J+O1;^+RYV_P!MC\8-#W;3
M5L/W09-^4^.G?I/AKF10OI*B"ED9,(88HJ]II7"2J?3Q-;##(^5KV30-;:.6
M-[77=<GS\-5B]+V$],HI:W$J?'<*Q3&:2?#W5^(U==HP]N.POIL$I\6JYY<2
MQ"DIL/EIYL/Q*68FLP^JADC#(2R)EE=]+5MD,<K2#4:*G!J50Q-]V-F;.#C^
M'FY&-UTXU:Q*!R511RVT;QFRY,N1:E-T.'3SS&*O-$FBFJNV<71NCHI(ZNHQ
M&2FCAGU<+@=4.U0R6J%YZF(!KB9J2$-,8.JW7F:2<EW_ &8=(M(Z6KP'"-$J
M?%JK$<+;-ISBD6$P\*9Z# WB/#<'KR9(PR@Q[$'S1U!9PDO!8=*&1G6)4QN:
M^X6%GO26V'\]TB5137X2#KXR5)KAX^^&2&G5B43TD"?E=6FZFSUZSV8MW^JG
M+<GMKPCQHXUXYXT4&&U$E-I!1-IN&KH.U8VQL8))&OBK@V8Q&VL!JM=K%MKL
MVY%=GI3IEA5)C/8HTCFQD8;HSBW=VKFJJBH?2T4U/6Z,.GPT5HUA$YQEEB,+
M)@[4G(U;/%U$>]DOBO$&J"U$;'"D8DS0DLN$U1O8\XK9#L2-)Q9@]$-('-J\
M(M"_-A"VJR3^MQJS4L,.D3NR"C5JXX9EQN_1V";MFNHS2R,G)B@?6BEIZHX6
M]DSFO-33U37,-*]P+:MP+'QMC!!<-9C^L[+V)X<<(T9TB9CE+/AD3*_$Z?1P
MXYB^!,TV@GP^&6FCPC%L$FCJ1C5/&YLV!0/CJ*>KGK"UT<<@BJ8.C E[R2%C
M2/+-Z.Y(#V;WD>22\@18\NFZ:_+-^AXZGD7K;RGD'27C[^37T4T\?;W/=Y\L
M]NH][-9K]5SFZ[#=CM4D:S#87:ZUVFPN",E]PII>V*>"<Q2P&:&*7@9VZD\/
M",:_@IF7.K+'K:DC;G5>'"YM=<=9W*G/-GV3PK-; ;]QV';6"!*9K]G+)NT8
MNJ#WE=>)Z<LZ\9D4H05J<G5KF:FI[*GX=PV0D&QI8F:;G!8Q!M[FF@':=(>U
MZ8X$[!:F2OJ70TY(Q,051LZJ+34,K65;:=E-"V0.,0C#(W1O?K?F+%\1D[OX
M]K8KC+.R?#V2,'I-%L&BQ'%XXGZ''$<$:#'@D4[<*J-'*C1]^*U6,XC-2OB9
M6=M/J*J.KIZ=C+YM2N)):O>M *HHH\@<7Z]U+(#(UU9%P0=)HJ1MRX&A4C&F
M5:R,")*R5R-%LVZ_$IU<M.4&@U+;W$?'XYZ^CJHJ/1PR !M3-BE=$Q[:6AJ"
MX-H:!T;)G5<4DC(0][B.!LZ[GD9KV&D6!UVD79>92%QEP?#]"]&ZVJIY,=TG
MPAL;I])=)XZF>@BP&NHZ:IKI(*>*-XQ$/B+(Z=I^!<+I!GE%]S7*_I77UQE+
M!)7"1+$ T TFW:^-G]"5NV',R%LOM>PDF$01=W5\@8IP>LF59"8X1#!BD:*/
MRA\:Y9\+(M&3EP@E[''ZJ@92LH6,;)4]K8++&645+ RB;W+A?4@5D3C45;JM
M\K9)&2L:R)X=8N< 3^>>Q7@NE%1C<^D\]3/2X*,5[(M#6"?27&L4FTDF&FE?
M2X0^31^MA;A. 18!34,]+2U%!435%;"^,/9%$][6^GT[+Q8GV/OOB4SP"1L9
MK>O90?%XLYM:U7TZ; 1UJ25HU2?5J4D:E:M(NPC*2? !P* :NV[+1FMINGMX
MRF98ZR9F%8;P--(VE.'82^69M'1-IS*^BB+BVK9$*MTSIB>%#Y""XN!'$M78
MQJ</J-.=,1B&,4D^.1Z7:=08?AS](](I<7CHX-(JZ.-LN U%<<!CP^&@:T4<
ME/1B5D0B<"W-R]V'=@9^^[LD9,]93I/KW.Y-).K<5(.AOB5UQ+ZT:[& ,Q'$
MM'6VZA>2V.RNRO'"_ [AF09MX'SH4W\GHWUQGPRF;H^V)KJ<XG3118Q,P.';
M7 5;N#E@<VPM'%2NP^J UM9KC4W9G=;<+TSQJ;LKSU\L.+-T*QBOKNQ[AT\D
M%L$[IX!&ZJH\4AG$A)J:_'(M*\$>[@.#FBCP@MJ'6#!U/SQR_0R81,(F$3")
MA$PB^;;ZJ-^X J#\,.O_ ."O8+"W0=^?FGSA=B_![_<#]'_P0>M7\&(5A:W]
M^[YSO.5M]A8IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%\VWU4;]P!4
M'X8=?_P5[!86Z#OS\T^<+L7X/?[@?H_^"#UJ_@Q"L+6_OW?.=YRMOL+%,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(OFV^JC?N *@_##K_\ @KV"PMT'
M?GYI\X78OP>_W _1_P#!!ZU?P8A6%K?W[OG.\Y6WV%BF$6ELLNBYI!V^VZWU
M2O543CM;5#4]Z6U);,CTIEI^:1NV+-LR"#8550J/3>!M(\4"LJ=EI$_/) M,
MQ@TG(H,)UACK5\^=HE;"USQD@?0!MYQTK3"I?"ES,^K'0\NI$U-IO.05&I0:
M&U0UA\>T-R6VD.\4B<D])39-SMAB$7'1KIV9&+CS+*/G1<@0<OF2\P&RD6UC
M99%EKYC+,WO_ -4;CG=RL>J_">A[;F#".U]3]CV$]LYM6TPI2'B&%=P^1.:I
ME_6ZK.PAF;R^1S.XF\6Y]%CK3CXE,,CJ D"9LHS"H@RXQ@7FK<L2+<?M<C\K
MKS,O":1^?W8)I:L884;/AO96MJJDTIES)N_ATYJVQ1_9]D,L6G)'&Y'RT,\;
MS3K+*0BSMZBZ'C=4UV2[5T8X?-@175L+G=TW&WG!MYEA>S'?2\.LMK7J+E-9
M1U_#X[$XT8ZSPG6/G!Y_L4@Y>TP(L"5L+Y<SK:LXR^K.06#,!Q^D)%  TY?@
M(P"GD;EAP$=*-H\0-N!8^7D)O86VYV&>P7MM5FSOPF54UJQ.JS"N+29EH]-+
M)KA['&"4))%%Y[6\3JN1+QE@Z3F*0)9>2%;>B\/ %')AF!T-:/WQLJ(CB.AI
M0IJGGSYS;]?(J]J3PF_!>7;U==%/RB#VY+[UEE6U'!@N\6)J2L?%[\WIV7L_
M2S2='!1214?''(*V+H(BGB05. G&Y2(M29%!V!;E2WC!OEGR9#H-\N/;?9=0
M&XO"8S^F.]TTHJ1Q^&J4)78W8[,">L$GJ$S9PL'U8G/8V=S0;:*DNVK<U(8S
MO$F0D=1X^$K6!*8^4(RL:02$18Z[;$ N"?S')Q;>/;L6'+^%Y=%7=>R$#15E
M5950D)>UL]@)5;L(%%RHREZ"IV,7";VK$9&[8!-3QZ1BI@Q#:GA[V9I1*3 S
M01Y!SZ"[(UH5U-N8N" +'C)M<Y;.3(YB^Y7%%_"LP>2*"45^N?8>+J:Q>];$
MG2TK$P4,P@55]>0M#22P;&4>+3?;6<A$@_8.)M!P^N$I6?<2H)+8RL+;JA]7
MKDIJ\HXN<WRV9'+CLHBGX8NNE8.O-]>L/9Y%$;$+3LTT))!ZR".F-4T_7D,M
M293L>2.66-CTH191"8ZM.(_%BYB0ZS$&5CRC#1BH+D! FJ<\QD;;>6VZ_/UV
MM6;>$V@</AYBPT:3N61P)S?$AZTU?)@_P=;:VY;T'E4^A]@"@(%>>)RJ-@8@
M5JVPUG$AFH( B8'Q(@Y!-2&Y"-H'BECR;+^3CXUO13UF#;FJV 6L'C\NB8VP
M(J(E+6+SX$I&IK'=2K1-PH$E()19SP-."U=E&1!%N[>LMG".ZH]^_8J-WBY0
MY$\?*-BLC")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(OFV^JC?N *@_##K_ /@KV"PMT'?GYI\X78OP>_W _1_\
M$'K5_!B%86M_?N^<[SE;?86*81:.]B^BT-[*69#K2E=E2X"<KQ-ES!6HRJNI
M$R2B;UH29FMWX4]<W6JTINVW=FQ8<VX'[2Q0&D9"B2K$4S?L$%]"H-A;\S^1
M"KL%X-T-&"(8Q'>RMQA"D=<#'0$@,ICH S>!G 7X4O0ZHQ='I7HHRV%<7?<.
MH[S?9/AEI9DVT;\)Z2(GJX)?D'.[DY>0<P4:(^"JKDL"#Q@G>-D/8_'MXGN!
M$N*&\'MNS#>\6%-*VB&@Q+GI-_R*("O&#."#T&W*:"</0TC>R>X?G9GL5UN0
M<[M]]^_/RKSQSP6L"A\B=2Z*7S9\<D[V4B9LY/!*,\'R,**RT 2DI@%(.7;3
MI0DKJ3#%)G+GPIQIMKL.7E$@W:<(^F"'#@FMQ6RW7=U\@YE[DG\&'#YI+)Y.
MY?V"M23S.SXLK";"E!ZCO!]%3DOBC@>&%.01PB]Z4+.7C!R,CD;8.D]U.-G+
M..1YNONHD#%:M":W(.=W6H^IX)BJ5RAHVYN.>O#$DB:\$D))]U_\'B^>FX<Z
MBX:$O8X5</.DBZC\40B,<CL<(M76RNA$0 !LGWG"(@?JW)K&UN+==UM^_>O>
MC?@M8W#))5,FAO:;L#$75(OK&,5@/C-9]#P8:+2*VQOH>QI.V'#NF#=-U(I8
M*Y68EBC_ '=+.-';U?;CSQXX<J$ULB+#.W&[B_\ B4YD7@^=9<3*FI3VFNR1
M%CDAC,M,D35.= 2;PI)H:%=QJ+'7Z[SI6JHZ)@HX_(1X<[6VV50!$'XCC;D<
M]=-E2E^0<[NM1Z*>#-B\&"L(W$>Q%LQ^/#&<P'#P8ZD?!]I"6HVP!(D!-AB0
M_GI3LUX&2D  ! #0WE+EB^!!A0=9#8:/:-4BNMMR&>W-V?ESS7O0CP< BMFH
MAE NS%S11J  S2+AD U-] FB8Z-6,YB;N=@&W&O2SGQ TM7@<)Y/#?=Y9D4H
MC'&[A'=N&'I-R:W)R[7;=^WE*P0/P7,'C465@X"_;3$0]8/.XZI&6%'^#[;A
M-H_9P$/%K!!<#M.E/#;4-+XO'@$;."]$]6+V/@Q 91#T:-9MD2:W)TN\N_?F
MO3,>"HK>0.)F[-7C9))W89(:;FCES1'@]]UY"=$/&Y$<>?+<=)^%/3[<BT:D
M?3B&R)54@V;O5GBCI!)70I?D'.[CV\:Z*5G".*U@$2@&DB+2MO$ K, Q.&Q4
M*!DG0T;IRW%MU0]<Q."P@:@,'Z-A;%G'(D#8(,&3;3AIRMPLNJ44YPB81,(L
M/LU5<KN?(2$@GRDMY-9LVU!J:M%-DDG&K??A42NNGMY!=%;71=797E%9)3GG
M;133;F_0.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$]&/?6$Q
M^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$]&/?6$
MQ^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$]&/?6
M$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$]&/?
M6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$]&/
M?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$]&
M/?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$]
M&/?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M$
M]&/?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>M
M$]&/?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ>
MM$]&/?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-PZ
M>M$]&/?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-P
MZ>M$]&/?6$Q^0 ?0>+C<.GK1/1CWUA,?D 'T'BXW#IZT3T8]]83'Y !]!XN-
MPZ>M%YVS)R@KPHJ8(O-..-N.4'*0G5+;GGCW..>>6@MJO[NO/]NOBK:\>[Q_
MQ<;<>[QB_(.GK19'(B81,(F$3")A$PB81,(F$3")A$PB81,(F$7S;?51OW %
M0?AAU_\ P5[!86Z#OS\T^<+L7X/?[@?H_P#@@]:OX,0K"UO[]WSG><K;["Q3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HP _O6;?YG:?Z,B.4[&^3\RJ
M=C?)^94GR*)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3"+YMOJHW[@"H/PPZ__ (*]@L+=!WY^:?.%V+\'O]P/T?\ P0>M7\&(
M5A:W]^[YSO.5M]A8IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$48 ?WK-
MO\SM/]&1'*=C?)^95.QOD_,J3Y%$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PBA;\I(W$D>@@?H1!,<##%G#@LB_<[K;F7\@9Z(HZ,W+75+5OJ"YW
MVWWV4Y5Y<\<<<)\)<\[W*US?:1MMLMR'>B_?D[ _QD._1IOZ5QEN/..I$\G8
M'^,AWZ--_2N,MQYQU(GD[ _QD._1IOZ5QEN/..I$\G8'^,AWZ--_2N,MQYQU
M(GD[ _QD._1IOZ5QEN/..I$\G8'^,AWZ--_2N,MQYQU(GD[ _P 9#OT:;^E<
M9;CSCJ1/)V!_C(=^C3?TKC+<><=2+U=B<N&&(TT+;1QRQ/%W0E3D<V)MG3?=
M&.GCB:^FSEZY1WUYW#<-]T]M->?%7YWUWXY3XUV96.W(7VWXP-PWHIWD1,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?-M]5&_< 5!
M^&'7_P#!7L%A;H._/S3YPNQ?@]_N!^C_ ."#UJ_@Q"L+6_OW?.=YRMOL+%,(
MN9/=&#'C]_47)I]2MO=B>M(*L[;'.ZVJ!VFY6#]AB<CK!W6TVF<1WFT&U.L=
M84+L2/1&3OW[X%79XD\?EM0?)]E(1Y7B/+;FSO\ DM98U,/"DV#>5@1 IM=E
M-U!*+VA"(.3:PKKN?D-45LG(.S0BP@T-E9>H',6D\<7 ANN<I#G)3#I\6&;R
M5<,RG$N<-)0[U++X.668!OML386OGEG<9$7M?)5,V-^%I"1>6RU=2_U;0L2)
M=+3<J$MHU3[^$UV"2K("![)OJ?#/:YGR0*V$K59.G!V#K 9F+XBLAEDIC\&+
M%&D<=L"97XB 76O<7MLOF-M^0Y6NKS8PSPCLT@<B+VS8LZ-G(W;W@^DHG6X"
MMJ0 0:8PU&<]69GV'GQI(C6BEBI2*/<<6HI(&XZ:1L. *ACVD8CJ+-J :L2F
M6X;#?.^>=K<7DV\^:L'NO"+0F';>B7%/5;< B31JNK +J]EXEP6>1-A+"</L
M6OJBI@LBK*&P(%"-Y78)*W;D/[QEYLY;06M JB)U5SHXAI3B/0.:YO\ 0!;E
M.SCU?KGK;V65ZR6DPBT5[%TWSM8/1(['*Q?SMPPFLMGL!1K<+VTD,A<HRJ1N
MR<$FKUP2*2I1*0CT;0D4#-2]WJ= 21=S+RMP#Q$6=Q;[VO<#/E&0RM;-;)=<
MZC[ A>]LOG,LB-B!FB<B[HKVG9QXYYS7UK5S/K1J8KTLBD1::R-^B4>UE5P8
MX'U20CXO>NW F9#WJS9U8.W,A?K[>VS/Z1M;B.RPW6V\YY]O$MO[\+]K@W5R
MZO>( B4G[''6I*&TFWKO<NR"A",[?"X9#YM*',I5W4;(5RZ.N9]-W*.WF>L>
MC;O@<BL[YT05*"UQ>]N/E\FZ^SD7-.KAOA0H##H%6;9.RXNQZRBXY!F0_A.I
MK1!]@(^%[,04)&5);8TP@BTYD.B'3V2+MY@?B1"MCKNQX5)) FX;KH^CGI9?
M!/T[[Y99G;;OM@N<C95!+YYX3TNQD-GSR(3^()TE:4]O6KGED!*NX%5.B6Z$
M>$5A:L9DY^)AJIBMD5K6MR.*';JR"3,>$W"LM;&GDL+Q3EE)6I4!N8RS &1V
M_#:;YWL;7%N18?JKV9\)OV*,U9(H):)66TXZL\@(/356*T_/QS4F+LB.<R>K
M[BE->4##0,@ B:8<#2@">TTTJ<0C+I7*PY>;2:4P/>+\E"&@;,]QN/I&9X^(
M@Y*UQK_PIC@7$IJZ&V_)IY"X1V$@!F;FH!008S( A.X^B9+:U*KK#:OH=K#)
MJ[JASV70K:HK()6"$)3BHAW!&0V#&R8 U)"6;?BVC>?WK F^8.5R+9'8#D-Y
M^O4F[4[]HE0LO(]@YYUQ,T0F4!GKDKZFZN?P>?"2\7;:I35G"JMC3^<36P&[
MZ0D&"\5D</!P84&>!)33^Q%\$F?)0VMQ7!MMO<9YC/8.K/:NE.%BF$3"*, /
M[UFW^9VG^C(CE.QOD_,JG8WR?F5)\BBY(&(OX4SGO7,#D1DT(:]8E1[CB+IS
M=865KG41M'T4QXU:(QTJ*LGWYI2+QW+PMJLQ;[*:.-MRKD#NS#N/;1S:'>YR
M".>&H.,!XX8TX>RJU^%)<\3RL?2=KF*P#+.=LLQLFM(/S;58?_M!^^[B=7AE
M?A,>@3H7C#VXLZ"HP,4IHF"&!V&T-13XZ<4;6WDEJ0^%A<'WJ9*(QTLFVGF'
M?3UJZB?J#<O\RLZ36T<^)QO[Q0>BKZ/P/9B\8]C3\&TI]>IYAWT]:NHGZ@W+
M_,K&MHY\3C?WB@]%3@>S%XQ[&GX-I3Z]3S#OIZU=1/U!N7^96-;1SXG&_O%!
MZ*G ]F+QCV-/P;2GUZGF'?3UJZB?J#<O\RL:VCGQ.-_>*#T5.![,7C'L:?@V
ME/KU/,.^GK5U$_4&Y?YE8UM'/B<;^\4'HJ<#V8O&/8T_!M*?7J>8=]/6KJ)^
MH-R_S*QK:.?$XW]XH/14X'LQ>,>QI^#:4^O4\P[Z>M743]0;E_F5C6T<^)QO
M[Q0>BIP/9B\8]C3\&TI]>IYAWT]:NHGZ@W+_ #*QK:.?$XW]XH/14X'LQ>,>
MQI^#:4^O4\P[Z>M743]0;E_F5C6T<^)QO[Q0>BIP/9B\8]C3\&TI]>IYAWT]
M:NHGZ@W+_,K&MHY\3C?WB@]%3@>S%XQ[&GX-I3Z]3S#OIZU=1/U!N7^96-;1
MSXG&_O%!Z*G ]F+QCV-/P;2GUZGF'?3UJZB?J#<O\RL:VCGQ.-_>*#T5.![,
M7C'L:?@VE/KU/,.^GK5U$_4&Y?YE8UM'/B<;^\4'HJ<#V8O&/8T_!M*?7J>8
M=]/6KJ)^H-R_S*QK:.?$XW]XH/14X'LQ>,>QI^#:4^O4\P[Z>M743]0;E_F5
MC6T<^)QO[Q0>BIP/9B\8]C3\&TI]>IYAWT]:NHGZ@W+_ #*QK:.?$XW]XH/1
M4X'LQ>,>QI^#:4^O5I0&BGA>$^XQLR_EU3<TGN#5T;*/$M5Z540V!)Z,F(F"
MM)"E;C:3)'_=<.2+PHEKRJF[Y6-O 2C$2X]!)-H.<"BC;!6]T1)\+5-J\'A#
MK.?4.B-"Z(QY!C6$VM9C9-9X^5TN'?[2K>R=5U4V):.>Y5U(X,=*T/T4+#1M
M;%#381'6MTECKVU@X22>6H;\(2EU7+1NAIG[K^8=]/6KJ)^H-R_S*SS^MHY\
M3C?WB@]%7U3@>S%XQ[&GX-I3Z]4VJ!&[$9I.N+K)582)[1> \@]ZM"2T(Q28
M\%K#X<Z%4I9() X7=\N/%Y04:+-T=4?&U42WW]S;.#6'#R8^T&5C66=PG;DD
M,CB[X-M0PQQ@-MM#@3?8;+U6CS-*V0U TKGT>GJ#*SM0Z/4F)4D+8=4\(*AN
M)5M:]\I?8L=$YC0VX<TG-7'+]$%(G*$W(HV=;*1XUHX"1IUNQD9A#<:YU6%@
M'R90&HS-/T^=FHMTF:$*-WRJ"NA1AOIPZ2X2]"N5,MAW:$QTB&4ZRCMUA;+;
MSAB;(3EF20+ED*U7[&SPJ%8,X]K>(J=%D=:R 1#4U4+VVT#<+KV;!HPO:$XD
MD4/)/2RN+WXK;-G%Y+;>3;N6UG6>(7;'99(RMK.I[R//==>J:6@:8SP=.V<7
MM@&)M-A<4?#DAB;)J^?-%-X2O)I5H,1XF11SJ7U?/-==6PXH;<6\[+C+B\G&
MM".E[*Z$(_UPM06)MRPHJUJVM)6\D0"RFTEB$LJEQT^C$?EU4IQL]9+06]NS
M?N@M*Y^;('@C4PU'LGS1[-&[?5M'>"&W'MMTDWOY+?Z<:L2[8!W=,%.VCHL+
MD4B4E\;I[;JVWI>T#;8-"97&)7V+\FS2;NEZ=6A1TK#G5>I3ZP9$1LF.@[$D
MT9F2\;G4#B#2O(F5%LN0YWX]GZ_1RK=V[EC5MT/:8F#PJ5NYBB;-P6&L2!<G
M"TU9F+D^D2%3M8O%I8%).JY &5.)<:X:&FI$M%0I9AP*W+;:B=R@R(]O.J0N
MR'RL-#J"J*O8-V1D"=5V?4<36MT9/':YIK7\%!1.826PBN^EFAWUFD9FD&3I
MTD[G;%R[0D,HF\F=A#4;8/6LL)?;LX^G=D;>V:MOI,_9$J.)N11?DZ"T["]P
M64:)\&5Y U6BHWMO=PZ+HC"[AV_V>!&4?:C6(+E%VLS0#MF+9CSJR10TU(=O
MT#S!6C<R=B*L83I5CR%L9KS-N?1CFP!QPK%M$.(5-.2/#YC'"H8LJKNPX<:L
MMFY!+1-WRBHOJJCKNGMR*4THE';C9W4^J[7%,Z-DQ-O@ZKI6/8!K6UKM-VW
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MDM]=]OU<%?\ OPB>A);Z[[?JX*_]^$3T)+?7?;]7!7_OPB>A);Z[[?JX*_\
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M O"HWNQK[JY:EU51!=5KYZ?+6R'AU6V*IS%I3:DX[-=1.O==-Y&3FU;,S%2
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M<G;<7V+-KVNN6/#K9$M<#;D-BH/<Y:GZ,@!>S)75@XI%(YXKJ3N8S#H<]>
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M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%\VWU4;]P!4'X8=?\
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MBUI[1=:8UVFB,$@LR=#?>G%[>@=ER2/F8TWE0:=@H@X?\EH"7&NR#!LD,E;
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MU\5YN/*PIY'S(1^KS[F^A4(1'%$%M=5V[Q);77?@FQ:OE_!Q]/382M #JLI
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M4L ,]XO8C8;Y#E]AD+FZ/"37?:G7\+3UJA;9,5C1D0=S:3]D4:N<T4\O$E%
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M(Z+.WB[9FW<.$N=AN&U>+5<=%11B2>0.(!<UC6L8-9[WO<0&M:-IS)-@T%Q
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MEMIW>WM_JJ*O?N#UAZ\R@S#9TS;JG@4"WG!#0:#C;<,W=O)_4]:1:"/)5(B
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M.5=./2$JEIH3' +7_P#JE#!%HP::JN%M-.2*!M>P]0N[39TMI*'3>R2/,_\
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M7R>P/\)H/1UK]8G2SJY?*)Z/V7342)#@$Z8E1/(-!U"G[1QQ#(MPLAP5ACH
M35'.]5E>'@Q9VHP<;[:N-V_G:#=PCSZ''\8PU[I:2OG8Z2,QOX0BH:6EQ(.I
M.)&!S3FUX <,P#8D'S>D_8J['NE]+2T>.Z+89/#2SBJ@-&R3"IV2 .8YIJ<*
MDHZA\,C/@RP/E="^S'%FO'&]E[,*-I88Q9#6%25HV8CVC=BR;)P>-<Z-VC1'
M1NV0T\89MMXB2*>B>OC;;;>YKQ[O///N\YPG8A7O<Y[JVJ+GN+G$U$MRYQ))
M/P^,DE>@AT2T6IX8J>'1O HX8(V0Q1MPF@U611-#(V"\!-FM:&BY)L,RO;^!
MNH?BJK?]1HQ]%YCV]6^&57WB7^=;/<QHU\GL#_":#T=/@;J'XJJW_4:,?1>.
MWJWPRJ^\2_SI[F-&OD]@?X30>CI\#=0_%56_ZC1CZ+QV]6^&57WB7^=/<QHU
M\GL#_":#T=/@;J'XJJW_ %&C'T7CMZM\,JOO$O\ .GN8T:^3V!_A-!Z.GP-U
M#\55;_J-&/HO';U;X95?>)?YT]S&C7R>P/\ ":#T=4Y.>D'5.QIY!;*E5*Q%
MQ+ZZ<MG49?"T7D=9:J,GWI1CH9"1YV+"R5NQ)?\ /-&\A'DD4E=E=.-.6[AR
M@MSZ;2'&:2FJ:2'$)VP5;2V9KRV5Q#FZCC')*U\D1<SX+C$YA(M?,-(\OB_8
MG['>.8QA&.XCHMAK\3P.2.2@FIVRT,0,4W;$+:JEHI:>EKV13_M8V5L,[6N+
MV@:DDC'[5YTR^B)A$PB81,(F$3")A$PB81,(F$3"*MW1L4 GQM<P\3'H/HA$
M4F:SC57A)PJS,SC=VDDIKIMILHWT>--UM..?&TU<H[;<<<*:\\VQ(%A?,[/H
M10VTAE3VV 8 I%*B(M4+(14LCDBB9TC')1&9(&Y7T9F 9ECIY5JYV9O" IXD
MJFX:/Q),B->MEVKQ5/E8[CS%%&0]=T&"CT/B(XN^TBM=RB#2FOX^YDQY\-A2
MM<PT-!HD#CJ;U9PJQC X.$2<[@^5E6KLT_,&77E7Q1TKNL=QYBE^KG7B'Q6"
M)7-8%GFI=#)($F8ZKE144*PW9R3B4QJ_F4)#Y8.E+LR\:**+M9+SJR;MHH-*
M!GC51TA(7*;SEHW6.X\Q18R1U+1,B@<OK;F:S #$)VE=J<I&QB=2 'Z44[!3
M)Q.;%>*JM>?&U(+&"!E"//M/<<Q@4?-C@JC1)_OMJL=QYBE_RZ%!M^MU!MGB
MYT%9,["2_D([8#Y4WF93SX/)7<)2J_2S1K)JDP&(V0*K!!M @9K9KN*8@6 Y
M!R!?^;*<.%CN/,5;[.3?YO)UK865HU/,C<4D9<_ND;A/$GYC1$85(#' Q671
MUW%S#E+=IQISLY]%/%N&2^WNJ,77";MOSHLGKMPL=QYBESF-^WZ%0\NZR=09
ME(Q,[?APXVSPPINQ:VW'_(![0=EF4BJF5#9B>F38;Z4E$R'&:7@>Z!R3;E]U
MAK,J!?H/ !\R,>+'<>8I?_0_3UE2&A:TKF@RTVXCLY#+0\N"JB&P6*MQ1ENX
MA4+J.$IPT$++2,Q)9(_FAEVGY9X]D*Z )1779%%=@Y=IN2;Q8[CS%3:KU(R8
M$=D4 ;!R2)!=O*7[M=-MJKORBVU@LS;\KJ\^3XU32X7<-T?'WYXUY5623XYY
MVWUXYMB ;@C+C\H16=F*)A$PB81,(F$3"+3?N[U/$=R:T@E2RAO'B,&87;6L
M\L(%(]R23>1P6*/7ZLB!#' E+=XS/OFKSCT(_27'[CGZ23Y FP=-V[C0J#:_
M*.+Z#^2JWKST7DM3=1;.ZM3>Z3<_?SJT+JEZ=PDAX\K-B(>S+,)SH20F#4JP
MU"F)P@R>HLY40X9[#C)C1V8020Y><-T"$YWV;.A6]!:%L;KYUDE]645,H[)[
M6T&S%[7$JM42B B+&9'T=_0CR5BX&'75< @;_9%Z[9C1WGIA%ORPW=-.7/+Y
MN2]S<WY;6OU+EOOX+3LN1J3FO'$CH4,7M3K1<G4KL7)N9?9$Q,&P5WV6)M:P
M.S $P_K:-;R:\9A+3EM$Y)"#(J*1!0M)(L0&S)B-C>T=<EEK#6UL\B"!Y-@V
M[!D+YFPY5U?IVLV3V'=A85-J&@=:1"QKENE%V CVS5?2Y8;+/(ABMI6 U:HH
M\(RRT-?2VYM)PX>O'HE,62=.45B&S!D6-]AOLM]%O:_0N1IOP-UL\]::EK!Q
M;L4N"P8E>4PL6V?A/V&-8A=\60JE7KM1Z,B>RFF+Q#MY34%(16KV+%0S4,L:
M.)(PF#\0^ %RP^6LRRUA<Y6%K #.V=]X.9W$6X[YW\DO\#K-G2EG!(HTH4Y!
M#D:ZD/QPZ]B;VY9G:]F]7YYUI-:/[*LH[1J,Z@D5FE:4G+JEF8(1(+3B4K1F
M[*:H5[$2+65A9BW^U_+[% [G^$,N+6!Y<]M^+9QK\W-X(BS)])IT< 1#IVX&
MV&=[=EV<6F#&3<Q^DY#VFJ+I/"6=L5DR$U>IY_9E7S+K=84L$.FF]=DBRDN#
M/F\SCA=\;4'E=?( WN+9[[%QL>2S@..UE([)\%OV6F;"W:W0LNHG]=RH5WD>
M12?R4O.UK1-2SN#U4<42UVG<=;Q!>/#VD0EJ[@^:-"98??R<2]\N@(#$6.S$
MF4#@#>W&TV^:1RG:%B[&\$I>\_DMM%6,_I>#F)RE?)O:Y0_OW?7!9;2Z:_BL
M3%]:;?=-P4=76Z[5PL#W&BG@N8%2).-"(AP+@4-*CB:Y,@=:V5[;!Q9<?'8[
M[<>>=\J_?^# M(+-8+$@5>UA58CL/V6L@AV/BG7 2XWZ]1+HK(*]ZZE;(ID@
M8+12KN-938%H==(O&8JT&0)9PI'[9M%^U9L6N\H)-B7&=R<AE?:3G8\=K7W\
M0MN5JGO [FGK VJ%<44+E$V9]M'%CR'2//D'\]E5L>$,J/MKU\DDJ(-XMR^D
M12E:LA,M@ LJ8W<DHD:D28^&J\QQR_>I$ULK9\0\@U2TY<M[\MELATOZ/WEU
M^[9]B.P=D22I2@V\PDB9'MZYTW DIC)$[IE\_A,VDL+$5=!(T')LH--G</*<
M.I#8<GW*B',@)3V5.)D2Y"%";@#=OV[!E?=Q]5EUAPL4PB81,(F$7S;?51OW
M %0?AAU__!7L%A;H._/S3YPNQ?@]_N!^C_X(/6K^#$*PM;^_=\YWG*V^PL4P
MB_&ZJ2?/'&ZB>G//'N\<;[ZZ\\\?_GCCGGCW>,(OW_U_Z81,(O$JX00Y2U66
M21V7WV20U54T3Y64T15<[II<;[<<J;ZMT%U]M-/=VU1155YXXT3WVU(O+QSQ
MSQQSQSQSQSQ[O'/']O'/'/\ TYXY_P#'CG"+P<NFVNBZFSA#5-KSMJYWY53X
MT;[:::J;<+[<[>*CSJGOHIMPISKSQIMKMS[FNW'/)%YN=M>/[>=N../<YY]W
MGGCC^SC^WGG^W_PXX_MYY_Z<?^.$7YT4T4U\9/?137W>>/&TVXVU]WC_ *\>
M[KSSQ[O'_CQA%^\(F$3")A$PB81,(F$48 ?WK-O\SM/]&1'*=C?)^95.QOD_
M,J3Y%$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBB!$^;U/.00,(/
M)*L1 PL\<$CJP=/1,N\,LVJ+?1N$,;+[Z[!'6Z^RG+?7351#C3RO.V_D[86N
M3S"^RW*-Z+\>D9[ZJ1G]=2'L3C+>>8=:)Z1GOJI&?UU(>Q.,MYYAUHGI&>^J
MD9_74A[$XRWGF'6B>D9[ZJ1G]=2'L3C+>>8=:)Z1GOJI&?UU(>Q.,MYYAUHG
MI&>^JD9_74A[$XRWGF'6B>D9[ZJ1G]=2'L3C+>>8=:)Z1GOJI&?UU(>Q.,MY
MYAUHO%K(9*U*@6!N.B6;8\1<BT78Z2N2:R#E &8.:[*-%XV*UV141#+H<[ZN
MO'T452V\GOKX_BK#.Q.7)R@;SO13?(B81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB^;;ZJ-^X J#\,.O\ ^"O8+"W0=^?FGSA=B_![
M_<#]'_P0>M7\&(5A:W]^[YSO.5M]A8IA%SP[Q],Z_P"STSZGR60=>JCN)U7?
M8>-D+%,6!":XD) ?1J, M=$V$<.9LT4>FHFK-S<2?.H4-V(ZO"W+0UZ$7V&+
M/6A9 D7L2+@;"1F"/U6FL3K;PH4KN>:QR4[V74'7F1WI7KT>G"9Q3+%2 U2!
MD?90=-@]<2#2S+!ESF'R:&+]<'+;3WD5F7$JZ/QD8K:*D@)J22$K\'+.YL>(
M[;"U\AQW!V[,R<E##-7>$[K&/L812$9O)\]#=Q.UELF)_)+8IB:C);7$G[3M
M9_3<1"B)1?4,=CZ\EU!2J3M94XEP&0R"*6+'G\>&5>BQDH.=QXGP3M/^ZT;#
ME86/%MN!R$';Q+5"IQ7>#N ]GHJ4+V=8\JIRTIVW=;FI14C^'"-)QTI\([1[
M"9Q(AP:;P2.D9A9]@5@$G'7I5@5D-2 G</*R!0]#9&D_%%38;",]F5CDYN1M
MG86.>TYKJ=U' >$!C_; @E=$5,17J\A0CV),029NKR\+863#6_7X77!Z)[ K
M4.RMEO) 25Y;2J/C*GK>*1HN@,9:OY^@L$D+$L<M7_K7YAG?B\G&>/8M4Y%U
M-MF07!?L]YZ!G8_6YSM-2TEDE'@"O4-*N^TO7^H'EQN59,8")7NF.FMW3JW[
MC<7I*DKS"P0=S!H#7,"3/$Y/&MFI0K<6:+B^>>=P3;DV6%K"Y!).Y757?1NW
M@@?JFSL 7.#B<8\&OVAZQW2+CML,'[.+'ITXH1>KZ_@P*6R?6$\RUN"'61$D
M;+'@-A;_ $B(!&<R/T TA[;4H2,^5P-N3/\ 3CX\N-;1>#1I";=?*'E5<R>N
MGE5Q1G;DE>TY#)*#Z]!+,'U4K&86R'.+=YZN-D:;+SU]+6$R=:F@3DH6=PU2
M()2HJ\DK8ISH4<;F][D[3F<\]^>RVV^:Z&X43")A$PB81,(F$3"*, /[UFW^
M9VG^C(CE.QOD_,JG8WR?F5)\BB81,(F$3")A$PB81,(F$3")A$PBJ"_RUJ :
M4LXS2 5E(K:&PXR[@(5_JFHW?R%)MMLT3X;K+-T'CI/7RBS%@NND@_?)-V2R
MFJ2^_.<[#&4<N(4<>(2.BHGSQMJ9&WNV(N^$;@$M!V.< 2UI+@"0O,Z9U.D-
M'HKC]5HG215VDD&&54F#TLP:YDU:UA,8#'.8V61HUGPPO>UDTS61/(:\K0?J
M1:GA.Y-4#8G<5%5:2E.Q\N@U(V?/C-'S-Z%2U:<M52D"BE-S48TTT=[OV[-_
MNK'W;YH@ELK']$TT3)GTN-T>B$-<YE!B5:V'@V$MHZ6/$*=LAUM8,J9Z^G>[
MX.J7-M*UKB0)2;QQ_'>QOI#V?:_1J.HTFT1T?GQ#MRI9'/I!C%5HGBDU*T1\
M&ZHP?#M&,5IX@V0S,CF+J*2:-C2ZB :VJJO[VVM3PG49J!V4IZB:M'2K4Z(0
M<D:QGYF[YHR#*\.O.UA4!E5-PH8\UW=:L&[M]JL?=,6BZVZ4?43W6,!F"4>B
M$U<UE=B-:Z'@WD-JZ6/#Z=T@MJA]3!7U#VY:Q:VT8<X &4&S)'9)TA[/M!HS
M)4:,Z(Z/P8@*RF9)/H_C%5I9BL-*X2<(ZGP;$M&,*IY0Z00LDF!K9(8WN+:(
M@NJJ6WZNL#PAI&N80^FW7WK_ ,2UW& [B0\F+[EL1+[E%626[I0K%Q%%S 7'
MR2N_/E'PAA)C#5@ZV5;(NN-$^$D^#64VB[*JH;3XGBG -FD$7!X;!.S4#CJA
MDTF(P/E8!DU[H8W.%B6W-SZ;1_&>S5/@>$S8KH9H9W2EH*9];VUIAB6&U)J'
M1-,AJ,/IM$<3IZ*=QSFIH:^ICAD+F-DL-5NLG:JX/"Q1R6T\VIZB:^:""AM9
M*2)5Z=<7,*++<.Q^J R>')57]?.J_CN[7=?;DN-:-N-N-G*JDH:*-DF>W;8-
M0Z%2PUSJ_$JISV1@P]M1"@>P:KKOIXX*FJ;4RW '!O<;9#@7 EP\%V1-)O\
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MD515TM(_#<3IG5DKH(I:CN:Z(2,IYJC5?VMB51* 8Z>0-(B<-8-!(!N+8G\
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M^5UG'I;I3*R.2*E9+'--VO#)'03/9+4$7$$;FN+7S$9\$TE]L]6R\KOM5*6
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M*"DJ^U^!,$TG[*$L=K,U=7X1>[+,W%LUOAG4+Z*F$3")A$PB81,(F$7[$?\
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M30<Q0%\LR!9\=:NUY$L[?LM/(/5GZ#M^0443VWQ0F+7:!'P<DLKW#.X:\"P
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MF$3")A$PB81,(F$7S;?51OW %0?AAU__  5[!86Z#OS\T^<+L7X/?[@?H_\
M@@]:OX,0K"UO[]WSG><K;["Q5-W$$D!=O#EX^">R!0/)G#Y\S8.@[5RFS6C,
M@&:KZ[&B8EJIKJ[?MM-T]'/*WBJ<[ZI[:Z;\Z\^@EBC,XED;&'Q!K7.;(X%P
ME8ZW[-CR,FDW(MEM7G-(Z:LJ&8:^CI):PTU>^:6.&2FC>V)U!6P!X-5/3QN
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MH:<OY<CP4U%FSI\ /3WV%BQ#$/PFP3=O0? _M<)++ 7CJ_A #5 <.!U>]RN
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M4]"S_P"+*5_I2O\ VWQPU+X7%]G5>CIVOBWB/$/O&#^M4]"S_P"+*5_I2O\
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M]-=M]]N->.>>"*CHM>X:96^M6<>#[E(ZK48*W([:@V11@S#IH'/'W(-%"*\
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M497;%? (^8]*E-7,CB!(O?;;BL!D3].\ K]77X0CMM+Z^K*'2&5T_09F9!Z
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MG55V6?E,OMP ";7@"AL4VXC78Z&QIH\Y%VS6%E+,P,+KH<<L,2^X=MR#%^4
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g105292g33i33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g33i33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1X@4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     B@   =C          $                          0
M   '8P   B@                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   B@     4F=H=&QO;F<   =C    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   (H     %)G
M:'1L;VYG   '8P    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M^FB@   " -  G224Y/76UO:QECMK30
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ L0)= P$1  (1 0,1 ?_$ !X  0 !!0$! 0$
M           ( 0(%!@<$"0,*_\0 8A   00" 0$"!0P*#P8#!@0'!0(#! 8!
M!P ($1()$Q054A88(2(Q45>1DI?2U2,R.$%48G&5T=,74U5687=X@92AL;6W
MP?!"<IBBLM<D)>$H-6-U@L(*)S.S96ASI-36\?_$ !P! 0 !!0$!
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MU0JM=Q+X8CM. 5 EZJ_8Z3(<B$48FR,G"<*5!&3*Y,:?A[=XT9FV&CE\*1-
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M-1-7L T!JNO[Y9+3*P1JU>+E4KR&0B,W$4W,5'>4EO-I;>5Y'B"@/&&+AW5
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M;BXZ-Z@M8)KB6UMN%ND[RK'D\7-,OJL2W%R@MXKQYVE@MF6YFB2-I8[=EF=
MA!KL.FV>B'?UC/5356P=[6$R!&J.X1+WYUI5N!9*PDN^ 5<:$8L^PPXC8=+P
M;C.BLVZCSC]>\L5';\X]V;"7(MR6\L*JTB@!CH:96T=!M,%8E25(.FT=>[M6
MNR."RF*BBGOK=8HY7\+V;BVG>&?PUE]7NHX)I9+2Y\)A)ZO=+%-QV>'LMKA$
M7<O1&1W:G5XHIU%3:>@!WW-LYWWUP1JH5NY#>NONGVO52CRY-N;#[#$$;[?6
M19&]TT^8JX":/>8*2FHWCYT6Z;.41>(=!N6O#Y)R"B)YBS#EM"%785E#'?Q[
M5M6Z/RB8PWT@B2X\;0L/6+0W"6R8N[RTMQ<JMR9+21;6U+I:W,44\JOM%+ (
M=_,W7H5&6252A]DZJ+3<XT?:4A5?J&QO"!6YUAK3EUL6N;[**2ZI9CL8.+$7
MFL$JZ@K/4W$*2U#U!5$VRHS,R@6LI4.0BJ2@#-(B_P#,4.NN3#9*D'7N[[UJ
ML.+IC+20K<M';06[-8H);C(8^W#-D;:&\M%19[J)I'DM9TF*+[2*'\3AX;\=
M.UWN/H(M\76\*Q77?=.M=[IFO+/.9?WOUW2]<ULIL?4L/<X*LS=QD;$ HC9*
M?27Y9,+&-3:^9+LC9;> <0DVX-;J>SG7F0H95+CLR<R$<QLWAAR^@W8D @;W
MO7>LF[Z0S,#7C0P)<P6MQ>0J5N;%;R:.ROVQTTZXY+R:Z\-+H+'(T:RQ1EU/
MBLGMGI6OC70]M#7^V-GT^S=44FGZ5#MV&_22VT.O*LF88.13D; @E@]3LES%
M6NS02E,>C6$,]7@I))D;,@OBO+,3(WC*7MI8WC1@O*0\5 D1AL-P(+!BJD-V
M.R-'SK"N^G<K975C97$=LMQD9#%:K'?V,\;2BX-HR23P7$D$+)<AH9!-(GAN
MKA^/%M6XLG0'(E&H 7:6[[<1KTFZ12XRB[^ZT;R4BN:^US7=JVQ:1M3V(8G2
MHXVGVZKN-R8<=]B>>/#*D.<E6F2@/QZI/VVG$-QT695'MN8U[LP'=@?N!)[=
MZG_;6:58GDL_ 286QC>YGM[9&];O)K&W'.>6-%+W%O,"&8%(HGG<+ IDKD8O
M=W0Q8-@:MKE=L>]S-1V[2[05I]AC=1_6>BXE-AUK:M;U9(U5$U*]=T7I5DBS
MBQLU8,R8,1VL@JN5.%X+-=BSC<&X;*8([,-,C@,"5XJA0OXADY<='L!\2=;W
MVK8R=&9>&SO;B:,1SV%S!'<0F2W-O'9S6$M\M^U^LYM?!94BBBXLPFEF2*-S
M,RQ-W[6C'1'M[8A_5NO]@;W-6^OQ[',\6]OOK2# +)!IM@C5*XD*#<#FPQU2
MV*/J-HFQ*_9IU&-V"*$+2HT0@ZPM]GOVGMYHT61TTC$#?)206!*AU!+(6 )
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M!*.V_'>=BI:D,K<M21O$W&12IT"-Z((/D01L$=B-@D;!'F#6NO;"[QTWJ][
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M0V^+O/7(0@:X0,Y<E7YR!9$TAX@DG@VD?!.TV+4J5*ZBYP"S[*I9ZUY&RZ<
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M.N->*$+0!L5J+"9P^.0LLA8 "Z-J];DXJA6,HJ&/@0Q!4E"=[;?FB_TD =]
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M)/UB?L2SR8JPY>".)Y?AM&8,]B&EIQ%<M$J+P1O#E\5&/(%6(0$=B 00@'M
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M@ED,1"LQ9$=='7X,0C1S6B\::W 7J3U/OUQ,WK;D.C:'K^U(M+E:,N>L*C6
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MI)^3GZ?%*=B_23\G/T^*=_N^S]=_I3L7Z2?DY^GQ2N?;7V?4=*ZWNNV=@S2
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MN7TDEDL)C3:T&=?PZX"@Y\NG0HEE.$K!51E8;P>?7U]&J2='W>[S^9U_G7O
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M&4_'%5=U!)8<=">Q.GOC%)S"$QI$EKM2SA"M@L8C"Q*@C$8$:QA0@0)[(0*
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M8XXWC*GW!;_V:"I>>W.8SOV1K[5?ML9X,D<I\2%2D3^TBMODJGN =@'8\CL
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MG9W6U         'D .P ^0%:5LOH\TAM.>W/MD&P>.:I0B@L(A6:;'2W6PE
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MK[NWY=JL_K7/]#=")[6@?=[&X;?0Q8:V;?VSL:N%JS.>G+G*O]&-ZTJMDO\
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MNN5]#[@ACIEU: '0R4$G5JV-#7!HK4#M,FOW9<&,5LY"2./"1+\N65)DGB9
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MV++6MJZIV%>=+ G686L$UZT:*.72HU/"Y$IN!+HM1%5B862%R\L8TV#MI][
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M.(R%CG)$:.B*ZIJ6QU&+ZLEM'>>2Y%\DD9C!-S;!B2=[:XDM[F5P/,()$'(
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M/N.J_;O?BJ^+D51OY'\OE\_G^1UNG>_%5\7%"=>XG?P_6G>_%5\7%3]?7O\
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MLKB^FXL@$EZJEP%S9NJ28R+J"ULU2:&5B1+8WSRF-@PX/#X:1#@0T7(OOU;
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MS8=213QPB^_CML($M^[6OK>U'J85B9U"C=@Z"G-O1H;T:\4&S' TF7(2YE.
M=XUP/NM%L#*E-+SV#;"N?&0ICSF.'.OMLYV=QU-CL>G++K=XEN07C=VLTD;,
M0=>'=62W5I*#H]DG+CMS1"P%>?8;T!=;]9WGJ_HSN>F?23"\<LZ2=/=28K'W
MT4,17D<AT_U3<X#J+&N Z][O%K;RD2>J7-TD;25W4?;-?[AUJ\:&GYF:1:@D
MSQQ-$RT:[.11;N'F)$A;[V:Q<*E*;2A;C<I?F<E&1XN4PXTE33N=W9W\$L<5
M];R(T0 F5IXM* AWN6"ZC&E&O:2>( CS71KS;(X#J'I+J-L1?X^-<WCKR.+U
M6/\ AV>M9;H<'CC@DLWR6*RB,65=6\EW [\HCMU9!@]7:LU!5::6IM"PS9*4
M0G/N$Q!R['MHBTR)33:I,+&;@>M"8461A6);XIAQB&[(D/3G(JI$IYYW.ER<
MM_*MUX\+RQZ02VJ6\)4KW')K5(P7 ( 9MN%"@'B  SV3ZEFR-O>YJ*?'9)(5
M-O*F+AP5PT:.P24"SM+$RLA4QK.0SJL:QAPL841JH/2QNW4]VO=RUEM'6%-$
M6@@T88U0 UM8A^KY4J", A(L&>$DWPIY@\>,#ONO6"E-A";1:>AZ9&-@AL*M
M)W=QE["\M[:"[M+RXDA0QF\ENXVNU5GDD+*XMD\73N ([@R)P4A3'*[35U63
MZTZ>S>.QMAF,-F,A/9QM"^;N<O:RYE%DEN;B26*X3&0>M:FG4+:Y$W$!@B*Q
MM;W,LEX?V*=:-[IVTP^I-@=+FSH)\A!\Y++T-Y[: ":,C/CX90O6WJK7W2$\
M=#F$H;>4'X-6)1VY$11<>)=G0&I=*8.WGM'O;;+6;1HW#A<@6<JN0S+'*)I0
MJLZ(Q_E-,A*MP>3BW&F'T?XW(8:XSF*ZRP\MK%*81!DU7#7,<S++)#;W8O;I
M8HII(X9"#;/=PNR.+>6<1RF/G_4?U4=3U>(4QC3&D+K7(9K,A,Z=L_2]HO@S
M,?#B$X+R'-)W*W6BKM0NU+:PQNEY,$O'Y?AM)1%>1G)QF)Q,JSF^R%O*8]<%
ML[Z*W?EW_E@9"W@AEY:)\2.X\--:8[(UL^E.B^C[J*_;J#J+'7<EN4,4>'Z@
MM,=+RT?Y"C/V%C:79D[L)[>_\"(H%D;;J:S74W1MW7S4R\;7ZG=%=.%<GSQJ
M6YT6NG!T<>0D09Z&F<['N&Q*D^\5<0X^[ 8CU< \UXAU>6%R(Z'H^O@S73^!
ME%W<PNT2_P LSY&_M+6!F8@JOA&%XARXD<3<2%AO1UL&OH-L9_N(6W270?5_
M7>32WG<VEL4R%S+;QR1>)*,+B,1D"MLC>&)IFN[F/;H"X23BW3>GO:,"D5JB
MZUN9BG$Q!;#P[5^[J*:EF]2;=EJG2?*AL4T0.61RJ[!44\X,KIQ6Q$HAER,^
M[2RLY,<C7Z[8F:VR\<F6Q,ZW=LX\26)'AEEMU4^&71[8+%=6J%>+7,**8FVM
MS&AXRRZ7K/IN_DR>6O4Q^6QV1LV23/\ 2N<L3C^I.GE,,312SV/JMBUUBS;-
M!(E]%9PR0)+'Z_!'XD5U=34]O^+_ %\UE>:U^:7D+5E"'65KQV]J4N84K'=S
MV9[4XSG..S/L9]CV,^QGD;'Q%5%' #%6"GR)4@'8V-$C1V._;W5^GM_Q?Z^3
M5-6+[_9C[7[=OW_VQ/%#^WG]OUKYU?[?\7^OBE/;_B_U\4I[?\7^OBE/;_B_
MU\4I[?\ %_KXI5%=_L_V?=3[_I8XJ#^H_N*K[?\ %_KXJ:>W_%_KXI3V_P"+
M_7Q2GM_Q?Z^*4]O^+_7Q2J9[WL?:^ZGW.WTL<5!_4?W%7\5-.*4XI3BE:'M+
M%85K38#=W#YL-+>IEE8MX+#D)GSO5WP\QD^/4Z1(B(3:)0IR6TXJ04@(PA2L
M^5-*[JL*@]@?TJ*71+8]>7*)M6SZY8V@?"KLPNOP=J;2V%8]BE+V"K\8@@#!
M&3[2\HF#'5YF=*(>IS#;CD)^U+DV29F_S;F)#* [WV_?[Q[OB/D:G3Q4TXI6
M%)_^\:[G_P#BDK^XR_Z.*?7U]>^LUQ2G%*<4IQ2G%*IGW4_E_P L\4K#&ZU7
M+,PS&L@ )8(T9[,B/'-BH)5AA_*%-Y?9:GL2&VGLMK6WEQ"4KRA2D=[NJSC*
ME9*'#B#XL:! BQH,&&PU&B0X;#4:+%C,(PVS'C1V4H9889;2EMIII"6VT)PE
M"<)QC'%*QM@K=?M@J6"LX,380T]ER/-%&A\4G E,O(4VXV]%F-/,K2M"LISV
MH[>S/L9QGBE0'IW@G?!\:R64E:AZ;J]I P91'02L^B[5L/2UNDHB.//1FW+9
MK"WU6Q*:9=?><2QDEEC*W5J6TK*L\4J*47P'6IIW4<>W5L7J8ZI-O:[L$XI)
MF]/6QMHV@O2WHLX2H?%'S[I&.PMF'V(<GQ<Y]-DM)A@NA+HXI&DPI"V\: ]*
M],G)',-@,2^5,_K1R#V-N]WZR- 3^,Z%O&70X2?U)I2I!4$<]+TIT[/?RY*X
MQ%I<WDY<S2W*O<I(9%*.&MYWDMB"IT%,/%?- K:8;YMWP-O3_>-CTRVZQ.$N
MGBFUM@,R7U5J2$4K51MJQ4IQ;[Y!L%;038B1/'XBP79M=A"RBG8V)\PC/><R
MA/I=OG\)+!._4O1'2O669<%;7J'J;#8C+Y>SC5%$")>9'&7ES<+!(#)&MW<3
MQCEP1$ V<"_Z'Z>O[Z._;'6<,RNLDO@VT<?K$BN7\29HC&2^]?S!J3:@L[#V
M:D%L#P5O@\]HUP)5[OTHZM+#@!.49A3(\(H$LTHI.8\FG3CUS E!EPM$B:CL
M<EKLIPMY3)0W,>PN6VV^G27F7R=^D<-W>SR6T'_X>S5_"L;4:("VMC"([.U4
M E0EO!&JK[( ':MZN%Q"1&!<7C_!,IF:-K2W=7F((,SAXVYS$,W*5MR'9VQV
M=\1V=X$#P=^Q:?ZDQ6K+3JE^*-'BP5FUAM"_#2]<C#GHBV\C!%G.VNC2G7XL
M3S?*</5 SXR-(?=3A$_$>:QE8/J3.]-W4=YA,G=6$T9D8+$_.VD,J/&YGLYA
M):7/9V91<02A).,J<941UMO@,(ZLO\)QR<AIFAM(()"-@Z\2%(Y-; _ZJYQ3
MO BZWU!5)=?T=U<=85$D.29Y.-F7?ZE*#++3(K<=,@C"J%%H1MUI&6(REI&V
M45(7AG&,2<=N>W=W_I$ZNR=P+K(Y&TOI0BQ[N\'@+E3&C,RH4FQ;IQV[;T 3
MOS[#5<.&Q]M'X5M"]NFRW&"YNXNYUL[2=3OL//?E7!M">"6\)'4C)B=M'PP^
MTB$)2!S8UG7%;O,B5E^,Y,5/8*IV;M^Y!T,N(=BY9S%#YFH6ASMD-(SV+P<Q
MU.F?@CM\IT[TW)#&YD3^&VE[TY.KL I/KG2V1P=ZXX^4<MQ)""0_A<@#6'=]
M.072*IR&=MF7VDEM<YDX'!((V0)_#D'O"RHZ C8 .]R'KW@PNIVO;;QLN)X0
M8WE]$TA*P8>T!2)VP9'EPR0/6[/LQ*Q3!4V:^E]2)TEZN*;?C*<::CLN*0ZW
MSHP?HZC87MOT_P!6V^6V',Z^D/,3V2R,.,O"UO[2]G:-D+JJW%Y<2*6#&9RH
MJ3;]=M:KB6]+7I$;IZ-5CBZ?FSLUWB(X8F$D$(QUYZQCFCAE59HU>S98Y562
M-4D577;=@]%WA*3EE%SJ=X5"8%!1(T6.Y%+=+FMWB:G6ILJ0\\M80T(%35YB
MN--(7)')4M3>$/X6SA.,=ECNI>E\?9M:-T!CLC(>16]R&=S,MP"T:H#)P9%?
MBP+ZA]6!Y$*$/M54F-RT<:1#J7(2!5T[S6F+\24[)+,+>SMH?Z2%T(>X'M%M
MUI&V_!P^$#V? &1G_"V65M8^>[,RV:Z1=531N,.L*8QY)$KETI[[$G&5=F7I
M$V8PIK.6TQ$.=U[&OAZCL(_^;T3T7=KK06[LLU=*K;_J07>?N.+$=B0=D=MZ
M[5N;";.8LO)C^I\]832J$EFQUU!CI)(P0PC=K.UB+QA@&".6 8!O.OT+^"OZ
MEK;KI%$OGA-]P6UMP,'&S84O1NGX],>=%K@NX\36D-NE6AJ'H27!\%^V2Y<3
M*8V9)0@IAQ4C77$W2>5NEDSO0>&O+(EA-88S-]:X.*5 K>%&B6G4\EE"L4GA
MN%6P9.,815C)#KC =1V]Z<KBNO.N\+E_%EG&3Q/4^1QUX)YPRSRBZL);2\C>
M=9)5E:"YA,@E=7Y1NZ-J]?\ !#=0M+J;]:HGA*=F4[#LF;+2T$T5KJ(&5(EM
MM(4ZZ-9-MRLNKPRA,AYLHA;B$HPVEG*,9SA3V'0,-PCX3H"WQ=HJH392]8^D
M"[0S!F9Y0T/5&/C D7@I0P,?9)+MR 6W>KU;EYA=9[TG>DW-W@58Q=9'K?/7
MD_A(28XA<7UY>7:HA9BJK<A$+%D16))YGH[P/77'0B!Y^Y>%.N<*&2BP&&$:
M@U>9JA)]49V4MWSF0L6U[$G+3:7D^1)AQFG&G')"G'%=K>$]1<=48OV&QO17
M3&.E7D'DDCR66Y@@!0L.7R%Y;QE3LEA"6;>BVAWK,.8N'5LIUCUSG!%R,$>;
MZPS^5A@+Z\1HX+Z_GB5W"H&<)LA0#Y5NM7\"?L(9MW.RK!X2KJR(17IQ6=-<
MJT^14=E2G2(^3%QV;#E6RT"F5*>?Q@BI- 5Y:,\<.82/>=008'KG+F 6YL>F
M#$H4!6Z1Z9/92"H+?PKD=:&R6V?CNM<F%OA<M+-U=U==V3&3>&N,I;C%!75@
MB+';V$%XJP,5DAU>\A(BERZ\E:21/P3.N34J&^?ZM^OBP=Q++,QDYU)R)R2S
M+3JWW&)J\U1M]+,A*EM/(@NP\H0I3D=3#^<N\U)RF%F60W_0/H_R<\I8FYON
MFXWD'( !5BBN8;0(C#FL?JWADE@Z,K$5K;GH;"W<OBS3YM_+E&^?RTL3 ,3Q
M99[N7V#OB4!":\E![U^=I\"GX/\ NK,9%IH6T#3\9]<E,V?U#;UD2EN.-Y;7
MW_&[ 7&QA6,][.6H[:\JQC'?[OM>7,9U-D\&TC=/08'IOQ5"2+T]TITMAED0
M$,$E-AAH9)E#*& F>0@@$'8K*AZ,Z5@&H\%CMGS=X%ED;R_JDDY.WD/-CY"I
M%U?P<_0U4Z>$I$7I;TP:$@14(1%G7"B@;G9I,>"RTRT^4MEGAE+&4(.X90Y*
M(323TJ2[E;CSJE+5VY9ZZZS,IF'5.=1RQ<B')7-O$&._Z;>W>*W1>Y 2.)44
M=E4#M6W7%8Q8E@7'V0A1%C6/U:$JJ+H*H!0]ET-?#0J2.LM2ZPTM6LTW4E J
M6MJGDC++YKM+!#ZZ&R4G(8;FD,CQC$>/F9*1&CH?D9;RZZEAI*U9PVG&-)DL
MKDLQ<^N96_N\C=>&D7K%Y/)<3>$FRD8>5F8(I9BJ@Z!9CK9.\J"W@M8_"MH8
MH(@2PCA18TY-YGB@ V?>=;-=#YKZO4XI5,^ZG\O^6>*57BE1MHWW4W4-_%;T
MX?WIOGBE65'[KS??\GSI8_Q ZN.*5&G=FP-4+ZM->T]W2U<N.THMNUW'EW$I
M>HP( /!1R 0J!)G82I\4$6OU -6>.=I%3MPXE8VIQ:ID=;IE%+2Z]7E4$]P.
MWF-[/N\_LW_CSWV^E?%5TXI6ODWFG2->2TZVXID\^T^E"TK4R[ZFS3OBW<)S
MG+;GBW&W.XONJ\6XA79V+3G*H^'V_+X'Z[=_NW6E[9E[FAA1KFDP^OC)]13"
M"S&Q"9P8,:#^22<Y>@N@H\B0Y/\ +<1$>+>PEGR=3RNW*\)[-!U#)U-':PGI
M>WP]S>&<"=,S-=0P"W\-]M$;16<R^)P&G(7@6/<ZUJ\L^:2&(X.''37!FU,N
M2EN(HE@\-SRC:W1V,GB>&.+ +P+'>P*YFYK?J!V'6UPMC;EAZ[<+0\((!M&U
MQ(N>+<4K"LQXNP+9/L):1E&4IQF>+"UR0O&5(1AM&5=[2-A>KLQ8F+,]2QX9
MKF+4]OTM9"WFMV)!X19>_FO;AB-#E+!;VCGN%X@G>J;&=19&V9,EG$QOC)J2
M# 6HADB).^*Y*\DN9GUH#Q8;>S8]^P!U6KM4>Y].X"608ZH(I&O^5+(DE=4,
MV,6B^,4PRQEB!?&#M5G5R(IN,WE+3\4]"8?4_*;@9=?>PY&.Z:ZBP,31XOJN
MZRZ-(97@ZMB?)NSE50K!D;6:SN;2/BBD(T5W$K\G$6W;=-IA,SB(V6PZ@FR"
M-(9)(NH8VOF9BJKQAO+>:UFM4(4>RT=U&KEG$7)FY?"'I3ZLO!]]1NW]EB*P
MTW8]CQ8[I[-S!=;%O>VF(.IEAZYZI*,?W7M2J2!IU8X('#2G*F966GU\5  E
MX4^LLKA8Z/%^F/TPS,;/-=!6=OA[2,I%:XN/H\07L8FE86]UCYC8PW=JQFN+
ME(I6Y17$K3QA)W\0::QN<ZUS<-?]'7D<>N4=U:9N*>Y\3:KXD8O[ZU,6XT56
M,<@=D18V#1]JD2YUI=<=-ZKPFH:H_8]G:@@N9B2B.W=64R!:'U9K<@M'9+6'
MI_([!-6V.VVY$=58JAK$1*DOLY\>"4,5*.9[H==>A:XP<W\7M^I.G^LB=28/
M$=/]9YAH'\8%A"HQ-QA=M!N?PXNHLE;K W)+L3*+9'^[;R#*"REQV>\)-JYN
M,%-(4<(7 DN,2+^.X4KHA[6+L2$=20[+Z^J?KQZZJ5>:%&UVK1 >NRACLBU"
M&7CXDJXM)"0QE2'-[4*CFATO#.&L-JB5HL*4VEQ+KS4M78UC8KTA_P"G"SMK
MJ/JCJ?J''Y!V_P"!3)].=16SA  I=[?&V<X,7B!U)FF@E##:AD4DLEUS:6<D
M"O?65F7VSP7<5_:3M'W&PE_802*>0UOP64CDO9M$2,ZDNN'IQD:=>@=9&JMH
M5K7I(M'&396LMEUR_P!%M$R6.)L^:LVS1>TX)Z>)FPE$77:]=P->;((CIF.
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M+K?7L+)ZMCO'805!CJX\*1U5;;<J$G6=>VAJ9X'-LL*PTJEQ=CT<^+ROS*J
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MZ9$%N.E[,A*HK;;3BG5H2VOQV$HRI2%]VHHHC5Q("[,P,>CM5 &F)UH\B2-
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MJYQ1OR[[);DIV2>Y)]_?SJ"FS/!$Z5O^VP^RQ&U=VZZ""55SNZUJ=N\IK"&
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MN27%.")IFO6$3%5.0/GN2@LM[(],!\9-GJ [/V>?F#[M=OQ\_NKLOJGK?[X
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-4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g105292g37a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g37a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3 \4&AO=&]S:&]P(#,N,  X0DE-! 0
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M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     #J   !V0          0                         !
M    =D   #J                      !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   #J     !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   Z@     4F
M=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    %.$))300,     !TE     0   *    !/   !X   E"   !
MT) !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B
M!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M    $  /;6  $     TRU(4" @
M                             18W!R=    5     S9&5S8P   80
M!L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   B
MP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M   TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&
M5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M@,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($
M-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M     2<U)'0B!)14,V,3DV-BTR+C$
M                                   %A96B        #S40 !     1
M;,6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M   !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#
MHO+W=W=RYI96,N8V@
M                  9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6
MQT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.3
M8V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                   &1E<V,         +%)E9F5R96YC92!6:65W:6YG($
M-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V
M4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                    !V:65W       3I/X %%\N !#/%  #[<P !!,+
M-<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                */     G-I9R      0U)4(&-U<G8        $
M4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@
M!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .
M4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@
M%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B
M8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#
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M0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,#
MP,# S_P  1" !/ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRR>-D\Z[92$2 QED.41E>;")*+M$CC=FGN/W2W'DS2T[G?1_)05ZF>U;HAM
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M%&Q7F.,7>4&#&4S/)FYLPHPE*;ORBT7=^3+4-E<;7I R)[U85&U*E"O;(:$
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M)IP<K08CCWH\1H2=XQF\-=YH/*,HM)VT=XNS/JSK&KTVHUD Z)N>X?8%O*3
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M.G>@T&E+0L68KV8SGOM%CZC9UXNEBMLV,3)U\=[0!VR;,;(T=K;.0/>?,VK
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MBC(T[I:S0K0I#LNSUH2B,,7;AE>N^])W?9LX[;+W1C 90NW.7V>MCVOD*IB
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M0QL>09 8SD<TY"D[QW&<COI^5XHNTN5VHR;8R>UU@E;;G;K'YD]RY>)LDVS
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M^6;9 (LE7H1WJ<I=F;9^5"T^,C(<#"R#PUT0K6ET-EJSE,O1[73]%"N>T8Z
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M^,E.5*ED[6,!=R>';.!HODR4*PH'GC=Z\(%J%6Y.HX9DJB(<0I?JO;>LB@-
MG#G)1ZZ<G*79M4)7#K)B+-Y'+MF#6+Q"8-7*\&?O5HT=4T,,8Y(]!NT9?R=F
MR"%#@1L1U*HFP]J,]TS1BS0O.[B-6+*):(7*<,FX\(L4;;DBC>;%B)Y3A"<H
M[CV?M!P9JT38\AB$G9V;A"%_'YG'C)3VFR$*6.R,)RQA22I6WC8%3NL%Z1;H
MQ5C6:T#,>.JP[MKB2E6#DM'VD/B!^[K+J8"0EK"Q8Z^R/J.,6,9EQT@\)0).
M--2JSJ NG; (^,"AS4$SE"3Z29ED9=1A7*?#N*$F@1S&'0JW"1#*L5MZX6M
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MSL[M+6VCQ9<K7IY&J(-K(5I!N4;(3S?'VK%6<P#F*,K+$<#NS 8CQ(\JTO\
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MJK5H3S33!BZU?''R\9YVS2J6YU;TL<,$B4:P+486;@8#LFKQE:?%1OND<EC
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MS99CB&U7!8&XS@+&,(5N+7,45F$&:O"$!S!;%*R,K0>3S*2)&G"3L^4GLUI
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MM/"#%A',&NF)*,&?<=P/=E&#.^DFA%Y<W=:I)^N(9U!:YA]>E1]8.ZTF,=G
M<P!AH%PV?'0$>*QW=R5 :^P#W:A-J666>+[;^ORLFEGUF^->919*;6+)[(Y6
MHV@E!,9#$9XP*2)&:!-929H/%FBW=IKR9:%[8RM/$X;&X>P+!$PN0I9.M9J8
MVI.);5.H:F\SU-!!)(XSRD6;_J>48\WT6CS/IX)M;:4%;;L>92J6'*W85R(.
MQM^9K@?%T!IR0R9N>:Q>)2%L%.E-CY0"46;RA(R)W<PF-[Z,$\IN\N<X,S.I
MPHTZH A':E:F,L867*\AC$XY%,-YP@PX$BSB>$M#E_5S;3EY+V<U\\]X^T&:
MR=^_:PH<-7M4C6<**C$%JW>C;'2QUL=:T=[9ZIY0NQL >6-IZ";0F_F^PO5I
MEV''A!\DF/LFC*!SB!%<.X> DS-?2>,P+8C,8V+/;.1T4L 7@&HWC\I3;E%A
M HZ?'MF^%7R3YM\8W+2QLYS$#>=[%>Q#0Q!29Z\B2B$DQZ3+7GQ&<@G>+3F,
M<G=VB\7V=L-A!;8@K O9+AQ'B<IB;#$QU2Z*;98=49\C3!;>8:.6 U5X5+S0
M/*N"U;#"&\6)825 JK)P6=V%+$9ADD'LMR"D,@C*T?;-\MYR&A<,@"IX4:3(
M;N6P=]'(.)QM''35[LW)*NWJ9G=-35IIJV+<+%>L%P;DZK$&,K$=]03.:PPY
MC>.CSB0\_P#+%XZQ9HO#5M5V\3@3XK*Y?(1R3FKYJ=2W;HSJ#AN92MC,;B'M
MU[,2O.%<M+%UF>F2!7@9R$:R[.PVBZQNK*ENR"2%[$L\X09N(=.87!&0&.1Z
M./X.RF\BBDHR07,I)/5962BY2$1G,9P2:-AJ2;#9<R.-$U]B6NW5RW8ACA6J
MCC)C@/8D0I21.X!&%NM!WBP8EB<O%W7>3[S-"4(-NOP<SL'_ ,BN7+.8SEHP
MYXW*8W%"J4Z=,F+'D[F/O<:=AHE?('HGQ='L/'' ,6$\K ;)IN9L.XZFG5"K
MF>M;LD ZY3)&8;2:Q&D/C>61*.S6)0>%D(P.A[C9=@':"AM;0HK'G>2!!RSD
MPIP4)X,M"CX4I]MF!M!J[T1RI0B#A5I&)O0* QSQ+([,TIRG.R>)8[L6D*;0
MCN/&,VUI^SZU(\\M#::V':2R;(O?S(\=2X=BGD\?C,::B+'3>0:XZX,-C3TR
M<4I!7 3.;M SE!*8_P AD7:,>O88$Y>!@77,LQ>Q 7IC1WAZ.%U/,:C&B"#E
M;.%=4FH67;O?:D\965=CD--]?5K*YQH]N+*61F1FF3)0E$T_^N[*=P-R4XLW
M+5R!:.C\FC)_%F7IO^+TABV2K52$K5-CSB)CP,S$XH08'(8 %<I).TF:%:^Y
M7(S/*1 Q9^4I*L\^Z=;,*K# X::E)^00NLZRK>/ZBG 2.'U$:_LX3/49,(,N
MR8=,/(]?9%TV^S,]'UT\:XU82 4Y4U>)=6OFMZU,AAB&,UJU:)OM,H];%6==
MQ3&T)[X^;.[2&2+O_P!ASBVC^(ROLX8."KUL=:OV[F.PF$PM3@3JT[;PQ.<!
MEHW:]DAJ\:UQMV;0<=JI-F9F%;!.7$:8Z<JR;B^MJM4RMRC!Y&1'V$&;E8ZO
M[Q/B!LK.R)P+D9E^L4+MB5F+L"Z9V7%T3!9@_F[@D23?$4ELK+Z5VV">3:V%
MG.*,JTW@5MT<Y"&-IBA%H0>%5I0<88/",H@:$7C'31O1[-X')U]BY8"_.&,N
M%%EZT#TY<:W7!?M7)@N62S-8&;-S%8:UD+$3V ER<S'8AHR>4IED5;Q.25D<
MJ%R/PQ@QZ"DJX7%"\ZL\,HH3 +1E1@-VQIOJU]F$+Y;L]L:;X0SHEG&NWH>6
M=(5DPK0[D9:V!GC9:<N>IH$8K2DW+76;:R;EKS7I+F%Q]W"6MGB!X>+M8LV&
MF +M#AT#5)4G$%])-#<KRW!OH[1T;D^FBK&CU$,IG6EC[7,4S= DW'W@6?(P
M:--@S<#'(#)JY:1LC!4E\#223T+,#Q,H23),':TBW%N66H\&(:1[G4?,0<<J
MW8H=BF,D25W.1R.0E@5ERPL.SR@\9A'",-V3<+?C+>G-R+Q$/9Y9C:'F?^2V
M/^25[-0E;+1QE.%:%2GB;F&'2/BHR8!XDK7[)SFXPB2N=G()A5JPZC?W'^ET
M>BJP 0$L"3:UVW<U$=FD*(C0;Y>>36E'+$E%):_DFC9J\$NBYD+&R\R'C6>&
M)IS'1Z(_0&S<%6Y$3.%,Q)DKB[2[7!@/&1(M7!>C*!@Q&[R:;1@0L RG)Y08
MLGD\Y-!XJGLTI4)5:];+7?<\2;.V\EC#!JFEE<GLR01Z&0-=X<"@G8LUJ1\B
M$0W'8G3#$/91R/ LEVEUX$6B8G!=])"0I2;UE%JS=(M&;5?1@RB\X*S= HWV
M6WUV5=.W)11@L@IC"*:"6BNF<J;;8YJ5<C.K $(CC-@6BVFUD[;TB@B#=?3N
M:+1WF=N;N^C\EW<YLC7SEC)V"W# ?)82EA9Q@*$V$.EDS9.)XO*3/*9)F<4H
M/I%HQ:3/J^BK%V4ZF2>2N31NO4I#)"TUE]D24RR9F0T;'(Z3F 5="-XE*5%9
M)%"4AK4KBLV#F6!$RI1J107WT>PR0.V8-X&ZN,RXA,.%AQ"@ -8<)..99.]>
MQ;.QA,PS1':AVJ3")N0>+LSQ,.,B-/PVVOL_O7IV+.(:W<L9+(9F[9&*S6I!
MC'*8K!XWW??>5RB:YA3^Y1$OU8G- T928N/M3'5G7L#;%:VQ,S?6\M%C,>B1
MZOSTD*S&0-!"!T$%W+U'*XFK[FC94D*=DV"YPPBS')>V)N6+=1!Z\T61;.6Z
MO.IVJ@!Y.!AD-"R,4 C>;C)/<MB-^LL(S:,FA!WD^Z[2?6+:.[.WK=H,)G\E
M;V+LT+53'6L/:O'R-H=>-JK7>SL_>H/V:E8,"9Q2M6(C#'B,04)1(1I1A.,M
M"C'1J!P^11LV,(!#Z3,5#V4NUL:LH'/3<E*1)Z[?JR8-(B0ULXA)F4JOE=)&
MD):.0NFB+-Q&Q,=)(;OUM@N=L&$4<XD&\IFD'LUJQ7&*!HM'A3%&3L> FBW"
M><FGWQ+,L7:+<JA[+L5C;E.S7-6MQ@#'#R+9G"XK*V;UC'E(9[U>X8(YXRS=
MF6?;(UQSK-NCG3KTS1<LK)0ZJPT5KA_6:[MT:"%'$_W?K.,:LW*[6P9-(Y&3
M9XRUVQZK5MF2.6#=9/;"N4D4U\YU5VV\N8:W,MF-IHM"<&K[K?\ 9F>N(0XN
M^]WZ\)I.S\N;MW+VF-P-:AA2821"6:QI97BRFS#G,>6N7+9Q_H?].YVR8H29
M][=C&7*3JL&>E3UX+3'G[A?2C(B%577<>3.0./JAW,0J.8.Y9'Q5A 6CYFQG
MJ9C+O8=*D<?#H\JF@V<MQXY7171?J^_(M-Y#I1%Q#V[!''8(Q&-<"PB3KDE&
M4J[PT:8G_P DH.[L\I<G;P__ *:E)7B"UM$6\U?&8/#TXVL53E7ECL!D)WJM
M?+51E&++1LM/@7XOV0-B,(3@$+M*,O$TZC.Q$EZ]QIFXV)0>II58\XE,E5;Q
MV.MI(,EL\5MD!6J,0!H91PG'KB$P2;L7K1B!"B@L/0"L<+K$WS;GT^8:8LB6
M3-&Q<#5KB&SE(XY!KM3):XTWUU)2D<$HRD2<YG><M&A%UA'[/25KNR%()'+B
M]G\AFLK?N2A2J1NAR.5EGZN$CCZH]UHU-H@XO*"*,=6N"OCH5AM.1RP5F+5I
M&)6Z7K,Q)=WJ2U9S-K+F:3)35),Z@TPF^UC!STM=LN8XO)Q41E3UAC&-7A2'
M!-5O2;:+)J<NI>+3A:@-HNUH#A=Y=XW?]/%AY$84C"C+_P",33=N>CKVV>V7
MQ^T-G"6;KEC+"9*&0'$3LS6X#9B-1M:L^_3G=!C[Q1-_[A\=6:7Z-YGQ%;TA
MM ;.M"S%95@@O966.B\=#QH;$@+?W<7/DVQLRS&+KI2:<;M#:$>?3-PDP(DP
M(,*V(H.G37=ZK]V;[6*E2JP=UJN\[%F61B/O0'%QPE-F<0&E!R1 SRC$A)O%
MV9VBVOAMEWQ.<SF;E?XT\UPHRIUJ0,?4@P;-L\+-D8)2C>RCCM1IER4XB,>K
M5K0-&9(.25<@/3<],H2_ V].B+5%)EV&"0F.1P4"0^"];GFTA?;RQT;]:4^*
MC3>/.FFH=FZ0'BAR!0DS*CB9#"+UGTB9H83Q)3KP=W?'3.0LB/QWI %'A1@V
MYP1N2,N(\7E.;QC*$H1UB_C:GLWMY'&%J;0Y4T(P%M;6Q=.G7J0;&?\ (\G;
M,]\EG4_;[,*DQ-7&2 @!B8PSA.7=(/.GNCH.93=_,IO.UI"H<>2QW(O*'!&,
MB+-Y]2QBE97'=9GATY.CH:@(-D#D-B[%1)C&"[IQN[VD&/9-V?P/.D""( 5V
M&T(A8;<8DA0E7O0O!+P-&A(SSA$9BRUD6#-IP]'9]NU[+ZN1R9<CD\I*Y*R7
M($MO[NJBNGAEMF[&S5^DV2WYV@XV(+);6.HA>(J-B<WF]IGAP]BEG50S8 R#
MXL&S1$[D=9DEU863EE0PPS'U Y"/[QTT-F4-=N-QLC?%TM6!A4T*=194>>$C
MW 9H-%[DQ!+$++0KS/V>K.N*U%F/ -P\";\2<6$PF;]8HP?>APYL5I#G)IO*
M>Y.&Y?V"LY8.*?+9P&4O8,TWQEB_L]C;-1ZQZ?8K(<CCB2<-PMB+"L2L@)1F
M*T 4J\ @D>N?^GG45HZ?.6:$[R'@<@9U UF\& 06+ F9_%-$-389(.Z%Z-6<
M0'2,UE9:5#A ;?14<K[O +1Y;UI!>1S$FBSO7W[ Y7'!8*<I''VV'#(\XSU<
MTQPT84YS;23;Q&(VD6I/9\.92#CE>SXJX/9Z&4Q=3%T:HK?_ !PK6:T:TP-"
M&.%<LL\KPJ]=VD%^%4>I+>-+;:NZW-JVDT5+*38G(X_647F<+J6+N0XT=K#X
MW.CH(R6;E2[7=1Y*W[!O&0<>!/W*8W#,$T6P0;%C+UR9WQ6\F]H18,"(B6B@
M-<*TY2XY*XR0@\(2Y!C)RS(2+/+>([;KPA%H+?P6Q8\)=H'?)GN4\)1R6-V?
MH3KA#''4\I:K6;$3V!NY+YA0IUJ=4LXA8=6$N*,]DL[+V:YRU[=.$3A%R#[V
M?;R,_9'$/YRLSA%>+J5]EDK_ 'FNZO\ 63?/"*S7")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PBY!][/MX&?LCB'\Y69PBO%U*^RR5?
MO-=U?ZR;Y\__ +\(_IZ?CG]U9KA$X1.$3A$X1.$3A$X1.$7('Q3^TT]Z&%^M
M_;](U*"%!1XK;U2WW60O*ST5(7L[JB12:C9/N.305PT*BK;@ :%)%T]TMO9;
M$W8J^GHLGC6LVNK?3]_MJ_R59M=?/P_?T[M7^2Y Q'Q&._(J!6  GQ60M[]\
M+/J'VHM+MJU604VBML73+73<%U3;2ULFT9;EHD"K@N5MMVTUPPR1?1CTEL9T
M3PJG=&?TU=F;]_CIR;U^/<T;U9G?D_IX_'3E\>:O2;L2V_#\MOI=*Y)W"N3L
MU7_9FF.RDF[ @;D.1*0@42-*=;"O8I&Z*<1"1P#O6X%,D!5BCZ,#GKR&?#<J
M"I>Q;FVS0HO._7EIIH_WT_?O?RT3OU\-&U^[-^ZI-U \6CM!-I_X6U+6HXE2
M<PC]AGH+WW>DDFJ7O9]V&BYP5TLT/;:HZJ)XEK.2 9IIZ7LVSPP&1USJJHEG
M7>NS<_\ ^OKY_'3S^::-S^/+3N]?DS?E6OH/Q9'\T\2KLK!G%H0:;TA,Q%UU
MIUDJ./2Z/%)H)LCI, %&Y@<*1X<]<&0XOL4I(+9>0T\19)M9"*J((D+R[URC
MNH=N6NC_ !\'U^W+E\W]$\.NYV9_M^ZN-X7\/M6Z*7H7O?;_ &UO.RY]?M?+
M61(ZG92F-#>M$;0G[99R)@48J\;%M5!6:L:[H!DBVTC6DKZ2#2KR1DR.JWL#
M>/RY>3O\^NO%'_"\=G]ONS%6>(U=D#(M*Y)]/Z2Z*!>STR#X*$D;):C&YFU4
M#LIC#5K7SGW_ #=\:@>L61A16<"(>TB*#:4H%E),2=@FC3DWF[Z?CK^/%IRU
M]7;\=?QXTZ[ >+!W&CO6>U2N:=J.EK;GGA^O>^G6:5Q:SR-K,8Y6[&8UR!DP
M"R1,EJ42*UM:,QBS 4DC[9@QD5=R<SJX O2XQNU4?JUF;7O\69_CS^W+O[_1
M-.;-ZLSZ]:Z?1_@IY[?^*9=G2F)UHYGE6TG9$_%5:SM[L?6]7R[L%+)##Z\(
MSK>*"9E'#P+K8]A4;CS\8W>.])!=Q>J@Y*6#BL5!9>H--3&\9M?3U?3KXZ=R
M:=>O7?Y*V72JR)M.NROB;A9-+I#(XY7G::MXS70<P4>/1D-BY#JC0\K<A(VP
M<*[MPPYY(9 9..FC)-%-P5*/7JV-W"ZF^3^'JW[NC^'JW[NNCO(HG")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_.
MY;WC'6-UPLHU2EK1**E["@GB&/:NL3((&68HQ[H&7CD-FT;[".FBAYYE J'#
M6Q  A\SLMD X+#)%ND,:;[)M6]T;S\-?GW:?/P]%=&\'\-?GKIIR^K=.MBKK
MQ".X/:2:5S4]$/J7KQSV6M#N/8=0W',J[DDV%0SI-U@FD7J>(2E2!-; BF9Y
M9UQ6(3</F#Q:31Z/ X6[T?9"OUM&BZ]T9N_7P].;\_7P^Z::=_I]7YM_?KR]
M5K4E\8JTJ/C%>1F]HU73ZUX=XFSSHWV%D,#$2)K"3-21V!MIS(>P$, $SI(K
M#4V,?FE?&) (,')*TCVZ,B1V<K-'#%1HTUUY_P#QWF^7@_W_ #Z)IZ^&O[:?
M7KP4W5AXN8N5T3XG=Z&@@U45TRO">02FA8IF^26M6':!@D6I,@GNL\7V-.+?
MN)K)PP J*PT9.Q[T4U:MO:6+E=>:=VGC^?Z;37R33NY]_CX,_P#3::KQ,_$@
MOR8=8>I,;@L8K8=WO[!]@Y+TRL0?-6I=W5M(WE1S";N.QTN/QL":9&C0L(.K
MDO)(-"V,G9*F6TJBN5I!N/U<*NVC<_)FUY?+3X=_/OT33O\ 1M?Q_/R^RZCU
M.A=U:U2=<]E[(@MO3"-*R(YO,:OJ\E4S C$6 ](@S:.X88L.PT])(WV0))+O
M&4E:BWR&P_75@R62=+N(HJ:43XKU0WKB.X0HWLK6:ED]>I3V:HG%HQ.N@;3L
M#6\+#A#,F1JXR&M*0 -I2+;2,&HJ!FI6&J88E&9I1PD"4W))UV=O+OT?X]?=
MG5TY:^NGKU_"AO/C UW;<"A$@I$'.XJ:W[N]>.JEGM9/#ZPM1K"]K<DD;V:J
MDBE:]A?@[8%.PI=2-@)]#)E82\4DV76#$%?*"W3;1H_VU^7ST\DT_&O\_31U
M/E6^*33=IW/$*B:U+V$B VP[ANWK_7]Q3.'1%C44RN6@'<X2GL%#F!$^-2;1
MYEC7LF* 2A*)CP9A-BN-2))'&9 6T:<OAIR\='[G473'D1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$7(/O9]O S]D<0_G*S.$5XNI7V62O]YKNK_63?
M/"==?%6:X1.$6$DNI_>/'-(JJ.0DVPDAK'URZ"KH6B9RU5P-5(MD'#19PRT>
M>IV<HI.FZBB.-]=%D]LXVP11:QGDRBZM11>RQ8!S,[.EDIC3ES#GKW,="^YH
MA-)VT<(>]FB1!^FJ+BJ8S;&Z;-7#EYJYWQZ*6Z6Y3GUU^_KZ*;>%4X1.$3A$
MX11=<=+UEV @;NLK?B;";05^=ALD>QXDH[2:.3$ F(&>Q5RKNR<-7&V@^41H
M._5;>NPV?HMU1Q!)T.=NVJ[KZIU]5B6_7BE6\JNZ:?DZCCF0]CPT:CUXNB#/
MWDVLD'$HR_AH(3)1C[=P-=L&L7)O@BS;#31)\P7V1?:N<:Z>B15%B'A)=!X0
M%G\?#TT<>B[&J>0T063E-TWK-'4>I:5IZ(R&KJU)RZRC1.IX:51TU;NA5:/(
MKA1MKHUV5RV2113NKO\ Z;[^:*:)5T2ZI3+>9+&JD')O9^>H642@J!/2R)G'
ML@ZPN![FBBS8]%3P8T+=U]L*8(CMQ;]GJ^9(9'&=2+!9=LK->OBB\ #P_NH,
M5A%"U[&J7$ XYUDG0"RJ5W&'I@TD<3FL<U/)L##V:)2'68S#5VG*) E(!DW.
MR,1*DRKE.3,"^F=,:75^NOIY>"NK]=?3R\%@JC\-_I]1-LMKFJ>M3T-E(PM+
MC\=CX^VKA7J>''9ZS*#YD8A-(OYZ[I^'/I Q-%&KM2.0@;HW0?.$QZ;+53;&
M6K],WW?O?YJ*2+%Z==?+4NZ)]B9I#2CVUXA#7-=(&AD\L"-AI/7SEZ4)Y@UC
MPJ.2@5";0B+<J:*%6D>L./244U)/%':+757&F=8BAN"^%QT:KR.69$@5,.B,
M=MFJWE%2D;-;/MZQ=!])/5U'BE10%Q/9[(W=6URB_5]Y,XI6KB*"F)-!@0:(
M(NQ0M5G=7\_'7Y^:NK]_S^?G_/GXK49;X0_1"> A4=F==V9)AX^MUZB?J%NS
M79QP2F==YE,BFPJ,646Q;^A*SF$3EDJ,G8/B?.9$I"'BK'6+;B6P8,@/:OZ?
M1OMRY?)-?'KS5QJRZ]U/3LRMF?5['GX64W@6AYZSW[F5RXZWDIR"PL37L=,8
M%2 Z4$B"B<1!"!10@$8CG<A]W-'L@6)OT4W6L44T\(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(H@LT+;Y4A'-ZRDX:/CF^-]9(D35;I
M+N_.3PMZFLQ]?#95C=5.-#ID*PGLLP0W<'6NZNBJB3=\*)UW_P"M.N:V$3+G
M9"R9K"%&C=-G%XI )"V?:**9<.EI@1GS)RW62VQZK1)GI$&VZ&Z><[J;O%\*
M8QJFGYD6_<(G")PB<(G"*@-L^'%U]N:\;ZOB:#5W<H["=0G'3F9M-6S'+-*#
M/S1PN3DK-15)1;XL=IOH\.2>[YQAFTAP3U']O7?.MU=FT\GU^:NK_?7YK29-
MX9\3:UWT]!4/<]@]=+4Z0UZO5U-7/# 4$E!-]"#T1!1&>QVP83.X^>ATQ%SC
M6."),03=L6[P;,6#0^+?(+ZN4G;7O\=?SYIKW^.OY\U&[;P;J$>#1K&=6!8]
MG/'T>[>+VA(9K\..#MN7!W.CT/B%E77(]Q0D6)"R..Q.(-XS7P&*" T>BX==
M)%NV5<,DW2K5_AW?+3^^;^O--7^']=?-^;\UJS_P1>O;[$%BVMA6&RI<)#NI
M,1LJG!^6 X)=>.GC.R]( 5FLB&98R1J^D1:Q$I%,50KUHZ(FHF!>-GC135?;
M=K^[_737\)J_W=_KWK97/@VT>$1L-"GK0MFD=2MYUUV@I1S#RC,\2Z[=@X5"
M7-?R6=P\C8"4M6EXNW(RJB-LR&6%B0@C35-5-IJ/4406:->[7P;3Y>NB:Z_3
M3X_'KP97>KJF+6@5(V-";$O^=]F[#F*,R?Z3:>QVMX/LU5-1AL"%1*-1NN(S
M$XT B['=@F[12=IDB&Y8J9(OC*J3I%NSBBY%T!X+QZ>=1:BKONK>]LFIQ%>E
M6.LL+K\&WJ4*!ZO(SH/!]K*9Q0Q"8TLG9YC#F# (GB038M)F).&#W@EVF25,
MO2ZM=]7?EWOK^?Y_"?+KU_K165A'A&1J.+RTE)>P4VF)F<=@NHG8\\X;5M4=
M>A6LRZA&4WD5!QF)UO%HQ&X]#I,%'1X 5%H#W)!E@2X+(EG)$L[WU:_NWR?7
M^75UT^_W;133#_#D@4.4H51I8DO>9H/N'V#[BA,.& 77!Z5]A=[IW.Q KZI'
M'J8]'\W67P)=-/0)+X##?;%5/6NO3:_AF^FG\)KW^K,WTT_A=&.11.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7(/O9]O S]D<0_G*S.$5XNI7V62O\
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M+]1QFLK?$+0?,>OBNUAD>G6BJ,3;I-&I!XEAZVFX@4CI[/K';$!F0K'#C#H
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M0#%B!#4 Q(?')26._8O=QH2FXR59VO*SI$BS1D+QTX,E?:BRY%D$*J.7K^.
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MM8-=[6M1\0N1QNI,K1C"TIAT=FSI:.UO&2JLDFS99VR(NG(.HV<4([DC&57
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M#731_)3RZU^*ACK/T(O7K_?-VV.&N8" @MH6^)DZ %N@E8,AS53&T+VM@C6
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M<AY6T-#E]F>J2K;=!19)0BU6K.C'4VE&1<;5M)1*'#9+4 FBYB/%ZD,,I[7
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MVW,X0,)$9OC1'99BY]:<:.&(TB/S[A$J#R+8F8TV9L-_1=N%=Y(I,=MRFO\
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MY)PB?'5W?\!V?^+$>_R3A$^.KM\_+\@[/S_3Y?E9CWGY?[__ ()PB?'5W?\
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MKIGV&ZV]7[?@KT+-V-T75+;F:T]I++#JY_K-%@=>!!3ZX1CBN(4=CMA/9H.
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M^>OQ\N:OYPOI.$3A$X1.$3A$X1.$3A%^;?HS_P"&?_+A%0[PQ?\ Y$>NW_\
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M<0USU;L9)X=3G#D82=-4<B=W@EX++DB*39?W)J&')5L1<(3(S&;,@0*TV,N
MQ[1T!C5<R200J+B9A+=7A >;8BU3-@Q9)TB,#&"@UD\>&"8]H&#F"#$BC^/>
M(;1,M(M <::2PN?>S.2P1N-;+U_NSW/1R)QF::-D94E/5860?'@<M$. 48#2
M,I.G&&TIW>1-BA!)TM'"+-R[M7)V/2P7W BE4[;>U56(N$A6DUD)!D8:Q8C'
M,R'#)L6KJ*V:BN0=ZK#4VA%VP'@!(=^O*)@0C; ,4:(NNNY%^5;VV=SNQBX.
M0PV/Q2N'83L<?@TY;3A0X3>#NJ=PQZE+8=34#B,#14;:/)+)61N%.P<IER!6
M,-W;HKN&?:Z,=B*/6/B058T=/GL[B4RK^*$)W7,0@Y&3ZQD5(3HRR(= I0#E
MY&&D9,UDC86X4L(&ED*%'GYJ'8*K/Y;%(YD8<0%D4FQ[O124KEU=0L"E,71:
MR%A@UFN\##00N-2EZTV?$J^E9&0G!*+*SXPUV9N9%60OWQ.V[%XH4'@"0D'*
M'X$BEVZKXB%%CX\ZD@J6R(A*7IYJ#CD("IG#SQO%(B>GDL*Y;N7HQDW&1V)Q
MHN4>*N2"+A\XT8  ;8M)C04,1(JDN?$<BC3?$C6JJ?;U8S.7VT*3L9O'SF5(
M=1;6,$2MHB0XXQEZK"UPQQX9?(/]6,H0:,VC4. /%B*([4BW9AXA]!'I:0@T
M/;SB=2=*<.*] C8>) F-I;(F!N71HKH,7UE"+< T%'80>:.5[!5A6S@<FTE8
MM(A"WK>1[D5[,?GQC/EG'GC]&?+SQ_W9\LYQYX_[LYQ_NSGA$X1.$3A%P<MV
MKJEKCQ,6][-KQ[.US;$PF<38K!X[U%WFM821G*H;4]>%H?F\7U4&=%(>7#0B
M,>]$D)GD;7\@?'33/(4PZ?.,D72JSNK*UE]GJ+[#N;$4"#Z092/#&$CH:%V)
MGBDCB<[AKI=W/5'6I1L(]V3G=UH+W%/G@TF$;+1DU'6L@FK.2D7'CP.*;B%-
MWMXE\/C?5J3U\G%>X9P*QMF?2&KII.!S!S4]5FMZU,RX+)C4V*[+/2KR>H;(
M:NHNDUFR#?+_ %.I&V;4B_T@<(N>OBOU- KI\./N/"[("9/QMO0\^FJ+##\B
M-SI)*Z!NIW$2&'0MTS=9P+D\>$D-FV5LMGFK;9H]1<,UUT%"+3^NWAJ]0(71
ME+#J_@<SK+(NKH,DV(U=>%Y5J56WWCC!=1V2>PBQ0.QE^LLNJHN]+Z/G"^V^
M<*J;ZXQK@BF]_P!0RJ+-1I$NT79($CLFHEJTE)ZOKF'[)J:XTV1=:W374\+O
M$-]?/5714UA173/H;*^CC&,$4<[=3.P#-?U_Y;Z-GB::[UPCB==5A\<.Y4(I
M-T7ZF\IJ"SZ^]6Z>I,V>KAVC']=]MFK9;U>=VR&$R==_77BF8)W'B*RZHF$5
M9+6^ZCA3*D9[67S!W.V7 Y,9MLUBT_KNU8XUV3100=((:G4VR)+3=]KG#ET]
M7<D6%>W-VHBFS=*2=>.U+%NV50]H*PMQU;O8(X23:N&ZWFV'RN!3]7"ZRZ#[
M;="-IK:+,M4TFV&ZR[=0IY+((]W!,8T34L>02Z!MTM!VCQ>W.HW8>M&:2B3;
M5,NJO+461V%HX7<Z;NVVVI'=FU3V4;Y<.TM$WG'V5ZZZ_O=X1W:KJ=X;-HA9
M_5JPBNV1R3D7">Q\?U,X65W=)E/5 #P)@^1W:ZZ,UFK1TLFLYPN[06W;*,TM
MWQ3G_7\]?54*\5?N<M2)/P]$I#0EHF_B_OA3ZC1S$R$'D#/.13:7C7#5BJ,D
M;M9X16T,,"+)N];"6[EDMY8>Z/$7C1J3PY^7-=A][7&HH[K.H=9[7":65=]/
MR=R9ZKC7#MNTSKKH+9/\J*>DYT7PFEZ>^S1-=SKC*2"NVA7KKKX+[JVU$FV%
M=G;::,]4,/\ *FSBN+!QKC4<]78.=]=DXRIKOKLLANJUSIG;VUGLD^9^O9K)
MK[$7B=7C5C#VW)*6(BM1V2GMNY86=%)-]0KAJU)J;JD1;9/*359ZUQE;7;9)
M5-;1=#=5#S4P1>C:[:?3T546LV#-M$-B&J^SN2B6>$LBM&2I/UF73I+T,,$B
M0]1YG;RPW3>-MU<ZZK:9R19Q&R*\<JJH-YY#5EFZBR2Z*4G";JHJMFN'SA-5
M/5]G=/=!EG#Q;3?7&R37/M&^-4O[?"+/MSP-WY^RF13GRWRGGV<BS6\E,:85
MRGGU:VWEOA+.%,Z9_M8TSC?./1SC/"+(ZJI;_GT43WQG\^,Z[Z[>>,XQG&?S
M9S^G&<9_\,XS_MX1?3A$X18PR7$@!)(T>)C@H44R</BA<N];#18UBV2V5<O"
M#]ZJBT9M&Z6NRB[ARJFBDGKMNIOKKC.>$7,[PY;CJV&^&77-IGIS'](#4U>6
M-)K'D@IYB1MXF'B1Z72B1+E&L<U+$?:AD?TP55&-V;@JJT4;[-F2VSEOJJ13
MN'\0/JE(C,8C4=GLKD$HE;\R+:Q4%2=[&)6 ?QTO'09YM8<8&UHY/57N((RV
M,:D<V:/B6C1H>%DUMM!CQ%YLTZ_CS^2*P<3N&M)WI96\,EPV4?D?F9RN[)3!
MZ/"+B*3B-A1$A.19ZV;-MW#@P.$'A#E=H/2>;Y4>Z,T_3>IK-DR* <^(#U'T
M"1L^ZMC<:RDTHD</1:&(!9X601LU#C,9CTMVL>*%H4RE%3A(N:FL+'R*56@'
MB$6"KS*)>\C+;23!-WQ%*E8]EJ/N243J&UO/6DCD5<;>E*661$B#H:L,'Y)%
M-CT=*'@XL3-HJG*H=+(PK+H4^D,71D<;-@E2^A48[:)$4IMY=$W>76&LGCSG
M+%J]?/<-S0U;+1B-7V;$7CK";G;+=JP<Z;MWKA7T$6J^NR2^Z:FN=<$60'%Q
M)A@F5$%!Q46KZ_U1(<];/F"OLJRK9UZMXV55;[^S.$%T%_14SZE9%5)3T=T]
M]<$7S8'@95BL3&&11(:WV6T<$&!%F\8H;MM,*.-5G;=91NEL@GMC=;7=37*6
MF<;;XUUSC/"*(H7V4I*P[1E],PV=-C=BP=,VJ?")!Y&T9;XBI85'YDG'I.0#
MM(I,G$%D!X''I^UAYPZY@<@-" <P2"%23)HN11P1[V]5!9&>AW-JZJEZY+MH
M^<$C858IDH;.N9PM66P:M!PB(OGER%&%C-G,"-,*C1F[H!,FZ\:.)#S**C/4
MBD>"]EZ#LV0PF)0"UX=+)58E1[WS#XV'*:N3I2GM2L=!ZS]83Z&KX2!7-2H,
M):*FD!SAX24(,6C=9R$-ICB+GKWL^W@9^R.(?SE9G"*\74K[+)7^\UW6_K)O
MGA%9KA$X1?GECS\_+'GG&,9SY?GSC'GG&//]/EC.<YQC_9YY_P!_"*D?:R;]
M,XCO,6_9+2)F#SWK7;,@+0XQG=V:D]#0-X#E-B(B1+EZR&.UAI)L'.,LIN&D
M@07$N# =VW;@2CU@1>F$Z]$(H_-O(C-J.56OX/,$5&3RV@\J%32)!RTW,3V/
MPH#():9##8(,//+&+RV(P0>,B+0UO,21<2F03,+Z$6M!ZJZ#K0\=:S6:1&3U
M_7!L.&4L0]V9FLYAK J+D0%["HI-)3);3. Y"TALQ>QLO5\-F[TL*K^7$Q9N
MOQ $\40>.2+YN@OAYCR+8@E9-21,Y7*\/9*E8UV,>P20@6N8S$85&(K(RT9L
M@&87BLACM=PD:\@LD<N8K-5(>#>G09HD';NT2+ZAJ<\/@>C/80,>U,X]EC\U
MK*<Q]W<CTV^BD,5B)89*:QR@4G3\A H/%88 D:(ROA.0,8K<0.DZT9"QM/0V
MKDBW52L>FEG'9Y%1I*"FYF+5S(IVR@]N%1<^B#IW9B=S)R%P]A4T'RZ!O?RE
M83EK0TP= W39YM[*T=)#5-F6Q%%T4A'AL*OF$QBDYI<WO-)<ZBD<?H=AW4G"
MOI9)(_8(C$&A#!U9!,$,5=1[LC/4PL%B+1BR8M[7V=@PS54P(7XYMZ(M[C2?
M1)\UG5:Q>PJ?-#>Q^2,%E%=LKN1/!Y\]"0AE#I&$CD,VF[X8PD&(5J-93+>$
M#!ATHFBP)2A9X2;MGJ;N3[?;KT6O)1KP]9*'&C-K J.5H3Z3NPX0T0["NY1*
M9=8&@*IHLHY#3DA8I&7F++8,(/3:@^0CSR\W$R ?#Y,,)M)03:EGQ%_$<-=!
M+8@T5U#VU#Y *MP%$G40-DNP$R86C+A]&GI%-XV7$2\U/V5O;'H":=28V_.H
MF49.UT]YZR!\HR;+(I$4/5I3/AC,'UK.@-O4[.HXZ#X,J0U;L6C(813M>1ZG
M:IZ^DUP4:TL9X"C"2,4C $$0LU=@UF+0--MX3F5I1,JP#+._3K5%.T.J7J#;
MN\S@D+;FI7"V1F"VV2$QRY+/?4L86EKN8&@6D7  K'6@#B#ORB,B)R*O1 9M
M7!<NHV?&8V4>MFJS0BE6P.HG7JT9.>F$Y@2YHW*&CYJ?RG-)^($DE24%=5F]
M,+QL'*1L;UE"L$<I1K$N1$IRE%@(C64#";B)QE<21?1+J1U]0E;&:)0-;4^P
ME;B;XW^,IYL)(R9:9.+(;OY!&MI1F-2=$+9;TE9L6%R,05$Q&RS!RPHLQ#S(
MX7-O2+SZ=.NLS4(X B*BCD7:+A(;'D7T*<&H/)!0NO)?*9]"-8[+X@4"2R,/
MHQ,9O+9"),1TT+,-B$@)[X?Y3<;)X(LT&ZPTH L,-:HR+ETYT"U8JLRSJ?6*
M2:.C ^ [U6A+SL>)RQY&Y/82E;[)PA]9$D$%I\3C30>*)21VU&#TVQ%A!G3O
MK<(+N#K&L66I-8H1*MUW,@ES],+DI&+/A[H-%VC^0.F<1B&@&Z;608P6+MQ$
M+%OIY(C0P"S-O<D=2+8YIUII2Q%(;B;0U61#X!'RT8BT<?RB8YAC(2;B)N!/
M_;H.C($H>>*?!TDD$=8GY #*'A(TT31%$V67J^VY%H!'HWUB-.%'1^ &9*X7
M':,'*THM&W)-N]=)0S\G:4I?Y/3LC[?8:4(281E*SGGK[$3%@XRAI*-<Q6.;
M"R+)PKJ35, L^%V7'FY3VBN819D2A0TX5)R]^P)75/VEBVO-3,YF;Z16!*93
M+#8UCHF]/25WJ';/97HRUSF6E/)KUU^$6P#^K%"BYPZL9I 4?B]Q)5)>V(.I
M#+7[(%('1Y_*RSV( 7YYS'H2E))83?2V8#H@*"#)G*U_B:5LS)Q-%^F1;)8-
M!TQ:Q9([8]:Q.9&4 +>+IDCHM)X[^'6<XB5E-0NZNWEE4<VGD$B,J0:J^FDD
M7!,W&FNOFOJL1:D=ZGT!(RR9LI MMB&'4O=O-F$KFP9F<4G4TUL61I2@8&DC
M 9+62T[U^+10Z3LRX^-'MUB,9:B'"ZVZA%E$>LM%MY6SG"->C4Y4/-FI&S,8
M(G<K(&Y"4N(T9?ZHY*Y:;*/R=_W [43W;[(:;S=_HBDFDR#Z#B+29'TVI652
M^J3QD257C%-5NUK2&UHC)).R@B@83(H5(XW\5@V)QLSGS2-NX&"V%@IVA)06
MKML@758*%VC5XD1?D<Z2]:HHF!; X,<;#(T=BLC% 7-IVX5B_O2!ZB=(%[SB
MI:=OHX>&P+2/1Q." SHLD$AB4;C:49'"TX\&U8D6VN>K]-.Z;!4 J&ER=2QQ
M#+ 3%VELVXP63!Y0),L1)[)6,Y;RPM!-1)9Y']("7.OH6G%_9(MH"UCHT<,:
M$64AO7.E:_DTPET2@8\48G31^//I;/S1$"F.,OMBLB'1R)E2;Z*0H=+36V3T
MU80P* 9S60ZZ2"5HF#*:;[4BB9'H-U508-1NE>G]FS/95-OLO;MT.7F@Q1I#
M62,9V(N;#5(*PH:C7< W"055UO#@#J$1)\$!CWT=$.&CKKZHLI#^FM/QP=A,
MLU,2<TXN^4]C3)38V:C F0W#)Y0+EB4ID4'B!,)"I-K%2<=B:D-82L)($0+N
M*!#R6ZTI3=GG9%M13JY4<EJBNZ?FK"332.UB)'BHX:,3F8L9UOAI%7T*(.B<
MYC1L#)WRLHBY4P#F#38EH)E <R4#&1SL0\589(OBKU*Z]KK3512NT<M; %RT
M+)0FLDF*<6V&3V."XG-FH&(IR'6+P[$M!A1;>1*P\0"7,.VFA=\JN8W5?[D6
M=C_7&GXN;7/!8T3;N%)SO93,8XF\])Q2/SA?67>W'X?""DG>PV$+EUYY+WYY
MK$ (0?("QUX9-M'Y7"+Q(BG#A$X1.$3A%_G_ /$WCD$GG>;I:/)QT6\+ #T-
M7S/LZ3.2/XT3%VQ%B*$)'CXC7\T8P@T7&'O?#N02$I%<.QZX5VF08*@A1IB1
M=8YWV6;03L;5'7M>O).;5M./2&1)S8(3C#T?%!\:%2(F3*R6+Z%\S%A%6*P0
M8 (3!R';@M)5.H+'1;@P1*E$@9%0GPF+'A=MV/XIUBUX;TD<-E'B$E'@(VFR
M)#M'[=OUJZ[CUE-69=F/)(>K>,W*&=73-#;;*6=]-=D]M-]B+LGPBH;XG\6?
MRWP^^WP\?,Y7!EF77ZUSBI2'JA$B)%H%@QY^ZC;_ &/ SS7("0I([##J;5JU
M)J#EU]!Y,<YVT<Z$5@.LL;>Q'KU2\>(RV33EX.K:(X6E,P4#JR,I[4':O4_>
M2@ . $[99).-!S7+42US[$T;8<>O=86<K$;G_7-3EPBT&!6K6-J)2->LK$A%
MAHP^3$H7+%H3*@DI2C,O#^K][1<\H$?/=1,@&^N2]N$/\H/VOK-/7(:>ECS(
MM/*=DJ%#().25L0ILV7='6#=Q[Y061<$HT?=Q8V);JM_6Z+F&4B'OP^!".VY
M)T^8/46;5QEHX]61;U";&@=D,R1& RT#,!X@HL%(OH^1;DVC4HW2165:;N&V
MZB.^^J2Z6^-TM]TM\;9]!3;.N^-2+=,XQG'EG&,XS^G&?SXS_P N$4=RNH*F
MG:>Z,XJ^NYDDIY^L2E<)C4B3W\\^>?3T+C'FNWGG\^?2QGSS^?/"+_.YXS'1
MGH8L9Z)[2"F+%@N^>U\737QU7JJ<(MW\:>-<K2%H1S4D),I#Y-ET( [Q-FQR
M+E#U+!YT 3=Y'.UQY%V'8=%H((V3=PF].Y4*QOZ"Z+9OVNNB6,D<;:XVUT]R
MVQ(Y^.TQC&<8W078YQC/GKOIC.,XX1;-\NERCL8Q'.[?8%LGICR30E$2ZZ3!
M'7'_ /3A1=W2C JMY?FQG=0GE7;'GYJ>>?/!%CW%6]V!NFWN#ME5I_.,?V$K
M$ZO:N]]_+/\ V57D$N.#)X]+'GC;9,9C&,^6<:>7GKPG77V6&49^(4-SG1T.
MZ4V6W\]L;[*[7)5+A=+;7&-\;);L+B;I;*>CKC;&5%M,ZXQC;&WHXSDIIUI\
MOQR7JUD7:+7;;$LZ9TL<VVPIAPXA?8$:8]HV5;[M%]M$)Q2T'V\EVN^[?.B[
MGSW;[[-U=_5[;8X5;E_2P)BPBHS"FTI\-^TB:>''M:KB(->K$W2V<Y:Y8;N]
M4%+>#EEEO8MLL_6:B\NMV>=D/0]3G*?"+74+RZ_H;-%)1T[[&U^H/6;N&JCO
MJ--3";%=FSP-;JI/:H#S9FGLV'ZX9)*(N<Z:M-,(I[;(XUQQU^?X_":=:NO8
MG?71=IHCDF7D5=ZI)CM-?C&%7_4J+=(8Q5',-%5I/'8NU23;,EE&V<**X3SI
MKIE;TMFZ6R9-/'S7W#7#X?I-9D/ =N("B[;JB<M1[3N*89OO2"JOEFB"S%U:
M6CI?7?)!RF1;NT5/>:.K5 GHZ28LM&Y%(,QK"E+*J6PP.;ZE2T"/5\>!R<^A
M=FDL$"8RH%>(DS;QY)R$D"ZZ,QVZ[M^0+:K-5$4=ER.RFFFRF"/S^WV?5<H_
M"\ZQTHR\"J94;&>P0/$(MVJ^S@NP[N.E8B7"UHZG8^61D^9D#H86""TAD#CV
M&)MXU/21@X0'I;;/#(U@HWW:&[VZ_E&[VZ_E2H1ICIG"[LZU7EU\[B]/X2@J
MUG(F.HW+8I._Y'><QF%@P%S)IO$[5.=JHQ,YM9"3B*B()[SD1*U=6:;D.%W&
M83&"A>MY_C71M&_K5.OJK.]*^FI7K*5N0G%.U*US';!CX\9;^DBA\,4'">U;
M,I+)O,;/U$P-_'G0GXN6LY)Y(:]EY(_-]@;*&-'%FK#6 KU37T9NNONBIB3Z
M+UDTC>N)#WLH./H=DIMV+J::)L0 @5"YN,O2U:AD5E5#UY:R*^S1:-V4*FU-
M%Q.7!"46B\8R:PICJM#VRH:,@Q#QY=W?Y]WRT?Q16FZJ=5J^B4IO,!&>SE>6
M^0AE4%.K 2)PAD%Q(J-A!.R;9L1N(N%$=84J>G+%1)S;X?4>O!U>HN1T#]<G
M'6Y4F;62B*I5A^"@/C5.2-E3TBB*EAM8HV'#D8]442BSR8[CNN%#TMJ"*.7T
MV% B @G.J77N=_&YB^>PH_(92Z!RX<6:8+%3CRUYZ?C773[IY>BO-TJI3LC4
M?7O6E['C-8Q:*C:ED3<"$C.VN):YMF<6A=4FEI([@*5=UY&@96,R"NB.L,A2
M;B,PR8$9E'(H;)08/&E<D5>.K/A/I1;K7'()>,K81Z;$8EUJ>%H?2D6#12L(
MW,Z0IU"OUMY]7<C*6C578B2'WS\HO8,EL:*EHS+'X6$GP,4C<@A48D3,BD^J
M^MR44['66\J7MK3)ZPZX+7P9C%3N8@SD\QJ /W.[%U?V)O5"WA(*XF!T_L77
M@.\<I]^H%KU&+,Y#J3-(3I1BW06?'K_7)% 1?JE5\=FLJG:/?CKZ"-=0+%.3
M& LY*+BVXSK_ *W+V6,7K*HYV;3_ "W"7I_:5%B^M;PE\H[J%V+:#FY/1"12
M!R[24(KI]<.K];U+(^I1R)7%&9L[K+J!<%8"5638#J1NH'9\\ZUSPW<P9P+/
MO<:1,,:@ ])NP%HR$*S0M$$W3D;;1!CJ>(H,[V?;P,_9'$/YRLSA%>+J5]ED
MK_>:[J_UDWSPBLUPB<(G"*F79BAX%>IQV'-W C 21&CK(I&8QQNK%79$M779
M$I'(Z*>Z,S2N'P0LK8$%#LX673278GR:!F*^P$GCI+8<15<LKJGUML2V!X1Y
MV]9#)-,9G8LICE0ZS6NW[UY+']CV4YG*\'B;M_[>D5;OB4Y@DS>"Q;L\JM!A
M8M^088B,F#FR*R8>AZ2'PJP6J%K#GD9E-C]<NU)PON:B*@T,'Z_B:#91(M[5
MIGW>A Y(AU88.R$C>;>S>D[E*@LBCH,0]BNOX=OKK_**O<UZ5]?])I+ZTSV(
M 02VKCE$XL:KFV^]?M>PT(UL*=2NT[$)4^==/V<];N-I8Z*F(S)HTT:.8TWC
M#1J7WE(\::0(1%N,[Z;1AG"]:Q)=HRD#C8#6ZYG#&Q(35Z)V+5=/P$\C-U:O
MR1]CZ4E&"4[L;J:3\PS]9$W;:&J254V\*&G,G(I)HSJ96U5R*Y#<"F0R9D3#
MJS(^EH^91UY(*Y.VK(D[2L:*DI4(PH63:&926!R#$=>,V#H<'2CFKY,QEH+?
MZD5=PWAFJ'8+!H]8O8:4/K CL1JX;,VD;%QM&&*?DXCL %UVJQB>&0])=]%#
M%:/M0D]D#-S("8>66$-9)1_+\!\&$4K2?PYX=)P5.1!S:UA(0JI1H0?K%M,#
M/=QQ8/9"-B+G$-$$VR<;D\@S[7&I!)12&3:X+9DW&/A.$RVIPBT^9]5J6@$A
MHJ0=@^RL/RYBC '4\4'6V,J:'A+"@L2-Q&0Q&%,0CE0$-7F@@Y'F3UQ(H^VS
MN^5.N<)QAALQA6T6(LB9\.<(['5R$.]@9VI#JO3"QR!1T@,C.@X0)&S @1C#
M%MJIKHQ^*GPV0.(7()8W8(R"6,V$10TW'HC2HV2D6XD?#S@;K9T[8S^7#"^L
MOBT_!D-!T;=IAI=!8IU4C\0>*#W0W=H6%CB?4> GR(9YKA QL8D0I99!FJPV
M9NOJBE7K+U^BE0K2F:0RSGUD,+38HE)"3WUC+@.9FJ]AVI84KF8)Y&T$FK)I
M(9%:)IIB.-E78D&R#C&@]7"VC]5T16RX18M8X&;FA\;7+#D9"6%F#8L&J];I
MER(:/.P; \58CME,.W0X,]DT<:%'J"6[=@Y/!T'2B2A%IJL1>4=*HP7=:,1,
MC E'JC5X^39CC ]ZZ48CR:H1^\T;MG"JV[5B906$/'&NF46Q-%5@MOHZ3W2P
M1?UO)XTF0P)4D(-,KL61 ZC-RS#4AL<<!5I*W#89;.,.<EEXZV<'T1V$_;%0
MJ"Q71'9BENOJ19===%LBLY<K)-V[=)1====31)%!%+3*BJRRJF==$TD]-=MU
M%-]M=---<[;9QC&<\(O[TWT4TT43WU434UUW34TVQOIOIOC&VN^FVN<Z[:[:
MYQG7;&<XSC.,XSG&>$6!,RR*QQ11*0R:/@54H_()8JF9,CA:B<5B>PO65293
M1\Y0VTC\9V.!=9 9VQ@<&V,"\$7+;)!IZXB]A X%$LVQ$H8%C1[U\&&,WY @
MT9LW9*1$V06/CFSIPLF@N^.F"0X2&:);[N"9-^R8,DUW3I!)0BRG"+&F3(>.
MB29^0%1H($%8.RADT9?-18D2,8(;N7Q$F2>JH,V#!FV34<.WCI9)NW03W564
MT3TVVP1?'XBC_MK 9[\#^\BJA=(6/]YLO;22L?5PB>38-/7^O>*!%MM4B^C=
M-38:KG";S".^<8X19CA%CF!<25:+/Q90<18MGI4:X>,'K9XU0( 23P.<8+.&
MZJB*3P,7'OQ95KOOJN/(LG;)WHBY;+):$7F'2./%WST8).""9$:S$D"#$>1:
M/';%@>2<K@WKM!NLHJ@T,(,W2PQPKKJD^2;+J-MU=$M\ZD7[K(X]N67 Z'@V
MQQKLUT<A=2C'8LWW?,WA%EHN.POEXCL\'CB#YKJHCKEPS8O'26-T&J^^A%\V
M4HC)*--IF.D0)_#W@5.2-)6R+CW4:=1U5E@DD>;'4'"@M<*J.SA^F42=;,=V
M6<.M5\H9PIPBRS5TU?-6SYBY;O&3QNBZ9O&JR;AJZ:N$]5F[ELX1VW27;KI;
MZ*HK);[)JI[:[Z;;:[8SDB\(4Z$D@Y,O'BXTX*6</VJ1(0^;$6*CD6_<BB3=
M-VT450W7'DV3P>]2UWSNV>M7#5;719%334BRO")PB<(G")PB<(G"+_/EXD82
M+"_$4Z-;$(<#0;S<P*)LRZ$1.I$)/9HFRZ^8>O5D,$H:SBIH\,A8@2GNUF<K
MA@-D %L5=#+!HR=OF9%V_)TK4)JS@=U%ZS@Q*WHR&S'8]9KV,B7,Y"@-LE<Y
M"C).JUV+LQ6=CAG?V!!WHU],H_W]5Z;I;;<BYX>&[C&M]^+;C&,8QCQ$7N,:
MXQY8QCY7>MW^S'YL?\L8X1=7>$54.ZW5 -W8Z]2_KK(K1M:H8_-UAFIR5TU(
MD(Q,7 AFY]:1C>Y!TQ(MEX_)&FRHJ0C'+-9 D,76:+:Y34VQDBWOK11S?K71
M-;46TL&P[4:5L"W -9]:YW22V#(6OO%\^;K2,VFV::/EV2+S08SSHV1T0&LF
M3;73T4<9R129-7D9&Q0Z2F2*:\7',%2!M-4:[,:>Q,LZNM]_=;!J]>OMDMTM
M%=$&K1POMOIKZM+;;&,<)]UQ&\':U/"LL/?MJW\.V!SBLRQ:V).;O$G+P$J%
MDR<H?^L6>O@!Z0%9(S%QL6LY57"@/;1*8U9PX<-@GH^U*:$6JM)3X?3C$3 U
MO^7Y5F-DS(C"AL;G ? X#9*CL?!H++!9^9F7B8\]8P.+-+&13=G?<<D!/49K
M-(\[?M],A2==W7T\5TCZ&/:"?5S*U>O B9AH7K+?10:31=-9PBRP+9^Z&H1+
M#MX[&QYLW]=JP#FMTSS!7=S[Q1337:8R3NZZ^ZO1PB<(N4?B@WC#ZB)]'490
M'LLINY[H5=*D]H#4ME66EH,BXF5MR2#E6!1B0)MC"^YQGL& K[IF3R2))8,Q
M?)"2.[4BZL(JZKI)+:8WQHJGHIKA1/=)3&N^N-L8W24UU43WQC/ELFIKKOIM
MYZ[ZZ[8SC!%].$3A$X1.$3A$X1?F<8VQG&V,;8S^G&<8SC/_ (XS^;A%HDDJ
MNL)EING,*X@<K34QG"FDDA\>.Z*8SGSSC?4H.=:[8SG\^<;8SYYX15RL+P^>
ME%C1*71$SUAI 4TF$:/1@F7B58PF*25LQD MV*>.A1X(":/F!-%!VJJR>Z;[
M[MG6J:^-=\Z>CDBYM>'WT?C CP/Y=UCH-3W&4['4QV2',7TZ.$'HEI8%K#)A
M 6I F0:#"#]C'T%&H=1XFQ%$7#=!)TNW9NUM\(;DZZ[E,&/#QL.F>S%87=1F
MXVU6*;.Q25T$K@OJ04_+I;8MBS.K"K^9N0=/]?#U<2\.SB]<-!*->)QRN(RH
M]9"WV<ID%'Y50BS'5KI#VPIR+=J0$_O*N'I+MQ7I^=2"3UP$EP(G5G;NPM)N
MVGTO >^B9)29QE-A(H4,CDFU<UZ^;B:HBHYO783U[ERG>77C_&OQ3KKO548S
MX5_;)A5 *L2<NI_>.*UO9/7$1%"UH6-/4NME*STEU=-XD]13<Y4@@[8,M&R>
MBI[*Q$+D(>O1P!Q8,-C@F=(1^MVR1"(KE=6^D-S4N>M$E*9% $?4T&9Z]58:
MB!Z3/)!.FKNX+GMIE;5K*OHF VBTRV7LT8/<!0;Z>8;FD9C)$96X]_MAS8BI
M#/O#C[H593$P/5[=DV/3UK!U6)08'[#]F)<2F+;;K?1$=/ 6PPEN1(O$)/V5
MA%I6(>^'4Q4R*16;/M@)D7)I X%BWQ_CKKT17[Z(H]D /61E6-G4]*H4J&J&
M42)C,9//21V7'K)F]IW8]=Q,;'#@].;!8\%BJ$#D\0<38MM-A8.:!H7+&?Q=
M%3[Y8BKEU*Z0]N2?5<,(M&[Y[0TEE\;ZUR=Y6[.V;AMA8@>A=1LP]JZW%*SQ
M"J[?AY"XI6];F;!KBEK)A;*.R*',\+3J:BY'. A^_#[]/UZIUUS4U59U%['4
MW?<KMH$UI:3CP!SM6M7.'LYF,?D-BB>ZG::G[SFV]I;H5B71BCNB8G7YB,P!
ML((6 A8+M8-J^7KEBBOKJY>O]M_/VU?DZ=?PH.6\.;LB.L,+88M>AC*U%VE.
M9U500K+IH+QV!'69VU.]E2^EZ%D*N,9KL[!1Y=L'AKL*-N% A-6KV5.,QYJ^
M39-IUUW=[_3\E:3K!T6+4!/^JDZ>.8"1-4]TMMGK;9LB"M7[0U(9!-;.Z]V)
M#1D:RY%ZK.*Q@N]?V<P!-"Q$>Z#IR 7NP![*&3JC BC#O7]O(S]D<0_G*S.$
M5XNI7V62O]YKNK_63?/"*S7")PBBD=5S@?=$HN+:S+1?MI+7\8@:=2$)*W7I
MZ.K1LT=,;S>-Q+ Q-P.G4@U-ZB9"<V++Z$1 D0SV::88H;Z$55NY_3(UV?D-
M>'8U.4X$I&P$V#2E5)-[J]/.6Z8RP:',(N6.Z>^CZG>Q4+K^T!6%MO5[I#S;
M#RWT*+HK$4!C>B]ZP.,I5U"7]52,5)S?5.U9E:\PE,J%S\':_6XQ"YK)V0*.
M,8">:2*/W#/H*K(U3CF9Q9Y#S5JVA(]X])7&6H@Y>FZ_VBB>)>%Q>D)"JUZ*
MMBO#D ET% 4-.]YLA-9!IGKI$)9 K6$P):&-7(9M-=3TS-]G:ZDK9:80?TZH
MMP/ZHLY(@/=7&O\ /S]/+P16LZ[]?>T5(/3@J7?D@NAG/HG"H[-+1(V//H-8
M3+\D]<K5+&41@II6LK4(,9T%CL9L MHG.X\O K!L*V=Q:\LT1$E9#$6X]C^G
M2O9*LZ#@1=\QAC*(N@T<N,*UD,DF&LMHTS$TQMKTFSFQMNPDTA%3 R$A.'DG
MD35D7.LHSH0+-T"+M5'!%4V+^'MV8$D [N67E)I4\*U[*7LX.U]?4BH932Y9
MDO<IR<+C!0VCK((D(_.3%BQH+K*F\NBL@B@&(QTAD%)R%=P5CJ1>W/1WM)[C
M.;)G:]$RR55Y1X"4'HA;4NCI8XTIVZ9])756O"1.F92%3 S:L9/%DI)-&<-;
MAG\HBIF':4^.K>8*H"G7XU_"*3XMT1L%'6/I3.Q)1*6J-CUX_/:R6^;1E!UQ
M4$<ZPZ5X>KQ:1C %?-#B[R[-49.[?IQ:+:S@ ,''9;C4YID F?X=<_/Z>*+U
M6+U2[%'H+ &+<G55FSLQTA)]0+C)VK*I;H.%'Y4*BFLGN.+/48+*"4^R1,"B
MKB3P\ZU@KR=:LX@X=2Z/K#7.F'GX>2===.M&.]";GPCAPG+0UD[-IQK.GL;L
M&WK4:C)F_B?<E*X*UT?D,@)2A$G@2@7!2!8> 8^Z;#3JK0(W8/X^V:G69%F(
M9TX[,/;U6E]K3T,[J9_?#6U#\(C-OV-D<:'#89W!CJ:#2*M81$DQ;8L1MWKT
M_+0X[,)L/<KU.Z>/9,^; X:!0O+R^?T_OZ^B+,=?.HG9:K;*J4Q,;,%GXS!G
M;)Z=/(6C9I<R_A3*@SM6XH!&"& +6-%HBM;!$=V'5LHS(-9(I)!R,;6BBFK-
MA(48BT5STD[42NTIV7FUEB$:PE]FFIHXBT;N>SQK5XVTK_N7%H^Y:@0D*BSB
M.K.2]R]=2QD$]FLUUU?T\N62DCE"/P..L;RT]>?[:?NBF#KSUB[ 5_?[:V+8
M-Q&;NQ=67+#EK$_*E8LAE<Q?V9)>N\AB@-U7I^',XG!(W6["I#\7U(1J3/UI
M5ERQF3T PD,IE239X.WJWVU_E%5.OO#1[)5>T$DA]M1>8E&$'C$%*Q9W.+#@
MPZ31=2S*9[$6Q&'TX @"Q]JE95WH=EA[@XW!XV3K"Q(=&"@4F-%EPV[K\]/\
M$6[.?#Z[!O;:=7>RF\!BIA:?57: "K_C.Q9E$H-,Z@"5=4$7<,IL\ QF12=D
M]Z[O^R<,E.A"/B7!\U,X21RLQ<#'1-E.OSWHM2CW0#M^Y _"LSL.,/PY[>[
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MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1:M. TBD,.DP*(R]U7\H+A"
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g105292g41a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g41a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3?.4&AO=&]S:&]P(#,N,  X0DE-! 0
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M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     $&    _T          0                         !
M    /]   $&                      !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   $&     !29VAT;&]N9P   _T    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !!@     4F
M=H=&QO;F<   /]     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    $.$))300,     "2X     0   )P   "@   !U  !)(   "
M2< !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B
M!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M    $  /;6  $     TRU(4" @
M                             18W!R=    5     S9&5S8P   80
M!L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   B
MP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M   TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&
M5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M@,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($
M-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M     2<U)'0B!)14,V,3DV-BTR+C$
M                                   %A96B        #S40 !     1
M;,6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M   !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#
MHO+W=W=RYI96,N8V@
M                  9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6
MQT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.3
M8V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                   &1E<V,         +%)E9F5R96YC92!6:65W:6YG($
M-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V
M4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                    !V:65W       3I/X %%\N !#/%  #[<P !!,+
M-<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                */     G-I9R      0U)4(&-U<G8        $
M4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@
M!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .
M4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@
M%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B
M8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#
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M0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,#
MP,# S_P  1" "@ )P# 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M9'UK_\469_UK_SU6L:WZ _KU_]6Q3C%'
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@% * 4 H!0"@(NYM[^>C3X6LF_=NS%0'DTK>OU)_&MRY]1&* E;0"@% * 4
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M"@% * 4 H"QLG][3(?O&EOV X4!I/\S,^TPZ4?TOG_[Q65*$6=77V(WTT**
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M 4 H!0"@+&R?WM,A^\:6_8#A0&D_S,S[3#I1_2^?_O%94H1;^OL7O<WTT**
M4 H!0$+\I:T&;#.=<=8@R#A3-;+$<JY&BV'81J !M@JW$;OE69Q]9(H[#[2$
M4[49,3VK2&]:V7R55CTF*IGU*>V*'FR\L31J4SR4A*9Y2_-[^[L9HU#:@,6Z
M7,-S[.N9),ABT!QY'G)_=EBM4C3JW(Q C/5)8_'TRU2DM=Y._'$ V1YC3&BL
M=W10G1);+C#0VF8S,-X6UE0N:8&B6>\X+,4:;XYD!T/(A'HEU"XKES _-1EA
M=[4>3/61R10XV0J#;5Z%UBS4YO![,Y-:U(+@N OMM6+PK]WG+%X5R^9+J/:F
M74MA'3<T1TV3..8,899RZJEK>\I+&N'0W&"N M"=>J1VI5-[Q;+W[(32UM%Z
M98D*+M2KUG9JK"1*I%IYP3W]_,6?.M:F)(]F#".#X-((;EF?Y:S$Z8GD##"\
MA1IQ><4VL6+\@90>I)-69L,=W% 4B;X$<UV-3B4T'J5[LD"Q58)8E&R/O],"
M/O\ 3!,.@% * CCK%]B-JF^+GF[^[234!@WHI/:T-!OQ4<'_ +@,E6K-]7ZR
MO-]??(V 5""@% 8-U/>QLU!? GE/]QWRM_JKY4U;]/T/ZQAG%>W7S)[8?JOK
M_P"RM+/S^[?6VCL([V]8]0;>YPW$>(\MM^K:O2)^.BRW[MWH\R3M#>7"*B(\
MPW'@/(-M@X@ _P"WAL&X[;"-"Q*Z0HEQ>.??9W?2[EOU>'@'  ]P=A\'$.._
M5N-"0XWM0X<1*;6]\KW5L[J#&.)_Y.OG/CDS*^WTC23EQY\^?A\@;?)U-^]=
M(_I36_VGI1V#X1_EO5.7S&\'SOP_0O4D[GT[]YDX WY .W4/(>'7P#B/'8/[
M>&X?6.OIBS<S.UW[ISBRR].13P!U]>P!U?(._+CPZ]^/*@E+<X?&TQ#F)]6=
MDMYT=^9_OYU'@_U-_K_UG;_Y_P"-=7>$C/5'33O7HI[<_(\R[?;OFW_YX^+O
M>6MTG1W76![9% * B[FWOYZ-/A:R;]V[,5 >32MZ_4G\:W+GU$8H#67TA>F_
MH\)IK:T]:G<IZ[8WHTU::?[88>J3H<\0?&KMD_$""4GR<F"3^-O$@8G\^,R*
M\7MJL=D"Q(6L:EZ] N3O*,A.G3 6%TF^/>A,Z4G';?&\TZU=+$2R3$B%)>.,
MX0G4#AM//H=8I&\Q0SJ+U<D,2R>'KCKQ.<(J\!<D$\;EK8I:7,>[P VU:#<5
M1+!NC'3'AZ!Y/9,U0S&N&(+#HOEJ-%H26#(C(R,J9&WRUH*;'J1-UB!Y3EV*
MTX(GUV3=K, 2EQ]HA>($M* 4 H!0"@+&R?WM,A^\:6_8#A0&D_S,S[3#I1_2
M^?\ [Q65*$6_K[%[V]<F^FA10"@% * TBR=QFFJ?7[I!R1CS3]JO@A6!Y!DD
MC/"_4?!'R'X%C4.)ATT8V%PQI'I>M60V5YM>YF],XQK*F'2W-S1P 7EM?Y'8
MT*P;"JLGE>V^<T^GGX6''G;?R\RMOM.5[K[/2(XVG+3HP=,&Y6S0\ZAI#JAU
M3Z;L-1!?-(%C.+&QEHR'F6"IWUA9&V Q5C1K+&.%M4T>['ER(7/]I-B@+EX%
M$6W 6;:M";SR]WN[IWCOB+S,9%@:BX);CW6#E9SEVB&=:EH$YZ4H7BW1+$,?
MX=:YQAB)S!U>,@J\RQ:3G&)+H/@UVF3VL@2AZR%,2&-I60MOM3DO2LQO.:#5
MFENO?V/S3;VN]]W['E]YA*,Z6]7N%6'*.*8E'YZZ9RQIT*L)P%IRRTPIE1D"
M<LR%/N0W7)\:9,B*CK&^.S-LD)F+D4$;7LYO7N+(VV/"<R]"TJ3$R9<[IE^\
MJ8OPSS&;X7\WJ,CZ.L6PR4:SM)S]BK0]E737B?3'HTRR@5Y$RU@59B-]E>8<
MA2'%D561-<YO+:GD,H?F9I;IH^+9"\J3K9*L?GY\9%3JB/4NJNMV<N[?'W7"
M.@;SERY]^7"(X'0-6)!0"@(XZQ?8C:IOBYYN_NTDU 8-Z*3VM#0;\5'!_P"X
M#)5JS?5^LKS?5\_3O-@%0@H!0&#=3WL;-07P)Y3_ ''?*W^JOE35OT_0_K&&
M<5[=?,GMA^J^O_LK2S\_H.5H\?6\=QZO  ARW 1Z@X[@''A7I$_'1.R49Y1T
M3FWGA\I:@_KP@ #M\G+JX#MN.XAMOQV'8./&@:R<J>KZ7<WLG,)3?DG01W#E
M[G#B//COQY=8!S$1'GR"\\[QP5HRMPS4JV^QC/$X?]77T>'#)>5QX[<O3&DO
M[/=Y;\_!\G4W[UTC^E-;_:>E'/\ PD?+FJ%Q[#>#Y3_W,U)Y^F?7)Y,';ASV
MW#GS /"'$>?7PY]0<*^L< F[NF^^6\EP7FW<;E/!PV\N_/B//J#E^RA7-Z9G
MEESA+?RWJ(R9T>>9_OYU']#7N<LF\O\ ;U\/='J[PD9ZHZ:=Z]%/;?Y'D1V^
MAS\V_P#SSWR5H.CNNL#VR* 4!%W-O?ST:?"UDW[MV8J \FE;U^I/XUN7/J(Q
M0&HCIK.A1BFO1XQSJ@P]CF%RW53C.40)#)8?D.72"+8[SYA=G=C0?,<2]R:5
MI"B.N+>B7JEC!*&,QN<RR@6MB@\^Y0VG-X'WSN@KZ!MKG41Q))--^)(YF6;Q
MU5)XYB1QU"Y.*R ^-#82<8^.4>BYF62GQ_:66](M+7.[4W'H"01J3##2[2S.
MQ W@8BQ-C_!&,('AK%,>*B>-L91=IAD(C)"UR<26.-L:6Q$UMA:]X6.#HKL2
MIB["@/7KE2HP [(T\RX1NH#(M * 4 H!0%C9/[VF0_>-+?L!PH#2?YF9]IAT
MH_I?/_WBLJ4(LZNOL1OIH44 H!0"@,,8WSO!LJ3W.6/(I:]7O.GV=,>.9TM7
MH"4K,HE+Y (MDBQ''%EBP\UT+;8_,&4IV--2HA2.9AZ2RP^PH%%X%GEMV(\Y
MYB7KY7B:7GS+27,BTL(E^18D^-,)ODDVA#0[*IMB)2X*1C$S4-3*ZWQ8^;)&
M\UUB;M?)X\W+4'=KH"T"[\JYX@V'Y!A.+RD'I2\Y^RH3B" )F) 2X=G*+X7,
M,@JE;O>:L2 WL#9%H+('!Q<K 57D=I3EV)3;E%NP&9AOL"WLQOM"S8![,;@[
M'8>0]EOML/4.^U 4$RRT &Z^P &T;@$;@ !M#81N 1'8;0 0W'D&X;CQ"@/[
MY\J 4 H"..L7V(VJ;XN>;O[M)-0&#>BD]K0T&_%1P?\ N R5:LWU?K*[-]6;
M *A!0"@,&ZGO8V:@O@3RG^X[Y6_U5\J:M^GZ']8PSBO;KYD]L/U7U_\ 96EG
MY_=H#M;SW$ W$=]M^>P\./ /<$?)7I$_'1-1GSYRN&7+_*O%MZ+7D4H,CIB4
MNR*S&1@J+,ONOBS2C<BDHE76V@6M%4Z-HE7F]GV1-MEIH7VVWW#=8(  [/2M
M+>C.A+0]-TK:3<Z)A8>(J(:48CKQL+9=4^3"JF',6GD>H^SU&O,/2*Z^T79K
M4?P>NBE4Z_UAI.A8FD+$3>UHRP-"TQ8E&&Z4L1UU4.FJJE).\6V.2SPW <89
M<Z__ ,+-([;_ /U./6&^V_/CU!6T_.M=_P#%.M_ZM@>G_P!JL?=?8'!;OV_\
M'/.=?:PFS?\ U)[-UK6++@DM=HXT.:)RQ?E7MZR8SM])[GC;4:7W!(Y>\O3<
M-UPR,L;3^X5Q'=)78B!1O9E6WF!:%X[+5^F8VBX&+1BZJUMM8FG:PTBG9T;!
M:\7I.FXVD8;;>DKRO%XE.TE*54J6H;Y5VP[-:MUYK+0-+T+M]X/UA:-V9[)Z
MIK>/KK3\.IZ7J7LYJW5FF[%*U/6JL'X5HN+XG$E/$PMFMTT;3I5])LAG*529
M,.-LJ)@4*"2.Z5<9:RDJ<#3+2^WJ3K)&9>6F)[/MAQMI9EUI=EUUMEXVA:._
MIUI55512]5ZVHVZJ:=JO1L%44JII;=36DMJE3-35+A)N^1Q#2.P^#H^CXVD+
MMSV QW@X.)C+1]&UUIU>D8[PL-UK"T?#KU-ATUX^(Z=C"HJKH56)4J770FZE
MD<0WWW'B B/N[<!VY>#KY^38:^J<%X/<HG-9S>UE\:4E>_*W1UYG^_G4?T-?
M_<[;_;S'?>NKO"1GJCIIWKT4]M_D>9=OO^[?KUY;=EEDCH[KK ]LB@% 1=S;
MW\]&GPM9-^[=F*@/)I6]?J3^-;ESZB,?YX4!\O5QK\T>:$HZTR;5?GF&8@22
M"\ZV.-;M>YO,MD8)KRRU1T?A,7;WR7/25%>:5:N6MS(H1H1,L[K4$]E;N!SU
MJ.DCZ*#5#TN.D;65$ND+Q_$R<,8;R5A&S'.1L4Y=@14N=\AA(BD#N1DZ91V/
M0:-HTQC^27W/(%">]6:0)1)UIB@L"P.M DXE224H3G%*$Z@HLX@\DRPTDXDV
MP#"CBC2QNL,*,LNMO+,LNNLOLN"ZT1 0&@/]: ^58_,9KJ:Q%O+28]DE=O.9
MK'%'>ZE$]C;?VXUOM.%665V%]EW;+B0L[&^V[?:X!$#^E[TS-1R).Z.S8VJ'
M([N=N(7KTJ,Y>H$;0 A$4H-+O5'"-]H=J(M,OWNM#L=Q#<#_ '<'%O:4AR]T
M7(VU G +E"UP5$(TA%MUP66W'*5-Y9)077W6V@-]]H#<(6AQ$ H#_5,J3+4Y
M*M&H(5I%)=AR=4F-+/3GDF %Q9I)Q5UY9I=]HA=899==;< @-HB T!9N3^]I
MD/WC2W[ <* TG^9F?:8=*/Z7S_\ >*RI0BS?7V(WTT** 4 H!0'+@S8=8I>V
MXLU6-+5+&W4)JMZ:!:LA,[0/TQ2N42PY!,MRM@>$R)F*7DL"&/RW V '!))+
M3FBQ)(4KV@3NYRZU*U6$96Y6I]+\^4Y92F[7*_9/G^[*.3?$^5E!CD42T>YF
MU+,,%=)]@A[Z5'.V5LRZ=44PF./;LS8::7E[TX1"-C(V9H?#6J*DY*C$5RU+
MT+Z6UP9S0('Q;)EZ=K,5&GE$Q_-X)[I?"^:G-9!+=RZQ:;<[1YSW:7M-4*R[
M(] 6'L@+XADS%BYAUPZ\Y8T8IR=+IMB.,(9/(8EAK%^'&3)*=P2NLOC$ CLW
M=H2H;U*].UO!4;D+,:S71],#>%;S[DI6:5YNNC[^@;]25UFO>&N&YPD1;OE6
M36;$NA&(Y(.C16D&1PK5EDZ+0[49D3/,*PY*9:YZCY03AG&<\EV,87D&42LO
M&N%5S6[8NQ++26YFEY2DX4ZT]SCC2F*D=5DHB7QRLU^/4>AV49WC[_7R-DF(
MM%J>1:BM,>E#.<KDF:L:Z;-#>4<ES"TIWR#'(+*Y7J=S^1;"X,L;ULB4O[G
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MKVI+!F:S^Q<$12:]Z7MQ"Q6J(1)3CEAQ9%P$C $+@"ZT0&T0 0$! 0$!#<!
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M!=;=:PKQ 0$$^X" @ @(<0&F8--7F9GVF'2C^E\__>*RI0BS?7V(WTT** 4
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M)!I%C!FP%A=IQK+U0KI7CYLQ="$$)DRT32SA62"*I6,IC>57;B23>Z'%"H-
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M[Q^[9"<CGH#\:EJ;BES<TFH40(25%X+32Q/M+("\P+:^?+\7^ ,T^>'2F?\
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MH!DW%>GW#F.,T9+49ERS"L>QJ.Y%RJJL5EJ)_+VUN)(?)098N-/66BZKK35
M=TF7'#;< WA8(]A:!G*@% * 4 H"QLG][3(?O&EOV X4!I/\S,^TPZ4?TOG_
M .\5E2A%G5U]B-]-"B@% * 4!K]U,^S6Z-7W_:GONRS/]?\ D>J@-@5 * 4
MH!0"@% 1QUB^Q&U3?%SS=_=I)J P;T4GM:&@WXJ.#_W 9*M6;ZOUE>;SSWY]
M_,V 5""@% 8-U/>QLU!? GE/]QWRM_JKY4U;]/T/ZQAG%>W7S)[8?JOK_P"R
MM+/S^P#^+;MOOL' 0#?CY0ZP$.O;E\E>D3\=.$[DG>8R5O5/5J&XESV$1Y^
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M[#BY7 7)Z0%*EL5D%BA UJ =&93>8B5=O;4!HF%")B1/>(E6@9MH!0"@% *
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M3TW:T7!TI8RTU:/'C:\:C8>'\%Q_B^*G:VU.U&RHEX?#7^5UXJ,#_P"M+?\
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MQS13?;GMR_X<!ZMN.VW#AR'A0L6^Y*R4[X3FW%.^7%Q]WR=?D$0X[\PY[B-
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M;LICC:9YWX*&#?F/$/#MOPYCU#Q#LM^/#<.O:A.5GP3O,66Y)RDTDKS?I7@
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M:R;]V[,5 >32MZ_4G\:W+GU$8H"5M * 4 H!0"@% * L;)_>TR'[QI;]@.%
M:3_,S/M,.E']+Y_^\5E2A%G5U]B-]-"B@-1&N#OUIO>)'_M215S/4'[Q=O\
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M/V_(_239;G&/ELTB;]&4DXAKD8H[@ED24/2%&5(HZN#84KTTWJVY0 VB4HN
M;: WV4 H!0"@% * B[FWOYZ-/A:R;]V[,5 >32MZ_4G\:W+GU$8H"5M * 4
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M4 G9;F]O[8B,KQ*FG*I\I0W"E\V^/%[]Y=MWREJ&XNU[I>TFU6F8"@% * 4
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3212:><)28A&F4777B:)1=X'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g105292g41r43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g41r43.jpg
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M ?_$ !X  0 " @,! 0$            '" 4& PD*! (!_\0 4!   00" @
M"00,"P<$ P$!! ,%!@<! @ ("1(3%!<85EC5$165EA89-SAXDI.7M-+4UQHA
M-5=U=G>SM;?6(C$R-'-TL@HC.;@D)3,G0?_$ !T! 0 !!0$! 0
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M*4XI3BE.*4XI5QF?_P"/RQ?PQJ7_ ,E+ZYH5_7/%_J&=_P!PMU>G1?L,WO\
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M'6<=_%<T$J*5*"5%*,;E $I3N)"=Q P-Q! R1D@XKAY6K:<4IQ2G%*N,S_\
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MWP8KBI%QF/R=1P)UQG,-_P#.!#;3Z%.L-Q6R&0PV!S00A6U9X$Y2D>@\FO*
M=4:DOD5%LTII^V6GDBU1IO2&FKE+2FP*?ESK=(:@W*9>YB57!=TEK5T]4F2V
M'XZ5;DIVO.KP=.5TV5GVQ5[)]E=NMM;1*HJ]<+::XG0#_7$CC)\SCB(,5@C5
M'83$YH;JO)MY&8C-/FOYV!5<C6!8A<H$<G*^E\^6J991:;3V6EOSI282WKFW
M*:>2PZ5/25.R'V$X:YI/,;]B@A+H 2HC!Q-,61BP\HRM=:[.AK%;=-65[4D>
MW:-FV.= >ND%+-NL\:#:K9=70N>9SB+KT?I+)D.PUK6ZTAPK$,]Z7.K;EJ/K
M[V KVTBK)E4? )Z\VVY2YF:X/8D@<X:)J_0.;NT%'E4N.R@X1ES,8'"3?.QP
M993&V([DHF*[ C;#3:)L"==+9*AIB,NJ3=(2&'%R(K2'U%J3'1)++*<I=0EQ
M+6Q*DAQ9P1W1Y?E<D:?U1IO1FLK+J%V^W&$RYHK4C]SBQ[1>ILBUM";9[M(M
M"+C<G2A^WR'8;\\27FG'(;"%+0ZHLHM%TFF\??>J-.U6P-_5][:F/LT_27M9
M'.PQ=?C+BUHZ!,P@UAQT2?.0&%<"1+=X8?GZ,I'21K<&T0,5%,,APU(T^HH[
MK5ZG3757AM;EH;:LKMK3)(5,;4M1C.JC)5@%_FW"V\4M+2HJ)W)1CT#DINT*
M7R=Z9T]#9Y/Y4>)KV9/Y1(.M7+*VMNQ2&8K3=ZA-WA]G=S=M,J'TRWI>GQWF
M&FFTAI;P<U<V,5EV JZK(#U[G]=QN)];^YEZ.C@%/+%C,$,;Z*FLV:)%";31
MS-GAI-D+(R1MH^:B]F_+E(TUTM$U&W?=3.W)0],MDR;)ND:4Z_=K!;T(5&BN
MR$KN4>.MI^&>CMK2TXXZO>-^QK!SO &!KG8%@UE8-/6;1EYLD&VZ&Y4=7OO-
M7B]P+0XUI"ZW:+-M6HDFZR8SLV+$@Q>CN<R7YP6E*2PHJS6WW[(HAWRADZC]
M+3JNF-UB7>*=SP\2;SJ+5SJZU+*HLQL -Q@J3!T8TW9K (CY2KF$!L5(@12A
MMMVO*A0Z2D%L:?TV_'=N$:4XV_IV-&28\9Z5LFLO..J@K#"'"A9#H"%*VM*(
M(WX236SUE.MO*_:KO#TM=[)#DVWE9O-W=;NUWMUC$C3=QM\2&SJADW21#$F.
MRN$XI]EGG)[3;C9,<J<2E5$>V%MPJX/"&S:T88Y"E0=TN2$(M3]C?5%O<FV)
M)Q6+KR%)=7R>F&UU482'@<I7R>% RDR%,:>-MC'2V2#(@Z6CPY"%)D(@2"MH
MC*T+?+SP:(&>[0' @I&<*!%>0\H^I+5J;EINVH+6^VY:9&IK4F/,!"6'V+:F
MWV]<U*U;0&)!AKDH<5C+3B5JQDUV+W=W/L@"/^$=6B=\I(.$$["5*AU[69'Z
M.9,9(R]R6;!316LU!-=EE&YS:PVS$D.8\K:E)%D$.1&^[TX*G<I;;#$6[I4/
MVTE$FUSC<PXVZ$N/--L&.)><#<A15S27,8*0$CN$A/MVJ^5&^,P^7%5MU@E#
MUHUKIM&BU1)D$NQ($J==F;JJPJ;!66'X[4<3GHA4'$N+6^LF4^IZQ['*H&[7
M)VQ4KFYX;3;MO?'6>S#YY6\NID.36G&R:1CYT\K\A&<S6!,&T..F^'-R>'("
M1G^5F3V<(Y1MR12<QU=2XS)1!LHEP'YR!;;M$1&EL3U-0W1/=3'D@QF)+O/I
MC[$MH6RD!AM)2Z@E!'<P[C9Y.J.4=5CU3:]+R3K#0=]>N]BN6EFKAJ& O2D-
MZ\65:+O=;/"-K=NW2'Y3[,Y_=<Y3S;\!]")"%= O=TV4N?;?L(Z3.(.\!D3K
M9TC=#(@^N8;PZL0[D3@YJ%*<VTYS:C/':%P"4%&=P-9L#+HZ,Y*S9J+OGT[3
MR646.UHCOHDM(AM(2^VA3:'%(&UPA"TH6G#@4#O2EPJ!*P%DBOCCE7=N$CE(
MUI(NMLDV:=)O\Z0[;)<AJ5(B(D.<]';<D1WI$9W,9;+B%17W8NQ:1%<5'#9-
M6>;FO/J<4IQ2G%*]0?\ Z?G[F_9#^N\"_P !?N>/\IW\KM/XO)_:-5]_?P,_
MYBUS_6UG_P '+KI#\(3]^YV?_M?EGZ9ST'2WUNV?\2:_?7RART_97U_^4MQ_
M:"J<<W]>84XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*5<?NY]TBJOP3NH__P!>J_YH-._R2=_7=[_[G)KT[E6_GS3O_3GDV_R5
M9:IQS?UYC3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE7&9__C\L7\,:E_\
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MMMMG&NNNN,[;;;;9^3&NN,?+G.<YSC&,8QG.<Y^3''5UT )( !))P .))/4
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MF$>A3$HXDZJ;C@)NTE<6P#<U?1)7=$74C*ZNJ2FVB>V--LXH5)2,J(2.K)(
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MU8KNRF.3L0=KI'2G6-BIRFE,Z_3#,AJ-!94OA'YN4^&XZ&W7V5 K"W4J#A4
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M#C.Q"6N%G45%(5QW)'TU3Q:S9+1'9D1V;;#;8E!(DM)91M>"22@. @[@@DE
M/!"B2G!XU/<.4;7EUN%JNUPU=?Y=RL:G%VB8[<I)?MRW0E+[D106.9<D(0A$
ME:0%R&T);?+B$A(R:G<KM8KI-T\]@[7TTL@G!LXU0F+L-]D9F&%MB^2C<CD)
M9U(4C;.TL*ZPV4%"&AM!;U]E!144M+!8+*#'/8N$>B IC980KFDEQ;V$Y!R
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MY%@.BBQ2D'ZP5J/4K?J*64(B3<MXB,4^L9;5<%9!1-TA54-M2!M#@BO@UO\
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MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7LQJ_[A_7/\&R@/\IHESYTN?\
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M6"S>)QB(J1ML=G.52869/ JPDJB\>28W;!);: .Y')BX):FHY!=#92HU"ZS
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M86<&L9=S0-.2%Y%*U1;HSLAOFITA,1N._)?BQ%/QV(\EI+S+[CJ5 !M3:MW
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MPHBM[=EDV3; <"L)<NC(\CD@J+>&2HYKL$43+03.>=!"!@T=52G,D73171#
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M='L?&* B4; ?B/0S,;EL-Y-<UP-8FW)2-FAM4L>FB(9F-C;-D/V>J"EKZ>1
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M"2Z2Z%M4@A4R0+@:XIN2FQ]&69Y''Y(@,FDLHVY GB,#(\!\.< YQC_9HMI
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M./!@'CQX\00,=7M]X^#%2".DM!>Y62VIS=M^I#82"A2LYWG   '6I(XYX9*
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M,8J])(%BI.\;DS6*],;HF,>.(<,F>UFBEZ(&BC%HZJX3)'16UW3UH"" 1Q!
M(/K'JJJDJ0I2%#"D**5#AP4DD$<.' @CAPK"--JUT_6)+*F9)@R.UCP-BCLD
MFD2;BL&.D6:):LZ(1M=^U0UW0;"'G+,XKA-Q2Z;DH$BDX9$U +#)(;ADISQ
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M%-P=2L(-HISJRMBI6KD]M(AMV1D#OGJ'L=?_ -^QX14 2HI4H#N4XW'O J.
M/9.#@#C@$]0)%?(7W1ZZV-96M50*7R282/=]?HNB^QVJK;=JN(DD7&<2Y$Q#
M72%!EJ?(<V=)I<M3AT9QOE(L-=O^7+AID7EH<0HX2<G)' *QD=?=8V\,>'UJ
MF7%?;;YQ: E. K"G&PYA1 !YHKYW!R..SOU--96=!KCA;985;OR<FASP8_@-
MKTD"Z-NA)<7D3M$WU' ;R"W.*>0) QNK=MNL&FFOL)D@7=<15 A6X*"AD'(.
M>/L'!_M%1.-K:64.#:H8)&0<;DA0X@D<00>OOUN1YX+4"8YN9HC:VMPI!S@X
M'DHA@@!");KE&&%D;ICBBC()J+$$+J:(HI:;J*;ZZ:[;8KU==6 $D  DDX '
M$DGJ '?)K5:ZL:$6U"V*Q*WDC=+X/)T"2H])FC951J>@Q3BFY0UM7521R6"H
M4&1@0Y+780Y#70P)8@-=!=2@(4,@Y!ZC_95RT+;44+24K3C<D]8R <'U\$<.
M]WZX[$LR!5+&MIA8\H:XC&\.["P:.;JKOJF0^2AY"CT=9PT$$UBSG-Y>G$)O
M !#07)777U\5/Q-5-]!4$C).!P'MDX X<:JAM;BMJ$E2L%6!W@D$J)[P  ))
M-;SRM65']?6K75KCR@RMY@R34&&3%V@$E<8\5AP;6Z8L(K<6]L.'%+7()IC3
MHZAH..S<06.&X9):R%DW( \0:@4%9P<X)!QX1UBKUMK;*0M)05)"TA0P2DYP
M<=8!P<9QPX]1%13=7;JC.O;\%&K3=YZV.A[!I)D,QBD+RLMKT9E#7$#!!C_6
M5<3!A;R-"&HWRS:X.8SF@/HB:N&F$8&01:I:4G"L]6>"5$8]D CO5(U&=>!4
MV$$!6WNG6D'. <!+BTD]8X@$=[.0:W*JNP-0W6T0Y\K:7Z/@%@P1.SH5@YDD
MD6<)+ 5';YDS*6MGEK.Q.Y#6BX[A)%J>8ZJ!(/4;.,20 D\>)<ZI4E6"#G(R
M.!&1U9X@?[QX15KC+C14'$X*%\VO!2H)7C.TE)(SC/?XX4!Q2<3)RZHJ<4IQ
M2K5]=OY+DW_?M_Z.OS"E]:/85^L5O[-_%O\ ]-']TUXN_"$_?N=G_P"U^6?I
MG/H;2WUNV?\ $FOWU^2_+3]E?7_Y2W']H*[X:_M*H)7VFZ>TO;B(,9G594OU
MUG_76R!TAQUG)QD=2-HDPIF5+[[)Z&-TISOJ^0U=;?0D23CJMPQ"N[H*TN/F
M\J'/8L]]N$$J>C2[A=8MUB$DA"6IJE1Y[(X[5,_Q;X PIDA2@ DK1]=V74&F
M;ERA<F6EM2):@7>P:6T1>=$WQ"4(4^_-TU';N>EKBM1 =8N!(EVM9*7&[@A3
M"%K,EN,]4N,V;4K?U(Z7T-V!$$$J&ZI3V=6S8:8Z6S[3MEQ"]=L0"QP25,Z^
M,PAJO[JS31OV41T+C;L4ODC1(-<8W=O0YJ[W?[E;%%4ZWL6<=%)/-SHDBV_\
MU%4.\XH-(<87@E+J  "5 I\Y@7[3C/)MR6:0UFVVWIK55PU\KLT$),O3%^MF
MKB+-?65G&8C1FR8MU8*D!V#)<65A+2VW>**JI$>'*GJZ"J:R"SK=JJ*R6^JB
M2J2G6>9;IJI*:9VT434TVQOIOIG.NVN<;:YSC.,\J\".3N("""! !!&""+LR
M""#Q!!ZQ5EO4E?\ "TO"T*2M"Y6K5)4DA25)5H.ZE*DJ&04D$$$$@@Y'"NA<
M4A0,H8M+5+=45=$A/5=%(A#91!357358=?7=%=+.VN,*(K:;I*Z9VT4UVTVS
MC/I2@%)4DD@*!!()20",9!&"#X"#D'B*^06UEMQ#B0DJ;6E:0M*5H)0H* 4A
M8*%I)'=)4"E0R% @D5Z()H[,]Q=N:.CLYAE6RB0,/0!EL>DX.XP:&,K#.[^?
M:=;7>)PZ0#A-[6A(H[AR;-E8G"'0C>/,ZP_S:Q@"#G$"D>5QT.0+'<78TB8R
MTYJ9R)<)"9#ZW(]L;FJ0^^TI2EEETI6 _(0 XX#N<4HI"A]J763%U/RD:3AW
M>UZ?N$V)R,Q;YI2T/6BU18=XUE,TNQ*MMKFH:8CIFP>?CE5NM,A:H452.8B,
MMH>6VOZ:\@S8M(NLLQ['T75S%V.<*Q[CODYK1TJN(Q(:50:$00]QK.36-5;2
MT-;.T.>CL.Z-S&Y;,;0Y.S6)L1HJMNVCKC4E2%!J[Q[3<9CEI3,L3<>6B8^^
M69,B0E$MF+,<6M:T%!0IQ'.+0A9P0-Q!DLEHCKFZ"N>N-):?B:Y>L'*=,NUA
MD:=MEM1<+3:;0\]8+A?-.QHL>-%D)DHD,0WS$BR),9HK"EEA"V^A*S[.D=N2
MM:8RD.* .:P(#;J'"X9%H$P#AMJ/D!4QH[#VIF9D-\)__P!2-0_.2-ODV754
M\77Q?3(<-F"P&&5/J1O4O=(D/272I9RHEU];CA&>H%6!W@*^/K_?IVI+BNYW
M!JW,R%-,L!JU6NWV>&AIA&QM+<*V1HL5)"?/+#7.+/%:E8&.UGL;33PQ=515
M[0ZZSNP[C8XE#SDNP<1H>14=#ZMC0PC6DJP6-*%$&X&\',)LP,Q9?W"OV3<4
MC7"P\[?L8\H1Q5JN#;EZ4(=UCQ(#K[R3:W[BU<7YCI4YAR(R"M5O0I>7.;3)
M6% X,=O&!]#ZWTO*A\GC2K_HF[WK4\2VVMY.L[;H^?I.UZ?@(:CI5"O=Q4AA
MG5C[3'-PNF/66(6EC<B[S0 5[LX,L^MCJ_9TB[:]9*\K:%5?TWK?'7N_468E
MHF\AE\?:(FUU/'AYDI)#TI0E-6TIP7>HL@$FFQ*J9!, ;G#;;QL=+D:#>(;5
MDO$J7(F7Z5V4MA6%QVF'7'ES73'YI/,F.I*0AXJRX!N2I2*VKL6\ZBY/[]-Y
M1]!62Q6FP<E]B&B]9)BKC7:;<X4:VQ]-PD714]Y,]-UCN/+E6]#0$11YEUAA
MXD&:'5C= NR\F[>J@*)]1B>@>!VB;841Q""&\VBP8 %509>%?,U)6M/\*M^L
M)U^1V3<<YRH!IMG&V=>AQ"K0U8PO_P#-C4V5Q\'I 4FXJD*F%.-P8$?"ND><
M*>I1!KJ9$20UKN?REJ9(Y-7.1P(C7;<GL2MA[2#-F:TZTYNYLW%=ZW,"TC_F
MDOGNF 3FHOJ>9S:WZ;<Q+)0V:[3M&LK!L>-,%*PM-6Y)G73,QQ&J)M8*+>Z.
MAHZUF7*TL:4$CQ#2W-S<)5\5N"0C1]4N6@N2V9.CQX-P0J(=\*',BQ'G;A(Q
M 8E../S6(I4A"2(<!;ADNA:EK5,>A-*<"65('/Z=NMUU-I>0U?6^CZ@O]@O5
M\@0]*VI*M3W2R1(EMTY=KREB1(>2J_:IC0Q9X3D9AAAO3]NU/-;AK=N3+ZNO
M:NJU#ISPC-7U4!(496%7W;^M8H+(44DA_G1%FMI@#T7(&0),1$.UPGY%Q$1+
M*2$/2)&3(6U2PIMU$N6J?I2;-4T6%2K%,>+1).PN0G58!(25).<H44@J20<#
M->,V.Q-Z8Y;]/Z=9FHN+5EY3+%;FYJ$I0)"8NI(;06M"%N);> 3M?:2XXEIY
M+C86L)W&XMQ6O5<BN2[>F=*1>0P=W[*]SFH*Z[8N*6,LKCH3W%[B>]1OL1A3
M<Q,K8WQO63.A+IOAZ<3',]H21C[H05JJD<#H8$&:U;[=?[@\U(;M-@6JWPH#
M+C+RFGX#>>?D+<6I3H92$#FT)2EPEQ 3@I5Z9J?46GIVI]5\E^E;?-M,G7G*
ME&9U5J+4]RBW&$U*@:GE!OL;:V(<1AB")\AR2KI3[LAZ,E,*0XX%)=9M/>U;
M-++&J'GCK2ZK=.8/WVAE+&/]E=>*<K;6=55*VAY:W W:O(0PHQUWK1R>&W76
M"/,I <S$3%"\MSNNMMXVNFMLI;CURC(N 5'DZ;D3PU$NDZ68TUA;:T)Z5(<+
MJ):&U'I*&5(24XW( %>A:NL4:+!T?=Y&E5,7:U<L5KTL[,ONB=+V+LOIVY1I
M4=YU5EM4),"58GY4<"T2;@S(=2ZITL25*.1"%I/S'U]@]]S: U92BT@T\*W<
M54"%2RH8%+TFJM$XHTNV\)8Q7YC-'8V)18!-!,=J2$4;A2#DVA5OW-)44V$-
MIRZ2+;&DS;@&NTN%.4EB;(8*Y?2'$"0X6W$EQP!625D[U)25[@D"N2U#,B:+
MM&LKM9M/:55-3_"(U/IUIRY::LUS3'L*;<Q)-IB-S8CJ(D-2F4H2B,EI3#:W
M4QE,%U:E4 [BP.)UEWTM>$09E#CL39+B;L,K$W)X1;FD=Q59G90!N&U^1,1O
M')/73!"1UU0"$PB*/IH@BGIKU%BDO2],PY$AQ3KSD!?..+.5K*0X@*4>M2B$
MC<H\5')/$FO'.4VT6ZP\L&H[3:(K4&W1-3LB+#82$,1FWEQI!98;'<M,(6\M
M++2 $--A+: $)2!VX=O7"&20OPE,4H>(*M'8)!T@RM^ZO,B<I.=.>O+,%'GB
M1S&KH_C1L:V5RB[K\THS!J*$>%A(SE9R;7GSYQ2%"XBQHD,ITF_<GPY:]DCL
M9S;2&4QKFXIU#3$UTE2W$/(WEA8* 7<(6C:@J5](<I;UKG.<NUNTA;3%UFB1
M:5:Q$J:_/=N^BXK4*5-N>GX8$>/$?M\GHZ;I'<;E*;@;GV)7.OI:9^#M/#.O
M]959;K(V4'/)+UV#I!GUINP85UOJ'>!M,Q?V1@'@-LI=IQ+#2LB3.#G,W 0>
M8B.S6NJ6(X.#>M&E01M2#%FD729-@N*N49JZ*N"^G1I%VF])6PTXZ9,)5G5&
M,5I"&$J+!0L;2E*@\%G"8>4*U:,L.G]21&-'7F=HEK2<7M8O5KT-IDV>-<YD
M2&BSZC3RA-7I-]GOR+H\VBYM265+<:??85 ++86[I4G:@W5TL=KD<1C+ZQG>
M!0@MBQETD418WHUODD&@+*T,T@AL@=&XH]E( 6D#V@4NP&B><&)![F947:P-
MA\IA:D(B+:?>;<1R@2(KR&GW&TJ:DR5N.-OM(4E+@4&FRD.)5A)4$X"U9U4Z
M.U(?O<>=;+?,BN_P5;/>X$B=;8DIYB=:;+$C19MKFR&''HBV53):'%PW6][J
M6B[N7'9*-YDT+Z]5W2,7\TH:?V5UJ/ZP-TB?I;7O6RH96SGRUVB2V[K9;KV7
M<+$;;&BM@1F8K?\ [-A5  09!VQ:/AQY4'"9.F(S(NDJXNE5RC1;LF\*9;9E
M7:<RXEE#^$1$6E,545Z*ZP.X<W*+A6'%.A1Q6XG6K15DTI;BWHZ\WW0KV@&9
MTRY670NF;C&>N4FVJ,F^R=>/7MB^6Z]0+FO#\-33*(J(ZH34)302X.O_ ,(+
M9;]*JHZ+,KBVPT01PZMQ":KK,4'B<?<$W9:4SYCW$%<F9I".#CWF@B9&L9&7
M28M'3<AVU PXDKDJ=3I>&TQ.U&XA<A2D7A^. Y(>=24!F,X%*0XM25.[B1SQ
M!<V81NV@"O&>6:_3;CI[DCB/L6QMIWD]MEU6J):;;"?$E=QO4,MHD18S3S<+
MFFDK$!M:88D*<DAGGW%.'J[YV-> U[,:O^X?US_!LH#_ "FB7/G2Y_SK=OZU
MN/\ C'J_7+0_UB:#_(?2/^7[?6W\PJZ:G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*W5'[G3E_75D_P*0<C/\:G\&K^\BLH?R)?XTU^Q>K2N25BTXI3BE=2
MGA,&)TIYZJKOS";@@%;6)U_CMA5HTQ2T(,_V)';=0MX5O2 @T5CL1D4:EJMF
M$O#&EF*CL1V='/95?#XH&P-SB1F%X$%+@4 49&% D*![P P<GO8]GO5L8*@Z
MER&II:T/*0X5-K2A39:))6I2DJ3S>#W15U?:Y40*E[P5M)V?071RG8/<R&[;
M9CFI-K%ED>V1T%S$W"T)U(I_K&% DL:I-YK4-($$WEN1TU1;WW=S#2QLFCKO
MO5E*DMI"NOB2/!DDX_MX^O4=P=;>ENK:.6QL;2KKW!M"4;L]_.W@>^,&NOB5
M)R)TZZ]B+%E[0[R5AK?PR[E9W8QC ;"WQP<:'IJZH8UCJE, B))LB8875\9K
M64*-F!B-5HC$]"/(Y$0^7$1SL63U!_*QUY2%#O=\ 8[W4,UF(VAYA"5!*G+8
M&V23M >=:62 KO%;BG$YX=TK'7UV>[]=G^NU[]">XC%2EU5M;+FRT6G)7I&N
MI8TS%!G:'IZ#&;%'8Y@)/ ;32EA5\8:#2D'=+33"RX*2.^BFU[JTJ:6$J"L)
M!.#G&2.OR==8\-AYF9&+K3C8+VT;TE.2 2<!0!(&>L</7J\34346>VTO$!M.
M5F7EBB8FL_4VM,'\B%,U;XFC[JS3\&#JI_8T%)'-_4-93GT8C=VV;AQ!U11A
MS,D'R=SO/='=M&4YX8SUX\.>'M^O6*><Z,DEM(9YY6'=HWES:,H*_/%(3@A)
MX9)/L5*\(O".P]H-N\18ZS9)SU=8:WE<WL]IUM,*#/E@SMJ%<EXG%I("6P.>
MYM7PW((TW>F$1?3>PI#JP,3HJ)&F9[;)18\%D$  H"22-V"2,X!X>='7COG'
M>''(A*90=REE#ZG$(;/-E80@D;E)((PXK.P$^<&XC)(*=YZ..'84WK'T34$C
M=3LE6^J_4 TX1>9)*'*R-< P 0*-.<2U:&1.)K"OS*-%WPP%Y+&,9E'1U:-E
M#%FY$HJK>_8U@)V[$YR3NZN&,#'$8/'JJV6&0_+R7"[TAW9@)#?%>5!63NR#
MN (X' /#.!'%;PMOJ7OMW:'HVN8JC(2>H77^;M<31(0B;7-K,?;)[6.ZI<HD
M281RZ1LKD&R";[*3AG0])%7SA1,K45$?E$C:ZYM SL20.H$DJ/$^N>LU(XHN
M0XG.K5MZ2\@J\\4MA$<=RGAP2GSJ1@<,#%5TZHP>^8%X26,.UY5LW8N&U.HU
MPR.Z;)0M!MDR3PKK;%0?-BL79!F(;['X'"B&V/5Q Z\0,65:H^>M)W-W=7[:
M1GOMB H/#<.Z4VHJ.<_;)ZN' #@ GO#CFI9*F5PE!I?U)N0VEI'-E)'U-S.X
MD\5J!*UK[ZNY  QB[G@V"W56CK-;5\J;12-=ONX\8K+?;Y=DO1TS=C+"'9!P
ME<_+Y1N;3LN[2W8TVV1&# 1!0\1 5-).5K.U7@"UA/\ 1W']1R*Q9P'.MG[9
M4:*MS\(IA!4?9/ GUSGOYKL&Y)6'3BE.*5NLU_XXM_4J._W"W(V_M_PBOW5D
MR>MC\69_4:TKDE8U.*4XI73? JDKFJ/#9292OHHVQE>R/!Y3ZT9V6)DE<Z53
MV7=O8^4_2-X/.(*,*+(\D,&(ALO@)I:@@&9H&!:0 PT( D)D' QEHJ/KDKXG
M_?4. X5LEN..6M(6HJ#<Q#: <82A,=6$@# 'A)ZR22222:O;CN5UX.J?L%<L
M;L &40OK$Z61&[>*;@W0-:/RZJVG5VE<613>@6SYT<DTE11FTEKR:U/!9@Z#
M6X&;;YQK)SB2E2@<A&0>L<4C)'$5B]%>#C+2D%*Y ;4T#@[DN'"5<"<#K)!P
M0!Q J ?!D5K*@*0>>RUM"XTOKNI)]NQ%D[J^.HLP1V1":)T[6P:J^NI:3%7E
M9?,8#<V%Z:KM;@XO8V^/&SMRUD';O5Y]SNE>P?.IZAP2. X5+.6DNAALY9BI
MYE'@4H?QKGLK<R2>^ / *UJP@IY+>_?8**,1JK<_I>#/";J4,ROD9%MD\^M>
MS 92[!%;9UU$,4?8M6.KLJGOKE(=FCRR_BX\AMFB@2XH#KYDA/LE1SX.^!_9
M5R.;3#94H9!G$NC'6A#:"D$=1&%.8]DBOUT![3]7&KKCU8Z^"6+"(/=$>@D,
MI=^Z^.SD&U6_'+9A47T;[ 9'^N=\ZRP%=.0LS\YF25R:1VIVP0F\[.2GSL@H
MN:6@(0C("@ DIZE!0'$%/6.(/'&*3(\@OR'BA:VE+4ZEX EI32E904K\Z1M*
M0$@Y&,8X<(NZ:$U$AU8Z.Z69:<KKN0+=FKY3J5CCDP?XP!9T_P!KD[ :(PB5
MM[,FH)*(^NT;N3ANSOFPS:J>&$CN5G8K !]K>-C>5$=VK !QN.Y7 ^$5)*#A
MD2^;;2M(8:YQ2DI46T<VSW:2?.JS@93QP3[([9IW (3:$7/A-B1=EFD/=2&@
MIUC$C!1=&-U48GEOD#6FZ-A.NXCB(.[M0!B@)B2X1?F^$#!R!E%45)R H8(R
M#U@]1P<\?)6N0M3:@M"BE0SA23@C(*3@]8.">(XCK&#77'X/NVJUI/P:?4V5
M6A*VN%1H]CC\+ <W/4GS5:22^?.S!&6=/0(8E355R="QQ4U-DM11M,[DEK#B
M(K+IQ-*"64%1P.KVR3BLV8VX[.D);25J'=D#KVI;2I1X^ <?#[=5.\)W$.RT
MF(EME3RI&&0U!5=H]:@.MZ+?;S<VBL+\Y]A*D#D-H2R)K1M8MVL&;+%[5I'5
M]SM&VLX$\OQ(B#DXR60K*V.A9[HI!"5(V=UU96D$D8XD]0[R1GPFLB"IA(2A
M#I2XXV_S^6B24\RX0VE0/!",<XKON* ' ) KN)%:K?F,DG4;M*.U-FAY/"]V
M=M:F=ZEYUC$F/;4V!2-EEVJS:WQC#-MH7)PDCF!QR:LAJTK820W6+PA/A1)"
M@G81@ $[N(&0>]CKZO6K6DM)2A39=YY*LDD)"  24E."59X).",=?K52WHXZ
MUE0-6=Z7MPQ':SJ.I.YO9AR,U;FQ)IC$+A$2:(>2O@)G9A/)AM;.U![>;M[6
M#MG5%'4<,7??*:6;&]J$N=24I6KV !BLJ6''G(@&YQUR*P!DDJ6M14!DD\22
M>))]<FMV[G62G:-8TGU_J22[JNG?%_;(6T2QA750*:^NZL;^S^\K':%]]$5$
M<ZU"D1'6$K;88@>3SV+J)YU6QC7!P[@E*3Q<X CO(ZU*'_\ / >N15L5OFW'
M7G$\(@*BE7?>W;&D''__ $[H^LA5?#V%;$X)VH\&"P5RW(,HC?-KRKG#(UH^
M;MX50#];I&>YLN4DODP@QM;O#*\+%0SG ^KJS1_3.-E=1T]RQA;.!U%0]A.W
MC^H=_P!VC)WQYY<))*&5@GK+O/I /KDA2\GP%5=CO):PJ<4IQ2K5]=OY+DW_
M '[?^CK\PI?6CV%?K%;^S?Q;_P#31_=->+OPA/W[G9_^U^6?IG/H;2WUNV?\
M2:_?7Y+\M/V5]?\ Y2W']H*KI%H/9TZ<V-*$Q"=S%X=#S&R-)Q9@D$A<W%SC
MC:D]N#>QZ-(A919["T;H.Q@@&%"&MMW1/730%VT5SM7I$**AWI#\6.VA(6]S
MSC32$H=46TJ=WE*0EU8*$E6 XH%(R017#V^TWZ[/Q$6JVW>YRI#SL> FW0IL
MV0_(@L)EOL1$QFW7'7H<4HDNM,A2X[!2\M*&R%5FG6FKP;I4S5T^55:H$W=M
M2E8]!'6#2X65.>N-%BS566,%M>CN;KC09<DK<$%7'B(++*Y\5+?;6Q$^W+9<
MEMS82HZ"D.R426%,H/!* X\E90DY4$I"E#K '6*RI&E]6,7&+9)>G=0LW:2'
M%0K1(M%R;N,@84XZJ+ <CB2Z-J%N.%II7!"E*X))";U+>-8I!2"QZSM:O4#R
M?FQN?)O#)?$TC2]0]_\ ]>$Y/S:WZ$DZMZ*G_P"(@ONK@-+?_P!O"&FWR(\V
MW3"IJ)+A2B@;U-QWV'RD;O/J0VM6T;R.Z( W'KR:K=M-ZLL"6IM]L.HK*AYS
MF&)=VM=RMR770T?J+3\QAD..!E*OJ:%E0:2>&P&M >(^^QY4%%_979C6=&AL
M?VU)W;C&U5P8GL1,]F>@4S$4=BVEV!52,;'%#"@9PJFA JRJ6^N^<EMUIT*+
M3B' A:VEEM:5A+C:BEQM123M6A0*5I.%)(P0#6FDPY<)3*9D63$5(C,3&$R6
M'6%/Q)38=BRF0ZE!<C26E)=8?0%-/-J"VU*20:^#<LI11)90DA19#5+1!7=9
M391'1#Y/(:);[;9V3U1^3'DM=,XPG\F/$QCY,<O"4@$!*0"22   2>LD=\GO
MYZ^_4)<<4I*E+65)"0E14HJ2$>="23D!/VH&,=[%?00[NI9BKB4YN!+@MIE-
M8\@TE8Q73*?D<Z*E**[+J:91_P#:SKOOG&4__;SCQ?XN6AML)" A 0#D)"4A
M(.<Y"0, YXY Z^-7KD2''5/N/O./+&%O+=6IU0V[,*<4HK4-G<X)/<]SU<*Q
M_+ZAK=XRTV+83GK%8D%+YB[$A.)OS"R)NSV6HVLX!#JZF;@"^<;^8-;:&2XN
M!*B>!@@A5BB%$D4=]]<9Y<.(CGWS'CH"D)YUSFVP%N*"$)"SCNEK4$I .5*(
M R36U@1KU>I M]M9N5SDK:?=Z'$3)ENJ8BLKDR72RUO/,QX[3C[RRG8TTVMQ
M92A)(U95S<EPAFU=P.6;@]U% V]4LA0(517.<JJ#"[J;((;J9SG*FZ2>NV^<
MY\;.?ESR<(0%%80D+4 %+"0%* Z@5 9('>R:UZGWUM-L+>=4PT5*:94XM33:
ME$E1;;)*$%1)*BD DDDYK\Y<7#(&K7D\S+9J1DO5NR4OD#4O.GD\E:B9W\WP
M1E/.=,K83PIG3_9SMXO\7&Q&[?M3OQMW[1NV]>W=C.,\<9Q3GGBR(Y>=+ 7S
MH8YQ?,APC:7 WG8%E/<[]N['#.*Y='AV3*$.3=''0T!!$8$S0TG4H(8=+* X
MXA&JN%AT$$,Y1121WT322SE/3773^+E"VV4J24(*5DJ4DI3M4HG)*AC!)/$D
M@DGB>-5$F0'&W1(>#K*4(:=#K@<:0VG8A#:PK<A*$=RA*2 E/<@ <*R\GB<Q
M@3P.V2^/R"(ORC>TR 8!^;SF9V^;GH-!V9';08U,<Q,=R!7&<6\K.FN"!ED2
MD=MDU--\V,OQY+:E,.M/M!:VBIM27&][:BAQ&4DI)0H%"AQP04GB"*R9]MN=
MGDHCW.%,MLM3$:8VS,8=BR.8E-(DQ) ;=2AP(?96A]ES "VUH<02E0)UI111
M53=553=557?91153;;=113?;.VZF^^V<[;[[[9SMMMMG.VVV<YSG.<_+R8
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M\??&YPGD\>4M45 =RD*/@*MH]W"OU5>V&RK#BU-IP>Z2@.'/>&TK1P/AW</
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M9SSQ#R9\=QDO*C/J)99=B[2VA.0"X"5=/:;5H#6MFU7%T5I2S1]3/3]42[5
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MC""6MOON2BX_.V=BD,6VR9EMA1ID:Y*7S^H7X2K0M$=33S;]P=0YS1#8E(?
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M*W]F_BW_ .FC^Z:\7?A"?OW.S_\ :_+/TSGT-I;ZW;/^)-?OK\E^6G[*^O\
M\I;C^T%:4Y]G;!,C5)(-;D[QBQ:)CLKKZ*6A&WTUJD)-7R+<U=NAAGFVJ:R>
ML<WD$R; W 8Y/4R-27YB*!PFVIDE9"+/%2]<2M#;T2Y.L2GH;S:5M)F-!(6^
MD*R#SW-L+4E23M=:YQ*LJ(3J9&O;T[!THB._)M][TC"N-FMVH($QZ-.<L$XN
MJ8M;O-A*P()FW1AIYMY(=@3^AN,[6$N.0G#9I+J[DS5,X))7N(2UC5679I)'
M7$II>FM8@5<%=4!Q"41*&46#*)%4V24USN@NJEMG.F^V,[&1'8E,KCR66WV'
M  XTZ@+;6$J"@%)4"% *2" 1U@&N5METN5EGQ[I:)\NV7*(I2XLZ"^Y&EQU+
M;6TM3+[2DN-E33BVU%*AE"U)/ D5-;SW%[62+87=^[%7(\;@I.: 2CC8,E+4
M#2>FY=H=]!5%G#?<?#DU%$MQOD=M,D!$+#*YV24WTSKV[#96@H-VJ V%%!4$
M16DA1;6%HW )&=BP%ISG"@%#B :ZF5RF<H<XMF9K;5$HLID(:+][GN%I,MA<
M62&RI\E'/QG'&'=I!6TM;:LI40899YU,X]&Y;#6.4OS3$YYHS)S6-@.98S)*
M](X=NYL&']L25U$=,LKBHH<U[%I*[ E*;KC934VSMG/<C1W76'W&6UOQBLQW
M5(27&2ZD(<YI9&Y'.) 2O:1N2,'(KEXUVND.#<;9$N$R-;KP(HNL%F0ZW$N(
M@O&1"Z9'2H-2.B/J4['+J5%EQ2EM[5$FOBC\IDD45=%XT^NC"L]L+Q%W=1J-
M7"W<XY(0]V]\8SLH;Z9):W8)3<4\);QT"4=O%4TVQC'R7.LLOA >;0Z&W6WD
M!:0H(=:5N;<3GJ6A0RE0X@]51P[A.MRI"X$N1#5*AR;?)5&=6R9$&:T69<1X
MH(YR/(:46WFE90M)PH'A4A1CL'><*@+W5D0MRPXS7$CR=E[A3'+'ELCKEAT0
MT&=="&P0M(?R3L,GH,ZHZ:Z).8^OD#M"$LYTSBO6NVR)3<U^#%>EM;>;D.,H
M4ZG8<H(6022@\4$Y*#Q3@UN8&L]6VJSR]/VW4E[@6.=SO2[5$N4IB"^)" W(
M"X[;J6]LAL!N2D )D([AX+3PK>^KO95ZZP2&T)7&VYR(D<\I&?5-'WMGDBL8
M=(.]3#=F7;)T <@VN*Y1<:,9DBQVY#=L5)6VTVT=@MDL;;X]XM+=X:AL.J0&
MHUQC376W&@\B0VQS@7&4DK2$AU+A25G> ,Y0K/#<<G^NY6@)NH+C 8?7.O&D
M[SIR'+C3E6^1:95S,5<>[L/(8?6X[ =BI<0P@QU.*(*9+13DZ@?V2O\ =+);
M[A<KEL@ZTF@)=M:9X5+GE>3-+:4&:WDMC6YJ%[+MS:N$Y.(ZK>'LB'NF>9C9
M'.25L[S)M%K1$7 1;XB8;B@MR,&&PTM:5)4E:TA.%K"D)(6K*AM3QX"M8]KG
M64B^LZF?U1?7=01FEL1KPY<Y:Y\=AQIUE;$>072MEA33[Z%,M%#12\[E'U16
M<I&^UW9F'Q=JA46ONV6"(L:IJK1&VN=2$1F ^<4C$CD1P$C]1]0R=7 [94'.
MFP6RQA)'F^%UMU-K'K)9WWER'K9"=?<"0MU<=I2U;""DE13G<"E/=#NL) )P
M *R(/*)KRV0(]JM^L=20[;$4ZJ-!CWB<U%9Y]+J7D(92\&^:<#SQ4R4EHJ<6
MO9O455B67LA?\<KEPJ%AN:RVBL'01P;SH&WS)]&C"S<[85P[-F&E(W49%L=L
M+D8=6U#1,%RP23@T=?SA?RE[EHM;LM,YR!$7,0I"DR5,-EX+;QS:]^W)6C:G
M8LY4G:-I&!C&BZXUE!L;VFH>J+]&T_(;>9=L[%TF-V]3$G=TF.(R70VF/)WK
MZ0PA*6G^<<YU"^<7N_1W9+L"YUJE3CC=%F'58B*( G 2YD^D1?5M 517 :LM
M2INPVS0"N..L$T[Z[-PBHZ"@XR>R*6=2;1:T2S/1;XB9I45])2PV'=Z@0I>X
M)R%J!(4L=VH$Y)R:J[KG6;]B3IA_5-^>T\EMMD69RZ3%V\,,J2MF/T93I;,9
ME:$+:C$%AM2$*0VDI21]TH[2]D)K"U*XEEY6E(("JF$@K#G.:/I,<5$;4ADF
M\!5IV,\S4;0M0Q=Q6W=+(""Z"9*8^I&N%>6LV:TQY EL6Z&U)!40^AAL.A2B
M2I07MW!:MQ"E@[B"4DXX5-/Y0=<W2U&QW'5NH9MF4EI"K9(NLQR"IMA*$LLJ
MCEWFU,-!MLML%)90M"7$H#@"JQ6G8F^4ZTVIK2XK)TJG9+8;:O=9B^XB>0MU
MLD;MOS-@WS3#5N3MDG=JPGAMW*SDG87*^<J<D-JMIF=/,"(9H.[I7,-\]NQC
M?OVYWXX;_/XX;L5C#6VKTV$Z7&I[Z-.E)0;*+I,%N+15O+'1>=YKHY<^J&-M
MY@N9<+>\E5<UEW0YS^"TU6(C9I'X)2L5<FI@9]#-SUG&52YTS(K#FKF7N@-G
M<^4/VR28@2:6$&6.-+"RIJ&+ E.;A2';T19,^8I?.R;@\E;CFT)"&&$<U%CH
M3D]RRWG<HG+CJW',)"DH3=?=4R+S:-,6%N.F%:-+6]^/"BI=+RG[A<I'3;W=
M9#JD()>N$PI#;02$1(,:'$275,N2'X4YL*Y:G%*<4IQ2G%*<4IQ2G%*]F-7_
M '#^N?X-E ?Y31+GSI<_YUNW]:W'_&/5^N6A_K$T'^0^D?\ +]OK;^85=-3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE;JC]SIR_KJR?X%(.1G^-3^#5_>1
M64/Y$O\ &FOV+U:5R2L6G%*<4IQ2H:[%U+M?= W91^C_ *Q7>X*IG]9ZR;9L
MR]ZQ[:<19TC>'K9GPX-.77#9ER\\RW8=&[)F$?-\'"^4\MI:M.Y*DYQN!&?9
MJ1ESF7FG<;N:=;<VYQNV*"L9P<9QC.#CKP:Q=(]9:*Z\B%XJ.IZZ@+P]-K.W
MRE]AL.9HTXR35E&P@'HX$-Z&"<MXRFRZ[>T9)W;FW<E?S-%/957=0E"4>=2
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M\PJZ:G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*W5'[G3E_75D_P*0<C/\
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M>A:P^FZB:"BVR6BBFNN-\\#)N"I,J5)+24F5*D22@*)"#(=6Z4 D D)*\ D
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M2G89'W=7P8^53U=6WVG.^CA_VGCI9] /=/DIV&1]W5\&/E4]75M]ISOHX?\
M:>.EGT ]T^2G89'W=7P8^53U=6WVG.^CA_VGCI9] /=/DIV&1]W5\&/E4]75
MM]ISOHX?]IXZ6?0#W3Y*=AD?=U?!CY5/5U;?:<[Z.'_:>.EGT ]T^2G89'W=
M7P8^53U=6WVG.^CA_P!IXZ6?0#W3Y*=AD?=U?!CY5/5U;?:<[Z.'_:>.EGT
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LQMX^<YSG./D^3Y/DY"ZZ72"0!@$=>>NLZ)$$1*TA97O(.2D)Q@$=XGPU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g105292g44i44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g44i44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     T<   =D          $                          0
M   '9    T<                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   T<     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   -'     %)G
M:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MZ2P/+O2'IM+W^X>UK26O>[7Z+7-<O/7?7KIK@ [H(,1J<HD^WZ$GT?=M4O\
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MBO8Q?__1])Q?Z!7I.O'C[UG/LS:?T-F=ALR&%WJ>K6&@AP;Z'@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!#0)= P$1  (1 0,1 ?_$ !\  0 !! ,! 0$            ' 04&" ,$
M"0H""__$ '$0   % P$!!!$,#08)!PL%  (#! 4&  $'"!$)$A07$Q46&"$Q
M45565Y25EIC5UM<905AA<7B!D:&UT_ B)30U-SAVE[&WP=+4(S9UM-'A"B8G
M14=E=[;Q)#,Y=(2'LS)"4F)D9H62IL+%1&=R@Z7_Q  < 0$!  (# 0$
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M4_.2$C1Q];FY>6B18$"C"'GA8C6MHTWC6C<2%Y1;G=E;-^H-RC&5I'K;8L@
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MDJC\36R*0,;$=+$S:E52%)'UXFTV0MA3:Y.8>4RU84I*1#4F$*QW3'<E2E;
M[[6M:RXMCSADH\6#%C-A0XD002\B$Z(V\(3R]C#PC6D%P (%1BNYR"RWD/2#
M8(RCLN1M&2LV+.SDI)NM)D"'$G8<G%,%\Y ; F)@>JQ(K7LAF(61"8;[T-H
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MUIY*V[,^F^P,JH4@XY/RN0-J6--6EPLL&PK0F)V+%@RSH)C":<2QX??; =#
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MNOT3"/\ [A(?.8"IZOON7?;X?OS196\T*>R9[\FW^)#\2GT2Y=_HB'^(6?\
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M8N L5"(,&2<%.E$18\\1)I1I1MBBQW+,*, />B *UK44)J*#/R85QZ"%R"/
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M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(OD^_PI7^8ND/\
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MB]!MRCO:VZ.Z.MM[6_RTQ_IWM;IIU]OTWM;X;5J3W^4F/^5$_P!#EXOTA_\
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M.! @L=$BQ8K@R'#8T5<Y[W$!K0,22:!2M"M-.H7)$FFT-Q_A/)TTE>-KK Y
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M4:42,=;DNV(R7CN#7,OQ(L2$VZ6N#79CP?W"XU==H"*Y@OH&3<O-R^3>4LU
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MY$@66_)J8M2++VM .3T[%F9*-9CY&9;$;&-NB3=+R[8$0P!-PW1(4"%"?%,
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M-1*Q6E ZN$<13)%)!-03 #&G2B6 'O$9UP:4>&[UF \?9<V+!)H>*YX8]E2
M<'<$6\Y .<+Y]E-*QQE)8<X&-,M.6=;-@F,X/+9>;GX4&/*.B.:QW!MC.E7P
M;^MP9G>%L[G?=?8[F.":UL6+XM,7:.9;RM%Y]IPF+DE9&Z=Q&)-.46>?..,)
M>N YNX6R-D'D/#]$[MILC*8)"ZN95D!Z-RWZ3BA2!A.EGAP#H<)T.*UI(:YQ
MA%@B-P^V#0.) O- TM%[I+*]',Q9TUDS/LCRT.+(6?'D[9EF.BNE8\Q%D(LH
MR>EVF&R_'-84*8OB$8T&&PU#H?'TG7:]Y<9.,43.%O.7,8R#'4Y32,B9*,@Q
M_*2]J0JD*MC?!L\5<,>PEI7K3V-S<4HT+RY'-3JE/.:UY(4RHPXOG;*BY%:\
MMB"(R[=(NBM002>,1B!B,1@1FQ]+#R/A-E;1EYMEGS\&=DW0/5A+1I-KWM>V
M+"X2.)F8>QK8K(;K\-@B0W-$1AO- /HSC[7^VY\UO.VIEU0DLF!-'>B_+L3C
MZ26IHC')'*&=SB#O F9:[L$.0(XPGF.4LG9#:"CXO$6T;*PI5UB$@#4;<I5F
MZCY3@I<01C%CS#'$MON -^'$=0O-;D.'"(!<;SJ5SD@>.G<D8ED9,0;%8[A+
M7RCRDD)B*Z7=,1X,N]DS!G(K8<>9>Z,Z7D9&1?=C3,3A8KF5<;SVM;\[-[[Z
MXA;VP=\(0M[;I!WU[WWMO:MMV?!7;+[.!0 :@!N'3\52BJ41*(E$3Z_7Z_%1
M$HB?LHB41*(E$2B+Z&VG67 L0XNTQ:@$3A,1DN>YL9/T0M:B$*&8^08^U&P1
M\1GMZIR2'O[4X,+8-O<XY,D[ZF"H/,3.2,Q"E4JTJPA-U1EGQ'Q81#:"<AS/
M'!HZ"X-!H0T@FK7-+37-C0.!/QA^34Y:-H6U8[H<M6%EG)93/$T(@@SECS4(
MA[89$*(R*^_!C2SX3J .80]S6N:7:[Y\W5%)G%/I>F#E!Y8U92Q7BR?P7+)T
M(D+'CEHE\HE4G97P4Y9'(B/2ZUAR<3:I>)6SFQIL 5(5QYJ%8<E%:U<L*2,,
M1VAXNQ(C'L!!<6M:TM+'5H2 *!AK4- !JNYLK(")9GMR5AS4N^1G[0E)NS_6
M8<:;B2\"7@180E(K#%@FD#A R7B",\F T->T."LVE?=/7+!.=YKE9V693,@+
MO%V5R,PVJ60#)J')62(,(V\!(F4IED08N8Z/-ZE>J7J9/#8X.:(B$@&QL4V$
MLLN0V-)"+!9#-V\TN'"<9I8Q];]P-/&<: !KC<K0NJ!0\EN9!BU+)E;/8)$3
M<./%9[2:)N3=)24W_FS+P($=YF8KPUK&P)F,)9Q=PD0$,X.)U\AYX623<V,K
MN>3E[:MRQK#U[..96M"B4I!*@M,(C)W-M)AMH51RQI8A2F2E1AD+5 +$H$F4
MEI>3)D9AH:V"!-LN5#($J(9U5<]I8*Z3=AU=JJTK*2LEL#+:SX<BQ[9#)S)5
MEG1'N#KG"3,=GJ\"^6AL2(($L8L0BH;>9>H7 +R-K>7TA*(GU^ON41*(E$7H
M/N47_2.Z.O\ ;3'_ .K+ZU)[_*3'_*B?Z'+Q?I#_ /!>4/\ Z?%^2_IHUXI?
MB-*(M-M&OW%J:]^3J#^?FZB+GCGX_P!F/WGNFO\ 73JOHBW"HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%Y'[JSI(PWJJ8L.(LO(Y(
MM30]ZE2IE!'Y :PB+.=4#84L$I,)3*!*+"+2$6+#?>6+O85]M]]LK?D9F)+F
M)P=WC72;P)S7@*8BGVCKKT!>KR7RLMG):)-OLB)+PW3;(38QCP!'J(1>6!H+
MFAN+W5.-<V@+QE]1]T4]8<E?G&6^3:['VG,_L^H?$O8_2YEK^=6?^'L_W53U
M'W15ZS#DG\XRWR;[EO\ AT7M.9_9]0^)/I<RU_.K/_#V_P"ZJ^H^Z*NL.2O:
M_P HRVWN?YMI[3F?V?5/B3Z7,M?SJS_P]G^ZJ>H^Z*NL.2NC>_\ I&6^MZ]_
MM;\'K^M?I=)[3F?V?4/B3Z7<M?SJS_P]FC3_ -[KU5T*OJ/NBGK#DK\XRSR;
M3VG,_L^H?$GTN9:_G5G_ (>S_=5/4?=%76')6SH_Z1EOM_ZMM^WH^MZ]/:<S
M^SZA\2?2YEM^<V?^'L_W?)WIZC[HJV[>4.2>I^$9;MV=[>KZWP[?6I[3F?V?
M4/B3Z7,M?SJS_P /;_NKH'[DGH52*K(E:6<I5@D@U]DJG*@R%%T!:DA&8MY"
M<B 9P0"Q4F2"4[WD-E*@DBX^2F@!>>U)@?D^H3\#YZ5#Z7LM!GF[/_#V_P"Z
MNP+<A]$ !V)$TY" :.Y80E#R8H"8(1V_Y%:Q=V^PKW.Y&;R*UK?RMRS+ WV\
M%LOM.9/Y/J'Q;QH3Z7LM/SJS^FSVC_\ MT4.Y<_J/NBJ^S[0Y)Z>WHY&6WO[
MMOM;T+VO?9\ONO:<S^SZA\2OTN9:_G5G_A[,VO\ [W7@GJ/NBKK#DG\XJWR;
M[GN^U3VG,_L^H?$GTN9:_G5G_A[/]U/4?=%71^T.2?:MQC+>CT/7^UOP>Y3V
MG,_L^H?$GTN9;8_]JL_D_P#A[,?_ +J>H^Z*O68<E?G&6]3^C>KLZ=^K3VG,
M_L^J?$GTN9:_G-G_ (>S'_[J6W'[15UAR5TNV,M\F]"WN]'W-E/:<S^SZA\2
M?2YEK^=6?^'M_P!U/4?=%76')7K_ .D9;T^]GK]7Y*>TYG]GU#XD^ES+;\ZL
M_P##V?[OG4J^H^Z*MOWAR5[O&,MV_-GN>O3VG,_L^H?$GTN9;?G5GT_]/;\.
M$^:IZC[HJZ/VAR5^<9;[7^K>GU/@I[3F?V?4/B3Z7,M?SJS_ ,/;_N]B>H^Z
M*MOWAR5L_P!HRWXMG*WH_7X7M.9_9]0^)/I<RVK_ )JSZ:_9[/\ =3U'W15T
M/M#DF_5_RC+=O2];[6_II[3F?V?4/B3Z7,M?SJS_ ,/9_NIZC[HJ]=AR3;J_
MY1EODRWK;/K:GM.9_9]0^)/I<RUTS5G_ (>S_=3U'W15MO\ :')7K?Z15OM]
M/[6VV[/=V_)3VG,_L^H?$GTN9:_G5G_A[?\ =7[!N0&BT%Q7 R9,!<01 O<.
M1UP;B ,.]& 5PMUKW",.T(@WZ @]"]KVI[2F?V?5/B4/I;RT.!F;.(KILYAS
M8@_][H7X]1^T5>NPY*V_[1EM]O5V6Y6[?KZ]/:<S^SZI\2?2[EKIFK/%!7__
M ![.FGUM<.8+HIMR3T*K33"4:2=*CRE*Q&80FRF,\X"QN-Y X)1%%(A&64H#
M_P"16D;WDB4W^3/"6/[&I[4F/V?4/?T<^&=/I>RT_.[/_#VTW\+32NR5N1.B
M(RXBD[9D,RYA5C!ED9.4CWY(3A!",02V\6_*LI)$$([VN"QQ0K6OR0N]K7VG
M,G\GGV",:'];/2IIJQ4^EW+0D?\ :K.)%2*V<VH.(P^LP/;1<WJ/NBKK#DKU
MO](JW]'*WH?LI[3F?V?4/B67TN9:_G5G_A[?]U4]1]T4V_S#DKI[?PBK?=]9
MMZ?0Z?N?"]IS/[/J'Q)]+F6OYU9_X>W_ '4]1]T5=8LD^U_E%6]3^COK;W>@
M]IS/[/J'Q)]+F6OYU9_X>S_=3U'W15Z[#DKX,BK>I_1W5]K^VGM.9U0^K_\
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MO6N[:G5JV!W;U[BU<G4MR%>H;C]^(I&>.X00?(]@*AK0TSX_T^2UZC>Z7O\
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M-I[R0[/*R$)L>&.;>YCCBTF--TR9<A,@$9T=G36)&[QJ:,#9(HO(4G(GZ..
M% F=P1EKEI9Z[^NS>?#OUZ5;HVFX_O=O%Y/AH64S.&PW(F+D>()QB+,<IB*
M<:5HU#Q(U:J8)W>'NR%^C,C*GPI[:9AE#.]MB%T1R,+[9Y N3@/$L%>XM\N_
MKLWGPYN3,I=%/M-.?0[P]'DE1F'3=@RSQ/'(>!,R*&O)9<UO-8*IFC^?BY[7
MY':+LD]?3,7FY*% TTCEJ U5=]?TC G=5RY>Y.IBKEHX+%AR[FX[,.>N'+=0
MM&TW13/F&8?9J ,]#3-JHK"DTH8-;$,D2,V)]33&IFC/'6";/['FW)+3*IJT
M10I[2,**72A%F E]D0&]ND#@T%B=%ZDP;*% T&#&WM;<G3+OZ[,.>F/)=HE
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MO+>/3V9W)*D(!&G-;@66'E<[6WPQI#@AMM$@L&VT5[6VWO:UO7O:U4,=48#
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MP[DYELB=M,WP*CW[U2K=GWBI4;'ON[O[+KV8)U=4-%;+@+K $%JAI+1"-<*
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MTU[M72!5:OH-<6I!WU':<F]]D3_CTU_FF#,1:D<-R!QA+2BB+OE_ X)(XO\
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MN_6_0?5ZW[F]Z<76[JCQ<_DX6QZ5Y8NS.]CV6!A)NV.%C1%OKX(RQ?!#=_<
M1,P B'8.VX0B$$-Q;+7$&U[WM1<J*%]:C0*9^= &ZW5KLCXWOD59( JRB&#0
MX+>S0@Q#:+L-D9BI[>BU1B:S6FY"-044SF%%GB+WMS2RS#  '<00C%:UKW.N
M7G5+JU-: 4K7&F-:50TJ:DYSH'+RCF\XY;PS+O6. =_GWI=Y.I\?M5/J];]S
M>_\ MRIQ=;NJ.G[W9T5TJO"\N=9(#W^??(E/J];]S>].+K=U1XDX7ESK) >_
MS[Y%^OM4^KUOW-[THS6[JCI^\J<,R[UC@&S^GWW]'*3]M/J];]S>]3BZSU1X
ME7A>7.LD![_/OD2GU>M^YO>K1NMW5'B7%8W*X31GACV/ G&  68=9[>[&F%E
MW%< !F68]^(!=QCN (A7"&XA7M:V^OM?5ZW[F]ZG%UFG[H^%[YJ,5V*I8LS&
MPYU PQ%!D!D@SSC8]8@E3\2@D,-=W9$_%-$B0B81EN%F-\0\M8^IL(I2V*%[
ML648).Y*BC'U>M^YO?RI1M<[NJ/%S:?ZR5_E2Y )+S-8XNE'OM^GY</-B!<D
M'<PS?$\HKEBWYE[F"VAOOABN(5]]>][OJ];]S>]7BZ"ZG*T>+NKR:8L38AE)
M&;G34$<Q11?D)=CALQ4@-72Q^.:(W#D+\MDR]''FVS  M KD;TJ2*I$NN,U0
MY 9&)/<19#<67=Q,U7TSYFUKOS=.E2C:UJ[-AQ1GZW;V8E2WPS+O6. =_P!]
M\AT^KUOW-[TXNL[AXE7AF7>L<![_ #[Y$IQ-;]P[TXNL]4>+G\G"G#,N]8X!
MM_I]]_3RD_93ZO6_<WO3BZS7]T?&]\E7AF7>L< [_OOD2GU>M^YO>G%UGJCQ
M)PO+G62 ]_GWR+3ZO6_<WO5HW6[JCQ+#I4HGYCC 0R-LBB5OM/V(7)6AU=%:
MNQ]BEW(P\B5MB4KD=[7%OQ<DWUKV#:P;VO>X<FW>-=+JW'9P,U,<QT#'SB %
M'9SQ3G%/F5/=<2Q2B+3;1K]Q:FO?DZ@_GYNHBYXY^/[F/WGNFO\ 73JOHBW"
MHBPK)/X/9O\ DH__ #6IK)GVV_O-^(5;G'./BL@8OO&S?T4W?U0FH[.><_%1
M7,8PEA$,8@@  (AC&*]@A"$-KW$(0K[+6"&UKWO>][6M:U[WJ(OFNGNZ&SJ3
M,6OY9$<RN &O(. \IY)TLIVI.[QYUQ2MP*[F8Z=TS8^&HBR%9V1V4;%EUM/:
MU:W@Z8YY/)N(FY59TS5&-17E!Z<*9MRHT<^/+S!;QJM=&>X;D%ITNRC'^*7/
M4?-))B)KQC)6F03 .'U<3R7#<ARY1()U=P;[RUMD,71XBG!!\?;#%EI.>?'E
M#:X(0*70MMQH,::!7'H&BN?LUG.I\L_-R:\2%KCIZUQZI6V$9=C1C9 LESS#
M*G5GGG+#_D&6RU R&X^@VHG)D%C>,<5*0HEBY*>6C@[V4T+9.,QLC#0E8T:Y
M*L&NL:52!IP& PIGH*GYX UUJ5&H@8 9S7 8G54G3IYE-;=ND&9)E)V<R"XM
MQL5 YUJ.C.EZ#'2Q_EB*7)9E/L"LV<XI-):@0MAK>3&&M(YCC\C8&PXQZ4*@
MA5MKB42 0#%T:S@"3A3,:4Y.D=RHKIIKS'-6F?GSG-HSE0P_;I#E5M5(LXN4
M*1;^'Z.-0LV<<:LN19$E@3SDG$FIR)82DMUK8ICQMG!N5F%C=(/)S#$KZR-B
MYS:G-J67664$KNBHSTKT5\C23R*:>2M*TQH02*C.,V\*?Y5K^S5#!Y?QF_Q;
M#0,]XURI$(8R-3"1F.:,>06*:8<'EQ"&(PV)1=UR"ZR=D3)EZ24WL6ECS(PH
ME,N4KPE%A9C%,Q&;37"FCFQT9].I*_ G'D//S'1GYUEFCO5#)M36H9%-PJ7U
MA@60M!.G?,*#&2IS-6LT5F,QR'E5#(U"8H9*<!C@,#2F:37*Z9.>N0-B*YQ!
M(@<B ( !UWJ=%%>C2?/GEQ(HHGU'ZK=0$OR5!D.*1QR 8<Q]NCN"-,4L=A/D
MD*R9D)[NH1KYNB.;VTHN/(<8K37QN83VUP4JW9]3HESG:Z).:A(,"F-:UH3H
MI3ITX:.]->-,#T<]3CFKIU#2K=IDUIYM.BFFMJE#6PL$0RZ]Y@;G/-67Y%.Y
MVRNV44.H3)L,:<,1J5M;2T$QQU.:8^F<867D'@:->TJ6^'L:AS=FD9BL1B>G
M#3KYJ#?30-#-7Y#-KY\=2MF*]>VJ".:;=.KAD)DBV6,UZC<D9AC<+=X? <CO
MK>SQC%3O,54A<YC#,>,RN0.[@0E94K(P(XLWMR<2$XAX?5P36]QNL$"ISBF>
MN?H'><R>?.OST720[ICJ.8XY-90\:<8QCX&#\)0'-V:(ID=TFK-,5K))LMSC
M&B]! 6J[$F4H+N#1!U$ZBRN9(T:D:!U:V9X:4JHQ2M3*5I0YS3-R _/'>*IA
MACGK\OB31<.HG6MFDW'.I5H>&QEQ*_XXR9BYOCD":Y!/()G!UQ"_9Z@\#09:
M8IQ=I<8B]1B7I7QO4$+XD@=FM&!8Z0B2*$3S<X1,I3EZ*C$9M]1H.D*9Z:,-
M6-=%?GBI$E.Z*96BJ!9E)5BR!J<(RK).I?#&*DQ,CD ,IBF^GN)Y2>R)+/&X
MUNLQHH;+WG"TW:CV]H&8_P 80.$8>%0W LYS3HZ133B #R8TY37..U7NKHU@
M?/R<%.^DW5CDO,>1WC&66H9!(R]K<!8=U*PU1CYYD#NA!!<O*Y*W$Q>3&2!O
M0#%*HRNCP2U3DU@"TO"=:!0F2(!$C(O*85Y2//=Y#SYQ\ZUZ!5$2B)1$HB41
M*(HWD.SC'QSU>!33^HMNS]M9C[#^=OQ/G-NTT?9?JXOQ-?DI(K!1*(E$2B)1
M$HB41>(\6R[EQRS)!<M&Y(G"AUEVZ2Y7TH/&,;/ZWBW;<(PZ)SY$U-)< WPF
M9/(42F)-V0%$W"C*E:E8X')E3N..&%-@<J9^8'>1_;>G1YW^=R]N*Q1*(E$2
MB)1$HB411G"/YV97_*YJ_P!S(Y6;OLP^8]CBJ<S>;YE296"B41*(E$2B)1%J
M_K7RC+\)Z2M0^6(!8%II \4RV0QE08E M+;W9(VFV2NQB,T!I*HMG&9RU,(/
M+&G- C$!1:Y-S*H%2 =*#.%!.E5;+85J3SC@8S(D\R?C^/X1TXY8:W[(DJ<9
MP^(IQD8S);',+(Y"ZFJ5B5EDQ$%9I*DC):@+,R+5+B..H6YL7V2%CF!TXX4I
MAKP'/Y"889M.:FBE*TTFNG4O1:HB41*(E$2B)1%:)!]X7O\ HAR_J1U5N<<X
M^*+'\:?@[@GK?XH1WYI257_:=^\?B579SSGXK-ZQ42B)1$HB41:%8@F>6U>O
M+5%CR<SP,@A4=P]A"58_B#8TA9V&'I97+,N)#[7L)2L6/<C<D# U&/[\L/)+
M./**0MC:WH$1=U5T \I[*=ZFD#G/P[U9CI?D#(.O_+, CTI&S-> ]*4*=8@R
M.9*X^)JLHYSE<U)/F<C:T"IN.D1$=CD :FMM0B7%!(Y:/W!S4RE5P@IH'*3C
MR#^Y3O/93/CIK4=%>74MQS7J7ON34\S,UYG5%99C;YFDZ0Y,71] HDKBU1[-
MLOC29%%T!)I+#$U!R1.WM:(^R1R(C;(6,IK3'+R$:XN@ N S"@U:@=5#7M5
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A0*N&O3NXO<I=7M]<5[@IV&'J%SDH']B$ +@+ $%B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g105292g57q01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g57q01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2D\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     $]@  !V0          0                         !
M    =D   $]@                     !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   $]@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !/8     4F
M=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    $.$))300,     !8F     0   *    !K   !X   R*   !
M8* !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,"
M@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,#
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M2P-,D@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!E@)= P$1  (1 0,1 ?_$ !X
M 0 !! ,! 0             !!@<("0($!0,*_\0 A1    4"! ,"!P@("@T5
M"@H+ 0,$!08"!P ($2$Q05$280D3<8&1H? 4%1<85['1X189(E)6F,'3,D)8
MDI.4EM76\20E*#<X4U5BLK?2U-@C)B<S-#4V0T5&1TA4<G1X@I6BMN)D969G
M:'-U=G>X1&.#A8:'B)>DIJBUPCFCM*6GL\7(_\0 '0$!  (# 0$! 0
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M%RXVROSE<;\C5[9ME_N!*&ZVF6O,1E4O!"K9L*2370ASK(KWQ&<0R]ZF&EO
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M^UOY =(<MF9)!EG:I(I6-[E6NRKY<\GN;BWD1S NIA2LRI"-]+K7?3J' N@
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M$,(0PA#"$,(0PA#"$,(1BO:3^B8S<_\ "+$_VMU&$(X92Q_QNWK[LU>90/\
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M+#/ <*CB<#$C5IRU >&^_3@._MWX1 K1U AW[7S ;YXZ1':#<-^F^VXZZ]!
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M,*%F@ ZCH&_'?41#NU\N_7337AOA FE;PPSKO:F3 Y.21C2([6^P"/7[H1
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MZL :*?%]1W#F6AVN&H#OKMOKKMMIW[:#\V^$1K55*O>R<U< [Z8TW-$@.PZ
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MAOCQ&GP?5OS)"DFUR[LWHO;<% ZV>-;YM<9;;1$X-T5LA+76<0ZWB%CMO;*
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M>TQ"=Y(/-41!L=^,7Z39Q[^MTM]X$EZK;/BR!7ARA9>VJUI\+9SYWF,C^86
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M'*[%4.53(BR$7];;;0>(>^YUPB#72BYK))47PB/2I'0H0BSTT0U*PJUBAR!
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M(F)J]V*QI%:Y*B41)53@[N-9=!KF\N%2IU<U "H7K%)XB8.XE*4 )0E*$I
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M6.IPR2E" 0.Q+05+4E /W0I:SB2IR8RVS&6GMS>^RD_MG=EP5,T!?VI.L?9
M@>2(ZX1@R,NB"5,TL;GM66>A;'"+/K&UR%"J<DZML+5-I7OFB6H!4)#O8S[/
M*M,B;9K1+3-DSY4R3.EJ#IF2YJ2B8A0HZ5I40H4<$Q?-EHG2UR9B;\N:A4N8
MER'0M)2H.""'!(=)!&((-8_.IE@(\'];"_D,DM=@;NWWAT[N=#;?V:S89A9&
MUS%["9R^J'IH;-FNPLFB%MT<:@DOD4C;TD$NM$(U+9^II+6O"EIB]M$Z%V3?
M.=A]).@5DZ33>AVPY4J7M679U3.LLMF$VRJZDS1/LJ+8A4Q4J?9NI6N>B8)4
MLE0"5S)JE)'$V=L_8&R;09&S[)(L]HGJ)*T2U*FK4)8609R@J966ZG4H!7;+
MJ))-S_"I7DNI LUD>89#?"YMB8E\';"]9<'BW$Z*A#"ZR92M=4=Q'5T0N#\S
M,%RKDQJ0(XFU&PV>)I-!D%NIBS*T,0=ECS,CT^C^TK;'3?8D[95LZ,2)4_9\
ML3IUOE]2N:N=/EE(19[8!+F*18IDE2YB5R!*G)G2E*5/2$RTK;;VG-V:++,
M4)2S,$R8):ERD*"%*'7J167+( "5E21>O5)8"WD#SOYMVI%2KC6<%-/D%8G"
M2HOO96#.K,G).1M3DT=M_M%%[:>-).;5;P>I4J)8Y5T4M25769XJNJAY^92_
MVX=+MG%2=K]&[%/2FZ4ILGM%FM*[I7+FA29\^8 HS$@!/4 A04D)Q4G0L_24
M36:99)CD]E76RELR2+W:7<*>V%@I*@9:NR 4F,JK>>$FS'-LQMZSWFAE@YG
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M\X0XAR#?OYZZ=?X@'F.[O]>F9O!H0ZZ>7Y^X.&O=IIY,2!AQ9\14ENYP7QA
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MSQA6QF<Q6-S&..)59#C'Y8QM<B9%Z>O:LE:TNZ58@4DU:4]HH\BNBKLTZAL
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MMQY<.&N@CH/#8 XAP$>N$(!Q .6W/F.H]_#B.HCR$.6J$0/3??<1'CKMH'
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MIT#7341LTA)=$B2DYE,M(HS9!Z[ARC*ZE@Q .A&!W,#N]4CTB1II#[D I =
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M\!'"$-!Z<_,(:ZAMOH'DWWX#J.$(Q[LEK\8[-MKL/NJQG?\ ['*G%*_O'N^
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M77V] ^W73= JEC )(_RC7>DGGKGB6E777T<AVTV'ZATT[T N6&9@0<;H!W8
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M;$9L,3F1#M#U'TX1 EI<X< !3F^7&M'H\.U5U'T_7A H2,DCC4Z9=QH#5ZL
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MCCA$70S-3UZW90WY;?QZ_DP@$@8#T[Q.H]1]@T^;;R80NCT3PUTIPI$:CY=
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MUT6BV;.:S3!-1?2A<R4$]1- OJ)%P+92BA:)B@L<:U;!L4Z\9:39U*![4E@
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M63-T&;&B?6OB-QK.-9R]S!$[M%O"+J,@.13&ROLN<'-(\)&5"[KFVIH/P=N
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M,2]*N2G-[J4F(H-,%4C-))5(5)5&2;I#DMHWZ</AC&:5!6!XX]V(&/TQ$7O
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M57+.;4\]C<6.DX*8,7"TL:EZEY0QJ=K9R?)R88C8GI<PN"5N<:WZN++5/N1
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M_60O*B=9NX,HC]P'F=7R1S]D5,WP?>[K5PN6,CD@G'NE26O0)[;&2Z/7$2%
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MW>ZZ6VMQI:$B6E72VT."PAM+."HMO3J34Z*@A./BL2R'Q-<<3KNH.>)H,8L
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M D243)Q2F+ZVU>W>5PZ.R)^CJB)N[PVIEZ^-JE)2Q4T'J"J311J%)--!1AI
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M#U8D"CYL3AH ?H3FYJ:.C%G+R&ETL[>GZJ-AV_\ L@93_-[>?$##_P @W&O
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M1*0G8$W9J$J5M&Q;0/6)6@*";(29R57;P5^A?V"';6U=H6_]GMOV8.D/[/\
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MO8_[3AT9E2;5:9]HLDU5IEV+V0O.MHGS%-*LZK'*2HJ$Y 3/$HI*.K(F$)+
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M4AJ)T.9C!$?*-6NFNVH8]#*(NRW8"Y+)R (ECN K7*/IMFF 6>S)>@L\L8J
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M78@;4[52!KA-V)U$&Y_$*0J>T,9=:F5&[U!1772%3H0B*6B%-==("HTIJJ
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M(.)2 H]VK**/&J?<J4ZI,E/.HI*JXVW+8=G;.M=L38+3M7V=(7[%8Y:)EHM
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M#WEIYE?]'7;ST^VP>2;R=/\ >FGAZWP]H&[U_P"42++3_2O)]SIUUX4\/GQ
M6,TG$_SI\O(:8P]H&H]?^41[RT\/%;#QVW[N77O^?$WPQHSM_,#\&!XG#QA[
M0,KN6/C@=./",$V=/[ES^7(* - &U=BZQ#30=17W9IWY#^A$== 'EUQN2B]F
MMAQ8T/!*:UP;+NCF6A5^>I3U"0.X4:KLSD-EE0D1N(0"/N4G2JH/\3HZ!K]S
MMH&@^VW+'%4 Y< \:Y#T^)SC2&)KGRH(Q=SK&FDY?W<XH::C2KAV',+\9J-(
MUEW\ME51V@ITJ[/: ->R(#IMKN.,I<P2EI60[*2:,'J SEV<4P/P@4=8TMVO
M*2/'D]<]\?;[('0:2QK*2F5#_EE)2@\# '3<:*#TA1%6HZ!]VIH$/NM $0I[
M7=1;[*1VT3);\%@8L2H$4P% ":ELHW%[*M0>Y=7H 0Y/ D4Q^F,<!E DZ"J*
M4)Q$:@&H^G_$@[(4B(4J2*C$M8Z"%0!0?5J B(<*M-^49$^DF;+6K&X.RML
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M09]U:Y*)TLF3+*1,!2E4HW4W%!E+"U)JB^E0+[MG*EK*"$@H>JV#J# AG_E
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MO>(E[_GMLPF5RJ0.-@;TMK.%2MYME$[>SFSDP/0%4^.4IXQ-Y#=RY[ YOY9
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M&+.ZQ.D7/,0D[!+J10NIZ0JDN2M,QCVE2N.KAIUK#8I=CE3$2T@*,TE0%*,
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MOS]I6.8I:KJ )H4% "64**@S]6I*DD)(20E0(I=4Z2H*LDB;("0@S"H-59)
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M<<*,:-X,.0C;2@'5(1]T'^5TZ &N_P!R'  J#F(!S ,<I3 YG%ZX.7TW^L\
MEWH*5)[J?#*HC"OPC2(7/*!<]MI^ZJ<'2U2+0-=?Y*O);\@ XB.HC7IU#S82
MPDJ2%87DX#^M.-1OXD\!%]E9-JLI%?WJ"7R'6(HSUS[A0-CIU26GE485%N4=
M<7IC7D5>,)7,[BL;E95?9&FH:%"(XHZCM4B-%0A4 54#514%5-0TX[4RRR)A
M[<M!WE)2I_Z:N.Y4?4%IE3**0A1/\H":M4O=4].!JYB\D4S!W[MZ84G?CTUP
MF4FJ@*TLC+J3O-!%.H54I9"@+!14?V!'4YX2/5=8TTT_<B-5>-698 !>E3)B
M3DF8L3 =P44WV.3DC/CJ3=GR%OU?85@&SH:$*P UJ<,W?U[Q9JAO$W0RPMJ%
MTC@-P;J+E9<^=Q$E$_VVM.R4IAFDHCKF768D5/+ZJ7-$!B;BB,!:QO4K3R4]
M#3[QU(S_  O3;;ZNBVQK3;52DFV3!U%DEJ;JYDZ:"RC5[LM-Z8M)#FZP91!C
MR/2";-V=9@E"KTV>\M J5)0D.I;,[!Q6IS-UGC/RR\<AUH8O'HY#&E'%F*'L
MZ1LB[0S$%IT;:F3E!26632 C4-0U#4::<8)RA2H,./4&&*#33:_SKT9VW9;-
M;K;MK:TZ9:-H-,4@+[8FS%@N9BE-]TD!+)(8    -X:RKE@3%3)A5,(*6(!2
MJM27(8@X$.*8N8HB_MW6P8L\H5!I02I4G45)$= @%;T;514()T= "(>^50 -
M5"*D>TLJ$2T8>/&A-5Y3:A7MV?.FV= %KG35S%R +PGA1%T2"3V6Q,HDXFZ0
MQ!XNTI:ITLHE)!J& 8%0O.0 U2F@O.!=K0@/KDR3YI4MH[+*6-1'XZK1M<VN
M9<:1/TON4Q6W0-T,NYF?OBV6_;8:MD3>I9)&_2'[")W)D3&ZO4(8"6M$WC5)
M@4OB:BC]V]$K-:['T2Z.6.UWA/LVR+*B:%EF+F4E*G([20FZ5,]$AJT[MC>5
M(E)4"2F6D*).Z@J'<L7<BKN2T9FN7A&6Z/N,M1UP6'')XW<F06W%Z.N\I2L<
M=<([F%^+_6;=Y>5:]95;!=(57CIM$65O3SU0]QMJD &GMQ[3VUF]-F, 2E5T
MD@*(#4"KS]IB'04I+]K%@(V3,HS?S$4.#*8$LDL^37N),5LP^$C95:1&\5VP
M/2,IUD7F[R9<?*WNLZ5N;5&+NRY)!K85I;:*([-5\@8+1K)&P*'.40Y_<8D_
M)) 1"ZC6IX:4VG,5>#T8LPHZG>HJ#=P)!2^1(^]%97@R<LR'.G$X4Y"-B67*
M\?PTP F9&-K.Q.!+T]1]YCS0^/K]4P.K(L]SG-;L9)X1;J0-KS214F5J6IUB
M+8>F(6)3R*UR%4D<%.BL4R+5Q&!PS.[OIN@DDUKI7=R&Z@&&>66#2?KV>@Z>
M@0 !^L--?)RT)R6+\^\DAM?6^*5!CP/Z8\=>]HJ/%,(80AA"-".681#,CFRT
M$/Z*R_?'?A<!WX>G'H4!]DV<Z*G][S5#Y?".I9S_ -.D<1_O6?/UCM*H#6D/
MN@X!L&OY!#RZB&N- W7..3,>_3*@;NK%MT&MT*<5+$O4BO)^X;XQAS%5]F3Y
M7:MNR&99B$1';C:>\8>33U\^.V,I0_>RQ@;Y!P."3ES$46C[H! 8K! !RWE@
M00_ 5K&1M)NH!V>SQ'A2  &XU".NVNHB(C_7"(CQUQTKH;/B]:XXTX^%8UC0
MEZ.!1L:A@P=B:<@\:W,_Z"Y!KMEZD)2>-/%DHW=6-)93%C)"^-DJ<[H39\;H
M7;>5U-)$2=X_(8K;4IX?9'2QN3^QJ#I<JCTF3'$KH4UTKZ)R5$I8.DFI#.,
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M4:N[4NC$#O:Z&SUWG$:3O,<2L3756<ADZY\(K;T=:4FNNK%1"7H7NO6F;/N
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MV';S;\>'HQZ&6/\ ^TR#OG#_ .LO/Z?7JV<?].E3BI-/_)>'H1M'H$>R <=
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M@4)B3*ZC.QXDK6C?0VFNRV9*926M,]-2$@$!0#YD(2 076L@  NK,624*31
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MM5R..>O>SZYZQ6<#P,=7+>UU59=<O]?Z6JQ]I:@$-=]8!'A#N#Y\5H5V *L
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M7@5SB%.D*EK!9'9%U\PPHJN/#*L8_3OP->=C-,8T*KWS[++E^50:"HHI&G"
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M=DV.>#6TB4;0M2E-VD2UHNW@?YUETDT%(Y%DZ&RTK25>SW4&IN7IAP+H"PE
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ML;$GK$0H2(532B>W1Q)I$1"DUV5*:$IIU(@)A+8G(UTI,IJ]_8)296S9*D@
MV@K7,6SJ4KK3+1+)%60$!5W!U$D9B^RH':61VD !-'*00ZCB]7.&ZCB+CTW>
M16E:5Y"U46#^^IJ"UL62IS"T[0G.0H3T:NHA4L6DJ"U04G"<-"@*:*CA,H3E
MC7V:=0;+5M.9+4A!,B0HE%I40535!:PM(4A$LI*7#.EV#%1 <U3!>62JI!]
MOZX1BRS/KC,I8B7**VHE)54KK.,2-B9 30D$JBK0D$])?C*R_%%UU&F5&55C
M354.M50B/I9LE%DLRT)$TK%T)"IBIA*W-57G8*)(8  $M3",:'!FW#2H:M0.
M^O Q?=P?%<471*6M05.#S$79(^T]DNBBE[:0H/1/S)08%=%)2E<RK58)0KJ
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MF>YT:B!1NHHJJHU3(%)Y8T*/H5@Z6 @)M,M!H*R@%)O70'59UK2F][ZY,]*
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M@=>MPY*SCD'4U,J4.0+ 9QUEDDG'%_GSQKY15-W]K5W&'F$'E?#C_G"X8TU
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M@=H\_P!\KB(2WERM/.8ZJJ@JFZKZU-4%9'M%)%"% \VJM81';BG2]SC#ZW7
M8I='4"PF&D(7B;'BA+$X$)Q>E-:8JH,<<-(1R3YC\W%L[Z7>BSDV%S=B?\SE
M"2W34[VPNBH/E5MG63VHMZOAMN7YNF2R*PH;*0=>]7GE\E=6-0SW$*.<JVUH
M9#$$I?6ZLM1J,'PKAG09M7>^X/7UBYS[*LX5VK<Y#',*:([.KOL#W<"]L?@T
M@F]AXU'B'.UI<O98JZ2!9#+WRIJ61->YIF4U ZH6W[*W]N5GFUQ\*BF4@&K3
M#@=1AG5N&_.&&#!N XQ80^_^=^3QN[,!8X;?%AF^9":Q:;Y4Y0:QVW*<H3:%
MXDDS42IN;U#DY)XM#SHS92VT6D1+?>U9'995<F[:YLK0*A*;&D((;NQW_/4/
MPPS?+X^O Q>RV=_,W-R9"Q2-? UL*@4COSET02=I>7![33:WZ.09>+=/-T[=
MH8H%M%+&^PYGNFKDK:]S<RX**LAUH=2T)%:9(D+51$QC'X-VG2US:(@&ZR0<
M@X?9([:!UZ#Y]=^./23Z6*R# FS23H7NG+P\0T=E'^'E:,*_^('A&T?&D&8&
MF7TUUI7. *LG8:8:_.&)B74!5QQ\X:CUX\<&&F&$'5J=>?JGA$ZCU'$,-/0P
M@ZJ?>KAC7SB-1ZXEAI$.K4UX^$,*;O7H1+J_J\=_D>6Z/ RPC_DX9K>Y?94/
M_P @K,<VT?Q5?^/_ !!^<<RTOURW=^SC_E3%J;(B'CKZ!L _&BS#\0'</A,>
M]N [>??<.HXV+.#U;L6<X?$5J<A3X-'1LO\ AY?_ )_\U1? !#F([Z;[\--^
M6W -^([<..+R-!@]&S>AWBII@'J^$;$3V@]8[#ORY[#Q\XZB/+77%CD[L'(!
M%7?&F P=@P&;,AV@ZZAKOJ Z_-P\V_=Q%=.A! HV%/GW\W A#M4\Q$=AY#ST
MUWT#CR\_D RA@&<CP<BE<,\2:8EW0&JG4-PVWU[(]^P!IN//CQ#73AK(!#T5
M6C/P&/<V&&%'(0[0:;#YA#B ;:;;:<=AX\M.(+IQ9P:N#K5ZU?"HKN-048E.
M5WWK+M?NZTX<;'W?N9$YY:VR;(U/=L:[2*"43S!)-?5;(&QU13V[%OW<D^A'
M-XZJ2*$3<X-ZBA4<6"R@]*<30ZJ9-F=E+FK.H 84J6&68&N1C0M,F9,F"X'+
M-CJU*G?N&/".W]M B]'W-64W-T TCH/\J,NW'C^J.W#O#8<6^P6PT$I/=-EF
MFC7_ !R&$4&QS_='YAEB]<1GC',/"CQ?;7*=F\VY^]67<>_]4@'$=PXB [[:
M8Q^R[77]RG\\H>%[1Z;XCV2?[H_,G?O]/'V#PI<5I$-,IF;T XB%+3EV#70-
M-Q^,@'=MW  "&FU9V7; [H#Y?O)6NE_C5\R^<3['/9PD'' Z1S^VG10!_H2<
MWO\ S3EVWY:#IF/[QVUX;XC[+M=>PG_4E<:/,[OH\!8Y^:6?"H.1;/-F&^/J
M'A4(F&FN4G-[KKO_ "JRZ] WWS'#L'G\G/$_9-L_#'YY?]\0;'/8LD?F'.A^
M<?0/"IQ,-_BDYO!'_P!%9=>>@<\QPZ>;\@8?9-M_#'^I+_OX>L8]CGO5*2^0
M(&;U+L<6WUU+TF7X1NTQ4X4W)IR79MZIPJC">%UR$U%E_/5$Q=,YG/0,J D_
M,L:C;$BIU-I7.8MR9*<[GHVNIU-6@T-0(X^R;=^$G_4E_P!T3['/]T8G^9._
M?OBK_MJT2#AE'S>\_P#4O+KMSTWS&]=P[_/A]DV[\)/^I+U_S=_#?2'L<\?R
MC\PKO9\^&D/MJ\2_4BYO>O\ G7ET](_S1VFHZCN._'$?9-N_!'^K*_OA[)/]
MT?F3Z^<3]M6B/ZD?-YKOKJU9=?G^,;B?LFW?A)_U)?\ =#V2?[H_,GSB?MJ\
M2_4CYO/^:LNO+A_MC>6'V3;OPT_ZDO\ NA[)/]T?F'GZ[X?;5XD'#*/F\#G_
M )UY=>/7^B-P^R;=^&G_ %)?]T/9)_NC\R?.,8,W^<KXUUE@LK"LM.8Z*O;Y
M=6PTC&0SI+9)'%FIHM[>Z 7 D2IR/C5[I0^"-##&7($9#<Q.!ZE<*9/XLN@V
MH\N^S;-M<F?)FS)8")<Q*E$+26"2"<%<.]J&,Y=FG(F))3=8A3N,' )?OR?2
M,SK+-ZAMAS:F5T"690G+"H*J=PTITX"''4>>O'OVMM:^LG35)J+S@.0:ERX#
M',\=(ZI]<<\,HJFY;>K>;?S1I;RP4+W2*R)N0DC725XY6N:5B5*4)AHT%%]L
MXZFD3#*RRZ '6NH*0UQK $@@#$!A0AVXYT:I.>L8G [PW.,:+;^$8:[)6DM+
M;.:94,U02."6R@4.>ZFI-ET<6ZMVC,5:65RJ0JR\Q5(GHQ6(CA3'&$D5FD]B
MNHHNJKL!4C9ELF!TRTMOF2Q7O5E'*]CM'N-E50\XJC[;I;_GE1S=_P#,^7KO
M#]44/0>'Y<9_9%N_#1_K2O[XGV*T>Z.?E ?"Z6^V'XJ.;L=_ZCY>N(:;_P!$
M5Q#;OZ8?9%N_#1_K2O[X>Q6CW1S\2\2/A<[?\\J.;O;JSY>O5_-%:\N(?D'#
M[(MWX:/]:5_?$"Q3\DCN(]4IS$1]MTM]^I1S=!Y6?+SSY_T17/7GW]^'V1;O
MPT?ZTK^^'L5H+]D:?>\OH8?;=+??J4<W7F9\O7+R9B>\=_+A]D6[\-'^M*_O
MB?8I^:1SX-XX?I#[;I;[A\5'-UT_SGR]>3]45OR#;Y@P^R+=^&C_ %I7]\/8
MK1[HXOAQ@/A<[?!_M4,W6X\/>;+UJ(^3XQ.NH]_7OP^R+=^&C_6E?WP]BGL]
MT$<8IB9^%!LW<**OT(E^3_-X[Q:3MI[._-/N.Q3>6Z-2L I6-QZAKS*(EON-
M83VDZY.4IH*6(S3D:JDU*H/),?9%N_#1_K2O[HCV*?[HI_5Q'I_B(J!-X6NV
MR-,0B292LVJ9(D(*2IDJ=BR[DITZ<@NDH@@@DO,126422712666733071333
M32%( &'V1;OPT?ZTK^^)]BM'NCG](^_VW.WPZZ94,W8CH/\ J-EZU$!_^T3S
MV\N'V/;V?JD-_P"K*_NB#8YX_E'YO"'VW.WW'XJ.;O;7?WFR];<Q_P!L3SYZ
M>7D.C[(MWX:/]:5_?$^Q3_='/UG3C#[;I;\ T#*AF[#3E[SY>@T#R#F*#;Z0
MYCB#LFW#_MHKI-EG_P"Z(]CGY)!X*'K*,0&VXZ[,AG-F5]6FV5Q+<1)TMY::
M$MS?<HN%D/ZQRARZXBYW6EIH/-9RW%-@42EL)3&*W-.L//I5_P A4$E4''=6
MQR9MCLD^7. 2I:[P2%!3@)37LE6:6R/&-ZRRER4K"P 2K5P0S<W?]!&UEO\
MN49(#M]Q2 >BGIH/+0=.', Y\TU.'$9C$;QFX?*KG+8]<XL7F::9"[6G54Q6
M/.$L>&B;6DEQ<;9U+*E=WA#!KN06:/*)J.DCNP,5+D8S,#@* MU>FQ&>JI*(
M,6D>-"L(4"I"T@54V.8-*%Z.,2[.,JF*IH>6H)#J46/=1AAG33"/#=O"4LC,
MK,1KLI>;:DXNJJFH"V[+D< U4CH.E969&N@?UWSX(L%JF!TRP1_ZDO\ O]=X
MC5ZF:">P:DL"H5:CYMWEN0;RQ\*!&!#;*9F[U[VG+KZM,QX\>NH;XS^S+;^$
M/]27_?$"1,.*,,KR7\S49D#2D=8SPG;#6%04Y4,W5 5!OHU9>*=0TTU'LYCQ
MX;Z<0]8X?9EKH\H?GE4X=OA%HE*S0[%PZDG##G1_EA'F&^$O8Q[7B\JF;FD:
MM>T/O9EZI$>T(#5VA#,: B(U  U=1W'< TR&SK6&>2#B'ZR7@[BE\UY18 H?
M]IZBH4@X'"I&&'RQCR3O"/,IE.@94\V@[ZZ"UY>M!J'34=/C&#YQ'R^3(6"U
M5_=#7^+*-.]=.&$67E#_ +9K_4GGCSSCK%>$?94RLA2JRK9M_<Q-=1U5!+7E
M],,/4=JD2::J:<Q8?XE08'NBNH1U$THH=NR/:A>SK8H "2 !BRY51A7M[ZTX
M,<<)EY0NIEEMZD<,C\L*:@TS"\\MB[>R"3RN&Y(<V+)(YC4(R!V):[&JU:@@
M7M]DHMJ$7#,PM+9&,)'*)+(/L?82VUC]_) \NP-_O@Y*U!M7V;:PSR  2W\2
M2W>R]U>$:PLZP21+J147DMD3GD1G3%M_:EN?2W=RV=WCD[R<YKY%$GQ014Z1
MU>W6$I;G1(C5I5*9 Z)B<R:6EP;CP1)275J5^.:GI("AM=4:UK5*$A]HV=:V
M8RO_ *DK6M>LP/=2*U6:<S"6JKO48D[N^CXT81>=#X4N*)2PHJRDYO:Q#AHU
MY=0 .>H".8\1W'?378=^.*E[+MJBXE)%!_W)>0_S.V[AC5J_8K1CU9IC7&AR
M.>\5RCT/MJ\2_4CYO._^5677?EJ/\T;OMUWQA]DV[\)/^I+_ +H>Q3V^Y3<6
MW4%#RB?MJ\3#AE'S>?\ ->77_"-P^R;=^&G_ %)?]T3[':/P]^(]=V,/MK$3
M_4D9O/\ FO+K_A&X?9-N_#3_ *DO^Z'L=H_#/,0^VL1+]21F]WZ-674=_P 8
MWUX?9-N/_;3@36;+_NKW1!LD\8H\1ZXZ1B=E-12-_N5>JYKK#I'!T5S;XW6N
M&RQZ651^J1-S#*I@Y.C+2\T1=^D[&2N.0G$GG)T+ZOI( P"S#@,IKHHZ)2N1
M8)5G6D)F KO!TJHM2E.Z20 Y.]@,3CTI"%2Y*4JH15MQ)+]SGG&S^@0"B@/N
M=>S2&X<- T'\F^^_=PT2Y)^\ 'P..C>-,N.-L8V9C*Y$TFV5G3!"I+<$NV=Z
M6:;/\;AZB*)Y*HCY<#N)&E*IJIFTHAL?5')%TF;#3TRB0HSZDGNDQ-2H-* @
MQ=*PD)2[*=G #U&.#!RW<T46A"IB $AS>!HPSWT;=2K811ZGPC[*WJ#$Y^5#
M-J!M C14%#7EW,IU =P[=&8ZJ@0VX@(@(#QTUQM)LEI4 1*!%&_>(W:JR?/,
M:QJFS3@?N'O*0^']4<:/"7QZG0!RGYM]M0'^5.7?AY?C'".@:\-N0Z;CI!L%
MK+_NL0"W62Z85:]IF^#U,1[/-]S_ ')_NBC63/+9.-3.37$8,A^85CG\T*3$
MRV;-,"RO-\KDQ*2A,6G*?I ES!%.KL670A0TA2N5'TB"%"%7:!&F J#L^UT_
M=4R:8AN+%8#UJ0'UQK'LTUWZLOJ&/P)WOFT7!#PG4: /Z$_-R.P:_P J,N^@
M@&W/,?KV0'@',1WWQ'L%K#O* QQF2P7I3[^)KI$&SSOPSQ< Y.]*/J-V$?:G
MPGT9I  '*?FZ$ ZM&7?3J&@?&0'3GUUYCSQC[!:R_P"[2?NL!-EY'6\-VZ(-
MEGG_ +9&C-B]7I^AXQ]_MH<7 =\IF;OEK_*G+MQ >GQC]= 'AP$-N@8@[.M;
M#]TD.V$R4]>\.]:.VE(Q]DM'X9C[T^%&BH#K\4[-V(Z:"(M&7;@.PZZYD-1#
M?301$ #IOC#[+MF'5#NF2Z;QVJ&'LD_W.9 PXM'TI\*3%:!WREYN]P#<&C+J
M.H< T'XR CH&G,> ;!N.N*MEVPL\L#>9DO\ O KG2!LD[)+]X^1(IO(CZ?;3
MHJ&G\R7F]VZM.77;B.G]$ARJ'APUUQ'V3;/PQ_J2^[^?]8>R3_<+>GY1] \*
ME%0#^A*S?<O]2LNH<N/]$AT#GKZM0?9-M_#'YY?]\1[).QN#FEZ5U?)X^H>%
M6BGZDC-Z&V@?RKRZ]W_E'"'+NQ'V3;?PT_ZDO^Z L<YJHQ;%JG5V[ZF.0>%7
MBNW\R1F]T#C_ "JRZ^0 $?C'#N/'#[)MWX:?]27_ '0%CGA^R*_U)U._?X".
M0>%5B=8A0&4C-[K5L'\JLNO/F/\ -&AMIOB#LJV#[R$)&^8C&FBOEI V2?[C
M\%)+:YX4K&.O@_X;)HG:M@3REC6QUV.*6K5;*XFH#US68Y.:UQH0+3FE<YMA
MBQ,2I+*4BWN*Y&!]-=*=8H+"DVOI6@@2+/*4P7+DRTJ ((%QQ4N7<-QX%AUI
M:2B4A"A4);5PP'#(QL9[0 (>?78>8B(< XAOZ=-=PQH$%B^H P%0&S.!89N6
M=HR ;Q\8XZ@&VX[:AIKMN.FNW$-1X#IW#QQDQ.@R+C'!VW%LZ[P(1/: !#3K
MH'333B.P< X!KMP#;37%B0Q&(/%WP!<XG-JBI>I" C3V@Z;\ATY!IIIT\NO#
M;38Q8XOS.9=^.0(;&KU1.M/ =]>8!P]0;!TWU#7;3;!B32C9'/>*G'6C'-ZP
MAVN>NNP"'+0===!VXZ#IJ&FO 0P(9Z-J6)#$8XY&K5(QR,(\/*_I\-^:W3A[
MOLMI^X%9UQHSWZPOBP^$<BU_QU<$_P#$1:.RHC[HOKH(A_-0YA^>G^R6]XVK
M-_"K7M'?IYQOV7_#R_\ S_YJB]N^G$=]?1L'Y/4&V-CU\^^-B&H]1].##3UZ
M Y0@ CU'TCR#"$-^_G]?Y=<*;LOI\FA#?<-=@VX[?6&WK##>V+/@_?P_2$1A
M"/.<&I$YT#0L)H-I'B%0 (#Y0'80W';V$ET_=)'>?.# /OQBG1@4:$=1;4PC
M_P":H#KT#J/S=^M@FS!0*([R],_B]3KP1'V QK^I:7]CI_N<2)TRO;5S!^(,
M"'UYD?"'V QK^IB7]CI_N?;3 SIF-\CO;.GTX\(1'V QK^IB8/\ Y.C0/^@.
M'73/>)[SHVND(G[ 8U_4Q+^QT_W.'7S??/A!O3F*7E[)$XJS5.ZAM2^+I4IT
MX]HJC34\:P#]*&^M.O0 ]6)GS "RR],5>&.&.-<81U82W1&8MRI>F;$G83+1
M1U#251H%0$%':B.@CP-Y:Z\PX8@3IIQ6=17([J^C"*Q^P&-?U,2_L='J^Y^?
M7&?73/?5S/JOZ0B?L!C7]3$OF+I_N1]N.(ZZ9[ZN\GY-"'V QG^I:7]CI_N<
M.MF>^KG"'V 1K77WL2Z?^;H]>E(B'$.?';#KIF%]7%SYM"'V QK^IB;R>+HW
M_P"CYOKQ/73/>/,^<(^A4%C9-8&%MR>FJD>UJ!-''AKKV===^.W?KSQ,V8<5
MG=5_CF815*=.4E+ HFD***0T *0TT#;;U8P-2YJ:58980CZUT 92-%7"H! ?
M1^3NW'AOKIA$74EZ8Q0[G;R-.QPGK$!!I@\:JRZ:N?>&O#O^NT3IJ00%*&7W
MCWN"^>6%!N:8\OX)8=_4I'^P4?1B?:)WXBN8\H1'P20[^I23]@H#YL/:)WXB
MN8\H0^"6'?U*1_L%'?W>KZ P]HG?B*SS^@P]"$/@DAW]2DG[!3]&)]HG4_>*
MWU%?"D(GX)8=_4I'MK_\'H_(&@]<0;1.SF*WN0WRW;W\$6FE::WT8>U#,H:4
M FIZ$U=0B46 Z*$]!]/37[FL.?3$>USW+*<-D2^6\_##. KA7A6+L!:6'" #
M[U(]PX>(HY^;3\N,O:9I [2JC%\\OTKQU1/P2P[^I2/]@H^C$>T3OQ%<QY0B
M/@DAO]2DG[!1A[1._$5S'E" VDAW]2DG[!2'?T]@P]HG?B*W5'EY0B?@EAW]
M2D?[!1]&'M$[\17,>4(CX)(=_4I)^P4]?;?S8GVF;^(KF*\P:^&Z$>RT0*/,
MQOCD2$DFOK0732.P[;AN'#@ AWAKKBM4R8O%:L-?)OAII"*VI#L@ !L !H'=
MRQA".)A=)M T5AK35L.N@_/W#Z]^6(^/?Z]%LX@ !VSQ]=\4JJA<?5F":>@3
MF5B.HU5%4".NW,0$?K#ATL$Q:<%$#04$3'6^P",_U+2_L5']QR_CUQD)TP%[
MQ?5SYY_HT2Y.9YGSA]@$8_J6D_8J/[G#KYOOGUX\OC$.=5?F5YP^P",?U+2>
M3Q5'I#[CY\09LPXJ/IO5&PK$N=3S,!@$9X>]:7]BHVX[;T>VO' 3IGO'F:[Z
M'N]/"\KWCS,/L C.H#[V)=MP#Q=.GH[/$-1Z>?B,]=,9KQYU[O7A0'-:FN-3
M%OIQ1#H96VEJ6Q'JOH55T:ET:@":HBFK38 T_P 7I]'4-\%3YH-%'F6SIWMK
M$153!%HL^,S<[%-B7Q:].!]&A=&F@UUT:!]SR['I'3EM*;1,(^_ANICE33EN
MAK'L?8#&OZF)>/\ 2Z/1^AX>VN,NNF>\<&Q([Z$5A#[ 8S_4Q+^QT_W/MRWQ
M'73/?5S/GZSI"(^P&-?U-2_L5'J^Y^?7CB>NF>\K\QY&O?3?E2$3]@,:_J6E
MY_Z73_<\OX\1UTP?SJYGU4PB/L!C.W\K$H"'/Q- ^H:0X\_)PQ/73*]M7,T\
M<OU>$>XW,#8UZ^XTQ9(CO]Q2% =^U.@>KR;\:RI1)))+[_7H"$>T(B/Z;CY=
MO5\V,=:?"OC\81\%!!2DNHLZD*Z*@$!"H '4!ZZZ^CT8D4J*'UZWYPBEC8/'
M#JZJS&]-754.HB)- CSUW$!UUUY\,6=:L8*4VA4?DWUSQAA'R^P",!_J8F#C
MP)H\W+B&OFX#KAULRG:4P_J(\,W_ $RB7)Q)YP^P",_U-3_L)?\ <]<.MF/]
MXM4_>5B=SX=^.+FL1#[ (Q_4U-K_ .9+X_K>[#K9CN5$]YW]]./F9<ZF'V 1
MD?\ 4Q-Q#_2J!U'4=/TO=R^L77+JZCFSDEAGNTQ<4Y1$_8#&?ZFI_P!AH[^[
MVT\N),Z:?YSX##>T&X\S%HWYUA++(SX^<V(O'$J4J<>T53KJJ+(,H$=O_CZ=
M/)Y\8&?.R4HC_-Z\'YQ(?$/3,1=P8!&=1#WM3!OK_E5'G#AI^41]>773,U'=
MNR>GSRQB/6/KUPB/L!C/]34_[%1]&),Z95E*W5/KUW0A]@$8_J8FU_\ ,T;B
M'7;7Z.6(ZZ9[ZAWFOZ0<Z^CC (!&1V][4WD\51OW</K'#K9GO$O3$[^=<C"'
MV 1C;5M3:_\ F:/+I^AZAMY?0ZV9C>+T&)H,]3ZY'.L2$!C-(@(-J8!#3_2J
M--0_Y/FX<.6)ZZ8S7CS--&PRRKWPBH6]J1-M 4)":"J>E-/9#RZ<-=/;I6HE
M1)+DDO4[WB&'B^)Q]981Z?:'J/'7<?R_1IB&_6)@ B',>OGZ_3U#;GA"&H]1
M]N[SCMA"(X<!]&$(G77GL'(1]O5B&SS;$ /X_.$-1#F/'O\ IV'TXF$>7E<_
MGV9J^?\ )]EN/_J$LQSK1_%/ ?".1:_XZN"?^(BT=EZP!3?4-/\ ;0YAM]?_
M !EO?+ZP\F-FS#]T-ZE?(?*-^R_X>7_Y_P#-47K\9W?D_)Z\;$;$/&!TPA#Q
MFO+U_EPA#QG=Z_3[?-A")&L.@^P?3Z YX0AVPZ#ZOIPA#Q@=/7Y?JZ_2A#Q@
M=!X>OZ._U80AXP.@\OR=_MW<GU\?7G"'C Z#IKMP'Z//A"'C Z#[>?"$.V'0
M<(1BOG'D%4=LLI<BZQ+$)/'B.T Z:>-K6:^JCVWQBK _#6O$>L*M!P*F*3R/
M2FN3VYE:LRL313S4U, B.NWO$SG:<> >-'7;B.F(1G1B,OG5_ UTP@X.#< ?
MJ8S4\8'(!]OJU]AVSA#Q@=!]@V]>OF]&'KUX0AXP.@X0AXSH ^G3Z<(0 SN]
M?IZ>W3"$/&!T'ESY?EY:<,(0[8=!PA#Q@:ZB ]_I\OEW'#UZPA$>,#I_%[<O
M7A" F=WI'^/"$/&=WK^K"$3XP.@^VOMZ>.$(>,#H/U<>H>C"$/&!T'T[:[?Q
M>CR80C4'FTN(<P7VDK72<)=)""+UA2%6@ !\?;CATU'B/C!UT -^&V*E8XG,
M%\L6%-6<5WD:HV\EF -% @'&BD0WZ@'MSUQ;Z]8PCGXP-.'M]?/R!A"(\8'3
MUZ_D#"$3XSCL/=O\_3UX0AXSN'T_5MMY<(0\8',!]/M[>304(>,#H/?PX=W?
M[;\T(>,#H/J#V]O,A#Q@=/;3\GKYX0AXP.G/KR]OX\(1';[A]O8>OT(1(&!T
M'7?VY>W7"$.V&O =/;;R>?7"$/&!KPV\O\?SX0AXP.GS=WM_&.$(UTY[)F;%
MW&VM!9E17NQ#*:QT'CXA0Q!ZO'>7?%:\11Z9_&A'C3Y.Y^?R(C+#+R["\63M
MPYU#574LCU!M50C^BT6JZ->']9Z@VXXR2*8<.\5\21PA%YA,Z!^3Z<90AXP.
MG'S:>0 VPA#Q@;[#W?7A"'C.X=>''EZ!Z!\WE0AXP.@\NG7?VVU[L(0\8'0>
M'L'D[_5A"'C Y /MW_5A"'C TX#KZO;S80AXP.0:^7;YL(1'C.[I]?U80B1,
M#7@/GX]WE]6$(CQ@=/7[=^$(GQ@=!\G+\N$(=L.@X0C3_?NXQS5F4D+-2=53
M03)8D3V>UH >/:V"NKGS\;KOQ'73@.*CBY&IXU+/H&#"C8/C1&X*NL.U4&@[
M55!YM1]?E'NUVQ;Z]?H(1P\9W?D](:=>/IWPA$^,#I[<_J^<,(0\8'0?;N^O
MYMT(>,[N?7\NGY,(0$SNU\H_4/MY,(0\9W#Z?1[<N_"$/&!T'Z_;GZL(1'C.
M[V]'\?7"$/&=WKPA#QG=Z_;V].$(GQ@=!^CR80AXSNW]'T^W/;"$>?E;'M7L
MS5CU7V7_ .H2W'.M%)IX)^$<BU_QU<$_\1%H+,?YJOK_ ,:',-_;+>\;5F_A
M#BKXQOV7_#R__/\ YJB]6+XV(80AA"&$(80AA"&$(80AA"&$(80AA",&?"'F
M5E9<5]1=0TU!,XGN'03'#4.F@XQ5_+_F9^+O"*$\&8<8=:&=5&5C6/PCG  C
MIP^QB.CIZ1'TX)SXD#@,.[A2$;(<90AA"&$(80AA"&$(80AA"&$(80AA"&$(
M80AA"/S_ .?VM6CS.2JNJJLHE4PPU4GJX4F$T1U"DK,HV^Z %*504(@.U158
M:Z@.*U.YH6!'CBY>@+<-:PC?HWJB5J!$L3UTF)U:1,J3F4B TF$*":#23*1#
M4!IK+KIJ 0$0$! 0V$,6# ?/'OA'<PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(
M0PA#"$:>?"@NE)<EM"WD'A2J(8I:M/*I_14IUK@R$)3*@^],-;U=%(CIJ)56
MXZ:8P550#EB*_+CR85WLC/\ RF%G%Y;K.@HIJI,KAR4_2L!"H2U2I6J(KT$
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MW&6_;_)AB7[(X>O^0/H].%Y.OQA#XW&6_P"6&)?LB_\ O#"\G7XPA\;C+?\
M+#$OV1?_ 'A[>C"\G7XPA\;C+?\ +#$O+XQ?_>'S!Y<+Z=? PA\;C+?\L,2_
M9'#^\,+Z=? ^4(?&XRW_ "PQ(>/^F.'?_P!P!ZN[RX7TZZ>/EGYPA\;C+?\
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M ]?TX0AVQZ!Z_IPA#MCT#U_3A"';'H'K^G"$.V/0/7].$(=L>@>OZ<(0[8]
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M(#4 7>FM1DX+Z"F]\1OB+O:=Z\0!AZSQC]#J%R1N:)(Y-Z@E:@<$Q"U$L3F
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MTQAVPZ#B;G]7A]87/ZAZ[X=L.@XBX/>'KOA='O#Z\X=L.@^W=A<'O"F/IX7
M_P!X4QUY/#MAT'U?3B>K&9\,L\XFX/>\/K#MAS <.KW^'UB+FI&[](=L.@XB
MX/>&_P"&O=X0N#W@_K?K2($VD/7S#S>WSXFYO\/KW<87-^N7Q^>AI6./CR^O
ME\O/VZ[;8=7O\,?&(NCWAZTW?.'CR_OL3U1W_E/G$W1[PW^GAX\O[[#JCO\
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MF'<MR.-<:C$AC@1H^+1O.I.)HIIHI"FBFBD*::: "FBFFD "FFFD  *::0
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M$=H.@?K?^U[>;"$.U3KKISU_0[_V6$(=H/:G_M=XX0B>V'/?_D_]H>6OIPA
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M[_\ L?HPA#4/O_73]&$(:A]_ZZ?HPA#4/O\ UT_1A"&H??\ KI^C"$-0^_\
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MQDR7^_-'!8.&'WI8]914>CNSCB%G*BF(_P!H^(>/C5 <U%6PYR[W^:'Y8 ]
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g105292g59q01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g59q01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3 (4&AO=&]S:&]P(#,N,  X0DE-! 0
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M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     $(@  !V0          0                         !
M    =D   $(@                     !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   $(@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !"(     4F
M=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    $.$))300,     !SQ     0   *    !9   !X   IN   !
MS5 !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B
M!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M    $  /;6  $     TRU(4" @
M                             18W!R=    5     S9&5S8P   80
M!L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   B
MP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M   TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&
M5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M@,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($
M-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M     2<U)'0B!)14,V,3DV-BTR+C$
M                                   %A96B        #S40 !     1
M;,6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M   !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#
MHO+W=W=RYI96,N8V@
M                  9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6
MQT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.3
M8V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                   &1E<V,         +%)E9F5R96YC92!6:65W:6YG($
M-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V
M4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                    !V:65W       3I/X %%\N !#/%  #[<P !!,+
M-<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                */     G-I9R      0U)4(&-U<G8        $
M4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@
M!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .
M4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@
M%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B
M8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#
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M0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,#
MP,# S_P  1" !9 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M[O_)+4ZY_1:O\ CA_U%BQY20V0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@!4P)= P$1  (1 0,1 ?_$ !\   $$ P$! 0$
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M=(G_  ^R?T__ ))AK6@[7K2$_&S7W[^%_DN(_P! Q/LLCX305[:O&M.64/\
M#[+_ $]W\Q>+88^A7=!^-FOOW\+_ "7#_P"@8>R2/A/YE>=,O'C#_#[+_3U!
M_B+QTQYX-!^-BOOW\+_)</\ Z!B/99/P'\RJG=5AWG%MSO8+(/\ R_\ Y9F-
M=^H(_6D<G9;;RVJFU4YAQJ&9R:;*"S9SBIB+1_ C+TPM82E,U*QIJ!9"H>E#
M*KBQA8E@S%RX.JZ="@+AVNX=*K+J:IE2W/99B1BK(D:[HU39)#J%S!2@.VO
M*( ]ZK!@^>,8OZO?:N_A03_F/EY_JGAU4OX?]1\X>RR/Z?\ J7_R@_5[[5O\
M*"?\Q\N_]4\.JE_#XJ\X>RR/Z?\ J7_R@_5[[5O\*"?\Q\N_]4\.JE_#XJ\X
M>RR/Z?\ J7_R@_5[[5O\*"?\Q\N_]4\.JE_#XJ\X>RR/Z?\ J7_R@_5[[5O\
M*"?\Q\N_]4\.JE_#XJ\X>RR/Z?\ J7_R@_5[[5W\*"?\Q\O/]4\.JE_#XJ\X
M>RR/Z?\ J7_R@_5[[5O\*"?\Q\N_]4\.IE_#XGSA[+(_I_ZE_P#*#]7OM6_P
MH)_S'R[_ -4\.JE_#XJ\X>RR/Z?^I?\ R@_5[[5W\*"?\Q\O/]4\.JE_#XGS
MA[+(_I_ZE_\ *#]7OM7?PH)_S'R\_P!4\.JE_#XJ\_*'LLC^G_J7_P H/U>^
MU=_"@G_,?+S_ %3PZJ7\/BKSA[+(_I_ZE_\ *#]7OM6_PH)_S'R[_P!4\.JE
M_#XJ\X>RR/Z?^I?_ "@_5[[5W\*"?\Q\O/\ 5/#JI?P^*O.'LLC^G_J7_P H
M/U>^U;_"@G_,?+O_ %3PZJ7\/BKSA[+(_I_ZE_\ *#]7OM6_PH)_S'R[_P!4
M\.J1\/BK=O\ 3P]ED?T_]2_^4'ZO?:M_A03_ )CY=_ZIX=5+^'Q5YP]ED?T_
M]2_^4'ZO?:M_A03_ )CY=_ZIX=5+^'Q5YP]ED?T_]2_^4'ZO?:M_A03_ )CY
M=_ZIX=5+^'Q5YP]ED?T_]2_^4'ZO?:N_A03_ )CY>?ZIX=5+^'Q5YP]EL_\
M3_U+_P"4'ZO?:N_A03'_ / ?+OR_J3^WUX=5+^%N]7C7Z=T/9;/_ $_]:_\
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MI7#_ .@?'JP]ED5[!H^*E>M?(@B'L%EK_"P_^Y,W[]U=(3\;-??OX7^2X?\
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M7^[F'WXAFW'5Z'>0*/NUSP,,C44I51;'/0[N["% QK6 P@&]O %Q -[AO<;
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M/174<R1E)Z]%04EPQ8L<;H&!(^]@,-'B?:$F\"E8( )!+L#< =E''K!0%\B
M6=JJ?:T3/DC6V:U*4G/Q4M2N9^7663ZFJUAE)>IV+JO,R<MZ-5D9;+O+^8G*
M[+)L8NODYUCE^^9PM=SCMDU9,X8K:8AY)^,T&62E+75)2 7+/1V#EF-!CIA
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MNK!4LN2DM>(*B36ER@H?AU&/!M5IW,YW3[&%9?,45(A KLGC%1VM)I&%]#5
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M '4[OQ;M_P W/QWY4?\ #F!_Y4 ?47 398^_*W_Q4\S4_,F M4G^K*_]U/\
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MJSU,2B3:4I:8JB-<EKB2IF79Q\[!O*H6CJBC8V?0DV+="+J80C@CL3 'X*U
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MU;,'OPQ<,:C",:TE1!#9 ZL"],BX=C0I-0<HD>/S:HFEJF7" IE-:#B9E/\
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M))=GI= 9B(B5I F/P((]X@&F@!SO?[>_B%J8,,,P7=R0*8$T&);!\HS!(!P
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MA!A"#"$'L^/=\6XX0@^/@+>["$6IR;_:@?\ QN]_S+3'*MO\X?V)^:HXEO\
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MHY1_95(N0RSGH5"14*<JH(DFF^9TVK#$,J1)071X*H%$C)E,""ARE$OE+/\
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M]%(8V@ /Q]_WX@K8.5,!J8%1%2H@;S&21H<UKWU#EY_IQ@5:Y:<5'/,X#/\
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MX8$,YYT)I$53OR=.74JFHI1M<UG23D0,+1I*&CZO@D#F'_KZ3Y%A4SHI;_1
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M@Q-7$4>VE-GFJJRSDI>>AI>7>MZG6:LHMP]?NW9:-?L%5'SU./,JJ*D=%()
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MSJOMIRCMOE73K@!,:!0S)I0]5 41%+YM[&4"'%>P_P!;"LS4L8F@[KD$!L
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M:-G(%[5$AP^+=%_LX.QNGEOZ2J2%6>T6K;$^3)7+E]3*]MG39LDRTW $&4%
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MJ<\2,.8?PBENTDEL:4A-/*@K'+?*NLL[9KYN>*4I!4O\]YF5JR=O64#\YUW
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M_-%;O'B GMV#IRD(::=FJ<EK7#\VUKV[K<+4-7^>OSUIAF](R#T[_K#4K/D
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M/,/?A"#<-T\P]^$(LSE, A2I@']]'G^;;8Y]I_F_Y1]8Y5M_G#^Q/S5$#SY
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M"DZ<HJG$7KI5^\1@:5AV<%#I.GRXBL[<)Q[!N1=TJ(J+G*=0UC&&WWA:;I
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MK-/M=IFIDS9QEV>SRU39RQ*D2YDZ;<0DF[*EJ668)BP07[1N@8J4P2D9DJ8
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ME=UL9@2&"KSJND!0! 6+P(%\YB-1<MUVSE!-=LX2.@X;KID60715*)5$54E
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M 4+C<0TN-PXAQ-K65<O9NT5E =%AM:P6^&SS2#GHXY81S9^SPE"UW2&0M35
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MUB&WGGO?ANX4A=PO3S'OZ?=[,.9RRW5R\*8YP(WD-H?3^)C\R>: @&<&>@7
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M16ZK0\H02 -M MP'4>\.(^P>?( P"&S)]9XO\HD))R]>O"/$Z%P'PX=U_
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M[,.H\.H>X;> X5]?OI3C6%?1Y9?MO@W ZC\>K$5U'+]=?+?"N?S?Z"$[/O\
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MH$ 1MNWQ\WZ.]/K+M_I!:]ARUH*[*FVDM10%DGIE%R#2JN=(Y%DVHFU6I5F
MJD3'+? 0,=^/ QMM/0,K4#Y&*A(YU)R*R3I=)FS2%9<R#%JL^>+ 4O!)LT;K
MN5U!$")()**&$I2&''T? .2!@Y.\E@[;S^[1V 0D7E$)2X#EL26&=#H^;,"6
MC=F^6=>+/7<:G2$[Z:P;-'KMNI&N$CHLWYE",G@BJ0A#-'ATE0:N2&,@X%-0
M$3G$AK"I.HJXQ%6.'=2A)--U*F8G&^FI8&\ [98U(SJ2(8%J6J#LJ@6"%?F1
MI4Z*=2+$:JG1A#N'OS:@625( I->W??T(CVIB]JN D)O"!K'&HJ*;\Z;]^(#
M\(L%)<!2AV@R0X=6=-6#FCD##*-'>DWBC?Z0 %B@(\ X6U'2W"VFE@M8 Q56
MA.+'R[BP8"IJQT$,2-(TB13T/< O8=/#R&^O'[<6%4C$MF=_?1V?>]<!$1&T
MNF%C?1X;W/G81M;U<O 0X8D8'#CH''K#AB81&SH0(J8 #F-@]>G+[?#$LY<]
M^56=N)9N..]&+V@WX!P_3\6YAK@PQ\3OPHW-B<#NA!V@] \\"!CNJ'#]S!N=
M=PA!OCT#S]^ N[^8^H'TA!V@] ^.'/!A2A#YN/+GICHZ#M!UT =?4'7Q]_D(
M%,J/B[Z94/TTA!V@] X=_P ?'*^(ID#S& ;&GZ<80=H-KZ>/+OYXEA@<='_3
M1J-5Z5#0CM5\F64#;-KX=0OFYFD B'_G":]]!OSN%[Z!T'!!(O76:^<37+AJ
M/,QB=0)89G /7E'0OLPN%P-;GW!PL-@#7F/B VY#:\K\/,>?RIEE1>7IS!^G
MC'SV8<M[OTMS\]?#6V)=6B3WC1]='\<H.O0\OT@[,!_.#32VM^GM[O9@ZAH:
MFKAANR]&M8.O0\OTC(02#> P /2X\/&XAK?3D'< 88@WF+58&HQI3P\8.JA(
MPW9Y8YOIW-&QM$ N&FHV[Q^OEIRO8>.F,2CF?H/TU.^(<L]"36II7##O%26#
MAJUXN?*!JUR&T/0?SA3C=1K&1,/^+]:+!ZX/5:!YX[LS)RD(*;DTUFSJ1:[%
MD*ASH*QSPJ:?SB@F%11R2'ST%*;\-^K0O-7-\<*>#CB2*,!'=JC/PA<4Y!.J
MO91T;5#J*9N*@C8A=1U&1LJN@FJ]CV3I8QU':#%<YFI7@F KKL?24TTTU 3)
MB)<^ X91K$TT'EK@#Q9XW=%(!$!$-1]0!ST#6W4;6MX\:DL/E0GY10D@.6!J
MP8]PQ\O"'A%$"AO" 7$->M]/LTZ^R^,))./KUSUC$5$FO[#U^](R "W=W>_P
M\<1%"H#>=/6$+A%"LY4];X,(JYU/,P80O*&9^?S@PBX7@#S]81Y'3 Y;6MST
MMY>'+2WKX(R.00?3_K^E7AI71L(EMJ Z6^O3O +];8RI4]#C\_7ZZME2HFCU
M[J]U,J8C7@TN$MX#7#0+\^?4 '3KISMRYWBR3S!8\<VS:-:=H )3!T"X" V\
M>7'7CTYABX)]X8NQ&NA;4U[^^,J5,1BSL'#Z-RS& [Z:@[1"YKAS'X]7'CTZ
MCC('S]>N3X4:,^-#E2E3CN?, 9.X?*-9<I\0L-@N.G'NOSY".,H9@:.^)+88
M\7!8\\H.<AAWMB #GKNKE&!V9>6\//U:W'0--?'QY#+KT&F.>F,+R]#Q;UQ_
M2 $PZ&'3] \/N'"\K-AWC'0U]%LG@Z]#R_2%!,O0PAI?[0#0-=0]G$;X@E>@
M'>.>,+R]">[RA.S +W 1\>7CH'P(8.LY#N(\SI\^Z;R]">(\FBPV6 ;M-&#7
M^R3J]^/];;_9C2M!)F.?A&&&)CF6LDS:XW!DV9B%IJ_SS+W_ 'TD._\ NM8<
M;DM*3+06?LI>IK3*K8]WSC=E@]7+H:H0=<4B&S%[J1EKF?/]HNQT/(P874Z#
M/,X\]QI^L&.AY&"P],+J=/$^<&.AY&"P],+J=/$^<&.AY&(LS#S=IO+6:H2
MFF,T_DLPY9S$0242$$0I5&*T2D]4.,[/01Y9XB69:NFU*4FG4M?33!O,25.T
MC,,*>J!S%XUJ0@I!2[O5V;+OJU.6<54;I (+J+"AW#YD #$O0&K:3,;66SO"
M-W:Z^:5//3-*:)5QFT+Z=..EX%Q1D=F#'/&J,4T=BN::I.9@Y."0(/;S1Y^!
MCXQ-S)348T="N4,\GST?-O'.FK05)&*A@_=KKPUANIS; R J*(E9<U<(T\2(
M>K-7,;4[)Y#SJJ";J52))-(-1)23<,A8PTC.OR$;>GTW -7,M5K& ;-'AF\=
M9*8DT8@-5V- 6&5.[.L+Z<RV&-,<,=<=PJ6C9)#:4R8C73M)Q6T8=G'KU4PD
M9-NH5PW;R]'U11]&2T0T9)&--S[D*EK1A$%>4S%3<.UD8Z9CI23CY%D1HNOR
MG(%0'!(?$-3%R[Y#(Q%]-:BCN>#<\<G&-8G0AR*$*HF<BB9RE.11,Q3IG(8
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MJ(P85:C8DG0Z 9G1ZQF)<DZO&CR2@%*;01L Z ( (V#D)M '3GH&E]+B%@&
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M*ESI0ESY2W94J8$3$$$@RYDJ8QE3D8*DS52Y@H;I2M!5L%&U&A/1;:310<-
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MU@WX4^O\L(!QX"(VOR$;Z7'6_41XZ#?72P8DD5(QW@;A1CDV%:;G@WX4^O\
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M+\O#GWXQQ6/O",2D'$8:9_K\X,(I!A"#"#$X!X,(R!!SY:QYG.!0O8+]]K^
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MTZ\]./+KSUOPOYX,:Z9.<,],J-BWA"^G-.NF?GG!IPN-NEM/\K$UQ8/J]?\
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M#?6AQUJVD*_ .8\H.T'\X_EA>'PCQ]9[LM!"OP#F/*#M!ZF]H=W=X_?R. <
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M";=HU1('Y"3=!--)(O I"@ =_12E*$H0A*4(0D)0A*0E*4I%U*4I 8  70D
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MTMQ'AT"W*_'NUUX8[X#$5;/5N/EB[#$QFKZ^8Q\8C>6D@$3!?CW]XATXW^H
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MJ#Z]91ZNA-*<::^JG-JXPY)N"CK?B-@M>PZ!Q"_?B(J15\P_#2HC+*OPU ?
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MOI_W=,1TY  &]E\&^6&>['+.CT\#:ZL^7.O/ ;WAO5EV8 -W2(WM8.U3[[
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MD$!171,<BA1 Q#& 0$?RBJU;:EH5LZ8B<A4M1EJE*1,2M*@2"E4M5UE)(-%
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M %++0!Y G.[.2(!T "I9@)@'0 MPQO)ZI "0#NODK.GO+4H[L:QGO2!]QGJ
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M3MH$4+$)M,^8@$9* "JXQLU-[&WRM=!2!I2@LFZPRY?GW>V<9?YFY045Z4!
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MW-VNW"\;C;3X'333WCA=&IYYAJ\0T&1FSY#-B6;W6S/'!H7LPZCW_;R]?Q?
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M%01$&\%'IHTVV( B5)O#))%T);&IMRS(LFTY\A "6EV2:M*0 $3;18[/:)R
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M'K]WSX4A=WX;DY8-H-T=>/DF&+5_/YYE<D$_91F6PD#Z-@%1[6X&XA8+@F4
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M[LN$05 5KDU,7]9P;@]0\_=WX7=3GIDV-6H]/UI$ON/AOICNX-B8-P>[PO@
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MP:]W$QKSK;9GTC;J>253%L([_;NW1# /  L6&L%^-AL-_;B?9AG,!X?J8L+
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MRAY:#S[O'CKA!TZ'#A6N%3NQ?Z$[<=?RM./&P=_7K?XN@Z=/G_RH=<1H\'I
MZ?E=^HZ6X\]/K"P]0P@XT'CW?>YZ;X_3-\D&!E-CAB8"F$!S8S<O8!'7\+W=
MO7>W6WLQAJZMRBQ<#(/QSX1C<7E@D>\P&0%U-*US:NF K'4+L5 #^MFZZE$>
M/'OUYWN(<],2Y?B&':;A@0*848&N;Q+IU',0O9'X=F;3ENCI>_*W/7X'$=JI
M\7&5-6+.*ZZ&#C4<Q'R8NX4QCE$ *%["%K]=!#7D.,B I2@ ,2P )Q( R=P&
MSS)SC#/FIE(5,) "022XRWBN?+2L4HSFVEZG@,P([)K)7+*6SES<D(HU0/:=
MCY>.IR#I6FP6,V3G*MJB7$(R(0>.2*-XULK_ $2_6()$BE,HW!;TAD[*V18Y
M5MVS/ZI,\W9$I*"N=.(<J*$@*4$I8I*PE0"@ I@ZD_*+9T@V[MS:=IV7T<D2
MYBK&/^]VN<LHL]G)*2F71NLGE"Q-,HS)*1*4A1G!4R5+FZ?1^U)F!!UE2- ;
M2&3DQDE4&81#_@'*GJ.#K.BZH?)I X4@DJDI]51"+J1-$04)#2B2"[DH@+=0
MYE42*39CL';R9PV/:%+M$A!6JSS):Y:S+8GK$&8A"EI+.3<3<!0E7;4$QKG;
M/2GHU/LQZ16:2+%:9B9(MMGGA2)<U:D(1+M$HKF"3UDR8F7*,NT6@K7>*Q+0
MRU7.!T59,%"B(@8 ,&NEAUXAU /$0[^/#7)5*FJ0H>Z2#AP<@O6F_E'URQ6E
M%JD2YJ&(4@%WU8Y 4:GRC&45 +Z!Z^(!?NX>%A[QM;%:TQ>H#8$MF^+=U7I&
M\2!@ >(&#X9-KF=6:,!1>]^7(> >=O?XCB0'KWC2N>.? :L*O8#-03RX?)M_
M%HQ#*@'&X\N?N'UXM\_&G[^,6CP%P <[> 7^T?LQ#[CE3C]?185A'SZ3W^7_
M .KB3Z]./G".2.W3F$:FMI/)"(!10"R4+2BFZ6X (K9@2[76P\P)80Z:B'/&
M-6-6!8-B7J:' -W=\(Z\$5#U=+Z>/#34.GE?&2$9J2_4-;<>.GB'U\]-!'%6
M(9CW"FKL[@\#AD1%""'+)(S&X?5N[=JX)J /#0; '3SL-AMP$./ ;:8@G%P2
M'PX<@:T(+X''$0X4&H":#TV+!@1CFU!&>DKZ@Y@/3V7L/AI]>-22*C/ ZXL#
M^GG%"*UIINQJQJV._P"1>VRU[7OIUY\>[2]A]_ ,4(S KED035]"*\^):#44
M;D[CGZX,SF4F^%REN ]"W$.X=./337@&*"]O-,S3>7I2F1RQRB'#5(!Y>OGK
M'WV1_P#<S  <?HZ<+]/7IW>M7<2<.T-&R(?#Z%X.G4<QKSSX#=!V1Q'\@U^7
MT=>NEPXA>]L!> HS?W#7<=S<X.G4<Q"=D?AV9N !^2/>''R[AOA73?CO=\6.
M1+O1C05@X^(<QZ]9PH)'_P!S-_[(AP]7+RT[L07&9I^)ZX9&A_7)X.G4<QWP
MG9'U#<,/@41ZVO<!U\=;\L3VOKB&9@^>'!F<B#C4<_U]=T'8G_W,P?\ H#8;
M]=/=WX FN!?50<,^\88Z9P=.HYCUZ,2I1Y1+$" A8?2U]+6'@GQ\?,+8P3/>
M'#5\RP!W1H6D@S*%^R/K&B/2"+QX-BZNG-KW_P!V/:^G.P>JW@&4"E6J :%L
M='^H_7:0L!"<3V4X  5 =L#2N..>L8W9CRMQUU$/$>&OKQ+<!D:CAO[QC0X.
M(M?&;YZ=V#>'-GCY,42W'3@-A#74 'N#ZQTOIUE#/O#YX^&F^*K4Z20[@'3>
MWTW:Y1RZVRLZ*!RTS_V1F.82J+>*/FE(U0*\RR.K2Z!HREIRGXV0E'I".18J
MP]35/!2B#LK-T>+*U4FDR&6CD4U?1[3D39O0W:-GLH>U33*F(EHODSI-CF2K
M1:I/82I9*Y(+(2%+FLI"$++I5\:,\G[1K!:+0E[#8+):>OFKZL2[/.VBHV6P
MST]8I+F7-E34K6 $R$S4S)BI:5I5%IGNT1'Q9YN6J"-B(6FFD219Y4LI-'/3
MC9K%)KO73E>3104<OVZ;<QE$$T(P ?E5(@@*2C9<$OSQ9]K+M-IEV>79+RYZ
MT29(3,F3>LF%13+0E$N09DXS%J2A"$H!)4$@I>GW:=8)<B0N=,M%R7(3,G35
M*"981+0+TQ:E+F!$M,M*5*6I2RE*4DD$,#3GY.+-:D,P\M*V:44*R,336:^8
M1$(TL4M%1\+%5+5,K55.1$:F-VG8,X.59D.T9J'1CQ,5H'T2$,?]*6V61L/9
M,J;-,ZV62Q2;%;9BE*4M5MD2T&<5+((F%5]"NL2J8E1)%]2P8^%]$#:)'2SI
M&@V=5GL=OMJ=K[+E#JTRQLRW R9*DHEK5U1-IL5N2J3-1*FI(O\ 4B7-E+F=
M&3JB7Z07]NEOTASY!WX\RQ9J4IX/1\VKE4XAJ_:TN$CLN6J<1X9ZC 98QY@_
M N@B(:\0Y#W_ '@.EN&N(NDU('/'*K:;FP-*AI8_#ED0&]5=W[HS$I(+Z*!H
M.E[@/UA?R]>(N&E&UJ_R%/&)8N]<\17<S''?344AP2DQ#]U< OP'7KISXC>V
M@A;4.D7#H*Z$>O0B2&!H1DPK1L6HYR\=\.24N8MKF\0$!MTUO<!L%^%N(VQ2
MX[T-6-.>7<_ /6L2V395HW<&H*XD>.(SDYJUKB'0>&EA#H( '#OZXJ4 N<S4
M8CF[GC](J98/W<W+$AZ<7&AU^6#4$R7\'IT!,-QAI7GIJQ<<0]G 1Z6#$%!;
M$4=_W K37ZQ4RQHJM#F::'!B*9%ZU,<8/D:I(J+': &]KJY8 %AL V1KNPC8
M>%Q#F&+*!+4#5QXC!N'SB52P2*8/@02QXTW8%FQ)CMP:7MSMQL&]?W:Z!K[\
M+HT'(>1P[][Q7JQ5W.]QB->U1CD/"/(9>]_R=0[QL/'GWCQ#GKTQ%VM/G=[J
M#+%Z8YM%;C:L#4$AG9FWL!0=QCQ-*G$0L8 X\S![=?5Y^$E+YX<3KEJ-7XQ-
MP X"N#X^+'P TQ$ 2AA&YC@-O(>F@V]?LY"%"@^AE3?X;N$5NAF%,]7.3OEJ
M/1R$I QAMI8>G.]^8#Z@]P#A=.1PU<<GXUPJ=[Q4I.&K#'#"K-N[]S@1G;HF
M#>T&^NH^SEI]G3$  Z/_ '#Y-6NFHXQ)4'P+@<GTR??1VQ@!,0X;H>&GV8$<
M!WC7'4X8"K\HB^-YXL/$8>,'9C?2P<A[^G+EPM\"(X4?.N#Z#.CZL(7QH>>_
MRJPIS,'9FT_)MSL(A;PT]O#J'3!LPPW7AF*^G<;\87QOX^L]V&1I *6O .O=
M<;]W'36]^6%W*E,:M]'K1C4?1> U-=:Y5Y[VQX0=F/0 #@.GK'D'JL-KCW8-
MCD!D[U9Z$ C*N[$YQ-\-GYY98:X!N4?B=VF3VVF]IL!Y;2VT,'A_LSUQIX]>
M&+R_<&.>-791#^$7D 7 >TXO5I7M$8G/CF\0IV@=!^/7B\92EJ]HXZ$_J^E<
M]3!V@=!^/7ZO#"#"H91WT+]YW'=A2KN=H'0?CU_'?A ) <,ILW9CZQI\Z1F,
ME2@J%QL%PT$ X_5?I[L:ML<R%L":'T:BF._(8L>WT?NC:5F*W83$U+4[0?#(
MU'Z-%Y-B;;6A]GG,;,C+W,,SRF:<K=I2SZGJMB6QUR-746T=(JFF$3,Y%R\C
M9)K)NFAWL2@#N)D88&B")R/I-0/E-MLL^RV.9;;(N9,7.M$\6D!4N_9YB)JD
M7"@H)*#)3+F(2H]:TT34&[,*3]TZ=[#MW32U;+DV"R2INT=CV"RV>R6-)ZO_
M !39=ID2IZ+39YTZ=+E+M%FMJK1(G(2H(4 N6$";93?LI\HMMMQL%EA5>SDP
M=/ZQS/GGL=&S+)FSD$XB!C"NXNH%B*-UVIG<I+2+)FR1:H-9!ZU;%DWD@;T9
M^T;MT\6R[-;;9:%R+;,4B19R3.GS)DM$J4"/BN@*4"4KOS%JEH+W4]87'C.B
M?1FW;,M6SNEDZQ*19$B9:-DV= 3/M.U[6DSK/+E2)-GF+GHE2IJ9BYJNJ2M0
ME"6@J2LD<EY1RX6!%5ZBFW?*MVZC]LBH"Z+9\=$AGC=%8;=JDBX%5--40_9$
MRE/:YK#]#Z.(ZNQ(0E2URD@IE+6FXM<M*B):EH<W5*0 I21[JE%)-(Q_:I/]
MIVW.GS)<N3:9H0NTR9*NLERK2M*56B5*6W\1$N<5HEK9U) )Q,,>^'0?CX^[
M'HH^3M_<,!0C(?IGF:8P"H'(!^/;QYX09L H/_:W?EZ+0;X=!\O?A!JOVM?N
MCG^N/=!V@=!^/6&$&_O/$C@^+AG[L\([E_(^4A4K!OG%6[V)5;TI4J=$Q,',
M]NU5;OY.FWM7&G&()HN%73=U'IRL:LJD\0;F.@^:N$050734-AFJ";HJ]3W4
M;ZQJ6H@W4U<!0((K6ZQWNQPTCD#G+2-2T%FC6U,U?%*PD^UGW[QU&++LUW#9
MO++&E8XR_H3ERFB=U&O6CPB*ARKE1<)&43)O@&,H(4 07!X_4"-A!24I*;Q!
M #TRICB,P6(;"D1EOATZ_=[?7;$Q<"F"JZLX:G<X#;\]8.T#H/QZ\(77R4*[
MF=A7%SXY[X-\._X]>$+K9*T^Z1KG!OAT'"%T:*QQIZ:@QI1H-\.@^OX'"%T5
MH=0:98-Y$-P@WP[_ (]>$+K8!7^FM=<?E00=H'0?CUX1+;E#@0 .X'Z$^$&^
M'0?+WX16Z-%9YI[\_P!X.T#H/QZ_CNPBS;CF/NG1R<7)[\Z0=H'3X^/'WHAL
M?>KK=/AAN\!1X.T#33Q^+^["#-\6E+O#Y-AH":B/U _([E$^QC'&L @.;&;U
MN'_#!WU\+7YV]08"UY6-%%_*O=&LX"UOK@Y^$8L""_AB ](ZE[AN8!?3A8/M
M&]N5_+#B_/\ 2+7TZ_/=NX^L#LS= [N'&XZ\O5PYWU'"F\?7PINQQB+PU/B6
MY@]^+-0&&Z5.9)DL//<-;KW6Y7Y<P$=--;;UA2%3Y0(/O/CC3Y<SH^!XVW)B
MD6"T+3C<+,[X-N^5,M_*C9FVE,OC9V[7T9'(,7>8#?,A@BNTF4SPM2/H&E:<
M:T<+>).5!V>=B82HV$J["+%RP40;5 E(-"KGD7B*'&^U2=-L=JV;;9:3.L2+
M%+V>E-^8E,NW2U3I\\)9"T@SI4V6NO5]<B2JXI?5*2GQGV32>NL6UY-H!DVN
MU[6M>U$*4B6J9.V<KJ;)9UJ(6%D29EGF(*57E2#-EI6F6)@=FV\MI.AX3("E
M&E:(Q<%4+/,O+*0IULJ4TI4S)6B*NAYBHIZ):-BKA&LV4 VEXY640>F5E?G-
M*+0; A)NC!Y_[-;9.M'2"Q6KJS9[)LM*YFTIB53%M9S)F29:5 2TI"9LY2;L
MH*FS)AEE2)83*5,3Z/[2=GJF]%]J;-LJ1:MI[6D3;/L>0>I256X?Q):TF<M*
M4*DBZ3.F&5)E&8@3)@,U"5= :,G&\_3,).LNV]!F(F/E60N456R_HD@U1>-1
M7;K 59%;L%R=HBH *(G$4S@!RF#'T_;4OJK9-2D"DQ25!F<@J!Q2" ^1 9JC
M37Z"6KVO8&S[0.TF?9+//058F7-E)F(JDD52M)[*B,@3C#\LL(WU$ [A\=./
M$=/'@.H8Y #8UI5]?J-'J,,#'NP^)%>/H 88=^#PVJ+VO8;6\M/C4=/5;%CZ
M?U^\3&"=81OJ.E];V ._O\@TTQ#;\6?R%:8G4UQA&.*O>/J^ OB0DY GF8EC
MH>4?/:CU'V#_ -+$W3ICN^<+JM#RCB/\HR?_ *K#9X$#?WBHSB/_ -DV:Y#Q
MM[..,2P7 8AM7S]:.=](D.'IKB,R,-S[JF@T;N(FN(6N.G?J'C\:]+XO5J58
M^ HV+/R#Y"*PX)+WYW'S\_"^NO,.&)KGZ$(<D51"P7$>''C[>//0>6E\54,Q
MD[]^-,,L,ZYUBI<&@QQ:C^GQ!XPYIGY@%NH< L/U>'77K:,0U"]"7<N#COI7
M>*8 /4AQ[I!RRI\APUKF8=&RP@(!O<;:6O?N'7CW!KSXWQA4"*-F>=6(IKF?
M%XQU?7-W]95^;1L;57Z0 (Z#8.H=P];Z>H?$;8R#0X%SCKN(P<X#OP<Q6HP
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M>GB"G%@*ZN7\NY^Z/<CPR@Z#8?7IP]NM@OIIH.F(NMC7'0;L2'#"N?A6I!?
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MYUH6A4R5,49DN8A5^7,EK 4E:%H=*D*24J2M)(4DI4DE)>-<,<Q1&X:AQ"W
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M.@C7=+=>OSJ(<O@>-;IQ"54I1)8<:#/ #'NI2XOX5?E,/;?-_*8=TP9J9;"
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MJ%Q=^5+P/G1AO"'IK(;<@=(W]?[(/6W ,=[$4SPCY<H%)()8AWPIEF,*$O\
M,8+\YL>;QIZG*/U;P_;B*[N3_4>O&&_$?#RA0DF0\'34?!PD/U&'IB:[N7ZP
M8ZGP\:0?.#/7^BFW_OT_^EK\>.(K3QI^M/'S5#.?EY#/A](^@?-1U!PW$/\
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M6[<'"Z:0%(=ZX=N1 55U#&U]LSE3MIVP$FY9Y\VR24Y)DV68N2@ 8)O73,6
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M(9PY4K+V!%+,BASJ"/ I2U-&")N(?DVWO5SX8V-C_P#YMLL4KM&PBN )M,H
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M1=,K=D@MV@&6,DGBZL(=B>TS!L+J$( QS"1@,S2*(E"6%I3>*5%!R=-R4B4
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MQU2H"K$%L)BB 1= (E&KJ+S-X(H"00XJ*.*&+)GS9B0I(E@$2'>\2\]L"%)
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M=!S(J&65$X:& GS6QD[&#0%^Q*8! YL>7ERU6[I-84!0"+$F?;IS@N4(1U"
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MEL/Y"IZW. 06(=B^T&3-DJZ-[72'1L_:RK':SV1U5FVI*"$++@J[>T++L^S
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M0\A--$DVLL],<SB2;)D;O%5TB%($W02S .PJ P9V#-D<-#@(FXCW;B68 "Z
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MMJ[8>H,ZR[&V))V1+1^) MHM"L*3)8+N(U;+V=- S#9V!Q(9%4BQ# -A Q#
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M>A)&&A-,1ID<6T+=:;/]F/2BV65756NS=$=N3[+,/W+3*V3:5R%X@F[-2E3
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M80M16H"K+"6N*]UDNHS'N@A\*DL$@ D/@$Z9UJP %!$T(*.K727<0HJ,T*"
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MO %3XJ!(S913GF6?/2CO&>6I2T7E$%5Y8) 8&ZM279RSLY#XX1JJ(#8+ZC8
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M LX#5/9P=1."S,JXKVB:XM1XA:LJ^GJ]?0TE4BK=RZ@:-HJA(T[=JBU*G3M
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M3!R'C\?IP=7P_P"H0;"HKQIQI'Z!ODS@$-F]>X6OF)5 _P#VA ?H\<:-I+S
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MDJMUIV!LC9$L.HA*PJS6G::3*!)4M<E8J@@232&P1G-)9>TNFWF<OD"H1QD
M3=3%0)* "3EP0-$Z45* "&I;GX<;"(@.I:+2%6>S(J"BSRD'#[H:O:? #?CE
M6/6;!LR;+;-K+->NVMM">&#L)UI7,+ZD+4<'9O>9H]E/D[L\>'S[EF&EP_I[
M40]>M(7X<>(Z:=,:25L00-<2--Q?"/8IGH>\7P)>CNV=68&FZ,9;Y/?/7LTT
MS3V7*I$M[LDOP@J(2)@H.\<4RGI,"D Y@N8"6$Q@ 1 >.,O6"INE\Z!_G7G&
M06B6YHH/BP&&7WMQ%7QC'6^3[SW4,<ZDWEX<ZA2E.)ZBGSF.4E@(4PFI;4H
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M=:@@XD.<L*!WX[FKOQQ^TRM5<OU]5AX1^3VVA1 -U.B##?0H5,H!A$. !>*
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MH^T\I:Z Y3?-[2Y1O<))EW?]V[@Z!@X8B[CO?UW_ "I$B<AQ4XC(Z_//TT2
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ME .6M><Z>7UU_P!M1HAS#7^C1X@'7AB 4_JZN-&3KKG#K9?Q>"O*#\6M>?\
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M;B%MJ7:(X[P_]N*M,;DK^6GO^9]>4=B0#U,MB0X.N+D9 Y YOW8UJ[<?SO\
M*QDC*RM2_P#F\H.W'\[_ "L(,7!J6_N^=WGWZQ]BZWTA14L8EP,!K#OD.4;E
M.0>1@&^H6$2B8MPWAQ4H257J@L0V(*30I5@X[C5G=HVT6E:9:I1)N$A21VNP
MM)=*D%G!22:BK%0P),?3YX9^F@58=XR '^F-Q$PG*D4PB%A +BF V"P!O:=!
MQR9")"EE% N[04:Z5%N2F' 4SC/:]H3K:B0)RE+5)"Q>))O%81>.'WC+!+4K
M05 AM[%/KY<O_9X^OUC?38*CJKGX4^?@(T'KN.X^'9J^F38Z>RX)JF(8--U%
M!(;A<1[%(B0#P'B! L&F@8JAT@@DU7,52GOJ*F[B36O",DZ9UBDD.&E299)!
MQE2D2GH"[A(.1?%ZQ\I$33534#4$U"'MJ _0,!@"X%"U[ %[XE7:2I+J[22F
MM0Q!!TX^&^(EK*)B%M[BDJP4_94",MP^<.BTD=98BYQ$QTDS)HE,)A*CV@F[
M0Y "WTSE$"&$?W(6&]BB7719Y:$E"0P4H*4U"HI]T*-20DU R-1B7WI^T[1/
MG"<M:U+0A2)85>*9871:DI^):2$*.)2 #@F[C&<F.83".H] -;KH'MN//U8S
MT9@&;>_T&[QUCG+4I9<DDDDOVG.%2;N5.&31\]N/7_*PBC*U/^KR@[<>O^5A
M!C@YX=K _P"7.#MQ_._RL(,=2?S9'^TX>!@[<?SO\K"#*U/^KR@[<>O^5A!B
M6J?]1Y=GA!VX_G?Y6$&5J?\ 5_Q@[<?SO\K"#&N.?Q9Z]FN_6#MQZ_Y6$&.I
MR?WL,_N\M-\';CU_RL(,=2PR[7EH>6Z#MQ_._P K"!2=34?BUS[/AWP=N/YW
M^5A!E:G?[V+<,/I1X.W'\[_*PA=Q%7S]YJ_Y=VM6@[<?SO\ *P@QU+9^]E_E
MHV4';C^=_E808ZG_ %8Y?=\/&#MQ_._RL(,K4_ZO*/VH?(.#?Y/BF##Q-FYG
M4("/$0_#I_UUMC2F>^KC'*M !G3* U#TSNCECXQV)>$ Q+A;4!#AQOW]]^\/
M'AB@H0=(PMY>M(BJIZ48S3AD[7*4'3!3>14$@"&Z)BG$A@MPWBE'C<+&ZAC<
M1-4FX1B@A2-Q+.#Q  [A%39$3TSD*]RT252IH&:;RB@\4%2KHS"R^3QU/Y>1
M#X&I=PA$V+4K-(@EWQ*DF(B0N\8+Z7-8;ZB(CQOBZYQ6$@I[* 4I 9KH&%03
M0;\\\]JR646<S2E3JG*"YBC0J62I2UTNAUJ4Y  &@3&AN<LH<+W*G_[HO>(\
M0M]7$+Z8#]^^N&6/'C2.BDD@LQ !S)#!_J=]<\89G>6T,J83;A"[I$B?UH."
M2)$@'QLF ].(8R%U,<2P2SX7$A(?N S&(;"M9,OJTD NRYTPEV+SILR<K7[T
MPXXMQAF#+F(;.4%P*03H+)+%_8P"YD5"J%'AU*&NN+RP4*2L&J% @;P<"QQP
MSC)-EB?(FR543-ES)2L^S,24*XN">+Q[N:9CSR#=^=$@G:KKO$2V$?Z*7!,%
M%C":_P#N28@4H%#>)?F(#G5.4I2"?N7FU=20DJ<YLD'B*!VC2E;+D2A."7_C
MJE&9[H=,F8N=+0& )'6+43>O.DW-"<TY U"P#</K[^/W>S%4N2?Q!0&CX\JQ
MU$!NR,+K#N8UW4KKSC#4+;6P -K<. Z\PM]@_9=A@4C5F!K3#O:K ;XSL6=Q
M\V)U ]4X1BF !'@(\M;"-^&G'3XY8JFZ*,=S@8$TPQR Q[A$E!=^R*#!P!Q^
MF+$G!X )?]R'&W#[L6+?#_I'SP],T5*3\63T;ZC'#!Z<X4@!>P!J(AP"VG/V
M\-/;8=:FZ2  ,:]D5SSP;G%KI%2U0P!.#]V/'#=&6F33@&HCKR .&NFG._LU
MQ) 8ND"HK3!\=WSTK%#>:E#E74X]X#\MT9R90Z!QZ?;RY<_'EC&:JI05;  Y
M<,L>68C$74<<V%>Z'5NGJ A:]K<!"_'7UVX]UNN(KF!EOW^'[B*P\MTQ,8!T
MMW^6@Z#<?9BI;1\0 "W'?1LN!$47@P8_,5 'U$/3=,1'AW^WU\0#CPX^O%%Z
M>5&?P+O^K@4- !GCS%>\!AP)I@3L3-/AH "-N&NH@'$ #7U7U#CC$32K$YAV
M#8'2FCO6***F9R7X\:Y8XX/5GSW!BC8"AIIW6N&O6W'7A?NOC$3P [OW[^.^
M,2O%M<\S1VP9M,HV]BG?=T#[ #2W(=0'U:Z=U5%@>!RSKX><:<U1/ TQQ;=H
M013!Q&VH% J07MJ-]=-.06'VXP1AIR\(]K /(/NPB&&@Y06#H'L#XYX1,%B]
M UX:!KA" +<K6[L(0N$(02@8! P (#Q >&$(QS,VI[[R"9K\;E#7Q]V)<ZGF
M8D$C D<"1\H\#1,:>^^R;FOQNF ]^)"E# G%^^+"8L8+5SC&&GH,W&+9#SU1
M+B>L6[WCI$B=-%;ZN<>0TM3IORH=@/\ _ +@)DP8+4.^)ZZ;_45S]:#D-(\A
MI"F#?E0<<;GJW*.O77$];,^-7. GSAA,5S?YQYC1=)F_*I^+'Q:D]V'73?ZB
MN9BWM,\835COCS&AJ/'C3D4/$?\ :I.?'EAUTW&^IS4E\2,##VF?_57SA/P$
MHT>--Q(_^J)^[$]=-_J+T]XX:0]JM']9?./D:!HL1N-,Q'_)$\1UTWXU<XGV
MJT_UIGYC"?@!17'\&8B_7T1/$]=-_J+_ #&'M5H_K3/S0H4#18#?\&8B_P#Y
M(3PQ'73?C5SA[5:?ZTS\QCZ_ 2C@X4W$A;A_0B>GEB>NG?U%_F,1[5:/ZR^<
M*%#4>7A3D2'_ *HG[L1UTW^HK%\3CKQA[3/_ *J^>N,?84529>%/Q8>#8@?5
MAUTWXU<X&TSSC-6>^/4M(4P7\F#CB^#<@8=;,^-7.(,^<<9BN?TSCU+2U.E_
M)AV 6Z(%Q'63/C5B^.?KPIA%>NFT_B*IA6/4M/09;;L4R+;A9 H?9[>N'6+^
M(^O5-(DSIIQF*YQD%B8PGY#%N7P3 ,05J.).L5,R8<5JYF,@K-J3\A!,MNA0
M#X^\>N(<ZGF8J23B2>))U\SS,9  !0L   = Q$1"X0@PA!A"*@5+L ;%58U'
M4%753LRY13M3U7.2]2U'.25)LG$C-3\_(N9::EY!P8-Y=])R;QT^=KF^DJX7
M44-J8<6"E ,%$#0$CY1D$V:D )F* & !( AD_6W-@W_!0R5_F:P]V%]?QJ_,
M?.)Z^=_47^8P?K;FP;_@H9*_S-8>["^OXE?F/G#KYW]1?YC!^MN;!O\ @H9*
M_P S6'NPOK^)7YCYPZ^=_47^8P?K;FP;_@H9*_S-8>["^OXE?F/G#KYW]1?Y
MC!^MN;!O^"ADK_,UA[L+Z_B5^8^<.OG?U5_F,'ZVYL&_X*&2O\S6'NPOK^)7
MYCYPZ^=_47^8P?K;FP;_ (*&2O\ ,UA[L+Z_B5^8^<.OG?U%_F,'ZVYL&_X*
M&2O\S6'NPOK^)7YCYPZ^=_47^8P?K;FP;_@H9*_S-8>["^OXE?F/G#KYW]5?
MYC!^MN;!O^"ADK_,UA[L+Z_C5^8^<.OG?U5_F,'ZVYL&_P""ADK_ #-8>["^
MOXE?F/G#KYW]1?YC!^MN;!O^"ADK_,UA[L+Z_B5^8^<.OG?U5_F,'ZVYL&_X
M*&2O\S6'NPOK^)7YCYPZ^=_47^8P?K;FP;_@H9*_S-8>["^OXE?F/G#KYW]1
M?YC!^MN;!O\ @H9*_P S6'NPOK^-7YCYPZ^=_47^8P?K;FP;_@H9*_S-8>["
M^OXE?F/G#KYW]1?YC!^MN;!O^"ADK_,UA[L+Z_B5^8^<.OG?U%_F,'ZV[L&_
MX*&2O\S6/NPOK^)7YCYPZ^=_47^8P?K;FP;_ (*&2O\ ,UA[L+Z_C5^8^<.O
MG?U%_F,'ZV[L&_X*&2O\S6/NPOK^)7YCYPZ^=_47^8P?K;FP;_@H9*_S-8>[
M"^OXE?F/G#KYW]1?YC!^MN;!O^"ADK_,UA[L+Z_B5^8^<.OG?U%_F,'ZVYL&
M_P""ADK_ #-8>["^OXE?F/G#KYW]1?YC!^MN;!O^"ADK_,UA[L+Z_B5^8^<.
MOG?U%_F,65RLRBRRR1I%"@LHZ'IW+RC&K^2E&]-4O'I1D2C(S#H[V4>$:H_0
M*X?.U#N'*G%14PF'4<0227)).IJ8QDE1*E$DG$G$T:O<!$B"4#!8P (=!Q$1
M&.=FU4_+03-S^D4!Q+G4\S$@D8$CA3Y1CGB8Q3\MBW-XI@.)"E#,U[_G%A,6
M,%*YD_.,<U/09ORHMF-^-T2C?QPOK^(\V];M,HGK9GQJYQXC2U.CQAF ^*!<
M3UDP??5S]>GUB>NF_P!17/2/,:0I@WY4''#XMRCQQ/6S/C5S@)TT8+5SCS&B
MZ3'C3\8/BV(/UX=;-^-7.)]HG?U%<X^!H:D#<:<BAOQ_H4FOCIAULSXU<X>T
M3G?K%<_7./G\!*-'C3<2/_JB?NQ/7SOZB_S&)]IM']5?./G\ J,_X-1'/^Y$
M^?'EB.NF_P!17,Y8<H>TVC#KE_F/KRRA H&BPX4S$?\ )"8GKYW]1?YC$>T3
M_P"M,_,?./K\ Z,_X-1'_)$^?JPZZ;_47^8Q/M-H_K+YPH4)1P<*;B0\&B?N
MPZZ:<9BS_F,/:;1_57SCZ"AZ0#A3L4'_ *JG?VVQ'6S/C5SB/:)W]16N,>@4
M92@<(",#P;$PZV;\:N</:)W]17./0*1ID.$)'AX-RA]6'6S,;ZGU>(,Z:<9B
MN<>A:7IXOY,.Q#P0+\<L09DPXK4:-B8CK9OQJYQ[E@(4EMV,9EMH%D2Z8=8O
MXCZIZ$.MF'%:CWQD%BHX@6(R;E#H5, #3PQ6\HYGY?*(*UG%2CWF,@C9N2PD
:1(6W"Q0#!R<23WQ2/?$0@PA!A"#"$&$(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g105292g61q01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g61q01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3 \4&AO=&]S:&]P(#,N,  X0DE-! 0
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M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     #S   !V0          0                         !
M    =D   #S                      !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   #S     !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   \P     4F
M=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    $.$))300,     !TF     0   *    !2   !X   F<   !
MT* !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B
M!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M    $  /;6  $     TRU(4" @
M                             18W!R=    5     S9&5S8P   80
M!L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   B
MP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M   TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&
M5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M@,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($
M-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M     2<U)'0B!)14,V,3DV-BTR+C$
M                                   %A96B        #S40 !     1
M;,6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M   !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#
MHO+W=W=RYI96,N8V@
M                  9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6
MQT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.3
M8V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                   &1E<V,         +%)E9F5R96YC92!6:65W:6YG($
M-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V
M4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                    !V:65W       3I/X %%\N !#/%  #[<P !!,+
M-<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                */     G-I9R      0U)4(&-U<G8        $
M4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@
M!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .
M4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@
M%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B
M8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#
M,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!
M,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%20
M58!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L
M &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@
MAN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"C
MT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0P
MQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#I
ML.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q
M$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^
M44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA
M;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&B
MH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1
MW#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((7
M4AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"
M67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*=
M J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"
MZ"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T
M8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#
MB,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>
M ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4
M/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:
ME)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5
M G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5J
ME6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%
MW)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.
MEE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5V
MRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='
M!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7
MSA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4
M>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_X
MYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW
M67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*
M%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP
M*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[
M6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_
M7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\
MLVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE
M76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.
M)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[B
MCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_
MKG^W?\!_R8_2G]NOY+_MS_;?___^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!
M$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!
M0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,#
MP,# S_P  1" !2 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MKL5M%AI"D-/(7B2"&FT)+I4L:)(20+Q!E0BYW5FU(V7:M)UF.?6NQ[2D=,N
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M>(OB]C8A,UR?GW$C&.H6HSUI05\#DHU-LZ0<>(C,E2>$(*)>$@N0RG1=$<4
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M1DD)%A )A(40-:N\';YM9R="NLG,]:7*1VCN?E3$Z*+$YBG51;LPUCH!FF(
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M,5$R+0[AZ[750;)NXXJXO$M-BMB878@.)?<=Q1;C*EQIII'3$G(A*.D?#JB
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M2DDY3/ P1"HRJ!$%)RJ21< B*N=C8.)F'%P^.91S&)*.$%RF,FY*!-U;=26
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M:-8(19I*/E&C#QS%(SCAPDU4D9):?168 VEHM%LX51Z>-'3XG%8K#8C!LX?
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MYF0EGC"(:O9.8EX=RO&RDV_<.)>09JF0=O52#IAIIYY0;=VZVZ! 2!H.6I(
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MQ[9-0Y$G*B)5U'73';H',5 HBH0B2)EW1@T,H*X[Q2DJ:2A#A;6V"HG,HB5
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M1AT!1A96@I3(,'>9F20)(Z]^['PJ27;#ZTD=76!PU@S!WUAEBDU6E\3)'&
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MD@DE&:20D"% S!5:8,ZS2#F?@CK0T@V<H*(G,F('(8"FW1$ ,7AH(CIP'CJ
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M@02:!9Z/$-$AIVQ)LE9R@&UR0F2+B0F#$BQJ^O9[[26^B<2MQS,5I0HY6DR
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M?0:\:=BPMM0K+UPWN#6V*24;#-:\]<JP11CQP,1B'76VVUKE#1.1, 1( ))
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MDJ0>F-+;[K+B&,9E.<E+&*0D(;>($A#J9/1/D D 'HW/[,@_LQW)+314!W1
M=X-!TT$!UU 0Y" AP[^6-1)L 3:_,$3?E X6WUF^(OKUGPX<N-0,JE)UL/%1
M&#B7@TC"6)<LE6PO8MH(CT<8_:O'#8SALQ#1)B]9JN%SM 2;NFA5&WACS;NJ
M8QW_ !"GD8;%J$XA#J7 T^Y'M/M+:0X$..GVGFG4H0'"I;;A2YT36.TEQC]E
MD4XP+-J04YVT2(;6E:DRE&B%H*B4@)4@$%:H,S6DFCJ,BVQ3*(NO+?+PPM':
M"S1P8A;Y6P,HBFX(GX2B01*4Z[4RZ)3"!3* ([N,=;#K;#CA"5ME) <;6EQ
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MW)-DN*M(F201%0%9LRZ[7IIQ27C26->&*Y& T:%8A.R@*E0*HENOHI5S6V;
M6^Z<9.7FXM@R R3>67C7R@-,88<"Y425+,J43,DJ))).MS<DVO-;-"D$ )L
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M\5>*.S*.7@MD$#M<9&SO5DE!"EJ,E3B@ -#[*$!2H.HDR3[I(%AU_I5Z:_\
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M!($A,JN8F(.H&T,4=2B40 2B \P$.0E$!$! > @(@/7@+&18\1KQ^-ZLY=P
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MZ>87'AIE[9&)P39"1TF&4G$8=LY;=(IP8;HD$7%UDB"!<Q8=D*D9[9(V3/\
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M(/P;[G>73AJ&=^:VG+7GY7<QU[/OCA^NMHF#TQ,[K3OXCKI^JMFG_P *C?\
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MBD2*@^ML8BRL#@K@$@27DSI*&+T8@748G:3CBNGQ;JWL0Y)*EDJ)DB!(]E(
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M2?\ Q3B/4,5?_A\1_HN&_6$1'F:GUS!?WW!_^Y9_F^%/?!4G_*[K^1+!Z?\
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M?0.G;A4^3?S-4 P .N@]6G'AR$./FY!P#AWZX4JN_J ]_+K#377K^^'JT#"
M-!%.WSQ\\:@6W&WMI+9TZO\ @>;0Z#IS\CTM>7MU\,4K]T<)[-#H/CV=M*YR
MCAF\8_IY-;;XLU9IA2F%*84JF@:@.@:@ @ Z<0 =!$ 'GH(@&H=>@=@84H(
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M7]!%JV2:-6S-(H BU01;I%'B!4T"%33#C]B4A=!YZAKSQ@FY)XU\QI$)2G@
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M%)*1A+(=@4P@"IF, !!$Q$@ OIWZ/\:5L;4V4LDA*&]IX<$^ZME:,/B0D?\
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M*UJUXE*9D:"HC;[ 2A-B<,_T<V%F]O2R2-FXWK Q4/Y")0B51&U^32\F!36
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MTP+F %)48$1,Q>:U^$6VIQP(:6V025%2DJ!_:/(A,.+RI"TN%*0$I$D@#-?
M?='VBKG+^H*)@84VUH:G6 /L%@%L77JT!58@><0TQ5M)). 40;)>;*ARE8!/
M:H;J]1]"?W6T;2 6IY#*Y_3MK0K-"6SV8[+ES38*9[CL]H,GQE!:LLQ#9-E.
M22 '"'C4C0U8+7BS '3<,R/PI_CKI&BJ7C03H&T0)D:;C;*%98DW][+EU/NQ
MRJPG_LJG;(*CASCTO*44DOEGUA.94$6PA>Z0#V3<N6CI+#]>>P_5RTO8VV5Z
MN"!6YH?9]RC;KI%/T@ [4HT(X>'$^\;?.J[665.;>'4YS#KC7K,J.^]?.Y6M
MU3CKGOO.NO+O/M.N*<49O,E1-17GKM&1NRKFOT*M,=2]:S;CXBP3]A-848Z)
MK68#BS4S*VIM7,82!>.$T+ZW=H1!YH\IT1+9$T^NMXE5W<%9!G345;6WNE&1
MJ]9D[2>I9OLF3.O-+7&-)2GQ\/(VF!E*S*V^&?5AO,6&/3D@E8.*651*9=N5
ML[4*S?J-5478MU*O$IM_Y=14DI!.LN\SF\V21\5"W=%R_)&,G);3;Z LI/6%
MI?'L)6VB&8-)F::5:9>-%)264B25Y&:&;B"/5*Q: ]THRTE*]'34AE7G&P55
MA EI86T+6W,!'*1M%LUXN*+2S25GA6$PWJ251EHATX:)D<R+U6,<QT>M&N7;
MQ@I5;5[H?4X;QFUAZ#:Y6:A+] U&QPCL]6CUJPS3S6R[RGO#ER^"W.6=FD(N
M>O9&]?;4LTXA*ND$ =*LH]<LB=3CX>?.G.MU,ILS(;-^APU^@F$K$L9=24;'
MAYXC!">AY"&EGL+)Q4XQCW\B2*EV$A'N6TA#NUTI:)<IJ1\RQCI1N[8-U*D;
M"E:M;1OZ==E3^'V4_H SQQ<;][_*KX&KC7[Q/;_RFN_DA^J=M.?PC43^A/+C
M%*_>/9\!1W]XKL_Y16.Y)B/B.^@ Z?H\;0W'EK^C7>>8]O$.SJU'EBXV8&@-
MSJ//X=VM]GW/\Q_#SNJ8A$0'F/7W=NO=KYM>? =<5SN@=TGO/XSPJ[0##VZ]
M0<1Y]NGJ[^_CA/(:SIX=7PW12J_"T#B/+M$.O3B(]G+Y0'MPGD-VZUN'"=_Q
MI5!$W =1]/S<NKGQ'GU\)GD-9T\+S ZJ4WA'K'@  '?ZQXZ_/SX8B>0U)_*V
MZE-1[1#AP#J$-=.T-/6/,<)Y#N\]=YORM2JZCUB//CQX^CGS$>L. :<!TPGD
M.X_/\N\TIJ(:\1'J#7D/'74-!UY??YZ::B9W =0\]G?<WI340XZCYA$>(#R\
M_7RTX\?,)G<.P#SWR*5QJB/1J!Q^L-UZ_K?3SX]W+0.. ,=GGSUTK6K)%,AL
MODQ$.(W/-77@'VU;KW>K'1L$AEN"1["=_*N5Q0_XK$:?O5;M\"]2ST1>O3^*
M'+%V3Q/>:QX&X#?N%5Z(G9Z@^;S82>)[S2.2=V[\^N.$]_1DGL;#,'<I+/6D
M;&L&RSQ\_?+)-6;1JW3,JNY<N%S$21012(=1550Y4TR%,<YBE*(XD9E& 23U
M\-3R XU"BA().4 <ANW=>G;;4BO,]WM1Y:7'.IY=MG/9ID-H2Z,*6I7 SN@J
M;3*A&K,2R)E"0\?G;;FS*P3=26*<#-C58D_4WHJB[8*O!U..R;V2\4I??4Q@
MTK3F;=Q;I:+J";%MH!;[C<W#J&2@S99%ZQW\:UADA#[K3()"^B<4HN0;9PPV
MAQW+-I4@:W,1."9X9Q[>UK5AJS'9>PNRW47X&&>S'K=CB\][FY.?X*</7V U
M:'AZTIN"*KF4E(>=.*8*':C&"T!P[W6R-DX!U3[F)Q:,4&<N3#8);B5.YM5.
M.XIAM;3:#:&6'EN'1QJ,QJP6+V5BRK/CFPL 9<.M+N#S@&2I6(>0EH)%A <0
MJ2 HF36N#C9EI=FC49JSY[[0.8UH7D7J<RG+YZYGD<1BZ":*95B,6$\S@HL5
MC"J4L=&,69HTY!3%)'4I0WJ6L&EQ;:=BX)#*4)Z-UY*L3TA5F"P/6'774J1E
M )]E,DY F(&Y+3+67_A<.@*&9)4PE>9)@I<#KB5](E8)*5I6H$)F2""<$L;W
M,W9V*,ID'M+YOEGFKU+PO+N^VUWGA67:9BF7,V?QE]>RDI7T5=4BF/#S$*\.
MBKO).$BE*H3$QY]&64J3M-M&SUK;*FUX);Y?,D!*DX)1?:6V=Y2VR"08>2J3
M6^V+Z'X_TC).!V<4,B0<<C_A<,E8B4E:LK#B@#);2VM8@$I$WV1IGNN$G6H2
M*#:&V:,P89\F4&TW;LJ']4NM74.0Y$R2A8)W8XVSQ"+L@G<GAP+/N8\Q3LD)
M&9,5-TOYVYCL%TSB6G7E-!:@TZM"6RX@$Y5J:Z59;)$2V%N9= M6M;K$_HD]
M+V$K5AD[,VD$7#;&++6(4F).5O$LLMJ4#;V78, @ 6KTTR"VF\B=IRN*V7)?
M,"(MR#$R*4W$ 1S$VJLNERB=)E9ZG,-V-BK[I8A3*-B2L:U*^0*#MB9TT,FN
M>ZE6=)6A>=(,%22;'@H&%),7A0$BXD5Y]C<#C=F8I>"VE@L1@,6BZL/BF5-K
M*9@+1(RN-DSE=;*VU?174_=$7L#NX!\O5U^VN$GB>\UC1R3SMW;]WF*=$7V
M.7MU^K"3Q/>:0."=.&_CKIR\:=$7L]082>)[S2!P3W?G3HB]GJ#YL)/$]YI
MX#[O]?.^G1%Z@Y=P#W=@=N$GB>\T@<$WY1^/*8^509M!IE+1X(>L,V,E_P!:
M'#]%2I!Y_E[],6WB>C-YTU,[Q67@0/6V+ >TL6_])?*MJ&0B#1KQYH)<AX_6
MAS[_ )-./+77'.$P38&YW<_.D'G:*Z>NR)A[1ZN0]W;S^_KZQB>0[NO=IO\
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M*:"*9-\YC:;QA$5*NN%*U7VC_P!.>RI_#]*?T 9XXK;]\=2O^4U<:_>)[?\
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M=-#:@&@"!@^%\$P[H5%21&4J4=\@)&I-H)UMPC2XU@3O '"#/X#\:Y_!0X<
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M*Q.( W.-MJ2V@BZ'74K!_9P=YXV)?.&9SQK$P,(Y))(101(DU9HE*5)%,H$
MJ2"12E*DD70B90 J9=-  /5E.-)4 M9"EDY0HC,HZF ;D[S7S$I0!*E23,DP
M294;DGB3J=379)$3"D0^GR-%/%,:_:1;YV*S8G@[]\1RHU;F;'7*[.*I6;H0
M420.B0R1RJ*$.(%&@OX</-X<K5TSK:W6T92<S;>7.H* R )SIL5 G,"D$3%4
M2) $2)-M\D?B9X\ZU(SMK[=C(L;"T3!(DL*C9^0A="B_0*"B;CGION4-X%.6
MIVPJ#J=4PXW> =S)4T23D@I)URF;=23IUQH!6YV<^HH4T3^[@HY)),CJ!TX
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M5BBY7PEQE:=F5D%,U%FHWIS]G!V!_E;M042XIIV[,F[5BBSS.8@#%2-HB2#
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M@V_.*SM2GB:M95O 4;2&4)KY6%6O3BL@FT)F+9E8LR2IB)**@K%+L504,W1
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M=1CG68 R<S8TXC]3:\\!X<?)F3T#J'0>''O[ $<5)N0)WSY_'D-Y@5"@0DF
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M5N"A*E 6(%K) B<C2/=EUG482*CFG@8%%9ZM8+ Y0?=-^>)@S1!PT=L!$"F
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MUS-JEG-LR=>SU7AI4V6N<IW?AUKS(CLC[-$Y>IMJ8+?,U=QF>PA\OI@E"0N
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MK=.A]G(A/LI&^3?4VD\JC7-5%_9LM)N%;$%=T2,=RC9QO"===S"OD7*I$BE
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M36>'CX&-:Q3([M9-%NDJZ,V:)"X4300346$YB(I%$"!/X5= (@ &$@:VTFW
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M<CBFRD<0IM"B(L0I)B]6W6P\AQHP$J*HL"94D+! XI61J)D$5^5K;OBU,O\
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MV-\>0L+Z#@8N'>3S\%%C@_FW4<T;KRKOI%W!Q=/CN%]]=8^^)E3B;+3)U(,
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MI_: &?J).Z:@D$!4?06N8!(G+DCA(22(TSF17CG[LJ"<?L[618Q" XDTLL(
MY4MT%$7JN9];%45EBB8K@YA=&.J0@FW!*0IS%% -[9]*!Z.[4!)REU)028!2
MMUE"<HL4B$B)B8S#6:VOHDT7?3[T30GWE;2PBE"#(+2ENK)B0; DJFVD2#7C
M)E,1XFPD53&*+%5=)-,FH[Y7**1.D. ::;BB2J91'GO)!KIU^?I,R0($\=_'
M@-VE?;&*4G,D?2 OIH38<9!TW>UWRPX(5RW7;'+J1P@LW,&OZU9,R9NKL..*
MA8BL28N#$00>J]NNMPLG9]>P96T*5=&WG:M9C&ST3#\(S^-0+&OC&X_7"[9K
M"8.8"(@/$,>][$>.(V1L]TJ)4K"M!1L94A.11F^JDDWDU\B^E^$3@?2?;N%1
M(0C:6)4V($!I]9?; N+=&ZD#21RJ2>E[R^WRXVD'B?#Y5SD@7!/W1\_Z[]:@
M^:F7T&QS.LL2Y*RLDU,0F7%9DQ #C$2=GDH&E1LD4IP$FL;(3H2 E$-TXMB@
M;741"UZ8[5=]&/T;^DOI P@J>P&SL7BTI%\PPS"\0$G4A*W"@&-PY5X;^D?%
MM[:_21^COT*Q*B=G^KO[7Q+2IRO//'$I2%1&;+A\*XE'!3BC4JQ^U7E%D'87
MF3DK57E/J.6DVSI\7.G>IN6$Q7X[)=3-FPV)DB1J=Z]DX-TM"5ZR,7*JCYU*
MW."L2TDL,JN@E^1+>R=I[?>_7N*QIVACMK%['XSI0HO^MO[65@D)=6I41B5=
M-B&G![.5AYH(&0$^\L,)Z%I+02A"4)2AM(R);0@Y&VTI2,J4I2D!(2,J0 (B
MM\:7MK[,#"MM)^36M4JW?3D=564?!5&7EY5]8Y9PP9,(V/;QJ#I.1!R\DVC=
M"18+NHAT4X/F4@XC#$?']4]&<#LS#@M[08:E+2G%*Z5M"0A""HJ4I<%,)224
MJ 6D#*I(5(&<VVD64!$[B-PXG=SB2;";5@>96VOL\F.FG"%M;AU+)"YK;,]8
M>,?*1BZ-)H0#^(>OS-V+IK9GD-+H0)"KC)O&T--S8QJ=>AI27:Z#THV3AL2I
MU6#0PAM*B'%%Q*BUEREQ*TH!4DLI=;*R0$I4MMO,7'&T*H>;DV(/$B_5) -X
M,FV@C?6JCO;@R*E(YD1PXLC*5? R2>0Z=>=2Z\$_6JDI<9II,+1 O4(].KPT
M',K33UX+9N)8URK'&?(D.8GG"_17:J77%-I84TDN%MTO);2\A.(;PK1:#N0N
M%]UUH-)0"KVTAP(-CA.LK(D1;0R " H =942,HO,Z").D&?FU30&Z-N:1\7,
MOYN!@#R@596,E8^R^,$HNPSSII*,UHE1C%1R$##MI4TLG)R"PHR:*)HM-V+1
M!]U&QO1[&'U92W&D-.O!'K <;6P$=(PRE3:PX%+67G%-ALMH&9LD.%(64:UW
M#*44R4I2I0&>92 2E,B""HE1B(&A,QF(]0_<L[!*1I,Q<IW:XA66847,6J,G
M*P@VA4[W(V&/LL#&I%4(=-HZF:RZG$$"@#=!S./2) @3HTR_9WZ/\1BL1Z)X
M%.**W'<(TZVE:AF7T ;26 I1! 2T<P%Y"0GW@*RDMJ#.&4HP7$-B5&,V0Y5
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M#4@&$5K;F YZ134B8M3YPVQ58@'T, _!07*! T$XM2D$  P#CJ&'D)PV&<)
M*4N(@>T<Z6E)!*=1.9)))MGD<*XS&MK5C<6@7ET+$R 4EP*-XC<1%]-TU,;:
M-?NE7)TR&(JUDIX%14,!3HKOV+<[5=(! 2+'3.()@8APT*IT@& Q<75O-)"
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M,NE4R"0+">$SO$& :ZS*WV^5F&9#Y26'P%1QN/9S,.SP[4(Y+>. .D*93E[
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M\:G$JV5G(","TN_3O:E8VR[6I.T<7*D=&A64QF*5IS#I0DJ$@I@)*DA.;-[
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M004KH*P4&N#@J\-%+ Z9$C70*QS10',<F<ZA&#@#HF!9D11110C53>0*<YS
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M*&9))'T<V8W$ 2.(%9&&V6K#XAMXNI5T9)RA!$RA28G3Z5R?RK;- >C13(8
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M3JA:>Q?2-J22E4C=,S.^1O'PYVSL#@#A%K65A96C) 0I/T@J3,"+7WZ1SVK
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M]OHPD<:4T#L#"1Q%*:!V!B)'$=]*8FE- [/8>?IQ$CB.^E,3(XBE,*4$ 'F
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M69F4#I^2 G,G:(PS)M]FLT:RK]%803EO#V2>!M:9)P@V3E*1'6:CV6^-WB3
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MZF?K*M\^$ULV?W2.H_$U/?RAZ_FQ$KX W/G=PXS?=5[M'C\J:=X?/B97P'C
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MA5TBXC6P/;\8.IX5N2(,2._R=_#CPK)/E^_\V*?:Y>3UWMU?..WX_*GR_?\
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MSZH&4'9IS\N/ETY8>LB/=,\9YS^ $ZT];:F<KD<,J.$:Y^V-*"7/7]SK:O\
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MS87[-W[P^=/)#;O^,FT)_.?9!_$>)S8/[!W_ %E>?ZTS87[-W[P^=/)#;O\
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MOI:J[N>HCK[W6U?Z0<HOZ\\/;0 'CAZR(C*8[/&U^/Q)&L^MM$S#G<G^>WF
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M5;S>H*6@H5U.0,\_\50^7-.K"KMXXKC^3C6YEY2'D"H-@>JK^#IIK+%2Z8I
9QW%YU%41-8C[B77,R00(  ,38<B?C7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g105292g66i66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g105292g66i66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2E.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *3*^$%1CA"24T$!       .1P!6@ #&R5'' (   (_^QP"4  (<G(Q.3
M4V-S8< @4 &$UI8W)O<V]F="!7;W)D("T@0D,N9&]C>  X0DE-!"4      !
M"712!N(.T\Y$W1X! +P07\.$))300Z      #E    $     $       MP<F
MEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&
M4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F
M%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &
M\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F
M5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      B
MT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F
M)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M   $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$
M1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M   $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M  0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&N
M     *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&
M=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M            !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6
MYT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F
M5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W
M)O<%)E8W14;W!L;VYG       X0DE- ^T      !  W     $  @#<     0
M ".$))300F       .             #^    X0DE-! T       0   !X.$
M))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M    H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "
M]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M &       !.$))30/X      !P  #_____________________________ ^
M@     _____________________________P/H     /________________
M____________\#Z     #_____________________________ ^@  #A"24
MT$"       $     $   )    "0      X0DE-!!X       0     .$))30
M0:      ,U    !@             !,@   CT          0
M             !              (]   !,@                     !
M                       !     !        ;G5L;     (    &8F]U;F
M1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&
M5F=&QO;F<          $)T;VUL;VYG   !,@    !29VAT;&]N9P   CT
M &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&
MEC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6
MT    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6
MT    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   3(     4F=H=&QO;F<   (]     W5R;%1%6%0    !
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M   *    !5   !X   GV   !Z^ !@  ?_8_^(,6$E#0U]04D]&24Q%  $!
M ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M  245#('-21T(               $  /;6  $     TRU(4" @
M                                                     18W!R=
M   5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<E
MA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M!P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _
M@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3
M@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@24
M5#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                           %
MA96B        #S40 !     1;,6%E:(                     !865H@
M      ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "
M2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M           !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                          9&5S8P         N24
M5#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W
M!A8V4@+2!S4D="                             &1E<V,         +%
M)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M           "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C
M$Y-C8M,BXQ                                  !V:65W       3I/
MX %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YV
MUE87,          0                        */     G-I9R      0U
M)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10
M!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +
M< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@
M$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =
MD!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@
M*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z
M(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q
M33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B
M<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K
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M/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*
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MV6WAS>HM\IWZ_@-N"P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( (8 ^@,!$0 "$0$#$0'_Q  ?  $
M @(" P$!            "0H'" $&! 4+ @/_Q !5$   !@$# @,$! <*!Q #
M   ! @,$!08'  @1"2$2$S$*%$%1%2)A<188(S(XD:$7,T)2>(&WP='P)2<W
M<G>QMAD:)"@I-CE&1V)E=8>2X?&6Q]?_Q  = 0$  04! 0$
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M13D(8IQ P7-G/]%N[>XQ_!2!B>.!V/J/0]OE4-U%I2ZWHFIZ4Q ^FVDD2$Y
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M"!O"8I7B:*<<H8H^HD>"40]!$0$-2L.A:C* PA*J>P<@$'[.#@_>?M]<'O\
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M=L_4L=VL[51B#6065 C=HW7]X(D85Q3 Z1KG5-.ALDB>)Y&,C$%9"O "Y_-
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MN)(V9&4G9+4;68UQR'S#]>E*X$Q0]3%#[Q#^W2E!.0/4Y0^\P?VZ4KD#%$>
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M*1PJ$5H5? )(R68$_$2>V.YK&/%C0-*Z=ZAMK+2+5;2W?3HIGB1G8&4RS(S
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M3S=76*RRAVD)9ZE-5RG615D@8WEHK66(L]?]^,0 %4M58\E'P"8//4$ V17
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M[?<*-4Q.("8" HO@TA?&)0,8" /C$"B(!P B'T:]>C(VV_.?^3;V(X/F?O\
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M.,%T!#D>O.>Y^>:U]IOAIT_IM^E\IN;D0R"6"VN&C,$<@7"LP2-6D*G!7<<
MCD'G.;\JYIQGA*NJ6C)MLBJK$>,4T#/%Q4?2#@I -[G$Q;4B\A*N?!]84&+=
M94A>55"E3*<Y;"TLKJ^E$-K"TKDCA> /FS=@/M/-91KO4>B=,V37^MZA;Z?:
MI@*TS_'(W.(X8ES)*Y]%16/J< 9JMKU5=Y6*MUV)(2JT*IV])[0;NA:FUIGD
MHR/0<QPQLA"R35M'-G3Z0\AV5^T>&.Y.T,08X@K-!$"G2VCT9HE[I&H&>XE@
MVSPF)X58LZY8,K9^KE<=@W8G'M7#OX1/B=TOX@]*1Z5I%GJ+S:7JD.HP:A.L
M,4)1(I[>=5A$CSE6256&0F>"P &:K]"''/KP @'/;@1$!^T?EK:M<2 YX/?^
ML>_[\>Q.*XTK[32E-*5)GTI,.Y<R-NWQS=L;,5 K^);-"3^2;"J[:MFL16)5
M*59K1RJ:JH.'J]D9-9:+9M&K=<QC>8X6,V00.N3#.M[ZRMM'FM[IF::[A>.V
M5?\ VB2(2QX "KD;B22, 8/..@?P:^E>H]:\1])UK1X@-.Z=NXY]9NV9%C@M
MKB.=! %+AGENXUE1 JM@!R2-M7<RE OH !]P<?/[1^8ZT%7ZKU^M*5#KUCNF
M:AU%,%1Z-+<1L)N Q*O)3N*)J4 C>,GD))JD6?QW/2/@,HPB[,+&/<,I,043
MB9V-CW"Q/H]:1*>1TV_^A3,67?%* D@!.5&<[U]"1Z@CD$CVK8'AYUJ_1NKF
M697FTN\"Q7\*EBRA3F.XC0$!I(CSCNR948)!JD?MPW1[V>D!N$LS-G7)6AV8
MYD(G*.%,IQ$B6I7:/8G6%BX>,VKUD9=9F*[AS5[I5Y41*FY5]SD)*$D)!B_R
MNXM[35(5.X,WUDFB()CR/JD<GVWJW(/H#BNF]:T+I?Q(TF*074,Y"AK+4;9X
MS=6S$*TB.C-D(./,@D 92#MVMR;!D#[5Q3CP21[-LVLZ-D!$I5D('+T4XA%G
M/<#&2=R%(:/VZ)@X,0IV3A0HB)!,/A YH4]/2Y^&X4C/?RV[<?X7?]'W9Q6I
M9? 34/.*V^OVC6Y.$:6TG68CV9$:1,^G#D<9. >(?.H3UF=S_4L:1F":S0T\
M7XEEYZ-4;8FH+F;N5QR/-MW1303.US:3)BXL;=K( @]B*O"UR.8_2Q6KMXG,
MOF$4Z9R5GI=M8GSI9"SA3^48*L:*< E0>0V"5R2>^,<\[!Z3\-=!Z)+ZMJ%V
ME[>+$Z?2+Y8K>UMT92)!&CE@C-VWNS/C*X ;!GMZ"W2#N6UYTXW<[F8$8#,]
MCKCR!QCCA^FW4D\956>33"9L%E* K PO5F8%"*2B2'3=UJNNI1A+&&3FWT;"
MPNK:BERPA@_@E;<7  W,O Q@# &2<@<^Y R=2^*O75AKLBZ'HBPOIMK*'N+R
M.%$%W.F]0L+* QMT!^L>)&&Y?AQGWGM3!?#L<P84.1XW6UOU]>/W(LQ?'[.>
MP<:^Z"<7CY]8']#_ #D]>P^TUY\#OY67?!.-'N3@<G'TBUR0O<X')P>,5&3[
M+#Q^-9N0[]OQ?6(?;_E&K0CV[_/G[OGWXD.H<^3!V(,N<_/R_;OCGD^Y K./
M'LG\4Z&N#M.I3LK8([V\O!/8GXL\8X(X]:\[VJ80_&>VR@'H&"IP.?M"_28<
M<>H<!Q]_J';7GIYL1W '.9$X^P'D'Y'.17CP$(_%NOY^K]-M@3SPQ@8J, $\
M[3SC (.<YQ4C_LM'/XEN= ].-R\R' ^H .,L:=Q_7Z\>@#JRU_\ C49((_N=
M<Y_P7D']0R1WY_3AOCG_ "KM.W.D0'U[F:<GN!Q[''-=SZ[/23LF\Z A-QVW
M>)0D=PV-H :_/4XKAFP/E>A-5W,@S8Q[IT=NV"ZU=T[>JPA73E$DW%O'4,9<
M[QM!(AYTG41:,T,W,,A&">R.2!D]\*?4XX[FK7PM\0$Z6N7TK4V<:3?2!A.,
ML;*X.%+^7V,,O EV@%?K@^E5?MAW4_W;]*VY6C'K>LJ35$<SJJ^0]O>5V4W7
M58NQI)I-7<I KJ(H3-#MJK=NW9OG"D;)QD@V21&6K\DNTBW;*>N]/MM0C60-
MMDP-DJ$/N' PV!\0]%'PD'UY(K>?5/0O3GB!%#?07:17:Q*L.J6)BG62+.Y8
MI%&U)XU))R&\V/ZBL "IG8/[5Q0QAO&79I;OP@%$W+0V7X4(;SQ2'P<2/X#&
M>"D*PE W^"P.5+ZP_6[!$_\ !Z7/\83;[^6V<9]LXS]_S[5JL> VHF7:NOV1
MB#8+?19_,"Y[E-QP2,X!;&<<D5!1O/Z@>\CJ]Y6IE 9T1\I!,)=8<7;><21\
MU84B2[_QMC6"=<"520M=E28K>Y*V!XUB8:'CA=C&Q4&D_F%7TK:V-IIT;/*^
M2>'D? '&2 H[<\G&6R0,GBMG].]&],>'NGW5[=W$$LSQ_P!U:GJ+1(I1&#&"
MUB<%5#<\1LTK'N?J@6[NB7TL7W3]Q+/W?+24<XW(YE;QGX9(QR[6198ZJ4<=
M1U$X^C95L95"0?G>+C+V^38K#&/9,D=',1=M*^VE9'&]4OEO)5$2A88@0A P
MSG.2[9Y (P N> /<USUXC=:Q=5ZE'%I\2PZ/8;TM5$:QO/*21)<N BM@C"1J
MV<*-Q&YN*]WM00"&_?&A1$ XVRT\ YYYX-D+)_<1[_/U^WTU.=/G%I(,X)N#
MZ=_@7YC]1S\JW+X%<=,ZADX5=6D.[&0#]'@^MCL", <<G//I4Z_LU1Q+TV6W
M !_EXRF'</@*-7X]!]1]0^SX"'?4/K>?I[?Y*/\ JS_;^XK4_C,5/7%T1G/T
M&QR",$?DVP<>Q&/?[><"P0/ %'Y 4>X_( ^.HBM5?O\ O^_%?-&ZZP\]5S=P
M/_C&*N/AV# ^+/GZC_?CMK.-'XT^WQS@/^<,8\UR/WS[9'H>T?"3!Z$TCU9G
MO@/B4?$+J8*,$Y.<<#C)X[5>SZ4/(=-[96''KMYQV/\ /]#(\_M$?[^N)7_-
M[<G_ .-)ZY_.]_NKEKKS^6?4H!R/QQ>\XQG\J3GN1Z^YSZ'BI!%!  #[ ,/Z
MBB'V?QOF&K,]U^W]AK$_?Y_V@_LKY*6Z81'<UN. ?0,\9A$/N'(-B'Y?S_U\
M=];$M/XI #P#;+QW)^ $8.0.<GC!(Q7?/3ASTKHJ'L='L@A&3D?1D/UL8_3B
MOJ\8[4!/'-$.(E*4M,K0G,//!0+!LQ$?4.P<=_CQZ!K7S_78>I<@?:3@?KK@
MR[(%Q<D]A-,3]@=C6A69.H=$8]&S2,!6&DM5:DV?.Y&=DWSAH:2;QR2AW7T6
MT02,8A53)BBQ775.+@YB&]V#QE(.2673DMRJ%YEC9^R@9P"!];/.1GD8X[?.
MM&]3>,EGHC7SVM@+JUTY9&FN)YFA$OE F0Q*J-M08*J[M\1(( %5SLJ[K+7N
MXNTQD6UKK-5$ESM(FH@Z47BZC"B8WN$=%%,!"*)G33 [V0!!NO)/P7<+I)CY
M:*>R=-TNWTJW2WB578KNFEQEGD/?+8SP>R@@ <>IKB7JOQ#U+Q&U:ZU:^D>.
M)&,=IIZ2EK>PMU8F*.-0%5G9<%YPN9'+$XP ,9K(I.D5FS@A54'"1T5DSE 2
MJ(J%$BA#  !R4R9C$$!Y 0'@0[CJ34D,K X*G</NY].3V]_EG%8J4256BD4-
M&ZE9%P,NI&".<\D'MV]:TRNM5<U2959F(H9BN<ZT:Y'L1=L(_5*(]P]X0Y!)
M<H\#R!5 *":A##DMK<K<Q[P0&'!7U].<<X!/O_76J=7TY]-NF0 F%SNA<KD>
M6?S21CXDP01P.,^HQU$P<?#]H?W[?']FKC/)'MC]=1@.?4?=^_KZ=N*_.OM?
M::4J>'H&V*0:;CLP59(XA&3F'"S;U,!/X3/JW<ZZRC3B0# 03)H6:5 #& QB
M@J8$S%*HH4VL_$J)&T[3Y^SI=N@'L)(V:08X[E5/;'ZQ78_X&E_.G5?5>G*0
M+:YT&&]D15&!-:W\<49+ =]ES* O!P21DY-6Q]:;K]$::4K\B4IN0$.0'N/<
M?EQ\![=OE\>_KWTI6',P;=\$;@85*O9OP_C?+$.W%06C/(%.@K45@=4 !1:-
M5F&3I>-<#P40<L%6ZY3%*8BA3%*(>XI9(23"[QD]]C%<_;@C/WU?V&JZEI4O
MGZ;?W=C+_/MIY(B?\;8P##W# @^U:&N^B)TM'LD$JKM#I1'(&*?RFEIR8PC>
M2<<!]#,;NWB!*/\ "(++P'_AE-SJ\&IWX&/I,GZ%/Z25R:RE/$GKA(Q$O45[
MM'8LML[C_K&@+D^N2Q.>>];<X/V6[3]MBHNL%;>\38PDS-SM%IZJTJ&8VATU
M4.*AF[VU&;*V-\D)A#ZCN46*!"))% $T4B$MI;B>;^%FDD'LSL1^C./U=^>]
M8_J/4&N:OQJ>K7]\N2=EQ<RR1@GU$1;RP?F%'M6>K7:ZM0J[*VZY6*!I]6@V
MHO)NS6>780,!#LP.1,7<I+RKAK'L&P*'33%=VX22 ZA"B<!,'-$!F("@DDXP
M 23\@!ZU%PPRSR)!!$\LLC;8XHD+R.QY"HB@LS'G@ FM*,K9YZ9F=8)A6<U9
MIV3Y9KD5+)SL=7\BY'PC<H>/G$6CR.2F&<;8)E^U;R2+&0?LDWJ2)')&KYXW
M*H"3A4AKF.*]B8M''<(2I7,:2J2#@D''ID<9^X]\Y%9Z3UAILIFL-.Z@LIRI
M0RVMK?6\I4D$H9(D1MN<$J3@X!;M7AXCD^FMAMU#W';PWVIU%UDV]P&!V%IV
M_P %C]4;)>[&BO/P&.I.;Q='.BINWZ,6I+(,)MPW9) V1>*G3$S<YODINI>)
MC.VQ3)B1G^%00I;#GL3@<#]=?-07JN_WPZJ=9N/H<#W[0ZC)<L8+>/\ )R7(
M2Y;A5)V,R@G)(Y(.-CLJ;7]N&>9.+GLUX'Q#EJ9A6"D7#2F2,=5.Z2$3&JN#
M.5H^/=V.)D7#1FHY,=P=L@=-$RYSJB3S#";7B.::($12R1ACDA'902/?!%1E
MAK.KZ6KIINIWU@LA#2"TNIK<2, 0"XA=-Q )'.>#CM79<4X.PW@N%D*WA?%N
M/L3UZ5E#S<E!8YJ$#2XA_,J-6S%25>1U=8QS1Q(G9,F;0[Q5$S@S=JW1%04T
M4RE\O))*0TCO(P& 78L<9SC))]23]I/N:H7NH7VHRB?4+RZO9E01K+=SRW$@
M0%F"!Y6=@H+,<9QDFLI"0I@X$.0[>O(^GI_]:\5:5KCG#9_M=W)D3#.^ \59
M3<(MRM6LK<*9"RMA8MRG$_E1MD4:EGXL@")N/H^2;" '4+^:H<IJT5Q/#_!3
M21Y[A'90?M .#]XJ6TW7=9TAMVF:G>V7NMO<21H?DR!MA'R*D9YK3=OT0^EF
MVDQET]H=*.Z%4RPHN+3DUW&>(PB(@$*ZO"T,5,!'D$08 B4>Y4P[<7!U*^/!
MN9/_  C[P0N0?F.?G61'Q*ZY*&,]27^T@C %NIY&TX980Z\?S6'//?FMY<,;
M9=O>W:-<1&#,+8QQ.R=I-TGP4*EP%9=2A6I1*B:8D(MDWD)A8GB,<7$HY=KG
M4.HJ=4RJJAS6LDTLIS+(\A]-[%L?8"<#[L5C.H:QJNK/YFIZC>W[CL;JXEFV
M^VT.Q5<9XV@8]*SD!0+V . YY_G_ +AJG4;6OV4MIVV+.%B;VW,VWS#&5K.S
MC$(1G8,B8TIURF6L.V7<NF\4WDK##R+M&.0=/7KE%FFJ5NDN[<JD3*HNJ8]5
M)YHAMCFEC4MNPDC*-V ,X! [ 5)V6M:QIT;0Z?JE_91.VYXK6[GMT=OYS+$Z
MJS=N2"< #T%=]QCB+%N%:W^!N(<=TG&%1]_=R@5>@U>&J, 63?@D#V0+$0+-
M@P*]=@@B#ER#<%E_*3\PYO 7CP[O(VZ1V=L ;G8L<#L,DDU;7E[>:A.;F^NK
MB\N&"JT]S-)/*57A09)&9B%] 3@>E9"4,4I#"80 .!#OV#T^?P^_X:\U:_O[
MUI1N"VZ["6<5D3<=N1P!MVET86&/:<DY2O\ AZFVZ;)#5V*;,#2<W*NJW,3\
MFG%Q$>S9( (.W"+%FV:H)^4BFF6O'+<_#%%+*.<(B.R\L>P (Y)/;U-3^F:O
MU*C6VF:3J>JPL\@BM;2TO+B!?,E<.%C1)44%G(;/'/J.:VBQM#42 H=/BL81
M$# 8[:5V*"E0M6BFD'7(ZLK,T7$0WA(=BV9M8V-!DLB9JS0:MTT$3%("*?A$
MH46)))8DMDY).23ZY)Y)S4/=27,US-+>22RW32/](DF=GE>4'#F1V+,SY!!+
M$G.<DUW8Q0,' _W[\_U=_CQKYWJA6HDIT_=C,Y)24S-;/]M$O,3#][*RTM)X
M1QN^DI.3DG*KR0D9!ZZKBKIV]>NUE7+MRNJ=9PNHHJJ<QSF,-<75RH 6>8
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*4II2FE*:4K__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
